Unnamed: 0,headline,url,publisher,date,stock,Sentiment_DecisionTreeClassifier,Sentiment_finbert,Sentiment_LogisticRegression,Sentiment_KNeighborsClassifier,Sentiment_MultinomialNB,Sentiment_SGDClassifier,Sentiment_GradientBoostingClassifier,Sentiment_XGBClassifier,Sentiment_RandomForestClassifier,Sentiment_VADER
850715,shares of several healthcare companies are trading lower in sympathy with the overall market following an increase in coronavirus cases in some us states that have reopened leading to concerns of a second wave of the virus,https://www.benzinga.com/wiim/20/06/16233278/shares-of-several-healthcare-companies-are-trading-lower-in-sympathy-with-the-overall-market-followi,Benzingaâ€ƒNewsdesk,2020-06-11 10:22:31-04:00,MRK,0,1,1,1,1,0,0,1,0,0.79295
850716,johnson johnson to start coronavirus vaccine human trials ahead of schedule in july,https://www.benzinga.com/general/biotech/20/06/16229020/johnson-johnson-to-start-coronavirus-vaccine-human-trials-ahead-of-schedule-in-july,Neer Varshney,2020-06-11 00:16:21-04:00,MRK,1,2,1,0,1,1,1,1,1,0.5
850717,the daily biotech pulse keytruda setback for merck denali pulls the plug on neurological asset,https://www.benzinga.com/general/biotech/20/06/16219829/the-daily-biotech-pulse-keytruda-setback-for-merck-denali-pulls-the-plug-on-neurological-asset,Shanthi Rexaline,2020-06-10 07:30:59-04:00,MRK,1,1,0,1,0,0,1,1,1,0.6806
850718,merck announces that the phase keynote trial evaluating keytruda as monotherapy and in combination with chemotherapy in patients with advanced or metastatic urothelial carcinoma,https://www.benzinga.com/news/20/06/16216257/merck-announces-that-the-phase-3-keynote-361-trial-evaluating-keytruda-as-monotherapy-and-in-combina,Benzinga Newsdesk,2020-06-09 16:13:02-04:00,MRK,1,0,1,1,1,1,1,1,1,0.625
850719,the week ahead in biotech viela fda decision hematology conference take center stage,https://www.benzinga.com/general/biotech/20/06/16193531/the-week-ahead-in-biotech-viela-fda-decision-hematology-conference-take-center-stage,Shanthi Rexaline,2020-06-07 13:43:52-04:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850720,the daily biotech pulse adamas rallies on fda acceptance oxford immunotech reportedly gets m bid,https://www.benzinga.com/general/biotech/20/06/16188016/the-daily-biotech-pulse-adamas-rallies-on-fda-acceptance-oxford-immunotech-reportedly-gets-400m-b,Shanthi Rexaline,2020-06-05 07:34:09-04:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
850721,merck reports fda approved recarbio for treatment of adults with hospitalacquired and ventilatorassociated bacterial pneumonia,https://www.benzinga.com/news/20/06/16187771/merck-reports-fda-approved-recarbio-for-treatment-of-adults-with-hospital-acquired-and-ventilator-as,Benzinga Newsdesk,2020-06-05 06:52:00-04:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
850722,exfda chief on white houses coronavirus vaccine shortlist they chose very novel platforms,https://www.benzinga.com/government/20/06/16179215/ex-fda-chief-on-white-houses-coronavirus-vaccine-shortlist-they-chose-very-novel-platforms,Jayson Derrick,2020-06-04 11:02:25-04:00,MRK,1,2,1,1,1,1,1,1,1,0.6902
850723,the daily biotech pulse positive readout for kezar astrazeneca stitches oncology partnership dday for mercks triple combo antibiotic,https://www.benzinga.com/general/biotech/20/06/16178099/the-daily-biotech-pulse-positive-readout-for-kezar-astrazeneca-stitches-oncology-partnership-d-da,Shanthi Rexaline,2020-06-04 08:13:59-04:00,MRK,1,2,1,1,1,1,1,1,1,0.7787
850724,revisiting the coronavirus vaccine race updates on the candidates in clinics,https://www.benzinga.com/general/biotech/20/06/16174248/revisiting-the-coronavirus-vaccine-race-updates-on-the-10-candidates-in-clinics,Shanthi Rexaline,2020-06-03 17:53:42-04:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850726,update five companies chosen for vaccine finalist are moderna johnson johnson merck pfizer and astrazeneca,https://www.benzinga.com/news/20/06/16171726/update-five-companies-chosen-for-vaccine-finalist-are-moderna-johnson-johnson-merck-pfizer-and-astra,Benzinga Newsdesk,2020-06-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850727,pharma large and midcaps race against covid,https://www.benzinga.com/markets/20/06/16161758/pharma-large-and-mid-caps-race-against-covid-19,IAM Newswire,2020-06-02 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
850728,attention biotech investors mark your calendar for june pdufa dates,https://www.benzinga.com/general/biotech/20/06/16135090/attention-biotech-investors-mark-your-calendar-for-june-pdufa-dates,Shanthi Rexaline,2020-06-01 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
850729,new ebola epidemic in northwest dr congo health ministry afp,https://www.benzinga.com/general/biotech/20/06/16149216/new-ebola-epidemic-in-northwest-dr-congo-health-ministry-afp,Benzinga Newsdesk,2020-06-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850730,merck and astrazenecas lynparza receives a positive opinion from the european medicines agency,https://www.benzinga.com/news/20/06/16147505/merck-and-astrazenecas-lynparza-receives-a-positive-opinion-from-the-european-medicines-agency,Luke J Jacobi,2020-06-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
850731,astrazeneca announces lynparza recommended for approval in eu by chmp for brcamutated metastatic pancreatic cancer,https://www.benzinga.com/news/20/06/16147105/astrazeneca-announces-lynparza-recommended-for-approval-in-eu-by-chmp-for-brca-mutated-metastatic-pa,Charles Gross,2020-06-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.436
850732,the week ahead in biotech asco menlo and merck fda decisions ipos in the spotlight,https://www.benzinga.com/general/biotech/20/05/16140357/the-week-ahead-in-biotech-asco-menlo-and-merck-fda-decisions-ipos-in-the-spotlight,Shanthi Rexaline,2020-05-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850733,merck yesterday announced keytruda plus lenvima combination demonstrated clinically meaningful tumor response rates in unresectable hepatocellular carcinoma and advanced renal cell carcinoma,https://www.benzinga.com/general/biotech/20/05/16138224/merck-yesterday-announced-keytruda-plus-lenvima-combination-demonstrated-clinically-meaningful-tu,Benzinga Newsdesk,2020-05-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.58895
850734,the daily biotech pulse asco presentations begin altimmune pops on insider buying immutep gets rd grant,https://www.benzinga.com/general/biotech/20/05/16136395/the-daily-biotech-pulse-asco-presentations-begin-altimmune-pops-on-insider-buying-immutep-gets-r-,Shanthi Rexaline,2020-05-29 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.6806
850735,cramer shares his thoughts on teva oxford industries and more,https://www.benzinga.com/media/20/05/16135751/cramer-shares-his-thoughts-on-teva-oxford-industries-and-more,Craig Jones,2020-05-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
850736,mercks keytruda pembrolizumab superior to standard of care chemotherapy in patients with msih colorectal cancer,https://www.benzinga.com/general/biotech/20/05/16133066/mercks-keytruda-pembrolizumab-superior-to-standard-of-care-chemotherapy-in-patients-with-msi-h-co,Benzinga Newsdesk,2020-05-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
850737,merck ceo cant give a timeline or date for covid approval,https://www.benzinga.com/news/20/05/16110822/merck-ceo-cant-give-a-timeline-or-date-for-covid-19-approval,Benzinga Newsdesk,2020-05-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
850738,merck ceo ken frazier to appear on cnbc,https://www.benzinga.com/news/20/05/16110346/merck-ceo-ken-frazier-to-appear-on-cnbc,Benzinga Newsdesk,2020-05-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850739,merck chief casts doubt on coronavirus vaccine timeframe financial times,https://www.benzinga.com/news/20/05/16107402/merck-chief-casts-doubt-on-coronavirus-vaccine-timeframe-financial-times,Benzinga Newsdesk,2020-05-26 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.3194
850740,mercks coronavirus plan of attack partnerships ma deal aimed at treatment vaccine development,https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16105423/mercks-coronavirus-plan-of-attack-2-partnerships-m-a-deal-aimed-at-treatment-vaccin,Shanthi Rexaline,2020-05-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.26165
850741,benzinga pros top stocks to watch for tues may nvax ewj sny soxx mrk,https://www.benzinga.com/pre-market-outlook/20/05/16105068/benzinga-pros-top-5-stocks-to-watch-for-tues-may-26-2020-nvax-ewj-sny-soxx-mrk,Benzinga Newsdesk,2020-05-26 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.60115
850742,merck to acquire vaccine company themis bioscience also announces collaboration with iavi for coronavirus vaccine and collaboration with ridgeback bio for coronavirus antiviral candidate,https://www.benzinga.com/general/biotech/20/05/16104018/merck-to-acquire-vaccine-company-themis-bioscience-also-announces-collaboration-with-iavi-for-cor,Benzinga Newsdesk,2020-05-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
850743,the week ahead in biotech asco presentations in the spotlight,https://www.benzinga.com/general/biotech/20/05/16097022/the-week-ahead-in-biotech-asco-presentations-in-the-spotlight,Shanthi Rexaline,2020-05-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850744,us health official says vaccines from jj sanofi merck may be added this summer as they complete phase safety studies,https://www.benzinga.com/general/biotech/20/05/16096380/us-health-official-says-vaccines-from-j-j-sanofi-merck-may-be-added-this-summer-as-they-complete-,Benzinga Newsdesk,2020-05-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.79295
850745,us says will test experimental coronavirus vaccines in people health official says oxford vaccine may be tested side by side with modernas starting in july,https://www.benzinga.com/general/biotech/20/05/16096378/us-says-will-test-experimental-coronavirus-vaccines-in-100-000-people-health-official-says-oxford,Benzinga Newsdesk,2020-05-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850746, biggest movers from yesterday,https://www.benzinga.com/news/20/05/16092291/64-biggest-movers-from-yesterday,Lisa Levin,2020-05-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850747,midafternoon market update dow falls points l brands shares spike higher,https://www.benzinga.com/news/earnings/20/05/16087959/mid-afternoon-market-update-dow-falls-50-points-l-brands-shares-spike-higher,Lisa Levin,2020-05-21 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.648
850748, stocks moving in thursdays midday session,https://www.benzinga.com/news/20/05/16087446/51-stocks-moving-in-thursdays-mid-day-session,Lisa Levin,2020-05-21 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
850749,midday market update crude oil rises over aurora cannabis shares jump,https://www.benzinga.com/news/earnings/20/05/16086911/mid-day-market-update-crude-oil-rises-over-1-aurora-cannabis-shares-jump,Lisa Levin,2020-05-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3194
850750,midmorning market update markets mixed best buy tops q expectations,https://www.benzinga.com/news/earnings/20/05/16085659/mid-morning-market-update-markets-mixed-best-buy-tops-q1-expectations,Lisa Levin,2020-05-21 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.9088
850751,the daily biotech pulse mixed filgotinib readout for gileadgalapagos akorn to file for chapter dday for aquestive,https://www.benzinga.com/general/biotech/20/05/16083034/the-daily-biotech-pulse-mixed-filgotinib-readout-for-gilead-galapagos-akorn-to-file-for-chapter-1,Shanthi Rexaline,2020-05-21 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850752,midafternoon market update crude oil up surface oncology shares spike higher,https://www.benzinga.com/news/earnings/20/05/16078688/mid-afternoon-market-update-crude-oil-up-5-surface-oncology-shares-spike-higher,Lisa Levin,2020-05-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3194
850753,why surface oncologys stock is surging higher,https://www.benzinga.com/general/biotech/20/05/16076354/why-surface-oncologys-stock-is-surging-higher,Shanthi Rexaline,2020-05-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850754,checkpoint therapeutics ceo on tapping into a billion cancer treatment market,https://www.benzinga.com/general/biotech/20/05/16074435/checkpoint-therapeutics-ceo-on-tapping-into-a-25-billion-cancer-treatment-market,Chris Dier-Scalise,2020-05-20 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.17015000000000002
850755,the daily biotech pulse aldeyra jumps into covid drug fray fda nod for myriads companion diagnostic test,https://www.benzinga.com/general/biotech/20/05/16073679/the-daily-biotech-pulse-aldeyra-jumps-into-covid-19-drug-fray-fda-nod-for-myriads-companion-diagn,Shanthi Rexaline,2020-05-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850756,astrazeneca and merck announce lynparza approved by fda for treatment of hrr genemutated metastatic castrationresistant prostate cancer that has progressed following prior treatment with enzalutamide or abiraterone,https://www.benzinga.com/general/biotech/20/05/16073155/astrazeneca-and-merck-announce-lynparza-approved-by-fda-for-treatment-of-hrr-gene-mutated-metasta,Benzinga Newsdesk,2020-05-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.30910000000000004
850757,astrazeneca says lynparza approved in the us for prostate cancer,https://www.benzinga.com/news/20/05/16072674/astrazeneca-says-lynparza-approved-in-the-u-s-for-prostate-cancer,Benzinga Newsdesk,2020-05-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.30910000000000004
850758,telemedicine a covid winner,https://www.benzinga.com/markets/20/05/16066297/telemedicine-a-covid-19-winner,IAM Newswire,2020-05-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.79295
850759,merck and upmc announces infectious disease connect has combined mercks ilÃºm health solutions to advance precision treatment of infectious diseases and antimicrobial stewardship ,https://www.benzinga.com/general/health-care/20/05/16062744/merck-and-upmc-announces-infectious-disease-connect-has-combined-mercks-il-m-health-solutions,Benzinga Newsdesk,2020-05-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.58895
850760,merck reports keytruda plus chemo showed statistically significant improvement in progressionfree survival vs chemo in certain patients with metastatic triplenegative breast cancer,https://www.benzinga.com/news/20/05/16026992/merck-reports-keytruda-plus-chemo-showed-statistically-significant-improvement-in-progression-free-s,Benzinga Newsdesk,2020-05-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5640000000000001
850761,merck reports keytruda superior to brentuximab vedotin in patients with classical hodgkin lymphoma in headtohead phase trial,https://www.benzinga.com/news/20/05/16026982/merck-reports-keytruda-superior-to-brentuximab-vedotin-in-patients-with-classical-hodgkin-lymphoma-i,Benzinga Newsdesk,2020-05-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.77115
850762,merck reports new combo data for keytruda showed benefit in stage nonsmall cell lung cancer,https://www.benzinga.com/news/20/05/16026967/merck-reports-new-combo-data-for-keytruda-showed-benefit-in-stage-3-non-small-cell-lung-cancer,Benzinga Newsdesk,2020-05-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.32999999999999996
850763,merck reports novel hifa inhibitor showed objective response rate of nearly in patients with von hippellindau diseaseassociated clear cell renal cell carcinoma,https://www.benzinga.com/news/20/05/16026936/merck-reports-novel-hif-2a-inhibitor-showed-objective-response-rate-of-nearly-30-in-patients-with-vo,Benzinga Newsdesk,2020-05-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
850764,abbvies potential is underappreciated says morgan stanley analyst,https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16022153/abbvies-potential-is-underappreciated-says-morgan-stanley-analyst,Shanthi Rexaline,2020-05-13 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
850765,the daily biotech pulse gilead signs manufacturing deal for remdesivir bristolmyers gets refusetofile letter,https://www.benzinga.com/general/biotech/20/05/16019554/the-daily-biotech-pulse-gilead-signs-manufacturing-deal-for-remdesivir-bristol-myers-gets-refuse-,Shanthi Rexaline,2020-05-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
850766,merck animal health to acquire us rights to sentinel brand of combination parasiticides for companion animals for m in cash,https://www.benzinga.com/m-a/20/05/16018885/merck-animal-health-to-acquire-u-s-rights-to-sentinel-brand-of-combination-parasiticides-for-compani,Charles Gross,2020-05-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850767,update cocrystal says collaboration with merck for discovery development of certain proprietary flu ab antiviral agents ongoing,https://www.benzinga.com/news/20/05/15999348/update-cocrystal-says-collaboration-with-merck-for-discovery-development-of-certain-proprietary-flu,Benzinga Newsdesk,2020-05-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.436
850768,astrazeneca and merck announce lynparza approved in us as stline maintenance treatment with bevacizumab for hrdpositive advanced ovarian cancer,https://www.benzinga.com/general/biotech/20/05/15998340/astrazeneca-and-merck-announce-lynparza-approved-in-us-as-1st-line-maintenance-treatment-with-bev,Benzinga Newsdesk,2020-05-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
850769,astrazeneca announces lynparza approved in the us as stline maintenance treatment with bevacizumab for hedpositive advanced ovarian cancer,https://www.benzinga.com/news/20/05/15997357/astrazeneca-announces-lynparza-approved-in-the-u-s-as-1st-line-maintenance-treatment-with-bevacizuma,Charles Gross,2020-05-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
850770, biopharmas where bofa would put its money to work,https://www.benzinga.com/analyst-ratings/analyst-color/20/05/15989612/5-biopharmas-where-bofa-would-put-its-money-to-work,Shanthi Rexaline,2020-05-08 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
850771,merck announces recarbrio demonstrated noninferiority compared to piperacillin and tazobactam in primary and key secondary endpoints,https://www.benzinga.com/general/biotech/20/05/15964448/merck-announces-recarbrio-demonstrated-noninferiority-compared-to-piperacillin-and-tazobactam-in-,Benzinga Newsdesk,2020-05-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
850772,why shares of gene therapy company genprex are surging higher,https://www.benzinga.com/general/biotech/20/05/15957202/why-are-shares-of-gene-therapy-company-genprex-are-surging-higher,Shanthi Rexaline,2020-05-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
850773,attention biotech investors mark your calendar for these may pdufa dates,https://www.benzinga.com/general/biotech/20/05/15891850/attention-biotech-investors-mark-your-calendar-for-these-may-pdufa-dates,Shanthi Rexaline,2020-05-03 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
850774,the week ahead in biotech smidcap earnings news flow picks up pace,https://www.benzinga.com/general/biotech/20/05/15926105/the-week-ahead-in-biotech-smid-cap-earnings-news-flow-picks-up-pace,Shanthi Rexaline,2020-05-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
850775,servicenow ceo bill mcdermott says company hungry and humble with b ambitions,https://www.benzinga.com/news/earnings/20/04/15916996/servicenow-ceo-bill-mcdermott-says-company-hungry-and-humble-with-10b-ambitions,Shivdeep Dhaliwal,2020-04-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
850776,guggenheim maintains buy on merck co lowers price target to ,https://www.benzinga.com/news/20/04/15911306/guggenheim-maintains-buy-on-merck-co-lowers-price-target-to-93,Vick Meyer,2020-04-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
850777,barclays maintains overweight on merck co lowers price target to ,https://www.benzinga.com/news/20/04/15909139/barclays-maintains-overweight-on-merck-co-lowers-price-target-to-90,vishwanath@benzinga.com,2020-04-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.2706
850778,merck analysts focus on fundamentals keytruda strength following guidance cut,https://www.benzinga.com/analyst-ratings/analyst-color/20/04/15907712/merck-analysts-focus-on-fundamentals-keytruda-strength-following-guidance-cut,Shanthi Rexaline,2020-04-29 00:00:00,MRK,1,2,0,1,1,0,0,0,0,0.6366
850779,the daily biotech pulse inovios mers vaccine data fast track designation for erytech fda approves higher dose of mercks keytruda,https://www.benzinga.com/general/biotech/20/04/15905401/the-daily-biotech-pulse-inovios-mers-vaccine-data-fast-track-designation-for-erytech-fda-approves,Shanthi Rexaline,2020-04-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
850780,svb leerink maintains outperform on merck co lowers price target to ,https://www.benzinga.com/news/20/04/15904495/svb-leerink-maintains-outperform-on-merck-co-lowers-price-target-to-95,vishwanath@benzinga.com,2020-04-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.436
850781,fda approves mercks keytruda for use at an additional recommended dose of mg every six weeks for all approved adult indications,https://www.benzinga.com/general/biotech/20/04/15901479/fda-approves-mercks-keytruda-for-use-at-an-additional-recommended-dose-of-400-mg-every-six-weeks-,Benzinga Newsdesk,2020-04-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8714999999999999
850782,a cure for the common earnings play,https://www.benzinga.com/news/earnings/20/04/15891787/a-cure-for-the-common-earnings-play,ETF Professor,2020-04-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.67
850783,morning market stats in minutes,https://www.benzinga.com/intraday-update/20/04/15895851/morning-market-stats-in-5-minutes,Benzinga Insights,2020-04-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850784,earnings feast bring a plate with healthcare and caterpillar in morning googl and amd later,https://www.benzinga.com/news/earnings/20/04/15896240/earnings-feast-bring-a-plate-with-healthcare-and-caterpillar-in-morning-googl-and-amd-later,JJ Kinahan,2020-04-28 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
850785,merck shares are trading lower after the company issued fy guidance below consensus estimates,https://www.benzinga.com/wiim/20/04/15894789/merck-shares-are-trading-lower-after-the-company-issued-fy20-guidance-below-consensus-estimates,Benzinga Newsdesk,2020-04-28 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.5
850786,the daily biotech pulse pfizer earnings roches spinal muscular dystrophy treatment moderna covid vaccine update,https://www.benzinga.com/general/biotech/20/04/15893205/the-daily-biotech-pulse-pfizer-earnings-roches-spinal-muscular-dystrophy-treatment-moderna-covid-,Shanthi Rexaline,2020-04-28 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
850787,merck sees fy eps vs est sales bb vs b est,https://www.benzinga.com/news/20/04/15893150/merck-sees-fy20-eps-5-17-5-37-vs-5-56-est-sales-46-1b-48-1b-vs-48-72b-est,Benzinga Newsdesk,2020-04-28 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
850788,merck co q adj eps beats estimate sales b beat b estimate,https://www.benzinga.com/news/earnings/20/04/15893146/merck-co-q1-adj-eps-1-500-beats-1-340-estimate-sales-12-100b-beat-11-460b-estimate,Benzinga Newsdesk,2020-04-28 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
850789,earnings scheduled for april ,https://www.benzinga.com/news/earnings/20/04/15892498/earnings-scheduled-for-april-28-2020,Lisa Levin,2020-04-28 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
850790,apple and amazon earnings fed meeting among highlights in busy week ahead,https://www.benzinga.com/news/earnings/20/04/15884587/apple-and-amazon-earnings-fed-meeting-among-highlights-in-busy-week-ahead,JJ Kinahan,2020-04-27 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.58895
850791,merck and institute for systems biology collaborate to define molecular mechanisms of sarscov infection and identify potential prognostic biomarkers for coronavirus,https://www.benzinga.com/news/20/04/15882548/merck-and-institute-for-systems-biology-collaborate-to-define-molecular-mechanisms-of-sars-cov-2-inf,Benzinga Newsdesk,2020-04-27 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850792,lynparza demonstrated overall survival benefit in phase iii profound trial for brca or atmmutated metastatic castrationresistant prostate cancer,https://www.benzinga.com/news/20/04/15881959/lynparza-demonstrated-overall-survival-benefit-in-phase-iii-profound-trial-for-brca12-or-atm-mutated,Charles Gross,2020-04-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.32999999999999996
850793,the week ahead in biotech april may cancer conference earnings news flow in the spotlight,https://www.benzinga.com/general/biotech/20/04/15877610/the-week-ahead-in-biotech-april-26-may-2-cancer-conference-earnings-news-flow-in-the-spotlight,Shanthi Rexaline,2020-04-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
850794,astrazeneca merck announce lynparza demonstrated overall survival benefit in phase iii profound trial for brca or atmmutated metastatic castrationresistant prostate cancer,https://www.benzinga.com/news/20/04/15872479/astrazeneca-announces-lynparza-demonstrated-overall-survival-benefit-in-phase-iii-profound-trial-for,Charles Gross,2020-04-24 00:00:00,MRK,1,0,1,0,1,0,1,1,1,0.32999999999999996
850795,shares of several healthcare companies are trading higher movement appears marketrelated as equities gain amid a rebound in oil prices,https://www.benzinga.com/wiim/20/04/15866991/shares-of-several-healthcare-companies-are-trading-higher-movement-appears-market-related-as-equitie,Benzinga Newsdesk,2020-04-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8404
850796,merck reports resubmission of supplemental biologics license applications for keytruda week dosing schedule,https://www.benzinga.com/news/20/04/15863495/merck-reports-resubmission-of-supplemental-biologics-license-applications-for-keytruda-6-week-dosing,Benzinga Newsdesk,2020-04-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850797,shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows partially stemming from weak demand caused by the coronavirus pandemic,https://www.benzinga.com/wiim/20/04/15849176/shares-of-several-healthcare-companies-are-trading-lower-with-the-overall-market-on-continued-downwa,Benzinga Newsdesk,2020-04-21 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.18155
850798,merck broadens patient support and assistance programs as part of overall covid relief efforts,https://www.benzinga.com/general/health-care/20/04/15846003/merck-broadens-patient-support-and-assistance-programs-as-part-of-overall-covid-19-relief-eff,Benzinga Newsdesk,2020-04-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.85015
850799,cue biopharma announces clinical trial collaboration agreement with merck to evaluate cue in combination with keytruda as firstline treatment for hpv recurrentmetastatic head and neck cancer,https://www.benzinga.com/general/biotech/20/04/15838565/cue-biopharma-announces-clinical-trial-collaboration-agreement-with-merck-to-evaluate-cue-101-in-,Benzinga Newsdesk,2020-04-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.352
850800,barrons picks and pans dropbox ford johnson johnson teladoc and more,https://www.benzinga.com/media/20/04/15836229/barrons-picks-and-pans-dropbox-ford-johnson-johnson-teladoc-and-more,Nelson Hem,2020-04-19 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850801,gileads encouraging remdesivir data rapid reaction on the stock,https://www.benzinga.com/analyst-ratings/analyst-color/20/04/15825027/gileads-encouraging-remdesivir-data-rapid-reaction-on-the-stock,Jayson Derrick,2020-04-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.76335
850802,sp futures up after hours many other stocks moving higher with futures investors reacting favorably to white phase guidelines on reopening economy,https://www.benzinga.com/news/20/04/15824869/s-p-500-futures-up-3-2-after-hours-many-other-stocks-moving-higher-with-futures-investors-reacting-f,Benzinga Newsdesk,2020-04-16 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.6909
850803,next days will be most critical period for us says alan lancz who predicted and crises,https://www.benzinga.com/news/20/04/15815752/next-45-days-will-be-most-critical-period-for-us-says-alan-lancz-who-predicted-1987-and-2008-crises,Shivdeep Dhaliwal,2020-04-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.30979999999999996
850804,every member of trumps great american economic revival industry groups,https://www.benzinga.com/news/20/04/15808727/every-member-of-trumps-great-american-economic-revival-industry-groups,Tanzeel Akhtar,2020-04-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.81245
850805,the daily biotech pulse applied dna ships vaccine constructs for animal testing herceptin biosimilar now available in us,https://www.benzinga.com/general/biotech/20/04/15806223/the-daily-biotech-pulse-applied-dna-ships-vaccine-constructs-for-animal-testing-herceptin-biosimi,Shanthi Rexaline,2020-04-15 00:00:00,MRK,1,2,1,0,0,1,1,1,1,0.5
850806,merck announces us launch of ontruzant trastuzumabdttb a biosimilar of herceptin trastuzumab,https://www.benzinga.com/general/biotech/20/04/15805781/merck-announces-us-launch-of-ontruzant-trastuzumab-dttb-a-biosimilar-of-herceptin-trastuzumab,Benzinga Newsdesk,2020-04-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
850807,ubs maintains buy on merck co lowers price target to ,https://www.benzinga.com/news/20/04/15788753/ubs-maintains-buy-on-merck-co-lowers-price-target-to-92,Vick Meyer,2020-04-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
850808,astrazeneca and merck announce approval of koselugo for pediatric patients two years and older with neurofibromatosis type and symptomatic inoperable plexiform neurofibromas,https://www.benzinga.com/news/20/04/15787115/astrazeneca-and-merck-announce-approval-of-koselugo-for-pediatric-patients-two-years-and-older-with,Luke J Jacobi,2020-04-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
850809,fda approves generic version of mercks proventil hfa metereddose inhaler,https://www.benzinga.com/news/20/04/15768977/fda-approves-generic-version-of-mercks-proventil-hfa-metered-dose-inhaler,Benzinga Newsdesk,2020-04-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
850810,merck receives priority review from fda for second application for keytruda based on biomarker regardless of tumor type,https://www.benzinga.com/general/biotech/20/04/15755087/merck-receives-priority-review-from-fda-for-second-application-for-keytruda-based-on-biomarker-re,Benzinga Newsdesk,2020-04-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.30910000000000004
850811,shares of several healthcare companies are trading higher as markets gain amid optimism that coronavirus cases in several us hotspots may be peaking a sooner peak could mean a sooner return to economic activity,https://www.benzinga.com/wiim/20/04/15748126/shares-of-several-healthcare-companies-are-trading-higher-as-markets-gain-amid-optimism-that-coronav,Benzinga Newsdesk,2020-04-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.9220999999999999
850812,cannabis opportunity in the time of the coronavirus,https://www.benzinga.com/markets/cannabis/20/04/15733775/cannabis-opportunity-in-the-time-of-the-coronavirus,Luke Jacobi,2020-04-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
850813,morgan stanley maintains overweight on merck co lowers price target to ,https://www.benzinga.com/news/20/04/15727586/morgan-stanley-maintains-overweight-on-merck-co-lowers-price-target-to-89,Vick Meyer,2020-04-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.2706
850814,merck reports keytruda significantly improved progressionfree survival as firstline treatment for msih dmmr colorectal cancer,https://www.benzinga.com/news/20/04/15725637/merck-reports-keytruda-significantly-improved-progression-free-survival-as-first-line-treatment-for,Benzinga Newsdesk,2020-04-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
850815,rbc capital maintains sector perform on merck co lowers price target to ,https://www.benzinga.com/news/20/04/15717183/rbc-capital-maintains-sector-perform-on-merck-co-lowers-price-target-to-89,Vick Meyer,2020-04-01 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.436
850816,shares of several healthcare companies are trading lower amid market weakness as growing coronavirus concerns in the us weigh on equities,https://www.benzinga.com/wiim/20/04/15717065/shares-of-several-healthcare-companies-are-trading-lower-amid-market-weakness-as-growing-coronavirus,Benzinga Newsdesk,2020-04-01 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.3634
850817,shares of several healthcare companies are trading higher as the market rebounds on extended measures to help curb the coronavirus note the sector could also be trading higher due to increased demand for medical products amid the coronavirus outbreak,https://www.benzinga.com/wiim/20/03/15695285/shares-of-several-healthcare-companies-are-trading-higher-as-the-market-rebounds-on-extended-measure,Benzinga Newsdesk,2020-03-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.83525
850818,barrons picks and pans tech picks softbank reits tesla and more,https://www.benzinga.com/media/20/03/15689945/barrons-picks-and-pans-tech-picks-softbank-reits-tesla-and-more,Nelson Hem,2020-03-29 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850819,cramer reveals stock favorites says intuitive surgical a winner,https://www.benzinga.com/news/20/03/15679929/cramer-reveals-stock-favorites-says-intuitive-surgical-a-winner,Shivdeep Dhaliwal,2020-03-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8825000000000001
850820,shares of several healthcare companies are trading lower selling off from this weeks strength while the us stimulus legislation has boosted economic optimism demand concerns still exist amid the coronavirus outbreak,https://www.benzinga.com/wiim/20/03/15682782/shares-of-several-healthcare-companies-are-trading-lower-selling-off-from-this-weeks-strength-while,Benzinga Newsdesk,2020-03-27 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.91355
850821,shares of several healthcare companies are trading higher following senate passage of a trillion economic stimulus package which has lifted stocks across sectors,https://www.benzinga.com/wiim/20/03/15674560/shares-of-several-healthcare-companies-are-trading-higher-following-senate-passage-of-a-2-trillion-e,Benzinga Newsdesk,2020-03-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
850822,ups seeks to accelerate growth of dronedelivery,https://www.benzinga.com/news/20/03/15663327/ups-seeks-to-accelerate-growth-of-drone-delivery,FreightWaves,2020-03-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6909
850823, biggest price target changes for tuesday,https://www.benzinga.com/analyst-ratings/price-target/20/03/15650459/10-biggest-price-target-changes-for-tuesday,Lisa Levin,2020-03-24 00:00:00,MRK,1,2,0,1,0,1,1,1,1,0.5
850824,argus research maintains buy on merck co lowers price target to ,https://www.benzinga.com/news/20/03/15650127/argus-research-maintains-buy-on-merck-co-lowers-price-target-to-95,Benzinga_Newsdesk,2020-03-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
850825,the daily biotech pulse milestone pharma flunks latestage study cytomx strikes cancer drug collaboration barda grant for genmarks covid test,https://www.benzinga.com/general/biotech/20/03/15648204/the-daily-biotech-pulse-milestone-pharma-flunks-late-stage-study-cytomx-strikes-cancer-drug-colla,Shanthi Rexaline,2020-03-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.09899999999999998
850826,shares of several healthcare companies are trading lower amid market volatility sundays fiscal stimulus bill failed a procedural senate vote while the fed monday morning announced further stimulus measures to support liquidity,https://www.benzinga.com/wiim/20/03/15636398/shares-of-several-healthcare-companies-are-trading-lower-amid-market-volatility-sundays-fiscal-stimu,Benzinga Newsdesk,2020-03-23 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.42345
850827,merck donates a half a million masks to support covid emergency response in new york city,https://www.benzinga.com/news/20/03/15625304/merck-donates-a-half-a-million-masks-to-support-covid-19-emergency-response-in-new-york-city,Charles Gross,2020-03-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5129
850828,shares of several healthcare companies are trading higher rebounding from mondays crash stocks may also potentially be getting a boost from expectations of further stimulus proposals,https://www.benzinga.com/wiim/20/03/15568177/shares-of-several-healthcare-companies-are-trading-higher-rebounding-from-mondays-crash-stocks-may-a,Benzinga Newsdesk,2020-03-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
850829,the daily biotech pulse setback for dbv in peanut allergy patch review roche starts coronavirus test shipment regeneron aims for cocktail covid treatment,https://www.benzinga.com/general/biotech/20/03/15567007/the-daily-biotech-pulse-setback-for-dbv-in-peanut-allergy-patch-review-roche-starts-coronavirus-t,Shanthi Rexaline,2020-03-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850830,merck announces topline results from phase trials evaluating gefapixant for refractory of unexplained chronic cough gefapixant demonstrated statistically significant decrease in hour coughs per hour compared to placebo at week and ,https://www.benzinga.com/general/biotech/20/03/15566827/merck-announces-top-line-results-from-phase-3-trials-evaluating-gefapixant-for-refractory-of-unex,Benzinga Newsdesk,2020-03-17 00:00:00,MRK,1,0,1,1,1,1,1,0,1,0.60115
850831,shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus the virus has had a negative impact on the global economy,https://www.benzinga.com/wiim/20/03/15558425/shares-of-several-healthcare-companies-are-trading-lower-in-sympathy-with-the-overall-market-on-cont,Benzinga Newsdesk,2020-03-16 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.352
850832,barrons picks and pans roundtable picks airline and oil stocks and more,https://www.benzinga.com/top-stories/20/03/15554245/barrons-picks-and-pans-roundtable-picks-airline-and-oil-stocks-and-more,Nelson Hem,2020-03-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850833,intec pharma posts q net loss of m down by nearly half yearoveryear,https://www.benzinga.com/markets/cannabis/20/03/15546600/intec-pharma-posts-q4-net-loss-of-6-6m-down-by-nearly-half-year-over-year,Nina Zdinjak,2020-03-13 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.3409
850834,shares of several healthcare companies are trading higher as the market rebounds following thursdays selloff note since the coronavirus outbreak the healthcare sector has been extremely volatile,https://www.benzinga.com/wiim/20/03/15546640/shares-of-several-healthcare-companies-are-trading-higher-as-the-market-rebounds-following-thursdays,Benzinga Newsdesk,2020-03-13 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.648
850835,the daily biotech pulse astrazeneca faces setback in ovarian cancer study mallinckrodt to explore covid treatment imara ipo,https://www.benzinga.com/general/biotech/20/03/15534482/the-daily-biotech-pulse-astrazeneca-faces-setback-in-ovarian-cancer-study-mallinckrodt-to-explore,Shanthi Rexaline,2020-03-12 00:00:00,MRK,1,1,1,1,1,0,1,0,0,0.17015000000000002
850836,merck co shares are trading lower after the company announced its phase gy trial for cediranib and lynparza did not meet its primary endpoint,https://www.benzinga.com/wiim/20/03/15534285/merck-co-shares-are-trading-lower-after-the-company-announced-its-phase-3-gy004-trial-for-cediranib,Benzinga Newsdesk,2020-03-12 00:00:00,MRK,0,1,0,0,1,0,0,0,0,0.5
850837,webmd acquires merck subsidiary staywell,https://www.benzinga.com/m-a/20/03/15533817/webmd-acquires-merck-subsidiary-staywell,Charles Gross,2020-03-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850838,astrazeneca and merck announce phase gy for cediranib and lynparza in platinumsensitive relapsed ovarian cancer did not meet the primary endpoint of progressionfree survival vs platinumbased chemotherapy,https://www.benzinga.com/news/20/03/15533638/astrazeneca-and-merck-announce-phase-3-gy004-for-cediranib-and-lynparza-in-platinum-sensitive-relaps,Charles Gross,2020-03-12 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.17015000000000002
850839,shares of several healthcare companies are trading lower movement appears market related amid selloff in equities the global coronavirus outbreak has caused volatility in global markets and impacted stocks across sectors,https://www.benzinga.com/wiim/20/03/15525133/shares-of-several-healthcare-companies-are-trading-lower-movement-appears-market-related-amid-sellof,luke@benzinga.com,2020-03-11 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.5
850840,cdcs redfield says will know by april if ebolatied drug helps coronavirus,https://www.benzinga.com/general/biotech/20/03/15518554/cdcs-redfield-says-will-know-by-april-if-ebola-tied-drug-helps-coronavirus,luke@benzinga.com,2020-03-10 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.6909
850841, healthcare stocks moving in mondays premarket session,https://www.benzinga.com/pre-market-outlook/20/03/15506193/52-healthcare-stocks-moving-in-mondays-pre-market-session,Lisa Levin,2020-03-09 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
850842,barrons picks and pans coronavirus picks bonds safe havens and more,https://www.benzinga.com/media/20/03/15504011/barrons-picks-and-pans-coronavirus-picks-bonds-safe-havens-and-more,Nelson Hem,2020-03-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7202
850843,fda issues warning on mercks singulair warns of mental health side effects,https://www.benzinga.com/news/20/03/15481092/fda-issues-warning-on-mercks-singulair-warns-of-mental-health-side-effects,luke@benzinga.com,2020-03-04 00:00:00,MRK,1,1,0,1,0,0,0,0,1,0.28925
850844,shares of several healthcarerelated companies are trading higher after joe biden secured several key wins in super tuesday bidens more moderate healthcare policies have been seen as more favorable for the sector,https://www.benzinga.com/wiim/20/03/15476997/shares-of-several-healthcare-related-companies-are-trading-higher-after-joe-biden-secured-several-ke,luke@benzinga.com,2020-03-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.9711000000000001
850845,attention biotech investors mark your calendar for these march pdufa dates,https://www.benzinga.com/general/biotech/20/03/15431740/attention-biotech-investors-mark-your-calendar-for-these-march-pdufa-dates,Shanthi Rexaline,2020-03-02 00:00:00,MRK,1,2,0,1,0,0,1,0,1,0.5
850846,merck shares are trading higher after the companys keynote of keytruda met one of its primary endpoints of progressionfree survival,https://www.benzinga.com/wiim/20/03/15455998/merck-shares-are-trading-higher-after-the-companys-keynote-204-of-keytruda-met-one-of-its-primary-en,Benzinga Newsdesk,2020-03-02 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.648
850847,merck announces new data from broad hiv program at croi ,https://www.benzinga.com/news/20/03/15452710/merck-announces-new-data-from-broad-hiv-program-at-croi-2020,Benzinga Newsdesk,2020-03-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850848,a peek into the markets us stock futures down ahead of manufacturing reports,https://www.benzinga.com/news/20/03/15452708/a-peek-into-the-markets-us-stock-futures-down-ahead-of-manufacturing-reports,Lisa Levin,2020-03-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850849,mercks phase keynote trial of keytruda met one of its primary endpoints,https://www.benzinga.com/news/20/03/15452665/mercks-phase-3-keynote-204-trial-of-keytruda-met-one-of-its-primary-endpoints,Benzinga Newsdesk,2020-03-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
850850,shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook,https://www.benzinga.com/wiim/20/02/15440922/shares-of-several-healthcare-companies-are-trading-lower-as-the-global-coronavirus-spread-continues,Benzinga Newsdesk,2020-02-28 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.2798
850851,the daily biotech pulse gilead kicks off coronavirus drug trials adcom nod for lily fda approves esperions lipidlowering adjunctive combo therapy,https://www.benzinga.com/general/biotech/20/02/15425291/the-daily-biotech-pulse-gilead-kicks-off-coronavirus-drug-trials-adcom-nod-for-lily-fda-approves-,Shanthi Rexaline,2020-02-27 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.70095
850852,the daily biotech pulse menlo flunks midstage trial gw pharmas earnings covid updates,https://www.benzinga.com/general/biotech/20/02/15415577/the-daily-biotech-pulse-menlo-flunks-midstage-trial-gw-pharmas-earnings-covid-19-updates,Shanthi Rexaline,2020-02-26 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.28925
850853,what drove mercks keytruda shortfall in q,https://www.benzinga.com/analyst-ratings/analyst-color/20/02/15393284/what-drove-mercks-keytruda-shortfall-in-q4,Shanthi Rexaline,2020-02-24 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
850854,the week ahead in biotech biopharma earnings pick up pace,https://www.benzinga.com/general/biotech/20/02/15384645/the-week-ahead-in-biotech-biopharma-earnings-pick-up-pace,Shanthi Rexaline,2020-02-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
850855,benzingas bulls and bears of the week merck nike target and more,https://www.benzinga.com/trading-ideas/20/02/15389993/benzingas-bulls-and-bears-of-the-week-merck-nike-target-and-more,Nelson Hem,2020-02-22 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850856,why merck has had underwhelming start to ,https://www.benzinga.com/analyst-ratings/analyst-color/20/02/15375258/why-merck-has-had-underwhelming-start-to-2020,Shanthi Rexaline,2020-02-20 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.5
850857,the daily biotech pulse heron pain drug review extended disappointment for teva in tourette syndrome study,https://www.benzinga.com/general/biotech/20/02/15372320/the-daily-biotech-pulse-heron-pain-drug-review-extended-disappointment-for-teva-in-tourette-syndr,Shanthi Rexaline,2020-02-20 00:00:00,MRK,1,1,1,0,0,1,1,1,1,0.12104999999999999
850858,elanco signs agreement with merck animal health to divest worldwide rights for vecoxan,https://www.benzinga.com/general/biotech/20/02/15369445/elanco-signs-agreement-with-merck-animal-health-to-divest-worldwide-rights-for-vecoxan,Benzinga Newsdesk,2020-02-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
850859,the daily biotech pulse fda snub for merck priority review for roches tecentriq sbla,https://www.benzinga.com/general/biotech/20/02/15362093/the-daily-biotech-pulse-fda-snub-for-merck-priority-review-for-roches-tecentriq-sbla,Shanthi Rexaline,2020-02-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.28925
850860,merck receives crl from fda for sblas for keytruda sixweek dosing schedule,https://www.benzinga.com/news/20/02/15362117/merck-receives-crl-from-fda-for-sblas-for-keytruda-six-week-dosing-schedule,Charles Gross,2020-02-19 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
850861,the week ahead in biotech baudax bio merck esperion await fda decisions,https://www.benzinga.com/general/biotech/20/02/15315400/the-week-ahead-in-biotech-baudax-bio-merck-esperion-await-fda-decisions,Shanthi Rexaline,2020-02-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.55135
850862,ervebo now registered in four african countries within days of reference country approval and who prequalification,https://www.benzinga.com/news/20/02/15338164/ervebo-now-registered-in-four-african-countries-within-90-days-of-reference-country-approval-and-who,Benzinga Newsdesk,2020-02-14 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.7383500000000001
850863,merck says keytruda in combination with chemotherapy met primary endpoint of progressionfree survival as firstline treatment for metastatic triplenegative breast cancer,https://www.benzinga.com/general/biotech/20/02/15308229/merck-says-keytruda-in-combination-with-chemotherapy-met-primary-endpoint-of-progression-free-sur,Benzinga Newsdesk,2020-02-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
850864,the daily biotech pulse logicbio slapped with clinical hold agile inks debt deal ahead of twirla approval gilead builds stake in sierra oncology,https://www.benzinga.com/general/biotech/20/02/15296635/the-daily-biotech-pulse-logicbio-slapped-with-clinical-hold-agile-inks-debt-deal-ahead-of-twirla-,Shanthi Rexaline,2020-02-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.57655
850865,kalvista pharma reports option deal between co merck related to intravitreal diabetic macular edema candidate kvd future oral dme molecules has expired,https://www.benzinga.com/news/20/02/15294077/kalvista-pharma-reports-option-deal-between-co-merck-related-to-intravitreal-diabetic-macular-edema,Benzinga Newsdesk,2020-02-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
850866,the week ahead in biotech smidcap earnings in the spotlight,https://www.benzinga.com/general/biotech/20/02/15280585/the-week-ahead-in-biotech-smid-cap-earnings-in-the-spotlight,Shanthi Rexaline,2020-02-09 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
850867,barrons picks and pans gm kraft heinz tesla under armour and more,https://www.benzinga.com/media/20/02/15285621/barrons-picks-and-pans-gm-kraft-heinz-tesla-under-armour-and-more,Nelson Hem,2020-02-08 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850868,the daily biotech pulse assertio to sell opioid pain drug milestone payment for aduro myriad genetics ceo resigns,https://www.benzinga.com/general/biotech/20/02/15277159/the-daily-biotech-pulse-assertio-to-sell-opioid-pain-drug-milestone-payment-for-aduro-myriad-gene,Shanthi Rexaline,2020-02-07 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.15960000000000002
850869,twitter up tesla down strong user numbers help twtr but tsla selling continues,https://www.benzinga.com/news/earnings/20/02/15269601/twitter-up-tesla-down-strong-user-numbers-help-twtr-but-tsla-selling-continues,JJ Kinahan,2020-02-06 00:00:00,MRK,1,0,1,1,1,1,1,1,0,0.7294
850870,ubs maintains buy on merck co lowers price target to ,https://www.benzinga.com/news/20/02/15267721/ubs-maintains-buy-on-merck-co-lowers-price-target-to-96,Vick Meyer,2020-02-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
850871,merck to spin off slowgrowing womens health legacy biosimilars businesses what you need to know,https://www.benzinga.com/analyst-ratings/analyst-color/20/02/15259072/merck-to-spin-off-slow-growing-womens-health-legacy-biosimilars-businesses-what-you,Shanthi Rexaline,2020-02-05 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850872,earnings bonanza results keep pouring in with investors looking over merck disney,https://www.benzinga.com/news/earnings/20/02/15258839/earnings-bonanza-results-keep-pouring-in-with-investors-looking-over-merck-disney,JJ Kinahan,2020-02-05 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
850873,merck co shares are trading lower after the company reported worsethanexpected q sales results,https://www.benzinga.com/wiim/20/02/15257559/merck-co-shares-are-trading-lower-after-the-company-reported-worse-than-expected-q4-sales-results,Benzinga Newsdesk,2020-02-05 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.5
850874,the daily biotech pulse merck spins off slowgrowth businesses ziopharm announces offering phasebio data,https://www.benzinga.com/general/biotech/20/02/15256778/the-daily-biotech-pulse-merck-spins-off-slow-growth-businesses-ziopharm-announces-offering-phaseb,Shanthi Rexaline,2020-02-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850875,merck reports mixed q earnings,https://www.benzinga.com/news/earnings/20/02/15256790/merck-reports-mixed-q4-earnings,Tanzeel Akhtar,2020-02-05 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
850876,merck sees fy adj eps vs est sales bb vs b est,https://www.benzinga.com/news/20/02/15256560/merck-sees-fy20-adj-eps-5-62-5-77-vs-5-61-est-sales-48-8b-50-3b-vs-49-53b-est,Benzinga Newsdesk,2020-02-05 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
850877,merck co q adj eps beats estimate sales b miss b estimate,https://www.benzinga.com/news/earnings/20/02/15256557/merck-co-q4-adj-eps-1-16-beats-1-15-estimate-sales-11-87b-miss-11-98b-estimate,Benzinga Newsdesk,2020-02-05 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.42345
850878,merck to spin off products from its womens health trusted legacy brands and biosimilars business into new independent publiclytraded co co says transaction enables it to achieve b n operating efficiencies by ,https://www.benzinga.com/news/20/02/15256552/merck-to-spin-off-products-from-its-womens-health-trusted-legacy-brands-and-biosimilars-business-int,Benzinga Newsdesk,2020-02-05 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.8453999999999999
850879, stocks to watch for february ,https://www.benzinga.com/news/earnings/20/02/15256099/10-stocks-to-watch-for-february-5-2020,Lisa Levin,2020-02-05 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
850880,earnings scheduled for february ,https://www.benzinga.com/news/earnings/20/02/15255970/earnings-scheduled-for-february-5-2020,Lisa Levin,2020-02-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850881,attention biotech investors mark your calendar for these february pdufa dates,https://www.benzinga.com/general/biotech/20/02/15200922/attention-biotech-investors-mark-your-calendar-for-these-february-pdufa-dates,Shanthi Rexaline,2020-02-03 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850882,merck co shares are trading higher after the companys recarbrio supplemental new drug application was accepted for fda review,https://www.benzinga.com/wiim/20/02/15237949/merck-co-shares-are-trading-higher-after-the-companys-recarbrio-supplemental-new-drug-application-wa,Benzinga Newsdesk,2020-02-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
850883,surprise surprise stocks wearing their rally hats despite china market tanking,https://www.benzinga.com/news/earnings/20/02/15236843/surprise-surprise-stocks-wearing-their-rally-hats-despite-china-market-tanking,JJ Kinahan,2020-02-03 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.74695
850884,mercks recarbrio supplemental new drug application accepted for fda review,https://www.benzinga.com/news/20/02/15234796/mercks-recarbrio-supplemental-new-drug-application-accepted-for-fda-review,Benzinga Newsdesk,2020-02-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6366
850885,the week ahead in biotech merck bristolmyers earnings conference presentations in focus,https://www.benzinga.com/general/biotech/20/02/15229115/the-week-ahead-in-biotech-merck-bristol-myers-earnings-conference-presentations-in-focus,Shanthi Rexaline,2020-02-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850886,position scrimmage coronavirus endofmonth profit taking influencing markets,https://www.benzinga.com/news/earnings/20/01/15227238/position-scrimmage-coronavirus-end-of-month-profit-taking-influencing-markets,JJ Kinahan,2020-01-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7202
850887,february market outlook coronavirus dc proceedings earnings season could mean volatility,https://www.benzinga.com/news/earnings/20/01/15211766/february-market-outlook-coronavirus-d-c-proceedings-earnings-season-could-mean-volatility,JJ Kinahan,2020-01-29 00:00:00,MRK,1,1,0,1,1,0,1,1,1,0.5
850888,turnaround tuesday stocks look to bounce back as apple earnings loom later,https://www.benzinga.com/news/earnings/20/01/15198490/turnaround-tuesday-stocks-look-to-bounce-back-as-apple-earnings-loom-later,JJ Kinahan,2020-01-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.38685
850889,a peek into the markets us stock futures down dow futures tumble over points,https://www.benzinga.com/news/earnings/20/01/15187293/a-peek-into-the-markets-us-stock-futures-down-dow-futures-tumble-over-400-points,Lisa Levin,2020-01-27 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
850890,mercks dificid receives fda approval to treat clostridioides in children aged six months and older,https://www.benzinga.com/news/20/01/15187141/mercks-dificid-receives-fda-approval-to-treat-clostridioides-in-children-aged-six-months-and-older,Benzinga Newsdesk,2020-01-27 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.85015
850891,shares of several companies in the healthcare and pharmaceutical space are trading lower not currently seeing sectorspecific news note the global spread of the wuhan coronavirus has caused equities across to sell off,https://www.benzinga.com/wiim/20/01/15181653/shares-of-several-companies-in-the-healthcare-and-pharmaceutical-space-are-trading-lower-not-current,Benzinga Newsdesk,2020-01-24 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.5
850892,the daily biotech pulse fda nod for epizyme sonoma explores options for dermatology business roches cancer drug flunks study,https://www.benzinga.com/general/biotech/20/01/15178675/the-daily-biotech-pulse-fda-nod-for-epizyme-sonoma-explores-options-for-dermatology-business-roch,Shanthi Rexaline,2020-01-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.09899999999999998
850893,ubs maintains buy on merck co raises price target to ,https://www.benzinga.com/news/20/01/15172467/ubs-maintains-buy-on-merck-co-raises-price-target-to-99,Vick Meyer,2020-01-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850894,fda accepts regulatory submission of supplemental new drug application for mercks lynparza in hrrmutated metastatic castrationresistant prostate cancer and grants priority review,https://www.benzinga.com/general/biotech/20/01/15152496/fda-accepts-regulatory-submission-of-supplemental-new-drug-application-for-mercks-lynparza-in-hrr,Benzinga Newsdesk,2020-01-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.352
850895,the week ahead in biotech focus on epizyme merck ahead of pdufa dates jj to kickstart big pharma earnings,https://www.benzinga.com/general/biotech/20/01/15136889/the-week-ahead-in-biotech-focus-on-epizyme-merck-ahead-of-pdufa-dates-j-j-to-kickstart-big-pharma,Shanthi Rexaline,2020-01-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
850896,cannabis media company the fresh toast expands again announces its now cash positive,https://www.benzinga.com/markets/cannabis/20/01/15143785/cannabis-media-company-the-fresh-toast-expands-again-says-its-cash-positive,Javier Hasse,2020-01-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8714999999999999
850897,astrazeneca and mercks supplemental new drug application for lynparza granted priority review by the fda,https://www.benzinga.com/news/20/01/15111153/astrazeneca-and-mercks-supplemental-new-drug-application-for-lynparza-granted-priority-review-by-the,Benzinga Newsdesk,2020-01-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
850898,california gov gavin newsom wants the state to become the first to create its own generic drug label an attempt to create more competition and bring down prices axios from earlier,https://www.benzinga.com/general/biotech/20/01/15106641/california-gov-gavin-newsom-wants-the-state-to-become-the-first-to-create-its-own-generic-drug-la,Benzinga Newsdesk,2020-01-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
850899,the daily biotech pulse mercks keytruda snags another fda approval dbv announces positive peanut allergy study findings applied genetic soars on trial results,https://www.benzinga.com/general/biotech/20/01/15097311/the-daily-biotech-pulse-mercks-keytruda-snags-another-fda-approval-dbv-announces-positive-peanut-,Shanthi Rexaline,2020-01-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.88585
850900,merck reports fda approval of keytruda for patients bcgunresponsive highrisk nonmuscle invasive bladder cancer with carcinoma in situ with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy,https://www.benzinga.com/news/20/01/15094987/merck-reports-fda-approval-of-keytruda-for-patients-bcg-unresponsive-high-risk-non-muscle-invasive-b,Benzinga Newsdesk,2020-01-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
850901,merck announces fda approves pembrolizumab for bcgunresponsive highrisk nonmuscle invasive bladder cancer,https://www.benzinga.com/news/20/01/15093876/merck-announces-fda-approves-pembrolizumab-for-bcg-unresponsive-high-risk-non-muscle-invasive-bladde,Benzinga Newsdesk,2020-01-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.29905000000000004
850902,the daily biotech pulse xeris jumps on positive data mixed results for mercks keytrudachemo combo in lung cancer intracellular announces offering,https://www.benzinga.com/general/biotech/20/01/15082070/the-daily-biotech-pulse-xeris-jumps-on-positive-data-mixed-results-for-mercks-keytruda-chemo-comb,Shanthi Rexaline,2020-01-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.39885
850903,mercks announces phase of keynote study did not meet other dual primary endpoint of overall survival results to be presented at upcoming medical meeting,https://www.benzinga.com/news/20/01/15079340/mercks-announces-phase-3-of-keynote-604-study-did-not-meet-other-dual-primary-endpoint-of-overall-su,Benzinga Newsdesk,2020-01-06 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
850904,merck buys exclusive global license from taiho and astex for its small molecule inhibitor candidates for m upfront and milestone payments,https://www.benzinga.com/news/20/01/15074244/merck-buys-exclusive-global-license-from-taiho-and-astex-for-its-small-molecule-inhibitor-candidates,Benzinga Newsdesk,2020-01-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5258
850905,speaker of the house nancy pelosi says enough is enough housedemocrats passed the bipartisan lowerdrugcosts now act last year to stop big pharma from charging americans more for our medicines than what they charge for the same drugs overseas,https://www.benzinga.com/general/health-care/20/01/15064126/speaker-of-the-house-nancy-pelosi-says-enough-is-enough-housedemocrats-passed-the-bipartisan-,Benzinga Newsdesk,2020-01-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.352
850906,attention biotech investors mark your calendar for these january pdufa dates,https://www.benzinga.com/general/biotech/20/01/15053527/attention-biotech-investors-mark-your-calendar-for-these-january-pdufa-dates,Shanthi Rexaline,2020-01-01 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
850907,merckastrazenecas lynparza snags fda nod for pancreatic cancer,https://www.benzinga.com/general/biotech/19/12/15051634/merck-astrazenecas-lynparza-snags-fda-nod-for-pancreatic-cancer,Shanthi Rexaline,2019-12-30 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.17015000000000002
850908,mercks lynparza approved by fda as firstline maintenance treatment of germline brcamutated metastatic pancreatic cancer,https://www.benzinga.com/general/biotech/19/12/15050452/mercks-lynparza-approved-by-fda-as-first-line-maintenance-treatment-of-germline-brca-mutated-meta,Benzinga Newsdesk,2019-12-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.30910000000000004
850909,astrazeneca says fda approved lynparza for pancreatic cancer,https://www.benzinga.com/news/19/12/15050194/astrazeneca-says-fda-approved-lynparza-for-pancreatic-cancer,Charles Gross,2019-12-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.30910000000000004
850910,week ahead in biotech pdufa date ahead for astra zeneca mercks lynparza pending clinical readouts in focus,https://www.benzinga.com/general/biotech/19/12/15047719/week-ahead-in-biotech-pdufa-date-ahead-for-astra-zeneca-mercks-lynparza-pending-clinical-readouts,Shanthi Rexaline,2019-12-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850911,merck co option alert jun calls sweep above ask vs oi earnings before open est ref,https://www.benzinga.com/markets/options/19/12/15047627/merck-co-option-alert-jun-19-92-5-calls-sweep-49-above-ask-4764-4-107-vs-5293-oi-earnings-131-bef,Charles Gross,2019-12-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
850912,a perspective on biopharmas record ma run in ,https://www.benzinga.com/general/biotech/19/12/14981726/a-perspective-on-biopharmas-record-m-a-run-in-2019,Shanthi Rexaline,2019-12-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850913,how the dow jones industrial average changed over the past decade,https://www.benzinga.com/general/education/19/12/15027623/how-the-dow-jones-industrial-average-changed-over-the-past-decade,Wayne Duggan,2019-12-22 00:00:00,MRK,1,2,1,0,1,0,1,1,1,0.5
850914,stocks that hit week highs on friday,https://www.benzinga.com/news/19/12/15026655/stocks-that-hit-52-week-highs-on-friday,Lisa Levin,2019-12-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850915,newlink genetics announces fda approval of ebola vaccine v,https://www.benzinga.com/general/biotech/19/12/15025804/newlink-genetics-announces-fda-approval-of-ebola-vaccine-v920,Benzinga Newsdesk,2019-12-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
850916,the daily biotech pulse axovant surges on gene therapy study results fda approves mercks ebola vaccine abeona announces offering,https://www.benzinga.com/general/biotech/19/12/15023225/the-daily-biotech-pulse-axovant-surges-on-gene-therapy-study-results-fda-approves-mercks-ebola-va,Shanthi Rexaline,2019-12-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
850917,merck reports fda approval for ervebo,https://www.benzinga.com/news/19/12/15024204/merck-reports-fda-approval-for-ervebo,Benzinga Newsdesk,2019-12-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
850918,merck reports keytruda approved in japan for new firstline indications across advanced renal cell carcinoma recurrent or distant metastatic head and neck cancer,https://www.benzinga.com/news/19/12/15023810/merck-reports-keytruda-approved-in-japan-for-3-new-first-line-indications-across-advanced-renal-cell,Benzinga Newsdesk,2019-12-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
850919,fda approves first ebola vaccine,https://www.benzinga.com/news/19/12/15022881/fda-approves-first-ebola-vaccine,Amit Nag,2019-12-20 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.70095
850920,stocks that hit week highs on thursday,https://www.benzinga.com/news/19/12/15018550/stocks-that-hit-52-week-highs-on-thursday,Lisa Levin,2019-12-19 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
850921,the daily biotech pulse seattle genetics bladder cancer drug gets fda nod paratek wins contract for antibiotic,https://www.benzinga.com/general/biotech/19/12/15015890/the-daily-biotech-pulse-seattle-genetics-bladder-cancer-drug-gets-fda-nod-paratek-wins-contract-f,Shanthi Rexaline,2019-12-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.41105
850922,the daily biotech pulse positive adcom verdict for merck homology medicine slips on mixed gene therapy efficacy data,https://www.benzinga.com/general/biotech/19/12/15008477/the-daily-biotech-pulse-positive-adcom-verdict-for-merck-homology-medicine-slips-on-mixed-gene-th,Shanthi Rexaline,2019-12-18 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.81845
850923,merck reports fdas oncologic drugs adcom recommends keytruda for treatment of certain patients with highrisk nonmuscle invasive bladder cancer,https://www.benzinga.com/news/19/12/15007127/merck-reports-fdas-oncologic-drugs-adcom-recommends-keytruda-for-treatment-of-certain-patients-with,Benzinga Newsdesk,2019-12-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.32999999999999996
850924,the daily biotech pulse roche gets us antitrust clearance for spark purchase an orphan drug designation for prevail dynavax names ceo,https://www.benzinga.com/general/biotech/19/12/15000539/the-daily-biotech-pulse-roche-gets-us-antitrust-clearance-for-spark-purchase-an-orphan-drug-desig,Shanthi Rexaline,2019-12-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.61315
850925,the week ahead in biotech avadel epizyme in focus in a quiet week,https://www.benzinga.com/general/biotech/19/12/14982366/the-week-ahead-in-biotech-avadel-epizyme-in-focus-in-a-quiet-week,Shanthi Rexaline,2019-12-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850926,oncosec reports interim data from keynote study evaluation tavo in combination with keytruda,https://www.benzinga.com/general/biotech/19/12/14987242/oncosec-reports-interim-data-from-keynote-890-study-evaluation-tavo-in-combination-with-keytruda,Benzinga Newsdesk,2019-12-13 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850927,the daily biotech pulse second times the charm for sarepta pfizers xeljanz snags third approval newlink genetics rejects competing offer,https://www.benzinga.com/general/biotech/19/12/14985701/the-daily-biotech-pulse-second-times-the-charm-for-sarepta-pfizers-xeljanz-snags-third-approval-n,Shanthi Rexaline,2019-12-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
850928,ema reports positive opinion for mercks recarbrio by chmp for treatment of infections from aerobic gramnegative organisms in adults,https://www.benzinga.com/news/19/12/14986314/ema-reports-positive-opinion-for-mercks-recarbrio-by-chmp-for-treatment-of-infections-from-aerobic-g,Benzinga Newsdesk,2019-12-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
850929,traders circulating materials from mercks keytruda presentation at esmo,https://www.benzinga.com/general/biotech/19/12/14981555/traders-circulating-materials-from-mercks-keytruda-presentation-at-esmo,Benzinga Newsdesk,2019-12-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850930,stocks that hit week highs on thursday,https://www.benzinga.com/news/19/12/14980573/stocks-that-hit-52-week-highs-on-thursday,Lisa Levin,2019-12-12 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
850931,merck highlights exploratory analysis of keytruda which showed improved overall survival as monotherapy for the firstline treatment of metastatic nonsmall cell lung cancer regardless of kras mutational status,https://www.benzinga.com/news/19/12/14978211/merck-highlights-exploratory-analysis-of-keytruda-which-showed-improved-overall-survival-as-monother,Benzinga Newsdesk,2019-12-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
850932,cantor fitzgerald says thinks arqule may see other bidders but thinks merck makes a great strategic fit says thinks mercks proposed acquisition is fair,https://www.benzinga.com/analyst-ratings/analyst-color/19/12/14974757/cantor-fitzgerald-says-thinks-arqule-may-see-other-bidders-but-thinks-merck-makes-a,Benzinga Newsdesk,2019-12-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.9580500000000001
850933,the daily biotech pulse correvio faces fda panel rejection iterums antibiotic trial narrowly misses primary endpoint,https://www.benzinga.com/general/biotech/19/12/14969305/the-daily-biotech-pulse-correvio-faces-fda-panel-rejection-iterums-antibiotic-trial-narrowly-miss,Shanthi Rexaline,2019-12-11 00:00:00,MRK,1,1,0,0,0,0,1,0,0,0.17015000000000002
850934,stocks that hit week highs on tuesday,https://www.benzinga.com/news/19/12/14966014/stocks-that-hit-52-week-highs-on-tuesday,Lisa Levin,2019-12-10 00:00:00,MRK,1,2,0,1,0,1,1,1,1,0.5
850935,the daily biotech pulse ash meeting wraps fast track designation for equillium pfizer to buy m in contrafect shares,https://www.benzinga.com/general/biotech/19/12/14960785/the-daily-biotech-pulse-ash-meeting-wraps-fast-track-designation-for-equillium-pfizer-to-buy-3m-i,Shanthi Rexaline,2019-12-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
850936, biggest movers from yesterday,https://www.benzinga.com/news/19/12/14960489/80-biggest-movers-from-yesterday,Lisa Levin,2019-12-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850937,midafternoon market update dow falls points xbiotech shares spike higher,https://www.benzinga.com/m-a/19/12/14957024/mid-afternoon-market-update-dow-falls-90-points-xbiotech-shares-spike-higher,Lisa Levin,2019-12-09 00:00:00,MRK,1,0,0,1,0,0,1,1,1,0.648
850938,premarket prep recap small biotech firms looking healthy street fades macys downgrade,https://www.benzinga.com/trading-ideas/long-ideas/19/12/14956323/premarket-prep-recap-small-biotech-firms-looking-healthy-street-fades-macys-downgrade,Joel Elconin,2019-12-09 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.70095
850939, stocks moving in mondays midday session,https://www.benzinga.com/news/19/12/14956144/48-stocks-moving-in-mondays-mid-day-session,Lisa Levin,2019-12-09 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
850940,midday market update synthorx jumps following acquisition news biocept shares plunge,https://www.benzinga.com/m-a/19/12/14955928/mid-day-market-update-synthorx-jumps-following-acquisition-news-biocept-shares-plunge,Lisa Levin,2019-12-09 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.648
850941,midmorning market update markets mixed merck to acquire arqule for share,https://www.benzinga.com/m-a/19/12/14954838/mid-morning-market-update-markets-mixed-merck-to-acquire-arqule-for-20share,Lisa Levin,2019-12-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
850942,kalvista shares sink on failed midstage study of diabetic macular edema drug,https://www.benzinga.com/general/biotech/19/12/14953530/kalvista-shares-sink-on-failed-mid-stage-study-of-daibetic-macular-edema-drug,Shanthi Rexaline,2019-12-09 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.3634
850943,benzinga pros top stocks to watch for mon dec mrk pcg m dplo chwy,https://www.benzinga.com/pre-market-outlook/19/12/14954070/benzinga-pros-top-5-stocks-to-watch-for-mon-dec-9-2019-mrk-pcg-m-dplo-chwy,Benzinga Newsdesk,2019-12-09 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.60115
850944, stocks moving in mondays premarket session,https://www.benzinga.com/news/19/12/14953041/20-stocks-moving-in-mondays-pre-market-session,Lisa Levin,2019-12-09 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
850945,arqule to be acquired by merck for b,https://www.benzinga.com/m-a/19/12/14952879/arqule-to-be-acquired-by-merck-for-2-7b,Tanzeel Akhtar,2019-12-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850946,a peek into the markets us stock futures down crude oil falls ,https://www.benzinga.com/news/19/12/14952881/a-peek-into-the-markets-us-stock-futures-down-crude-oil-falls-1,Lisa Levin,2019-12-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.21405000000000002
850947,arqule to be acquired by merck for share cash,https://www.benzinga.com/m-a/19/12/14952567/arqule-to-be-acquired-by-merck-for-20share-cash,Benzinga Newsdesk,2019-12-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
850948,the week ahead in biotech ash presentations pick up steam correvio awaits adcom ruling,https://www.benzinga.com/general/biotech/19/12/14947992/the-week-ahead-in-biotech-ash-presentations-pick-up-steam-correvio-awaits-adcom-ruling,Shanthi Rexaline,2019-12-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5386
850949,stocks that hit week highs on friday,https://www.benzinga.com/news/19/12/14946306/stocks-that-hit-52-week-highs-on-friday,Lisa Levin,2019-12-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850950,the daily biotech pulse cassava gains on alzheimers presentation bristolmyers hikes dividend,https://www.benzinga.com/general/biotech/19/12/14943789/the-daily-biotech-pulse-cassava-gains-on-alzheimers-presentation-bristol-myers-hikes-dividend,Shanthi Rexaline,2019-12-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.67
850951,stocks that hit week highs on thursday,https://www.benzinga.com/markets/cryptocurrency/19/12/14938471/stocks-that-hit-52-week-highs-on-thursday,Lisa Levin,2019-12-05 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
850952,the daily biotech pulse aurinia rips higher on positive readout sesen bio on track for vicinium bla submission,https://www.benzinga.com/general/biotech/19/12/14935535/the-daily-biotech-pulse-aurinia-rips-higher-on-positive-readout-sesen-bio-on-track-for-vicinium-b,Shanthi Rexaline,2019-12-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
850953,astrazeneca merck announce lynparza approved in china as a stline maintenance therapy in brcamutated advanced ovarian cancer,https://www.benzinga.com/news/19/12/14935675/astrazeneca-merck-announce-lynparza-approved-in-china-as-a-1st-line-maintenance-therapy-in-brca-muta,Charles Gross,2019-12-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
850954,stocks that hit week highs on wednesday,https://www.benzinga.com/news/19/12/14930298/stocks-that-hit-52-week-highs-on-wednesday,Lisa Levin,2019-12-04 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850955,the daily biotech pulse astellas to buy audentes for b applied genetics chief medical officer quits axsome aces midstage trial,https://www.benzinga.com/general/biotech/19/12/14918916/the-daily-biotech-pulse-astellas-to-buy-audentes-for-3b-applied-genetics-chief-medical-officer-qu,Shanthi Rexaline,2019-12-03 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
850956,shares of several healthcare stocks are trading lower as us equities dip following escalating uschina tensions over hong kong us stocks further fell on worsethanexpected manufacturing data,https://www.benzinga.com/wiim/19/12/14913297/shares-of-several-healthcare-stocks-are-trading-lower-as-us-equities-dip-following-escalating-us-chi,Benzinga Newsdesk,2019-12-02 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.29905000000000004
850957,stocks that hit week highs on monday,https://www.benzinga.com/news/19/12/14912587/stocks-that-hit-52-week-highs-on-monday,Lisa Levin,2019-12-02 00:00:00,MRK,1,2,0,0,0,0,1,1,1,0.5
850958,seattle genetics announces collaboration with merck to evaluate its enfortumab in combination with keytruda,https://www.benzinga.com/news/19/12/14910986/seattle-genetics-announces-collaboration-with-merck-to-evaluate-its-enfortumab-in-combination-with-k,Benzinga Newsdesk,2019-12-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
850959,mercks keytruda granted priority review by the fda for patients with highrisk nonmuscle invasive bladder cancer,https://www.benzinga.com/news/19/12/14910250/mercks-keytruda-granted-priority-review-by-the-fda-for-patients-with-high-risk-non-muscle-invasive-b,Benzinga Newsdesk,2019-12-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.23665000000000003
850960,national business daily reports drugmakers including johnson johnson roche novartis and merck have agreed to massively cut the prices of some drugs to get included in chinas medical reimbursement list,https://www.benzinga.com/news/19/11/14904233/national-business-daily-reports-drugmakers-including-johnson-johnson-roche-novartis-and-merck-have-a,Charles Gross,2019-11-29 00:00:00,MRK,1,1,0,1,0,0,0,0,1,0.5
850961,stocks that hit week highs on wednesday,https://www.benzinga.com/news/19/11/14895231/stocks-that-hit-52-week-highs-on-wednesday,Lisa Levin,2019-11-27 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850962,the daily biotech pulse tonix says no surprises in fda meeting minutes aravive offering fda nod for qiagen,https://www.benzinga.com/general/biotech/19/11/14892362/the-daily-biotech-pulse-tonix-says-no-surprises-in-fda-meeting-minutes-aravive-offering-fda-nod-f,Shanthi Rexaline,2019-11-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.4614
850963,merck reports keytruda now approved in china for firstline treatment of metastatic squamous nonsmall cell lung cancer in combination with chemotherapy,https://www.benzinga.com/news/19/11/14883417/merck-reports-keytruda-now-approved-in-china-for-first-line-treatment-of-metastatic-squamous-non-sma,Benzinga Newsdesk,2019-11-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.30910000000000004
850964,astrazeneca ceo closing in on a cancer cure,https://www.benzinga.com/general/biotech/19/11/14857223/astrazeneca-ceo-closing-in-on-a-cancer-cure,Elizabeth Balboa,2019-11-22 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.17015000000000002
850965,trump says he will release a plan to let states import prescription drugs which are much cheaper,https://www.benzinga.com/general/politics/19/11/14868610/trump-says-he-will-release-a-plan-to-let-states-import-prescription-drugs-which-are-much-cheaper,Benzinga Newsdesk,2019-11-22 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
850966,european commission approves two new regimens of mercks keytruda as firstline treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma,https://www.benzinga.com/general/biotech/19/11/14846717/european-commission-approves-two-new-regimens-of-mercks-keytruda-as-first-line-treatment-for-meta,Benzinga Newsdesk,2019-11-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
850967,merck raises quarterly dividend from to share,https://www.benzinga.com/news/19/11/14841645/merck-raises-quarterly-dividend-from-0-55-to-0-61share,Benzinga Newsdesk,2019-11-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
850968,merck and bayers investigational drug vericiguat meets primary endpoint in phase study of patients with worsening chronic heart failure,https://www.benzinga.com/news/19/11/14827609/merck-and-bayers-investigational-drug-vericiguat-meets-primary-endpoint-in-phase-3-study-of-patients,Benzinga Newsdesk,2019-11-18 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.1285
850969,merck reports its animal health unit announced us approval of bravecto plus,https://www.benzinga.com/news/19/11/14819044/merck-reports-its-animal-health-unit-announced-us-approval-of-bravecto-plus,Benzinga Newsdesk,2019-11-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
850970,astrazeneca merck report fda acceptance of regulatory submission for new drug application for selumetinib in neurofibromatosis type priority review granted,https://www.benzinga.com/news/19/11/14806339/astrazeneca-merck-report-fda-acceptance-of-regulatory-submission-for-new-drug-application-for-selume,Benzinga Newsdesk,2019-11-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8062
850971,astrazeneca announces fda accepts nda for selumetinib,https://www.benzinga.com/news/19/11/14805286/astrazeneca-announces-fda-accepts-nda-for-selumetinib,Charles Gross,2019-11-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
850972,morgan stanley maintains overweight on merck co raises price target to ,https://www.benzinga.com/news/19/11/14796406/morgan-stanley-maintains-overweight-on-merck-co-raises-price-target-to-95,Vick Meyer,2019-11-13 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.3194
850973,the daily biotech pulse merck goes shopping nuvectra files for bankruptcy protection opiant rips higher,https://www.benzinga.com/general/biotech/19/11/14794260/the-daily-biotech-pulse-merck-goes-shopping-nuvectra-files-for-bankruptcy-protection-opiant-rips-,Shanthi Rexaline,2019-11-13 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
850974,merck reports its ervebo granted conditional approval in eu,https://www.benzinga.com/news/19/11/14779571/merck-reports-its-ervebo-granted-conditional-approval-in-eu,Benzinga Newsdesk,2019-11-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81245
850975,nextcure shares give back some gains after data readout,https://www.benzinga.com/general/biotech/19/11/14777526/nextcure-shares-give-back-some-gains-after-data-readout,Shanthi Rexaline,2019-11-11 00:00:00,MRK,1,0,0,1,1,1,1,1,1,0.7787
850976,the daily biotech pulse therapix calls off merger alimeras reverse split biotechs to debut,https://www.benzinga.com/general/biotech/19/11/14765419/the-daily-biotech-pulse-therapix-calls-off-merger-alimeras-reverse-split-2-biotechs-to-debut,Shanthi Rexaline,2019-11-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850977,biotech stock on the radar alkermes at a crossroads,https://www.benzinga.com/general/biotech/19/11/14714299/biotech-stock-on-the-radar-alkermes-at-the-crossroads,Shanthi Rexaline,2019-11-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850978,astrazeneca named the most innovative global pharma company,https://www.benzinga.com/general/biotech/19/11/14734171/astrazeneca-named-the-most-innovative-global-pharma-company,Shanthi Rexaline,2019-11-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7463500000000001
850979,biolinerx announces data showing bl in combination with keytruda shows clinical activity in heavily pretreated metastatic pancreatic cancer patients,https://www.benzinga.com/general/biotech/19/11/14732106/biolinerx-announces-data-showing-bl-8040-in-combination-with-keytruda-shows-clinical-activity-in-,luke@benzinga.com,2019-11-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3634
850980,the week ahead in biotech smidcap earnings deluge sitc conference in the spotlight,https://www.benzinga.com/general/biotech/19/11/14704372/the-week-ahead-in-biotech-smid-cap-earnings-deluge-sitc-conference-in-the-spotlight,Shanthi Rexaline,2019-11-03 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
850981,wetrader competition round four wrapup,https://www.benzinga.com/fintech/19/11/14716207/wetrader-competition-round-four-wrap-up,Chris Dier-Scalise,2019-11-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
850982,us appeals court upholds lower court ruling that tossed b jury verdict for merck in patent case against gilead,https://www.benzinga.com/general/biotech/19/10/14690986/us-appeals-court-upholds-lower-court-ruling-that-tossed-2-54b-jury-verdict-for-merck-in-patent-ca,Benzinga Newsdesk,2019-10-30 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.42345
850983,decision day fed on tap later followed by apple facebook after close,https://www.benzinga.com/news/earnings/19/10/14690963/decision-day-fed-on-tap-later-followed-by-apple-facebook-after-close,JJ Kinahan,2019-10-30 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850984,alphabet misses on earnings but drugmakers mastercard beat expectations,https://www.benzinga.com/news/earnings/19/10/14682108/alphabet-misses-on-earnings-but-drugmakers-mastercard-beat-expectations,JJ Kinahan,2019-10-29 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.4423
850985, healthcare stocks moving in tuesdays premarket session,https://www.benzinga.com/news/19/10/14680305/28-healthcare-stocks-moving-in-tuesdays-pre-market-session,Lisa Levin,2019-10-29 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
850986,merck co inc sees increased pricing pressure in says demand for gardasil continues to outpace supply,https://www.benzinga.com/general/biotech/19/10/14680054/merck-co-inc-sees-increased-pricing-pressure-in-2020-says-demand-for-gardasil-continues-to-outpac,Benzinga Newsdesk,2019-10-29 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.42345
850987,pharma earnings merck pfizer trade higher on q beats,https://www.benzinga.com/general/biotech/19/10/14679427/pharma-earnings-merck-pfizer-trade-higher-on-q3-beats,Tanzeel Akhtar,2019-10-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
850988,the daily biotech pulse mirati tastes success with kras inhibitor rochespark deal delayed further morphosys halts study,https://www.benzinga.com/general/biotech/19/10/14678544/the-daily-biotech-pulse-mirati-tastes-success-with-kras-inhibitor-roche-spark-deal-delayed-furthe,Shanthi Rexaline,2019-10-29 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.6806
850989,merck co shares are trading higher after the company reported betterthanexpected q eps and sales results the company also issued fy eps and sales guidance above analyst estimates,https://www.benzinga.com/markets/wiim/19/10/14679325/merck-co-shares-are-trading-higher-after-the-company-reported-better-than-expected-q3-eps-and-sales,Benzinga Newsdesk,2019-10-29 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.648
850990,merck sees fy adj eps vs est sales bb vs b est,https://www.benzinga.com/news/19/10/14678750/merk-sees-fy19-adj-eps-5-12-5-17-vs-4-92-est-sales-46-5b-47-0b-vs-45-98b-est,Benzinga Newsdesk,2019-10-29 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
850991,merck co q adj eps beats estimate sales b beat b estimate,https://www.benzinga.com/news/earnings/19/10/14678746/merck-co-q3-adj-eps-1-51-beats-1-24-estimate-sales-12-4b-beat-11-63b-estimate,Benzinga Newsdesk,2019-10-29 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
850992, stocks to watch for october ,https://www.benzinga.com/news/earnings/19/10/14678274/12-stocks-to-watch-for-october-29-2019,Lisa Levin,2019-10-29 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
850993,earnings scheduled for october ,https://www.benzinga.com/news/earnings/19/10/14678211/earnings-scheduled-for-october-29-2019,Lisa Levin,2019-10-29 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
850994,more earnings and a fed decision in week four of the wetrader competition,https://www.benzinga.com/news/earnings/19/10/14673747/more-earnings-and-a-fed-decision-in-week-four-of-the-wetrader-competition,Chris Dier-Scalise,2019-10-28 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850995,merck shares fall following report astrazeneca trial of imfinzi imfinzi plus tremelimumab delayed disease progression in phase trial,https://www.benzinga.com/news/19/10/14673684/merck-shares-fall-2-following-report-astrazeneca-will-delay-imfinzi-imfinzi-plus-tremelimumab,Benzinga Newsdesk,2019-10-28 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.5386
850996,the week ahead in biotech adcom test for agile pfizer merck lead earnings,https://www.benzinga.com/general/biotech/19/10/14657740/the-week-ahead-in-biotech-adcom-test-for-agile-pfizer-merck-lead-earnings,Shanthi Rexaline,2019-10-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
850997,jim cramer gives his take on amd merck and more,https://www.benzinga.com/media/19/10/14637340/jim-cramer-gives-his-take-on-amd-merck-and-more,Craig Jones,2019-10-22 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
850998,merck co shares are trading lower on seemingly no companyspecific news the stock touched the resistance level and traded lower,https://www.benzinga.com/markets/wiim/19/10/14635717/merck-co-shares-are-trading-lower-on-seemingly-no-company-specific-news-the-touched-the-85-resistanc,Benzinga Newsdesk,2019-10-22 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.23665000000000003
850999,the daily biotech pulse biogen alzheimers program back on track novartis reports strong quarter takeda inlicenses autoimmune disorder drug,https://www.benzinga.com/general/biotech/19/10/14633980/the-daily-biotech-pulse-biogen-alzheimers-program-back-on-track-novartis-reports-strong-quarter-t,Shanthi Rexaline,2019-10-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.57655
851000, healthcare stocks moving in tuesdays premarket session,https://www.benzinga.com/news/19/10/14633930/8-healthcare-stocks-moving-in-tuesdays-pre-market-session,Lisa Levin,2019-10-22 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
851001,newlink genetics announces eu regulatory committee recommendation for conditional marketing authorization for ebola vaccine v,https://www.benzinga.com/general/biotech/19/10/14631133/newlink-genetics-announces-eu-regulatory-committee-recommendation-for-conditional-marketing-autho,Benzinga Newsdesk,2019-10-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851002,exclusive plus products hires the wonderful companys mackler as chief scientific officer,https://www.benzinga.com/markets/cannabis/19/10/14624010/exclusive-plus-products-hires-the-wonderful-companys-mackler-as-chief-scientific-officer,Javier Hasse,2019-10-21 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.81845
851003,who says ebola concentrated in congo mining area still an emergency,https://www.benzinga.com/news/19/10/14621901/who-says-ebola-concentrated-in-congo-mining-area-still-an-emergency,Benzinga Newsdesk,2019-10-18 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.30910000000000004
851004,merck reports positive eu chmp opinion for new regimens of keytruda as firstline treatment for metastatic or unresectable recurrent head neck squamous cell carcinoma,https://www.benzinga.com/news/19/10/14618264/merck-reports-positive-eu-chmp-opinion-for-2-new-regimens-of-keytruda-as-first-line-treatment-for-me,Benzinga Newsdesk,2019-10-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
851005,merck reports received eu chmp positive opinion for investigational v ebola vaccine for protection against ebola virus,https://www.benzinga.com/news/19/10/14618170/merck-reports-received-eu-chmp-positive-opinion-for-investigational-v920-ebola-vaccine-for-protectio,Benzinga Newsdesk,2019-10-18 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.7787
851006,bank of america reinstates neutral on merck co announces price target,https://www.benzinga.com/news/19/10/14609929/bank-of-america-reinstates-neutral-on-merck-co-announces-90-price-target,Benzinga_Newsdesk,2019-10-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851007,biotech stock on the radar assessing miratis oncology franchise with an eye on multiple readouts,https://www.benzinga.com/general/biotech/19/10/14579904/biotech-stock-on-the-radar-assessing-miratis-oncology-franchise-with-an-eye-on-multiple-readouts,Shanthi Rexaline,2019-10-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851008,the daily biotech pulse reata leaps on positive readout takeda divests fda nod for akorn jj earnings,https://www.benzinga.com/general/biotech/19/10/14591362/the-daily-biotech-pulse-reata-leaps-on-positive-readout-takeda-divests-fda-nod-for-akorn-j-j-earn,Shanthi Rexaline,2019-10-15 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.8404
851009,the week ahead in biotech fda decisions johnson johnson among big pharma earnings,https://www.benzinga.com/general/biotech/19/10/14575481/the-week-ahead-in-biotech-fda-decisions-johnson-johnson-among-big-pharma-earnings,Shanthi Rexaline,2019-10-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851010,shares of several healthcare companies are trading higher after president trump made positive remarks on the uschina trade talks as traders grew more optimistic over the possibility of a limited trade deal trump is scheduled to meet with chinese vice premier liu he at the white house today,https://www.benzinga.com/markets/wiim/19/10/14582266/shares-of-several-healthcare-companies-are-trading-higher-after-president-trump-made-positive-remark,Benzinga Newsdesk,2019-10-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8787
851011,goldman recommends selling puma biotech clovis oncology cites companyspecific competitive risks,https://www.benzinga.com/analyst-ratings/analyst-color/19/10/14560896/goldman-recommends-selling-puma-biotech-clovis-oncology-cites-company-specific-comp,Shanthi Rexaline,2019-10-08 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5640000000000001
851012,shares of several healthcare companies are trading lower with the broader market after the us expanded its trade blacklist to include chinas top ai firms the us also will increase its tariffs on billion worth of goods from to on oct ,https://www.benzinga.com/markets/wiim/19/10/14561148/shares-of-several-healthcare-companies-are-trading-lower-with-the-broader-market-after-the-us-expand,Benzinga Newsdesk,2019-10-08 00:00:00,MRK,0,1,1,1,1,1,0,0,0,0.8062
851013,biotech stock on the radar fda verdict ahead for pfenexs osteoporosis biosimilar,https://www.benzinga.com/general/biotech/19/10/14527152/biotech-stock-on-the-radar-fda-comes-calling-for-pfenex-osteoporosis-biosimilar,Shanthi Rexaline,2019-10-03 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.57655
851014,whats behind pds biotechs rally,https://www.benzinga.com/general/biotech/19/10/14539754/whats-behind-pds-biotechs-rally,Shanthi Rexaline,2019-10-03 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851015,pds biotech reports clinical collaboration with merck for evaluation of combo of pds mercks keytruda,https://www.benzinga.com/news/19/10/14538027/pds-biotech-reports-clinical-collaboration-with-merck-for-evaluation-of-combo-of-pds0101-mercks-keyt,Benzinga Newsdesk,2019-10-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851016,shares of several healthcare companies are trading lower in sympathy with the overall market on continued fears of a recession amid a weak adp jobs report there is also uncertainty in the market over the upcoming uschina meeting next week,https://www.benzinga.com/markets/wiim/19/10/14530664/shares-of-several-healthcare-companies-are-trading-lower-in-sympathy-with-the-overall-market-on-cont,Benzinga Newsdesk,2019-10-02 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.0937
851017,mercks keytruda now approved as monotherapy in china for firstline treatment of certain patients with advanced nonsmall cell lung cancer nsclc whose tumors express pdl,https://www.benzinga.com/general/biotech/19/10/14528042/mercks-keytruda-now-approved-as-monotherapy-in-china-for-first-line-treatment-of-certain-patients,Benzinga Newsdesk,2019-10-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5640000000000001
851018,fda accepts two applications for mercks dificid to treat children aged six months up to years with clostridium difficile infections,https://www.benzinga.com/news/19/10/14527983/fda-accepts-two-applications-for-mercks-dificid-to-treat-children-aged-six-months-up-to-18-years-wit,Benzinga Newsdesk,2019-10-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8062
851019,the daily biotech pulse safety scare for anaptys psoriasis drug newlink genetics to merge with lumos insider buy props up vbi vaccines,https://www.benzinga.com/general/biotech/19/10/14518431/the-daily-biotech-pulse-safety-scare-for-anaptys-psoriasis-drug-newlink-genetics-to-merge-with-lu,Shanthi Rexaline,2019-10-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.44865
851020,attention biotech investors mark your calendar for these october pdufa dates,https://www.benzinga.com/general/biotech/19/09/14491876/attention-biotech-investors-mark-your-calendar-for-these-october-pdufa-dates,Shanthi Rexaline,2019-09-30 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851021,merck shares trading higher over the level the company announced its restoreimi study of recarbrio met its primary endpoint separately the company and astrazeneca highlighted new lynparza data,https://www.benzinga.com/markets/wiim/19/09/14514901/merck-shares-trading-higher-over-the-82-level-the-company-announced-its-restore-imi-study-of-recarbr,Benzinga Newsdesk,2019-09-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
851022,movers and shakers at esmo immunomedics g therapeutics seattle genetics and more,https://www.benzinga.com/general/biotech/19/09/14513629/movers-and-shakers-at-esmo-2019-immunomedics-g1-therapeutics-seattle-genetics-and-more,Shanthi Rexaline,2019-09-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5386
851023,merck astrazeneca highlight data lynparza more than doubled median radiographic progressionfree survival in brca atm metastatic castrationresistant prostate cancer,https://www.benzinga.com/news/19/09/14513150/merck-astrazeneca-highlight-data-lynparza-more-than-doubled-median-radiographic-progression-free-sur,Benzinga Newsdesk,2019-09-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.2706
851024,mercks pivotal restoreimi phase study of recarbrio met its primary endpoint,https://www.benzinga.com/news/19/09/14511200/mercks-pivotal-restore-imi-2-phase-3-study-of-recarbrio-met-its-primary-endpoint,Benzinga Newsdesk,2019-09-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851025,the week ahead in biotech sept oct conference presentations ipos hit top gear,https://www.benzinga.com/general/biotech/19/09/14506690/the-week-ahead-in-biotech-sept-29-oct-5-conference-presentations-ipos-hit-top-gear,Shanthi Rexaline,2019-09-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.60115
851026,astrazeneca merck announced lynparza phase paola trial significantly increased progressionfree survival as firstline maintenance treatment with bevacizumab for newlydiagnosed advanced ovarian cancer at esmo ,https://www.benzinga.com/news/19/09/14509934/astrazeneca-merck-announced-lynparza-phase-3-paola-1-trial-significantly-increased-progression-free,Charles Gross,2019-09-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
851027,biotech stock on the radar anavex a neurologyfocused precision medicine company,https://www.benzinga.com/analyst-ratings/analyst-color/19/09/14475189/biotech-stock-on-the-radar-anavex-a-neurology-focused-precision-medicine-company,Shanthi Rexaline,2019-09-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851028,the week ahead in biotech spotlight on esmo conference,https://www.benzinga.com/general/biotech/19/09/14460216/the-week-ahead-in-biotech-spotlight-on-esmo-conference,Shanthi Rexaline,2019-09-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851029,shares of several drug companies are trading higher after senate majority leader mcconnell suggested a new democratic drug price reform proposal would be dead on arrival,https://www.benzinga.com/markets/wiim/19/09/14466308/shares-of-several-drug-companies-are-trading-higher-after-senate-majority-leader-mcconnell-suggested,Benzinga Newsdesk,2019-09-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.26165
851030,the daily biotech pulse fda approves merck hiv drugs five prime ceo quits htg molecular announces secondary offering,https://www.benzinga.com/general/biotech/19/09/14462927/the-daily-biotech-pulse-fda-approves-merck-hiv-drugs-five-prime-ceo-quits-htg-molecular-announces,Shanthi Rexaline,2019-09-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
851031,mercks pifeltro and delstrigo receive fda approval for use in appropriate adults living with hiv who are virologically suppressed,https://www.benzinga.com/general/biotech/19/09/14463456/mercks-pifeltro-and-delstrigo-receive-fda-approval-for-use-in-appropriate-adults-living-with-hiv-,Benzinga Newsdesk,2019-09-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
851032,newlink genetics rallies after ebola vaccine granted priority review status,https://www.benzinga.com/general/biotech/19/09/14450743/newlink-genetics-rallies-after-ebola-vaccine-granted-priority-review-status,Shanthi Rexaline,2019-09-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
851033,the daily biotech pulse newlink genetics rallies breakthrough designation for roche igm biosciences debuts,https://www.benzinga.com/general/biotech/19/09/14449081/the-daily-biotech-pulse-newlink-genetics-rallies-breakthrough-designation-for-roche-igm-bioscienc,Shanthi Rexaline,2019-09-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851034,fda approves lenvima plus keytruda combination treatment for patients with certain types of endometrial carcinoma,https://www.benzinga.com/news/19/09/14448756/fda-approves-lenvima-plus-keytruda-combination-treatment-for-patients-with-certain-types-of-endometr,Charles Gross,2019-09-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.79295
851035,merck press release confirms fda approval of keytruda plus lenvima combo treatment for patients with certain types of endometrial carcinoma,https://www.benzinga.com/news/19/09/14447786/merck-press-release-confirms-fda-approval-of-keytruda-plus-lenvima-combo-treatment-for-patients-with,Benzinga Newsdesk,2019-09-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81845
851036,fda says granted accelerated approval to lenvima in combo with keytruda for treatment of patients with advanced endometrial carcinoma,https://www.benzinga.com/news/19/09/14444976/fda-says-granted-accelerated-approval-to-lenvima-in-combo-with-keytruda-for-treatment-of-patients-wi,Benzinga Newsdesk,2019-09-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.86345
851037,merck reports fda accepted biologics license application granted priority review for v for ebola zaire virus,https://www.benzinga.com/news/19/09/14441260/merck-reports-fda-accepted-biologics-license-application-granted-priority-review-for-v920-for-ebola,Benzinga Newsdesk,2019-09-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
851038,the week ahead in biotech novo nordisk and merck await fda rulings ipos on deck,https://www.benzinga.com/general/biotech/19/09/14429608/the-week-ahead-in-biotech-novo-nordisk-and-merck-await-fda-rulings-2-ipos-on-deck,Shanthi Rexaline,2019-09-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.55135
851039,oracle reports early in surprise move as trump surprises with positive trade tweet,https://www.benzinga.com/government/19/09/14421607/oracle-reports-early-in-surprise-move-as-trump-surprises-with-positive-trade-tweet,JJ Kinahan,2019-09-12 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.8825000000000001
851040,shares of several drugmakers are trading lower on news of a drug pricing bill being developed by house democrats the proposed bill would set us drug prices based on prices in other wealthy countries,https://www.benzinga.com/markets/wiim/19/09/14407152/shares-of-several-drugmakers-are-trading-lower-on-news-of-a-drug-pricing-bill-being-developed-by-hou,Benzinga Newsdesk,2019-09-10 00:00:00,MRK,0,1,0,0,1,0,0,0,0,0.6806
851041,merck co shares are trading lower not seeing any news to justify the price action,https://www.benzinga.com/markets/wiim/19/09/14398766/merck-co-shares-are-trading-lower-not-seeing-any-news-to-justify-the-price-action,Benzinga Newsdesk,2019-09-09 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.5
851042,merck to present data from its phase trial for keytruda as neoadjuvant therapy at the european society for medical oncology,https://www.benzinga.com/news/19/09/14396085/merck-to-present-data-from-its-phase-3-trial-for-keytruda-as-neoadjuvant-therapy-at-the-european-soc,Benzinga Newsdesk,2019-09-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851043,aduro biotech announces first patient dosed in phase study of adus in combination with keytruda for firstline treatment of recurrent or metastatic head and neck squamous cell carcinoma,https://www.benzinga.com/general/biotech/19/09/14373032/aduro-biotech-announces-first-patient-dosed-in-phase-2-study-of-adu-s100-in-combination-with-keyt,Benzinga Newsdesk,2019-09-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851044,european commission approves mercks keytruda in combination with inlyta as firstline treatment for patients with advanced renal cell carcinoma,https://www.benzinga.com/general/biotech/19/09/14371834/european-commission-approves-mercks-keytruda-in-combination-with-inlyta-as-first-line-treatment-f,Benzinga Newsdesk,2019-09-04 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.7859499999999999
851045,xynomic pharma reportsinterim data from phase b study of abexinostat combined with keytruda in multiple solid tumors,https://www.benzinga.com/general/biotech/19/08/14355794/xynomic-pharma-reportsinterim-data-from-phase-1b-study-of-abexinostat-combined-with-keytruda-in-m,Benzinga Newsdesk,2019-08-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.57655
851046,deaths from e congo ebola outbreak top cases top ,https://www.benzinga.com/news/19/08/14354592/deaths-from-e-congo-ebola-outbreak-top-2-000-cases-top-3-000,Charles Gross,2019-08-30 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.6909
851047,uganda confirms another case of ebola a year old girl who traveled democratic republic of congo,https://www.benzinga.com/news/19/08/14352042/uganda-confirms-another-case-of-ebola-a-9-year-old-girl-who-traveled-democratic-republic-of-congo,Benzinga Newsdesk,2019-08-29 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
851048,stocks that hit week highs on thursday,https://www.benzinga.com/news/19/08/14349366/stocks-that-hit-52-week-highs-on-thursday,Lisa Levin,2019-08-29 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
851049,attention biotech investors mark your calendar for these september pdufa dates,https://www.benzinga.com/general/biotech/19/08/14328344/attention-biotech-investors-mark-your-calendar-for-these-september-pdufa-dates,Shanthi Rexaline,2019-08-28 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851050, biopharmaceutical companies trying to cure cancer,https://www.benzinga.com/general/biotech/19/08/14244894/10-biopharmaceutical-companies-trying-to-cure-cancer,Tanzeel Akhtar,2019-08-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
851051,jim cramer weighs in on pfizer teva and more,https://www.benzinga.com/media/19/08/14313822/jim-cramer-weighs-in-on-pfizer-teva-and-more,Craig Jones,2019-08-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851052,analysts share stocks to buy on fed uncertainty,https://www.benzinga.com/trading-ideas/long-ideas/19/08/14309842/analysts-share-stocks-to-buy-on-fed-uncertainty,Craig Jones,2019-08-22 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.4742
851053,the daily biotech pulse viivs longacting hiv drug meets study goal chinese cheer for fibrogen retrophin flunks latestage study,https://www.benzinga.com/general/biotech/19/08/14310766/the-daily-biotech-pulse-viivs-long-acting-hiv-drug-meets-study-goal-chinese-cheer-for-fibrogen-re,Shanthi Rexaline,2019-08-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5640000000000001
851054,the daily biotech pulse ra pharma earns milestone aimmune doses patient in egg allergy trial cara inlicenses platform,https://www.benzinga.com/general/biotech/19/08/14304545/the-daily-biotech-pulse-ra-medical-earns-milestone-aimmune-doses-patient-in-egg-allergy-trial-car,Shanthi Rexaline,2019-08-21 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851055,shares of several healthcare companies are trading higher as optimism increased for a resolution to the uschina trade war,https://www.benzinga.com/markets/wiim/19/08/14293088/shares-of-several-healthcare-companies-are-trading-higher-as-optimism-increased-for-a-resolution-to,Benzinga Newsdesk,2019-08-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
851056,shares of healthcare companies are trading higher as us markets rebound from recent weakness following a yield curve inversion which caused recession fears trump also recently announced the us would delay china tariffs renewing hopes of a trade deal,https://www.benzinga.com/markets/wiim/19/08/14285917/shares-of-healthcare-companies-are-trading-higher-as-us-markets-rebound-from-recent-weakness-followi,Benzinga Newsdesk,2019-08-16 00:00:00,MRK,1,0,1,1,0,0,1,1,0,0.15460000000000002
851057,benzingas top upgrades downgrades for august ,https://www.benzinga.com/analyst-ratings/upgrades/19/08/14284016/benzingas-top-upgrades-downgrades-for-august-16-2019,Lisa Levin,2019-08-16 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.60115
851058,svb leerink initiates coverage on merck co with outperform rating announces price target,https://www.benzinga.com/news/19/08/14282923/svb-leerink-initiates-coverage-on-merck-co-with-outperform-rating-announces-103-price-target,Benzinga_Newsdesk,2019-08-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851059,the daily biotech pulse regenerons bad cholesterol drug aces latestage trial oncolytics offering,https://www.benzinga.com/general/biotech/19/08/14263722/the-daily-biotech-pulse-regenerons-bad-cholesterol-drug-aces-late-stage-trial-oncolytics-offering,Shanthi Rexaline,2019-08-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.22885
851060,astrazeneca and merck announce lynparza phase paola trial met primary endpoint in ovarian cancer patients,https://www.benzinga.com/general/biotech/19/08/14263356/astrazeneca-and-merck-announce-lynparza-phase-3-paola-1-trial-met-primary-endpoint-in-ovarian-can,Benzinga Newsdesk,2019-08-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
851061,lynparza phase iii paola trial met primary endpoint as stline maintenance treatment with bevacizumab for advanced ovarian cancer,https://www.benzinga.com/news/19/08/14262802/lynparza-phase-iii-paola-1-trial-met-primary-endpoint-as-1st-line-maintenance-treatment-with-bevaciz,Charles Gross,2019-08-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.23665000000000003
851062,astrazeneca merck announce lynparza phase iii paola trial met primary endpoint,https://www.benzinga.com/news/19/08/14262795/astrazeneca-merck-announce-lynparza-phase-iii-paola-1-trial-met-primary-endpoint,Charles Gross,2019-08-14 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.5
851063,shares of several healthcare companies are trading higher with the overall market after the us announced it is excluding and delaying the additional tariff on certain products,https://www.benzinga.com/markets/wiim/19/08/14257980/shares-of-several-healthcare-companies-are-trading-higher-with-the-overall-market-after-the-u-s-anno,Benzinga Newsdesk,2019-08-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
851064,merck q out shows co received set of investigative interrogatories from california attorney generals office on apr related to conduct deal that allegedly affected delayed competition to lantus in insulin market,https://www.benzinga.com/news/19/08/14214561/merck-10-q-out-shows-co-received-set-of-investigative-interrogatories-from-california-attorney-gener,Benzinga Newsdesk,2019-08-06 00:00:00,MRK,1,2,0,1,0,0,1,1,0,0.3194
851065,the daily biotech pulse sanofis dupixent found effective for pediatric itchy skin novavax gets nod for latestage study allakos offering,https://www.benzinga.com/general/biotech/19/08/14206788/the-daily-biotech-pulse-sanofis-dupixent-found-effective-for-pediatric-itchy-skin-novavax-gets-no,Shanthi Rexaline,2019-08-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
851066,universal display and merck announce research and development collaboration for oled,https://www.benzinga.com/news/19/08/14198855/universal-display-and-merck-announce-research-and-development-collaboration-for-oled,Benzinga Newsdesk,2019-08-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851067,bulls and bears of the week boeing gm pfizer starbucks and more,https://www.benzinga.com/trading-ideas/19/08/14197061/bulls-and-bears-of-the-week-boeing-gm-pfizer-starbucks-and-more,Nelson Hem,2019-08-03 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
851068,the week ahead in biotech focus on earnings deluge midyear clinical trial readouts,https://www.benzinga.com/general/biotech/19/08/14177111/the-week-ahead-in-biotech-focus-on-earnings-deluge-mid-year-clinical-trial-readouts,Shanthi Rexaline,2019-08-03 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851069,sellas advances galinpepimuts gps in combination with keytruda program with dosing of first patient in phase basket study,https://www.benzinga.com/general/biotech/19/07/14168837/sellas-advances-galinpepimut-s-gps-in-combination-with-keytruda-program-with-dosing-of-first-pati,Benzinga Newsdesk,2019-07-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851070,merck reports fda approved new monotherapy indication for keytruda recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus in patients whose tumors express pdl cps with disease progression after one or more prior lines,https://www.benzinga.com/news/19/07/14168836/merck-reports-fda-approved-new-monotherapy-indication-for-keytruda-recurrent-locally-advanced-or-met,Benzinga Newsdesk,2019-07-31 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.79295
851071,apple on todays menu with starring roles from china talks fed meeting,https://www.benzinga.com/news/earnings/19/07/14160136/apple-on-todays-menu-with-starring-roles-from-china-talks-fed-meeting,JJ Kinahan,2019-07-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851072, healthcare stocks moving in todays premarket session,https://www.benzinga.com/news/19/07/14159569/33-healthcare-stocks-moving-in-todays-pre-market-session,Lisa Levin,2019-07-30 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851073,merck co shares are trading higher after the company reported betterthanexpected q eps and sales results the company also issued fy guidance above analyst estimates,https://www.benzinga.com/news/19/07/14158635/merck-co-shares-are-trading-higher-after-the-company-reported-better-than-expected-q2-eps-and-sales,Benzinga Newsdesk,2019-07-30 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.648
851074,a peek into the markets us stock futures down ahead of fed meeting apple earnings,https://www.benzinga.com/news/earnings/19/07/14158623/a-peek-into-the-markets-us-stock-futures-down-ahead-of-fed-meeting-apple-earnings,Lisa Levin,2019-07-30 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851075,merck reports q earnings beat,https://www.benzinga.com/news/earnings/19/07/14157814/merck-reports-q2-earnings-beat,Tanzeel Akhtar,2019-07-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851076,the daily biotech pulse european cheer for merck legal victory for coherus medpace picks up on earnings,https://www.benzinga.com/general/biotech/19/07/14156757/the-daily-biotech-pulse-european-cheer-for-merck-legal-victory-for-coherus-medpace-picks-up-on-ea,Shanthi Rexaline,2019-07-30 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.79295
851077,merck co sees fy adj eps vs est sees sales bb vs b est,https://www.benzinga.com/news/19/07/14157458/merck-co-sees-fy19-adj-eps-4-84-4-94-vs-4-75-est-sees-sales-45-2b-46-2b-vs-44-74b-est,Benzinga Newsdesk,2019-07-30 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851078,merck co q adj eps beats estimate sales b beat b estimate,https://www.benzinga.com/news/earnings/19/07/14157451/merck-co-q2-adj-eps-1-3-beats-1-16-estimate-sales-11-76b-beat-10-96b-estimate,Benzinga Newsdesk,2019-07-30 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851079, stocks to watch for july ,https://www.benzinga.com/news/earnings/19/07/14156849/15-stocks-to-watch-for-july-30-2019,Lisa Levin,2019-07-30 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851080,earnings scheduled for july ,https://www.benzinga.com/news/earnings/19/07/14156797/earnings-scheduled-for-july-30-2019,Lisa Levin,2019-07-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851081,merck q earnings preview,https://www.benzinga.com/news/earnings-previews/19/07/14153054/merck-cos-earnings-outlook,Benzinga Newsdesk,2019-07-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851082,mercks keytruda gets a double dose of positive news,https://www.benzinga.com/general/biotech/19/07/14150311/mercks-keytruda-gets-a-double-dose-of-positive-news,Shanthi Rexaline,2019-07-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
851083,mercks keytruda in combination with chemotherapy met one of the dual primary endpoints in pivotal phase keynote,https://www.benzinga.com/news/19/07/14149086/mercks-keytruda-in-combination-with-chemotherapy-met-one-of-the-dual-primary-endpoints-in-pivotal-ph,Benzinga Newsdesk,2019-07-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851084,mercks keytruda in combination with inlyta as firstline treatment for advanced renal cell carcinoma receives a positive opinion from the european medicines agency,https://www.benzinga.com/news/19/07/14148803/mercks-keytruda-in-combination-with-inlyta-as-first-line-treatment-for-advanced-renal-cell-carcinoma,Benzinga Newsdesk,2019-07-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8404
851085,the week ahead in biotech pending clinical readouts earnings dominate,https://www.benzinga.com/general/biotech/19/07/14136579/the-week-ahead-in-biotech-pending-clinical-readouts-earnings-dominate,Shanthi Rexaline,2019-07-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
851086,merck highlights presentation of phase b results for investigational hiv therapy islatravir mk at ias ,https://www.benzinga.com/general/biotech/19/07/14125581/merck-highlights-presentation-of-phase-2b-results-for-investigational-hiv-1-therapy-islatravir-mk,Benzinga Newsdesk,2019-07-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851087,the daily biotech pulse jounce jumps on licensing deal regulus hit with partial clinical hold genomic health added to sp smallcap index,https://www.benzinga.com/general/biotech/19/07/14121792/the-daily-biotech-pulse-jounce-jumps-on-licensing-deal-regulus-hit-with-partial-clinical-hold-gen,Shanthi Rexaline,2019-07-24 00:00:00,MRK,1,2,0,1,1,1,1,0,1,0.5
851088,merck reports results from phase study of investigational nucleoside reverse transcriptase translocation inhibitor presented at international aids society conference on hiv science,https://www.benzinga.com/news/19/07/14117359/merck-reports-results-from-phase-1-study-of-investigational-nucleoside-reverse-transcriptase-translo,Benzinga Newsdesk,2019-07-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.4614
851089,eisais cancer drug combo gets breakthrough therapy designation for liver cancer,https://www.benzinga.com/general/biotech/19/07/14115718/eisais-cancer-drug-combo-gets-breakthrough-therapy-designation-for-liver-cancer,Shanthi Rexaline,2019-07-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.06555
851090,the daily biotech pulse acadia schizophrenia drug fails viveve plummets eisai gets breakthrough therapy designation,https://www.benzinga.com/general/biotech/19/07/14113990/the-daily-biotech-pulse-acadia-schizophrenia-drug-fails-viveve-plummets-eisai-gets-breakthrough-t,Shanthi Rexaline,2019-07-23 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.28925
851091,merck and eisai receive third breakthrough therapy designation from fda for keytruda plus lenvima combination treatment,https://www.benzinga.com/general/biotech/19/07/14114688/merck-and-eisai-receive-third-breakthrough-therapy-designation-from-fda-for-keytruda-plus-lenvima,Benzinga Newsdesk,2019-07-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851092,the week ahead in biotech pharma earnings pick up pace,https://www.benzinga.com/general/biotech/19/07/14096172/the-week-ahead-in-biotech-pharma-earnings-pick-up-pace,Shanthi Rexaline,2019-07-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851093,who emergency committee says it recognises shortage of supply of mercks ebola vaccine says who should work with member states and manufacturers to take all measures to increase supply,https://www.benzinga.com/news/19/07/14090270/who-emergency-committee-says-it-recognises-shortage-of-supply-of-mercks-ebola-vaccine-says-who-shoul,Benzinga Newsdesk,2019-07-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
851094,who emergency committee chairman says ebola is a regional emergency and in no way a global threat,https://www.benzinga.com/news/19/07/14090202/who-emergency-committee-chairman-says-ebola-is-a-regional-emergency-and-in-no-way-a-global-threat,Benzinga Newsdesk,2019-07-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.06555
851095,world health organizations emergency committee says congos ebola outbreak constitutes a public health emergency of international concern,https://www.benzinga.com/news/19/07/14090198/world-health-organizations-emergency-committee-says-congos-ebola-outbreak-constitutes-a-public-healt,Benzinga Newsdesk,2019-07-17 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.18155
851096,mercks novel antibiotic for abdominal urinary tract infections receives fda nod,https://www.benzinga.com/general/biotech/19/07/14087445/mercks-novel-antibiotic-for-abdominal-urinary-tract-infections-receives-fda-nod,Shanthi Rexaline,2019-07-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
851097,fda approves mercks recarbrio for the treatment of adults with complicated urinary tract and complicated intraabdominal bacterial infections where limited or no alternative treatment options are available,https://www.benzinga.com/general/biotech/19/07/14086397/fda-approves-mercks-recarbrio-for-the-treatment-of-adults-with-complicated-urinary-tract-and-comp,Benzinga Newsdesk,2019-07-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.44865
851098,world health organization chief says ebola case in congolese city of goma could be a gamechanger,https://www.benzinga.com/general/biotech/19/07/14072417/world-health-organization-chief-says-ebola-case-in-congolese-city-of-goma-could-be-a-gamechanger,Benzinga Newsdesk,2019-07-15 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851099,the week ahead in biotech johnson johnson kickstarts big pharma earnings,https://www.benzinga.com/general/biotech/19/07/14061331/the-week-ahead-in-biotech-johnson-johnson-kickstarts-big-pharma-earnings,Shanthi Rexaline,2019-07-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851100,bulls bears of the week costco dupont ibm merck and more,https://www.benzinga.com/trading-ideas/19/07/14070748/bulls-bears-of-the-week-costco-dupont-ibm-merck-and-more,Nelson Hem,2019-07-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851101,washington worries trigger bearish merck options trades,https://www.benzinga.com/trading-ideas/short-ideas/19/07/14068727/washington-worries-trigger-bearish-merck-options-trades,Wayne Duggan,2019-07-12 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.28925
851102,novartis amgen scrap pivotal study of alzheimers prevention drug,https://www.benzinga.com/general/biotech/19/07/14067050/novartis-amgen-scrap-pivotal-study-of-alzheimers-prevention-drug,Shanthi Rexaline,2019-07-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851103,stock market eyes records on dovish commentary from federal reserve,https://www.benzinga.com/news/19/07/14067261/stock-market-eyes-records-on-dovish-commentary-from-federal-reserve,JJ Kinahan,2019-07-12 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851104,shares of several drug manufacturing companies are trading lower potentially on continued weakness after the trump administration on thursday rolled back a proposal to eliminate rebates from government drug plans,https://www.benzinga.com/markets/wiim/19/07/14067031/shares-of-several-drug-manufacturing-companies-are-trading-lower-potentially-on-continued-weakness-a,Benzinga Newsdesk,2019-07-12 00:00:00,MRK,0,1,0,1,1,0,0,0,0,0.28925
851105,shares of several drug manufacturing companies are trading lower the trump administration earlier rolled back a proposal to eliminate rebates from government drug plans and commented on continued efforts to lower drug prices,https://www.benzinga.com/markets/wiim/19/07/14061352/shares-of-several-drug-manufacturing-companies-are-trading-lower-the-trump-administration-earlier-ro,Hal Lindon,2019-07-11 00:00:00,MRK,0,1,0,0,1,0,0,0,0,0.352
851106,merck to present results from studies evaluating investigational antihiv agent mk at ias on jul ,https://www.benzinga.com/general/biotech/19/07/14051820/merck-to-present-results-from-studies-evaluating-investigational-anti-hiv-agent-mk-8591-at-ias-20,Benzinga Newsdesk,2019-07-10 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851107,judge rules against trump proposal forcing pharma companies to disclose drug prices in commercials,https://www.benzinga.com/government/19/07/14045927/judge-rules-against-trump-proposal-forcing-pharma-companies-to-disclose-drug-prices-in-commercials,Jayson Derrick,2019-07-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851108,fda accepts mercks supplemental biologics license applications for keytruda sixweek dosing schedule for melanoma and multiple other indications,https://www.benzinga.com/news/19/07/14044717/fda-accepts-mercks-supplemental-biologics-license-applications-for-keytruda-six-week-dosing-schedule,Benzinga Newsdesk,2019-07-09 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.6591
851109,shares of several healthcare companies are trading lower after trump on friday said he was preparing an executive order declaring a favored nations clause for drug prices lowering the price that consumers will pay prescription drugs,https://www.benzinga.com/markets/wiim/19/07/14041064/shares-of-several-healthcare-companies-are-trading-lower-after-trump-on-friday-said-he-was-preparing,Benzinga Newsdesk,2019-07-08 00:00:00,MRK,0,1,0,1,1,1,0,0,0,0.55135
851110,the daily biotech pulse fda approves karyopharms blood cancer treatment grifols immunodeficiency drug esmo isth conferences in the spotlight,https://www.benzinga.com/general/biotech/19/07/14032724/the-daily-biotech-pulse-fda-approves-karyopharms-blood-cancer-treatment-grifols-immunodeficiency-,Shanthi Rexaline,2019-07-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.29905000000000004
851111,benzingas top upgrades downgrades for july ,https://www.benzinga.com/analyst-ratings/upgrades/19/07/14027274/benzingas-top-upgrades-downgrades-for-july-3-2019,Lisa Levin,2019-07-03 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.60115
851112,mizuho initiates coverage on merck co with buy rating announces price target,https://www.benzinga.com/news/19/07/14025491/mizuho-initiates-coverage-on-merck-co-with-buy-rating-announces-97-price-target,Vick Meyer,2019-07-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851113,mizuho initiates coverage on merck with buy rating price target,https://www.benzinga.com/news/19/07/14021681/mizuho-initiates-coverage-on-merck-with-buy-rating-97-price-target,Benzinga Newsdesk,2019-07-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851114,attention biotech investors mark your calendar for these july pdufa dates,https://www.benzinga.com/general/biotech/19/07/13987454/attention-biotech-investors-mark-your-calendar-for-these-july-pdufa-dates,Shanthi Rexaline,2019-07-01 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851115,the daily biotech pulse verrica rallies aclaris flunked hair loss study biotechs to ipo,https://www.benzinga.com/general/biotech/19/06/13991647/the-daily-biotech-pulse-verrica-rallies-aclaris-flunked-hair-loss-study-3-biotechs-to-ipo,Shanthi Rexaline,2019-06-27 00:00:00,MRK,0,2,1,1,1,1,1,1,1,0.17015000000000002
851116,intensity therapeutics announces clinical collaboration with merck for a phase clinical trial to evaluate cos int in combination with keytruda for multiple solid tumor types,https://www.benzinga.com/general/biotech/19/06/13975746/intensity-therapeutics-announces-clinical-collaboration-with-merck-for-a-phase-12-clinical-trial-,Benzinga Newsdesk,2019-06-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.375
851117,the week ahead in biotech conferences pdufa dates clinical trial readouts and ipos,https://www.benzinga.com/general/biotech/19/06/13951321/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trial-readouts-and-ipos,Shanthi Rexaline,2019-06-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851118,morgan stanley maintains overweight on merck co raises price target to ,https://www.benzinga.com/news/19/06/13955992/morgan-stanley-maintains-overweight-on-merck-co-raises-price-target-to-90,Vick Meyer,2019-06-21 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.3194
851119,the daily biotech pulse contravirs volatile ride continues latestage disappointment for exelixis regeneronsanofi breathe easy,https://www.benzinga.com/general/biotech/19/06/13955011/the-daily-biotech-pulse-contravirs-volatile-ride-continues-late-stage-disappointment-for-exelixis,Shanthi Rexaline,2019-06-21 00:00:00,MRK,1,1,1,0,0,1,1,1,1,0.44865
851120,merck ceo frazier at investor day says the company has less appetite for big deals than mid or smallsized deals says most big pharma deals have not created the value they said they were going to create,https://www.benzinga.com/general/biotech/19/06/13951590/merck-ceo-frazier-at-investor-day-says-the-company-has-less-appetite-for-big-deals-than-mid-or-sm,Benzinga Newsdesk,2019-06-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.41405000000000003
851121,the daily biotech pulse diamedica reports positive data for chronic kidney disease drug eloxx offering ipo deluge,https://www.benzinga.com/general/biotech/19/06/13948279/the-daily-biotech-pulse-diamedica-reports-positive-data-for-chronic-kidney-disease-drug-eloxx-off,Shanthi Rexaline,2019-06-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
851122,merck highlights investor day presentation,https://www.benzinga.com/general/biotech/19/06/13948899/merck-highlights-2019-investor-day-presentation,Benzinga Newsdesk,2019-06-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851123,report merck searching internally for next ceo,https://www.benzinga.com/news/19/06/13945632/report-merck-searching-internally-for-next-ceo,Tanzeel Akhtar,2019-06-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851124,merck prepping for ceo departure has begun internal successor hunt,https://www.benzinga.com/news/19/06/13945237/merck-prepping-for-ceo-departure-has-begun-internal-successor-hunt,Benzinga Newsdesk,2019-06-19 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.61315
851125,the daily biotech pulse positive readouts from adamas and ironwood sesen bio to offer shares stoke therapeutics debut,https://www.benzinga.com/general/biotech/19/06/13941625/the-daily-biotech-pulse-positive-readouts-from-adamas-and-ironwood-sesen-bio-to-offer-shares-stok,Shanthi Rexaline,2019-06-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.85015
851126,astrazenecamerck announce lynparza approved in japan for stline maintenance therapy in brcamutated advanced ovarian cancer,https://www.benzinga.com/news/19/06/13941803/astrazeneca-merck-announce-lynparza-approved-in-japan-for-1st-line-maintenance-therapy-in-brca-mutat,Charles Gross,2019-06-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
851127,merck reports fda approved keytruda as monotherapy for patients with metastatic small cell lung cancer sclc with disease progression on or after platinumbased chemotherapy and at least one other prior line of therapy,https://www.benzinga.com/news/19/06/13934798/merck-reports-fda-approved-keytruda-as-monotherapy-for-patients-with-metastatic-small-cell-lung-canc,Benzinga Newsdesk,2019-06-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.30910000000000004
851128,astrazeneca merck report lynparza approved in eu for use as firstline maintenance therapy in patients with brcamutated advanced ovarian cancer,https://www.benzinga.com/news/19/06/13934714/astrazeneca-merck-report-lynparza-approved-in-eu-for-use-as-first-line-maintenance-therapy-in-patien,Benzinga Newsdesk,2019-06-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
851129,astrazeneca merck announce lynparza approved in the eu for stline maintenance treatment of brcamutated advanced ovarian cancer,https://www.benzinga.com/news/19/06/13934264/astrazeneca-merck-announce-lynparza-approved-in-the-eu-for-1st-line-maintenance-treatment-of-brca-mu,Charles Gross,2019-06-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
851130,measles cases in united states rise to cnn,https://www.benzinga.com/general/health-care/19/06/13931921/measles-cases-in-united-states-rise-to-1-044-cnn,Benzinga Newsdesk,2019-06-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
851131,the week ahead in biotech conferences pdufa dates clinical trial readouts and ipos,https://www.benzinga.com/general/biotech/19/06/13916631/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trial-readouts-and-ipos,Shanthi Rexaline,2019-06-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851132,from earlier drug makers amgen merck lilly and the association of national advertisers file suit to prevent the disclosure of drug prices in television ads,https://www.benzinga.com/news/19/06/13924153/from-earlier-drug-makers-amgen-merck-lilly-and-the-association-of-national-advertisers-file-suit-to,Benzinga Newsdesk,2019-06-14 00:00:00,MRK,1,1,0,1,1,0,1,0,1,0.5129
851133,jp morgan maintains overweight on merck co raises price target to ,https://www.benzinga.com/news/19/06/13922246/jp-morgan-maintains-overweight-on-merck-co-raises-price-target-to-93,Vick Meyer,2019-06-14 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.41105
851134,ibm walmart merck included in fda program to test blockchain usage in us drug supply chain,https://www.benzinga.com/news/19/06/13915400/ibm-walmart-merck-included-in-fda-program-to-test-blockchain-usage-in-us-drug-supply-chain,Tanzeel Akhtar,2019-06-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851135,ibm kpmg merck walmart report have been selected by fda to be included in blockchain program in support of us drug supply chain security act to address requirement to identify track trace medicines vaccines distributed in us,https://www.benzinga.com/news/19/06/13915003/ibm-kpmg-merck-walmart-report-have-been-selected-by-fda-to-be-included-in-blockchain-program-in-supp,Benzinga Newsdesk,2019-06-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81245
851136,who emergency committee meeting to decide if ebola outbreak constitutes an intl emergency will begin jun ,https://www.benzinga.com/news/19/06/13910135/who-emergency-committee-meeting-to-decide-if-ebola-outbreak-constitutes-an-intl-emergency-will-begin,Benzinga Newsdesk,2019-06-12 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.18155
851137,the daily biotech pulse nuvectra files for expanded label for algovita scs axovant earnings fda nod for aratana,https://www.benzinga.com/general/biotech/19/06/13907501/the-daily-biotech-pulse-nuvectra-files-for-expanded-label-for-algovita-scs-axovant-earnings-fda-n,Shanthi Rexaline,2019-06-12 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851138,fda greenlights mercks blockbuster drug keytruda for firstline treatment of head neck cancer,https://www.benzinga.com/general/biotech/19/06/13901459/fda-greenlights-mercks-blockbuster-drug-keytruda-for-first-line-treatment-of-head-neck-cancer,Shanthi Rexaline,2019-06-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.436
851139,fda approves two new indications for mercks keytruda,https://www.benzinga.com/news/19/06/13900422/fda-approves-two-new-indications-for-mercks-keytruda,Benzinga Newsdesk,2019-06-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
851140,merck strikes m deal for privately held tilos therapeutics,https://www.benzinga.com/general/biotech/19/06/13895566/merck-strikes-773m-deal-for-privately-held-tilos-therapeutics-what-you-need-to-know,Shanthi Rexaline,2019-06-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3194
851141,a peek into the markets us stock futures signal higher start on wall street,https://www.benzinga.com/news/19/06/13893413/a-peek-into-the-markets-us-stock-futures-signal-higher-start-on-wall-street,Lisa Levin,2019-06-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851142,merck reports purchase of tilos therapeutics for total potential consideration of m,https://www.benzinga.com/m-a/19/06/13893360/merck-reports-purchase-of-tilos-therapeutics-for-total-potential-consideration-of-773m,Benzinga Newsdesk,2019-06-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851143,the week ahead in biotech conferences pdufa dates and clinical trial readouts,https://www.benzinga.com/general/biotech/19/06/13876133/the-week-ahead-in-biotech-conferences-pdufa-dates-and-clinical-trial-readouts,Shanthi Rexaline,2019-06-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851144,sanofis leadership transition what you need to know,https://www.benzinga.com/general/biotech/19/06/13882098/sanofis-leadership-transition-what-you-need-to-know,Shanthi Rexaline,2019-06-07 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851145,shares of several healthcare companies are trading higher with the overall us market recent comments out of china and mexico has renewed trade optimism and lifted economic outlook,https://www.benzinga.com/markets/wiim/19/06/13859934/shares-of-several-healthcare-companies-are-trading-higher-with-the-overall-us-market-recent-comments,Benzinga Newsdesk,2019-06-04 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.8453999999999999
851146,i believe it is wrong to charge americans astronomical prices for lifesaving drugs developed with taxpayer dollars you will not find me encouraging pharmaceutical companies to continue ripping off americans like my republican colleagues sen sanders,https://www.benzinga.com/news/19/06/13859297/i-believe-it-is-wrong-to-charge-americans-astronomical-prices-for-life-saving-drugs-developed-with-t,Benzinga Newsdesk,2019-06-04 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.23854999999999998
851147,the daily biotech pulse asco presentations from roche celgene more edwards recommends rejection of minitender offer,https://www.benzinga.com/general/biotech/19/06/13855494/the-daily-biotech-pulse-asco-presentations-from-roche-celgene-more-edwards-recommends-rejection-o,Shanthi Rexaline,2019-06-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3106
851148,merck reports lynparza phase solo trial showed objective response rate in patients with platinumsensitive relapsed germline brcamutated advanced ovarian cancer compared to of patients receiving chemotherapy,https://www.benzinga.com/news/19/06/13852904/merck-reports-lynparza-phase-3-solo3-trial-showed-72-objective-response-rate-in-patients-with-platin,Benzinga Newsdesk,2019-06-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.23665000000000003
851149,fda grants approval of zerbaxa to merck co inc,https://www.benzinga.com/news/19/06/13852317/fda-grants-approval-of-zerbaxa-to-merck-co-inc,Benzinga Newsdesk,2019-06-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8062
851150,dynavax highlights presentation of results showing overall response rate in advanced melanoma patients with sd in combination with keytruda,https://www.benzinga.com/general/biotech/19/06/13851832/dynavax-highlights-presentation-of-results-showing-76-overall-response-rate-in-advanced-melanoma-,Benzinga Newsdesk,2019-06-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
851151,merck sat highlighted year survival data from keytruda in nsclc as first keynote trial at asco,https://www.benzinga.com/news/19/06/13849795/merck-sat-highlighted-5-year-survival-data-from-keytruda-in-nsclc-as-first-keynote-trial-at-asco,Benzinga Newsdesk,2019-06-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851152,the week ahead in biotech asco presentations pick up the pace,https://www.benzinga.com/general/biotech/19/06/13834066/the-week-ahead-in-biotech-asco-presentations-pick-up-the-pace,Shanthi Rexaline,2019-06-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851153,merck announces fiveyear survival data for keytruda in advanced nonsmall cell lung cancer from first keynote trial at asco,https://www.benzinga.com/news/19/06/13845831/merck-announces-five-year-survival-data-for-keytruda-in-advanced-non-small-cell-lung-cancer-from-fir,Charles Gross,2019-06-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.23665000000000003
851154,merck reports keytruda showed improved overall survival as firstline treatment of recurrent or metastatic head and neck squamous cell carcinoma at final analysis of pivotal phase keynote trial,https://www.benzinga.com/news/19/05/13838903/merck-reports-keytruda-showed-improved-overall-survival-as-first-line-treatment-of-recurrent-or-meta,Benzinga Newsdesk,2019-05-31 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
851155,top most overbought stocks via benzinga pros radar tool for tue may ,https://www.benzinga.com/trading-ideas/19/05/13815525/top-10-most-overbought-stocks-via-benzinga-pros-radar-tool-for-tue-may-28-2019,Benzinga Newsdesk,2019-05-28 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.60115
851156,goldman sachs initiates coverage on merck co with neutral rating announces price target,https://www.benzinga.com/news/19/05/13812450/goldman-sachs-initiates-coverage-on-merck-co-with-neutral-rating-announces-85-price-target,Benzinga_Newsdesk,2019-05-28 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851157,the week ahead in biotech asco presentations in the spotlight,https://www.benzinga.com/general/biotech/19/05/13790532/the-week-ahead-in-biotech-asco-presentations-in-the-spotlight,Shanthi Rexaline,2019-05-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851158,mercks keytruda vs bristolmyers squibbs opdivo in q and beyond,https://www.benzinga.com/general/biotech/19/05/13722540/mercks-keytruda-vs-bristol-myers-squibbs-opdivo-in-q1-and-beyond,Shanthi Rexaline,2019-05-22 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851159,merck to buy clinicalstage biopharma peloton therapeutics for more than b,https://www.benzinga.com/general/biotech/19/05/13778973/merck-to-buy-clinical-stage-biopharma-peloton-therapeutics-for-more-than-1b,Tanzeel Akhtar,2019-05-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851160,the daily biotech pulse setback for merck in breast cancer study arrowhead to join sp smallcap index oculars glaucoma trial fails,https://www.benzinga.com/general/biotech/19/05/13778396/the-daily-biotech-pulse-setback-for-merck-in-breast-cancer-study-arrowhead-to-join-s-p-smallcap-6,Shanthi Rexaline,2019-05-21 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.14079999999999998
851161,merck to purchase peloton therapeutics for b in cash will be eligible to receive further b based on regulatory sales milestones,https://www.benzinga.com/news/19/05/13778489/merck-to-purchase-peloton-therapeutics-for-1-05b-in-cash-will-be-eligible-to-receive-further-1-15b-b,Benzinga Newsdesk,2019-05-21 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
851162,update merck says keytruda trial did not meet primary endpoint of superior overall survival,https://www.benzinga.com/news/19/05/13775686/update-merck-says-keytruda-trial-did-not-meet-primary-endpoint-of-superior-overall-survival,Benzinga Newsdesk,2019-05-20 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.77115
851163,merck offers update on phase keynote study of keytruda in previouslytreated patients with metastatic triplenegative breast cancer,https://www.benzinga.com/news/19/05/13775656/merck-offers-update-on-phase-3-keynote-19-study-of-keytruda-in-previously-treated-patients-with-meta,Benzinga Newsdesk,2019-05-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
851164,argus questions logic behind bristolmyers proposed celgene buy steps to sidelines,https://www.benzinga.com/analyst-ratings/analyst-color/19/05/13773937/argus-questions-logic-behind-bristol-myers-proposed-celgene-buy-steps-to-sidelines,Shanthi Rexaline,2019-05-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851165, asco abstracts that moved stocks,https://www.benzinga.com/general/biotech/19/05/13758313/5-asco-abstracts-that-moved-stocks,Shanthi Rexaline,2019-05-16 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851166,iovance issues cancer trial updates ahead of asco meeting sending stock skyward,https://www.benzinga.com/general/biotech/19/05/13757484/iovance-issues-cancer-trial-updates-ahead-of-asco-meeting-sending-stock-skyward,Shanthi Rexaline,2019-05-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
851167,the daily biotech pulse fda nod for roche trial results for agios iovance and macrogenics,https://www.benzinga.com/general/biotech/19/05/13753938/the-daily-biotech-pulse-fda-nod-for-roche-trial-results-for-agios-iovance-and-macrogenics,Shanthi Rexaline,2019-05-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851168,intec pharma announces research collaboration agreement with merck,https://www.benzinga.com/news/19/05/13754038/intec-pharma-announces-research-collaboration-agreement-with-merck,Charles Gross,2019-05-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
851169,f from loebs third point shows liquidated stake in merck cut stake in american express,https://www.benzinga.com/news/19/05/13751544/13f-from-loebs-third-point-shows-liquidated-stake-in-merck-cut-stake-in-american-express,Benzinga Newsdesk,2019-05-15 00:00:00,MRK,1,2,1,1,1,0,0,0,0,0.3634
851170,the daily biotech pulse fda greenlights pfizermerck kgaas kidney cancer combo treatment adcom disappointment for daiichi,https://www.benzinga.com/general/biotech/19/05/13741945/the-daily-biotech-pulse-fda-greenlights-pfizer-merck-kgaas-kidney-cancer-combo-treatment-adcom-di,Shanthi Rexaline,2019-05-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.08645000000000003
851171,shares of several healthcare companies are trading lower in sympathy with the overall market the sp is trading lower ,https://www.benzinga.com/markets/wiim/19/05/13717298/shares-of-several-healthcare-companies-are-trading-lower-in-sympathy-with-the-overall-market-the-s-p,Benzinga Newsdesk,2019-05-10 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.5386
851172,merck reports results from phase trial of v in infants met primary dndpoint,https://www.benzinga.com/news/19/05/13693147/merck-reports-results-from-phase-2-trial-of-v114-in-infants-met-primary-dndpoint,Benzinga Newsdesk,2019-05-08 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851173,mercks belsomra civ meets primary efficacy endpoint in phase trial for treatment of insomnia in people with mildtomoderate alzheimers disease dementia,https://www.benzinga.com/general/biotech/19/05/13679705/mercks-belsomra-c-iv-meets-primary-efficacy-endpoint-in-phase-3-trial-for-treatment-of-insomnia-i,Benzinga Newsdesk,2019-05-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851174,ebola death toll in congo rises to ,https://www.benzinga.com/news/19/05/13678890/ebola-death-toll-in-congo-rises-to-979,Charles Gross,2019-05-07 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.20029999999999998
851175,canopy growth lockheed martin merck and more fast money halftime report picks for may ,https://www.benzinga.com/trading-ideas/long-ideas/19/05/13658941/canopy-growth-lockheed-martin-merck-and-more-fast-money-halftime-report-picks-for-may-3,Craig Jones,2019-05-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
851176,ubs maintains buy on merck company inc common stock new raises price target to ,https://www.benzinga.com/news/19/05/13650799/ubs-maintains-buy-on-merck-company-inc-common-stock-new-raises-price-target-to-88,Vick Meyer,2019-05-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851177,bmo capital maintains market perform on merck company inc common stock new raises price target to ,https://www.benzinga.com/news/19/05/13639803/bmo-capital-maintains-market-perform-on-merck-company-inc-common-stock-new-raises-price-target-to-84,Vick Meyer,2019-05-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851178,bank of america maintains buy on merck company inc common stock new raises price target to ,https://www.benzinga.com/news/19/05/13638474/bank-of-america-maintains-buy-on-merck-company-inc-common-stock-new-raises-price-target-to-91,Vick Meyer,2019-05-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851179,alphabet revenue disappoints ahead of apple earnings after the bell,https://www.benzinga.com/news/earnings/19/04/13627159/alphabet-revenue-disappoints-ahead-of-apple-earnings-after-the-bell,JJ Kinahan,2019-04-30 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.30910000000000004
851180,merck co shares are trading higher after the company reported betterthanexpected q eps and sales and issued strong fy guidance,https://www.benzinga.com/markets/wiim/19/04/13626494/merck-co-shares-are-trading-higher-after-the-company-reported-better-than-expected-q1-eps-and-sales,Benzinga Newsdesk,2019-04-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.83525
851181,the daily biotech pulse earnings deluge g therapeutics positive fda meeting mustang bio offering,https://www.benzinga.com/general/biotech/19/04/13623920/the-daily-biotech-pulse-earnings-deluge-g1-therapeutics-positive-fda-meeting-mustang-bio-offering,Shanthi Rexaline,2019-04-30 00:00:00,MRK,1,1,1,0,1,1,1,1,1,0.7787
851182,a peek into the markets us stock futures mixed ahead of earnings fed meeting,https://www.benzinga.com/news/19/04/13624641/a-peek-into-the-markets-us-stock-futures-mixed-ahead-of-earnings-fed-meeting,Lisa Levin,2019-04-30 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851183,merck co sees fy adj eps vs est sales bb vs b est,https://www.benzinga.com/news/19/04/13624064/merck-co-sees-fy19-adj-eps-4-67-4-79-vs-4-67-est-sales-43-9b-45-1b-vs-44-42b-est,Benzinga Newsdesk,2019-04-30 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851184,merck co q adj eps beats estimate sales b beat b estimate,https://www.benzinga.com/news/earnings/19/04/13624034/merck-co-q1-adj-eps-1-22-beats-1-06-estimate-sales-10-82b-beat-10-48b-estimate,Benzinga Newsdesk,2019-04-30 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851185, stocks to watch for april ,https://www.benzinga.com/news/earnings/19/04/13623749/15-stocks-to-watch-for-april-30-2019,Lisa Levin,2019-04-30 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851186,earnings scheduled for april ,https://www.benzinga.com/news/earnings/19/04/13623421/earnings-scheduled-for-april-30-2019,Lisa Levin,2019-04-30 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
851187,this week market eyes china talks fed meeting as earnings continue,https://www.benzinga.com/news/earnings/19/04/13615925/this-week-market-eyes-china-talks-fed-meeting-as-earnings-continue,JJ Kinahan,2019-04-29 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
851188,astrazeneca merck announce lynparza receives positive eu chmp opinion for stline maintenance treatment of brcamutated advanced ovarian cancer,https://www.benzinga.com/news/19/04/13613208/astrazeneca-merck-announce-lynparza-receives-positive-eu-chmp-opinion-for-1st-line-maintenance-treat,Charles Gross,2019-04-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5258
851189,the daily biotech pulse mixed results for mercks keytruda in stomach cancer roches sparkbuy delayed teva recalls hypertension drug,https://www.benzinga.com/general/biotech/19/04/13603940/the-daily-biotech-pulse-mixed-results-for-mercks-keytruda-in-stomach-cancer-roches-spark-buy-dela,Shanthi Rexaline,2019-04-26 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.1285
851190,merck offers update on phase keynote trial evaluating keytruda as monotherapy in combination with chemotherapy for firstline treatment of patients with advanced gastric or gastroesophageal junction adenocarcinoma,https://www.benzinga.com/news/19/04/13602562/merck-offers-update-on-phase-3-keynote-062-trial-evaluating-keytruda-as-monotherapy-in-combination-w,Benzinga Newsdesk,2019-04-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
851191,shares of several healthcare stocks are trading higher in a potential rebound from last weeks selloff in an upgrade of hca healthcare raymond james analysts noted the selloff was based on legislation that has almost no chance of passing,https://www.benzinga.com/markets/wiim/19/04/13579798/shares-of-several-healthcare-stocks-are-trading-higher-in-a-potential-rebound-from-last-weeks-sellof,Benzinga Newsdesk,2019-04-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6267
851192,oncosec announces triple combination immunotherapy clinical trial of tavo epacadostat and keytruda in squamous cell head and neck scchn cancer,https://www.benzinga.com/general/biotech/19/04/13576980/oncosec-announces-triple-combination-immunotherapy-clinical-trial-of-tavo-epacadostat-and-keytrud,Benzinga Newsdesk,2019-04-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
851193,mercks keytruda in combination with inlyta approved by the fda as firstline treatment for patients with advanced renal cell carcinoma,https://www.benzinga.com/news/19/04/13569521/mercks-keytruda-in-combination-with-inlyta-approved-by-the-fda-as-first-line-treatment-for-patients,Benzinga Newsdesk,2019-04-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.79295
851194,shares of several drug companies are trading lower amid continued efforts from washington to curb prescription drug prices the overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy,https://www.benzinga.com/markets/wiim/19/04/13561029/shares-of-several-drug-companies-are-trading-lower-amid-continued-efforts-from-washington-to-curb-pr,Benzinga Newsdesk,2019-04-18 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.18155
851195,shares of several drug companies are trading lower amid continued efforts from washington to curb prescription drug prices the overall healthcare sector has seen weakness recently due to uncertainty over the future of healthcare policy,https://www.benzinga.com/markets/wiim/19/04/13552551/shares-of-several-drug-companies-are-trading-lower-amid-continued-efforts-from-washington-to-curb-pr,Benzinga Newsdesk,2019-04-17 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.18155
851196,shares of several drug companies are trading lower weakness may be tied to uncertainty over healthcare policy going into the primaries and washingtons recent efforts to curb prescription drug prices,https://www.benzinga.com/markets/wiim/19/04/13547205/shares-of-several-drug-companies-are-trading-lower-weakness-may-be-tied-to-uncertainty-over-healthca,Benzinga Newsdesk,2019-04-16 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.18155
851197,the daily biotech pulse jj earnings fda nod for medicinova proteon to explore strategic alternatives,https://www.benzinga.com/general/biotech/19/04/13541554/the-daily-biotech-pulse-j-j-earnings-fda-nod-for-mediconova-proteon-to-explore-strategic-alternat,Shanthi Rexaline,2019-04-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
851198,measles cases worldwide rose nearly fourfold in first quarter of to against same period last year provisional data shows,https://www.benzinga.com/general/health-care/19/04/13537257/measles-cases-worldwide-rose-nearly-four-fold-in-first-quarter-of-2019-to-112-163-against-sam,Benzinga Newsdesk,2019-04-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851199,the daily biotech pulse mercks keytruda clinches another fda win kempharm close to nda filing for adhd drug,https://www.benzinga.com/general/biotech/19/04/13527457/the-daily-biotech-pulse-mercks-keytruda-clinches-another-fda-win-kempharm-close-to-nda-filing-for,Shanthi Rexaline,2019-04-12 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.79295
851200,merck reports fda approval for expanded monotherapy label for keytruda,https://www.benzinga.com/news/19/04/13526626/merck-reports-fda-approval-for-expanded-monotherapy-label-for-keytruda,Benzinga Newsdesk,2019-04-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
851201,nyc mandates measles vaccinations merck is the exclusive manufacturer,https://www.benzinga.com/trading-ideas/long-ideas/19/04/13514693/nyc-mandates-measles-vaccinations-merck-is-the-exclusive-manufacturer,Elizabeth Balboa,2019-04-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5640000000000001
851202,the daily biotech pulse nash cheer for intercept gilead layoffs biodelivery licenses constipation drug,https://www.benzinga.com/general/biotech/19/04/13520284/the-daily-biotech-pulse-nash-cheer-for-intercept-gilead-layoffs-biodelivery-licenses-constipation,Shanthi Rexaline,2019-04-11 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.7553000000000001
851203,astrazeneca merck announce lynparza approved in eu for the treatment of germline brcamutated hernegative advanced breast cancer,https://www.benzinga.com/news/19/04/13513036/astrazeneca-merck-announce-lynparza-approved-in-eu-for-the-treatment-of-germline-brca-mutated-her2-n,Charles Gross,2019-04-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
851204,the week ahead in biotech conferences pdufa dates and clinical trial readouts,https://www.benzinga.com/general/biotech/19/04/13488096/the-week-ahead-in-biotech-conferences-pdufa-dates-and-clinical-trial-readouts,Shanthi Rexaline,2019-04-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851205,myriad genetics astrazeneca merck report expansion of companion diagnostic partnership,https://www.benzinga.com/news/19/04/13485224/myriad-genetics-astrazeneca-merck-report-expansion-of-companion-diagnostic-partnership,Benzinga Newsdesk,2019-04-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851206,the daily biotech pulse fda nod for adma regulatory setback for apyx achieve life sciences smoking cessation drug trial,https://www.benzinga.com/general/biotech/19/04/13466474/the-daily-biotech-pulse-fda-nod-for-adma-regulatory-setback-for-apyx-,Shanthi Rexaline,2019-04-02 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.5
851207,biotech winners losers in q,https://www.benzinga.com/general/biotech/19/04/13441864/biotech-winners-losers-in-q1,Shanthi Rexaline,2019-04-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.4614
851208,advaxis shares surge after positive clinical trial updates,https://www.benzinga.com/general/biotech/19/04/13459673/advaxis-shares-surge-after-positive-clinical-trial-updates,Shanthi Rexaline,2019-04-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.85015
851209,astrazenecas rare pediatric genetic disorder drug granted breakthrough therapy designation,https://www.benzinga.com/general/biotech/19/04/13459091/astrazenecas-rare-pediatric-genetic-disorder-drug-granted-breakthroug,Shanthi Rexaline,2019-04-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.41105
851210,syndax pharmaceuticals highlights presentation of updated phase data from encore trial of entinostat in combination with keytruda at american association for cancer research annual meeting,https://www.benzinga.com/general/biotech/19/04/13459429/syndax-pharmaceuticals-highlights-presentation-of-updated-phase-2-dat,Benzinga Newsdesk,2019-04-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
851211,advaxis says its phase keynote study prolonged survival in metastatic castrationresistant prostate cancer,https://www.benzinga.com/news/19/04/13457592/advaxis-says-its-phase-12-keynote-046-study-prolonged-survival-in-metastatic-cas,Benzinga Newsdesk,2019-04-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
851212,alkermes merck sage therapeutics and takeda pharma announce a partnership to qualify biomarkers for schizophrenia drug development,https://www.benzinga.com/news/19/04/13456709/alkermes-merck-sage-therapeutics-and-takeda-pharma-announce-a-partnership-to-qua,Benzinga Newsdesk,2019-04-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851213,mercks keytruda approved in china for firstline treatment of metastatic nonsquamous nonsmall cell lung cancer in combination with chemotherapy,https://www.benzinga.com/news/19/04/13456552/mercks-keytruda-approved-in-china-for-first-line-treatment-of-metastatic-nonsqua,Benzinga Newsdesk,2019-04-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.30910000000000004
851214,merck and astrazenecas selumetinib is granted breakthrough therapy designation in neurofibromatosis type ,https://www.benzinga.com/news/19/04/13456447/merck-and-astrazenecas-selumetinib-is-granted-breakthrough-therapy-designation-i,Benzinga Newsdesk,2019-04-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
851215,astrazeneca merck announce selumetinib granted us breakthrough therapy designation in neurofibromatosis type ,https://www.benzinga.com/news/19/04/13455911/astrazeneca-merck-announce-selumetinib-granted-us-breakthrough-therapy-designati,Charles Gross,2019-04-01 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.625
851216,congo health ministry says has recorded new confirmed cases of ebola,https://www.benzinga.com/news/19/03/13451341/congo-health-ministry-says-has-recorded-15-new-confirmed-cases-of-ebola,Benzinga Newsdesk,2019-03-29 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.5
851217,attention biotech investors mark your calendar for these april pdufa dates,https://www.benzinga.com/general/biotech/19/03/13426792/attention-biotech-investors-mark-your-calendar-for-these-april-pdufa-,Shanthi Rexaline,2019-03-29 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851218,the daily biotech pulse fda nod for novartis jazz positive latestage data for sleep disorder drug genfit ipo,https://www.benzinga.com/general/biotech/19/03/13429944/the-daily-biotech-pulse-fda-nod-for-novartis-jazz-positive-late-stage,Shanthi Rexaline,2019-03-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.61315
851219,merck shares unaffected as traders circulate business insider interview from mon highlighting ceo hinted he could step down,https://www.benzinga.com/news/19/03/13424721/merck-shares-unaffected-as-traders-circulate-business-insider-interview-from-mon,Benzinga Newsdesk,2019-03-26 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.648
851220,these are some of the bestperforming leveraged etfs of the year,https://www.benzinga.com/general/biotech/19/03/13418052/these-are-some-of-the-best-performing-leveraged-etfs-of-the-year,Chris Dier-Scalise,2019-03-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851221,the week ahead in biotech conferences pdufa dates clinical trials earnings and ipos,https://www.benzinga.com/general/biotech/19/03/13404293/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trials-ear,Shanthi Rexaline,2019-03-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851222,the daily biotech pulse immutep gets us patent conatus nash disappointment eisai moves on after aducanumab setback,https://www.benzinga.com/general/biotech/19/03/13406921/the-daily-biotech-pulse-immutep-gets-us-patent-conatus-nash-disappoin,Shanthi Rexaline,2019-03-22 00:00:00,MRK,1,2,0,1,0,0,1,1,0,0.24469999999999997
851223,fedexs struggles may be less about global demand and more about notpetya,https://www.benzinga.com/news/19/03/13403427/fedexs-struggles-may-be-less-about-global-demand-and-more-about-notpetya,FreightWaves,2019-03-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.29545
851224,watching stocks with alzheimers treatment candidates merck roche abbvie neurotrope ac immune denali inmune bio bioxcel therapeutics intracellular anavex pain therapeutics grifols,https://www.benzinga.com/news/19/03/13400526/watching-stocks-with-alzheimers-treatment-candidates-merck-roche-abbvie-neurotro,Benzinga Newsdesk,2019-03-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3634
851225,merck and ngm bio announce extension of strategic collaboration to ,https://www.benzinga.com/general/biotech/19/03/13392768/merck-and-ngm-bio-announce-extension-of-strategic-collaboration-to-20,Benzinga Newsdesk,2019-03-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851226,morgan stanley drops bearish exelixis stance sees limited downside risk,https://www.benzinga.com/analyst-ratings/analyst-color/19/03/13378204/morgan-stanley-drops-bearish-exelixis-stance-sees-limit,Shanthi Rexaline,2019-03-18 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.19379999999999997
851227,enigma biomedical reports exclusive license deal with merck for global development commercialization of mk an alzheimers treatment,https://www.benzinga.com/news/19/03/13371039/enigma-biomedical-reports-exclusive-license-deal-with-merck-for-global-developme,Benzinga Newsdesk,2019-03-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5640000000000001
851228,merck reports ec approved keytruda in combo with chemo for firstline treatment of adults with metastatic squamous nonsmall cell lung cancer,https://www.benzinga.com/news/19/03/13358168/merck-reports-ec-approved-keytruda-in-combo-with-chemo-for-first-line-treatment-,Benzinga Newsdesk,2019-03-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.30910000000000004
851229,merck co option alert jun calls at the ask vs oi earnings before open est ref,https://www.benzinga.com/markets/options/19/03/13318617/merck-co-option-alert-jun-2020-85-calls-at-the-ask-1000-4-901-vs-113-,Charles Gross,2019-03-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
851230,the daily biotech pulse horizon pharma under doj radar fda greenlights jjs depression drug endologix reverse split,https://www.benzinga.com/general/biotech/19/03/13307490/the-daily-biotech-pulse-horizon-pharma-under-doj-radar-fda-greenlight,Shanthi Rexaline,2019-03-06 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.21405000000000002
851231,merck begins tender offer to acquire immune design,https://www.benzinga.com/news/19/03/13297338/merck-begins-tender-offer-to-acquire-immune-design,Benzinga Newsdesk,2019-03-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
851232,bioxcel therapeutics announces merck and pfizer join its clinical collaboration with nektar therapeutics to evaluate a triple therapy for pancreatic cancer,https://www.benzinga.com/news/19/03/13288493/bioxcel-therapeutics-announces-merck-and-pfizer-join-its-clinical-collaboration-,Benzinga â€‰Newsdesk,2019-03-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.25305
851233,merck says the european medicines agency adopts positive opinion for mercks keytruda for sixweek dosing schedule across all current monotherapy indications,https://www.benzinga.com/news/19/03/13287473/merck-says-the-european-medicines-agency-adopts-positive-opinion-for-mercks-keyt,Benzinga Newsdesk,2019-03-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8243
851234,merck reports positive chmp opinion for use in germline brcamutated hernegative advanced breast cancer,https://www.benzinga.com/news/19/03/13278420/merck-reports-positive-chmp-opinion-for-use-in-germline-brca-mutated-her2-negati,Benzinga Newsdesk,2019-03-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5258
851235,the daily biotech pulse bristolmyers squibbcelgene deal faces setback syneos hit by sec probe fda cheer for t biosystems,https://www.benzinga.com/general/biotech/19/02/13265063/the-daily-biotech-pulse-bristol-myers-squibb-celgene-deal-faces-setba,Shanthi Rexaline,2019-02-28 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.7553000000000001
851236,the daily biotech pulse fda panel vote sinks karyopharm refusetofile letter for adamis tandem diabetes earnings,https://www.benzinga.com/general/biotech/19/02/13254225/the-daily-biotech-pulse-fda-panel-vote-sinks-karyopharm-refuse-to-fil,Shanthi Rexaline,2019-02-27 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
851237,sellas reviews strategic options to fund clinical development programs,https://www.benzinga.com/general/biotech/19/02/13246349/sellas-reviews-strategic-options-to-fund-clinical-development-program,Shanthi Rexaline,2019-02-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851238,it could be time for this pharma etf,https://www.benzinga.com/trading-ideas/long-ideas/19/02/13241310/it-could-be-time-for-this-pharma-etf,ETF Professor,2019-02-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851239,the daily biotech pulse immunomedics ceo departs ultragenyx offering karyopharm awaits fda panel vote,https://www.benzinga.com/general/biotech/19/02/13242893/the-daily-biotech-pulse-immunomedics-ceo-departs-ultragenyx-offering-,Shanthi Rexaline,2019-02-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5386
851240,update merck astrazeneca report phase iii polo trial met primary endpoint,https://www.benzinga.com/news/19/02/13243704/update-merck-astrazeneca-report-phase-iii-polo-trial-met-primary-endpoint,Benzinga Newsdesk,2019-02-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851241,merck astrazeneca report lynparza reduced the risk of disease progression or death as stline maintenance treatment in germline brcamutated metastatic pancreatic cancer,https://www.benzinga.com/news/19/02/13243700/merck-astrazeneca-report-lynparza-reduced-the-risk-of-disease-progression-or-dea,Benzinga Newsdesk,2019-02-26 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.056999999999999995
851242,astrazeneca merck announce phase iii polo trial met its primary endpoint of progressionfree survival,https://www.benzinga.com/news/19/02/13242962/astrazeneca-merck-announce-phase-iii-polo-trial-met-its-primary-endpoint-of-prog,Charles Gross,2019-02-26 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.5
851243,pharma ma wave spark therapeutics clementia pharma among the rare disease biotechs acquired,https://www.benzinga.com/general/biotech/19/02/13233966/pharma-m-a-wave-spark-therapeutics-clementia-pharma-among-the-rare-di,Shanthi Rexaline,2019-02-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.61315
851244,the week ahead in biotech conferences pdufa dates clinical trials earnings ipos,https://www.benzinga.com/general/biotech/19/02/13222075/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trials-ear,Shanthi Rexaline,2019-02-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851245,cantor fitzgerald initiates coverage on merck co with overweight rating announces price target,https://www.benzinga.com/news/19/02/13228032/cantor-fitzgerald-initiates-coverage-on-merck-co-with-overweight-rating-announce,Vick Meyer,2019-02-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3194
851246,the daily biotech pulse biomarin slips on earnings therapeuticsmd posts inline results orchard to present immunodeficiency drug data,https://www.benzinga.com/general/biotech/19/02/13225988/the-daily-biotech-pulse-biomarin-slips-on-earnings-therapeuticsmd-pos,Shanthi Rexaline,2019-02-22 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.5
851247, biggest movers from yesterday,https://www.benzinga.com/news/19/02/13226103/65-biggest-movers-from-yesterday,Lisa Levin,2019-02-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851248,midafternoon market update dow falls points delphi technologies shares spike higher,https://www.benzinga.com/news/19/02/13222118/mid-afternoon-market-update-dow-falls-150-points-delphi-technologies-shares-spik,Lisa Levin,2019-02-21 00:00:00,MRK,1,0,0,1,0,0,1,1,1,0.648
851249, stocks moving in thursdays midday session,https://www.benzinga.com/news/19/02/13221201/50-stocks-moving-in-thursdays-mid-day-session,Lisa Levin,2019-02-21 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851250,midday market update immune design jumps following acquisition news carbon black shares slide,https://www.benzinga.com/news/19/02/13221199/mid-day-market-update-immune-design-jumps-following-acquisition-news-carbon-blac,Lisa Levin,2019-02-21 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.76335
851251,midmorning market update markets open lower dominos pizza misses q views,https://www.benzinga.com/news/19/02/13219439/mid-morning-market-update-markets-open-lower-dominos-pizza-misses-q4-views,Lisa Levin,2019-02-21 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.26165
851252,merck to buy immune design for m,https://www.benzinga.com/general/biotech/19/02/13218686/merck-to-buy-immune-design-for-300m,Shanthi Rexaline,2019-02-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
851253, stocks moving in thursdays premarket session,https://www.benzinga.com/news/19/02/13217902/31-stocks-moving-in-thursdays-pre-market-session,Lisa Levin,2019-02-21 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851254,merck to acquire immune design at share in cash or m,https://www.benzinga.com/news/19/02/13216879/merck-to-acquire-immune-design-at-5-85share-in-cash-or-300m,Benzinga Newsdesk,2019-02-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.76335
851255,the daily biotech pulse teva settles with ftc setback for merck in liver cancer trial sienna biopharma offering,https://www.benzinga.com/general/biotech/19/02/13206673/the-daily-biotech-pulse-teva-settles-with-ftc-setback-for-merck-in-li,Shanthi Rexaline,2019-02-20 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.17015000000000002
851256,fda grants priority review to mercks supplemental biologics license application for keytruda monotherapy for thirdline treatment of patients with advanced small cell lung cancer,https://www.benzinga.com/general/biotech/19/02/13207367/fda-grants-priority-review-to-mercks-supplemental-biologics-license-a,Benzinga Newsdesk,2019-02-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3194
851257,merck reports phase keynote trial evaluating keytruda did not meet coprimary endpoints,https://www.benzinga.com/general/biotech/19/02/13204176/merck-reports-phase-3-keynote-240-trial-evaluating-keytruda-did-not-m,Benzinga Newsdesk,2019-02-19 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851258,merck says us patent trademark office issued formal notice allowing cos patent application directed to its proxycrispr technology,https://www.benzinga.com/news/19/02/13198647/merck-says-us-patent-trademark-office-issued-formal-notice-allowing-co-s-patent-,Benzinga Newsdesk,2019-02-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851259,fda approves mercks keytruda for adjuvant treatment of patients with melanoma with involvement of lymph nodes following complete resection,https://www.benzinga.com/news/19/02/13197635/fda-approves-mercks-keytruda-for-adjuvant-treatment-of-patients-with-melanoma-wi,Benzinga Newsdesk,2019-02-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
851260,merck announces keytruda in combination with inlyta reduced risk of death by nearly half compared to sunitinib as firstline treatment for advanced rcc at asco gu ,https://www.benzinga.com/news/19/02/13193885/merck-announces-keytruda-in-combination-with-inlyta-reduced-risk-of-death-by-nea,Charles Gross,2019-02-17 00:00:00,MRK,1,0,1,1,1,0,1,0,0,0.19379999999999997
851261,merck reports fda granted priority review for cos supplemental biologics license application for keytruda combo with inlyta for firstline treatment for advanced renal cell carcinoma,https://www.benzinga.com/news/19/02/13186832/merck-reports-fda-granted-priority-review-for-co-s-supplemental-biologics-licens,Benzinga Newsdesk,2019-02-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
851262,merck highlights new phase trials,https://www.benzinga.com/news/19/02/13171032/merck-highlights-3-new-phase-3-trials,Benzinga Newsdesk,2019-02-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851263,hemispherx biopharma announces commencement of a new subject clinical trial combining ampligen and mercks keytruda in the treatment of recurrent ovarian cancer,https://www.benzinga.com/general/biotech/19/02/13137240/hemispherx-biopharma-announces-commencement-of-a-new-45-subject-clini,Benzinga Newsdesk,2019-02-11 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.17015000000000002
851264,merck granted fda priority review for its supplemental biologics license application for keytruda for the firstline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma,https://www.benzinga.com/news/19/02/13136131/merck-granted-fda-priority-review-for-its-supplemental-biologics-license-applica,luke@benzinga.com,2019-02-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
851265,the week ahead in biotech conferences pdufa dates and clinical trials,https://www.benzinga.com/general/biotech/19/02/13113062/the-week-ahead-in-biotech-conferences-pdufa-dates-and-clinical-trials,Shanthi Rexaline,2019-02-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851266,third point dissolves stakes in netflix microsoft cuts stake in paypal merck visa american express baxter raises stakes in campbell soup salesforce,https://www.benzinga.com/news/insider-trades/19/02/13134804/third-point-dissolves-stakes-in-netflix-microsoft-cuts-stake-in-p,Charles Gross,2019-02-09 00:00:00,MRK,1,1,1,1,1,0,1,0,0,0.352
851267,bank of america reiterates buy and target on merck due to keytruda driven upside undemanding valuation optionality animal health spin om expansion,https://www.benzinga.com/analyst-ratings/analyst-color/19/02/13120921/bank-of-america-reiterates-buy-and-84-target-on-merck-d,Benzinga_Newsdesk,2019-02-07 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851268,drugmakers offered cb in price cuts freeze of drug prices in response to proposed crackdown by canada regulator,https://www.benzinga.com/news/19/02/13108194/drugmakers-offered-c-9-6b-in-price-cuts-freeze-of-drug-prices-in-response-to-pro,Charles Gross,2019-02-06 00:00:00,MRK,1,1,0,1,1,0,1,0,0,0.375
851269,merck says ceo frazier plans to testify at feb senate drug pricing hearing,https://www.benzinga.com/news/19/02/13103344/merck-says-ceo-frazier-plans-to-testify-at-feb-26-senate-drug-pricing-hearing,Benzinga_Newsdesk,2019-02-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851270,codexis shares are trading higher after the company reported a multiyear agreement with merck to perform technology upgrades,https://www.benzinga.com/markets/wiim/19/02/13100485/codexis-shares-are-trading-higher-after-the-company-reported-a-multi-yea,Benzinga â€‰Newsdesk,2019-02-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.82985
851271,the daily biotech pulse gilead earnings codexis sings pact with merck eli lilly reports positive trial results,https://www.benzinga.com/general/biotech/19/02/13098290/the-daily-biotech-pulse-gilead-earnings-codexis-sings-pact-with-merck,Shanthi Rexaline,2019-02-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
851272,fda accepts for review new drug application for mercks investigational combination of imipenemcilastatin and relebactam acceps supplemental nda for zerbaxa,https://www.benzinga.com/news/19/02/13099263/fda-accepts-for-review-new-drug-application-for-mercks-investigational-combinati,Benzinga Newsdesk,2019-02-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
851273,update financial terms of codexismerck deal were not disclosed,https://www.benzinga.com/news/19/02/13095524/update-financial-terms-of-codexismerck-deal-were-not-disclosed,Benzinga Newsdesk,2019-02-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851274,codexis reports secured multiyear technology upgrade package for codeevolver protein engineering platform license with merck,https://www.benzinga.com/news/19/02/13095517/codexis-reports-secured-multi-year-technology-upgrade-package-for-codeevolver-pr,Benzinga Newsdesk,2019-02-04 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.70095
851275,merck announces the european medicines agency gave a positive opinion on keytruda in combination with chemotherapy for firstline treatment of adults with metastatic squamous nonsmall cell lung cancer,https://www.benzinga.com/news/19/02/13089687/merck-announces-the-european-medicines-agency-gave-a-positive-opinion-on-keytrud,Benzinga Newsdesk,2019-02-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.39885
851276,barrons picks and pans corning merck microsoft and more,https://www.benzinga.com/media/19/02/13088476/barrons-picks-and-pans-corning-merck-microsoft-and-more,Nelson Hem,2019-02-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851277,attention biotech investors mark your calendar for these february pdufa dates,https://www.benzinga.com/general/biotech/19/02/13041771/attention-biotech-investors-mark-your-calendar-for-these-february-pdu,Shanthi Rexaline,2019-02-01 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851278,merck co shares are trading higher after the company reported inline q eps figures and beat sales estimates,https://www.benzinga.com/markets/wiim/19/02/13083660/merck-co-shares-are-trading-higher-after-the-company-reported-inline-q4-,Benzinga Newsdesk,2019-02-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
851279,the daily biotech pulse merck earnings positive relaunch of titans opioid disorder treatment implant,https://www.benzinga.com/general/biotech/19/02/13080524/the-daily-biotech-pulse-merck-earnings-positive-relaunch-of-titans-op,Shanthi Rexaline,2019-02-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.61315
851280,merck sees fy adj eps vs estimate sales bb vs b est,https://www.benzinga.com/news/19/02/13081284/merck-sees-fy19-adj-eps-4-57-4-72-vs-4-69-estimate-sales-43-2b-44-7b-vs-44-54b-e,Benzinga Newsdesk,2019-02-01 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851281,merck q eps inline sales b beat b estimate,https://www.benzinga.com/news/earnings/19/02/13081283/merck-q4-eps-1-04-inline-sales-10-998b-beat-10-96b-estimate,Benzinga Newsdesk,2019-02-01 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851282, stocks to watch for february ,https://www.benzinga.com/news/earnings/19/02/13080807/12-stocks-to-watch-for-february-1-2019,Lisa Levin,2019-02-01 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
851283,earnings scheduled for february ,https://www.benzinga.com/news/earnings/19/02/13080759/earnings-scheduled-for-february-1-2019,Lisa Levin,2019-02-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851284,mercks q earnings preview,https://www.benzinga.com/news/earnings-previews/19/01/13076031/preview-mercks-earnings,Benzinga Newsdesk,2019-01-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851285,how to approach q earnings the technical perspective,https://www.benzinga.com/news/earnings/19/01/13057960/how-to-approach-q4-earnings-the-technical-perspective,Chris Dier-Scalise,2019-01-29 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851286,evelo biosciences announces first patient does in investigatorsponsored phase a clinical trial of edp in combination with keytruda in patients with metastatic melanoma,https://www.benzinga.com/news/19/01/13044961/evelo-biosciences-announces-first-patient-does-in-investigator-sponsored-phase-2,Charles Gross,2019-01-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851287,barrons on the cost of climate change,https://www.benzinga.com/media/19/01/13043937/barrons-on-the-cost-of-climate-change,Nelson Hem,2019-01-27 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
851288,the week ahead in biotech conferences pdufa dates clinical trials and earnings,https://www.benzinga.com/general/biotech/19/01/13033939/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trials-and,Shanthi Rexaline,2019-01-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851289,bristolmyers squibb withdraws regulatory application for lung cancer combo drug,https://www.benzinga.com/general/biotech/19/01/13031417/bristol-myers-squibb-withdraws-regulatory-application-for-lung-cancer,Shanthi Rexaline,2019-01-24 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.17015000000000002
851290,benzingas top upgrades downgrades for january ,https://www.benzinga.com/analyst-ratings/upgrades/19/01/13023773/benzingas-top-upgrades-downgrades-for-january-23-2019,Lisa Levin,2019-01-23 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.60115
851291,bmo capital downgrades merck co to market perform announces price target,https://www.benzinga.com/news/19/01/13022160/bmo-capital-downgrades-merck-co-to-market-perform-announces-80-price-target,Vick Meyer,2019-01-23 00:00:00,MRK,1,1,0,1,1,0,1,1,1,0.5
851292,bank of america jpmorgan merck stratasys fast money picks for january ,https://www.benzinga.com/media/19/01/12982785/bank-of-america-jpmorgan-merck-stratasys-fast-money-picks-for-january-15,Craig Jones,2019-01-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851293,merck reports keytruda reduced risk of death by vs chemotherapy in previouslytreated patients with advanced esophageal esophagogastric junction carcinoma whose tumors expressed pdl,https://www.benzinga.com/news/19/01/12981856/merck-reports-keytruda-reduced-risk-of-death-by-31-vs-chemotherapy-in-previously,Benzinga Newsdesk,2019-01-14 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.19379999999999997
851294,how new laws affected stocks in the last week,https://www.benzinga.com/news/19/01/12951083/how-7-new-laws-affected-stocks-in-the-last-week,Elizabeth Balboa,2019-01-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.42345
851295, topselling drugs with growth potential in ,https://www.benzinga.com/general/biotech/19/01/12935891/5-top-selling-drugs-with-growth-potential-in-2019,Shanthi Rexaline,2019-01-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6909
851296,amunix reports licensing deal with merck for protia immune activator platform no terms disclosed,https://www.benzinga.com/news/19/01/12928516/amunix-reports-licensing-deal-with-merck-for-protia-immune-activator-platform-no,Benzinga Newsdesk,2019-01-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851297,cocrystal pharma announces exclusive worldwide license and collaboration agreement with merck to develop influenza ab agents cococrystal will receive upfront payment on an undisclosed amount is eligible for up to m in milestones plus royalties,https://www.benzinga.com/general/biotech/19/01/12925034/cocrystal-pharma-announces-exclusive-worldwide-license-and-collaborat,Benzinga Newsdesk,2019-01-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7859499999999999
851298,the daily biotech pulse aevis adhd drug flunks midstage trial bristolmyers to buy celgene teva settles with amgen,https://www.benzinga.com/general/biotech/19/01/12923463/the-daily-biotech-pulse-aevis-adhd-drug-flunks-mid-stage-trial-bristo,Shanthi Rexaline,2019-01-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.28925
851299,merck reports keytruda received new approvals in japan including advanced nonsmall cell lung cancer as adjuvant therapy for melanoma in advanced microsatellite instabilityhigh tumors,https://www.benzinga.com/news/19/01/12924038/merck-reports-keytruda-received-5-new-approvals-in-japan-including-advanced-non-,Benzinga Newsdesk,2019-01-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.32999999999999996
851300,merck reports exercise of its option for ngm bios ngm for treatment of nash type diabetes,https://www.benzinga.com/news/19/01/12924011/merck-reports-exercise-of-its-option-for-ngm-bios-ngm313-for-treatment-of-nash-t,Benzinga Newsdesk,2019-01-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851301,merck exercises option for ngm bios investigational insulin sensitizer ngm for treatment of nash and type diabetes,https://www.benzinga.com/news/19/01/12924001/merck-exercises-option-for-ngm-bios-investigational-insulin-sensitizer-ngm313-fo,Charles Gross,2019-01-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851302,attention biotech investors mark your calendar for these january pdufa dates,https://www.benzinga.com/general/biotech/18/12/12900300/attention-biotech-investors-mark-your-calendar-for-these-january-pduf,Shanthi Rexaline,2018-12-31 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851303,the week ahead in biotech conferences pdufa dates and clinical trials,https://www.benzinga.com/general/biotech/18/12/12908869/the-week-ahead-in-biotech-conferences-pdufa-dates-and-clinical-trials,Shanthi Rexaline,2018-12-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851304,the week ahead in biotech focus shifts to yearend clinical trial results,https://www.benzinga.com/general/biotech/18/12/12875979/the-week-ahead-in-biotech-focus-shifts-to-year-end-clinical-trial-res,Shanthi Rexaline,2018-12-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851305,the daily biotech pulse proteostasis delays data akron gets new ceo pfizer halts vaccine trial,https://www.benzinga.com/general/biotech/18/12/12886868/the-daily-biotech-pulse-proteostasis-delays-data-akron-gets-new-ceo-p,Shanthi Rexaline,2018-12-21 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851306,merck extends pdufa date for supplemental biologics licence for keytruda by three months to april ,https://www.benzinga.com/news/18/12/12885146/merck-extends-pdufa-date-for-supplemental-biologics-licence-for-keytruda-by-thre,Hal Lindon,2018-12-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5640000000000001
851307,the daily biotech pulse tilray inks cannabis drink pact double delight for merck fda snub for spectrum,https://www.benzinga.com/general/biotech/18/12/12879213/the-daily-biotech-pulse-tilray-inks-cannabis-drink-pact-double-deligh,Shanthi Rexaline,2018-12-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6366
851308,astrazeneca merck report lynparza met primary endpoint in phase solo trial for treatment of relapsed brcamutated advanced ovarian cancer,https://www.benzinga.com/news/18/12/12879715/astrazeneca-merck-report-lynparza-met-primary-endpoint-in-phase-3-solo-3-trial-f,Benzinga Newsdesk,2018-12-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.23665000000000003
851309,fda approves mercks keytruda for treatment of recurrent locally advanced or metastatic merkel cell carcinoma,https://www.benzinga.com/news/18/12/12877281/fda-approves-mercks-keytruda-for-treatment-of-recurrent-locally-advanced-or-meta,Benzinga Newsdesk,2018-12-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7859499999999999
851310,astrazeneca merck report fda approval for lynparza for firstline maintenance therapy in brcamutated advanced ovarian cancer,https://www.benzinga.com/news/18/12/12877012/astrazeneca-merck-report-fda-approval-for-lynparza-for-first-line-maintenance-th,Benzinga Newsdesk,2018-12-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.4614
851311,merck announces fda approval of lynparza for ovarian cancer,https://www.benzinga.com/news/18/12/12876748/merck-announces-fda-approval-of-lynparza-for-ovarian-cancer,Benzinga Newsdesk,2018-12-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3409
851312,merck receives fda approval for pembrolizumab in merkel cell carcinoma,https://www.benzinga.com/news/18/12/12876520/merck-receives-fda-approval-for-pembrolizumab-in-merkel-cell-carcinoma,Benzinga Newsdesk,2018-12-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
851313,mercks keytruda as adjuvant therapy for adults with resected stage iii melanoma approved by the european commission,https://www.benzinga.com/news/18/12/12857456/mercks-keytruda-as-adjuvant-therapy-for-adults-with-resected-stage-iii-melanoma-,Benzinga Newsdesk,2018-12-17 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.71075
851314,stocks trading ex dividend for fri dec ,https://www.benzinga.com/news/18/12/12852538/stocks-trading-ex-dividend-for-fri-dec-14-2018,Benzinga Newsdesk,2018-12-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851315,a peek into the markets us stock futures tumble ahead of economic reports,https://www.benzinga.com/news/18/12/12851096/a-peek-into-the-markets-us-stock-futures-tumble-ahead-of-economic-reports,Lisa Levin,2018-12-14 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851316,merck reports purchase of antelliq group for b in cash assume b in co debt,https://www.benzinga.com/news/18/12/12850875/merck-reports-purchase-of-antelliq-group-for-2-1b-in-cash-assume-1-15b-in-co-deb,Benzinga Newsdesk,2018-12-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3194
851317,merck and instituto butantan announce collaboration agreement to develop dengue infections vaccine instituto butantan to receive m upfront and is eligible for up to m in milestones,https://www.benzinga.com/general/biotech/18/12/12838795/merck-and-instituto-butantan-announce-collaboration-agreement-to-deve,Benzinga Newsdesk,2018-12-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
851318,gabelli names clovis as top pick calls the biotech a likely takeout candidate,https://www.benzinga.com/analyst-ratings/analyst-color/18/12/12832359/gabelli-names-clovis-as-top-pick-says-biotech-a-likely-,Shanthi Rexaline,2018-12-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.60115
851319,merck and roche enter into collaboration agreement to develop companion diagnostic test to identify patients eligible for pd therapy based on the status of a biomaker in advanced solid tumors,https://www.benzinga.com/general/biotech/18/12/12831292/merck-and-roche-enter-into-collaboration-agreement-to-develop-compani,Benzinga Newsdesk,2018-12-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.85015
851320,the daily biotech pulse management change at merck jazz buyback arrowhead earnings,https://www.benzinga.com/general/biotech/18/12/12829431/the-daily-biotech-pulse-management-change-at-merck-jazz-buyback-arrow,Shanthi Rexaline,2018-12-11 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851321,merck names frank clyburn chief commercial officer michael nally chief marketing officer bz note these positions are both new roles for merck,https://www.benzinga.com/news/18/12/12826439/merck-names-frank-clyburn-chief-commercial-officer-michael-nally-chief-marketing,Benzinga Newsdesk,2018-12-10 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.55135
851322,merck reports fda orphan drug designation for m in biliary tract cancer,https://www.benzinga.com/news/18/12/12823622/merck-reports-fda-orphan-drug-designation-for-m7824-in-biliary-tract-cancer,Benzinga Newsdesk,2018-12-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
851323,the daily biotech pulse abbvie halts lung cancer trial oncomed merges with mereo momenta offering,https://www.benzinga.com/general/biotech/18/12/12805307/the-daily-biotech-pulse-abbvie-halts-lung-cancer-trial-oncomed-merges,Shanthi Rexaline,2018-12-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
851324,ra pharma reports received development milestone payment under deal with merck says is eligible to earn up to m in added milestone payments,https://www.benzinga.com/news/18/12/12806339/ra-pharma-reports-received-development-milestone-payment-under-deal-with-merck-s,Benzinga Newsdesk,2018-12-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851325,ahead of midweek pause investors fret over trade pact details,https://www.benzinga.com/news/18/12/12795841/ahead-of-mid-week-pause-investors-fret-over-trade-pact-details,JJ Kinahan,2018-12-04 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.5
851326,stocks which set new week high yesterday mon dec ,https://www.benzinga.com/news/18/12/12795152/stocks-which-set-new-52-week-high-yesterday-mon-dec-3-2018,Benzinga Newsdesk,2018-12-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851327,the daily biotech pulse ash presentations take the spotlight eiger gets a new cfo,https://www.benzinga.com/general/biotech/18/12/12792932/the-daily-biotech-pulse-ash-presentations-take-the-spotlight-eiger-ge,Shanthi Rexaline,2018-12-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851328,attention biotech investors mark your calendar for these december pdufa dates,https://www.benzinga.com/general/biotech/18/11/12751254/attention-biotech-investors-mark-your-calendar-for-these-december-pdu,Shanthi Rexaline,2018-11-30 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
851329,stocks which set new week high yesterday thurs nov ,https://www.benzinga.com/news/18/11/12779656/stocks-which-set-new-52-week-high-yesterday-thurs-nov-29-2018,Benzinga Newsdesk,2018-11-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851330,the daily biotech pulse ec nod for shire mirati gets fda clearance for cancer drug trials phasebios first earnings,https://www.benzinga.com/general/biotech/18/11/12777751/the-daily-biotech-pulse-ec-nod-for-shire-mirati-gets-fda-clearance-fo,Shanthi Rexaline,2018-11-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
851331,merck is up in whats driving the rally,https://www.benzinga.com/analyst-ratings/analyst-color/18/11/12740354/merck-is-up-40-in-2018-whats-driving-the-rally,Shanthi Rexaline,2018-11-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851332,ebola outbreak in eastern congo now worlds second largest ever with cases,https://www.benzinga.com/general/biotech/18/11/12775073/ebola-outbreak-in-eastern-congo-now-worlds-second-largest-ever-with-4,Benzinga Newsdesk,2018-11-29 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851333,merk shares rise after the european commission approved cos hiv treatments in europe,https://www.benzinga.com/markets/wiim/18/11/12774878/merk-shares-rise-after-the-european-commission-approved-cos-hiv-treatmen,Benzinga Newsdesk,2018-11-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8062
851334,stocks which set new week high yesterday wed nov ,https://www.benzinga.com/trading-ideas/movers/18/11/12773043/stocks-which-set-new-52-week-high-yesterday-wed-nov-28-2018,Benzinga Newsdesk,2018-11-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851335,the daily biotech pulse twist in protagonist tale catalysts autoimmune disorder drug approved,https://www.benzinga.com/general/biotech/18/11/12769777/the-daily-biotech-pulse-twist-in-protagonist-tale-catalysts-autoimmun,Shanthi Rexaline,2018-11-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5129
851336,merck receives european commission approval for delstrigo as part of an hiv treatment regimen,https://www.benzinga.com/general/biotech/18/11/12768165/merck-receives-european-commission-approval-for-delstrigo-as-part-of-,Benzinga Newsdesk,2018-11-28 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.7383500000000001
851337,the daily biotech pulse abeona fires ceo loxo passes fda muster bristolmyers flunks lung cancer trial,https://www.benzinga.com/general/biotech/18/11/12754156/the-daily-biotech-pulse-abeona-fires-ceo-loxo-passes-fda-muster-brist,Shanthi Rexaline,2018-11-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.09899999999999998
851338,data dive trade talks and powell busy postholiday week on the way,https://www.benzinga.com/news/18/11/12749682/data-dive-trade-talks-and-powell-busy-post-holiday-week-on-the-way,JJ Kinahan,2018-11-26 00:00:00,MRK,1,1,1,0,1,1,1,1,1,0.5
851339,the week ahead in biotech ash pdufa dates clinical trials and earnings,https://www.benzinga.com/general/biotech/18/11/12741000/the-week-ahead-in-biotech-ash-2018-pdufa-dates-clinical-trials-and-ea,Shanthi Rexaline,2018-11-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851340, policy catalysts for health care investors to watch before years end,https://www.benzinga.com/analyst-ratings/analyst-color/18/11/12745249/9-policy-catalysts-for-health-care-investors-to-watch-b,Wayne Duggan,2018-11-25 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.74695
851341,stocks of vaccination providers do not react following update from health ministry suggesting new cases of ebola were reported in eastern congo wed,https://www.benzinga.com/news/18/11/12740739/stocks-of-vaccination-providers-do-not-react-following-update-from-health-minist,Benzinga Newsdesk,2018-11-21 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
851342,octobers biggest losers and most surprising winners,https://www.benzinga.com/general/education/18/11/12739240/octobers-biggest-losers-and-most-surprising-winners,Chris Dier-Scalise,2018-11-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6669
851343,stocks which set new week high yesterday mon nov ,https://www.benzinga.com/news/18/11/12731510/stocks-which-set-new-52-week-high-yesterday-mon-nov-19-2018,Benzinga Newsdesk,2018-11-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851344,the daily biotech pulse denalis positive results novartis substance abuse therapy launch medtronic earnings,https://www.benzinga.com/general/biotech/18/11/12729398/the-daily-biotech-pulse-denalis-positive-results-novartis-substance-a,Shanthi Rexaline,2018-11-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.42345
851345,merck and pfizers avelumab in platinumresistantrefractory ovarian cancer did not meet primary endpoints,https://www.benzinga.com/news/18/11/12722194/merck-and-pfizers-avelumab-in-platinum-resistantrefractory-ovarian-cancer-did-no,Benzinga Newsdesk,2018-11-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
851346,newlink genetics announces merck has begun rolling submission of licensure application for ebola vaccine v to us fda in co entered ito license agreement with merck to develop manufacture and commercialize ebola vaccine,https://www.benzinga.com/general/biotech/18/11/12707803/newlink-genetics-announces-merck-has-begun-rolling-submission-of-lice,Benzinga Newsdesk,2018-11-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
851347,the daily biotech pulse mallinckrodt faces fda panel reshapes earnings vapotherm to debut,https://www.benzinga.com/general/biotech/18/11/12693509/the-daily-biotech-pulse-mallinckrodt-faces-fda-panel-reshapes-earning,Shanthi Rexaline,2018-11-14 00:00:00,MRK,1,2,0,1,0,0,1,0,0,0.5
851348,merck reports keytruda significantly improved overall survival compared to chemotherapy in patients with advanced esophageal or esophagogastric junction carcnimoa whose tumors express pdl,https://www.benzinga.com/news/18/11/12694497/merck-reports-keytruda-significantly-improved-overall-survival-compared-to-chemo,Benzinga Newsdesk,2018-11-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81245
851349,merck reports commencement of rolling submission of licensure application for v to fda,https://www.benzinga.com/news/18/11/12690991/merck-reports-commencement-of-rolling-submission-of-licensure-application-for-v9,Benzinga Newsdesk,2018-11-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851350,world health organizations emergency response chief says we expect democratic republic of congos ebola outbreak to last at least another six months,https://www.benzinga.com/news/18/11/12686696/world-health-organizations-emergency-response-chief-says-we-expect-democratic-re,Benzinga Newsdesk,2018-11-13 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.30910000000000004
851351,octobers biggest losers and most surprising winners,https://www.benzinga.com/markets/18/11/12679916/octobers-biggest-losers-and-most-surprising-winners,Chris Dier-Scalise,2018-11-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6669
851352,merck announces the fda has accepted a supplemental new drug application for lynparza,https://www.benzinga.com/news/18/11/12677162/merck-announces-the-fda-has-accepted-a-supplemental-new-drug-application-for-lyn,Benzinga Newsdesk,2018-11-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6366
851353,astrazeneca merck announce fda accepts regulatory submission for lynparza maintenance therapy in newlydiagnosed brcamutated advanced ovarian cancer and grants priority review,https://www.benzinga.com/news/18/11/12676745/astrazeneca-merck-announce-fda-accepts-regulatory-submission-for-lynparza-mainte,Charles Gross,2018-11-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.4742
851354,fda approves mercks keytruda for patients with hepatocellular carcinoma hcc who have been previously treated with sorafenib,https://www.benzinga.com/general/biotech/18/11/12673625/fda-approves-mercks-keytruda-for-patients-with-hepatocellular-carcino,Benzinga Newsdesk,2018-11-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
851355,stocks which set new week high yesterday thurs nov ,https://www.benzinga.com/news/18/11/12670025/stocks-which-set-new-52-week-high-yesterday-thurs-nov-8-2018,Benzinga Newsdesk,2018-11-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851356,the daily biotech pulse sitc presentations pick up pace sandoz voluntary recall,https://www.benzinga.com/general/biotech/18/11/12668402/the-daily-biotech-pulse-sitc-presentations-pick-up-pace-sandoz-volunt,Shanthi Rexaline,2018-11-09 00:00:00,MRK,1,2,0,1,0,0,1,1,0,0.5
851357,stocks which set new week high yesterday wed nov ,https://www.benzinga.com/news/18/11/12661652/stocks-which-set-new-52-week-high-yesterday-wed-nov-7-2018,Benzinga Newsdesk,2018-11-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851358,the daily biotech pulse nantkwest reports positive cancer vaccine trial results sarepta offering,https://www.benzinga.com/general/biotech/18/11/12657560/the-daily-biotech-pulse-nantkwest-reports-positive-cancer-vaccine-tri,Shanthi Rexaline,2018-11-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.39885
851359,merck reports early phase data from mk mk trial to be presented at sitc meeting nov ,https://www.benzinga.com/news/18/11/12648083/merck-reports-early-phase-1-data-from-mk-4280-mk-7684-trial-to-be-presented-at-s,Benzinga Newsdesk,2018-11-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851360,the week ahead in biotech earnings conferences pdufa dates clinical trial results and ipos,https://www.benzinga.com/general/biotech/18/11/12615052/the-week-ahead-in-biotech-earnings-conferences-pdufa-dates-clinical-t,Shanthi Rexaline,2018-11-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851361,stocks which set new week high yesterday october st,https://www.benzinga.com/trading-ideas/technicals/18/11/12612575/stocks-which-set-new-52-week-high-yesterday-october-31st,Benzinga Newsdesk,2018-11-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851362,citigroup maintains buy on merck co raises price target to ,https://www.benzinga.com/news/18/11/12612480/citigroup-maintains-buy-on-merck-co-raises-price-target-to-84,Vick Meyer,2018-11-01 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851363,attention biotech investors mark your calendar for these november pdufa dates,https://www.benzinga.com/general/biotech/18/11/12577238/attention-biotech-investors-mark-your-calendar-for-these-november-pdu,Shanthi Rexaline,2018-11-01 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851364,the daily biotech pulse abbvies leukemia drug trial meets endpoint denali strikes collaboration deal,https://www.benzinga.com/general/biotech/18/11/12608556/the-daily-biotech-pulse-abbvies-leukemia-drug-trial-meets-endpoint-de,Shanthi Rexaline,2018-11-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3194
851365,citigroup maintains buy on merck co raises price target to ,https://www.benzinga.com/news/18/10/12602149/citigroup-maintains-buy-on-merck-co-raises-price-target-to-84,Vick Meyer,2018-10-31 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851366,the daily biotech pulse kempharm fda nod for merck clovis q miss stocks to debut,https://www.benzinga.com/general/biotech/18/10/12599312/the-daily-biotech-pulse-kempharm-fda-nod-for-merck-clovis-q3-miss-3-s,Shanthi Rexaline,2018-10-31 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.42345
851367,merck reports fda approved keytruda in combo with carboplatin either paclitaxel or nabpaclitaxel for firstline treatment of patients with metastatic squamous nonsmall cell lung cancer,https://www.benzinga.com/news/18/10/12596378/merck-reports-fda-approved-keytruda-in-combo-with-carboplatin-either-paclitaxel-,Benzinga Newsdesk,2018-10-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.30910000000000004
851368,wild times market seems to seek solid ground after mondays manic,https://www.benzinga.com/news/earnings/18/10/12592910/wild-times-market-seems-to-seek-solid-ground-after-mondays-manic,JJ Kinahan,2018-10-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.57655
851369,the daily biotech pulse pfizer and allergan earnings cfo departures at acadia and assertio,https://www.benzinga.com/general/biotech/18/10/12589016/the-daily-biotech-pulse-pfizer-and-allergan-earnings-cfo-departures-a,Shanthi Rexaline,2018-10-30 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851370,reminder merck has pdufa date for keytrudacarboplatinpaclitaxel sbla today,https://www.benzinga.com/general/biotech/18/10/12590060/reminder-merck-has-pdufa-date-for-keytruda-carboplatin-paclitaxel-sbl,Hal Lindon,2018-10-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851371,benzingas week ahead can facebook apple earnings rescue the stock market,https://www.benzinga.com/markets/cryptocurrency/18/10/12584546/benzingas-week-ahead-can-facebook-apple-earnings-rescue-the-st,Taylor Cox,2018-10-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
851372,the week ahead in biotech conferences pdufa dates clinical trial results earnings and ipos,https://www.benzinga.com/general/biotech/18/10/12567829/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trial-resu,Shanthi Rexaline,2018-10-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851373,bmo capital maintains outperform on merck co lowers price target to ,https://www.benzinga.com/news/18/10/12575843/bmo-capital-maintains-outperform-on-merck-co-lowers-price-target-to-80,Vick Meyer,2018-10-26 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.436
851374,snapping back but can rally attempt last strong earnings might power market,https://www.benzinga.com/news/earnings/18/10/12566505/snapping-back-but-can-rally-attempt-last-strong-earnings-might-power-ma,JJ Kinahan,2018-10-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8326
851375,the daily biotech pulse abbvie takes full control of cystic fibrosis program amgen slashes cholesterol drug price,https://www.benzinga.com/general/biotech/18/10/12564067/the-daily-biotech-pulse-abbvie-takes-full-control-of-cystic-fibrosis-,Shanthi Rexaline,2018-10-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.39885
851376,a peek into the markets us stock futures rise ahead of earnings economic reports,https://www.benzinga.com/news/18/10/12564424/a-peek-into-the-markets-us-stock-futures-rise-ahead-of-earnings-economic-reports,Lisa Levin,2018-10-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851377,merck raises qtr dividend from to share adds b to buyback,https://www.benzinga.com/news/18/10/12564078/merck-raises-qtr-dividend-from-0-48-to-0-55share-adds-10b-to-buyback,Benzinga Newsdesk,2018-10-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
851378,update merck raises fy adj eps guidance from as of jul to vs estimate,https://www.benzinga.com/news/18/10/12564075/update-merck-raises-fy18-adj-eps-guidance-from-4-22-4-30-as-of-jul-27-2018-to-4-,Benzinga Newsdesk,2018-10-25 00:00:00,MRK,1,2,0,0,0,0,1,1,1,0.5
851379,merck raises guidance,https://www.benzinga.com/news/18/10/12564072/merck-raises-guidance,Benzinga Newsdesk,2018-10-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851380,merck co q eps beats estimate sales b miss b estimate,https://www.benzinga.com/news/earnings/18/10/12564066/merck-co-q3-eps-1-19-beats-1-14-estimate-sales-10-794b-miss-10-88b-esti,Benzinga Newsdesk,2018-10-25 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.42345
851381,mercks q earnings preview,https://www.benzinga.com/news/earnings-previews/18/10/12559618/merck-cos-earnings-roundup,Benzinga Newsdesk,2018-10-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851382,stocks which set new week high yesterday october nd,https://www.benzinga.com/trading-ideas/technicals/18/10/12549198/stocks-which-set-new-52-week-high-yesterday-october-22nd,Benzinga Newsdesk,2018-10-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851383,the daily biotech pulse regulus soars on positive preclinical data biogen earnings proteostasis and eiger to offer shares,https://www.benzinga.com/general/biotech/18/10/12546235/the-daily-biotech-pulse-regulus-soars-on-positive-pre-clinical-data-b,Shanthi Rexaline,2018-10-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.85015
851384, stocks that moved from esmo ,https://www.benzinga.com/general/biotech/18/10/12543092/11-stocks-that-moved-from-esmo-2018,Shanthi Rexaline,2018-10-22 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851385,benzingas week ahead can tech earnings restore the rally amazon google to report,https://www.benzinga.com/general/biotech/18/10/12541471/benzingas-week-ahead-can-tech-earnings-restore-the-rally-amazon-googl,Taylor Cox,2018-10-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
851386,bmo capital maintains outperform on merck co raises price target to ,https://www.benzinga.com/news/18/10/12542416/bmo-capital-maintains-outperform-on-merck-co-raises-price-target-to-82,Vick Meyer,2018-10-22 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851387,merck reports presentation of keytruda showing improved overall survival in patients with recurrent or metastatic head and neck cancer results being presented at esmo congress,https://www.benzinga.com/general/biotech/18/10/12542002/merck-reports-presentation-of-keytruda-showing-improved-overall-survi,Benzinga_Newsdesk,2018-10-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
851388,european medicines agency adopts positive opinion for mercks keytruda as adjuvant therapy in melanoma,https://www.benzinga.com/news/18/10/12539721/european-medicines-agency-adopts-positive-opinion-for-mercks-keytruda-as-adjuvan,Benzinga_Newsdesk,2018-10-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8243
851389,reminder esmo event continues today clinical updates presented today include cytomx therapeutics mirati therapeutics merck nucana protagonist therapeutics sellas life sciences epizyme kura oncology intracellular therapies and aveo pharma,https://www.benzinga.com/general/biotech/18/10/12539451/reminder-esmo-2018-event-continues-today-clinical-updates-presented-t,Hal Lindon,2018-10-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851390,the week ahead in biotech esmo conference pdufa dates clinical trial results largecap pharma earnings and ipos,https://www.benzinga.com/general/biotech/18/10/12521171/the-week-ahead-in-biotech-esmo-conference-pdufa-dates-clinical-trial-,Shanthi Rexaline,2018-10-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851391,astrazeneca merck announce solo phase iii trial demonstrates lynparza maintenance therapy cut the risk of disease progression or death by in patients with newlydiagnosed advanced brcamutated ovarian cancer at esmo,https://www.benzinga.com/news/18/10/12538856/astrazeneca-merck-announce-solo-1-phase-iii-trial-demonstrates-lynparza-maintena,Charles Gross,2018-10-21 00:00:00,MRK,1,0,1,1,1,0,0,0,0,0.05575000000000002
851392,leap therapeutics presents promising esophagogastric cancer data at esmo ,https://www.benzinga.com/news/18/10/12538700/leap-therapeutics-presents-promising-esophagogastric-cancer-data-at-esmo-2018,Charles Gross,2018-10-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.29905000000000004
851393,merck announces keytruda showed a complete response rate of nearly in patients with highrisk nonmuscle invasive bladder cancer unresponsive to standard of care at esmo ,https://www.benzinga.com/news/18/10/12538500/merck-announces-keytruda-showed-a-complete-response-rate-of-nearly-40-in-patient,Charles Gross,2018-10-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.352
851394,immunogen presents encouraging initial data from forward ii expansion cohort assessing mirvetuximab soravtansine in combination with keytruda at esmo ,https://www.benzinga.com/news/18/10/12538497/immunogen-presents-encouraging-initial-data-from-forward-ii-expansion-cohort-ass,Charles Gross,2018-10-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.76335
851395,dynavax announces sd in combination with mercks keytruda continues to show a overall response rate in advanced melanoma patients according to data presented today at esmo ,https://www.benzinga.com/news/18/10/12538493/dynavax-announces-sd-101-in-combination-with-mercks-keytruda-continues-to-show-a,Charles Gross,2018-10-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
851396,merck announces first presentation of early data for investigational sting agonist mk in patients with advanced solid tumors or lymphomas at esmo ,https://www.benzinga.com/news/18/10/12538492/merck-announces-first-presentation-of-early-data-for-investigational-sting-agoni,Charles Gross,2018-10-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
851397,the daily biotech pulse novartis positive liver drug trials krytstal prices offering logicbio to debut,https://www.benzinga.com/general/biotech/18/10/12532567/the-daily-biotech-pulse-novartis-positive-liver-drug-trials-krytstal-,Shanthi Rexaline,2018-10-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7787
851398,merck says pivotal phase keynote trial met both primary endpoints data to be filed with global regulatory authorities,https://www.benzinga.com/news/18/10/12526015/merck-says-pivotal-phase-3-keynote-426-trial-met-both-primary-endpoints-data-to-,Benzinga Newsdesk,2018-10-18 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.5
851399,merck reports keytruda in combo with pfizers inlyta improved overall survival progressionfree survival as firstline therapy for advanced metastatic renal cell carcinoma,https://www.benzinga.com/news/18/10/12526013/merck-reports-keytruda-in-combo-with-pfizers-inlyta-improved-overall-survival-pr,Benzinga Newsdesk,2018-10-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81245
851400,world health organizations emergency committee has said the ebola outbreak in congo is not yet a health emergency of intl concern warns situation likely to deteriorate significantly unless response is intensified,https://www.benzinga.com/news/18/10/12522123/world-health-organizations-emergency-committee-has-said-the-ebola-outbreak-in-co,Benzinga Newsdesk,2018-10-17 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.15960000000000002
851401,citigroup maintains buy on merck co raises price target to ,https://www.benzinga.com/news/18/10/12511535/citigroup-maintains-buy-on-merck-co-raises-price-target-to-79,Vick Meyer,2018-10-16 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851402,us fda grants merck and astrazenecas lynparza orphan drug designation for pancreatic cancer,https://www.benzinga.com/general/biotech/18/10/12511141/u-s-fda-grants-merck-and-astrazenecas-lynparza-orphan-drug-designatio,Benzinga_Newsdesk,2018-10-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.22885
851403,astrazeneca merck receive fda orphan drug for lynparza in pancreatic cancer,https://www.benzinga.com/news/18/10/12510599/astrazeneca-merck-receive-fda-orphan-drug-for-lynparza-in-pancreatic-cancer,Charles Gross,2018-10-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
851404,oncosec initiates keynote phase clinical trial of tavo in combination with mercks keytruda for treatment of latestage triple negative breast cancer,https://www.benzinga.com/news/18/10/12504473/oncosec-initiates-keynote-890-phase-2-clinical-trial-of-tavo-in-combination-with,Benzinga Newsdesk,2018-10-15 00:00:00,MRK,1,0,1,1,1,1,1,0,0,0.07790000000000002
851405, major market opportunities for the cannabis industry,https://www.benzinga.com/analyst-ratings/analyst-color/18/10/12479521/4-major-market-opportunities-for-the-cannabis-industry,Hannah Genig,2018-10-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
851406,barclays maintains overweight on merck co raises price target to ,https://www.benzinga.com/news/18/10/12498474/barclays-maintains-overweight-on-merck-co-raises-price-target-to-78,Vick Meyer,2018-10-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3194
851407,the daily biotech pulse fda thumbs down for trevena corium to go private immune design discontinues cancer vaccine program,https://www.benzinga.com/general/biotech/18/10/12497671/the-daily-biotech-pulse-fda-thumbs-down-for-trevena-corium-to-go-priv,Shanthi Rexaline,2018-10-12 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.25305
851408,credit suisse maintains outperform on merck co raises price target to ,https://www.benzinga.com/news/18/10/12492563/credit-suisse-maintains-outperform-on-merck-co-raises-price-target-to-81,Vick Meyer,2018-10-11 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.6909
851409,stocks which set new week high yesterday october th,https://www.benzinga.com/trading-ideas/technicals/18/10/12492008/stocks-which-set-new-52-week-high-yesterday-october-10th,Benzinga Newsdesk,2018-10-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851410,the daily biotech pulse clinical hold lifted off crisprs geneedited therapy endra to offer shares,https://www.benzinga.com/general/biotech/18/10/12489928/the-daily-biotech-pulse-clinical-hold-lifted-off-crisprs-gene-edited-,Shanthi Rexaline,2018-10-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
851411,stocks that made new week highs so far today include nextera energy wec energy verizon cms energy ameren firstenergy mccormick aes merck public service enterprise express scripts and public service enterprise,https://www.benzinga.com/trading-ideas/technicals/18/10/12487171/stocks-that-made-new-52-week-highs-so-far-today-include-next,Benzinga Newsdesk,2018-10-10 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.8243
851412,stocks which set new week high yesterday october th,https://www.benzinga.com/trading-ideas/technicals/18/10/12485360/stocks-which-set-new-52-week-high-yesterday-october-9th,Benzinga Newsdesk,2018-10-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851413,the daily biotech pulse novartis blood disorder drug improves patient outcomes audentes to offer shares,https://www.benzinga.com/general/biotech/18/10/12482335/the-daily-biotech-pulse-novartis-blood-disorder-drug-improves-patient,Shanthi Rexaline,2018-10-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
851414,reminder merck has fda pdufa date tomorrow october th for gardasil sbla,https://www.benzinga.com/general/biotech/18/10/12467504/reminder-merck-has-fda-pdufa-date-tomorrow-october-6th-for-gardasil-s,Benzinga Newsdesk,2018-10-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851415,stocks which set new week high yesterday october rd,https://www.benzinga.com/trading-ideas/technicals/18/10/12459146/stocks-which-set-new-52-week-high-yesterday-october-3rd,Benzinga Newsdesk,2018-10-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851416,the daily biotech pulse atricures guidance guardant health and kodiak to debut,https://www.benzinga.com/general/biotech/18/10/12455944/the-daily-biotech-pulse-atricures-guidance-guardant-health-and-kodiak,Shanthi Rexaline,2018-10-04 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851417,a peek into the markets us stock futures drop ahead of jobless claims factory orders data,https://www.benzinga.com/news/18/10/12456731/a-peek-into-the-markets-us-stock-futures-drop-ahead-of-jobless-claims-factory-or,Lisa Levin,2018-10-04 00:00:00,MRK,1,1,0,1,1,0,0,0,0,0.3634
851418,merck reports delstrigo phase driveshift trial met primary efficacy endpoint,https://www.benzinga.com/news/18/10/12456526/merck-reports-delstrigo-phase-3-drive-shift-trial-met-primary-efficacy-endpoint,Benzinga Newsdesk,2018-10-04 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851419,stocks which set new week high yesterday october nd,https://www.benzinga.com/trading-ideas/technicals/18/10/12451979/stocks-which-set-new-52-week-high-yesterday-october-2nd,Benzinga Newsdesk,2018-10-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851420,the daily biotech pulse endologixs q sales obsevas positive trial results kala to offer shares,https://www.benzinga.com/general/biotech/18/10/12448229/the-daily-biotech-pulse-endologixs-q3-sales-obsevas-positive-trial-re,Shanthi Rexaline,2018-10-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.85015
851421,stocks which set new week high yesterday october st,https://www.benzinga.com/trading-ideas/technicals/18/10/12441005/stocks-which-set-new-52-week-high-yesterday-october-1st,Benzinga Newsdesk,2018-10-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851422,the daily biotech pulse transenterixs positive preannouncement merit medical opens wallet gw pharma to offer ads shares,https://www.benzinga.com/news/18/10/12438109/the-daily-biotech-pulse-transenterixs-positive-pre-announcement-merit-medical-op,Shanthi Rexaline,2018-10-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.91125
851423,attention biotech investors mark your calendar for these october pdufa dates,https://www.benzinga.com/general/biotech/18/09/12397448/attention-biotech-investors-mark-your-calendar-for-these-october-pduf,Shanthi Rexaline,2018-09-26 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851424,merck board rescinds mandatory ceo retirement policy current ceo kenneth frazier to continue in role beyond december ,https://www.benzinga.com/news/18/09/12408603/merck-board-rescinds-mandatory-ceo-retirement-policy-current-ceo-kenneth-frazier,Benzinga_Newsdesk,2018-09-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5386
851425,stocks which set new week high friday september ,https://www.benzinga.com/trading-ideas/technicals/18/09/12395900/stocks-which-set-new-52-week-high-friday-september-21,Benzinga Newsdesk,2018-09-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851426,opgen reports partnership with new york state dept of health mercks ilum health solutions to detect antimicrobialresistant infections,https://www.benzinga.com/news/18/09/12395757/opgen-reports-partnership-with-new-york-state-dept-of-health-mercks-ilum-health-,Benzinga Newsdesk,2018-09-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.58895
851427,democratic republic of congo confirms ebola case in ituri province almost km away from closest other case and km from the ugandan border,https://www.benzinga.com/news/18/09/12389468/democratic-republic-of-congo-confirms-ebola-case-in-ituri-province-almost-200-km,Benzinga_Newsdesk,2018-09-21 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.5
851428,the daily biotech pulse exelixis liver cancer drug on track for european approval medtronic goes shopping opiant snags barda funding,https://www.benzinga.com/general/biotech/18/09/12387695/the-daily-biotech-pulse-exelixis-liver-cancer-drug-on-track-for-europ,Shanthi Rexaline,2018-09-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
851429,xoma reports purchase of royalty interest position from agenus on assets being developed by merck incyte for m,https://www.benzinga.com/news/18/09/12388227/xoma-reports-purchase-of-royalty-interest-position-from-agenus-on-7-assets-being,Benzinga Newsdesk,2018-09-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7859499999999999
851430,merck reports received positive chmp opinion for elstrigo pifeltro in eu for treatment of hiv infection,https://www.benzinga.com/news/18/09/12386068/merck-reports-received-positive-chmp-opinion-for-elstrigo-pifeltro-in-eu-for-tre,Benzinga Newsdesk,2018-09-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
851431,merck or pfizer which is the better largecap pharma stock,https://www.benzinga.com/general/biotech/18/09/12384215/merck-or-pfizer-which-is-the-better-large-cap-pharma-stock,Zacks,2018-09-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7202
851432,accenture and merck collaborate with amazon web services to launch a research platform to drive innovation in drug discovery and scientific research,https://www.benzinga.com/news/18/09/12362231/accenture-and-merck-collaborate-with-amazon-web-services-to-launch-a-research-pl,Benzinga Newsdesk,2018-09-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
851433,the week ahead in biotech sept conferences pdufa dates clinical trial results and ipos,https://www.benzinga.com/general/biotech/18/09/12351792/the-week-ahead-in-biotech-sept-16-22-conferences-pdufa-dates-clinical,Shanthi Rexaline,2018-09-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851434,stocks which set new week high yesterday september th,https://www.benzinga.com/trading-ideas/technicals/18/09/12355954/stocks-which-set-new-52-week-high-yesterday-september-13th,Benzinga Newsdesk,2018-09-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851435,the daily biotech pulse fda nod for staar supernus opens wallet principia biopharma to debut,https://www.benzinga.com/general/biotech/18/09/12354882/the-daily-biotech-pulse-fda-nod-for-staar-supernus-opens-wallet-princ,Shanthi Rexaline,2018-09-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851436,stocks that will be trading ex dividend for fri sep ,https://www.benzinga.com/news/18/09/12349751/stocks-that-will-be-trading-ex-dividend-for-fri-sep-14-2018,luke@benzinga.com,2018-09-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851437,fda grants priority review to mercks application for keytruda monotherapy for firstline treatment of locally advanced or metastatic nonsmall cell lung cancer in patients whose tumors express pdl,https://www.benzinga.com/news/18/09/12340712/fda-grants-priority-review-to-mercks-application-for-keytruda-monotherapy-for-fi,Benzinga_Newsdesk,2018-09-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3194
851438,the daily biotech pulse advaxis posts narrower loss endocyte announces m offering leadership transition at insulet,https://www.benzinga.com/general/biotech/18/09/12333621/the-daily-biotech-pulse-advaxis-posts-narrower-loss-endocyte-announce,Shanthi Rexaline,2018-09-11 00:00:00,MRK,0,0,1,1,1,1,1,1,1,0.3409
851439,a peek into the markets us stock futures down ahead of job openings wholesale inventories data,https://www.benzinga.com/news/18/09/12334436/a-peek-into-the-markets-us-stock-futures-down-ahead-of-job-openings-wholesale-in,Lisa Levin,2018-09-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851440,imv inc announces phase basket trial with merck to evaluate dpxsurvivac in combination with keytruda across five solid tumor indications,https://www.benzinga.com/general/biotech/18/09/12334429/imv-inc-announces-phase-2-basket-trial-with-merck-to-evaluate-dpx-sur,Benzinga Newsdesk,2018-09-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.375
851441,mercks zerbaxa met primary endpoints of noninferiority compared to meropenem in pivotal phase study co to submit supplemental new drug app in us and eu,https://www.benzinga.com/news/18/09/12334240/mercks-zerbaxa-met-primary-endpoints-of-non-inferiority-compared-to-meropenem-in,Benzinga_Newsdesk,2018-09-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851442,a peek into the markets us stock futures signal higher start on wall street,https://www.benzinga.com/news/18/09/12327344/a-peek-into-the-markets-us-stock-futures-signal-higher-start-on-wall-street,Lisa Levin,2018-09-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851443,mercks keytruda in combination with pemetrexed and platinum chemotherapy for the firstline treatment of patients with metastatic nonsquamous nsclc approved by the european commission,https://www.benzinga.com/news/18/09/12327196/mercks-keytruda-in-combination-with-pemetrexed-and-platinum-chemotherapy-for-the,luke@benzinga.com,2018-09-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
851444,european commission approves mercks keytruda in combination with pemetrexed and platinum chemotherapy for the firstline treatment of patients with metastatic nonsquamous nsclc,https://www.benzinga.com/news/18/09/12327192/european-commission-approves-mercks-keytruda-in-combination-with-pemetrexed-and-,Benzinga_Newsdesk,2018-09-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
851445,the week ahead in biotech conferences clinical trial results earnings and ipos,https://www.benzinga.com/general/biotech/18/09/12314714/the-week-ahead-in-biotech-conferences-clinical-trial-results-earnings,Shanthi Rexaline,2018-09-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851446,health care has been on fire will the uptrend continue,https://www.benzinga.com/trading-ideas/long-ideas/18/09/12323655/health-care-has-been-on-fire-will-the-uptrend-continue,Spencer Israel,2018-09-07 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.60115
851447,barclays maintains overweight on merck co raises price target to ,https://www.benzinga.com/news/18/09/12320628/barclays-maintains-overweight-on-merck-co-raises-price-target-to-75,Vick Meyer,2018-09-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3194
851448,the daily biotech pulse biohaven inlicenses drug retrophins debt offering proqr and bluebird report positive trial results,https://www.benzinga.com/general/biotech/18/09/12304870/the-daily-biotech-pulse-biohaven-in-licenses-drug-retrophins-debt-off,Shanthi Rexaline,2018-09-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6366
851449,ebolarelated stocks unaffected amid earlier report officials in congo announced the first ebola case in a major eastern city butembo,https://www.benzinga.com/news/18/09/12305396/ebola-related-stocks-unaffected-amid-earlier-report-officials-in-congo-announced,luke@benzinga.com,2018-09-05 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851450,eisai and merck announce china national medical products administration nmpa approval of lenvima for treatment of unresectable hepatocellular carcinoma hcc,https://www.benzinga.com/general/biotech/18/09/12304907/eisai-and-merck-announce-china-national-medical-products-administrati,Benzinga Newsdesk,2018-09-05 00:00:00,MRK,1,0,0,1,1,0,1,0,1,0.7383500000000001
851451,eisai merck announce china nmpa approval of first approval for lenvima for treatment of unresectable hcc,https://www.benzinga.com/news/18/09/12304403/eeisai-merck-announce-china-nmpa-approval-of-first-approval-for-lenvima-for-trea,Charles Gross,2018-09-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.86755
851452,benzinga pros stocks to watch today,https://www.benzinga.com/news/18/09/12298884/benzinga-pros-5-stocks-to-watch-today,Jayson Derrick,2018-09-04 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851453,fda grants priority review to mercks supplemental biologics license application for keytruda application based on data from phase keynote trial,https://www.benzinga.com/news/18/09/12297366/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-,Benzinga_Newsdesk,2018-09-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.61315
851454,the week ahead in biotech conferences pdufa dates clinical trials and earnings,https://www.benzinga.com/general/biotech/18/09/12277472/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trials-and,Shanthi Rexaline,2018-09-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851455,the daily biotech pulse fda blessings for mercks hiv drug combo veracytes test gets medicare coverage,https://www.benzinga.com/general/biotech/18/08/12289224/the-daily-biotech-pulse-fda-blessings-for-mercks-hiv-drug-combo-verac,Shanthi Rexaline,2018-08-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.77115
851456,merck announces fda aproval of delstrigo,https://www.benzinga.com/general/biotech/18/08/12287130/merck-announces-fda-aproval-of-delstrigo,Benzinga Newsdesk,2018-08-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851457,the daily biotech pulse verastem gets new cfo mesoblast earnings vertexs precision medicine collaboration,https://www.benzinga.com/general/biotech/18/08/12281784/the-daily-biotech-pulse-verastem-gets-new-cfo-mesoblast-earnings-vert,Shanthi Rexaline,2018-08-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851458, stocks moving in fridays premarket session,https://www.benzinga.com/news/18/08/12256014/30-stocks-moving-in-fridays-pre-market-session,Lisa Levin,2018-08-24 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851459,morgan stanley maintains overweight on merck co raises price target to ,https://www.benzinga.com/news/18/08/12249491/morgan-stanley-maintains-overweight-on-merck-co-raises-price-target-to-74,Vick Meyer,2018-08-23 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.3194
851460,eisai and merck announce european commission grants marketing authorization for lenvima,https://www.benzinga.com/news/18/08/12249086/eisai-and-merck-announce-european-commission-grants-marketing-authorization-for-,Benzinga_Newsdesk,2018-08-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.61315
851461,stocks which set new week high yesterday august st,https://www.benzinga.com/trading-ideas/technicals/18/08/12243632/stocks-which-set-new-52-week-high-yesterday-august-21st,Benzinga Newsdesk,2018-08-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851462,the daily biotech pulse fda snub for allergan myriads q beat mallinckrodts stannsoporfin,https://www.benzinga.com/general/biotech/18/08/12241949/the-daily-biotech-pulse-fda-snub-for-allergan-myriads-q4-beat-mallinc,Shanthi Rexaline,2018-08-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.28925
851463,incyte has quietly risen percent in the last two weeks and that uptrend looks like it will continue,https://www.benzinga.com/trading-ideas/long-ideas/18/08/12239930/incyte-has-quietly-risen-13-percent-in-the-last-two-weeks-an,VantagePoint,2018-08-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6806
851464,stocks which set new week high tues aug ,https://www.benzinga.com/news/18/08/12239706/stocks-which-set-new-52-week-high-tues-aug-21-2018,luke@benzinga.com,2018-08-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851465,the daily biotech pulse mercks keytruda secures approval for expanded label prophase labs q loss narrows,https://www.benzinga.com/general/biotech/18/08/12235573/the-daily-biotech-pulse-mercks-keytruda-secures-approval-for-expanded,Shanthi Rexaline,2018-08-21 00:00:00,MRK,0,0,1,1,1,1,1,1,1,0.7383500000000001
851466,rexahn reports clinical collaboration with merck for evaluation of rx in combo with keytruda for triplenegative breast cancer,https://www.benzinga.com/news/18/08/12236617/rexahn-reports-clinical-collaboration-with-merck-for-evaluation-of-rx-5902-in-co,luke@benzinga.com,2018-08-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
851467,fda approves expanded label for mercks keytruda in combination with pemetrexed and platinum chemotherapy for firstline treatment,https://www.benzinga.com/news/18/08/12233491/fda-approves-expanded-label-for-mercks-keytruda-in-combination-with-pemetrexed-a,Benzinga_Newsdesk,2018-08-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
851468,stocks which set new week high yesterday august th,https://www.benzinga.com/trading-ideas/technicals/18/08/12224603/stocks-which-set-new-52-week-high-yesterday-august-16th,Benzinga Newsdesk,2018-08-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851469,the daily biotech pulse aveo slips on stock offering fda greenlights generic epipen pfenex exec resigns,https://www.benzinga.com/general/biotech/18/08/12222856/the-daily-biotech-pulse-aveo-slips-on-stock-offering-fda-greenlights-,Shanthi Rexaline,2018-08-17 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.3409
851470,eisai and merck announce fda approval of lenvima,https://www.benzinga.com/news/18/08/12223554/eisai-and-merck-announce-fda-approval-of-lenvima,Benzinga_Newsdesk,2018-08-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
851471,eisai and merck announce fda approval of lenvima lenvatinib capsules for firstline treatment of unresectable hepatocellular carcinoma hcc,https://www.benzinga.com/general/biotech/18/08/12220986/eisai-and-merck-announce-fda-approval-of-lenvima-lenvatinib-capsules-,Benzinga Newsdesk,2018-08-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
851472,stocks which set new week high yesterday august th,https://www.benzinga.com/trading-ideas/technicals/18/08/12218447/stocks-which-set-new-52-week-high-yesterday-august-15th,Benzinga Newsdesk,2018-08-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851473,the daily biotech pulse no anxiety for biohaven strongbridges aboutface bristolmyers squibbs fda wait,https://www.benzinga.com/general/biotech/18/08/12216040/benzingas-daily-biotech-pulse-no-anxiety-for-biohaven-strongbridges-a,Shanthi Rexaline,2018-08-16 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.2798
851474,agenus receives milestone payment from merck of m for initiation of phase clinical trial of an undisclosed antibody candidate discovered by agenus,https://www.benzinga.com/news/18/08/12211353/agenus-receives-milestone-payment-from-merck-of-4m-for-initiation-of-phase-1-cli,Benzinga_Newsdesk,2018-08-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851475,cdc says theres no recommendation to avoid travel to democratic republic of the congo following ebola outbreaks,https://www.benzinga.com/news/18/08/12176756/cdc-says-theres-no-recommendation-to-avoid-travel-to-democratic-republic-of-the-,Benzinga_Newsdesk,2018-08-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.23665000000000003
851476,perrigo announces rxtootc switch licensing for nasonex,https://www.benzinga.com/news/18/08/12171733/perrigo-announces-rx-to-otc-switch-licensing-for-nasonex,Charles Gross,2018-08-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851477,stocks which set new week high yesterday august th,https://www.benzinga.com/trading-ideas/technicals/18/08/12165578/stocks-which-set-new-52-week-high-yesterday-august-7th,Benzinga Newsdesk,2018-08-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851478,the daily biotech pulse fda panel backs insmed eidos maiden earnings paratek awaits adcom verdict,https://www.benzinga.com/general/biotech/18/08/12162539/the-daily-biotech-pulse-fda-panel-backs-insmed-eidos-maiden-earnings-,Shanthi Rexaline,2018-08-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.58895
851479,stocks that made new week highs earlier today include sl green realty verisk analytics medtronics pfizer conoco phillips archerdaniels eli lilly merck phillips costco advance auto parts norfolk southern csx zoetis apple and disney,https://www.benzinga.com/trading-ideas/technicals/18/08/12155877/stocks-that-made-new-52-week-highs-earlier-today-include-sl-,Benzinga Newsdesk,2018-08-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851480,stocks which set new week high yesterday august th,https://www.benzinga.com/trading-ideas/small-cap-analysis/18/08/12155686/stocks-which-set-new-52-week-high-yesterday-august-6,Benzinga Newsdesk,2018-08-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851481,the daily biotech pulse fda snub for gemphire ligand earnings insmeds antibiotic faces fda panel,https://www.benzinga.com/general/biotech/18/08/12152105/the-daily-biotech-pulse-fda-snub-for-gemphire-ligand-earnings-insmeds,Shanthi Rexaline,2018-08-07 00:00:00,MRK,1,2,0,1,0,0,1,0,0,0.28925
851482,congo health ministry says ebola outbreak likely to have killed merck vaccine being deployed to control spread of outbreak,https://www.benzinga.com/news/18/08/12143565/congo-health-ministry-says-ebola-outbreak-likely-to-have-killed-33-merck-vaccine,Charles Gross,2018-08-05 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.16475
851483,merck reports co astrazenecas selumetinib granted orphan designation in europe for neruofibromatosis type ,https://www.benzinga.com/news/18/08/12136569/merck-reports-co-astrazenecas-selumetinib-granted-orphan-designation-in-europe-f,Benzinga Newsdesk,2018-08-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
851484,health ministry officials say ebola in latest congo outbreak is of the zaire strain which has been successfully treated by a vaccine in the past,https://www.benzinga.com/news/18/08/12134727/health-ministry-officials-say-ebola-in-latest-congo-outbreak-is-of-the-zaire-str,Benzinga Newsdesk,2018-08-02 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.7294
851485,update who says depending on the strain of ebola in congo outbreak merck vaccine may be an option,https://www.benzinga.com/general/biotech/18/08/12129980/update-w-h-o-says-depending-on-the-strain-of-ebola-in-congo-outbreak-,Benzinga Newsdesk,2018-08-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.4742
851486,who chief says that it has started moving staff supplies to the area of democratic republic of congos new ebola outbreak,https://www.benzinga.com/news/18/08/12120349/who-chief-says-that-it-has-started-moving-staff-supplies-to-the-area-of-democrat,Benzinga_Newsdesk,2018-08-01 00:00:00,MRK,0,0,0,1,1,0,1,1,0,0.5
851487, samples from northeastern democratic rep of congo test positive for ebola virus deaths from hemorrhagic fever recorded in northeastern congo,https://www.benzinga.com/news/18/08/12118290/4-samples-from-northeastern-democratic-rep-of-congo-test-positive-for-ebola-viru,Benzinga_Newsdesk,2018-08-01 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.7787
851488,benzinga pros stocks to watch today,https://www.benzinga.com/news/18/07/12106981/benzinga-pros-5-stocks-to-watch-today,Jayson Derrick,2018-07-31 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851489,a peek into the markets us stock futures up ahead of earnings economic data,https://www.benzinga.com/news/18/07/12105575/a-peek-into-the-markets-us-stock-futures-up-ahead-of-earnings-economic-data,Lisa Levin,2018-07-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851490,eisai and merck announce fda grants breakthrough therapy designation for lenvima in combination with keytruda as therapy for previously treated patients with advanced andor metastatic nonmsihpmmr endometrial carcinoma,https://www.benzinga.com/general/biotech/18/07/12105284/eisai-and-merck-announce-fda-grants-breakthrough-therapy-designation-,Benzinga Newsdesk,2018-07-31 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
851491,eisai merck announce fda breakthrough therapy designation for lenvima,https://www.benzinga.com/news/18/07/12104619/eisai-merck-announce-fda-breakthrough-therapy-designation-for-lenvima,Charles Gross,2018-07-31 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
851492,benzinga pros stocks to watch today,https://www.benzinga.com/news/18/07/12097897/benzinga-pros-5-stocks-to-watch-today,Jayson Derrick,2018-07-30 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851493,biolinerx expands its immunooncology collaboration in pancreatic cancer with merck,https://www.benzinga.com/news/18/07/12097034/biolinerx-expands-its-immuno-oncology-collaboration-in-pancreatic-cancer-with-me,Benzinga Newsdesk,2018-07-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.19379999999999997
851494,benzinga pros stocks to watch today,https://www.benzinga.com/news/18/07/12089888/benzinga-pros-5-stocks-to-watch-today,Jayson Derrick,2018-07-27 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851495,benzingas daily biotech pulse achaogen to trim workforce by amgens beatandraise quarter,https://www.benzinga.com/general/biotech/18/07/12088282/benzingas-daily-biotech-pulse-achaogen-to-trim-workforce-by-28-amgens,Shanthi Rexaline,2018-07-27 00:00:00,MRK,1,2,1,1,0,1,1,0,1,0.5
851496,endo intl reports par pharma has begun shipping authorized generic version of mercks invanz,https://www.benzinga.com/news/18/07/12089259/endo-intl-reports-par-pharma-has-begun-shipping-authorized-generic-version-of-me,Benzinga Newsdesk,2018-07-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851497,merck narrows fy sales guidance from bb to bb vs b estimate,https://www.benzinga.com/news/18/07/12088828/merck-narrows-fy18-sales-guidance-from-41-8b-43b-to-42b-42-8b-vs-42-07b-estimate,Benzinga Newsdesk,2018-07-27 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851498,merck raises fy adj eps from to vs estimate,https://www.benzinga.com/news/18/07/12088768/merck-raises-fy18-adj-eps-from-4-16-4-28-to-4-22-4-30-vs-4-23-estimate,Benzinga Newsdesk,2018-07-27 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
851499,merck co q eps beats estimate sales b beat b estimate,https://www.benzinga.com/news/earnings/18/07/12088737/merck-co-q2-eps-1-06-beats-1-03-estimate-sales-10-465b-beat-10-29b-esti,Benzinga Newsdesk,2018-07-27 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851500, stocks to watch for july ,https://www.benzinga.com/news/earnings/18/07/12088287/12-stocks-to-watch-for-july-27-2018,Lisa Levin,2018-07-27 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851501,earnings scheduled for july ,https://www.benzinga.com/news/earnings/18/07/12088246/earnings-scheduled-for-july-27-2018,Lisa Levin,2018-07-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851502,merck q earnings preview,https://www.benzinga.com/news/earnings-previews/18/07/12084057/merck-cos-earnings-preview,Benzinga Newsdesk,2018-07-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851503,sutro pharma earlier reported merck was part of m series e funding round,https://www.benzinga.com/news/18/07/12082712/sutro-pharma-earlier-reported-merck-was-part-of-85-4m-series-e-funding-round,Benzinga Newsdesk,2018-07-26 00:00:00,MRK,1,2,1,0,1,0,1,1,1,0.5
851504,merck reports keytruda approved by china national drug admin,https://www.benzinga.com/news/18/07/12079276/merck-reports-keytruda-approved-by-china-national-drug-admin,Benzinga Newsdesk,2018-07-26 00:00:00,MRK,1,2,1,1,1,1,1,0,1,0.71075
851505,benzingas daily biotech pulse mercks keytruda found effective nabriva to acquire zavante fda denies agile,https://www.benzinga.com/general/biotech/18/07/12069647/benzingas-daily-biotech-pulse-mercks-keytruda-found-effective-nabriva,Shanthi Rexaline,2018-07-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5386
851506,merck reports phase keynote trial investigating keytruda met primarry endpoint of improving overall survivalin head and neck squamous cell carcinoma patients,https://www.benzinga.com/general/biotech/18/07/12070365/merck-reports-phase-3-keynote-048-trial-investigating-keytruda-met-pr,Benzinga Newsdesk,2018-07-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
851507,merck announces keytruda monotherapy met a primary endpoint in the phase keynote trial significantly improving os as firstline therapy in head and neck squamous cell carcinoma patients whose tumors expressed pdl,https://www.benzinga.com/news/18/07/12069808/merck-announces-keytruda-monotherapy-met-a-primary-endpoint-in-the-phase-3-keyno,Charles Gross,2018-07-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
851508,merck announces week data from pivotal phase driveforward study of its investigational hiv therapy doravirine,https://www.benzinga.com/news/18/07/12062465/merck-announces-week-96-data-from-pivotal-phase-3-drive-forward-study-of-its-inv,Charles Gross,2018-07-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851509,morgan stanley newly public neon therapeutics has outperformance potential,https://www.benzinga.com/analyst-ratings/analyst-color/18/07/12057221/morgan-stanley-newly-public-neon-therapeutics-has-outpe,Shanthi Rexaline,2018-07-23 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851510,leap therapeutics announces collaboration with merck and pfizer to evaluate combination of trx avelumab and chemotherapy in advanced solid tumors,https://www.benzinga.com/news/18/07/12055978/leap-therapeutics-announces-collaboration-with-merck-and-pfizer-to-evaluate-comb,Benzinga Newsdesk,2018-07-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6909
851511,merck announces plans to cut drug prices,https://www.benzinga.com/general/health-care/18/07/12050907/merck-announces-plans-to-cut-drug-prices,Hannah Genig,2018-07-20 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.3634
851512,update merck says going forward we will continue to evaluate our portfolio of products to look for opportunities to further reduce costs for patients and the health care system,https://www.benzinga.com/news/18/07/12046628/update-merck-says-going-forward-we-will-continue-to-evaluate-our-portfolio-of-pr,Benzinga Newsdesk,2018-07-19 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.85015
851513,update merck responding to responsibility on drug pricing says we are also lowering our price on zepatier by percent and several other medicines by percent to reduce outofpocket costs for patients across the country,https://www.benzinga.com/news/18/07/12046626/update-merck-responding-to-responsibility-on-drug-pricing-says-we-are-also-lower,Benzinga Newsdesk,2018-07-19 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.375
851514,merck says we commit to not increase the average net price across our portfolio of products by more than inflation annually,https://www.benzinga.com/news/18/07/12046625/merck-says-we-commit-to-not-increase-the-average-net-price-across-our-portfolio-,Benzinga Newsdesk,2018-07-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.53065
851515,premarket prep opening nyse imbalance update exxonmobil k shares to sell pfizer k to sell merck k to sell cocacola k to sell johnson johnson k to sell ford k to sell kroger k to sell,https://www.benzinga.com/news/18/07/12023300/premarket-prep-opening-nyse-imbalance-update-exxonmobil-55k-shares-to-sell-pfize,Benzinga Newsdesk,2018-07-16 00:00:00,MRK,1,2,0,0,0,0,1,1,0,0.648
851516,cue biopharma produces immunostat biologic candidate for treatment of autoimmune disease under collaboration and license agreement with merck,https://www.benzinga.com/news/18/07/12010659/cue-biopharma-produces-immuno-stat-biologic-candidate-for-treatment-of-autoimmun,Benzinga Newsdesk,2018-07-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
851517,fda grants merck priority review to cos supplemental biologics license application for its keytruda hepatocellular carcinoma therapy,https://www.benzinga.com/general/biotech/18/07/12003645/fda-grants-merck-priority-review-to-co-s-supplemental-biologics-licen,Benzinga Newsdesk,2018-07-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.61315
851518,health care sector outlook checking in ahead of q earnings reports,https://www.benzinga.com/news/earnings/18/07/11994014/health-care-sector-outlook-checking-in-ahead-of-q2-earnings-reports,JJ Kinahan,2018-07-09 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.74695
851519,a look at biotech in and the biggest catalysts coming up in the second half of the year,https://www.benzinga.com/general/biotech/18/07/11955951/a-look-at-biotech-in-2018-and-the-biggest-catalysts-coming-up-in-the-,Shanthi Rexaline,2018-07-05 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851520,mercks supplemental biologics license for keytruda in combination with chemotherapy is granted priority review by the fda,https://www.benzinga.com/news/18/07/11963575/mercks-supplemental-biologics-license-for-keytruda-in-combination-with-chemother,Benzinga Newsdesk,2018-07-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
851521,astrazeneca merck announce lynparza approved in japan for brcamutated metastatic breast cancer,https://www.benzinga.com/news/fda/18/07/11963050/astrazeneca-merck-announce-lynparza-approved-in-japan-for-brca-mutated-metas,Benzinga Newdesk,2018-07-02 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.30910000000000004
851522,us supreme court agrees to hear merck appeal of lower court ruling that revived fosamax warning label suits,https://www.benzinga.com/news/18/06/11949731/u-s-supreme-court-agrees-to-hear-merck-appeal-of-lower-court-ruling-that-revived,Benzinga Newsdesk,2018-06-28 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.60115
851523,update merck says noninferiority was not demonstrated for second primary outcome of blood loss of greater than equal to ml of blood loss,https://www.benzinga.com/news/fda/18/06/11946209/update-merck-says-non-inferiority-was-not-demonstrated-for-second-primary-ou,Benzinga Newsdesk,2018-06-27 00:00:00,MRK,0,2,1,1,1,1,1,1,1,0.3634
851524,merck reports study results from heatstable formulation of carbetocin for prevention of excessive bleeding after childbirth showed clinical noninferiority to oxycontin for primary outcome of greater than equal to ml of blood loss,https://www.benzinga.com/news/fda/18/06/11946204/merck-reports-study-results-from-heat-stable-formulation-of-carbetocin-for-p,Benzinga Newsdesk,2018-06-27 00:00:00,MRK,0,0,1,0,0,0,1,1,1,0.5258
851525,astrazeneca reports lynparza phase iii trial firstline solo trial for ovarian cancer met primary endpoint,https://www.benzinga.com/news/fda/18/06/11940760/astrazeneca-reports-lynparza-phase-iii-trial-first-line-solo-1-trial-for-ova,Benzinga Newsdesk,2018-06-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
851526,merck to report q earnings on fri jul before market open,https://www.benzinga.com/news/earnings/18/06/11940629/merck-to-report-q2-earnings-on-fri-jul-27-2018-before-market-open,Benzinga Newsdesk,2018-06-27 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
851527,astrazeneca merck announce lynparza s met primary endpoint of progressionfree survival in women with brcamutated advanced ovarian cancer and showed a safety profile consistent with previous trials,https://www.benzinga.com/news/18/06/11940110/astrazeneca-merck-announce-lynparza-s-met-primary-endpoint-of-progression-free-s,Benzinga Newdesk,2018-06-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
851528,incyte downgraded as rbc analyst awaits more revenue visibility,https://www.benzinga.com/analyst-ratings/analyst-color/18/06/11935265/incyte-downgraded-as-rbc-analyst-awaits-more-revenue-vi,Shanthi Rexaline,2018-06-26 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5386
851529,mercks supplemental biologics license application for keytruda is accepted by the fda,https://www.benzinga.com/news/18/06/11926408/mercks-supplemental-biologics-license-application-for-keytruda-is-accepted-by-th,luke@benzinga.com,2018-06-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6366
851530,merck presents new data from comparative trials with sitagliptin clinical trial program with januvia at ada,https://www.benzinga.com/news/18/06/11925328/merck-presents-new-data-from-comparative-trials-with-sitagliptin-clinical-trial-,Benzinga Newdesk,2018-06-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851531, biggest movers from friday,https://www.benzinga.com/news/18/06/11891852/40-biggest-movers-from-friday,Lisa Levin,2018-06-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851532,midafternoon market update crude oil down over canada goose shares gain following strong q results,https://www.benzinga.com/news/18/06/11888802/mid-afternoon-market-update-crude-oil-down-over-3-canada-goose-shares-gain-follo,Lisa Levin,2018-06-15 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.81845
851533, stocks moving in fridays midday session,https://www.benzinga.com/news/18/06/11888001/30-stocks-moving-in-fridays-mid-day-session,Lisa Levin,2018-06-15 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851534,midday market update dow down over points affimed shares plummet,https://www.benzinga.com/news/18/06/11887966/mid-day-market-update-dow-down-over-200-points-affimed-shares-plummet,Lisa Levin,2018-06-15 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.648
851535,affimed shares slide on updated hodgkin lymphoma drug combo data,https://www.benzinga.com/general/biotech/18/06/11886928/affimed-shares-slide-on-updated-hodgkin-lymphoma-drug-combo-data,Shanthi Rexaline,2018-06-15 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.648
851536,benzingas daily biotech pulse hematology conference in the spotlight dr reddy to launch generic opioid addiction drug,https://www.benzinga.com/general/biotech/18/06/11885131/benzingas-daily-biotech-pulse-hematology-conference-in-the-spotlight-,Shanthi Rexaline,2018-06-15 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851537,benzingas daily biotech pulse fda nods for teligent and keytruda sonomas q miss sage inks deal with japans shionogi,https://www.benzinga.com/general/biotech/18/06/11878190/benzingas-daily-biotech-pulse-fda-nods-for-teligent-and-keytruda-sono,Shanthi Rexaline,2018-06-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
851538,mercks keytruda receives fda approval for treatment of primary mediastinal large bcell lymphoma,https://www.benzinga.com/general/biotech/18/06/11875980/mercks-keytruda-receives-fda-approval-for-treatment-of-primary-medias,Benzinga Newsdesk,2018-06-13 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.7383500000000001
851539,fda grants priority review to mercks supplemental biologics license application sbla for gardasil in women and men ages for prevention of certain hpvrelated cancers and diseases,https://www.benzinga.com/news/18/06/11871703/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-,Benzinga Newsdesk,2018-06-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
851540,merck press release confirms fda approval of keytruda for cervical cancer,https://www.benzinga.com/general/biotech/18/06/11868710/merck-press-release-confirms-fda-approval-of-keytruda-for-cervical-ca,Benzinga Newsdesk,2018-06-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
851541,merck receives fda approval for keytruda in advanced cervical cancer,https://www.benzinga.com/general/biotech/18/06/11868421/merck-receives-fda-approval-for-keytruda-in-advanced-cervical-cancer,Benzinga Newsdesk,2018-06-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.4614
851542,pharma stock roundup merck eli lilly abbvie and more,https://www.benzinga.com/general/biotech/18/06/11853189/pharma-stock-roundup-merck-eli-lilly-abbvie-and-more,Zacks,2018-06-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851543,benzingas daily biotech pulse mylans neulasta biosimilar approved portolas ceo to retire regenxbio to join sp smallcap index,https://www.benzinga.com/general/biotech/18/06/11828538/benzingas-daily-biotech-pulse-mylans-neulasta-biosimilar-approved-por,Shanthi Rexaline,2018-06-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8062
851544,merck and astrazeneca pres relase announces lynparza in combo with abiraterone delayed metastatic prostate cancer disease progression,https://www.benzinga.com/general/biotech/18/06/11826087/merck-and-astrazeneca-pres-relase-announces-lynparza-in-combo-with-ab,Benzinga Newsdesk,2018-06-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.1285
851545,merck gives an update on its pivotal trial of javelin into asco,https://www.benzinga.com/news/18/06/11821295/merck-gives-an-update-on-its-pivotal-trial-of-javelin-into-asco,Benzinga Newsdesk,2018-06-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851546,donald trump tweets we had repeal replace done and the saving to our country of one trillion dollars except for one person but it is getting done anywayless expensive plans will be announced this month drug prices coming down right to try,https://www.benzinga.com/news/18/06/11821277/donald-trump-tweets-we-had-repeal-replace-done-and-the-saving-to-our-country-of-,Benzinga Newsdesk,2018-06-04 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
851547,merck says keytruda showed promising antitumor activity in patients with advanced small cell lung cancer sclc in phase keynote study,https://www.benzinga.com/news/18/06/11820897/merck-says-keytruda-showed-promising-anti-tumor-activity-in-patients-with-advanc,Benzinga Newsdesk,2018-06-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.41105
851548,merck announces new analysis of fouryear data for keytruda from phase keynote study showed percent of patients were progressionfree months after completing two years of keytruda,https://www.benzinga.com/news/18/06/11820809/merck-announces-new-analysis-of-four-year-data-for-keytruda-from-phase-3-keynote,Eddie Staley,2018-06-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851549,five additional ebola cases detected by congo health officials,https://www.benzinga.com/news/18/06/11819997/five-additional-ebola-cases-detected-by-congo-health-officials,Benzinga Newdesk,2018-06-04 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
851550,the week ahead in biotech asco presentations dominate the headlines,https://www.benzinga.com/general/biotech/18/06/11806828/the-week-ahead-in-biotech-asco-presentations-dominate-the-headlines,Shanthi Rexaline,2018-06-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
851551,merck announces keytruda showed overall response rate of nearly percent as firstline therapy in patients with advanced clear cell rcc in phase keynote study at asco,https://www.benzinga.com/news/18/06/11819631/merck-announces-keytruda-showed-overall-response-rate-of-nearly-40-percent-as-fi,Benzinga Newdesk,2018-06-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
851552,eisai merck announce data from investigational studies of lenvima and keytruda combination therapy in four different tumor types at asco,https://www.benzinga.com/news/18/06/11819618/eisai-merck-announce-data-from-investigational-studies-of-lenvima-and-keytruda-c,Benzinga Newdesk,2018-06-03 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.30910000000000004
851553,merck announces keytruda plus chemotherapy significantly improved overall survival in firstline treatment of metastatic squamous nsclc in phase keynote study,https://www.benzinga.com/news/18/06/11819395/merck-announces-keytruda-plus-chemotherapy-significantly-improved-overall-surviv,Benzinga Newdesk,2018-06-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
851554,merck announces keytruda monotherapy significantly improved overall survival in keynote study as firstline treatment for locally advanced or metastatic nsclc patients whose tumors expressed pdl tps ,https://www.benzinga.com/news/18/06/11819394/merck-announces-keytruda-monotherapy-significantly-improved-overall-survival-in-,Benzinga Newdesk,2018-06-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81245
851555,attention biotech investors mark your calendar for these june pdufa dates,https://www.benzinga.com/general/biotech/18/06/11796974/attention-biotech-investors-mark-your-calendar-for-these-june-pdufa-d,Shanthi Rexaline,2018-06-01 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851556,ema says chmp has recommended restricting use of mercks keytruda tecentriq as firstline treatments for urothelial cancer,https://www.benzinga.com/news/18/06/11812504/ema-says-chmp-has-recommended-restricting-use-of-mercks-keytruda-tecentriq-as-fi,Paul Quintaro,2018-06-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.13245
851557,merck premier inc report expansion of preventative chronic disease care collaboration to include new effort designed to help reduce recurrence of c diff,https://www.benzinga.com/news/18/05/11804751/merck-premier-inc-report-expansion-of-preventative-chronic-disease-care-collabor,Paul Quintaro,2018-05-31 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8548
851558, biggest movers from yesterday,https://www.benzinga.com/news/18/05/11802915/41-biggest-movers-from-yesterday,Lisa Levin,2018-05-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851559, stocks moving in wednesdays midday session,https://www.benzinga.com/news/18/05/11798384/30-stocks-moving-in-wednesdays-mid-day-session,Lisa Levin,2018-05-30 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851560,midmorning market update markets open higher michael kors beats q estimates,https://www.benzinga.com/news/18/05/11797320/mid-morning-market-update-markets-open-higher-michael-kors-beats-q4-estimates,Lisa Levin,2018-05-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851561,benzingas daily biotech pulse chinese cheer for gilead immutep presents positive phase data fda accepts exelixis snda,https://www.benzinga.com/general/biotech/18/05/11794411/benzingas-daily-biotech-pulse-chinese-cheer-for-gilead-immutep-presen,Shanthi Rexaline,2018-05-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.92405
851562,benzingas daily biotech pulse biomarin gets fda nod amarin settles with teva mercks cancer drug review extended,https://www.benzinga.com/general/biotech/18/05/11777068/benzingas-daily-biotech-pulse-biomarin-gets-fda-nod-amarin-settles-wi,Shanthi Rexaline,2018-05-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
851563,eisai merck provide update on snda for lenvatinib,https://www.benzinga.com/news/18/05/11777076/eisai-merck-provide-update-on-snda-for-lenvatinib,Benzinga Newdesk,2018-05-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851564,mercks keytruda pembrolizumab significantly improved overall survival and progressionfree survival as firstline treatment for squamous nonsmall cell lung cancer nsclc in pivotal phase keynote trial,https://www.benzinga.com/news/18/05/11762339/mercks-keytruda-pembrolizumab-significantly-improved-overall-survival-and-progre,Benzinga Newsdesk,2018-05-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
851565,hearing a suspected ebola case is being treated at a main hospital in congos capital city kinshasa,https://www.benzinga.com/news/18/05/11758766/hearing-a-suspected-ebola-case-is-being-treated-at-a-main-hospital-in-congos-cap,Benzinga Newsdesk,2018-05-22 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.38685
851566, doses of ebola vaccine sent to congolese city of mbandaka on saturday vaccination campaign to start monday,https://www.benzinga.com/news/18/05/11746422/4-000-doses-of-ebola-vaccine-sent-to-congolese-city-of-mbandaka-on-saturday-vacc,Benzinga Newdesk,2018-05-20 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851567, dow companies with aboveaverage salaries,https://www.benzinga.com/general/education/18/05/11728469/12-dow-30-companies-with-above-average-salaries,Elizabeth Balboa,2018-05-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851568,merck bristol myers shares move on alleged fda alert on keytruda,https://www.benzinga.com/news/18/05/11741924/merck-bristol-myers-shares-move-on-alleged-fda-alert-on-keytruda,Elizabeth Balboa,2018-05-18 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.76335
851569,who official says who is considering using mapp biopharmas zmapp treatment for ebola in congo,https://www.benzinga.com/news/18/05/11741871/who-official-says-who-is-considering-using-mapp-biopharmas-zmapp-treatment-for-e,Benzinga Newsdesk,2018-05-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851570,merck shares dip lower bristolmyers squibb shares spike higher following fda alert on issue found in trials of keytruda tecentriq,https://www.benzinga.com/news/18/05/11741622/merck-shares-dip-lower-bristol-myers-squibb-shares-spike-higher-following-fda-al,Benzinga Newsdesk,2018-05-18 00:00:00,MRK,0,0,0,0,0,0,0,0,0,0.76335
851571,who emergency committee says ebola outbreak in congo doesnt yet constitute a public health emergency of intl concern,https://www.benzinga.com/news/18/05/11741516/who-emergency-committee-says-ebola-outbreak-in-congo-doesnt-yet-constitute-a-pub,Benzinga Newsdesk,2018-05-18 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.18155
851572,who says ebola vaccinations in congo will begin sun,https://www.benzinga.com/news/18/05/11741507/who-says-ebola-vaccinations-in-congo-will-begin-sun,Benzinga Newsdesk,2018-05-18 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851573,who raises risk assessment of congos ebola outbreak to very high,https://www.benzinga.com/news/18/05/11739636/who-raises-risk-assessment-of-congos-ebola-outbreak-to-very-high,Benzinga Newdesk,2018-05-18 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.3634
851574,who says will convene emergency meeting on fri to determine if ebola outbreak in congo is a public emergency of intl concern,https://www.benzinga.com/news/18/05/11732156/who-says-will-convene-emergency-meeting-on-fri-to-determine-if-ebola-outbreak-in,Benzinga Newsdesk,2018-05-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.18155
851575,who says ebola outbreak has spread to dr congo city,https://www.benzinga.com/news/18/05/11731506/who-says-ebola-outbreak-has-spread-to-dr-congo-city,Benzinga Newdesk,2018-05-17 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851576,first batch of experimental ebola vaccine arrives in congo vaccinations could begin this weekend,https://www.benzinga.com/news/18/05/11724189/first-batch-of-experimental-ebola-vaccine-arrives-in-congo-vaccinations-could-be,Benzinga Newdesk,2018-05-16 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851577,who says cases of ebola reported in congo outbreak so far including deaths,https://www.benzinga.com/news/18/05/11702264/who-says-39-cases-of-ebola-reported-in-congo-outbreak-so-far-including-19-deaths,Benzinga Newsdesk,2018-05-14 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
851578,jim cramer gives his opinion on exxon mobil pfizer and cisco,https://www.benzinga.com/media/18/05/11672316/jim-cramer-gives-his-opinion-on-exxon-mobil-pfizer-and-cisco,Craig Jones,2018-05-09 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851579,oncosec announces clinical collaboration with merck to evaluate combination of immunopulse il and keytruda for triple negative breast cancer,https://www.benzinga.com/news/18/05/11663730/oncosec-announces-clinical-collaboration-with-merck-to-evaluate-combination-of-i,Charles Gross,2018-05-08 00:00:00,MRK,1,0,1,1,1,1,1,0,0,0.07790000000000002
851580,jim cramer advises his viewers on prestige brands cvs health and more,https://www.benzinga.com/media/18/05/11661978/jim-cramer-advises-his-viewers-on-prestige-brands-cvs-health-and-more,Craig Jones,2018-05-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851581,astrazeneca and merck announce lynparza tablets receive eu approval for the treatment of platinumsensitive relapsed ovarian cancer,https://www.benzinga.com/news/18/05/11663108/astrazeneca-and-merck-announce-lynparza-tablets-receive-eu-approval-for-the-trea,Eddie Staley,2018-05-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
851582,premarket prep opening nyse imbalance update alibaba k shares to sell merck k to sell twitter k to sell,https://www.benzinga.com/news/18/05/11646946/premarket-prep-opening-nyse-imbalance-update-alibaba-91k-shares-to-sell-merck-51,Paul Quintaro,2018-05-04 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.648
851583,moderna snd merck expand mrna cancer vaccines collaboration,https://www.benzinga.com/18/05/11644295/moderna-snd-merck-expand-mrna-cancer-vaccines-collaboration,Brad Hammond,2018-05-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.26165
851584,merck says phase keynote met a prespecified secondary endpoint related to overall response rate in a cohort of participants at an interim analysis,https://www.benzinga.com/news/18/05/11635516/merck-says-phase-3-keynote-407-met-a-pre-specified-secondary-endpoint-related-to,Eddie Staley,2018-05-03 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851585,apple results fed decision jobs report in focus merck pfizer reports mixed,https://www.benzinga.com/news/earnings/18/05/11616376/apple-results-fed-decision-jobs-report-in-focus-merck-pfizer-reports-mi,JJ Kinahan,2018-05-01 00:00:00,MRK,1,2,1,1,0,1,1,0,1,0.5
851586,benzinga pros stocks to watch today,https://www.benzinga.com/news/18/05/11614454/benzinga-pros-5-stocks-to-watch-today,Jayson Derrick,2018-05-01 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851587,benzingas daily biotech pulse karyopharms storm study inogen rallies on earnings,https://www.benzinga.com/general/biotech/18/05/11612601/benzingas-daily-biotech-pulse-karyopharms-storm-study-inogen-rallies-,Shanthi Rexaline,2018-05-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851588,merck raises fy eps guidance from to vs est raises sales from bb to bb vs b est,https://www.benzinga.com/news/18/05/11613241/merck-raises-fy18-eps-guidance-from-4-08-4-23-to-4-16-4-28-vs-4-19-est-raises-sa,Paul Quintaro,2018-05-01 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851589,merck reports q adj eps beats est sales b misses b est,https://www.benzinga.com/news/earnings/18/05/11613239/merck-reports-q1-adj-eps-1-05-beats-1-00-est-sales-10-04b-misses-10-10b,Paul Quintaro,2018-05-01 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.38685
851590, stocks to watch for may ,https://www.benzinga.com/news/earnings/18/05/11612687/15-stocks-to-watch-for-may-1-2018,Lisa Levin,2018-05-01 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851591,earnings scheduled for may ,https://www.benzinga.com/news/earnings/18/05/11612667/earnings-scheduled-for-may-1-2018,Lisa Levin,2018-05-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851592,the week ahead tesla and apple earnings dropbox quiet period expires fed rate decision and more,https://www.benzinga.com/general/biotech/18/04/11604727/the-week-ahead-tesla-and-apple-earnings-dropbox-quiet-period-expires-,Taylor Cox,2018-04-30 00:00:00,MRK,1,1,1,0,0,0,1,1,1,0.5
851593,upcoming earnings tech giant apple reports after tuesdays close,https://www.benzinga.com/news/earnings/18/04/11605735/upcoming-earnings-tech-giant-apple-reports-after-tuesdays-close,JJ Kinahan,2018-04-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851594,pharmaceutical earnings pfizer and merck are slated to report tuesday morning,https://www.benzinga.com/news/earnings/18/04/11605524/pharmaceutical-earnings-pfizer-and-merck-are-slated-to-report-tuesday-m,JJ Kinahan,2018-04-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851595,busy week begins with mcdonalds beating estimates fed meeting jobs data loom,https://www.benzinga.com/news/earnings/18/04/11604347/mcdonalds-strong-results-start-busy-earnings-week-as-fed-jobs-report-al,JJ Kinahan,2018-04-30 00:00:00,MRK,1,1,0,1,1,0,1,0,1,0.20029999999999998
851596,merck is granted priority review of its sbla for keytruda in combination with pemetrexed and platinum chemotherapy,https://www.benzinga.com/news/18/04/11601904/merck-is-granted-priority-review-of-its-sbla-for-keytruda-in-combination-with-pe,Paul Quintaro,2018-04-30 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.625
851597,the week ahead in biotech pdufa dates clinical trials merck and pfizer earnings on tap,https://www.benzinga.com/general/biotech/18/04/11586719/the-week-ahead-in-biotech-pdufa-dates-clinical-trials-merck-and-pfize,Shanthi Rexaline,2018-04-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851598,upcoming earnings mcdonalds reports on monday as it continues on new growth plan,https://www.benzinga.com/news/earnings/18/04/11597143/upcoming-earnings-mcdonalds-reports-on-monday-as-it-continues-on-new-gr,JJ Kinahan,2018-04-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
851599,bmo sees balanced riskreward in bristolmyers takes neutral position,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11595396/bmo-sees-balanced-risk-reward-in-bristol-myers-takes-ne,Elizabeth Balboa,2018-04-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851600,earnings preview oil giants chevron and exxonmobil report friday morning,https://www.benzinga.com/news/earnings/18/04/11585487/earnings-preview-oil-giants-chevron-and-exxonmobil-report-friday-mornin,JJ Kinahan,2018-04-26 00:00:00,MRK,1,1,1,0,1,1,1,1,1,0.5
851601,merck reports ema validated type ii variation for cos keytruda in combo with pemetrexed platinum chemotherapy as firstline therapy in metastatic nonsquamous nsclc,https://www.benzinga.com/news/18/04/11560800/merck-reports-ema-validated-type-ii-variation-for-co-s-keytruda-in-combo-with-pe,Paul Quintaro,2018-04-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.61315
851602,keytruda is key to the merck thesis goldman sachs says in upgrade,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11557436/keytruda-is-key-to-the-merck-thesis-goldman-sachs-says-,Elizabeth Balboa,2018-04-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851603,benzingas top upgrades downgrades for april ,https://www.benzinga.com/analyst-ratings/upgrades/18/04/11557492/benzingas-top-upgrades-downgrades-for-april-23-2018,Lisa Levin,2018-04-23 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.60115
851604,goldman sachs upgrades merck co to buy,https://www.benzinga.com/news/18/04/11556849/goldman-sachs-upgrades-merck-co-to-buy,Eddie Staley,2018-04-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851605,astrazeneca shares are looking very weak right now,https://www.benzinga.com/general/biotech/18/04/11552596/astrazeneca-shares-are-looking-very-weak-right-now,VantagePoint,2018-04-20 00:00:00,MRK,1,1,0,1,1,0,0,0,0,0.3758
851606,stock market seems directionless volatility low as investors await news,https://www.benzinga.com/news/18/04/11544063/stock-market-seems-directionless-volatility-low-as-investors-await-news,JJ Kinahan,2018-04-19 00:00:00,MRK,1,1,0,1,0,0,1,0,1,0.41105
851607,benzingas top analyst calls from april ,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11537718/benzingas-top-analyst-calls-from-april-18-2018,Bill Haddad,2018-04-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
851608,one up one down morgan stanley flips merck bristolmyers ratings,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11530546/one-up-one-down-morgan-stanley-flips-merck-bristol-myer,Elizabeth Balboa,2018-04-17 00:00:00,MRK,1,2,1,0,1,0,1,1,1,0.5
851609,stock market gets lift from earnings as geopolitical fears wane,https://www.benzinga.com/news/earnings/18/04/11529549/stock-market-gets-lift-from-earnings-as-geopolitical-fears-wane,JJ Kinahan,2018-04-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.28925
851610,benzingas top upgrades downgrades for april ,https://www.benzinga.com/analyst-ratings/upgrades/18/04/11528887/benzingas-top-upgrades-downgrades-for-april-17-2018,Lisa Levin,2018-04-17 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.60115
851611,merck announces first phase three studies for pcv v its investigational pneumococcal disease vaccine,https://www.benzinga.com/news/18/04/11528148/merck-announces-first-phase-three-studies-for-pcv-15-v114-its-investigational-pn,Eddie Staley,2018-04-17 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851612,morgan stanley upgrades merck co to overweight,https://www.benzinga.com/news/18/04/11527114/morgan-stanley-upgrades-merck-co-to-overweight,Eddie Staley,2018-04-17 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.3194
851613,morgan stanley upgrades merck to overweight from equal weight raises pt to from ,https://www.benzinga.com/analyst-ratings/upgrades/18/04/11526739/morgan-stanley-upgrades-merck-to-overweight-from-equal-weigh,Charles Gross,2018-04-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3194
851614,dynavax reports interim data for sd in combination with keytruda results showed encouraging response rates,https://www.benzinga.com/general/biotech/18/04/11523720/dynavax-reports-interim-data-for-sd-101-in-combination-with-keytruda-,Hal Lindon,2018-04-16 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.76335
851615,update merck says keytruda combination improved overall survival in patients regardless of pdl expression including patients who tested negative for pdl,https://www.benzinga.com/news/fda/18/04/11521735/update-merck-says-keytruda-combination-improved-overall-survival-in-patients,Eddie Staley,2018-04-16 00:00:00,MRK,1,0,1,1,1,1,1,1,0,0.42345
851616,mercks keytrudaplus pemetrexed and platinum chemotherapy reduced the risk of death by half compared with chemotherapy alone as firstline treatment for advanced nonsquamous nsclc in phase keynote study,https://www.benzinga.com/news/fda/18/04/11521723/mercks-keytrudaplus-pemetrexed-and-platinum-chemotherapy-reduced-the-risk-of,Eddie Staley,2018-04-16 00:00:00,MRK,1,0,0,0,0,0,1,0,0,0.14079999999999998
851617,merck sunday announced updated overall survival data for lynparza olaparib in gbrcamutated hernegative metastatic breast cancer presented at aacr,https://www.benzinga.com/news/18/04/11519856/updated-overall-survival-data-for-lynparza-olaparib-in-gbrca-mutated-her2-negati,Charles Gross,2018-04-16 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.17015000000000002
851618,merck announces keytruda reduced risk of disease recurrence or death by more than vs placebo as adjuvant therapy in resected highrisk stage iii melanoma,https://www.benzinga.com/news/18/04/11519432/merck-announces-keytruda-reduced-risk-of-disease-recurrence-or-death-by-more-tha,Charles Gross,2018-04-15 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.14079999999999998
851619,the week ahead in biotech pdufa dates ipos and more,https://www.benzinga.com/general/biotech/18/04/11510798/the-week-ahead-in-biotech-pdufa-dates-ipos-and-more,Shanthi Rexaline,2018-04-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851620,mylan shares quiet premarket co looking for deal for mercks consumer products unit,https://www.benzinga.com/news/18/04/11514562/mylan-shares-quiet-premarket-co-looking-for-deal-for-mercks-consumer-products-un,Paul Quintaro,2018-04-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
851621,premarket prep opening nyse imbalance update pfizer k shares to buy exxonmobil k shares to buy merck k shares to buy general electric k shares to sell ford k shares to buy,https://www.benzinga.com/news/18/04/11502217/premarket-prep-opening-nyse-imbalance-update-pfizer-149k-shares-to-buy-exxonmobi,luke@benzinga.com,2018-04-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.9200999999999999
851622, biggest movers from yesterday,https://www.benzinga.com/news/18/04/11493646/40-biggest-movers-from-yesterday,Lisa Levin,2018-04-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851623, stocks moving in mondays midday session,https://www.benzinga.com/news/18/04/11490629/31-stocks-moving-in-mondays-mid-day-session,Lisa Levin,2018-04-09 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851624,cantor fitzgerald double downgrades newlink genetics after incytes disappointing trial,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11489403/cantor-fitzgerald-double-downgrades-newlink-genetics-af,Jayson Derrick,2018-04-09 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.25305
851625, stocks moving in mondays premarket session,https://www.benzinga.com/news/18/04/11488338/20-stocks-moving-in-mondays-pre-market-session,Lisa Levin,2018-04-09 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851626,a peek into the markets us stock futures signal higher start on wall street,https://www.benzinga.com/news/18/04/11487922/a-peek-into-the-markets-us-stock-futures-signal-higher-start-on-wall-street,Lisa Levin,2018-04-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851627,merck reports its keytruda monotherapey met its primary endpoint in the phase keynote study,https://www.benzinga.com/news/18/04/11487754/merck-reports-its-keytruda-monotherapey-met-its-primary-endpoint-in-the-phase-3-,luke@benzinga.com,2018-04-09 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851628,incyte falls after cancer drug fails phase trial,https://www.benzinga.com/general/biotech/18/04/11482030/incyte-falls-20-after-cancer-drug-fails-phase-3-trial,Jayson Derrick,2018-04-06 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.09899999999999998
851629,update incyte shares down after its phase ecgikeynot study with merck did not meet the primary endpoint,https://www.benzinga.com/news/18/04/11481826/update-incyte-shares-down-20-5-after-its-phase-3-ecgi-301keynot-252-study-with-m,Paul Quintaro,2018-04-06 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.648
851630,the first real test of the cancer immunotherapy combination thesis fails incy mrk adam feuerstein tweet,https://www.benzinga.com/news/fda/18/04/11481674/the-first-real-test-of-the-cancer-immunotherapy-combination-thesis-fails-inc,Eddie Staley,2018-04-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.09899999999999998
851631,incyte and merck says phase echokeynote study did not meet the primary endpoint of improving progressionfree survival,https://www.benzinga.com/news/18/04/11481661/incyte-and-merck-says-phase-3-echo-301keynote-252-study-did-not-meet-the-primary,Eddie Staley,2018-04-06 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.71075
851632,merck spokesperson tells benzinga fda postponed pdufa date on sbla for keytruda in mediastinal bcell lymphoma to july rd after co submitted addl data pdufa decision was originally scheduled for april rd,https://www.benzinga.com/general/biotech/18/04/11480297/merck-spokesperson-tells-benzinga-fda-postponed-pdufa-date-on-sbla-fo,Hal Lindon,2018-04-05 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.39885
851633,recro pharma ceo talks nonopioid pain management opportunity cdmo business,https://www.benzinga.com/general/biotech/18/04/11418585/exclusive-recro-pharma-ceo-talks-non-opioid-pain-management-opportuni,Elizabeth Balboa,2018-04-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
851634,benzingas top upgrades downgrades for april ,https://www.benzinga.com/analyst-ratings/upgrades/18/04/11476320/benzingas-top-upgrades-downgrades-for-april-5-2018,Lisa Levin,2018-04-05 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.60115
851635,barclays upgrades merck co to overweight,https://www.benzinga.com/news/18/04/11475081/barclays-upgrades-merck-co-to-overweight,Eddie Staley,2018-04-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3194
851636,stocks that made new wk lows today include incyte merck mallinckrodt celgene cerner willams cos amd albemarle kinder morgan western union walgreens kraft heinz nielsen and alliance data systems,https://www.benzinga.com/trading-ideas/technicals/18/04/11461929/stocks-that-made-new-52-wk-lows-today-include-incyte-merck-m,Hal Lindon,2018-04-03 00:00:00,MRK,1,1,0,1,1,0,1,1,1,0.67
851637,attention biotech investors mark your calendar for these april pdufa dates,https://www.benzinga.com/general/biotech/18/04/11422065/attention-biotech-investors-mark-your-calendar-for-these-april-pdufa-,Shanthi Rexaline,2018-04-03 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851638,reminder merck has fda pdufa date today for keytruda sbla in primary mediastinal large bcell lymphoma,https://www.benzinga.com/general/biotech/18/04/11458625/reminder-merck-has-fda-pdufa-date-today-for-keytruda-sbla-in-primary-,Hal Lindon,2018-04-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851639,astrazeneca merck announces ema accepts regulatory submission for lynparza in brcamutated hernegative metastatic breast cancer,https://www.benzinga.com/news/18/04/11458258/astrazeneca-merck-announces-ema-accepts-regulatory-submission-for-lynparza-in-br,Charles Gross,2018-04-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.26165
851640,the week ahead switchs lockup expires spotify debuts and more,https://www.benzinga.com/general/biotech/18/04/11451368/the-week-ahead-switchs-lockup-expires-spotify-debuts-and-more,Taylor Cox,2018-04-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851641,whats neuvax wainwright says sellas cancer vaccine candidate makes it a buy,https://www.benzinga.com/analyst-ratings/analyst-color/18/04/11452569/whats-neuvax-wainwright-says-sellas-cancer-vaccine-cand,Elizabeth Balboa,2018-04-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
851642,the week ahead in biotech pdufa dates clinical trials and conferences,https://www.benzinga.com/general/biotech/18/03/11432823/the-week-ahead-in-biotech-pdufa-dates-clinical-trials-and-conferences,Shanthi Rexaline,2018-03-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851643,merck reports received fasttrack designation for tepotinib in nslcl in japan,https://www.benzinga.com/news/fda/18/03/11423677/merck-reports-received-fast-track-designation-for-tepotinib-in-nslcl-in-japa,Paul Quintaro,2018-03-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851644,stocks that made new wk lows today include charter comms vornado realty colgatepalmolive merck hasbro ventas dentsply sirona johnson controls goodyear tire clorox ge kinder morgan comcast dish network stericycle and patterson cos,https://www.benzinga.com/trading-ideas/technicals/18/03/11418544/stocks-that-made-new-52-wk-lows-today-include-charter-comms-,Hal Lindon,2018-03-26 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.67
851645,the week ahead in biotech earnings pdufa dates and more,https://www.benzinga.com/general/biotech/18/03/11405010/the-week-ahead-in-biotech-earnings-pdufa-dates-and-more,Shanthi Rexaline,2018-03-26 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851646,merck announces anticancer agent lenvima approved for additional indication of unresectable hcc in japan,https://www.benzinga.com/news/18/03/11408451/merck-announces-anticancer-agent-lenvima-approved-for-additional-indication-of-u,Charles Gross,2018-03-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
851647,checking in on the healthcare sector ahead of q earnings season,https://www.benzinga.com/general/biotech/18/03/11390687/checking-in-on-the-healthcare-sector-ahead-of-q1-earnings-season,JJ Kinahan,2018-03-20 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
851648,jim cramer shares his thoughts on merck five below and more,https://www.benzinga.com/media/18/03/11364192/jim-cramer-shares-his-thoughts-on-merck-five-below-and-more,Craig Jones,2018-03-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
851649,mercks supplemental biologics license application for keytruda granted priority review by the fda for treatment of advanced cervical cancer,https://www.benzinga.com/news/18/03/11349398/mercks-supplemental-biologics-license-application-for-keytruda-granted-priority-,Hal Lindon,2018-03-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.32999999999999996
851650,the market in minutes coincheck gun violence oil and more,https://www.benzinga.com/news/18/03/11342522/the-market-in-5-minutes-coincheck-gun-violence-oil-and-more,Benzinga Newsdesk,2018-03-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.12104999999999999
851651,immutep announces clinical trial collaboration and supply agreement with merck to evaluate combination of imp with keytruda,https://www.benzinga.com/news/18/03/11340312/immutep-announces-clinical-trial-collaboration-and-supply-agreement-with-merck-t,Charles Gross,2018-03-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
851652,pharma bro martin shkreli gets years in prison for securities fraud,https://www.benzinga.com/news/18/03/11235627/pharma-bro-martin-shkreli-gets-7-years-in-prison-for-securities-fraud,Elizabeth Balboa,2018-03-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.1452
851653,eisai merck report global strategic oncology collaboration for lenvima will jointly develop commercialize,https://www.benzinga.com/news/fda/18/03/11323896/eisai-merck-report-global-strategic-oncology-collaboration-for-lenvima-will-,Hal Lindon,2018-03-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851654,height casts odds that congress rolls back pharma discounts,https://www.benzinga.com/analyst-ratings/analyst-color/18/03/11320275/height-casts-65-odds-that-congress-rolls-back-pharma-di,Elizabeth Balboa,2018-03-07 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851655, biotech stocks with clinical trial outcomes in march,https://www.benzinga.com/general/biotech/18/03/11268710/7-biotech-stocks-with-clinical-trial-outcomes-in-march,Shanthi Rexaline,2018-03-05 00:00:00,MRK,1,2,0,0,1,0,1,1,1,0.5
851656,pharma stock roundup astrazeneca merck abbvie and more,https://www.benzinga.com/general/biotech/18/02/11249954/pharma-stock-roundup-astrazeneca-merck-abbvie-and-more,Zacks,2018-02-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851657,merck astrazeneca reports lynparza received positive eu chmp opinion in platinumsensitive relapsed ovarian cancer,https://www.benzinga.com/news/fda/18/02/11249146/merck-astrazeneca-reports-lynparza-received-positive-eu-chmp-opinion-in-plat,Paul Quintaro,2018-02-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.39885
851658,merck to acquire viralytics for m,https://www.benzinga.com/news/18/02/11232266/merck-to-acquire-viralytics-for-394m,Charles Gross,2018-02-21 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851659,gilead merck quiet as traders circulate reuters article from feb th titled gilead wins reversal of billion hepatitis c drug patent verdict,https://www.benzinga.com/news/legal/18/02/11226294/gilead-merck-quiet-as-traders-circulate-reuters-article-from-feb-17th-titl,Eddie Staley,2018-02-20 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.8243
851660,merck reports co astrazeneca won orphan drug designation by fda for selumetinib for treatment of nf,https://www.benzinga.com/news/fda/18/02/11207314/merck-reports-co-astrazeneca-won-orphan-drug-designation-by-fda-for-selumeti,Paul Quintaro,2018-02-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7859499999999999
851661,astrazeneca says selumetinib granted orphan drug designation by fda for neurofibromatosis type ,https://www.benzinga.com/news/18/02/11206886/astrazeneca-says-selumetinib-granted-orphan-drug-designation-by-fda-for-neurofib,Charles Gross,2018-02-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
851662,cramer looks at the dows biggest losers,https://www.benzinga.com/media/jim-cramer/18/02/11196687/cramer-looks-at-the-dows-biggest-losers,Jayson Derrick,2018-02-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.23665000000000003
851663,bmo capital maintains outperform on merck co lowers price target to ,https://www.benzinga.com/news/18/02/11197250/bmo-capital-maintains-outperform-on-merck-co-lowers-price-target-to-65-00,Vick Meyer,2018-02-14 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.436
851664,credit suisse maintains outperform on merck co lowers price target to ,https://www.benzinga.com/news/18/02/11195693/credit-suisse-maintains-outperform-on-merck-co-lowers-price-target-to-65-00,Vick Meyer,2018-02-14 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.6366
851665,merck discontinues alzheimers mk study unlikely that positive benefitrisk could be established,https://www.benzinga.com/general/biotech/18/02/11191738/merck-discontinues-alzheimers-mk-8931-study-unlikely-that-positive-be,Hal Lindon,2018-02-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7787
851666,dz bank upgrades merck co to buy,https://www.benzinga.com/news/18/02/11184825/dz-bank-upgrades-merck-co-to-buy,Eddie Staley,2018-02-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851667,the alzheimers drug pipeline high failure rates in research on an increasingly common disease,https://www.benzinga.com/general/biotech/18/02/11011808/the-alzheimers-drug-pipeline-high-failure-rates-in-research-on-an-inc,Shanthi Rexaline,2018-02-08 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.24469999999999997
851668,leerink swann maintains market perform on merck co lowers price target to ,https://www.benzinga.com/news/18/02/11140636/leerink-swann-maintains-market-perform-on-merck-co-lowers-price-target-to-67-00,Vick Meyer,2018-02-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
851669,merck sees fy adj eps vs est sales bb vs b est,https://www.benzinga.com/news/guidance/18/02/11123898/merck-sees-fy18-adj-eps-4-08-4-23-vs-4-11-est-sales-41-2b-42-7b-vs-41-1,Paul Quintaro,2018-02-02 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851670,merck reports q adj eps vs est sales b vs b est,https://www.benzinga.com/news/earnings/18/02/11123897/merck-reports-q4-adj-eps-0-98-vs-0-94-est-sales-10-4b-vs-10-49b-est,Paul Quintaro,2018-02-02 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851671, stocks to watch for february ,https://www.benzinga.com/news/earnings/18/02/11123678/12-stocks-to-watch-for-february-2-2018,Lisa Levin,2018-02-02 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
851672,earnings scheduled for february ,https://www.benzinga.com/news/earnings/18/02/11123637/earnings-scheduled-for-february-2-2018,Lisa Levin,2018-02-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851673,hang on rate fears in focus as futures point lower after mondays big losses,https://www.benzinga.com/news/18/01/11101992/hang-on-rate-fears-in-focus-as-futures-point-lower-after-mondays-big-losses,JJ Kinahan,2018-01-30 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.11414999999999997
851674,the week ahead big tech earnings fed rate decision likely to dominate headlines,https://www.benzinga.com/news/earnings/18/01/11094350/the-week-ahead-big-tech-earnings-fed-rate-decision-likely-to-dominate-h,Taylor Cox,2018-01-29 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.436
851675,pfe lly mrk write up scripts for q,https://www.benzinga.com/news/earnings/18/01/11094446/pfe-lly-mrk-write-up-scripts-for-q4,JJ Kinahan,2018-01-29 00:00:00,MRK,1,2,1,0,0,1,1,1,1,0.5
851676,fed earnings are meaty filling between slices of job price data,https://www.benzinga.com/news/earnings/18/01/11093826/fed-earnings-are-meaty-filling-between-slices-of-job-price-data,JJ Kinahan,2018-01-29 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851677,biotech ma off to a strong start in more deals to follow,https://www.benzinga.com/general/biotech/18/01/11064912/biotech-m-a-off-to-a-strong-start-in-2018-more-deals-to-follow,Zacks,2018-01-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
851678,will johnson johnsons pharma segment pull up its q earnings,https://www.benzinga.com/general/biotech/18/01/11053061/will-johnson-johnsons-pharma-segment-pull-up-its-q4-earnings,Zacks,2018-01-19 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
851679,merck reports firsttime data for keytruda in patients with previouslytreated advanced hcc showed an overall response rate orr of percent ci n with keytruda as monotherapy,https://www.benzinga.com/news/fda/18/01/11051487/merck-reports-first-time-data-for-keytruda-in-patients-with-previously-treat,Paul Quintaro,2018-01-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
851680,merck reports lynparza for treatment of advanced ovarian cancer received approval in japan,https://www.benzinga.com/news/fda/18/01/11051436/merck-reports-lynparza-for-treatment-of-advanced-ovarian-cancer-received-app,Paul Quintaro,2018-01-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.4614
851681,watching shares of astrazeneca and merck as white house doctor says pres trump takes crestor for cholesterol and propecia for hair loss,https://www.benzinga.com/news/18/01/11036060/watching-shares-of-astrazeneca-and-merck-as-white-house-doctor-says-pres-trump-t,Hal Lindon,2018-01-16 00:00:00,MRK,0,2,1,1,1,1,1,1,1,0.4871
851682,early keytruda results win merck an upgrade,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11034578/early-keytruda-results-win-merck-an-upgrade,Jayson Derrick,2018-01-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.79295
851683,merck shares up on earlier news that phase keynote trial met dual primary endpoints of overall survival and progressionfree survival,https://www.benzinga.com/news/18/01/11033752/merck-shares-up-5-8-on-earlier-news-that-phase-3-keynote-189-trial-met-dual-prim,Eddie Staley,2018-01-16 00:00:00,MRK,1,0,0,0,0,0,1,1,1,0.648
851684,suntrust robinson humphrey upgrades merck co to buy,https://www.benzinga.com/news/18/01/11033746/suntrust-robinson-humphrey-upgrades-merck-co-to-buy,Eddie Staley,2018-01-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851685,fda approves astrazeneca and mercks lynparza for breast cancer with a certain inherited genetic mutation,https://www.benzinga.com/news/fda/18/01/11024918/fda-approves-astrazeneca-and-mercks-lynparza-for-breast-cancer-with-a-certai,Eddie Staley,2018-01-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.42345
851686,a strategy that beat the sp here are your dogs of the dow,https://www.benzinga.com/analyst-ratings/analyst-color/18/01/11013649/a-strategy-that-beat-the-s-p-500-here-are-your-2018-dog,Shanthi Rexaline,2018-01-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851687,key takeaways from the jp morgan healthcare conference,https://www.benzinga.com/general/biotech/18/01/11019205/key-takeaways-from-the-j-p-morgan-healthcare-conference,Zacks,2018-01-11 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.60115
851688,merck announces breakthrough designation from the fda for lenvima and keytruda as combination therapy for renal cell carcinoma,https://www.benzinga.com/news/18/01/11006125/merck-announces-breakthrough-designation-from-the-fda-for-lenvima-and-keytruda-a,Paul Quintaro,2018-01-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851689,alzheimers takes another hit as pfizer ends research in the area,https://www.benzinga.com/general/biotech/18/01/11000497/alzheimers-takes-another-hit-as-pfizer-ends-research-in-the-area,Zacks,2018-01-08 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
851690,mercks keytruda improved recurrencefree survival compared to placebo as adjuvant therapy in patients with stage resected highrisk melanoma,https://www.benzinga.com/news/fda/18/01/10999116/mercks-keytruda-improved-recurrence-free-survival-compared-to-placebo-as-adj,Eddie Staley,2018-01-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
851691,merck announces fda accepts nda for doravirine,https://www.benzinga.com/news/fda/18/01/10999055/merck-announces-fda-accepts-nda-for-doravirine,Eddie Staley,2018-01-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
851692,lower jobs growth in december but some positive signs for economy,https://www.benzinga.com/news/18/01/10995028/lower-jobs-growth-in-december-but-some-positive-signs-for-economy,JJ Kinahan,2018-01-05 00:00:00,MRK,0,1,1,1,1,1,0,0,0,0.86345
851693, reasons to consider adding celldex to your portfolio,https://www.benzinga.com/general/biotech/18/01/10972512/4-reasons-to-consider-adding-celldex-to-your-portfolio,Zacks,2018-01-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851694,mercks keytruda approved in japan for use in the treatment of patients with urothelial carcinoma,https://www.benzinga.com/news/18/01/10971595/mercks-keytruda-approved-in-japan-for-use-in-the-treatment-of-patients-with-urot,Paul Quintaro,2018-01-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
851695,merck shares down pfizer shares up earlier companies together announced fda approvla for their collaboration treatment steglatro steglujan and segluromet,https://www.benzinga.com/general/biotech/17/12/10956680/merck-shares-down-0-12-pfizer-shares-up-0-11-earlier-companies-togeth,Hal Lindon,2017-12-26 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.76335
851696,mercks diabetes drugs get fda nod as adjunct therapies,https://www.benzinga.com/news/17/12/10955483/mercks-diabetes-drugs-get-fda-nod-as-adjunct-therapies,Zacks,2017-12-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851697,fda approves mercks sglt inhibitor steglatro and fixeddose combination steglujan for adults with type diabetes,https://www.benzinga.com/news/17/12/10949786/fda-approves-mercks-sglt2-inhibitor-steglatro-and-fixed-dose-combination-stegluj,Paul Quintaro,2017-12-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.67
851698,merck reports fda granted breakthrough therapy designation for avelumab in combo with inlyta in advanced renal cell carcinoma,https://www.benzinga.com/news/fda/17/12/10946432/merck-reports-fda-granted-breakthrough-therapy-designation-for-avelumab-in-c,Paul Quintaro,2017-12-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
851699, biotech pipeline areas to keep an eye on in ,https://www.benzinga.com/general/biotech/17/12/10939349/3-biotech-pipeline-areas-to-keep-an-eye-on-in-2018,Zacks,2017-12-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851700,lightning round jim cramer shares his thoughts on tmobile electronic arts and more,https://www.benzinga.com/media/cnbc/17/12/10919102/lightning-round-jim-cramer-shares-his-thoughts-on-t-mobile-electronic-arts,Craig Jones,2017-12-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
851701,update merck says progression free survival did not show statistical significance in pdl positive population,https://www.benzinga.com/general/biotech/17/12/10918048/update-merck-says-progression-free-survival-did-not-show-statistical-,Hal Lindon,2017-12-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8629
851702,merck announces keytruda did not meet primary endpoint in phase keynote study,https://www.benzinga.com/general/biotech/17/12/10918034/merck-announces-keytruda-did-not-meet-primary-endpoint-in-phase-3-key,Hal Lindon,2017-12-14 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851703,merck says prevymis expected to be available in canada by yearend,https://www.benzinga.com/news/17/12/10916396/merck-says-prevymis-expected-to-be-available-in-canada-by-year-end,Hal Lindon,2017-12-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851704,mercks keytruda gets fda priority review for rare lymphoma,https://www.benzinga.com/general/biotech/17/12/10906928/mercks-keytruda-gets-fda-priority-review-for-rare-lymphoma,Zacks,2017-12-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851705,premarket opening nyse imbalance update att k shares to sell nike k shares to sell square k to buy disney k to buy us steel k shares to sell pfizer k shares to sell merck k shares to buy,https://www.benzinga.com/news/17/12/10908967/premarket-opening-nyse-imbalance-update-at-t-168k-shares-to-sell-nike-54k-shares,Paul Quintaro,2017-12-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.9200999999999999
851706, stocks in focus as biotech ma hopes for rise,https://www.benzinga.com/general/biotech/17/12/10897424/3-stocks-in-focus-as-biotech-m-a-hopes-for-2018-rise,Zacks,2017-12-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
851707,merck reports fda accepted sbla assigned priority review for keytruda for treatment of relapsed refractory pmbcl,https://www.benzinga.com/news/fda/17/12/10895723/merck-reports-fda-accepted-sbla-assigned-priority-review-for-keytruda-for-tr,Paul Quintaro,2017-12-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6366
851708,loncar investments brad loncar tweets roche is trading slightly down in europe and mrk seems not to be doing anything in this early premarket hour impower basically in line with high expectations,https://www.benzinga.com/news/17/12/10884034/loncar-investments-brad-loncar-tweets-roche-is-trading-slightly-down-in-europe-a,Eddie Staley,2017-12-07 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851709,merck announces publication of phase prevymis study results in ne journal of medicine,https://www.benzinga.com/general/biotech/17/12/10882289/merck-announces-publication-of-phase-3-prevymis-study-results-in-ne-j,Hal Lindon,2017-12-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851710,fda decisions in november the month in review,https://www.benzinga.com/general/biotech/17/12/10858623/fda-decisions-in-november-the-month-in-review,Shanthi Rexaline,2017-12-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851711,merck raises qtr dividend from to share,https://www.benzinga.com/trading-ideas/dividends/17/11/10841218/merck-raises-qtr-dividend-from-0-47-to-0-48share,Paul Quintaro,2017-11-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
851712,merck reports b buyback plan,https://www.benzinga.com/news/buybacks/17/11/10841216/merck-reports-10b-buyback-plan,Paul Quintaro,2017-11-28 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851713,bank of america reinstates buy on merck co announces ,https://www.benzinga.com/news/17/11/10838845/bank-of-america-reinstates-buy-on-merck-co-announces-64-00,Eddie Staley,2017-11-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851714,peregrine pharmaceuticals ronin trading and sw investment management announce settlement agreement peregrine board reconstituted with four new independent directors,https://www.benzinga.com/news/17/11/10838153/peregrine-pharmaceuticals-ronin-trading-and-sw-investment-management-announce-se,Eddie Staley,2017-11-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
851715,update merck pfizer on javelin trial of avelumab say safety profile was consistent with that observed in previously reported studies of avelumab no new safety signals were identified,https://www.benzinga.com/news/17/11/10838137/update-merck-pfizer-on-javelin-trial-of-avelumab-say-safety-profile-was-consiste,Paul Quintaro,2017-11-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.76335
851716,update merck pfizer says phase iii javelin study investigating avelumab did not meet its prespecified primary endpoint of superior overall survival compared to chemotherapy,https://www.benzinga.com/news/fda/17/11/10838134/update-merck-pfizer-says-phase-iii-javelin-study-investigating-avelumab-did-,Paul Quintaro,2017-11-28 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.77115
851717,merck pfizer offer update related to phase iii javelin gastric study in patients with pretreated advanced gastric cancer,https://www.benzinga.com/news/fda/17/11/10838131/merck-pfizer-offer-update-related-to-phase-iii-javelin-gastric-300-study-in-,Paul Quintaro,2017-11-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.23665000000000003
851718, biggest price target changes for friday,https://www.benzinga.com/analyst-ratings/price-target/17/11/10829436/5-biggest-price-target-changes-for-friday,Lisa Levin,2017-11-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851719,merck will miss a promised deadline for filing an ebola vaccine license with the fda according to stat news,https://www.benzinga.com/news/17/11/10806536/merck-will-miss-a-promised-deadline-for-filing-an-ebola-vaccine-license-with-the,Eddie Staley,2017-11-17 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.61315
851720,cue biopharma reports strategic research collab license deal with merck terms not disclosed however cue will receive upfront payment co eligible to earn up to m milestone payments in addition to tiered royalities,https://www.benzinga.com/news/17/11/10796670/cue-biopharma-reports-strategic-research-collab-license-deal-with-merck-terms-no,Paul Quintaro,2017-11-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851721,g filing shows merck reporting stake in spero therapeutics,https://www.benzinga.com/news/17/11/10793972/13g-filing-shows-merck-reporting-6-5-stake-in-spero-therapeutics,Hal Lindon,2017-11-15 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
851722,merck revisits low of move and rebounds,https://www.benzinga.com/trading-ideas/technicals/17/11/10791956/merck-revisits-low-of-move-and-rebounds,Joel Elconin,2017-11-15 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.3634
851723,merck receives a positive chmp opinion for prevymis in the european union,https://www.benzinga.com/news/17/11/10769145/merck-receives-a-positive-chmp-opinion-for-prevymis-in-the-european-union,Paul Quintaro,2017-11-13 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.7787
851724,pharma etfs down post q earnings,https://www.benzinga.com/general/biotech/17/11/10757139/pharma-etfs-down-post-q3-earnings,Zacks,2017-11-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851725,merck reports received fda approval for prevymis for prevention of cmv infection disease in adult allogeneic stem cell transplant patients,https://www.benzinga.com/news/fda/17/11/10753521/merck-reports-received-fda-approval-for-prevymis-for-prevention-of-cmv-infec,Paul Quintaro,2017-11-09 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.7383500000000001
851726,pharma stock roundup pfizer teva novartis and more,https://www.benzinga.com/general/biotech/17/11/10728634/pharma-stock-roundup-pfizer-teva-novartis-and-more,Zacks,2017-11-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851727,premarket imbalance update alibaba k shares to buy bofa k shares to sell merck k to buy ge k to buy,https://www.benzinga.com/news/17/11/10272851/pre-market-imbalance-update-alibaba-278k-shares-to-buy-bofa-111k-shares-to-sell-,Paul Quintaro,2017-11-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.76335
851728,benzingas top upgrades downgrades for october ,https://www.benzinga.com/analyst-ratings/upgrades/17/10/10255464/benzingas-top-upgrades-downgrades-for-october-31-2017,Lisa Levin,2017-10-31 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.60115
851729,the market in minutes a halloween scare for under armour qualcomm and other big tech names,https://www.benzinga.com/news/17/10/10255258/the-market-in-5-minutes-a-halloween-scare-for-under-armour-qualcomm-and-other-bi,Benzinga News Desk,2017-10-31 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.25305
851730,a peek into the markets us stock futures rise ahead of mastercard kellogg earnings,https://www.benzinga.com/news/17/10/10254150/a-peek-into-the-markets-u-s-stock-futures-rise-ahead-of-mastercard-kellogg-earni,Lisa Levin,2017-10-31 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851731,jefferies upgrades merck co to hold,https://www.benzinga.com/news/17/10/10253869/jefferies-upgrades-merck-co-to-hold,Paul Quintaro,2017-10-31 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851732, biggest movers from yesterday,https://www.benzinga.com/news/17/10/10253383/40-biggest-movers-from-yesterday,Lisa Levin,2017-10-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851733, stocks moving in mondays midday session,https://www.benzinga.com/news/17/10/10249218/35-stocks-moving-in-mondays-mid-day-session,Lisa Levin,2017-10-30 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851734,the bull thesis for merck is evaporating,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10248433/the-bull-thesis-for-merck-is-evaporating,Jayson Derrick,2017-10-30 00:00:00,MRK,1,1,1,0,1,1,1,1,1,0.5
851735,analyst grows cautious on mercks keytruda after company withdraws european application,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10247606/analyst-grows-cautious-on-mercks-keytruda,Jayson Derrick,2017-10-30 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.44865
851736, technical levels highlighted on mondays premarket prep,https://www.benzinga.com/trading-ideas/technicals/17/10/10247932/8-technical-levels-highlighted-on-mondays-premarket-prep,Spencer Israel,2017-10-30 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
851737, biggest price target changes for monday,https://www.benzinga.com/analyst-ratings/price-target/17/10/10247838/5-biggest-price-target-changes-for-monday,Lisa Levin,2017-10-30 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851738,benzingas top upgrades downgrades for october ,https://www.benzinga.com/analyst-ratings/upgrades/17/10/10247646/benzingas-top-upgrades-downgrades-for-october-30-2017,Lisa Levin,2017-10-30 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.60115
851739,barclays downgrades merck co to equalweight,https://www.benzinga.com/news/17/10/10247027/barclays-downgrades-merck-co-to-equal-weight,Paul Quintaro,2017-10-30 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.5
851740, stocks moving in mondays premarket session,https://www.benzinga.com/news/17/10/10246939/30-stocks-moving-in-mondays-pre-market-session,Lisa Levin,2017-10-30 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851741,suntrust robinson humphrey downgrades merck co to hold,https://www.benzinga.com/news/17/10/10246607/suntrust-robinson-humphrey-downgrades-merck-co-to-hold,Paul Quintaro,2017-10-30 00:00:00,MRK,1,1,1,0,0,1,1,1,1,0.5
851742,morgan stanley downgrades merck co to equalweight,https://www.benzinga.com/news/17/10/10246389/morgan-stanley-downgrades-merck-co-to-equal-weight,Paul Quintaro,2017-10-30 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
851743, stocks to watch for october ,https://www.benzinga.com/news/earnings/17/10/10245973/8-stocks-to-watch-for-october-30-2017,Lisa Levin,2017-10-30 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851744,merck announces it has withdawn keytruda european application,https://www.benzinga.com/general/biotech/17/10/10244043/merck-announces-it-has-withdawn-keytruda-european-application,Hal Lindon,2017-10-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851745,a peek into the markets us stock futures climb after amazon alphabet results,https://www.benzinga.com/news/17/10/10239540/a-peek-into-the-markets-u-s-stock-futures-climb-after-amazon-alphabet-results,Lisa Levin,2017-10-27 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.58895
851746,merck raises fy sales guidance from bb as of jul to bb vs b est,https://www.benzinga.com/news/guidance/17/10/10239368/merck-raises-fy17-sales-guidance-from-39-4b-40-4b-as-of-jul-28-to-40b-4,Paul Quintaro,2017-10-27 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851747,merck raises fy adj eps outlook from as of jul to vs est,https://www.benzinga.com/news/guidance/17/10/10239363/merck-raises-fy17-adj-eps-outlook-from-3-76-3-88-as-of-jul-28-to-3-91-3,Paul Quintaro,2017-10-27 00:00:00,MRK,1,0,0,1,0,0,1,1,1,0.5
851748,merck reports q adj eps vs est sales b vs b est,https://www.benzinga.com/news/earnings/17/10/10239358/merck-reports-q3-adj-eps-1-11-vs-1-03-est-sales-10-3b-vs-10-55b-est,Paul Quintaro,2017-10-27 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851749, stocks to watch for october ,https://www.benzinga.com/news/earnings/17/10/10238964/12-stocks-to-watch-for-october-27-2017,Lisa Levin,2017-10-27 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851750,earnings scheduled for october ,https://www.benzinga.com/news/earnings/17/10/10238947/earnings-scheduled-for-october-27-2017,Lisa Levin,2017-10-27 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
851751,healthcare etfs set to soar as q earnings unfold,https://www.benzinga.com/news/earnings/17/10/10217944/healthcare-etfs-set-to-soar-as-q3-earnings-unfold,Zacks,2017-10-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851752,the week ahead earnings season starts in earnest,https://www.benzinga.com/news/17/10/10210048/the-week-ahead-earnings-season-starts-in-earnest,Brent Slava,2017-10-23 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.7553000000000001
851753, firms to debut on the markets this week,https://www.benzinga.com/news/17/10/10210388/8-firms-to-debut-on-the-markets-this-week,Elizabeth Balboa,2017-10-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851754,astrazeneca merck rapidly advance lynparza in japan with a nda to japans pharmaceuticals and medical devices agency,https://www.benzinga.com/news/fda/17/10/10209687/astrazeneca-merck-rapidly-advance-lynparza-in-japan-with-a-nda-to-japans-pha,Paul Quintaro,2017-10-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851755,a preview of next weeks bluechip earnings,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10207797/a-preview-of-next-weeks-blue-chip-earnings,Shanthi Rexaline,2017-10-22 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851756,fierce pharma reports merck lays off us sales reps to overhaul primary care marketing,https://www.benzinga.com/news/17/10/10206026/fierce-pharma-reports-merck-lays-off-1-800-u-s-sales-reps-to-overhaul-primary-ca,Paul Quintaro,2017-10-20 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.74695
851757,oncosec shares spike after new data defended,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10201175/oncosec-shares-spike-17-after-new-data-defended,Shanthi Rexaline,2017-10-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
851758,white house shenanigans represent a buying opportunity cramer,https://www.benzinga.com/media/cnbc/17/10/10198951/white-house-shenanigans-represent-a-buying-opportunity-cramer,Jayson Derrick,2017-10-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
851759,benzingas top upgrades downgrades for october ,https://www.benzinga.com/analyst-ratings/upgrades/17/10/10193341/benzingas-top-upgrades-downgrades-for-october-18-2017,Lisa Levin,2017-10-18 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.60115
851760,boosted by keytruda citi upgrades merck to buy for the first time ever,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10192709/boosted-by-keytruda-citi-upgrades-merck-to-buy-for-the-,Jayson Derrick,2017-10-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6806
851761,merck reports fda accepted regulatory submission for lynparza in metastatic breast cancer grants priority review,https://www.benzinga.com/news/fda/17/10/10191920/merck-reports-fda-accepted-regulatory-submission-for-lynparza-in-metastatic-,Paul Quintaro,2017-10-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.32999999999999996
851762,update merck highlights keytruda data showed median overall survival of months for keytruda group compared to months for chemotherapy group,https://www.benzinga.com/news/fda/17/10/10191895/update-merck-highlights-keytruda-data-showed-median-overall-survival-of-30-0,Paul Quintaro,2017-10-18 00:00:00,MRK,1,0,1,0,1,0,1,1,1,0.5
851763,merck reports keytruda more than doubled median overall survival compared to chemotherapy after years of follow up in firstline treatment of patients with metastatic nsclc with high levels of pdl,https://www.benzinga.com/news/fda/17/10/10191894/merck-reports-keytruda-more-than-doubled-median-overall-survival-compared-to,Paul Quintaro,2017-10-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851764,citigroup upgrades merck co to buy,https://www.benzinga.com/news/17/10/10191804/citigroup-upgrades-merck-co-to-buy,Paul Quintaro,2017-10-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851765,merck reports passive stake in kalvista pharmaceuticals g,https://www.benzinga.com/news/17/10/10183748/merck-reports-9-9-passive-stake-in-kalvista-pharmaceuticals-13g,Charles Gross,2017-10-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
851766,aeglea biotherapeutics announces clinical collaboration with merck to evaluate the combination of aegleas aeb pegzilarginase with mercks keytruda pembrolizumab for the treatment of small cell lung cancer,https://www.benzinga.com/news/17/10/10180671/aeglea-biotherapeutics-announces-clinical-collaboration-with-merck-to-evaluate-t,Paul Quintaro,2017-10-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
851767,pharma stock roundup pfizer mulls options for consumer healthcare eli lillys pipeline setback,https://www.benzinga.com/general/biotech/17/10/10175753/pharma-stock-roundup-pfizer-mulls-options-for-consumer-healthcare-eli,Zacks,2017-10-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851768,bank of america sees newlink genetics as undervalued,https://www.benzinga.com/analyst-ratings/analyst-color/17/10/10176076/bank-of-america-sees-newlink-genetics-as-undervalued,Shanthi Rexaline,2017-10-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851769,update merck says co will not submit apps for regulatory approval for anacetrapib,https://www.benzinga.com/news/fda/17/10/10168609/update-merck-says-co-will-not-submit-apps-for-regulatory-approval-for-anacet,Paul Quintaro,2017-10-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
851770,merck offers update on anacetrapid development program,https://www.benzinga.com/news/fda/17/10/10168607/merck-offers-update-on-anacetrapid-development-program,Paul Quintaro,2017-10-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851771, pharma biotech stocks that could be big winners in q earnings,https://www.benzinga.com/general/biotech/17/10/10160332/5-pharma-biotech-stocks-that-could-be-big-winners-in-q3-earnings,Zacks,2017-10-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
851772,health care sector back in focus in congress ahead of q earnings result,https://www.benzinga.com/general/biotech/17/10/10156660/health-care-sector-back-in-focus-in-congress-ahead-of-q3-earnings-res,JJ Kinahan,2017-10-09 00:00:00,MRK,1,2,1,1,1,0,1,0,1,0.74695
851773,premarket imbalance update ge shares k to buy macys k to buy pfizer k to sell merck k to buy citi k to buy pg k to buy exxonmobil k to sell barrick gold k to buy bofa k to buy chevron k to sell jp morgan k to buy,https://www.benzinga.com/news/17/10/10155369/pre-market-imbalance-update-ge-shares-198k-to-buy-macys-75k-to-buy-pfizer-71k-to,Paul Quintaro,2017-10-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7294
851774,heaps of healthy health care etfs,https://www.benzinga.com/general/biotech/17/10/10093347/heaps-of-healthy-health-care-etfs,ETF Professor,2017-10-06 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.8548
851775,galena biopharma shares up following earlier sec filing showing sellas life sciences entered collab supply deal with merck for initiation of phase trial with galinpepimuts keytruda,https://www.benzinga.com/news/fda/17/10/10125599/galena-biopharma-shares-up-10-6-following-earlier-sec-filing-showing-sellas-,Paul Quintaro,2017-10-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
851776,merck to offer new updated data on keytruda at world conference on lung cancer no further details given,https://www.benzinga.com/news/fda/17/09/10119103/merck-to-offer-new-updated-data-on-keytruda-at-world-conference-on-lung-canc,Paul Quintaro,2017-09-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.1175
851777,merck reports discontinuation of mkb mkc development programs,https://www.benzinga.com/news/17/09/10119092/merck-reports-discontinuation-of-mk-3682b-mk-3682c-development-programs,Paul Quintaro,2017-09-29 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851778,cramers guide to profit from market rotations,https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10069482/cramers-guide-to-profit-from-market-rotations,Jayson Derrick,2017-09-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7202
851779,agilent technologies receives fda approval for use of dako pdl for treatment with mercks keytruda in gastric or gastroesophageal junction cancer,https://www.benzinga.com/general/biotech/17/09/10092187/agilent-technologies-receives-fda-approval-for-use-of-dako-pd-l1-for-,Hal Lindon,2017-09-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
851780,reminder mercks keytruda in gastric or gastroesophageal cancer indication has pdufa date today,https://www.benzinga.com/general/biotech/17/09/10089764/reminder-mercks-keytruda-in-gastric-or-gastroesophageal-cancer-indica,Hal Lindon,2017-09-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
851781,merck and pfizer get european commission approval for bavencio,https://www.benzinga.com/news/17/09/10084473/merck-and-pfizer-get-european-commission-approval-for-bavencio,Hal Lindon,2017-09-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
851782,this analyst predicts bullish growth outlook for incyte,https://www.benzinga.com/analyst-ratings/analyst-color/17/09/10044788/this-analyst-predicts-bullish-growth-outlook-for-incyte,Shanthi Rexaline,2017-09-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6909
851783,morgan stanley healthcare conference begins today presenters include veeva systems quorum health neurocrine biosciences vertex pharma merck ocular therapeutix biogen gilead and bristolmyers,https://www.benzinga.com/general/biotech/17/09/10039195/morgan-stanley-healthcare-conference-begins-today-presenters-include-,Hal Lindon,2017-09-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851784,merck reports findings from phase study of keytruda vs standard of care in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma,https://www.benzinga.com/news/fda/17/09/10039042/merck-reports-findings-from-phase-3-study-of-keytruda-vs-standard-of-care-in,Paul Quintaro,2017-09-11 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.74695
851785,what pharmaceuticals spend on lobbying to influence trump,https://www.benzinga.com/general/biotech/17/09/10008324/what-pharmaceuticals-spend-on-lobbying-to-influence-trump,Elizabeth Balboa,2017-09-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.4614
851786,incyte merck announce positive progressionfree survival data from echo trial of epacadostat in combination with keytruda in patients with advanced melanoma at esmo ,https://www.benzinga.com/news/17/09/10037036/incyte-merck-announce-positive-progression-free-survival-data-from-echo-202-tria,Charles Gross,2017-09-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8404
851787,merck reports keytruda plus pemetrexed carboplatin showed continued benefit in overall response rates and progressionfree survival compared to pemcarbo alone in patients with firstline nonsquamous nsclc,https://www.benzinga.com/news/fda/17/09/10033383/merck-reports-keytruda-plus-pemetrexed-carboplatin-showed-continued-benefit-,Paul Quintaro,2017-09-08 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.625
851788,european society for medical oncologyesmo congress begins today day of ,https://www.benzinga.com/general/biotech/17/09/10032830/european-society-for-medical-oncology-esmo-2017-congress-begins-today,Hal Lindon,2017-09-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851789,merck reports updated data for keytruda in patients with advanced gastric cancer across treatment settings,https://www.benzinga.com/news/17/09/10032451/merck-reports-updated-data-for-keytruda-in-patients-with-advanced-gastric-cancer,Paul Quintaro,2017-09-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.23665000000000003
851790,wall streets ma chatter from september cabelas merckrigontec alticecharter amazonkohls,https://www.benzinga.com/news/17/09/10026042/wall-streets-m-a-chatter-from-september-6-cabelas-merck-rigontec-altice-charter-,Charles Gross,2017-09-07 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851791,merck announces acquisition of rigontec for eur m cash may make up to eur m of additional payments,https://www.benzinga.com/news/m-a/17/09/10019095/merck-announces-acquisition-of-rigontec-for-eur-115m-cash-may-make-up-to-eur,Paul Quintaro,2017-09-06 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
851792,eisai signs agreement with merck to expand enrollment of combination study for lenvima and pembrolizumab in endometrial carcinoma,https://www.benzinga.com/news/17/09/10018974/eisai-signs-agreement-with-merck-to-expand-enrollment-of-combination-study-for-l,Charles Gross,2017-09-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.83525
851793,mercks keytruda approved by the european commission for a type of bladder cancer,https://www.benzinga.com/news/17/09/10012430/mercks-keytruda-approved-by-the-european-commission-for-a-type-of-bladder-cancer,Paul Quintaro,2017-09-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.30910000000000004
851794,merck shares down over last few mins remain up for session,https://www.benzinga.com/movers/17/08/10002217/merck-shares-down-0-5-over-last-few-mins-remain-up-0-1-for-session,Paul Quintaro,2017-08-31 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.648
851795,merck shares move to session lows up for session as traders circulating fdagov alert fda alerts healthcare professionals and oncology clinical investigators about two clinical trials on hold evaluating keytruda in patients w mm,https://www.benzinga.com/news/fda/17/08/10002212/merck-shares-move-to-session-lows-up-0-4-for-session-as-traders-circulating-,Paul Quintaro,2017-08-31 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.6909
851796,born on the battlefield acelrx awaits fda ruling on device that delivers potent opioid to wounded soldiers,https://www.benzinga.com/general/biotech/17/08/9991447/born-on-the-battlefield-acelrx-awaits-fda-ruling-on-device-that-delive,Mark Fritz,2017-08-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3409
851797,merck announces presentation of results of reveal outcomes study of anacetrapib investigational medicine for cardiovascular disease,https://www.benzinga.com/news/17/08/9986988/merck-announces-presentation-of-results-of-reveal-outcomes-study-of-anacetrapib-i,Charles Gross,2017-08-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851798,jon najarian sees unusual options activity in marathon petroleum caesars and merck,https://www.benzinga.com/media/cnbc/17/08/9974804/jon-najarian-sees-unusual-options-activity-in-marathon-petroleum-caesars-an,Craig Jones,2017-08-25 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
851799,playing the us pharma space buy portola hold corvus sell teva,https://www.benzinga.com/analyst-ratings/analyst-color/17/08/9972796/playing-the-us-pharma-space-buy-portola-hold-corvus-sell,Shanthi Rexaline,2017-08-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
851800,astrazeneca merck issue release confirming added broad approval of lynparza in us for ovarian cancer,https://www.benzinga.com/news/17/08/9946702/astrazeneca-merck-issue-release-confirming-added-broad-approval-of-lynparza-in-us,Paul Quintaro,2017-08-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
851801,you cant quit because youre fired trump disbands manufacturing council policy forum,https://www.benzinga.com/news/17/08/9940520/you-cant-quit-because-youre-fired-trump-disbands-manufacturing-council-policy-for,Dustin Blitchok,2017-08-16 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.2213
851802,market reaction to bristolmyers mixed clinical results a little excessive,https://www.benzinga.com/analyst-ratings/analyst-color/17/08/9939778/market-reaction-to-bristol-myers-mixed-clinical-results-,Shanthi Rexaline,2017-08-16 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.5
851803,martin shkreli calls merck ceo ken frazier selfindulgent pathetic,https://www.benzinga.com/general/biotech/17/08/9934016/martin-shkreli-calls-merck-ceo-ken-frazier-self-indulgent-pathetic,Jayson Derrick,2017-08-15 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.21405000000000002
851804,the market in minutes,https://www.benzinga.com/news/17/08/9932500/the-market-in-5-minutes,Benzinga News Desk,2017-08-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851805,merck higher despite trump bashing,https://www.benzinga.com/trading-ideas/technicals/17/08/9925770/merck-higher-despite-trump-bashing,Joel Elconin,2017-08-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851806,doug kass tweets i am buying mrk just on principle maddow msnbc carlquintanilla jimcramer tomkeene andrewrsorkin beckyquick,https://www.benzinga.com/news/17/08/9925731/doug-kass-tweets-i-am-buying-mrk-just-on-principle-maddow-msnbc-carlquintanilla-j,Paul Quintaro,2017-08-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851807,merck ceo quits manufacturing council to stand against violence trump promptly calls him out about drug pricing,https://www.benzinga.com/news/17/08/9924717/merck-ceo-quits-manufacturing-council-to-stand-against-violence-trump-promptly-ca,Elizabeth Balboa,2017-08-14 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.18755
851808,donald trump tweets now that ken frazier of merck pharma has resigned from presidents manufacturing councilhe will have more time to lower ripoff drug prices,https://www.benzinga.com/general/politics/17/08/9924127/donald-trump-tweets-now-that-ken-frazier-of-merck-pharma-has-resigned,Paul Quintaro,2017-08-14 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.23165000000000002
851809,cnbc now tweets just in merck ceo resigns from trumps manufacturing council amid fallout from the presidents comments,https://www.benzinga.com/news/17/08/9924029/cnbc-now-tweets-just-in-merck-ceo-resigns-from-trumps-manufacturing-council-amid-,Paul Quintaro,2017-08-14 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.3409
851810,merck q just out,https://www.benzinga.com/news/17/08/9897727/merck-10-q-just-out,Paul Quintaro,2017-08-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851811,nice recommends erbitux in combination with platinumbased chemotherapy for the treatment of recurrent andor metastatic head and neck cancer in the oral cavity,https://www.benzinga.com/news/17/08/9891777/nice-recommends-erbitux-in-combination-with-platinum-based-chemotherapy-for-the-t,Charles Gross,2017-08-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.41105
851812,merck animal health to acquire austrian manufacturing facility terms not disclosed,https://www.benzinga.com/news/17/08/9885994/merck-animal-health-to-acquire-austrian-manufacturing-facility-terms-not-disclose,Paul Quintaro,2017-08-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851813,august pdufa dates biotech investors stay tuned to a month of plenty,https://www.benzinga.com/general/biotech/17/08/9824945/august-pdufa-dates-biotech-investors-stay-tuned-to-a-month-of-plenty,Shanthi Rexaline,2017-08-01 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851814,merck to collaborate with generex biotech for keytruda in combination with ae study,https://www.benzinga.com/general/biotech/17/07/9847788/merck-to-collaborate-with-generex-biotech-for-keytruda-in-combination-,Hal Lindon,2017-07-31 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851815,a peek into the markets us stock futures down amazon earnings miss views,https://www.benzinga.com/news/17/07/9839103/a-peek-into-the-markets-u-s-stock-futures-down-amazon-earnings-miss-views,Lisa Levin,2017-07-28 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5129
851816,merck raises fy sales outlook from feb indication of bb to bb vs b est,https://www.benzinga.com/news/guidance/17/07/9838843/merck-raises-fy17-sales-outlook-from-feb-2-indication-of-38-6b-40-1b-to-,Paul Quintaro,2017-07-28 00:00:00,MRK,1,0,0,1,0,0,1,1,1,0.5
851817,update merck raises fy adj eps outlook from to vs est,https://www.benzinga.com/news/guidance/17/07/9838838/update-merck-raises-fy17-adj-eps-outlook-from-3-72-3-87-to-3-76-3-88-vs-,Paul Quintaro,2017-07-28 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
851818,merck raises fy adj eps outlook,https://www.benzinga.com/news/guidance/17/07/9838835/merck-raises-fy17-adj-eps-outlook,Paul Quintaro,2017-07-28 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851819,merck reports q adj eps vs est sales b vs b est,https://www.benzinga.com/news/earnings/17/07/9838833/merck-reports-q2-adj-eps-1-01-vs-0-87-est-sales-9-93b-vs-9-75b-est,Paul Quintaro,2017-07-28 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851820, stocks to watch for july ,https://www.benzinga.com/news/earnings/17/07/9838195/10-stocks-to-watch-for-july-28-2017,Lisa Levin,2017-07-28 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851821,earnings scheduled for july ,https://www.benzinga.com/news/earnings/17/07/9838175/earnings-scheduled-for-july-28-2017,Lisa Levin,2017-07-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851822,merck shares up after announcing oncology collaboration with astrazeneca,https://www.benzinga.com/news/17/07/9832395/merck-shares-up-3-3-after-announcing-oncology-collaboration-with-astrazeneca,Paul Quintaro,2017-07-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
851823,why is astrazeneca sinking today,https://www.benzinga.com/general/biotech/17/07/9831596/why-is-astrazeneca-sinking-today,Shanthi Rexaline,2017-07-27 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
851824,samsung amazon everyone is getting into pharmaceuticals,https://www.benzinga.com/general/biotech/17/07/9827012/samsung-amazon-everyone-is-getting-into-pharmaceuticals,Elizabeth Balboa,2017-07-27 00:00:00,MRK,1,2,1,0,0,1,1,1,1,0.58895
851825,astrazeneca merck announce strategic oncology collaboration merck to pay astrazeneca up to b in total consideration,https://www.benzinga.com/news/17/07/9829379/astrazeneca-merck-announce-strategic-oncology-collaboration-merck-to-pay-astrazen,Charles Gross,2017-07-27 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.44865
851826,update merck plans to submit new drug applications with the us fda in q for doravirine,https://www.benzinga.com/news/fda/17/07/9816410/update-merck-plans-to-submit-new-drug-applications-with-the-u-s-fda-in-q4-201,Paul Quintaro,2017-07-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851827,mercks doravirine meets primary efficacy endpoint of noninferiority to efavirenz both in combination with other antiretroviral agents in pivotal phase trial for treatment of hiv infection,https://www.benzinga.com/news/fda/17/07/9816400/mercks-doravirine-meets-primary-efficacy-endpoint-of-non-inferiority-to-efavi,Paul Quintaro,2017-07-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851828,update merck reports no safety signals identified in phase keytruda study,https://www.benzinga.com/general/biotech/17/07/9813409/update-merck-reports-no-safety-signals-identified-in-phase-3-keytruda-,Hal Lindon,2017-07-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.57655
851829,merck reports update on phase keytruda study did not meet primary endpoint,https://www.benzinga.com/general/biotech/17/07/9813396/merck-reports-update-on-phase-3-keytruda-study-did-not-meet-primary-en,Hal Lindon,2017-07-24 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851830,what you need to know about dow components reporting this week,https://www.benzinga.com/general/biotech/17/07/9811396/what-you-need-to-know-about-dow-components-reporting-this-week,Shanthi Rexaline,2017-07-24 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851831,ahead of earnings why you should be buying merck and selling bristolmyers,https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9812288/ahead-of-earnings-why-you-should-be-buying-merck-and-sel,Brett Hershman,2017-07-24 00:00:00,MRK,1,2,1,1,1,0,1,1,0,0.5
851832,merck gives results from oncemrk a study of isentress hd,https://www.benzinga.com/news/17/07/9809941/merck-gives-results-from-oncemrk-a-study-of-isentress-hd,Paul Quintaro,2017-07-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851833,merck reports ema chmp recommended approval for cos keytruda for treatment of certain patients with locallyadvanced or metastatic urothelial carcinoma,https://www.benzinga.com/news/fda/17/07/9804846/merck-reports-ema-chmp-recommended-approval-for-co-s-keytruda-for-treatment-o,Paul Quintaro,2017-07-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8592
851834,merck and pfizers avelumab recommended for approval by the eu medicines agency,https://www.benzinga.com/news/17/07/9804773/merck-and-pfizers-avelumab-recommended-for-approval-by-the-eu-medicines-agency,Paul Quintaro,2017-07-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7997000000000001
851835,hearing merck has said corning will make initial m investment related to modernization of pharmaceutical glass packaging,https://www.benzinga.com/news/17/07/9802182/hearing-merck-has-said-corning-will-make-initial-500m-investment-related-to-moder,Paul Quintaro,2017-07-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851836,trump says merck pfizer and corning announce that glass packaging will be made in america,https://www.benzinga.com/news/17/07/9802079/trump-says-merck-pfizer-and-corning-announce-that-glass-packaging-will-be-made-in,Paul Quintaro,2017-07-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851837,merck reports fda granted tentative approvaal for lusduna nexvue,https://www.benzinga.com/news/fda/17/07/9798928/merck-reports-fda-granted-tentative-approvaal-for-lusduna-nexvue,Paul Quintaro,2017-07-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
851838, biggest price target changes for monday,https://www.benzinga.com/analyst-ratings/price-target/17/07/9783412/5-biggest-price-target-changes-for-monday,Lisa Levin,2017-07-17 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851839,shares of eli lilly astrazeneca merck gilead abbvie other large cap biotech spiking higher,https://www.benzinga.com/movers/17/07/9775206/shares-of-eli-lilly-astrazeneca-merck-gilead-abbvie-other-large-cap-biotech-spi,Paul Quintaro,2017-07-13 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.648
851840,jj to commence pharma q earnings season whats up,https://www.benzinga.com/general/biotech/17/07/9768254/j-j-to-commence-pharma-q2-earnings-season-whats-up,Zacks,2017-07-12 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.625
851841,the royaltyamassing strategy of royalty pharma,https://www.benzinga.com/general/biotech/17/07/9757779/the-royalty-amassing-strategy-of-royalty-pharma,Elizabeth Balboa,2017-07-10 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851842,merck falls as fda puts hold on keytruda myeloma studies,https://www.benzinga.com/general/biotech/17/07/9745996/merck-falls-as-fda-puts-hold-on-3-keytruda-myeloma-studies,Zacks,2017-07-06 00:00:00,MRK,1,1,0,1,0,0,1,0,0,0.5
851843,merck to present new data from clinical trials evaluating isentress hd and investigational hiv therapies doravirine and mk at ias ,https://www.benzinga.com/news/fda/17/07/9744759/merck-to-present-new-data-from-clinical-trials-evaluating-isentress-hd-and-in,Paul Quintaro,2017-07-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851844,merck announces fda placed clinical hold on keynote keynote and keynote following review of data by data monitoring committee fda has determined risk of keytruda in compination with pomalidomide of lenalidomide outweigh potential benefits,https://www.benzinga.com/general/biotech/17/07/9742328/merck-announces-fda-placed-clinical-hold-on-keynote-183-keynote-185-an,Hal Lindon,2017-07-05 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.7202
851845,healthcare repeal bad for glaxosmithkline other hiv treatment stocks,https://www.benzinga.com/analyst-ratings/analyst-color/17/07/9739632/healthcare-repeal-bad-for-glaxosmithkline-other-hiv-trea,Wayne Duggan,2017-07-05 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.22885
851846,watch these huge put purchases in monday trade,https://www.benzinga.com/markets/options/17/07/9680620/watch-these-5-huge-put-purchases-in-monday-trade,Lisa Levin,2017-07-03 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.6591
851847,benzingas option alert recap from june ,https://www.benzinga.com/markets/options/17/06/9678587/benzingas-option-alert-recap-from-june-30,Ezra Schwarzbaum,2017-06-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
851848,aduro biotech initiates phase clinical trial of crs in combination with keytruda,https://www.benzinga.com/general/biotech/17/06/9673136/aduro-biotech-initiates-phase-2-clinical-trial-of-crs-207-in-combinati,Hal Lindon,2017-06-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851849,russia in the spotlight as second wave of ransomware grips globe,https://www.benzinga.com/news/17/06/9665914/russia-in-the-spotlight-as-second-wave-of-ransomware-grips-globe,Mark Fritz,2017-06-28 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851850,esperions combo cholesterol candidate enters phase iii,https://www.benzinga.com/17/06/9664960/esperions-combo-cholesterol-candidate-enters-phase-iii,Zacks,2017-06-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851851,mercks cetp inhibitor reduces cv risk in phase iii study,https://www.benzinga.com/17/06/9664402/mercks-cetp-inhibitor-reduces-cv-risk-in-phase-iii-study,Zacks,2017-06-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.32999999999999996
851852,ransomware rears its head again as countries hit by new virus,https://www.benzinga.com/news/17/06/9660113/ransomware-rears-its-head-again-as-150-countries-hit-by-new-virus,Mark Fritz,2017-06-27 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851853,hearing merck has confirmed cos computer network was compromised,https://www.benzinga.com/news/rumors/17/06/9658915/hearing-merck-has-confirmed-co-s-computer-network-was-compromised,Paul Quintaro,2017-06-27 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851854,merck announces reveal met its primary endpoint says will consult with external experts and consider whether to file nda,https://www.benzinga.com/news/17/06/9656907/merck-announces-reveal-met-its-primary-endpoint-says-will-consult-with-external-e,Paul Quintaro,2017-06-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851855,ablynx achieves m milestone iin immunooncology collaboration with merck,https://www.benzinga.com/news/17/06/9656447/ablynx-achieves-2-5m-milestone-iin-immuno-oncology-collaboration-with-merck,Charles Gross,2017-06-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851856,a surprisingly clean straightforward approval gives portola pharma shares a shot of upside,https://www.benzinga.com/analyst-ratings/analyst-color/17/06/9653648/a-surprisingly-clean-straightforward-approval-gives-port,Shanthi Rexaline,2017-06-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.92405
851857,pharma stock roundup nvs scores with positive data shire adhd drug gets fda nod,https://www.benzinga.com/17/06/9646371/pharma-stock-roundup-nvs-scores-with-positive-data-shire-adhd-drug-gets-fda-nod,Zacks,2017-06-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
851858,why you should add novo nordisk stock to your portfolio,https://www.benzinga.com/17/06/9642489/why-you-should-add-novo-nordisk-stock-to-your-portfolio,Zacks,2017-06-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851859,mercks keytruda on a roll can it retain the momentum,https://www.benzinga.com/17/06/9642216/mercks-keytruda-on-a-roll-can-it-retain-the-momentum,Zacks,2017-06-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851860,merck premier report expanded collaboration to address chronic care vaccination rates,https://www.benzinga.com/news/17/06/9640994/merck-premier-report-expanded-collaboration-to-address-chronic-care-vaccination-r,Paul Quintaro,2017-06-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
851861,ligand gets milestone payment on partner drug fda approval,https://www.benzinga.com/17/06/9639200/ligand-gets-milestone-payment-on-partner-drug-fda-approval,Zacks,2017-06-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
851862,small cancer biotech space in focus stocks up more,https://www.benzinga.com/17/06/9636269/small-cancer-biotech-space-in-focus-3-stocks-up-100-more,Zacks,2017-06-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
851863,leap therapeutics reports collab with merck for evaluation of keytruda in combo with dkn in esophagogastric cancer,https://www.benzinga.com/news/17/06/9635615/leap-therapeutics-reports-collab-with-merck-for-evaluation-of-keytruda-in-combo-w,Paul Quintaro,2017-06-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
851864,merck subsidiary announces collaboration with serimmune,https://www.benzinga.com/news/17/06/9631634/merck-subsidiary-announces-collaboration-with-serimmune,Hal Lindon,2017-06-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851865,bristolmyers opdivo positive in phase ii study checkmate,https://www.benzinga.com/17/06/9625444/bristol-myers-opdivo-positive-in-phase-ii-study-checkmate-205,Zacks,2017-06-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
851866,merck receives fda orphan designation for keytruda in treatment of esophageal carcinoma,https://www.benzinga.com/news/17/06/9622742/merck-receives-fda-orphan-designation-for-keytruda-in-treatment-of-esophageal-car,Charles Gross,2017-06-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851867,pharma stock roundup jj lilly present data merck keytruda study enrolment paused,https://www.benzinga.com/17/06/9618359/pharma-stock-roundup-j-j-lilly-present-data-merck-keytruda-study-enrolment-paused,Zacks,2017-06-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
851868,cerveau technologies reports fda accepted ind for mk bz note merck is a development partner for the candidate,https://www.benzinga.com/news/17/06/9618120/cerveau-technologies-reports-fda-accepted-ind-for-mk-6240-bz-note-merck-is-a-deve,Paul Quintaro,2017-06-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6806
851869,merck reports expansion of distribution deal with public health england,https://www.benzinga.com/news/17/06/9612401/merck-reports-expansion-of-distribution-deal-with-public-health-england,Paul Quintaro,2017-06-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851870,merck stalls enrolment in two myeloma studies of keytruda,https://www.benzinga.com/17/06/9601762/merck-stalls-enrolment-in-two-myeloma-studies-of-keytruda,Zacks,2017-06-13 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851871,the zacks analyst blog highlights facebook walmart merck kellogg and paccar,https://www.benzinga.com/17/06/9601775/the-zacks-analyst-blog-highlights-facebook-wal-mart-merck-kellogg-and-paccar,Zacks,2017-06-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851872,merck reports update on multiple myeloma studies keynote of keytruda in combo with other therapies has accepted external data monitoring committee recommendation to pause new enrollment,https://www.benzinga.com/news/17/06/9597969/merck-reports-update-on-multiple-myeloma-studies-keynote-183-185-of-keytruda-in-c,Paul Quintaro,2017-06-12 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.6366
851873,premarket imbalance update pfizer k shares to sell citi k to sell jp morgan k shares to buy merck k to buy,https://www.benzinga.com/news/17/06/9594501/pre-market-imbalance-update-pfizer-74k-shares-to-sell-citi-61k-to-sell-jp-morgan-,Paul Quintaro,2017-06-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.81845
851874,merck pfizer announce that investigational sglt inhibitor ertugliflozin met primary endpoint in two phase studies at ada,https://www.benzinga.com/news/17/06/9592928/merck-pfizer-announce-that-investigational-sglt-2-inhibitor-ertugliflozin-met-pri,Charles Gross,2017-06-11 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.4614
851875,inovios hpv immunotherapy moves to phase iii stock rises,https://www.benzinga.com/17/06/9588445/inovios-hpv-immunotherapy-moves-to-phase-iii-stock-rises,Zacks,2017-06-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851876,dynavax premarket co on friday presented updated data for sd in combination with keytruda,https://www.benzinga.com/news/17/06/9562301/dynavax-21-premarket-7-15-co-on-friday-presented-updated-data-for-sd-101-in-combi,Charles Gross,2017-06-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851877,merck gives update on phase ispy trial,https://www.benzinga.com/news/17/06/9562141/merck-gives-update-on-phase-2-i-spy-2-trial,Paul Quintaro,2017-06-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851878,merck announces presentation of new monotherapy data for keytruda in heavily pretreated patients with advanced gastric cancerasco,https://www.benzinga.com/news/17/06/9561134/merck-announces-presentation-of-new-monotherapy-data-for-keytruda-in-heavily-pre-,Charles Gross,2017-06-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
851879,merck announces keytruda shows continued overall survival benefit over chemotherapy as secondline treatment for advanced urothelial carcinoma patients postplatinum failure asco,https://www.benzinga.com/news/17/06/9561018/merck-announces-keytruda-shows-continued-overall-survival-benefit-over-chemothera,Charles Gross,2017-06-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.58895
851880,combination of incytes epacadostat mercks keytruda demonstrates activity in clinical trial of patients with advanced nonsmall cell lung cancer asco,https://www.benzinga.com/news/17/06/9560785/combination-of-incytes-epacadostat-mercks-keytruda-demonstrates-activity-in-clini,Charles Gross,2017-06-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.23665000000000003
851881,merck announces new data show durability of response for keytruda in advanced microsatellite instabilityhigh or mismatch repair deficient solid tumors regardless of tumor type asco,https://www.benzinga.com/news/17/06/9560735/merck-announces-new-data-show-durability-of-response-for-keytruda-in-advanced-mic,Charles Gross,2017-06-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851882,merck gives update on keytruda effectiveness with over years of follow up,https://www.benzinga.com/news/17/06/9555559/merck-gives-update-on-keytruda-effectiveness-with-over-2-years-of-follow-up,Hal Lindon,2017-06-02 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
851883,tracking the busy june pdufa calendar,https://www.benzinga.com/general/biotech/17/05/9503323/tracking-the-busy-june-pdufa-calendar,Shanthi Rexaline,2017-05-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851884,a peek into the markets us stock futures down ahead of economic data,https://www.benzinga.com/news/17/05/9533873/a-peek-into-the-markets-u-s-stock-futures-down-ahead-of-economic-data,Lisa Levin,2017-05-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851885,merck gets fda approval of isentress for the treatment of hiv,https://www.benzinga.com/news/17/05/9533721/merck-gets-fda-approval-of-isentress-for-the-treatment-of-hiv-1,Paul Quintaro,2017-05-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
851886,congo approves use of merck ebola vaccine dj,https://www.benzinga.com/news/17/05/9532573/congo-approves-use-of-merck-ebola-vaccine-dj,Charles Gross,2017-05-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
851887,reminder merck has isentress snda pdufa date tomorrow may ,https://www.benzinga.com/general/biotech/17/05/9527419/reminder-merck-has-isentress-snda-pdufa-date-tomorrow-may-27,Hal Lindon,2017-05-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851888,merck reports exclusive global license deal with teijin pharma for investigational antibody candidate targeting tau,https://www.benzinga.com/news/fda/17/05/9518234/merck-reports-exclusive-global-license-deal-with-teijin-pharma-for-investigat,Paul Quintaro,2017-05-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5640000000000001
851889,fda approves pembrolizumab for pancreatic cancers with mismatch repair deficiency,https://www.benzinga.com/news/17/05/9509994/fda-approves-pembrolizumab-for-pancreatic-cancers-with-mismatch-repair-deficiency,Charles Gross,2017-05-23 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.70095
851890,fda reports approval for mercks solid tumor with a specific genetic feature treatment,https://www.benzinga.com/news/17/05/9507683/fda-reports-approval-for-mercks-solid-tumor-with-a-specific-genetic-feature-treat,Paul Quintaro,2017-05-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6366
851891,zymeworks early but compelling data large biopharma partners and a potential june catalyst,https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9506563/zymeworks-early-but-compelling-data-large-biopharma-part,Ezra Schwarzbaum,2017-05-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.66455
851892,premarket imbalance update ford k shares to buy ge k to buy nike k to buy gm k to buy alibaba k to buy merck k shares to sell,https://www.benzinga.com/news/17/05/9504841/pre-market-imbalance-update-ford-397k-shares-to-buy-ge-200k-to-buy-nike-57k-to-bu,Paul Quintaro,2017-05-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.76335
851893,companies holding annual meetings today include waste connections eastman kodak alarmcom amyris achillion pharma gnc amazon nokia merck nvidia pinnacle foods wendys xerox,https://www.benzinga.com/news/events/17/05/9504763/companies-holding-annual-meetings-today-include-waste-connections-eastman-,Hal Lindon,2017-05-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3634
851894,merck gets priority fda review for kytruda sbla,https://www.benzinga.com/news/fda/17/05/9503909/merck-gets-priority-fda-review-for-kytruda-sbla,Paul Quintaro,2017-05-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851895,update merck says highest dose of mk evaluated reduced awake cough frequency by from baseline relative to placebo,https://www.benzinga.com/news/fda/17/05/9499315/update-merck-says-highest-dose-of-mk-7264-evaluated-reduced-awake-cough-frequ,Paul Quintaro,2017-05-22 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
851896,merck reports presentation of phase results for mk for treatment of chronic cough,https://www.benzinga.com/news/17/05/9499300/merck-reports-presentation-of-phase-2-results-for-mk-7264-for-treatment-of-chroni,Paul Quintaro,2017-05-22 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
851897,the most notable abstracts released ahead of asco ,https://www.benzinga.com/general/biotech/17/05/9488518/the-most-notable-abstracts-released-ahead-of-asco-2017,Shanthi Rexaline,2017-05-19 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851898,merck reports received chmp opinion recommending approval of isentress mg in eu,https://www.benzinga.com/news/17/05/9491525/merck-reports-received-chmp-opinion-recommending-approval-of-isentress-600-mg-in-,Paul Quintaro,2017-05-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
851899,merck issues release confirming fda has approved keytruda for certain patients with locally advanced or metastatic urothelial carcinoma,https://www.benzinga.com/news/17/05/9488856/merck-issues-release-confirming-fda-has-approved-keytruda-for-certain-patients-wi,Paul Quintaro,2017-05-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8548
851900,fda has granted approval for mercks pembrolizumab for treatment of locally advanced or metastatic urothelial carcinoma,https://www.benzinga.com/news/17/05/9487630/fda-has-granted-approval-for-mercks-pembrolizumab-for-treatment-of-locally-advanc,Paul Quintaro,2017-05-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.86345
851901,who says congo ebola cases present high national low global risk reuters,https://www.benzinga.com/news/17/05/9484524/who-says-congo-ebola-cases-present-high-national-low-global-risk-reuters,Charles Gross,2017-05-18 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.25305
851902,incyte issues release highlighting cos ido enzyme inhibitor in combo with mercks antipd therapy is welltolerated and demonstrates durable clinical responses across multiple solid tumors,https://www.benzinga.com/news/fda/17/05/9482955/incyte-issues-release-highlighting-co-s-ido1-enzyme-inhibitor-in-combo-with-m,Paul Quintaro,2017-05-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5386
851903,mercks glucophage sr has received label extension to include patients at high risk of type diabetes within uk,https://www.benzinga.com/news/17/05/9480677/mercks-glucophage-sr-has-received-label-extension-to-include-patients-at-high-ris,Paul Quintaro,2017-05-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3634
851904,aduro biotech reports clinical collaboration with merck for evaluation of crs keytruda combo for treatment of mesothelioma,https://www.benzinga.com/news/fda/17/05/9479172/aduro-biotech-reports-clinical-collaboration-with-merck-for-evaluation-of-crs,Paul Quintaro,2017-05-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851905,who confirms second ebola case in congo reuters,https://www.benzinga.com/news/17/05/9459509/who-confirms-second-ebola-case-in-congo-reuters,Charles Gross,2017-05-14 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
851906,sympathy moves explained unsympathetic earnings season continues as nvidia advanced micro devices diverge,https://www.benzinga.com/news/earnings/17/05/9452050/sympathy-moves-explained-unsympathetic-earnings-season-continues-as-nvid,Shanthi Rexaline,2017-05-12 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.77115
851907,heres what the fda approval of keytruda means for merck and for bristolmyers,https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9447190/heres-what-the-fda-approval-of-keytruda-means-for-merck-,Wayne Duggan,2017-05-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
851908,merck press release confirms fda approval for keytruda,https://www.benzinga.com/general/biotech/17/05/9443042/merck-press-release-confirms-fda-approval-for-keytruda,Hal Lindon,2017-05-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
851909,andy biotech tweets mrk fda approves keytruda chemo combo in l nsclc,https://www.benzinga.com/general/biotech/17/05/9442928/andy-biotech-tweets-mrk-fda-approves-keytruda-chemo-combo-in-1l-nsclc,Hal Lindon,2017-05-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
851910,reminder merck has keytruda pdufa date today,https://www.benzinga.com/general/biotech/17/05/9438543/reminder-merck-has-keytruda-pdufa-date-today,Hal Lindon,2017-05-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851911,oncosec medical premarket following announcement of clinical collaboration with merck to evaluate combination of immunopulse il and keytruda,https://www.benzinga.com/news/17/05/9436055/oncosec-medical-21-5-premarket-1-30-following-announcement-of-clinical-collaborat,Charles Gross,2017-05-10 00:00:00,MRK,1,0,1,0,1,0,1,1,1,0.5
851912,oncosec medical reports clinical trial collaboration supply deal with merck to evaluate combo of immunopulse il and keytruda,https://www.benzinga.com/news/17/05/9435552/oncosec-medical-reports-clinical-trial-collaboration-supply-deal-with-merck-to-ev,Paul Quintaro,2017-05-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851913,update merck q filing shows co eliminated positions in q under restructuring program activities,https://www.benzinga.com/news/17/05/9433065/update-merck-10-q-filing-shows-co-eliminated-545-positions-in-q117-under-restruct,Paul Quintaro,2017-05-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851914,merck q just out,https://www.benzinga.com/news/17/05/9433045/merck-10-q-just-out,Paul Quintaro,2017-05-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851915,array biopharma reports strategic partnership with merck,https://www.benzinga.com/news/contracts/17/05/9418605/array-biopharma-reports-strategic-partnership-with-merck,Paul Quintaro,2017-05-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851916,nearterm events cast shadow of uncertainty on bristolmyers,https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9394503/near-term-events-cast-shadow-of-uncertainty-on-bristol-m,Shanthi Rexaline,2017-05-06 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.32999999999999996
851917,premarket imbalance update ibm k shares to sell twitter k to sell ford k shares to buy merck k to sell disney k to sell pg k to sell,https://www.benzinga.com/news/17/05/9410964/pre-market-imbalance-update-ibm-110k-shares-to-sell-twitter-100k-to-sell-ford-63k,Paul Quintaro,2017-05-05 00:00:00,MRK,1,2,0,1,0,1,1,1,1,0.76335
851918,merck reports ec approval of keytruda for patients with relapsed refractory classical hodgkin lymphoma who who failed autologous stem cell transplant and brentuximab vedotin bv or who are transplantineligible and have failed bv,https://www.benzinga.com/news/17/05/9410219/merck-reports-ec-approval-of-keytruda-for-patients-with-relapsed-refractory-class,Paul Quintaro,2017-05-05 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.22885
851919,ahead of mercks keytruda pdufa date analyst says expect approval,https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9393743/ahead-of-mercks-keytruda-pdufa-date-analyst-says-expect-,Jayson Derrick,2017-05-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
851920,apple earnings in focus but fed meeting auto sales also could grab headlines,https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9384571/apple-earnings-in-focus-but-fed-meeting-auto-sales-also-,The Ticker Tape,2017-05-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851921,a peek into the markets us stock futures mostly lower apple earnings in focus,https://www.benzinga.com/news/earnings/17/05/9382526/a-peek-into-the-markets-u-s-stock-futures-mostly-lower-apple-earnings-in,Lisa Levin,2017-05-02 00:00:00,MRK,0,1,1,1,1,0,0,0,0,0.352
851922,merck raises fy guidance sees fy eps to vs est sales b to b vs b est,https://www.benzinga.com/news/guidance/17/05/9382259/merck-raises-fy-2017-guidance-sees-fy-2017-eps-3-76-to-3-88-vs-3-81-est-,Paul Quintaro,2017-05-02 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851923,merck q eps vs est sales b vs b est,https://www.benzinga.com/news/earnings/17/05/9382256/merck-q1-eps-0-88-vs-0-83-est-sales-9-43b-vs-9-25b-est,Paul Quintaro,2017-05-02 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851924, stocks to watch for may ,https://www.benzinga.com/news/earnings/17/05/9381662/12-stocks-to-watch-for-may-2-2017,Lisa Levin,2017-05-02 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
851925,earnings scheduled for may ,https://www.benzinga.com/news/earnings/17/05/9381612/earnings-scheduled-for-may-2-2017,Lisa Levin,2017-05-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851926,earnings preview q results from pfizer merck and gilead sciences this week,https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9376632/earnings-preview-q1-results-from-pfizer-merck-and-gilead,The Ticker Tape,2017-05-01 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851927,feuerstein on neurotrope the study failed and there was never a lot of hope here,https://www.benzinga.com/general/biotech/17/05/9375767/feuerstein-on-neurotrope-the-study-failed-and-there-was-never-a-lot-of,Elizabeth Balboa,2017-05-01 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.1543
851928,looking for action week ahead brings heavy load with earnings data fed meeting,https://www.benzinga.com/analyst-ratings/analyst-color/17/05/9375214/looking-for-action-week-ahead-brings-heavy-load-with-ear,The Ticker Tape,2017-05-01 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851929,watching volatility in vaccine names here as traders circulating wsj article from mon evening vaunted ebola vaccine faces questions,https://www.benzinga.com/news/17/04/9343071/watching-volatility-in-vaccine-names-here-as-traders-circulating-wsj-article-from,Paul Quintaro,2017-04-25 00:00:00,MRK,1,2,0,1,0,0,1,0,0,0.5
851930,mark your calendar for these days in may to play the volatility around fda decision dates,https://www.benzinga.com/general/biotech/17/04/9341495/mark-your-calendar-for-these-days-in-may-to-play-the-volatility-around,Shanthi Rexaline,2017-04-25 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.67
851931,earnings caterpillar lockheed martin and eli lilly report tomorrow,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9336445/earnings-caterpillar-lockheed-martin-and-eli-lilly-repor,The Ticker Tape,2017-04-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851932,merck reports study in us veterans affairs system evaluating use of zepatier showed high sustained virologic response rates in patients with chronic hep c,https://www.benzinga.com/news/fda/17/04/9329113/merck-reports-study-in-us-veterans-affairs-system-evaluating-use-of-zepatier-,Paul Quintaro,2017-04-21 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.5
851933,atara bio partners with merck to evaluate keytruda in combination with ata in npc,https://www.benzinga.com/news/contracts/17/04/9328408/atara-bio-partners-with-merck-to-evaluate-keytruda-in-combination-with-,Hal Lindon,2017-04-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851934,what would a billion nih cut look like devastation,https://www.benzinga.com/news/17/04/9308625/what-would-a-5-8-billion-nih-cut-look-like-devastation,Elizabeth Balboa,2017-04-20 00:00:00,MRK,1,2,0,1,0,0,0,0,0,0.32999999999999996
851935,exclusive leading biosciences execs talk about how the company could save hospitals millions of dollars per year,https://www.benzinga.com/general/biotech/17/04/9307049/leading-biosciences-execs-talk-about-how-the-company-could-save-hospit,Javier Hasse,2017-04-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7859499999999999
851936,healthcare sector earnings making a comeback in q ,https://www.benzinga.com/analyst-ratings/analyst-color/17/04/9293543/healthcare-sector-earnings-making-a-comeback-in-q1-2017,The Ticker Tape,2017-04-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851937,cardiovascular players could be eyeing esperion,https://www.benzinga.com/general/biotech/17/04/9282574/cardiovascular-players-could-be-eyeing-esperion,Elizabeth Balboa,2017-04-10 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851938,barrons picks and pans gold energy dividends and more,https://www.benzinga.com/media/barrons/17/04/9279601/barrons-picks-and-pans-gold-energy-dividends-and-more,Nelson Hem,2017-04-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6366
851939,premarket imbalance update amex k shares to sell ford k shares to buy merck k to buy bofa k to sell morgan stanley k to sell nike ge k to sell,https://www.benzinga.com/news/17/04/9275882/pre-market-imbalance-update-amex-89k-shares-to-sell-ford-71k-shares-to-buy-merck-,Paul Quintaro,2017-04-07 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.76335
851940,merck reports received crl from fda related to tecos study with sitagliptin,https://www.benzinga.com/news/fda/17/04/9275412/merck-reports-received-crl-from-fda-related-to-tecos-study-with-sitagliptin,Paul Quintaro,2017-04-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851941,there is value to be had with the right healthcare etfs,https://www.benzinga.com/general/biotech/17/04/9260682/there-is-value-to-be-had-with-the-right-healthcare-etfs,ETF Professor,2017-04-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.67
851942,benzinga premarket prep host dennis dick tweets notable opening imbalances pfe k mrk k baba k ko k t k cat k ibm k,https://www.benzinga.com/news/17/04/9248347/benzinga-premarket-prep-host-dennis-dick-tweets-notable-opening-imbalances-pfe-24,Paul Quintaro,2017-04-03 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.24469999999999997
851943,update incyte merck announce clinical program for epacadostat keytruda includes registrational trials across tumor types,https://www.benzinga.com/news/fda/17/03/9241055/update-incyte-merck-announce-clinical-program-for-epacadostat-keytruda-includ,Paul Quintaro,2017-03-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.30910000000000004
851944,incyte merck offer added details on previously announced collab investigating epacadostat keytruda,https://www.benzinga.com/news/fda/17/03/9241053/incyte-merck-offer-added-details-on-previously-announced-collab-investigating,Paul Quintaro,2017-03-31 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
851945,european medicines agencys chmp recommends approval of mercks keytruda,https://www.benzinga.com/news/17/03/9212180/european-medicines-agencys-chmp-recommends-approval-of-mercks-keytruda,Paul Quintaro,2017-03-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8062
851946,leerink presents your biopharma catalyst tracker,https://www.benzinga.com/analyst-ratings/analyst-color/17/03/9182637/leerink-presents-your-2017-biopharma-catalyst-tracker,Shanthi Rexaline,2017-03-20 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851947,prima biomed completes recruitment for second patient cohort in melanoma trial,https://www.benzinga.com/news/17/03/9173122/prima-biomed-completes-recruitment-for-second-patient-cohort-in-melanoma-trial,Charles Gross,2017-03-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851948,merck says submission of additional data is considered major amendment to sbla under pdufa thus extending target action date by months to june th ,https://www.benzinga.com/news/fda/17/03/9171536/merck-says-submission-of-additional-data-is-considered-major-amendment-to-sbl,Paul Quintaro,2017-03-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851949,fda has approved mercks keytruda for intravenous use in hodgkin lymphoma,https://www.benzinga.com/general/biotech/17/03/9170856/fda-has-approved-mercks-keytruda-for-intravenous-use-in-hodgkin-lympho,Hal Lindon,2017-03-14 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.71075
851950,adam feuerstein talks vulnerable pharmaceuticals drug pricing under trump,https://www.benzinga.com/general/biotech/17/03/9158311/adam-feuerstein-talks-vulnerable-pharmaceuticals-drug-pricing-under-tr,Elizabeth Balboa,2017-03-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.38685
851951,feuerstein on benzingas premarket prep discussing stocks which could be impacted by drug pricing changes believes worst case scenario would create vulnerabilities for drugs with high levels of competition,https://www.benzinga.com/news/17/03/9157645/feuerstein-on-benzingas-premarket-prep-discussing-stocks-which-could-be-impacted-,Paul Quintaro,2017-03-10 00:00:00,MRK,1,1,0,1,0,0,1,1,0,0.2213
851952,heres your march pdufa date preview,https://www.benzinga.com/general/biotech/17/03/9147705/heres-your-march-pdufa-date-preview,Manikandan Raman,2017-03-08 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
851953,everything we know about mercks keytruda,https://www.benzinga.com/general/biotech/17/03/9147190/everything-we-know-about-mercks-keytruda,Jayson Derrick,2017-03-08 00:00:00,MRK,1,2,1,0,0,1,1,1,1,0.5
851954,reminder mercks pdufa date for keytruda in microsatellite instabilityhigh cancer today,https://www.benzinga.com/general/biotech/17/03/9145619/reminder-mercks-pdufa-date-for-keytruda-in-microsatellite-instability-,Hal Lindon,2017-03-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
851955,merck pfizer report us fda and ema filing acceptances of marketing applications for ertugliflozincontaining medicines for adult type diabetes patients,https://www.benzinga.com/news/fda/17/03/9132281/merck-pfizer-report-u-s-fda-and-ema-filing-acceptances-of-3-marketing-applica,Paul Quintaro,2017-03-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
851956,why bermuda could be the next switzerland,https://www.benzinga.com/general/biotech/17/03/9115538/why-bermuda-could-be-the-next-switzerland,Javier Hasse,2017-03-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851957,mercks odactra approved for house dust mite allergies,https://www.benzinga.com/news/fda/17/03/9116638/mercks-odactra-approved-for-house-dust-mite-allergies,Paul Quintaro,2017-03-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
851958,merck says letermovir for prevention of cmvinfection in bone marrow transplant recipients is highly effective through week posttransplant in pivotal phase study,https://www.benzinga.com/news/17/02/9097222/merck-says-letermovir-for-prevention-of-cmv-infection-in-bone-marrow-transplant-r,Charles Gross,2017-02-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7627999999999999
851959,big business delivers christmas wish list to trump months early,https://www.benzinga.com/general/politics/17/02/9095312/big-business-delivers-christmas-wish-list-to-trump-10-months-early,Wayne Duggan,2017-02-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
851960,merck reports first phase trial of v reduced incidence of confirmed herpes zoster cases by in immunocompromised subjects,https://www.benzinga.com/news/fda/17/02/9095716/merck-reports-first-phase-3-trial-of-v212-reduced-incidence-of-confirmed-herp,Paul Quintaro,2017-02-24 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851961,merck receives positive chmp opinion for new pergoveris fertility pen,https://www.benzinga.com/news/fda/17/02/9092703/merck-receives-positive-chmp-opinion-for-new-pergoveris-fertility-pen,Paul Quintaro,2017-02-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
851962,merck says will record intangible asset impairment charge related to mk program previously reported q and fy nongaap eps remain unchanged,https://www.benzinga.com/news/17/02/9090640/merck-says-will-record-intangible-asset-impairment-charge-related-to-mk-3682-prog,Paul Quintaro,2017-02-23 00:00:00,MRK,1,1,1,0,1,0,1,1,1,0.6806
851963,breaking down the multiple sclerosis formularies stability fares well for the market,https://www.benzinga.com/analyst-ratings/analyst-color/17/02/9087784/breaking-down-the-multiple-sclerosis-2017-formularies-st,Shanthi Rexaline,2017-02-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6366
851964,icahn takes bristolmyers stake with ma in mind who could be the acquirer,https://www.benzinga.com/general/biotech/17/02/9076742/icahn-takes-bristol-myers-stake-with-m-a-in-mind-who-could-be-the-acqu,Elizabeth Balboa,2017-02-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851965,boeing pfizer and others band together to ask congress for more taxes,https://www.benzinga.com/news/17/02/9074793/boeing-pfizer-and-others-band-together-to-ask-congress-for-more-taxes,Shanthi Rexaline,2017-02-21 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
851966,the market in minutes,https://www.benzinga.com/news/17/02/9064683/the-market-in-5-minutes,Benzinga Newsdesk,2017-02-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851967,after merck stops study what remains of the alzheimers drug pipeline,https://www.benzinga.com/general/biotech/17/02/9061803/after-merck-stops-study-what-remains-of-the-alzheimers-drug-pipeline,Taylor Cox,2017-02-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.42345
851968,merck still sees path forward for failed alzheimers drug,https://www.benzinga.com/news/17/02/9055504/merck-still-sees-path-forward-for-failed-alzheimers-drug,Elizabeth Balboa,2017-02-15 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.24469999999999997
851969,merck on its alzheimers drug program tells benzinga too early to speculate what verubecestat trial results mean for validity of amyloid hypothesis hopes by evaluating drug in people wless impairment will be able to slow disease progression,https://www.benzinga.com/general/biotech/17/02/9055138/merck-on-its-alzheimers-drug-program-tells-benzinga-too-early-to-specu,Hal Lindon,2017-02-15 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.71075
851970,deutsche bank casts doubt on pfizers rumored takeover approach to bristolmyers,https://www.benzinga.com/analyst-ratings/analyst-color/17/02/9054293/deutsche-bank-casts-doubt-on-pfizers-rumored-takeover-ap,Manikandan Raman,2017-02-15 00:00:00,MRK,1,2,1,0,1,0,1,1,1,0.3194
851971,merck says apecs study in people with prodromal alzheimers disease to continue,https://www.benzinga.com/news/fda/17/02/9049008/merck-says-apecs-study-in-people-with-prodromal-alzheimers-disease-to-continu,Paul Quintaro,2017-02-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851972,meg tirrell tweets mrk stops study of bace inhibitor in mild to moderate alzheimers for lack of efficacy prodromal study continues,https://www.benzinga.com/news/fda/17/02/9049003/meg-tirrell-tweets-mrk-stops-study-of-bace-inhibitor-in-mild-to-moderate-alzh,Paul Quintaro,2017-02-14 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.25305
851973,mercks doravirine meets primary efficacy endpoint in pivotal phase trial,https://www.benzinga.com/general/biotech/17/02/9048076/mercks-doravirine-meets-primary-efficacy-endpoint-in-pivotal-phase-3-t,Hal Lindon,2017-02-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
851974,fda to review two of mercks supplemental biologics license applications,https://www.benzinga.com/news/fda/17/02/8990730/fda-to-review-two-of-mercks-supplemental-biologics-license-applications,Paul Quintaro,2017-02-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851975,q realtime call brief,https://www.benzinga.com/node/8985740,Scout Finance,2017-02-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851976,the market in minutes facebook beats trump tweets,https://www.benzinga.com/news/17/02/8984512/the-market-in-5-minutes-facebook-beats-trump-tweets,Benzinga News Desk,2017-02-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851977,merck ceo says trump focus on patients being able to afford copays rather than overall cost of drugs,https://www.benzinga.com/news/17/02/8985264/merck-ceo-says-trump-focus-on-patients-being-able-to-afford-co-pays-rather-than-o,Paul Quintaro,2017-02-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851978,merck sees fy adj eps vs est sales bb vs b est,https://www.benzinga.com/news/guidance/17/02/8984067/merck-sees-fy17-adj-eps-3-72-3-87-vs-3-85-est-sales-38-6b-40-1b-vs-40b-e,Paul Quintaro,2017-02-02 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
851979,merck reports q adj eps inline sales b vs b est,https://www.benzinga.com/news/earnings/17/02/8984063/merck-reports-q4-adj-eps-0-89-inline-sales-10-1b-vs-10-22b-est,Paul Quintaro,2017-02-02 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
851980,earnings facebook and merck scheduled to open their books,https://www.benzinga.com/analyst-ratings/analyst-color/17/02/8979196/earnings-facebook-and-merck-scheduled-to-open-their-book,The Ticker Tape,2017-02-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851981,ringing up the iphones strong apple results put a charge into markets,https://www.benzinga.com/analyst-ratings/analyst-color/17/02/8978816/ringing-up-the-iphones-strong-apple-results-put-a-charge,The Ticker Tape,2017-02-01 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.7553000000000001
851982,merck announces eu approves keytruda for firstline pateitns,https://www.benzinga.com/general/biotech/17/01/8974396/merck-announces-eu-approves-keytruda-for-first-line-pateitns,Hal Lindon,2017-01-31 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.70095
851983,taking a clinical road less traveled neurotrope hopes to succeed in alzheimers where competitors fail,https://www.benzinga.com/general/biotech/17/01/8962220/taking-a-clinical-road-less-traveled-neurotrope-hopes-to-succeed-in-al,Taylor Cox,2017-01-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.65205
851984,mixing it up markets await host of economic data key earnings and fed meeting,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8964318/mixing-it-up-markets-await-host-of-economic-data-key-ear,The Ticker Tape,2017-01-30 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.55135
851985,the market in minutes walgreensrite aid personal income and trumps executive order,https://www.benzinga.com/news/17/01/8963202/the-market-in-5-minutes-walgreens-rite-aid-personal-income-and-trumps-executive-o,Benzinga News Desk,2017-01-30 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
851986,can merck and pfizer beat low expectations,https://www.benzinga.com/news/earnings/17/01/8961933/can-merck-and-pfizer-beat-low-expectations,Nelson Hem,2017-01-30 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.3634
851987,a ceo whos who of trumps manufacturing council,https://www.benzinga.com/news/17/01/8959545/a-ceo-whos-who-of-trumps-manufacturing-council,Dustin Blitchok,2017-01-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851988,andrew left furthers comments following esrx release today points to comment made by merck president of us commercial to highlight thesis that drug cos offer incentives to pbms to stay on preferred drug lists,https://www.benzinga.com/news/17/01/8959441/andrew-left-furthers-comments-following-esrx-release-today-points-to-comment-made,Paul Quintaro,2017-01-27 00:00:00,MRK,1,2,0,0,1,0,1,1,1,0.7859499999999999
851989,wsj reporting merck raised list prices by last year,https://www.benzinga.com/news/fda/17/01/8956453/wsj-reporting-merck-raised-list-prices-by-9-6-last-year,Paul Quintaro,2017-01-27 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.5
851990,merck shares falling as ketruda brain tumor trial put on hold due to adverse event,https://www.benzinga.com/news/fda/17/01/8951405/merck-shares-falling-as-ketruda-brain-tumor-trial-put-on-hold-due-to-adverse-,Paul Quintaro,2017-01-26 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.22885
851991,mercks keytruda gains momentum at the expense of bristolmyers,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8950989/mercks-keytruda-gains-momentum-at-the-expense-of-bristol,Shanthi Rexaline,2017-01-26 00:00:00,MRK,1,0,0,1,0,0,1,1,1,0.67
851992,dow ks hottest stocks where are they now,https://www.benzinga.com/general/topics/17/01/8946256/dow-10ks-hottest-stocks-where-are-they-now,Shanthi Rexaline,2017-01-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
851993,which pharma players dominate the lung cancer space,https://www.benzinga.com/general/biotech/17/01/8945361/which-pharma-players-dominate-the-lung-cancer-space,Shanthi Rexaline,2017-01-25 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.1452
851994,update mercks payment to bristolmyers will be recorded in its q and fy results excluded from nongaap results,https://www.benzinga.com/general/biotech/17/01/8929780/update-mercks-payment-to-bristol-myers-will-be-recorded-in-its-q4-and-,Hal Lindon,2017-01-20 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.32999999999999996
851995,merck announces setlement with bristolmyers resolving keytruda patent litigation will pay m and provide royalties on keytruda in any market in which its approved,https://www.benzinga.com/general/biotech/17/01/8929760/merck-announces-setlement-with-bristol-myers-resolving-keytruda-patent,Hal Lindon,2017-01-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
851996,bristolmyers squibb falls after opdivo decision,https://www.benzinga.com/trading-ideas/technicals/17/01/8928204/bristol-myers-squibb-falls-10-after-opdivo-decision,Joel Elconin,2017-01-20 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
851997,wall streets ma chatter from january ,https://www.benzinga.com/news/17/01/8927095/wall-streets-m-a-chatter-from-january-19,Charles Gross,2017-01-20 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
851998,favorable news on keytruda drives piper jaffrays upgrade of merck,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8899022/favorable-news-on-keytruda-drives-piper-jaffrays-upgrade,Jim Swanson,2017-01-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
851999, biggest price target changes for thursday,https://www.benzinga.com/analyst-ratings/price-target/17/01/8899537/8-biggest-price-target-changes-for-thursday,Lisa Levin,2017-01-12 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852000,benzingas top upgrades downgrades for january ,https://www.benzinga.com/analyst-ratings/upgrades/17/01/8899439/benzingas-top-upgrades-downgrades-for-january-12-2017,Lisa Levin,2017-01-12 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.60115
852001,mercks leadership position in immuno oncology is improving,https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8899037/mercks-leadership-position-in-immuno-oncology-is-improvi,Jim Swanson,2017-01-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
852002,the market in minutes jobless claims lower trump conference shakes sectors,https://www.benzinga.com/news/17/01/8898552/the-market-in-5-minutes-jobless-claims-lower-trump-conference-shakes-sectors,Benzinga News Desk,2017-01-12 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.352
852003,guggenheim upgrades merck co to buy announces target,https://www.benzinga.com/news/17/01/8898655/guggenheim-upgrades-merck-co-to-buy-announces-70-00-target,Paul Quintaro,2017-01-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852004,morgan stanley upgrades merck co to overweight raises target to ,https://www.benzinga.com/news/17/01/8898340/morgan-stanley-upgrades-merck-co-to-overweight-raises-target-to-71-00,Paul Quintaro,2017-01-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3194
852005,all the markets trump moved during his speech today,https://www.benzinga.com/general/biotech/17/01/8896461/all-the-markets-trump-moved-during-his-speech-today,Elizabeth Balboa,2017-01-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852006,heres what mercks keytruda news means for bristolmyers,https://www.benzinga.com/general/biotech/17/01/8895927/heres-what-mercks-keytruda-news-means-for-bristol-myers,Shanthi Rexaline,2017-01-11 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852007, biggest midday gainers for wednesday,https://www.benzinga.com/news/17/01/8895802/15-biggest-mid-day-gainers-for-wednesday,Lisa Levin,2017-01-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852008, stocks moving in wednesdays premarket session,https://www.benzinga.com/news/17/01/8893998/22-stocks-moving-in-wednesdays-pre-market-session,Lisa Levin,2017-01-11 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852009,lilly and merck expand immunooncology collaboration financial terms not disclosed,https://www.benzinga.com/news/17/01/8893616/lilly-and-merck-expand-immuno-oncology-collaboration-financial-terms-not-disclose,Paul Quintaro,2017-01-11 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.6591
852010,bristolmyers shares down after hours as merck shares trade up following news keytruda accepted for supplemental bla,https://www.benzinga.com/news/17/01/8892354/bristol-myers-shares-down-2-2-after-hours-as-merck-shares-trade-up-2-5-following-,Paul Quintaro,2017-01-10 00:00:00,MRK,1,1,1,0,1,1,1,1,1,0.83525
852011,merck reports keytruda has fda pdufa date of may under accelerated approval,https://www.benzinga.com/general/biotech/17/01/8891561/merck-reports-keytruda-has-fda-pdufa-date-of-may-10-2017-under-acceler,Hal Lindon,2017-01-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
852012,merck receives fda acceptance of supplemental biologics license application for keytruda,https://www.benzinga.com/general/biotech/17/01/8891548/merck-receives-fda-acceptance-of-supplemental-biologics-license-applic,Hal Lindon,2017-01-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
852013,option alert merck jan calls sweep ask traded vs oi earnings before open ref,https://www.benzinga.com/markets/options/17/01/8884864/option-alert-merck-jan-61-5-calls-sweep-745-ask-0-64-843-traded-vs-562,Charles Gross,2017-01-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852014,exclusive ziopharm ceo talks partnerships balance sheet and jpm healthcare conference presentation,https://www.benzinga.com/general/biotech/17/01/8883742/exclusive-ziopharm-ceo-talks-partnerships-balance-sheet-and-jpm-health,Wayne Duggan,2017-01-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5640000000000001
852015,incyte merck to advance clinical development program investigating the combination of epacadostat with keytruda,https://www.benzinga.com/news/contracts/17/01/8882765/incyte-merck-to-advance-clinical-development-program-investigating-the-,Paul Quintaro,2017-01-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852016,the years biggest healthcare conference commences this week heres what you need to know,https://www.benzinga.com/general/biotech/17/01/8879397/the-years-biggest-healthcare-conference-commences-this-week-heres-what,Shanthi Rexaline,2017-01-09 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852017,merck acquires biocontrol,https://www.benzinga.com/news/m-a/17/01/8863187/merck-acquires-biocontrol,Paul Quintaro,2017-01-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852018,update merck says it will defend itself vigorously in response to government notice given they were neither a manufacturer or a marketer of the subject drug,https://www.benzinga.com/news/legal/16/12/8852659/update-merck-says-it-will-defend-itself-vigorously-in-response-to-governmen,Paul Quintaro,2016-12-30 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5640000000000001
852019,merck says nppa alleges overcharging of price of polybion syrup formulation from jan june ,https://www.benzinga.com/news/fda/16/12/8852658/merck-says-nppa-alleges-overcharging-of-price-of-polybion-syrup-formulation-f,Paul Quintaro,2016-12-30 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
852020,prima biomed announces first clinical data from combination of imp with keytruda show no safety concerns,https://www.benzinga.com/news/16/12/8848724/prima-biomed-announces-first-clinical-data-from-combination-of-imp321-with-keytru,Charles Gross,2016-12-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.57655
852021,merck gets a strong sell from vetr crowd,https://www.benzinga.com/general/biotech/16/12/8848031/merck-gets-a-strong-sell-from-vetr-crowd,Chris Dier-Scalise,2016-12-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
852022,technical alert merck lower,https://www.benzinga.com/trading-ideas/technicals/16/12/8847067/technical-alert-merck-lower,Eddie Staley,2016-12-28 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.5
852023,newlink cfo ebola vaccine highly unlikely to drive future profit in company,https://www.benzinga.com/general/biotech/16/12/8840640/newlink-cfo-ebola-vaccine-highly-unlikely-to-drive-future-profit-in-co,Nicholas Donato,2016-12-23 00:00:00,MRK,1,1,1,0,1,1,1,1,1,0.7202
852024,where does mercks ebola vaccine breakthrough leave competitors,https://www.benzinga.com/general/biotech/16/12/8840588/where-does-mercks-ebola-vaccine-breakthrough-leave-competitors,Wayne Duggan,2016-12-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.4742
852025,shares of newlink genetics up earlier today traders attributed move to partnership with merck whose ebola vaccine was shown to provide protection,https://www.benzinga.com/movers/16/12/8840497/shares-of-newlink-genetics-up-10-earlier-today-traders-attributed-move-to-partn,Paul Quintaro,2016-12-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852026, worst biotech stocks of ,https://www.benzinga.com/general/biotech/16/12/8832621/6-worst-biotech-stocks-of-2016,Shanthi Rexaline,2016-12-23 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.18755
852027,meet the new dogs s dogs of the dow include cocacola boeing,https://www.benzinga.com/trading-ideas/long-ideas/16/12/8831534/meet-the-new-dogs-2017s-dogs-of-the-dow-include-coca-cola-boe,Wayne Duggan,2016-12-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852028,what does biogens new ceo mean for the buyout argument,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8825441/what-does-biogens-new-ceo-mean-for-the-buyout-argument,Shanthi Rexaline,2016-12-20 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.3194
852029,jefferies global pharma outlook,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8820515/jefferies-2017-global-pharma-outlook,Jim Swanson,2016-12-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852030,jefferies huge pharma pair trade bristolmyers upgraded to buy merck downgraded to sell,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8820146/jefferies-huge-pharma-pair-trade-bristol-myers-upgraded-,Jim Swanson,2016-12-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6591
852031,benzingas top upgrades downgrades for december ,https://www.benzinga.com/analyst-ratings/upgrades/16/12/8820499/benzingas-top-upgrades-downgrades-for-december-19-2016,Lisa Levin,2016-12-19 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.60115
852032,a peek into the markets us stock futures rise ahead of yellen speech,https://www.benzinga.com/news/earnings/16/12/8819938/a-peek-into-the-markets-u-s-stock-futures-rise-ahead-of-yellen-speech,Lisa Levin,2016-12-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852033,merck gets approval for keytruda in japan,https://www.benzinga.com/news/16/12/8819839/merck-gets-approval-for-keytruda-in-japan,Paul Quintaro,2016-12-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
852034,jefferies downgrades merck co to underperform lowers target to ,https://www.benzinga.com/news/16/12/8819706/jefferies-downgrades-merck-co-to-underperform-lowers-target-to-48-00,Paul Quintaro,2016-12-19 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.436
852035,european medicines agencys chmp recommends mercks keytruda for firstline treatment of patients with nsclc,https://www.benzinga.com/news/16/12/8814576/european-medicines-agencys-chmp-recommends-mercks-keytruda-for-first-line-treatme,Paul Quintaro,2016-12-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.61315
852036,gilead to pay merck b in hep c royalties,https://www.benzinga.com/news/16/12/8812801/gilead-to-pay-merck-2-54b-in-hep-c-royalties,Paul Quintaro,2016-12-15 00:00:00,MRK,1,2,0,1,0,1,1,1,1,0.44865
852037, notable stocks trading exdividend tuesday december ,https://www.benzinga.com/news/dividends/16/12/8796954/10-notable-stocks-trading-ex-dividend-tuesday-december-13,Lisa Levin,2016-12-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852038,merck reports new keytruda data in combination with halaven for metastatic triplenegative breast cancer,https://www.benzinga.com/news/16/12/8795274/merck-reports-new-keytruda-data-in-combination-with-halaven-for-metastatic-triple,Paul Quintaro,2016-12-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
852039,european crohns colitis organisation issues new statement support a switch to biosimilar from reference product in inflammatory bowel disease,https://www.benzinga.com/news/16/12/8791110/european-crohns-colitis-organisation-issues-new-statement-support-a-switch-to-bio,Paul Quintaro,2016-12-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
852040,merck canada says zostavax ii showed vaccine effectiveness against shingles in observational effectiveness study,https://www.benzinga.com/news/16/12/8782699/merck-canada-says-zostavax-ii-showed-vaccine-effectiveness-against-shingles-in-ob,Paul Quintaro,2016-12-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852041,what if trump keeps badmouthing drug pricing,https://www.benzinga.com/analyst-ratings/analyst-color/16/12/8781602/what-if-trump-keeps-badmouthing-drug-pricing,Wayne Duggan,2016-12-07 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852042,technical alert merck lower,https://www.benzinga.com/trading-ideas/technicals/16/12/8781750/technical-alert-merck-lower,Eddie Staley,2016-12-07 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.5
852043,pfizer jj other big pharma names dip lower just after the open,https://www.benzinga.com/movers/16/12/8780747/pfizer-j-j-other-big-pharma-names-dip-lower-just-after-the-open,Paul Quintaro,2016-12-07 00:00:00,MRK,0,1,0,1,1,0,0,0,0,0.4742
852044,merck announces keytruda demonstrated improved healthrelated quality of life vs chemotherapy in firstline treatment of patients with metastatic nsclc at wclc ,https://www.benzinga.com/news/16/12/8779382/merck-announces-keytruda-demonstrated-improved-health-related-quality-of-life-vs-,Charles Gross,2016-12-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
852045,merck keytruda findings show orr of and in small cell lung cancer and malignant pleural mesothelioma respectively in keynote,https://www.benzinga.com/news/16/12/8774909/merck-keytruda-findings-show-orr-of-33-3-and-20-in-small-cell-lung-cancer-and-mal,Paul Quintaro,2016-12-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.2706
852046,merck announces keytruda treatment results in patients with relapsed or refractory classical hodgkin lymphoma chl presented at ash ,https://www.benzinga.com/news/16/12/8773627/merck-announces-keytruda-treatment-results-in-patients-with-relapsed-or-refractor,Charles Gross,2016-12-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852047,pressure biosciences ceo on biological samples its all about how you break open a cell,https://www.benzinga.com/general/biotech/16/12/8771991/pressure-biosciences-ceo-on-biological-samples-its-all-about-how-you-b,Javier Hasse,2016-12-05 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.352
852048,merck says will present updated keytruda findings at ash data showed keynote overall response rate of with of responses ongoing at the time of analysis,https://www.benzinga.com/news/16/12/8770613/merck-says-will-present-updated-keytruda-findings-at-ash-data-showed-keynote-013-,Paul Quintaro,2016-12-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852049,biothera merck further expand research collaboration to include phase clinical trial in head and neck cancer,https://www.benzinga.com/news/16/12/8770116/biothera-merck-further-expand-research-collaboration-to-include-phase-2-clinical-,Charles Gross,2016-12-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.26165
852050,cnbcs meg tirrell tweets mrk ceo we are now at the equivalent stage in immunotherapy where we were w first effective treatments for hiv forbeshealth,https://www.benzinga.com/media/cnbc/16/12/8758913/cnbcs-meg-tirrell-tweets-mrk-ceo-we-are-now-at-the-equivalent-stage-in-immu,Paul Quintaro,2016-12-01 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.7383500000000001
852051,forbes healthcare summit concludes today presenters include express scripts allergan ibm bristolmyers squibb merck anthem eli lilly and regeneron,https://www.benzinga.com/news/16/12/8758294/forbes-healthcare-summit-concludes-today-presenters-include-express-scripts-aller,Hal Lindon,2016-12-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852052,fda grants priority review to supplemental biologics license application for mercks keytruda in relapsed or refractory classical hodgkin lymphoma,https://www.benzinga.com/news/16/12/8757705/fda-grants-priority-review-to-supplemental-biologics-license-application-for-merc,Paul Quintaro,2016-12-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.61315
852053,fda grants priority review to mercks supplemental biologics license application sbla seeking approval for keytruda for new indication in microsatellite instabilityhigh cancer,https://www.benzinga.com/news/16/11/8741174/fda-grants-priority-review-to-mercks-supplemental-biologics-license-application-s,Paul Quintaro,2016-11-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.44865
852054,merck increases qtr dividend from to share,https://www.benzinga.com/news/16/11/8730342/merck-increases-qtr-dividend-from-0-46-to-0-47share,Paul Quintaro,2016-11-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852055,quintilesims forms new collaboration with bristolmyers squibb lilly merck kgaa darmstadt germany and pfizer to generate real world insights on usage of anticancer therapies across europe,https://www.benzinga.com/news/16/11/8728289/quintilesims-forms-new-collaboration-with-bristol-myers-squibb-lilly-merck-kgaa-d,Paul Quintaro,2016-11-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852056,vetr opts to hold on merck despite biotech optimism,https://www.benzinga.com/general/biotech/16/11/8708747/vetr-opts-to-hold-on-merck-despite-biotech-optimism,Chris Dier-Scalise,2016-11-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.2845
852057,gilead responds to cms blog highlighting high cost of harvoni most payers receive substantial discounts off the list price,https://www.benzinga.com/general/biotech/16/11/8696936/gilead-responds-to-cms-blog-highlighting-high-cost-of-harvoni-most-pay,Javier Hasse,2016-11-14 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.6324
852058,merck announces findings for investigational triplecombination chronic hepatitis c therapy showing high rates of sustained virologic response in people with genotypes or infection,https://www.benzinga.com/news/16/11/8688287/merck-announces-findings-for-investigational-triple-combination-chronic-hepatitis,Charles Gross,2016-11-13 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852059,merck announes keytruda significantly improves overall survival compared to chemotherapy in previously treated patients with advanced bladder cancer,https://www.benzinga.com/news/16/11/8688137/merck-announes-keytruda-significantly-improves-overall-survival-compared-to-chemo,Charles Gross,2016-11-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
852060,merck presents new findings for zepatier in patients with chronic hepatitis c at the liver meeting,https://www.benzinga.com/news/16/11/8688080/merck-presents-new-findings-for-zepatier-in-patients-with-chronic-hepatitis-c-at-,Charles Gross,2016-11-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852061,technical alert merck lower,https://www.benzinga.com/trading-ideas/technicals/16/11/8687030/technical-alert-merck-lower,Eddie Staley,2016-11-11 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.5
852062, big medical marijuana stocks riding high postelection,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8679451/2-big-medical-marijuana-stocks-riding-high-on-trumps-ele,Wayne Duggan,2016-11-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852063,technical alert merck reaches and retreats,https://www.benzinga.com/trading-ideas/technicals/16/11/8673412/technical-alert-merck-reaches-65-and-retreats,Eddie Staley,2016-11-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.67
852064,stocks hitting week highs,https://www.benzinga.com/news/16/11/8672591/stocks-hitting-52-week-highs,Lisa Levin,2016-11-09 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
852065,pharma stocks up post election ariad infinity up allergan progenics endo pfizer regeneron abbvie mylan medicines co perrigo merck bristolmyers eli lilly sanofi novartis ,https://www.benzinga.com/movers/16/11/8672426/pharma-stocks-up-post-election-ariad-16-infinity-up-13-allergan-progenics-endo-,Paul Quintaro,2016-11-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852066,biotech is getting a big boost following clintons loss,https://www.benzinga.com/general/biotech/16/11/8671658/biotech-is-getting-a-big-boost-following-clintons-loss,R. Chandrasekaran,2016-11-09 00:00:00,MRK,0,0,1,1,1,1,1,1,1,0.55135
852067,bz note related to traders passing around cnbc story on new cancer drugs possibly damaging the heart nbc news via ap published the same story pm edt wed evening,https://www.benzinga.com/news/16/11/8646193/bz-note-related-to-traders-passing-around-cnbc-story-on-new-cancer-drugs-possibly,Paul Quintaro,2016-11-03 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.0963
852068,traders passing around recent cnbc article on cancer treatments new cancer drugs may damage the heart,https://www.benzinga.com/news/16/11/8646187/traders-passing-around-recent-cnbc-article-on-cancer-treatments-new-cancer-drugs-,Paul Quintaro,2016-11-03 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.040700000000000014
852069,merck reports publishing of new research on early development of verubecestat says results of first phase trial anticipated in late ,https://www.benzinga.com/news/16/11/8641293/merck-reports-publishing-of-new-research-on-early-development-of-verubecestat-say,Paul Quintaro,2016-11-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852070,the election cant come soon enough for biotechs,https://www.benzinga.com/analyst-ratings/analyst-color/16/11/8625928/the-election-cant-come-soon-enough-for-biotechs,Brett Hershman,2016-11-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852071,technical alert merck higher after q report,https://www.benzinga.com/trading-ideas/technicals/16/10/8599076/technical-alert-merck-higher-after-q3-report,Eddie Staley,2016-10-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852072, big pharma companies left to report september quarterly figures,https://www.benzinga.com/general/biotech/16/10/8597972/6-big-pharma-companies-left-to-report-september-quarterly-figures,R. Chandrasekaran,2016-10-25 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
852073,epic earnings many us companies beating expectations as season continues,https://www.benzinga.com/news/earnings/16/10/8598230/epic-earnings-many-us-companies-beating-expectations-as-season-continues,The Ticker Tape,2016-10-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.2706
852074,the market in minutes ua gm pg earnings on the streets mind,https://www.benzinga.com/news/16/10/8595821/the-market-in-5-minutes-ua-gm-p-g-earnings-on-the-streets-mind,Benzinga News Desk,2016-10-25 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
852075,a peek into the markets us stock futures rise gm apple earnings in focus,https://www.benzinga.com/news/earnings/16/10/8596085/a-peek-into-the-markets-u-s-stock-futures-rise-gm-apple-earnings-in-focu,Monica Gerson,2016-10-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852076,mercks q results guidance look strong,https://www.benzinga.com/news/earnings/16/10/8595932/mercks-q3-results-guidance-look-strong,R. Chandrasekaran,2016-10-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
852077,merck narrows and raises guidance sees fy eps to vs est revenue b to b vs b est,https://www.benzinga.com/news/16/10/8595776/merck-narrows-and-raises-guidance-sees-fy-eps-3-71-to-3-78-vs-3-75-est-revenue-39,Paul Quintaro,2016-10-25 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
852078,merck q eps vs est revenue b vs b est,https://www.benzinga.com/news/earnings/16/10/8595772/merck-q3-eps-1-07-vs-0-99-est-revenue-10-54b-vs-10-18b-est,Paul Quintaro,2016-10-25 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
852079, stocks you should be watching today,https://www.benzinga.com/news/earnings/16/10/8595352/12-stocks-you-should-be-watching-today,Monica Gerson,2016-10-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852080,earnings scheduled for october ,https://www.benzinga.com/news/earnings/16/10/8595305/earnings-scheduled-for-october-25-2016,Monica Gerson,2016-10-25 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852081,merck reports fda approval of keytruda,https://www.benzinga.com/general/biotech/16/10/8594672/merck-reports-fda-approval-of-keytruda,Hal Lindon,2016-10-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
852082,big news out of merck this weekend,https://www.benzinga.com/general/biotech/16/10/8591746/big-news-out-of-merck-this-weekend,R. Chandrasekaran,2016-10-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852083,merck has an upcoming pdufa date for bezlotoxumab,https://www.benzinga.com/general/biotech/16/10/8588952/merck-has-an-upcoming-pdufa-date-for-bezlotoxumab,Brett Hershman,2016-10-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852084,are the drugs working pharma giants eli lilly and merck to update investors on cancer treatments,https://www.benzinga.com/general/biotech/16/10/8588232/are-the-drugs-working-pharma-giants-eli-lilly-and-merck-to-update-inve,The Ticker Tape,2016-10-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
852085,merck has an oct rd pdufa date for bezlotoxumab drug won fda advisory panel backing in june,https://www.benzinga.com/general/biotech/16/10/8587047/merck-has-an-oct-23rd-pdufa-date-for-bezlotoxumab-drug-won-fda-advisor,Hal Lindon,2016-10-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.79295
852086,jim cramer gives his opinion on merck and smith wesson,https://www.benzinga.com/media/cnbc/16/10/8586287/jim-cramer-gives-his-opinion-on-merck-and-smith-wesson,Craig Jones,2016-10-21 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852087,merck reports keynote studying keytruda in advanced bladder cancer meets primary endpoint stops early,https://www.benzinga.com/news/16/10/8586708/merck-reports-keynote-045-studying-keytruda-in-advanced-bladder-cancer-meets-prim,Paul Quintaro,2016-10-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.19379999999999997
852088,fed speakers and beige book bank earnings rising crude take center stage,https://www.benzinga.com/news/earnings/16/10/8578682/fed-speakers-and-beige-book-bank-earnings-rising-crude-take-center-stage,The Ticker Tape,2016-10-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.21405000000000002
852089,roche group competitor to bristolmyers and merck has pdufa datefor tecentriq drug,https://www.benzinga.com/general/biotech/16/10/8577145/roche-group-competitor-to-bristol-myers-and-merck-has-pdufa-datefor-te,Hal Lindon,2016-10-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852090,merck announces pivotal phase study of letermovir met primary endpoint,https://www.benzinga.com/news/16/10/8576684/merck-announces-pivotal-phase-3-study-of-letermovir-met-primary-endpoint,Paul Quintaro,2016-10-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852091, biggest price target changes for thursday,https://www.benzinga.com/analyst-ratings/price-target/16/10/8558887/7-biggest-price-target-changes-for-thursday,Monica Gerson,2016-10-13 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852092,benzingas top upgrades,https://www.benzinga.com/analyst-ratings/upgrades/16/10/8558549/benzingas-top-upgrades,Monica Gerson,2016-10-13 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.60115
852093,a peek into the markets us stock futures tumble ahead of jobless claims report,https://www.benzinga.com/news/earnings/16/10/8557961/a-peek-into-the-markets-u-s-stock-futures-tumble-ahead-of-jobless-claims,Monica Gerson,2016-10-13 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852094,bank of america upgrades merck company to buy raises price target to ,https://www.benzinga.com/news/16/10/8557822/bank-of-america-upgrades-merck-company-to-buy-raises-price-target-to-70-00,Paul Quintaro,2016-10-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852095,technical alert merck surrenders mondays gains,https://www.benzinga.com/trading-ideas/technicals/16/10/8550481/technical-alert-merck-surrenders-mondays-gains,Eddie Staley,2016-10-11 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.7787
852096,aetna and merck sign a unique valuebased contract for januvia and janumet,https://www.benzinga.com/news/16/10/8549025/aetna-and-merck-sign-a-unique-value-based-contract-for-januvia-and-janumet,Paul Quintaro,2016-10-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852097,the esmo conference proves its ability to move stocks,https://www.benzinga.com/general/biotech/16/10/8546528/the-esmo-conference-proves-its-ability-to-move-stocks,Wayne Duggan,2016-10-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
852098,technical alert merck reaches highest level since december ,https://www.benzinga.com/trading-ideas/technicals/16/10/8546683/technical-alert-merck-reaches-highest-level-since-december-20,Eddie Staley,2016-10-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.67
852099,bristolmyers opdivo vs mercks keytruda in frontline lung treatment,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8546165/bristol-myers-opdivo-vs-mercks-keytruda-in-front-line-lu,Wayne Duggan,2016-10-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852100,suntrust cuts target on bristolmyers as opdivo estimates revised lower,https://www.benzinga.com/analyst-ratings/analyst-color/16/10/8545894/suntrust-cuts-target-on-bristol-myers-as-opdivo-estimate,R. Chandrasekaran,2016-10-10 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.23665000000000003
852101,new data on the combination of lillys alimta and mercks keytruda show a neardoubling of objective response rate compared to standard of care alone in firstline metastatic nsclc presented at esmo ,https://www.benzinga.com/news/16/10/8544704/new-data-on-the-combination-of-lillys-alimta-and-mercks-keytruda-show-a-near-doub,Charles Gross,2016-10-09 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.648
852102,merck announces two major studies to be presented at esmo demonstrate potential of keytruda for the firstline treatment of metastatic nslcl in a broad range of patients,https://www.benzinga.com/news/16/10/8544702/merck-announces-two-major-studies-to-be-presented-at-esmo-2016-demonstrate-potent,Charles Gross,2016-10-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852103,merck announces keytruda showed continued overall survival benefit compared to chemotherapy with longer followup in patients with previously treated metastatic nsclc in data to be presented at esmo ,https://www.benzinga.com/news/16/10/8544696/merck-announces-keytruda-showed-continued-overall-survival-benefit-compared-to-ch,Charles Gross,2016-10-09 00:00:00,MRK,1,0,0,1,1,0,1,1,1,0.7294
852104,merck presents longerterm followup of overall survival data for keytruda in patients with advanced melanoma from keynote at esmo ,https://www.benzinga.com/news/16/10/8544691/merck-presents-longer-term-follow-up-of-overall-survival-data-for-keytruda-in-pat,Charles Gross,2016-10-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
852105,merck announces new keytruda data in advanced urothelial cancer demonstrate overall response rate of percent in cisplatinineligible patients,https://www.benzinga.com/news/16/10/8544686/merck-announces-new-keytruda-data-in-advanced-urothelial-cancer-demonstrate-overa,Charles Gross,2016-10-09 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.23665000000000003
852106,exclusive interview with delmar pharmaceutical ceo jeffrey bacha,https://www.benzinga.com/general/biotech/16/10/8535229/exclusive-interview-with-delmar-pharmaceutical-ceo-jeffrey-bacha,Brett Hershman,2016-10-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5640000000000001
852107,merck animal health announces usda approval of innovative canine flu bivalent vaccine,https://www.benzinga.com/news/16/10/8543465/merck-animal-health-announces-usda-approval-of-innovative-canine-flu-bivalent-vac,Hal Lindon,2016-10-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.76335
852108,merck shares indicated up premarket shares could be higher amid positive trial news from incyte incyte shares up in preopen,https://www.benzinga.com/movers/16/09/8504318/merck-shares-indicated-up-1-premarket-shares-could-be-higher-amid-positive-tria,Paul Quintaro,2016-09-28 00:00:00,MRK,1,0,1,0,0,1,1,1,1,0.92405
852109,vtv therapeutics shares initiated with buy rating target,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8494801/vtv-therapeutics-shares-initiated-with-buy-rating-13-tar,Manikandan Raman,2016-09-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852110,the market in minutes were waiting for you mrs yellen,https://www.benzinga.com/news/16/09/8480831/the-market-in-5-minutes-were-waiting-for-you-mrs-yellen,Benzinga News Desk,2016-09-21 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852111,clovis upgraded at credit suisse following acquisition rumor,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8480898/clovis-upgraded-at-credit-suisse-following-acquisition-r,Monica Gerson,2016-09-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
852112,some traders attributing afterhours upside in clovis to janney capital analyst comment during bloomberg interview there are many suitors for co including lilly roche merck,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8479674/some-traders-attributing-after-hours-upside-in-clovis-to,Paul Quintaro,2016-09-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852113,new year contraceptive coming to us adds to longacting reversible contraceptives list,https://www.benzinga.com/general/biotech/16/09/8478706/new-5-year-contraceptive-coming-to-u-s-adds-to-long-acting-reversible-,Javier Hasse,2016-09-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852114,citi research reevaluates bristolmyers lowers price target,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8476950/citi-research-reevaluates-bristol-myers-lowers-price-tar,Monica Gerson,2016-09-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
852115,seattle genetics no longer on goldman sachs sell list,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8461384/seattle-genetics-no-longer-on-goldman-sachs-sell-list,Manikandan Raman,2016-09-15 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.352
852116,update pfizer mercks vertis sita also achieved secondary endpoints,https://www.benzinga.com/news/16/09/8461586/update-pfizer-mercks-vertis-sita2-also-achieved-4-secondary-endpoints,Paul Quintaro,2016-09-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852117,merck pfizer reports ertugliflozin met primary endpoint of ac reduction,https://www.benzinga.com/news/16/09/8461569/merck-pfizer-reports-ertugliflozin-met-primary-endpoint-of-a1c-reduction,Paul Quintaro,2016-09-15 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852118,presidential merck jimmy carter oncology drug expected to dominate hep c drug approved across eu,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8453262/presidential-merck-jimmy-carter-oncology-drug-expected-t,Brett Hershman,2016-09-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
852119,barclays raises target on merck lowers target on bristolmyers,https://www.benzinga.com/analyst-ratings/analyst-color/16/09/8441099/barclays-raises-target-on-merck-lowers-target-on-bristol,Monica Gerson,2016-09-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
852120,another election year view on healthcare etfs,https://www.benzinga.com/general/biotech/16/09/8434271/another-election-year-view-on-healthcare-etfs,ETF Professor,2016-09-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852121,technical alert merck rangebound for third day in a row,https://www.benzinga.com/trading-ideas/previews/16/09/8432202/technical-alert-merck-range-bound-for-third-day-in-a-row,Eddie Staley,2016-09-07 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.648
852122,udpate merck to continue distributing product on behalf of aralez for months considerations also include salesbased milestones and graduated royalties,https://www.benzinga.com/news/16/09/8430239/udpate-merck-to-continue-distributing-product-on-behalf-of-aralez-for-12-months-c,Paul Quintaro,2016-09-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852123,merck gets fda priority review and breakthrough therapy designation for keytruda,https://www.benzinga.com/news/16/09/8429453/merck-gets-fda-priority-review-and-breakthrough-therapy-designation-for-keytruda,Paul Quintaro,2016-09-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852124,merck remains stable following discontinuation of odanacatib development program,https://www.benzinga.com/general/biotech/16/09/8420417/merck-remains-stable-following-discontinuation-of-odanacatib-developme,R. Chandrasekaran,2016-09-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852125,merck provides update on odanacatib development program will discontinue development and not seek regulatory approval for its use,https://www.benzinga.com/news/16/09/8419006/merck-provides-update-on-odanacatib-development-program-will-discontinue-developm,Paul Quintaro,2016-09-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.31379999999999997
852126,shares of celgene spiking higher hearing unconfirmed rumors that big restructuring under way speculation is that they are prepping deal with merck,https://www.benzinga.com/news/16/08/8410576/shares-of-celgene-spiking-higher-hearing-unconfirmed-rumors-that-big-restructurin,Paul Quintaro,2016-08-31 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.58895
852127,the flash crash was one year ago today why did it happen,https://www.benzinga.com/news/16/08/8387545/the-2015-flash-crash-was-one-year-ago-today-why-did-it-happen,Wayne Duggan,2016-08-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.29905000000000004
852128,write a prescription for more pharma ma with this etf,https://www.benzinga.com/general/biotech/16/08/8385130/write-a-prescription-for-more-pharma-m-a-with-this-etf,ETF Professor,2016-08-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852129,update reuters says merck sanofi pfizer gilead celgene have each submitted expressions of interest for medivation,https://www.benzinga.com/news/16/08/8363733/update-reuters-says-merck-sanofi-pfizer-gilead-celgene-have-each-submitted-expres,Paul Quintaro,2016-08-17 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.7294
852130,mirror image bristolmyers loss is mercks potential gain,https://www.benzinga.com/general/biotech/16/08/8357648/mirror-image-bristol-myers-loss-is-mercks-potential-gain,Wayne Duggan,2016-08-16 00:00:00,MRK,0,1,1,1,1,1,1,1,1,0.6366
852131,biogen cancels out of citigroup conference following weeks of rumors,https://www.benzinga.com/news/16/08/8340086/biogen-cancels-out-of-citigroup-conference-following-weeks-of-rumors,Nicholas Donato,2016-08-11 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.38685
852132,argus bristolmyers selloff is overdone reiterating target,https://www.benzinga.com/analyst-ratings/analyst-color/16/08/8332433/argus-bristol-myers-selloff-is-overdone-reiterating-90-t,Scott Rubin,2016-08-10 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
852133,bernstein says mercks lung cancer drug will lead the market nearterm but longterm market share harder to predict,https://www.benzinga.com/analyst-ratings/analyst-color/16/08/8325823/bernstein-says-mercks-lung-cancer-drug-will-lead-the-mar,Jayson Derrick,2016-08-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5129
852134,results from mercks phase study of zepatier hep c treatment published in annals of internal medicine,https://www.benzinga.com/news/16/08/8321560/results-from-mercks-phase-3-study-of-zepatier-hep-c-treatment-published-in-annals,Hal Lindon,2016-08-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852135,technical alert merck surrenders some of fridays huge gain,https://www.benzinga.com/trading-ideas/technicals/16/08/8320177/technical-alert-merck-surrenders-some-of-fridays-huge-gain,Eddie Staley,2016-08-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.89225
852136,after roaring to new highs on jobs data market faces retail sales job openings,https://www.benzinga.com/news/16/08/8319366/after-roaring-to-new-highs-on-jobs-data-market-faces-retail-sales-job-openings,The Ticker Tape,2016-08-08 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.5
852137,checkmate miss is a game changer credit suisse downgrades bristol upgrades merck,https://www.benzinga.com/analyst-ratings/analyst-color/16/08/8319183/checkmate-miss-is-a-game-changer-credit-suisse-downgrade,Monica Gerson,2016-08-08 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.625
852138, biggest price target changes for monday,https://www.benzinga.com/analyst-ratings/price-target/16/08/8319090/8-biggest-price-target-changes-for-monday,Monica Gerson,2016-08-08 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852139,the market in minutes can the momentum continue,https://www.benzinga.com/news/16/08/8318186/the-market-in-5-minutes-can-the-momentum-continue,Benzinga News Desk,2016-08-08 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852140,benzingas top upgrades,https://www.benzinga.com/analyst-ratings/upgrades/16/08/8318720/benzingas-top-upgrades,Monica Gerson,2016-08-08 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.60115
852141,citi doesnt see mercks lung cancer success lasting long,https://www.benzinga.com/analyst-ratings/analyst-color/16/08/8318084/citi-doesnt-see-mercks-lung-cancer-success-lasting-long,Monica Gerson,2016-08-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.41105
852142,fda approves mercks keytruda pembrolizumab for patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinumcontaining chemotherapy,https://www.benzinga.com/news/16/08/8317823/fda-approves-mercks-keytruda-pembrolizumab-for-patients-with-recurrent-or-metasta,Paul Quintaro,2016-08-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
852143,credit suisse upgrades merck co to outperform raises pt to ,https://www.benzinga.com/news/16/08/8317322/credit-suisse-upgrades-merck-co-to-outperform-raises-pt-to-73-00,Paul Quintaro,2016-08-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6909
852144,watch these huge put purchases in monday trade,https://www.benzinga.com/news/16/08/8317232/watch-these-5-huge-put-purchases-in-monday-trade,Monica Gerson,2016-08-08 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.6591
852145,bmo capital upgrades merck to outperform bullish on co,https://www.benzinga.com/analyst-ratings/analyst-color/16/08/8316071/bmo-capital-upgrades-merck-to-outperform-bullish-on-co,Javier Hasse,2016-08-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852146,bmo capital upgrades merck co to outperform raises pt to ,https://www.benzinga.com/news/16/08/8313970/bmo-capital-upgrades-merck-co-to-outperform-raises-pt-to-72-00,Paul Quintaro,2016-08-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852147, biggest midday gainers for friday,https://www.benzinga.com/news/16/08/8313955/25-biggest-mid-day-gainers-for-friday,Lisa Levin,2016-08-05 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.5
852148,benzingas volume movers,https://www.benzinga.com/news/16/08/8313109/benzingas-volume-movers,Lisa Levin,2016-08-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852149,stocks hitting week highs,https://www.benzinga.com/news/16/08/8312971/stocks-hitting-52-week-highs,Lisa Levin,2016-08-05 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
852150,option alert mrk oct puts sweep ask traded vs oi ref,https://www.benzinga.com/news/16/08/8312796/option-alert-mrk-oct16-60-0-puts-sweep-594-ask-1-71-605-traded-vs-1589-oi-61-04-r,Charles Gross,2016-08-05 00:00:00,MRK,1,2,0,1,0,0,1,0,0,0.648
852151,bristols opdivo misses endpoint in latestage trial merck rallies sharply amid keytruda potential,https://www.benzinga.com/news/16/08/8312389/bristols-opdivo-misses-endpoint-in-late-stage-trial-merck-rallies-sharply-amid-ke,Andrew Efimoff,2016-08-05 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.38685
852152,the market in minutes blowout jobs report pushes markets higher,https://www.benzinga.com/news/16/08/8311883/the-market-in-5-minutes-blowout-jobs-report-pushes-markets-higher,Benzinga News Desk,2016-08-05 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852153,update mercks keytruda is viewed as strongest competitor to bristols opdivo,https://www.benzinga.com/news/16/08/8312236/update-mercks-keytruda-is-viewed-as-strongest-competitor-to-bristols-opdivo,Paul Quintaro,2016-08-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
852154,merck spike in price likely attributed to negative results on bristolmyers opdivo,https://www.benzinga.com/news/16/08/8312228/merck-spike-in-price-likely-attributed-to-negative-results-on-bristol-myers-opdiv,Paul Quintaro,2016-08-05 00:00:00,MRK,1,1,0,1,0,0,1,0,0,0.21405000000000002
852155,merck shares spiking over last min,https://www.benzinga.com/movers/16/08/8312217/merck-shares-spiking-6-over-last-min,Paul Quintaro,2016-08-05 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.648
852156,merck reports acceptance of fda filing for nda for mk,https://www.benzinga.com/news/16/08/8312039/merck-reports-acceptance-of-fda-filing-for-nda-for-mk-1293,Paul Quintaro,2016-08-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7294
852157,celgene shares spiking traders circulating takeover chatter by merck,https://www.benzinga.com/news/16/08/8306256/celgene-shares-spiking-traders-circulating-takeover-chatter-by-merck,Paul Quintaro,2016-08-04 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.648
852158,benzingas ma chatter for wednesday august ,https://www.benzinga.com/news/16/08/8303222/benzingas-m-a-chatter-for-wednesday-august-3-2016,Charles Gross,2016-08-03 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852159,terms of the trade dogs of the dow investing strategy,https://www.benzinga.com/trading-ideas/long-ideas/16/08/8299150/terms-of-the-trade-dogs-of-the-dow-investing-strategy,Wayne Duggan,2016-08-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852160,biogen shares down over last min following reuters report co not soliciting offers allergan merck shares relatively quiet not impacted,https://www.benzinga.com/movers/16/08/8300051/biogen-shares-down-3-over-last-min-following-reuters-report-co-not-soliciting-o,Paul Quintaro,2016-08-03 00:00:00,MRK,1,1,0,1,0,1,1,1,1,0.76335
852161,the market in minutes downtrend continues,https://www.benzinga.com/news/16/08/8297518/the-market-in-5-minutes-downtrend-continues,Benzinga News Desk,2016-08-03 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852162,why is biogen attractive credit suisse sees upside takeout potential,https://www.benzinga.com/analyst-ratings/analyst-color/16/08/8297331/why-is-biogen-attractive-credit-suisse-sees-12-24-upside,Jim Swanson,2016-08-03 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.83525
852163,benzingas ma chatter for tuesday august ,https://www.benzinga.com/news/16/08/8295854/benzingas-m-a-chatter-for-tuesday-august-2-2016,Charles Gross,2016-08-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852164, stocks moving in tuesdays afterhours session,https://www.benzinga.com/news/earnings/16/08/8294808/6-stocks-moving-in-tuesdays-after-hours-session,Javier Hasse,2016-08-02 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852165,merck reports keytruda has received ec approval for patients with nsclc whose tumors express pdl,https://www.benzinga.com/news/16/08/8294980/merck-reports-keytruda-has-received-ec-approval-for-patients-with-nsclc-whose-tum,Paul Quintaro,2016-08-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
852166,wall street journal reports biogen drawing interest from merck allergan on possibility of huge deal,https://www.benzinga.com/news/16/08/8293082/wall-street-journal-reports-biogen-drawing-interest-from-merck-allergan-on-possib,Paul Quintaro,2016-08-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8243
852167,mercks q good but not good enough says bmo,https://www.benzinga.com/analyst-ratings/analyst-color/16/08/8285725/mercks-q2-good-but-not-good-enough-says-bmo,Manikandan Raman,2016-08-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.85015
852168,weak gdp data plunging oil renew questions about strength of economy,https://www.benzinga.com/news/earnings/16/07/8278985/weak-gdp-data-plunging-oil-renew-questions-about-strength-of-economy,The Ticker Tape,2016-07-29 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.5386
852169,a peek into the markets us stock futures mostly lower ahead of gdp report,https://www.benzinga.com/news/earnings/16/07/8277604/a-peek-into-the-markets-u-s-stock-futures-mostly-lower-ahead-of-gdp-repo,Monica Gerson,2016-07-29 00:00:00,MRK,0,1,0,0,1,1,0,0,0,0.352
852170,investors greet merck q results as key launches help beat,https://www.benzinga.com/news/earnings/16/07/8277502/investors-greet-merck-q2-results-as-key-launches-help-beat,R. Chandrasekaran,2016-07-29 00:00:00,MRK,1,0,0,1,1,0,1,1,1,0.8062
852171,merck reports ec granted marketing authorization for cos zepatier for treatment of chronic hep c infection,https://www.benzinga.com/news/16/07/8277370/merck-reports-ec-granted-marketing-authorization-for-co-s-zepatier-for-treatment-,Paul Quintaro,2016-07-29 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.625
852172,merck narrows raises fy adj eps outlook from to vs est sales from bb to bb vs b est,https://www.benzinga.com/news/16/07/8277239/merck-narrows-raises-fy16-adj-eps-outlook-from-3-60-3-75-to-3-67-3-77-vs-3-72-est,Paul Quintaro,2016-07-29 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852173,merck reports q adj eps vs est sales b vs b est,https://www.benzinga.com/news/earnings/16/07/8277235/merck-reports-q2-adj-eps-0-93-vs-0-91-est-sales-9-844b-vs-9-78b-est,Paul Quintaro,2016-07-29 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852174, stocks you should be watching today,https://www.benzinga.com/news/earnings/16/07/8276759/12-stocks-you-should-be-watching-today,Monica Gerson,2016-07-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852175,earnings scheduled for july ,https://www.benzinga.com/news/earnings/16/07/8276714/earnings-scheduled-for-july-29-2016,Monica Gerson,2016-07-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852176,can keytruda deliver earnings growth for merck,https://www.benzinga.com/news/earnings/16/07/8264853/can-keytruda-deliver-earnings-growth-for-merck,The Ticker Tape,2016-07-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6909
852177,merck gets breakthrough therapy status from fda and prime status from ema for investigational ebola zaire vaccine,https://www.benzinga.com/general/biotech/16/07/8251883/merck-gets-breakthrough-therapy-status-from-fda-and-prime-status-from-,R. Chandrasekaran,2016-07-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852178,newlink genetics announces merck receives breakthrough therapy designation from fda prime status from ema for investigational ebola zaire vaccine,https://www.benzinga.com/news/16/07/8251428/newlink-genetics-announces-merck-receives-breakthrough-therapy-designation-from-f,Paul Quintaro,2016-07-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852179,merck reports received breakthrough therapy designation from fda prime status from ema for v,https://www.benzinga.com/news/16/07/8251313/merck-reports-received-breakthrough-therapy-designation-from-fda-prime-status-fro,Paul Quintaro,2016-07-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852180,merck receives breakthrough therapy designation from fda and prime status from ema for investigational ebola zaire vaccine,https://www.benzinga.com/news/16/07/8251286/merck-receives-breakthrough-therapy-designation-from-fda-and-prime-status-from-em,Paul Quintaro,2016-07-25 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852181,merck presents data on its investigational oncedaily formulation of isentress,https://www.benzinga.com/news/16/07/8248207/merck-presents-data-on-its-investigational-once-daily-formulation-of-isentress,R. Chandrasekaran,2016-07-22 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852182,merck reports investigational oncedaily formulation of isentress showed noninferior efficacy safety to regimen containing approved twicedaily formulation,https://www.benzinga.com/news/16/07/8246609/merck-reports-investigational-once-daily-formulation-of-isentress-showed-non-infe,Paul Quintaro,2016-07-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8404
852183,merck animal health receives fda approval of bravecto for cats and dogs topical treatment for fleas and ticks effective for up to weeks,https://www.benzinga.com/news/16/07/8245171/merck-animal-health-receives-fda-approval-of-bravecto-for-cats-and-dogs-topical-t,Paul Quintaro,2016-07-21 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.86755
852184,merck provides regulatory update on biologics licensing application for investigational agent bezlotoxumab,https://www.benzinga.com/news/16/07/8244823/merck-provides-regulatory-update-on-biologics-licensing-application-for-investiga,Paul Quintaro,2016-07-21 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852185,the market in minutes jampacked day of earnings and economic data,https://www.benzinga.com/news/16/07/8241488/the-market-in-5-minutes-jam-packed-day-of-earnings-and-economic-data,Benzinga News Desk,2016-07-21 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852186,benzingas ma chatter for wednesday july ,https://www.benzinga.com/news/16/07/8240242/benzingas-m-a-chatter-for-wednesday-july-20-2016,Charles Gross,2016-07-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852187,bmo analysts say mercks fundamentals dont justify its valuations,https://www.benzinga.com/analyst-ratings/analyst-color/16/07/8227554/bmo-analysts-say-mercks-fundamentals-dont-justify-its-va,Manikandan Raman,2016-07-18 00:00:00,MRK,1,2,0,1,0,0,1,0,0,0.5
852188,benzingas top downgrades,https://www.benzinga.com/analyst-ratings/downgrades/16/07/8227007/benzingas-top-downgrades,Monica Gerson,2016-07-18 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.60115
852189,bmo capital downgrades merck co to market perform,https://www.benzinga.com/news/16/07/8226090/bmo-capital-downgrades-merck-co-to-market-perform,Paul Quintaro,2016-07-18 00:00:00,MRK,1,1,0,1,1,0,1,1,1,0.5
852190,merck pfizer report initiation of phase iii trial to evaluate avelumab as firstline treatment for ovarian cancer,https://www.benzinga.com/news/16/07/8187530/merck-pfizer-report-initiation-of-phase-iii-trial-to-evaluate-avelumab-as-first-l,Paul Quintaro,2016-07-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
852191,merck animal health announces agreement to acquire controlling interest in brazilian animal health company vallÃ©e sa will acquire of shares for m,https://www.benzinga.com/news/16/07/8176831/merck-animal-health-announces-agreement-to-acquire-controlling-interest-in-brazil,Paul Quintaro,2016-07-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.9063
852192,merck and premier join hands to prevent fractures for osteoporosis patients,https://www.benzinga.com/general/biotech/16/06/8171349/merck-and-premier-join-hands-to-prevent-fractures-for-osteoporosis-pat,R. Chandrasekaran,2016-06-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
852193,merck premier report collaboration to prevent fractures for osteoporosis patients,https://www.benzinga.com/news/16/06/8170557/merck-premier-report-collaboration-to-prevent-fractures-for-osteoporosis-patients,Paul Quintaro,2016-06-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5129
852194,merck moderna therapeutics report strategic collaboration related to advancement of novel mrnabased personalized cancer vaccines with keytruda,https://www.benzinga.com/news/16/06/8164513/merck-moderna-therapeutics-report-strategic-collaboration-related-to-advancement-,Paul Quintaro,2016-06-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.26165
852195,merck gets chmp positive opinion for keytruda for advanced nonsmall cell lung cancer treatment,https://www.benzinga.com/general/biotech/16/06/8153784/merck-gets-chmp-positive-opinion-for-keytruda-for-advanced-non-small-c,R. Chandrasekaran,2016-06-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5258
852196,merck receives chmp positive opinion for keytruda for the treatment of advanced nonsmall cell lung cancer,https://www.benzinga.com/news/16/06/8153054/merck-receives-chmp-positive-opinion-for-keytruda-for-the-treatment-of-advanced-n,Paul Quintaro,2016-06-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5258
852197,update merck says pivotal phase studies for relebacatam ongoing in treatment of serious bacterial infections,https://www.benzinga.com/news/16/06/8130672/update-merck-says-pivotal-phase-3-studies-for-relebacatam-ongoing-in-treatment-of,Paul Quintaro,2016-06-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.4614
852198,merck offers results of phase study for relebactam in combo with imipenemcilastatin,https://www.benzinga.com/news/16/06/8130651/merck-offers-results-of-phase-2-study-for-relebactam-in-combo-with-imipenemcilast,Paul Quintaro,2016-06-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852199,cramer talks about mercks fabulous news and why the market cant rally,https://www.benzinga.com/media/jim-cramer/16/06/8120542/cramer-talks-about-mercks-fabulous-news-and-why-the-market-cant-rally,Jayson Derrick,2016-06-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.76335
852200,merck rallies of drug trial results,https://www.benzinga.com/trading-ideas/technicals/16/06/8120380/merck-rallies-of-drug-trial-results,Joel Elconin,2016-06-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852201,merck announces keytruda met primary and secondary endpoint,https://www.benzinga.com/news/16/06/8117763/merck-announces-keytruda-met-primary-and-secondary-endpoint,Paul Quintaro,2016-06-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852202,jefferies shares pharma stock catalyst outlook,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8110237/jefferies-shares-pharma-stock-catalyst-outlook,Javier Hasse,2016-06-14 00:00:00,MRK,1,2,1,1,1,1,1,0,1,0.648
852203,merck reports mk met primary endpoint in two phase studies,https://www.benzinga.com/news/16/06/8103861/merck-reports-mk-1293-met-primary-endpoint-in-two-phase-3-studies,Paul Quintaro,2016-06-13 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852204,has cancer research become cancerous same cancer strategy targeted by too many drugmakers say regulators,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8103031/has-cancer-research-become-cancerous-same-cancer-strateg,Manikandan Raman,2016-06-13 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.06555
852205,merck pfizer announce two pivotal phase studies for ertugliflozin met primary endpoints showing significant ac reductions in patients with type diabetes at the american diabetes associations th scientific sessions,https://www.benzinga.com/news/16/06/8101558/merck-pfizer-announce-two-pivotal-phase-3-studies-for-ertugliflozin-met-primary-e,Charles Gross,2016-06-12 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.60115
852206,update merck to pay m cash upfront afferent holders eligible for addition m tied to clinical development and commercial milestones for multiple indications and candidates including af,https://www.benzinga.com/news/16/06/8095767/update-merck-to-pay-500m-cash-upfront-afferent-holders-eligible-for-addition-750m,Paul Quintaro,2016-06-09 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.44865
852207,merck to acquire afferent pharmaceuticals,https://www.benzinga.com/news/16/06/8095761/merck-to-acquire-afferent-pharmaceuticals,Paul Quintaro,2016-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852208,hearing fda panel has said merck has provided substantial evidence of safety effectiveness of bezlotoxumab,https://www.benzinga.com/news/16/06/8094903/hearing-fda-panel-has-said-merck-has-provided-substantial-evidence-of-safety-effe,Paul Quintaro,2016-06-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
852209,bz note relypsa shares still up from where stock was trading prior to apparent rumor manipulation ahead of negative streetsweeper report see body of this headline for more,https://www.benzinga.com/news/16/06/8092981/bz-note-relypsa-shares-still-up-0-20-0-40-from-where-stock-was-trading-prior-to-a,Paul Quintaro,2016-06-09 00:00:00,MRK,1,0,1,1,0,1,1,0,0,0.24469999999999997
852210,hearing merck may be interested in rlyp unconfirmed takeover chatter,https://www.benzinga.com/news/16/06/8092889/hearing-merck-may-be-interested-in-rlyp-unconfirmed-takeover-chatter,Paul Quintaro,2016-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852211,agenus reports lead product candidate selection in its collab with merck received first milestone payment of m,https://www.benzinga.com/news/16/06/8092500/agenus-reports-lead-product-candidate-selection-in-its-collab-with-merck-received,Paul Quintaro,2016-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852212,merck says ruling reversal in gilead case doesnt reflect the facts co will appeal ruling overturn,https://www.benzinga.com/news/16/06/8084421/merck-says-ruling-reversal-in-gilead-case-doesnt-reflect-the-facts-co-will-appeal,Paul Quintaro,2016-06-07 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
852213,goldman confident in mercks keytruda,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8080139/goldman-confident-in-mercks-keytruda,Manikandan Raman,2016-06-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
852214,fda staff has said overall clinical results from mercks bezlotoxumab trial could negatively impact cure rate of initial episode of infection with c difficile,https://www.benzinga.com/news/16/06/8078460/fda-staff-has-said-overall-clinical-results-from-mercks-bezlotoxumab-trial-could-,Paul Quintaro,2016-06-07 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.5
852215,us judge rules gilead wont have to pay m jury verdict to merck in hepatitis c patent dispute reuters,https://www.benzinga.com/news/16/06/8076544/us-judge-rules-gilead-wont-have-to-pay-200m-jury-verdict-to-merck-in-hepatitis-c-,Charles Gross,2016-06-06 00:00:00,MRK,1,1,0,1,0,0,1,1,0,0.39835
852216, key takeaways from asco,https://www.benzinga.com/analyst-ratings/analyst-color/16/06/8076107/4-key-takeaways-from-asco,Javier Hasse,2016-06-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852217,merck pfizer offers results from pivotal avelumab study,https://www.benzinga.com/news/16/06/8072921/merck-pfizer-offers-results-from-pivotal-avelumab-study,Paul Quintaro,2016-06-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852218,merck reports response rates from keynote show nearly one in five patients respond with keytruda,https://www.benzinga.com/news/16/06/8072414/merck-reports-response-rates-from-keynote-055-show-nearly-one-in-five-patients-re,Paul Quintaro,2016-06-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852219,merck announces new data from phase study evaluating keytruda for the treatment of cancers deficient in dna mismatch repair show durable responses across a range of cancers at asco,https://www.benzinga.com/news/16/06/8071263/merck-announces-new-data-from-phase-2-study-evaluating-keytruda-for-the-treatment,Charles Gross,2016-06-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852220,lilly announces encouraging data of earlyphase immunooncology studies of alimta and cyramza with mercks keytruda in nsclc presented at asco,https://www.benzinga.com/news/16/06/8071138/lilly-announces-encouraging-data-of-early-phase-immuno-oncology-studies-of-alimta,Charles Gross,2016-06-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.76335
852221,merck announces new data for keytruda in combination with talimogene laherparepvec dabrafenib plus trametinib or lowdose ipilimumab in advanced melanoma presented at asco,https://www.benzinga.com/news/16/06/8071125/merck-announces-new-data-for-keytruda-in-combination-with-talimogene-laherparepve,Charles Gross,2016-06-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
852222,new data evaluating keytruda in combination with chemotherapy for firstline treatment of nsclc demonstrate response rates ranging of data to be presented at asco,https://www.benzinga.com/news/16/06/8070831/new-data-evaluating-keytruda-in-combination-with-chemotherapy-for-first-line-trea,Charles Gross,2016-06-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852223,new keytruda data from keynote and keynote in advanced nsclc including survival data to be presented at asco,https://www.benzinga.com/news/16/06/8070815/new-keytruda-data-from-keynote-010-and-keynote-001-in-advanced-nsclc-including-su,Charles Gross,2016-06-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
852224,ouch jobs report miss sends rate hike odds down raises questions,https://www.benzinga.com/news/16/06/8068298/ouch-jobs-report-miss-sends-rate-hike-odds-down-raises-questions,The Ticker Tape,2016-06-03 00:00:00,MRK,1,1,0,1,0,1,1,0,1,0.42345
852225,merck gets favorable opinion from chmp for its zepatier,https://www.benzinga.com/general/biotech/16/05/8040933/merck-gets-favorable-opinion-from-chmp-for-its-zepatier,R. Chandrasekaran,2016-05-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
852226,merck receives positive chmp opinion for zepatier in the european union,https://www.benzinga.com/news/16/05/8040698/merck-receives-positive-chmp-opinion-for-zepatier-in-the-european-union,Paul Quintaro,2016-05-27 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.7787
852227,celgene rallies of possible interest from merck,https://www.benzinga.com/news/16/05/8036296/celgene-rallies-of-possible-interest-from-merck,Joel Elconin,2016-05-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
852228,celgene shares spiking traders passing vague comments of possible interest from merck,https://www.benzinga.com/news/16/05/8035733/celgene-shares-spiking-traders-passing-vague-comments-of-possible-interest-from-m,Paul Quintaro,2016-05-26 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.79295
852229,chardan initiates asterias biotherapeutics at buy on potential cell therapy competitiveness,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/8018041/chardan-initiates-asterias-biotherapeutics-at-buy-on-pot,Manikandan Raman,2016-05-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852230,jpmorgans take on big pharmas new asco abstracts,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/8006813/jpmorgans-take-on-big-pharmas-new-asco-abstracts,Wayne Duggan,2016-05-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852231,merck to present new and updated data on keytruda,https://www.benzinga.com/general/biotech/16/05/7986240/merck-to-present-new-and-updated-data-on-keytruda,R. Chandrasekaran,2016-05-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852232,berenberg unimpressed with pfizer initiates coverage at hold,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/7975970/berenberg-unimpressed-with-pfizer-initiates-coverage-at-,Dhiraj Surapaneni,2016-05-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.32999999999999996
852233,merck to present final stage data on investigational medicines ertugliflozin and mk,https://www.benzinga.com/general/biotech/16/05/7972602/merck-to-present-final-stage-data-on-investigational-medicines-ertugli,R. Chandrasekaran,2016-05-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852234,whats ma like in the biotech sector right now,https://www.benzinga.com/analyst-ratings/analyst-color/16/05/7939748/whats-m-a-like-in-the-biotech-sector-right-now,Javier Hasse,2016-05-06 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.6806
852235,midafternoon market update us stocks turn lower zynga shares rise following earnings beat,https://www.benzinga.com/news/earnings/16/05/7938610/mid-afternoon-market-update-u-s-stocks-turn-lower-zynga-shares-rise-foll,Lisa Levin,2016-05-05 00:00:00,MRK,0,0,0,0,1,0,0,0,0,0.5
852236,merck lower after mixed q report,https://www.benzinga.com/trading-ideas/technicals/16/05/7938245/merck-lower-after-mixed-q1-report,Joel Elconin,2016-05-05 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.352
852237,midday market update fitbit slides on weak outlook atlas air worldwide shares shares spike higher,https://www.benzinga.com/news/earnings/16/05/7937880/mid-day-market-update-fitbit-slides-on-weak-outlook-atlas-air-worldwide-,Lisa Levin,2016-05-05 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.5640000000000001
852238,midmorning market update markets edge higher merck profit beats views,https://www.benzinga.com/news/earnings/16/05/7936704/mid-morning-market-update-markets-edge-higher-merck-profit-beats-views,Lisa Levin,2016-05-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
852239,merck launch of zepatier in eu may be delayed until late early as regulator inspects recordkeeping of third party manufacturer reuters,https://www.benzinga.com/news/16/05/7936571/merck-launch-of-zepatier-in-eu-may-be-delayed-until-late-2016-early-2017-as-regul,Charles Gross,2016-05-05 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.60115
852240,mercks q adjusted profit beats but revenue miss narrows adjusted eps fy forecast,https://www.benzinga.com/news/earnings/16/05/7935288/mercks-q1-adjusted-profit-beats-but-revenue-miss-narrows-adjusted-eps-fy,R. Chandrasekaran,2016-05-05 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.50645
852241,merck sees fy eps to vs est,https://www.benzinga.com/news/16/05/7934954/merck-sees-fy-2016-eps-3-65-to-3-77-vs-3-71-est,Paul Quintaro,2016-05-05 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852242,merck q eps vs est revenue b vs b est,https://www.benzinga.com/news/earnings/16/05/7934948/merck-q1-eps-0-89-vs-0-85-est-revenue-9-3b-vs-9-5b-est,Paul Quintaro,2016-05-05 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
852243, stocks to watch for may ,https://www.benzinga.com/news/earnings/16/05/7934472/12-stocks-to-watch-for-may-5-2016,Monica Gerson,2016-05-05 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852244,earnings scheduled for may ,https://www.benzinga.com/news/earnings/16/05/7934436/earnings-scheduled-for-may-5-2016,Monica Gerson,2016-05-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852245,thestreets adam feuerstein tweets mrk bmy are not working with nwbo on cancer immunotherapy combination clinical trials per their respective spokespersons,https://www.benzinga.com/news/16/05/7921423/thestreets-adam-feuerstein-tweets-mrk-bmy-are-not-working-with-nwbo-on-cancer-imm,Paul Quintaro,2016-05-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.30910000000000004
852246,earnings drug makers merck and pfizer report q results,https://www.benzinga.com/trading-ideas/previews/16/05/7914024/earnings-drug-makers-merck-and-pfizer-report-q1-results,The Ticker Tape,2016-05-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852247,the market in minutes may she will stay,https://www.benzinga.com/news/16/05/7913023/the-market-in-5-minutes-may-she-will-stay,Benzinga News Desk,2016-05-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852248,merck and pfizer earnings will they beat expectations again,https://www.benzinga.com/trading-ideas/previews/16/05/7911003/merck-and-pfizer-earnings-will-they-beat-expectations-again,Nelson Hem,2016-05-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852249,pharma names under pressure amid perrigo warning,https://www.benzinga.com/news/16/04/7879293/pharma-names-under-pressure-amid-perrigo-warning,Jayson Derrick,2016-04-25 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.2213
852250,merck animal health to acquire rights to whisper veterinary stethoscope system terms not disclosed,https://www.benzinga.com/news/16/04/7859058/merck-animal-health-to-acquire-rights-to-whisper-veterinary-stethoscope-system-te,Paul Quintaro,2016-04-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852251,merck gives statement on blueprint project findings at aacr encouraged by findings and eager to support greater biomarker testing use,https://www.benzinga.com/news/16/04/7857769/merck-gives-statement-on-blueprint-project-findings-at-aacr-encouraged-by-finding,Paul Quintaro,2016-04-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.92405
852252,merck reports received breakthrough therapy designation from fda for keytruda in chl,https://www.benzinga.com/news/16/04/7850167/merck-reports-received-breakthrough-therapy-designation-from-fda-for-keytruda-in-,Paul Quintaro,2016-04-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852253,merck announces results from phase studies of zepatier in chronic hep c patient populations at ilc,https://www.benzinga.com/news/16/04/7848559/merck-announces-results-from-phase-3-studies-of-zepatier-in-chronic-hep-c-patient,Charles Gross,2016-04-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852254,jefferies maintains hold on merck co raises pt to ,https://www.benzinga.com/news/16/04/7844632/jefferies-maintains-hold-on-merck-co-raises-pt-to-54-00,Eddie Staley,2016-04-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852255,afterhours recap big banks liquidity servicess dod deal haemonetics cfo more,https://www.benzinga.com/news/earnings/16/04/7843083/after-hours-recap-big-banks-liquidity-servicess-dod-deal-haemonetics-cfo,Javier Hasse,2016-04-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852256,merck kgaa says filed answer in response to trademark right violation claims made by merck,https://www.benzinga.com/news/16/04/7839475/merck-kgaa-says-filed-answer-in-response-to-trademark-right-violation-claims-made,Charles Gross,2016-04-14 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.25305
852257,mercks zepatier showed superiority on efficacy and safety endpoints vs sofosbuvir plus peginterferon and ribavirin treatment regimen in phase trial,https://www.benzinga.com/news/16/04/7838478/mercks-zepatier-showed-superiority-on-efficacy-and-safety-endpoints-vs-sofosbuvir,Charles Gross,2016-04-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81845
852258,merck says fda accepts its sbla for keytruda and grants priority review,https://www.benzinga.com/general/biotech/16/04/7834313/merck-says-fda-accepts-its-sbla-for-keytruda-and-grants-priority-revie,R. Chandrasekaran,2016-04-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
852259,fda accepts supplemental biologics license application for mercks keytruda in recurrent or metastatic head and neck cancer and grants priority review,https://www.benzinga.com/news/16/04/7834119/fda-accepts-supplemental-biologics-license-application-for-mercks-keytruda-in-rec,Hal Lindon,2016-04-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.352
852260,merck announces license application for investigational house dust mite slittablet accepted for review by fda,https://www.benzinga.com/news/16/04/7833693/merck-announces-license-application-for-investigational-house-dust-mite-slit-tabl,Charles Gross,2016-04-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6366
852261,baird gilead set for q eps miss but hep c trends still good long term,https://www.benzinga.com/analyst-ratings/analyst-color/16/04/7829867/baird-gilead-set-for-q1-eps-miss-but-hep-c-trends-still-,Manikandan Raman,2016-04-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.77495
852262,notable imbalances before tuesdays open led by under armour boeing caterpillar,https://www.benzinga.com/news/16/04/7829752/notable-imbalances-before-tuesdays-open-led-by-under-armour-boeing-caterpillar,Jayson Derrick,2016-04-12 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852263,how one analyst is playing the biotech rebound this week,https://www.benzinga.com/general/biotech/16/04/7816192/how-one-analyst-is-playing-the-biotech-rebound-this-week,Spencer Israel,2016-04-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852264,bz note relypsa has been mentioned in rumors over past months in possible ma talk with sanofi merck astra zeneca,https://www.benzinga.com/general/biotech/16/04/7816176/bz-note-relypsa-has-been-mentioned-in-rumors-over-past-7-months-in-pos,Hal Lindon,2016-04-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.55135
852265,pph may be home to hedge fund hotels but this etf can endure,https://www.benzinga.com/general/biotech/16/04/7807835/pph-may-be-home-to-hedge-fund-hotels-but-this-etf-can-endure,ETF Professor,2016-04-06 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852266,socgen picks new favorites in big pharma,https://www.benzinga.com/analyst-ratings/analyst-color/16/04/7810497/socgen-picks-new-favorites-in-big-pharma,Manikandan Raman,2016-04-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
852267,societe generale initiates coverage on merck co at buy,https://www.benzinga.com/news/16/04/7810189/societe-generale-initiates-coverage-on-merck-co-at-buy,Eddie Staley,2016-04-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852268,merck will present new keytruda data at aacr meeting apr th,https://www.benzinga.com/news/16/04/7808801/merck-will-present-new-keytruda-data-at-aacr-meeting-apr-16-20th,Hal Lindon,2016-04-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852269,who says number of adults with diabetes has quadrupled since afp,https://www.benzinga.com/news/16/04/7808154/who-says-number-of-adults-with-diabetes-has-quadrupled-since-1980-afp,Charles Gross,2016-04-06 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5386
852270,advaxis merck combination trial evaluating adxspsa launches third doseescalation cohort,https://www.benzinga.com/news/16/04/7802117/advaxis-merck-combination-trial-evaluating-adxs-psa-launches-third-dose-escalatio,Hal Lindon,2016-04-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852271,the stocks that moved the sp dow and nasdaq today,https://www.benzinga.com/news/16/04/7799210/the-stocks-that-moved-the-s-p-dow-and-nasdaq-today,Javier Hasse,2016-04-04 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852272,this data signals the end for mercks anacetrapib,https://www.benzinga.com/analyst-ratings/analyst-color/16/04/7796690/this-data-signals-the-end-for-mercks-anacetrapib,Monica Gerson,2016-04-04 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852273,make a house call with a familiar healthcare etf,https://www.benzinga.com/general/biotech/16/04/7794107/make-a-house-call-with-a-familiar-healthcare-etf,ETF Professor,2016-04-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852274,biopharma names lly pfe mrk and more popping higher following reports china fda to investigate improper vaccine trading,https://www.benzinga.com/news/16/03/7764033/biopharma-names-lly-pfe-mrk-and-more-popping-higher-following-reports-china-fda-t,Paul Quintaro,2016-03-28 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852275,data shows gileads hcv franchise is surviving new competition,https://www.benzinga.com/analyst-ratings/analyst-color/16/03/7763582/data-shows-gileads-hcv-franchise-is-surviving-new-compet,Jim Swanson,2016-03-28 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.648
852276,patent expert its not over for gilead still has strong defense against merck,https://www.benzinga.com/analyst-ratings/analyst-color/16/03/7756866/patent-expert-its-not-over-for-gilead-still-has-strong-d,Wayne Duggan,2016-03-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.79295
852277,jury rules merck patents validbad for gilead,https://www.benzinga.com/analyst-ratings/analyst-color/16/03/7750018/jury-rules-merck-patents-valid-bad-for-gilead,Rebecca Sheppard,2016-03-23 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852278,gilead premarket following verdict tuesday validating mercks hep c patents,https://www.benzinga.com/news/16/03/7748933/gilead-2-5-premarket-following-verdict-tuesday-validating-mercks-hep-c-patents,Charles Gross,2016-03-23 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.7294
852279,organovo is a company d printing human tissue and its ceo is excited about creating livers,https://www.benzinga.com/general/biotech/16/03/7729069/organovo-is-a-company-3d-printing-human-tissue-and-its-ceo-is-excited-,Nicholas Donato,2016-03-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7787
852280,agenus shares spike higher following midday upgrade to buy from maxim,https://www.benzinga.com/analyst-ratings/analyst-color/16/03/7676980/agenus-shares-spike-higher-following-mid-day-upgrade-to-,Javier Hasse,2016-03-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852281,the stocks that moved the sp dow and nasdaq today,https://www.benzinga.com/news/16/03/7663922/the-stocks-that-moved-the-s-p-dow-and-nasdaq-today,Javier Hasse,2016-03-10 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852282,jimmy carter boosts social media buzz for mercks blockbuster drug,https://www.benzinga.com/general/biotech/16/03/7626124/jimmy-carter-boosts-social-media-buzz-for-mercks-blockbuster-drug,Wayne Duggan,2016-03-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.86755
852283,sanofi pasteur merck report intent to end joint vaccines operations in europe sanofi pasteur msd to pursue their own distinct growth strategies,https://www.benzinga.com/news/16/03/7624951/sanofi-pasteur-merck-report-intent-to-end-joint-vaccines-operations-in-europe-san,Paul Quintaro,2016-03-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
852284,gilead vs merck what to know,https://www.benzinga.com/analyst-ratings/analyst-color/16/03/7344979/gilead-vs-merck-what-to-know,Javier Hasse,2016-03-07 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852285,fda accepts supplemental biologics license application for keytruda,https://www.benzinga.com/news/16/03/7256551/fda-accepts-supplemental-biologics-license-application-for-keytruda,Paul Quintaro,2016-03-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6591
852286,update merck pfizer and verastem combination trial of avelumab and vs expected to begin in nd half ,https://www.benzinga.com/news/16/03/6796780/update-merck-pfizer-and-verastem-combination-trial-of-avelumab-and-vs-6063-expect,Hal Lindon,2016-03-03 00:00:00,MRK,1,2,0,1,0,0,1,0,1,0.5
852287,merck kgaa darmstadt germany pfizer and verastem report combination trial of avelumab and vs in ovarian cancer,https://www.benzinga.com/news/16/03/6796711/merck-kgaa-darmstadt-germany-pfizer-and-verastem-report-combination-trial-of-avel,Hal Lindon,2016-03-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
852288,watch pharma names following fda issuance of new mandatory clinical study for bayers essure requires product labeling including box warnings and patient decision checklist,https://www.benzinga.com/news/16/02/6754078/watch-pharma-names-following-fda-issuance-of-new-mandatory-clinical-study-for-bay,Paul Quintaro,2016-02-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.38685
852289, mega biotechs leerink loves,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6750139/3-mega-biotechs-leerink-loves,Wayne Duggan,2016-02-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7859499999999999
852290,aureogen announces licensing agreement with merck,https://www.benzinga.com/news/16/02/6608895/aureogen-announces-licensing-agreement-with-merck,Charles Gross,2016-02-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
852291,will merck encroach on gileads harvoni territory,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6526669/will-merck-encroach-on-gileads-harvoni-territory,Wayne Duggan,2016-02-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852292, patients contacted to arrange blood test following possible exposure to exnhs worker with hepatitis c sky news,https://www.benzinga.com/news/16/02/6519732/8-383-patients-contacted-to-arrange-blood-test-following-possible-exposure-to-ex-,Charles Gross,2016-02-23 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.5
852293,merck reports investigational onedaily formulation of isentress met primary secondary endpoints in pivotal phase trial,https://www.benzinga.com/news/16/02/6492532/merck-reports-investigational-one-daily-formulation-of-isentress-met-primary-seco,Paul Quintaro,2016-02-22 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852294,alk announces merck submits bla to fda for investigational house dust mite slittablet,https://www.benzinga.com/news/16/02/6238392/alks-announces-merck-submits-bla-to-fda-for-investigational-house-dust-mite-slit-,Charles Gross,2016-02-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852295,how to invest in an aging world with the live long prosper etf,https://www.benzinga.com/trading-ideas/long-ideas/16/02/6227065/how-to-invest-in-an-aging-world-with-the-live-long-prosper-et,Wayne Duggan,2016-02-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852296,a checkup on a big healthcare etf,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6218736/a-checkup-on-a-big-healthcare-etf,ETF Professor,2016-02-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852297,how to build a defensive portfolio,https://www.benzinga.com/general/education/16/02/6216146/how-to-build-a-defensive-portfolio,Motif Investing,2016-02-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5129
852298, companies that could still buy back mountains of stock,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6214523/25-companies-that-could-still-buy-back-mountains-of-stoc,Wayne Duggan,2016-02-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852299,immunogen merck partner for clincial evaluation of mirvetuximab soravtansine with keytruda combination for ovarian cancer treatment,https://www.benzinga.com/news/16/02/6213109/immunogen-merck-partner-for-clincial-evaluation-of-mirvetuximab-soravtansine-with,Hal Lindon,2016-02-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
852300,merck co inc falters after q report,https://www.benzinga.com/trading-ideas/technicals/16/02/6208475/merck-co-inc-falters-after-q4-report,Joel Elconin,2016-02-03 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852301,joe mccann heres how to play biotech market in earnings season,https://www.benzinga.com/analyst-ratings/analyst-color/16/02/6202307/joe-mccann-heres-how-to-play-biotech-market-in-earnings-,Leigh Drogen,2016-02-03 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.67
852302,shares of merck dip lower following q print,https://www.benzinga.com/news/earnings/16/02/6206246/shares-of-merck-dip-lower-following-q4-print,Jayson Derrick,2016-02-03 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.5
852303,merck sees fy eps vs est rev b vs est b,https://www.benzinga.com/news/16/02/6206157/merck-sees-fy16-eps-3-60-3-75-vs-est-3-72-rev-38-7-40-2b-vs-est-40-25b,Paul Quintaro,2016-02-03 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852304,merck reports q eps vs est rev b vs est b,https://www.benzinga.com/news/earnings/16/02/6206141/merck-reports-q4-eps-0-93-vs-est-0-91-rev-10-215b-vs-est-10-35b,Paul Quintaro,2016-02-03 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852305,merck sees fy eps to vs est,https://www.benzinga.com/news/16/02/6205583/merck-sees-fy-2016-eps-3-60-to-3-75-vs-3-72-est,Paul Quintaro,2016-02-03 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852306,merck sees fy revenue b vs b est,https://www.benzinga.com/news/16/02/6205582/merck-sees-fy-2016-revenue-38-7b-vs-40-2b-est,Paul Quintaro,2016-02-03 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
852307,merck q eps vs est revenue b vs b est,https://www.benzinga.com/news/earnings/16/02/6205541/merck-q4-eps-0-93-vs-0-91-est-revenue-10-2b-vs-10-4b-est,Paul Quintaro,2016-02-03 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
852308,keep an eye on these stocks for february ,https://www.benzinga.com/news/earnings/16/02/6205160/keep-an-eye-on-these-10-stocks-for-february-3-2016,Monica Gerson,2016-02-03 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852309,earnings scheduled for february ,https://www.benzinga.com/news/earnings/16/02/6205151/earnings-scheduled-for-february-3-2016,Monica Gerson,2016-02-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852310,merck sanofi exploring potential end to joint venture in europe,https://www.benzinga.com/news/16/02/6200085/merck-sanofi-exploring-potential-end-to-joint-venture-in-europe,Jayson Derrick,2016-02-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852311,sanofi merck considering ending jv to sell vaccines in europe bloomberg,https://www.benzinga.com/news/16/02/6198059/sanofi-merck-considering-ending-jv-to-sell-vaccines-in-europe-bloomberg,Charles Gross,2016-02-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852312,earnings pharma tends to top street estimatecan pfe mrk repeat,https://www.benzinga.com/news/earnings/16/02/6193464/earnings-pharma-tends-to-top-street-estimate-can-pfe-mrk-repeat,The Ticker Tape,2016-02-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.60115
852313,stock marquee is crowded in week ahead oil earnings labor data,https://www.benzinga.com/news/earnings/16/02/6193412/stock-marquee-is-crowded-in-week-ahead-oil-earnings-labor-data,The Ticker Tape,2016-02-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852314,mixed earnings expectations for merck and pfizer,https://www.benzinga.com/general/biotech/16/01/6191049/mixed-earnings-expectations-for-merck-and-pfizer,Nelson Hem,2016-01-31 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852315,gilead hits new week low here are two reasons why,https://www.benzinga.com/news/16/01/6187756/gilead-hits-new-52-week-low-here-are-two-reasons-why,Jayson Derrick,2016-01-29 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.3634
852316,merck confirms fda approval of hep c drug at a cost of per patient,https://www.benzinga.com/news/16/01/6186916/merck-confirms-fda-approval-of-hep-c-drug-at-a-cost-of-54-600-per-patient,Jayson Derrick,2016-01-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
852317,from conf call abbvie says mercks new hep c drug will crimp viekira pak sales,https://www.benzinga.com/news/earnings/16/01/6186391/from-conf-call-abbvie-says-mercks-new-hep-c-drug-will-crimp-viekira-pak-,Charles Gross,2016-01-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852318,merck receives fda approval of hep c drug zepatier to cost patient for week course,https://www.benzinga.com/news/16/01/6184301/merck-receives-fda-approval-of-hep-c-drug-zepatier-to-cost-54-600patient-for-12-w,Charles Gross,2016-01-28 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.7383500000000001
852319,adam feurestein reminds twitter followers today is mercks hepc elbasvirgrazoprevir pdufa,https://www.benzinga.com/news/16/01/6180045/adam-feurestein-reminds-twitter-followers-today-is-mercks-hepc-elbasvirgrazoprevi,Jayson Derrick,2016-01-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852320,adam feuerstein adamfeuerstein tweet reminder today is mrk hepc elbasvirgrazoprevir pdufa co spox knows first and most important postapproval question is what price,https://www.benzinga.com/news/16/01/6179493/adam-feuerstein-adamfeuerstein-tweet-reminder-today-is-mrk-hepc-elbasvirgrazoprev,Charles Gross,2016-01-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6358
852321,fast money picks for january ,https://www.benzinga.com/media/cnbc/16/01/6176956/fast-money-picks-for-january-28,Craig Jones,2016-01-28 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852322,abbott to sell alks house dust mite sublingual allergy immunotherapy tablet in se asia,https://www.benzinga.com/news/16/01/6177278/abbott-to-sell-alks-house-dust-mite-sublingual-allergy-immunotherapy-tablet-in-se,Charles Gross,2016-01-28 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852323,bank of america downgrades merck co to neutral,https://www.benzinga.com/news/16/01/6174236/bank-of-america-downgrades-merck-co-to-neutral,Eddie Staley,2016-01-27 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852324,merck reports fda acceptance of biologics license application for bezlotoxumab,https://www.benzinga.com/news/16/01/6174188/merck-reports-fda-acceptance-of-biologics-license-application-for-bezlotoxumab,Hal Lindon,2016-01-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
852325,merck reports fda acceptance of bla for bezlotoxumab,https://www.benzinga.com/news/16/01/6174127/merck-reports-fda-acceptance-of-bla-for-bezlotoxumab,Paul Quintaro,2016-01-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
852326,acarizax receives marketing authorization in france,https://www.benzinga.com/news/16/01/6173211/acarizax-receives-marketing-authorization-in-france,Charles Gross,2016-01-27 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852327,us big pharma what to watch for in q results,https://www.benzinga.com/analyst-ratings/analyst-color/16/01/6166545/us-big-pharma-what-to-watch-for-in-q4-results,Wayne Duggan,2016-01-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852328,affimed to collaborate with merck to evaluate afm in combination with keytruda for patients with hodgkin lymphoma,https://www.benzinga.com/news/16/01/6165203/affimed-to-collaborate-with-merck-to-evaluate-afm13-in-combination-with-keytruda-,Charles Gross,2016-01-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852329,sierra leone confirms second new ebola case in less than a week reuters,https://www.benzinga.com/news/16/01/6157085/sierra-leone-confirms-second-new-ebola-case-in-less-than-a-week-reuters,Charles Gross,2016-01-20 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
852330,credit suisse sets outperform rating target on gilead story,https://www.benzinga.com/analyst-ratings/analyst-color/16/01/6154907/credit-suisse-sets-outperform-rating-125-target-on-gilea,Monica Gerson,2016-01-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6909
852331,global vaccines alliance signs m advance order for mercks ebola vaccine reuters,https://www.benzinga.com/news/16/01/6154195/global-vaccines-alliance-signs-5m-advance-order-for-mercks-ebola-vaccine-reuters,Charles Gross,2016-01-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852332,write a prescription for this healthcare etf,https://www.benzinga.com/general/biotech/16/01/6145257/write-a-prescription-for-this-healthcare-etf,ETF Professor,2016-01-15 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852333,merck announces resolution of vioxx class action lawsuit cash payment m,https://www.benzinga.com/news/16/01/6145724/merck-announces-resolution-of-vioxx-class-action-lawsuit-cash-payment-680m,Paul Quintaro,2016-01-15 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.38685
852334,update sierra leone ebola victim said to have exposed to disease woman was living in house with people when she became ill reuters,https://www.benzinga.com/news/16/01/6145456/update-sierra-leone-ebola-victim-said-to-have-exposed-27-to-disease-woman-was-liv,Charles Gross,2016-01-15 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.18155
852335,update sierra leone health ministry confirms death from ebola reuters,https://www.benzinga.com/news/16/01/6145373/update-sierra-leone-health-ministry-confirms-death-from-ebola-reuters,Charles Gross,2016-01-15 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.20029999999999998
852336,sierra leone health ministry investigating suspected death from ebola reuters,https://www.benzinga.com/news/16/01/6144611/sierra-leone-health-ministry-investigating-suspected-death-from-ebola-reuters,Charles Gross,2016-01-14 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.14984999999999998
852337,who to announce end of ebola outbreak on thursday afp,https://www.benzinga.com/news/16/01/6138282/who-to-announce-end-of-ebola-outbreak-on-thursday-afp,Charles Gross,2016-01-13 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852338,fast money traders share their biotech picks,https://www.benzinga.com/general/biotech/16/01/6134115/fast-money-traders-share-their-biotech-picks,Craig Jones,2016-01-12 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.648
852339,merck acquires iomet pharma terms not disclosed,https://www.benzinga.com/news/16/01/6133313/merck-acquires-iomet-pharma-terms-not-disclosed,Hal Lindon,2016-01-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852340,why this codexis analyst is confident stock is worth ,https://www.benzinga.com/analyst-ratings/analyst-color/16/01/6120816/why-this-codexis-analyst-is-confident-stock-is-worth-6,Javier Hasse,2016-01-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.81245
852341,washington university initiates clinical study of verastems vs in combination with mercks pembrolizumab and gemcitabine in pancreatic cancer,https://www.benzinga.com/news/16/01/6119273/washington-university-initiates-clinical-study-of-verastems-vs-6063-in-combinatio,Charles Gross,2016-01-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
852342,watch stocks of small midcap cos with experimental drugs as ap reporting merck ceo frazier at goldman healthcare conference said co raring to go on ma deals this year,https://www.benzinga.com/news/16/01/6112808/watch-stocks-of-small-mid-cap-cos-with-experimental-drugs-as-hearing-ap-reporting,Paul Quintaro,2016-01-05 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.5
852343,ani pharma reports closing of deal to purchase two ndas from merck for m,https://www.benzinga.com/news/16/01/6110603/ani-pharma-reports-closing-of-deal-to-purchase-two-ndas-from-merck-for-75m,Paul Quintaro,2016-01-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852344,pfizer merck kgaa report syndax to collab to investigate safety tolerability prelim efficacy of avelumab entinostat in advanced ovarian cancer,https://www.benzinga.com/news/16/01/6103586/pfizer-merck-kgaa-report-syndax-to-collab-to-investigate-safety-tolerability-prel,Paul Quintaro,2016-01-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.42345
852345,who declares end of ebola virus transmission in republic of guinea,https://www.benzinga.com/news/15/12/6077040/who-declares-end-of-ebola-virus-transmission-in-republic-of-guinea,Charles Gross,2015-12-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852346,peering through the fog to find the best sectors into year end,https://www.benzinga.com/trading-ideas/long-ideas/15/12/6071250/peering-through-the-fog-to-find-the-best-sectors-into-year-en,Greg Harmon,2015-12-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.81845
852347,merck kgaa pfizer report advancement of clinical development program with two added phase iii trials of avelumab,https://www.benzinga.com/news/15/12/6067720/merck-kgaa-pfizer-report-advancement-of-clinical-development-program-with-two-add,Paul Quintaro,2015-12-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852348,merck ceo using keytruda could extend patients life by months on average,https://www.benzinga.com/news/15/12/6065692/merck-ceo-using-keytruda-could-extend-patients-life-by-13-months-on-average,Jayson Derrick,2015-12-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.58895
852349,alk sells european veterinary business to fidelio capital terms not disclosed,https://www.benzinga.com/news/15/12/6063983/alk-sells-european-veterinary-business-to-fidelio-capital-terms-not-disclosed,Charles Gross,2015-12-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852350,credit suisse offers us largecap pharma outlook,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6061487/credit-suisse-offers-2016-u-s-large-cap-pharma-outlook,Jayson Derrick,2015-12-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
852351,mercks keytruda significantly improves survival compared to chemotherapy in previouslytreated patients with nonsmall cell lung cancer whose tumors express any level of pdl,https://www.benzinga.com/news/15/12/6062798/mercks-keytruda-significantly-improves-survival-compared-to-chemotherapy-in-previ,Charles Gross,2015-12-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.30910000000000004
852352,merck reports fda approval of expanded indication for keytruda for treatment of patients with advanced melanoma,https://www.benzinga.com/news/15/12/6061788/merck-reports-fda-approval-of-expanded-indication-for-keytruda-for-treatment-of-p,Paul Quintaro,2015-12-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81245
852353,merck reports emas chmp has responded to maa for elbasvirgrazoprevir mgmg application will now be reviewed on standard timetable,https://www.benzinga.com/news/15/12/6060242/merck-reports-emas-chmp-has-responded-to-maa-for-elbasvirgrazoprevir-50mg100mg-ap,Paul Quintaro,2015-12-18 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852354,codexis premarket co announces agreement extension with merck,https://www.benzinga.com/news/15/12/6060170/codexis-7-1-premarket-4-50-co-announces-agreement-extension-with-merck,Charles Gross,2015-12-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
852355,update merck says expanded age indication for gardasil includes age range,https://www.benzinga.com/news/15/12/6050835/update-merck-says-expanded-age-indication-for-gardasil-9-includes-16-26-age-range,Paul Quintaro,2015-12-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852356,merck announces fda approval for expanded age indication for gardasil in males,https://www.benzinga.com/news/15/12/6050833/merck-announces-fda-approval-for-expanded-age-indication-for-gardasil-9-in-males,Paul Quintaro,2015-12-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
852357,fda approves bridion to reverse effects of neuromuscular blocking drugs used in surgery,https://www.benzinga.com/news/15/12/6050343/fda-approves-bridion-to-reverse-effects-of-neuromuscular-blocking-drugs-used-in-s,Eddie Staley,2015-12-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5129
852358,fast money picks for december ,https://www.benzinga.com/media/cnbc/15/12/6047187/fast-money-picks-for-december-15,Craig Jones,2015-12-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852359,hearing fda panel has voted improveit data for mercks zetia to statin therapy does not support claim of reduced risk of cv events,https://www.benzinga.com/news/15/12/6046497/hearing-fda-panel-has-voted-improve-it-data-for-mercks-zetia-to-statin-therapy-do,Paul Quintaro,2015-12-14 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.24
852360,major pharma group outlook in fundamentals to outweigh political headwinds,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6041783/major-pharma-group-outlook-in-2016-fundamentals-to-outwe,Jennifer Lynn,2015-12-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852361, healthcare picks for ,https://www.benzinga.com/trading-ideas/long-ideas/15/12/6036239/9-healthcare-picks-for-2016,Laura Brodbeck,2015-12-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852362,update merck says biothera research shows imprime pgg activates key immune responses,https://www.benzinga.com/news/15/12/6036964/update-merck-says-biothera-research-shows-imprime-pgg-activates-key-immune-respon,Paul Quintaro,2015-12-10 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.648
852363,biothera announces clinical study to evaluate combination therapy of imprime pgg,https://www.benzinga.com/news/15/12/6036924/biothera-announces-clinical-study-to-evaluate-combination-therapy-of-imprime-pgg,Eddie Staley,2015-12-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852364,eli lilly and merk announces expansion of immuno oncology collaboration,https://www.benzinga.com/news/15/12/6036228/eli-lilly-and-merk-announces-expansion-of-immuno-oncology-collaboration,Paul Quintaro,2015-12-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852365,merck reports samsung bioepis receives approval of renflexis a biosimilar of remicade in korea,https://www.benzinga.com/news/15/12/6025601/merck-reports-samsung-bioepis-receives-approval-of-renflexis-a-biosimilar-of-remi,Hal Lindon,2015-12-07 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.7383500000000001
852366,must watch stocks for today,https://www.benzinga.com/news/earnings/15/12/6025007/must-watch-stocks-for-today,Monica Gerson,2015-12-07 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852367,benzingas weekend ma chatter,https://www.benzinga.com/news/15/12/6024660/benzingas-weekend-m-a-chatter,Charles Gross,2015-12-06 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852368,merck spokesperson declines comment on speculation related to relypsa,https://www.benzinga.com/exclusives/15/12/6023143/merck-spokesperson-declines-comment-on-speculation-related-to-relypsa,Paul Quintaro,2015-12-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852369,exclusive relypsa being evaluated by potential acquirers sanofi seen as natural buyer,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6023057/exclusive-relypsa-being-evaluated-by-3-4-potential-acqui,Benzinga News Desk,2015-12-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7294
852370,exclusive wedbushs liana moussatos tells benzinga sanofi is a natural buyer of relypsa,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6022990/wedbushs-liana-moussatos-tells-benzinga-sanofi-is-a-natu,Eddie Staley,2015-12-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7294
852371,exclusive source tells benzinga merck is not involved with relypsa bid calls to merck were not immediately returned,https://www.benzinga.com/news/15/12/6022938/exclusive-source-tells-benzinga-merck-is-not-involved-with-relypsa-bid-calls-to-m,Jason Shubnell,2015-12-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5640000000000001
852372,hearing unconfirmed marker chatter of potential merck bid for relypsa,https://www.benzinga.com/news/15/12/6022837/hearing-unconfirmed-marker-chatter-of-potential-merck-bid-for-relypsa,Charles Gross,2015-12-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
852373,amgen merck report cancer immunotherapy partnership for patients with nonhodgkin lymphoma,https://www.benzinga.com/news/15/12/6022002/amgen-merck-report-cancer-immunotherapy-partnership-for-patients-with-non-hodgkin,Hal Lindon,2015-12-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
852374,barclays biopharmaceuticals blueprint for ,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6011335/barclays-biopharmaceuticals-blueprint-for-2016,Jayson Derrick,2015-12-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852375,barclays on merck too much underlying value to ignore,https://www.benzinga.com/analyst-ratings/analyst-color/15/12/6011290/barclays-on-merck-too-much-underlying-value-to-ignore,Monica Gerson,2015-12-01 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.4871
852376,barclays upgrades merck co to overweight raises pt to ,https://www.benzinga.com/news/15/12/6010831/barclays-upgrades-merck-co-to-overweight-raises-pt-to-66-00,Charles Gross,2015-12-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3194
852377,deere announces factory workforce adjustments employees on indefinite leave starting feb ,https://www.benzinga.com/news/15/11/6008031/deere-announces-factory-workforce-adjustments-220-employees-on-indefinite-leave-s,Eddie Staley,2015-11-30 00:00:00,MRK,1,1,0,1,0,1,1,0,0,0.4742
852378,miticure for house dust mite allergic rhinitis now available in japan,https://www.benzinga.com/news/15/11/6003629/miticure-for-house-dust-mite-allergic-rhinitis-now-available-in-japan,Charles Gross,2015-11-25 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.352
852379,merck increases qtr dividend from to share,https://www.benzinga.com/news/15/11/5999127/merck-increases-qtr-dividend-from-0-45-to-0-46share,Hal Lindon,2015-11-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852380,benzingas top initiations,https://www.benzinga.com/analyst-ratings/initiation/15/11/5998802/benzingas-top-initiations,Lisa Levin,2015-11-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852381,berenberg initiates coverage on merck co at buy,https://www.benzinga.com/news/15/11/5998108/berenberg-initiates-coverage-on-merck-co-at-buy,Paul Quintaro,2015-11-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852382,year old boy is first ebola fatality in liberia since country was declared ebola free in september reuters,https://www.benzinga.com/news/15/11/5998089/15-year-old-boy-is-first-ebola-fatality-in-liberia-since-country-was-declared-ebo,Charles Gross,2015-11-24 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.352
852383,three new ebola cases reported in liberia persons under observation reuters,https://www.benzinga.com/news/15/11/5996135/three-new-ebola-cases-reported-in-liberia-153-persons-under-observation-reuters,Charles Gross,2015-11-22 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.5
852384,merck announces initial results for keytruda with novel immunotherapy combinations from three investigational studies presented at the society for melanoma research international congress,https://www.benzinga.com/news/15/11/5996113/merck-announces-initial-results-for-keytruda-with-novel-immunotherapy-combination,Charles Gross,2015-11-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
852385,hearing merck planning to expand presence in african wants to more than double sales in africa by ,https://www.benzinga.com/news/15/11/5995285/hearing-merck-planning-to-expand-presence-in-african-wants-to-more-than-double-sa,Paul Quintaro,2015-11-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
852386,us stock futures edge higher ahead of jobless claims report,https://www.benzinga.com/news/earnings/15/11/5990030/us-stock-futures-edge-higher-ahead-of-jobless-claims-report,Monica Gerson,2015-11-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852387,lilly and merck expand immunooncology collaboration with phase iii nonsquamous nonsmall cell lung cancer trial,https://www.benzinga.com/news/15/11/5989132/lilly-and-merck-expand-immuno-oncology-collaboration-with-phase-iii-nonsquamous-n,Eddie Staley,2015-11-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.26165
852388,shares of sigma aldrich halted is being taken out by merck kgaa,https://www.benzinga.com/news/15/11/5984240/shares-of-sigma-aldrich-halted-is-being-taken-out-by-merck-kgaa,Paul Quintaro,2015-11-18 00:00:00,MRK,1,2,0,0,0,0,1,1,0,0.648
852389,merck darmstadt pfizer report fda breakthrough therapy designation for avelumab in metastatic merkel cell carcinoma,https://www.benzinga.com/news/15/11/5983926/merck-darmstadt-pfizer-report-fda-breakthrough-therapy-designation-for-avelumab-i,Paul Quintaro,2015-11-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852390,cambodia reports outbreak of highly pathogenic hn bird flu reuters,https://www.benzinga.com/news/15/11/5980176/cambodia-reports-outbreak-of-highly-pathogenic-h5n1-bird-flu-reuters,Charles Gross,2015-11-16 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.30910000000000004
852391,merck to release findings from integrated analysis of six phase and clinical trials evaluating investigational elbasvirgrazoprevir in patients with chronic hepatitis c genotype or infection and compensated cirrhosis at the liver meeting,https://www.benzinga.com/news/15/11/5978928/merck-to-release-findings-from-integrated-analysis-of-six-phase-2-and-3-clinical-,Charles Gross,2015-11-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852392,merck announces presentation of phase results of investigational elbasvirgrazoprevir in people with chronic hepatitis c genotypes or infection who inject drugs and are on opioid agonist therapy,https://www.benzinga.com/news/15/11/5978927/merck-announces-presentation-of-phase-3-results-of-investigational-elbasvirgrazop,Charles Gross,2015-11-15 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852393,hearing unconfirmed market chatter of potential merck bid for celgene,https://www.benzinga.com/news/15/11/5978021/hearing-unconfirmed-market-chatter-of-potential-merck-bid-for-celgene,Charles Gross,2015-11-13 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.436
852394,merck issues update on reveal outcomes sutdy,https://www.benzinga.com/news/15/11/5977660/merck-issues-update-on-reveal-outcomes-sutdy,Paul Quintaro,2015-11-13 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852395,merck issues statement regarding cubicin patent litigation says reviewing decision considering next steps,https://www.benzinga.com/news/15/11/5976133/merck-issues-statement-regarding-cubicin-patent-litigation-says-reviewing-decisio,Charles Gross,2015-11-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.39885
852396,patient in brazil being tested for ebola year old man came from guniea reuters,https://www.benzinga.com/news/15/11/5973986/patient-in-brazil-being-tested-for-ebola-46-year-old-man-came-from-guniea-reuters,Charles Gross,2015-11-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852397,who declares sierra leone ebolafree,https://www.benzinga.com/news/15/11/5967909/who-declares-sierra-leone-ebola-free,Charles Gross,2015-11-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852398,update merck says we believe that bridion has the potential to offer anesthesia professionals an important new option to reverse neuromuscular blockade in the surgical setting,https://www.benzinga.com/news/15/11/5966951/update-merck-says-we-believe-that-bridion-has-the-potential-to-offer-anesthesia-p,Paul Quintaro,2015-11-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.60115
852399,merck issues statement on fda panel meeting for bridion,https://www.benzinga.com/news/15/11/5966950/merck-issues-statement-on-fda-panel-meeting-for-bridion,Paul Quintaro,2015-11-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852400,fda panel votes in favor of merck presenting sufficient data to characterize risk of hypersensitivity with sugammadex reuters,https://www.benzinga.com/news/15/11/5966867/fda-panel-votes-13-1-in-favor-of-merck-presenting-sufficient-data-to-characterize,Charles Gross,2015-11-06 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.57655
852401,are you investing like a millennial or a baby boomer,https://www.benzinga.com/media/cnbc/15/11/5964355/are-you-investing-like-a-millennial-or-a-baby-boomer,Javier Hasse,2015-11-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6806
852402,merck announces samsung bioepis will present new biosimilars data at the acrarhp annual meeting,https://www.benzinga.com/news/15/11/5963433/merck-announces-samsung-bioepis-will-present-new-biosimilars-data-at-the-2015-acr,Hal Lindon,2015-11-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852403,merck pfizer report initiation of phase iii firstline trial of avelumab,https://www.benzinga.com/news/15/11/5960164/merck-pfizer-report-initiation-of-phase-iii-first-line-trial-of-avelumab,Paul Quintaro,2015-11-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852404,gsk merck to study immunotherapy combination as potential cancer treatment,https://www.benzinga.com/news/15/11/5957013/gsk-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment,Hal Lindon,2015-11-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
852405,merck receives breakthrough therapy designation from usfda for keytrudar pembrolizumab in advanced colorectal cancer,https://www.benzinga.com/news/15/11/5954836/merck-receives-breakthrough-therapy-designation-from-u-s-fda-for-keytruda-r-pembr,Eddie Staley,2015-11-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.23665000000000003
852406,these three pharma giants just crushed earnings,https://www.benzinga.com/news/earnings/15/10/5944808/these-three-pharma-giants-just-crushed-earnings,Jayson Derrick,2015-10-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.28925
852407,update merck sees fy sales bb vs b est,https://www.benzinga.com/news/15/10/5944147/update-merck-sees-fy15-sales-39-2b-39-8b-vs-39-67b-est,Paul Quintaro,2015-10-27 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852408,merck sees fy eps to vs est,https://www.benzinga.com/news/15/10/5944012/merck-sees-fy-eps-3-55-to-3-60-vs-3-51-est,Paul Quintaro,2015-10-27 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852409,merck reports q eps vs est rev b vs est b,https://www.benzinga.com/news/earnings/15/10/5944004/merck-reports-q3-eps-0-96-vs-est-0-92-rev-10-073b-vs-est-10-08b,Hal Lindon,2015-10-27 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852410,earnings scheduled for october ,https://www.benzinga.com/news/earnings/15/10/5943734/earnings-scheduled-for-october-27-2015,Monica Gerson,2015-10-27 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852411,earnings boom this week big pharma ecommerce giant baba and more,https://www.benzinga.com/general/biotech/15/10/5943039/earnings-boom-this-week-big-pharma-e-commerce-giant-baba-and-more,The Ticker Tape,2015-10-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852412,fed meeting a midweek bump in flurry of earnings news,https://www.benzinga.com/trading-ideas/previews/15/10/5942932/fed-meeting-a-mid-week-bump-in-flurry-of-earnings-news,The Ticker Tape,2015-10-26 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852413,mercks keytruda shows superior overall survival compared to chemotherapy in patients with previously treated advanced nonsmall cell lung cancer whose tumors express pdl,https://www.benzinga.com/news/15/10/5942279/mercks-keytruda-shows-superior-overall-survival-compared-to-chemotherapy-in-patie,Hal Lindon,2015-10-26 00:00:00,MRK,1,0,1,1,1,1,1,0,1,0.5129
852414,merck trading higher off of abbvie gilead fda comments up on the day at share,https://www.benzinga.com/movers/15/10/5938372/merck-trading-higher-off-of-abbvie-gilead-fda-comments-up-3-62-on-the-day-at-52,Hal Lindon,2015-10-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852415,biotech etfs get more refined with debut of cancer immunotherapy fund,https://www.benzinga.com/general/biotech/15/10/5913057/biotech-etfs-get-more-refined-with-debut-of-cancer-immunotherapy-fund,ETF Professor,2015-10-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
852416,nurse who contracted ebola in west africa now critically ill from complications bbc,https://www.benzinga.com/news/15/10/5913037/nurse-who-contracted-ebola-in-west-africa-now-critically-ill-from-complications-b,Charles Gross,2015-10-14 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.28925
852417,tianjin cansino biotechnology to mass produce ebola vaccine xinhua,https://www.benzinga.com/news/15/10/5911012/tianjin-cansino-biotechnology-to-mass-produce-ebola-vaccine-xinhua,Charles Gross,2015-10-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852418,incyte merck increase clinical collaboration to include phase study investigating the combination of epacadostat with keytrudaas firstline treatment for advanced melanoma,https://www.benzinga.com/news/15/10/5907395/incyte-merck-increase-clinical-collaboration-to-include-phase-3-study-investigati,Hal Lindon,2015-10-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
852419,incyte and merck expand clinical collaboration to include phase study investigating the combination of epacadostat with keytruda pembrolizumab as firstline treatment for advanced melanoma,https://www.benzinga.com/news/15/10/5907392/incyte-and-merck-expand-clinical-collaboration-to-include-phase-3-study-investiga,Paul Quintaro,2015-10-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
852420,watching volatility in other big pharma names amid eli lilly halt,https://www.benzinga.com/general/biotech/15/10/5904403/watching-volatility-in-other-big-pharma-names-amid-eli-lilly-halt,Hal Lindon,2015-10-12 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852421,who says nigerian suspected of dying from ebola did not have the virus reuters,https://www.benzinga.com/news/15/10/5901345/who-says-nigerian-suspected-of-dying-from-ebola-did-not-have-the-virus-reuters,Charles Gross,2015-10-09 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.38685
852422,keytruda pembrolizumab receives new draft recommendation from national institute for health and care excellence nice in uk for firstline treatment for advanced melanoma,https://www.benzinga.com/news/15/10/5901094/keytruda-pembrolizumab-receives-new-draft-recommendation-from-national-institute-,Paul Quintaro,2015-10-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.9511000000000001
852423,ten people quarantined due to possible ebola cases in nigerias calabar city,https://www.benzinga.com/news/15/10/5899516/ten-people-quarantined-due-to-possible-ebola-cases-in-nigerias-calabar-city,Charles Gross,2015-10-08 00:00:00,MRK,1,1,1,0,0,1,1,1,1,0.5
852424,dynavax reports initiation of immunooncology clinical trial of sd in combo with mercks keytruda,https://www.benzinga.com/news/15/10/5897321/dynavax-reports-initiation-of-immuno-oncology-clinical-trial-of-sd-101-in-combo-w,Paul Quintaro,2015-10-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852425,guinea liberia sierra leone see no new cases for week to october reuters,https://www.benzinga.com/news/15/10/5895411/guinea-liberia-sierra-leone-see-no-new-cases-for-week-to-october-4-reuters,Charles Gross,2015-10-07 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.352
852426,merck kgaa darmstadt germany and pfizer announce investigational immunotherapy avelumab given fda fast track designation for metastatic merkel cell carcinoma,https://www.benzinga.com/news/15/10/5893561/merck-kgaa-darmstadt-germany-and-pfizer-announce-investigational-immunotherapy-av,Hal Lindon,2015-10-07 00:00:00,MRK,1,0,0,1,1,0,1,1,0,0.5
852427,agilent company dako announces fda approval of new companion diagnostic for lung cancer,https://www.benzinga.com/news/15/10/5885936/agilent-company-dako-announces-fda-approval-of-new-companion-diagnostic-for-lung-,Charles Gross,2015-10-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3409
852428,merck pr confirms fda approves keytruda for the treatment of patients with metastatic nonsmall cell lung cancer whose tumors express pdl with disease progression on or after platinumcontaining chemotherapy,https://www.benzinga.com/news/15/10/5884595/merck-pr-confirms-fda-approves-keytruda-for-the-treatment-of-patients-with-metast,Hal Lindon,2015-10-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.29905000000000004
852429,bristolmyers spikes to high following fda approval of mercks keytruda,https://www.benzinga.com/news/15/10/5884489/bristol-myers-spikes-to-high-following-fda-approval-of-mercks-keytruda,Charles Gross,2015-10-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
852430,fda approves mercks keytruda for advanced nonsmall cell lung cancer,https://www.benzinga.com/news/15/10/5884459/fda-approves-mercks-keytruda-for-advanced-non-small-cell-lung-cancer,Charles Gross,2015-10-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.41105
852431,merck dnatrix report phase immunooncology partnership in patients with aggressive form of brain cancer,https://www.benzinga.com/news/15/10/5879933/merck-dnatrix-report-phase-2-immuno-oncology-partnership-in-patients-with-aggress,Hal Lindon,2015-10-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.14079999999999998
852432,roth capital upgrades ani pharmaceuticals to buy on valuation,https://www.benzinga.com/analyst-ratings/analyst-color/15/09/5869797/roth-capital-upgrades-ani-pharmaceuticals-to-buy-on-valu,Javier Hasse,2015-09-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852433,merck syndax pharma announce first patients dosed in phase b trial of entinostat keytruda,https://www.benzinga.com/news/15/09/5868370/merck-syndax-pharma-announce-first-patients-dosed-in-phase-1b2-trial-of-entinosta,Paul Quintaro,2015-09-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852434,merck reports japans pmda approved marizev mg tablets,https://www.benzinga.com/news/15/09/5868129/merck-reports-japans-pmda-approved-marizev-25-12-5mg-tablets,Paul Quintaro,2015-09-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
852435,merck announces new data from keynote trial evaluating keytruda across range of cancer types presented at ecc,https://www.benzinga.com/news/15/09/5867299/merck-announces-new-data-from-keynote-028-trial-evaluating-keytruda-across-range-,Charles Gross,2015-09-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
852436,merck presents new findings showing antitumor activity of keytruda in patients with advanced npc,https://www.benzinga.com/news/15/09/5867064/merck-presents-new-findings-showing-anti-tumor-activity-of-keytruda-in-patients-w,Charles Gross,2015-09-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
852437,merck pfizer reports fda orphan drug designation for investigation avelumab,https://www.benzinga.com/news/15/09/5864930/merck-pfizer-reports-fda-orphan-drug-designation-for-investigation-avelumab,Paul Quintaro,2015-09-25 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852438,merck and pfizer collaborate with dako an agilent technologies company on development of companion diagnostic for investigational antipdl antibody avelumab,https://www.benzinga.com/news/15/09/5864061/merck-and-pfizer-collaborate-with-dako-an-agilent-technologies-company-on-develop,Paul Quintaro,2015-09-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852439,ani pharmaceuticals to acquire two ndas from merck for m,https://www.benzinga.com/news/15/09/5852194/ani-pharmaceuticals-to-acquire-two-ndas-from-merck-for-75m,Paul Quintaro,2015-09-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852440,data in nine difficulttotreat cancers from mercks keytruda development program to be presented at european cancer congress ,https://www.benzinga.com/news/15/09/5852157/data-in-nine-difficult-to-treat-cancers-from-mercks-keytruda-development-program-,Paul Quintaro,2015-09-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
852441,mercks bezlotoxumab met primary endpoint in phase studies,https://www.benzinga.com/news/15/09/5851270/mercks-bezlotoxumab-met-primary-endpoint-in-phase-3-studies,Charles Gross,2015-09-20 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852442,update merck phase primary efficacy endpoint was similar across both relebactam groups along with placebo group all or higher,https://www.benzinga.com/news/15/09/5850349/update-merck-phase-2-primary-efficacy-endpoint-was-similar-across-both-relebactam,Hal Lindon,2015-09-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852443,merck offers results from phase study of investigational betalactamase inhibitor at icaacicc met primary endpoint,https://www.benzinga.com/news/15/09/5850343/merck-offers-results-from-phase-2-study-of-investigational-beta-lactamase-inhibit,Paul Quintaro,2015-09-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.4614
852444,eli lillys home run is jardiance says morgan stanley,https://www.benzinga.com/analyst-ratings/analyst-color/15/09/5849393/eli-lillys-home-run-is-jardiance-says-morgan-stanley,J.D. Singh,2015-09-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852445,merck to submit applications to us for approval of ertugliflozin by end of ,https://www.benzinga.com/news/15/09/5846222/merck-to-submit-applications-to-u-s-for-approval-of-ertugliflozin-by-end-of-2016,Paul Quintaro,2015-09-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
852446,merck provides diabetes portfolio update and underscores comprehensive longterm commitment to patients with diabetes,https://www.benzinga.com/news/15/09/5846152/merck-provides-diabetes-portfolio-update-and-underscores-comprehensive-long-term-,Hal Lindon,2015-09-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
852447,merck offers highlights for commitment to infectious disease with presentations of data at icaacicc ,https://www.benzinga.com/news/15/09/5842196/merck-offers-highlights-for-commitment-to-infectious-disease-with-40-presentation,Paul Quintaro,2015-09-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
852448,amgen and biogen lead short interest surge in biotechs,https://www.benzinga.com/general/biotech/15/09/5834103/amgen-and-biogen-lead-short-interest-surge-in-biotechs,Nelson Hem,2015-09-14 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.7294
852449,merck samsung bioepis report approval of brenzys a biosimilar of enbrel in korea,https://www.benzinga.com/news/15/09/5820065/merck-samsung-bioepis-report-approval-of-brenzys-a-biosimilar-of-enbrel-in-korea,Hal Lindon,2015-09-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
852450,mkm partners would sell these healthcare stocks on weaker relative trends,https://www.benzinga.com/analyst-ratings/analyst-color/15/09/5819760/mkm-partners-would-sell-these-healthcare-stocks-on-weake,Hal Lindon,2015-09-08 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.2798
852451,sierra leone to vaccinate people who came in contact with latest ebola victim reuters,https://www.benzinga.com/news/15/09/5811781/sierra-leone-to-vaccinate-200-people-who-came-in-contact-with-latest-ebola-victim,Charles Gross,2015-09-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3634
852452,fda approves pediatric indication for emend aprepitant capsules in combination with other antiemetic agents,https://www.benzinga.com/news/15/09/5809664/fda-approves-pediatric-indication-for-emend-aprepitant-capsules-in-combination-wi,Paul Quintaro,2015-09-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
852453,organovo ceo keith murphy people are missing the forest for the trees,https://www.benzinga.com/general/biotech/15/09/5807328/organovos-keith-murphy-people-are-missing-the-forest-for-the-trees,Jim Probasco,2015-09-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.352
852454,its not shopping its market research talking investing trends with td ameritrades nicole sherrod,https://www.benzinga.com/be-your-own-boss/15/09/5799678/its-not-shopping-its-market-research-talking-investing-trends-with-td,Rebecca Sheppard,2015-09-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852455,hearing buyside volume coming into staples drug and chemical names,https://www.benzinga.com/news/15/09/5807749/hearing-buyside-volume-coming-into-staples-drug-and-chemical-names,Paul Quintaro,2015-09-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852456,new analyses from the improveit study with vytorin ezetimibe and simvastatin,https://www.benzinga.com/news/15/09/5806257/new-analyses-from-the-improve-it-study-with-vytorin-ezetimibe-and-simvastatin,Paul Quintaro,2015-09-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852457,barrons recap whats next,https://www.benzinga.com/media/barrons/15/08/5801158/barrons-recap-whats-next,Nelson Hem,2015-08-30 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852458,sierra leone released its last confirmed ebola patient from hospital on monday reuters,https://www.benzinga.com/news/15/08/5787014/sierra-leone-released-its-last-confirmed-ebola-patient-from-hospital-on-monday-re,Charles Gross,2015-08-24 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.5
852459,new analyses from the improveit outcomes study of vytorin and the tecos cardiovascular safety trial of januvia will be presented at the european society of cardiology congress,https://www.benzinga.com/news/15/08/5779352/new-analyses-from-the-improve-it-outcomes-study-of-vytorin-and-the-tecos-cardiova,Eddie Staley,2015-08-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
852460,fda accepts supplemental biologics license application for keytruda mercks antipd therapy for firstline treatment of advanced melanoma and grants priority review,https://www.benzinga.com/news/15/08/5773075/fda-accepts-supplemental-biologics-license-application-for-keytruda-mercks-anti-p,Eddie Staley,2015-08-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81845
852461,calls of note wall street research moving the market on thursday,https://www.benzinga.com/analyst-ratings/analyst-color/15/08/5764144/calls-of-note-wall-street-research-moving-the-market-on-,Jayson Derrick,2015-08-13 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852462,what are payors saying about managed care giants,https://www.benzinga.com/analyst-ratings/analyst-color/15/08/5763534/what-are-payors-saying-about-managed-care-giants,Monica Gerson,2015-08-13 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.74695
852463,good data may be coming for merck and this analyst is bullish,https://www.benzinga.com/analyst-ratings/analyst-color/15/08/5763420/good-data-may-be-coming-for-merck-and-this-analyst-is-bu,Monica Gerson,2015-08-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
852464,benzingas top upgrades,https://www.benzinga.com/analyst-ratings/upgrades/15/08/5763419/benzingas-top-upgrades,Monica Gerson,2015-08-13 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.60115
852465,us stock futures rise ahead of jobless claims retail sales data,https://www.benzinga.com/news/15/08/5762771/us-stock-futures-rise-ahead-of-jobless-claims-retail-sales-data,Monica Gerson,2015-08-13 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852466,bmo capital upgrades merck co to outperform raises pt to ,https://www.benzinga.com/news/15/08/5762491/bmo-capital-upgrades-merck-co-to-outperform-raises-pt-to-70-00,Paul Quintaro,2015-08-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852467,sigmaaldrich merck darmstadt germany report antitrust approval in brazil for planned purchase,https://www.benzinga.com/news/15/08/5754661/sigma-aldrich-merck-darmstadt-germany-report-antitrust-approval-in-brazil-for-pla,Paul Quintaro,2015-08-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
852468,heres which it stocks benefit from healthcare ma,https://www.benzinga.com/analyst-ratings/analyst-color/15/08/5751903/heres-which-it-stocks-benefit-from-healthcare-m-a,Wayne Duggan,2015-08-10 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.7294
852469,alks partner torii pharmaceutical reports positive phase iiiii trial results for japanese cedar slittablet,https://www.benzinga.com/news/15/08/5746257/alks-partner-torii-pharmaceutical-reports-positive-phase-iiiii-trial-results-for-,Charles Gross,2015-08-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
852470,guinea sierra leone each recorded single cases of ebola in past week who says risks remain reuters,https://www.benzinga.com/news/15/08/5732493/guinea-sierra-leone-each-recorded-single-cases-of-ebola-in-past-week-says-risks-r,Charles Gross,2015-08-04 00:00:00,MRK,1,1,1,0,1,0,1,1,1,0.3634
852471,morning market gainers,https://www.benzinga.com/news/15/08/5732266/morning-market-gainers,Lisa Levin,2015-08-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852472,codexis reports codeevolver technology transfer license deal with merck will receive up to m upfront payment eligibile for up to m in milestones,https://www.benzinga.com/news/15/08/5729661/codexis-reports-codeevolver-technology-transfer-license-deal-with-merck-will-rece,Paul Quintaro,2015-08-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852473,merck announces global collaboration enabled vaccine for ebola will move from firstinhuman to initial phase results within one year,https://www.benzinga.com/news/15/07/5723671/merck-announces-global-collaboration-enabled-vaccine-for-ebola-will-move-from-fir,Paul Quintaro,2015-07-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852474,who says initial results from mercknewlink vsvebov ebola vaccine look promising reuters,https://www.benzinga.com/news/15/07/5723285/who-says-initial-results-from-mercknewlink-vsv-ebov-ebola-vaccine-look-promising-,Charles Gross,2015-07-31 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
852475,merck q profit beats estimates,https://www.benzinga.com/news/earnings/15/07/5708962/merck-q2-profit-beats-estimates,Monica Gerson,2015-07-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
852476,update merck sees fy adj eps vs est,https://www.benzinga.com/news/15/07/5708789/update-merck-sees-fy15-adj-eps-3-45-3-55-vs-3-45-est,Paul Quintaro,2015-07-28 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852477,merck narrows raises fy adj eps outlook,https://www.benzinga.com/news/earnings/15/07/5708787/merck-narrows-raises-fy15-adj-eps-outlook,Paul Quintaro,2015-07-28 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852478,merck reports q adj eps vs est sales b inline,https://www.benzinga.com/news/earnings/15/07/5708694/merck-reports-q2-adj-eps-0-86-vs-0-81-est-sales-9-8b-inline,Paul Quintaro,2015-07-28 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852479,merck boosts immunooncology portfolio with acquisition of ccam biotherapeutics,https://www.benzinga.com/news/15/07/5708624/merck-boosts-immuno-oncology-portfolio-with-acquisition-of-ccam-biotherapeutics,Hal Lindon,2015-07-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
852480,merck announces fda priority review for nda for hepatits c treatment,https://www.benzinga.com/news/15/07/5708591/merck-announces-fda-priority-review-for-nda-for-hepatits-c-treatment,Paul Quintaro,2015-07-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852481,earnings scheduled for july ,https://www.benzinga.com/news/earnings/15/07/5708328/earnings-scheduled-for-july-28-2015,Monica Gerson,2015-07-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852482, stocks you should be watching today,https://www.benzinga.com/news/earnings/15/07/5708297/10-stocks-you-should-be-watching-today,Monica Gerson,2015-07-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852483,dollar plagues pharma earnings but did street get it right,https://www.benzinga.com/news/earnings/15/07/5706466/dollar-plagues-pharma-earnings-but-did-street-get-it-right,TD Ameritrade,2015-07-27 00:00:00,MRK,1,1,1,1,1,1,1,1,0,0.5
852484,merck receives positive chmp opinion for investigational antibiotic zerbaxa,https://www.benzinga.com/news/15/07/5705101/merck-receives-positive-chmp-opinion-for-investigational-antibiotic-zerbaxa,Hal Lindon,2015-07-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
852485,msd reports european medicines agency acceptance of marketing authorisation application for grazoprevirelbasvir an investigational therapy for treatment of chronic hepatitis c infection,https://www.benzinga.com/news/15/07/5698272/msd-reports-european-medicines-agency-acceptance-of-marketing-authorisation-appli,Hal Lindon,2015-07-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
852486,rana therapeutics announces million in oversubscribed series b financing led by merck,https://www.benzinga.com/news/15/07/5696562/rana-therapeutics-announces-55-million-in-oversubscribed-series-b-financing-led-b,Charles Gross,2015-07-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852487,whats coming for largecap pharma stocks this earnings season,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5693254/whats-coming-for-large-cap-pharma-stocks-this-earnings-s,Wayne Duggan,2015-07-22 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852488,european commission approves msds antipd therapy keytruda pembrolizumab for both firstline and previouslytreated patients with advanced melanoma,https://www.benzinga.com/news/15/07/5692076/european-commission-approves-msds-anti-pd-1-therapy-keytruda-pembrolizumab-for-bo,Eddie Staley,2015-07-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7859499999999999
852489,strong dollar not so good for johnson johnson earnings,https://www.benzinga.com/general/health-care/15/07/5664205/strong-dollar-not-so-good-for-johnson-johnson-earnings,The Ticker Tape,2015-07-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.53495
852490,barclays expects ma in specialty pharma to continue likes valeant and jazz,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5660474/barclays-expects-m-a-in-specialty-pharma-to-continue-lik,Jayson Derrick,2015-07-09 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.71075
852491,allergan merck enter licensing agreement to obtain exclusive worldwide rights to cgrp migraine development program,https://www.benzinga.com/news/15/07/5651874/allergan-merck-enter-licensing-agreement-to-obtain-exclusive-worldwide-rights-to-,Hal Lindon,2015-07-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7859499999999999
852492, top sell ideas from oppenheimers technical analysis division,https://www.benzinga.com/analyst-ratings/analyst-color/15/07/5649868/9-top-sell-ideas-from-oppenheimers-technical-analysis-di,Wayne Duggan,2015-07-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852493,merck announces phase study of singledose emend fosaprepitant dimeglumine for injection regimen met primary endpoint,https://www.benzinga.com/news/15/06/5631481/merck-announces-phase-3-study-of-single-dose-emend-fosaprepitant-dimeglumine-for-,Eddie Staley,2015-06-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852494,barrons recap airline stocks ready to soar,https://www.benzinga.com/media/barrons/15/06/5610888/barrons-recap-airline-stocks-ready-to-soar,Nelson Hem,2015-06-21 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.6806
852495,barrons says merck shares could rise more than to ,https://www.benzinga.com/news/15/06/5610909/barrons-says-merck-shares-could-rise-more-than-20-to-70,Charles Gross,2015-06-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852496,hearing dept of justice has said mercks inspire pharma to pay m to settle civil claims of fraud,https://www.benzinga.com/news/15/06/5603603/hearing-dept-of-justice-has-said-mercks-inspire-pharma-to-pay-5-9m-to-settle-civi,Paul Quintaro,2015-06-17 00:00:00,MRK,1,2,0,1,0,1,1,0,1,0.7202
852497,the note moving pharma giants today,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5603207/the-note-moving-pharma-giants-today,John Seward,2015-06-17 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852498,organovo has upside to share cantor fitzgerald says,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5602001/organovo-has-upside-to-6share-cantor-fitzgerald-says,Monica Gerson,2015-06-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852499,piper jaffray initiates coverage on merck co at neutral,https://www.benzinga.com/news/15/06/5601232/piper-jaffray-initiates-coverage-on-merck-co-at-neutral,Eddie Staley,2015-06-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852500,benzingas ma chatter for tuesday june ,https://www.benzinga.com/news/15/06/5600252/benzingas-m-a-chatter-for-tuesday-june-16-2015,Charles Gross,2015-06-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852501,new report abbvie is jefferies top global pharma stock,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5599077/new-report-abbvie-is-jefferies-top-global-pharma-stock,Wayne Duggan,2015-06-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852502,alkermes declines comment on rumored potential bid from merck,https://www.benzinga.com/news/15/06/5598913/alkermes-declines-comment-on-rumored-potential-bid-from-merck,Charles Gross,2015-06-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852503,alkermes shares off the highs shares moving higher on takeover chatter upcoming presentation of data from latestage cns portfolio,https://www.benzinga.com/news/15/06/5598682/alkermes-shares-off-the-highs-shares-moving-higher-on-takeover-chatter-upcoming-p,Charles Gross,2015-06-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.76335
852504,hearing merck approached dublin based alkermes with b offermarket sources,https://www.benzinga.com/news/15/06/5598534/hearing-merck-approached-dublin-based-alkermes-with-12-4b-offer-market-sources,Hal Lindon,2015-06-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852505,jmp sees a negative market tone in biotechnology,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5595054/jmp-sees-a-negative-market-tone-in-biotechnology,Wayne Duggan,2015-06-15 00:00:00,MRK,1,1,0,1,1,0,1,0,0,0.21405000000000002
852506,merck samsung bioepis report pivotal phase studies for investigational biosimilars sb enbrel etanercept and sb remicade infliximab met primary endpoints,https://www.benzinga.com/news/15/06/5583235/merck-samsung-bioepis-report-pivotal-phase-3-studies-for-investigational-biosimil,Hal Lindon,2015-06-10 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852507,us stock futures signal higher start on wall street,https://www.benzinga.com/news/15/06/5582772/us-stock-futures-signal-higher-start-on-wall-street,Monica Gerson,2015-06-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852508,merck publishes alks data on phase ii house dust mite slittablet in leading allergy journal,https://www.benzinga.com/news/15/06/5582763/merck-publishes-alks-data-on-phase-ii-house-dust-mite-slit-tablet-in-leading-alle,Hal Lindon,2015-06-10 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852509,tecos mercks cardiovascular safety trial of januvia met primary endpoint in patients with type diabetes,https://www.benzinga.com/news/15/06/5582683/tecos-mercks-cardiovascular-safety-trial-of-januvia-met-primary-endpoint-in-patie,Eddie Staley,2015-06-10 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.71075
852510,benzingas ma chatter for monday june ,https://www.benzinga.com/news/15/06/5577830/benzingas-m-a-chatter-for-monday-june-8-2015,Charles Gross,2015-06-08 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852511,tecos mercks cardiovascular safety trial of januvia met primary endpoint in patients with type diabetes,https://www.benzinga.com/news/15/06/5577295/tecos-mercks-cardiovascular-safety-trial-of-januvia-met-primary-endpoint-in-patie,Eddie Staley,2015-06-08 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.71075
852512,this technology could disrupt us pharma stocks credit suisse says,https://www.benzinga.com/analyst-ratings/analyst-color/15/06/5576612/this-technology-could-disrupt-u-s-pharma-stocks-credit-s,John Seward,2015-06-08 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.6909
852513,option alert celgene jun call contract trade above ask now ,https://www.benzinga.com/news/15/06/5576341/option-alert-celgene-jun-116-call-1000-contract-trade-above-ask-1-14,Charles Gross,2015-06-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852514,update celgene shares at high following early rumored bid from merck,https://www.benzinga.com/news/15/06/5576323/update-celgene-shares-at-high-following-early-rumored-bid-from-merck,Charles Gross,2015-06-08 00:00:00,MRK,1,0,0,1,1,0,1,1,1,0.648
852515,hearing unconfirmed market chatter of potential merck bid for celgene,https://www.benzinga.com/news/15/06/5576096/hearing-unconfirmed-market-chatter-of-potential-merck-bid-for-celgene,Charles Gross,2015-06-08 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.436
852516,merck kgaa darmstadt germany illumina and genea create the global fertility alliance for excellence in assisted reproductive treatment,https://www.benzinga.com/news/15/06/5574617/merck-kgaa-darmstadt-germany-illumina-and-genea-create-the-global-fertility-allia,Hal Lindon,2015-06-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.86755
852517,alk announces mercks north american phase iii trial of house dust mite slittablet meets primary endpoint,https://www.benzinga.com/news/15/06/5567069/alk-announces-mercks-north-american-phase-iii-trial-of-house-dust-mite-slit-table,Charles Gross,2015-06-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852518,merck announces results from investigational improveit study of vytorin published in nejom,https://www.benzinga.com/news/15/06/5566412/merck-announces-results-from-investigational-improve-it-study-of-vytorin-publishe,Paul Quintaro,2015-06-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852519,merck reports acceptance of sbal for keytruda in advanced nonsmall cell lung cancer priority review granted,https://www.benzinga.com/news/15/06/5558068/merck-reports-acceptance-of-sbal-for-keytruda-in-advanced-non-small-cell-lung-can,Paul Quintaro,2015-06-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.57655
852520,merck dynavax partner on investigating combination of immunooncology therapies,https://www.benzinga.com/news/15/06/5555752/merck-dynavax-partner-on-investigating-combination-of-immuno-oncology-therapies,Hal Lindon,2015-06-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852521,merck announces new data on breadth of keytruda at asco antitumor activity now shown in different tumor types,https://www.benzinga.com/news/15/06/5555584/merck-announces-new-data-on-breadth-of-keytruda-at-asco-anti-tumor-activity-now-s,Paul Quintaro,2015-06-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.30910000000000004
852522,tesaro merck to collaborate on combination study of niraparib keytruda,https://www.benzinga.com/news/15/05/5554207/tesaro-merck-to-collaborate-on-combination-study-of-niraparib-keytruda,Charles Gross,2015-05-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852523,merck shares spike higher following report on study evaluating dna mismatch repair as genetic guide for immunotherapy treatment with keytruda,https://www.benzinga.com/news/15/05/5552927/merck-shares-spike-higher-following-report-on-study-evaluating-dna-mismatch-repai,Charles Gross,2015-05-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852524,merck shares spiking higher on durable antitumor activity with keytruda,https://www.benzinga.com/news/15/05/5552923/merck-shares-spiking-higher-on-durable-anti-tumor-activity-with-keytruda,Hal Lindon,2015-05-29 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.648
852525,initial study evaluating dna mismatch repair as genetic guide for immunotherapy treatment with mercks keytruda pembrolizumab showcased at asco annual meeting and published in the new england journal of medicine,https://www.benzinga.com/news/15/05/5552893/initial-study-evaluating-dna-mismatch-repair-as-genetic-guide-for-immunotherapy-t,Hal Lindon,2015-05-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852526,amgen merck report expansion of collaboration to support studies of talimogene laherparepvec in combo with keytruda in patients with head and neck cancer,https://www.benzinga.com/news/15/05/5551546/amgen-merck-report-expansion-of-collaboration-to-support-studies-of-talimogene-la,Paul Quintaro,2015-05-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.29905000000000004
852527,merck announces has submitted nda for grazoprevirelbasvir in us,https://www.benzinga.com/news/15/05/5549836/merck-announces-has-submitted-nda-for-grazoprevirelbasvir-in-us,Paul Quintaro,2015-05-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852528,option alert merck may call contract trade at ask now ,https://www.benzinga.com/markets/options/15/05/5540516/option-alert-merck-may-29-60-call-6682-contract-trade-at-ask-0-11,Charles Gross,2015-05-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852529,expert explains how to play merck in charts,https://www.benzinga.com/analyst-ratings/analyst-color/15/05/5532515/expert-explains-how-to-play-merck-in-2-charts,Javier Hasse,2015-05-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.67
852530,merck release confirms chmp positive recommendation for keytruda,https://www.benzinga.com/news/15/05/5534459/merck-release-confirms-chmp-positive-recommendation-for-keytruda,Paul Quintaro,2015-05-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
852531,ema gives positive opinion for mercks melanoma drug keytruda,https://www.benzinga.com/news/15/05/5534406/ema-gives-positive-opinion-for-mercks-melanoma-drug-keytruda,Charles Gross,2015-05-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
852532,gsk newlink vaccine trials may not produce useful efficacy data as ebola disappears in w africa reuters,https://www.benzinga.com/news/15/05/5501457/gsk-newlink-vaccine-trials-may-not-produce-useful-efficacy-data-as-ebola-disappea,Charles Gross,2015-05-12 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.20665
852533,credit suisse we prefer pfizer bristol over pharma peers,https://www.benzinga.com/analyst-ratings/analyst-color/15/05/5476290/credit-suisse-we-prefer-pfizer-bristol-over-pharma-peers,Mark Meadows,2015-05-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
852534,hearing unconfirmed market chatter of potential merck bid for lilly,https://www.benzinga.com/news/15/05/5467343/hearing-unconfirmed-market-chatter-of-potential-merck-bid-for-lilly,Charles Gross,2015-05-01 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.436
852535,bank of america reviews gilead earnings,https://www.benzinga.com/analyst-ratings/analyst-color/15/05/5466821/bank-of-america-reviews-gilead-earnings,Zoheb Sait,2015-05-01 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852536,whats wall street been saying about gilead lately,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5456231/whats-wall-street-been-saying-about-gilead-lately,Jayson Derrick,2015-04-29 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852537,morning market gainers,https://www.benzinga.com/news/15/04/5450441/morning-market-gainers,Lisa Levin,2015-04-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852538,bank of america on merck magniftecos,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5450288/bank-of-america-on-merck-magnif-tecos,Jayson Derrick,2015-04-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852539,benzingas top premarket gainers,https://www.benzinga.com/news/15/04/5449754/benzingas-top-premarket-gainers,Monica Gerson,2015-04-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852540,merck beats q estimates shares rise,https://www.benzinga.com/news/earnings/15/04/5449674/merck-beats-q1-estimates-shares-rise,Monica Gerson,2015-04-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852541,merck raises fy adj eps outlook from previously to vs est affirms sales outlook,https://www.benzinga.com/news/earnings/15/04/5449141/merck-raises-fy15-adj-eps-outlook-from-3-32-3-47-previously-to-3-35-3-48,Paul Quintaro,2015-04-28 00:00:00,MRK,1,0,0,0,0,1,1,1,1,0.5
852542,merck reports q eps vs est rev b vs est b,https://www.benzinga.com/news/earnings/15/04/5449093/merck-reports-q1-eps-0-85-vs-est-0-74-rev-9-4b-vs-est-8-99b,Hal Lindon,2015-04-28 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852543,earning economic calendar for thursday april ,https://www.benzinga.com/news/earnings/15/04/5448901/earning-economic-calendar-for-thursday-april-28-2015,Charles Gross,2015-04-28 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852544,earnings scheduled for april ,https://www.benzinga.com/news/earnings/15/04/5448618/earnings-scheduled-for-april-28-2015,Monica Gerson,2015-04-28 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
852545,merck offers results of trial evaluating cv outcomes with sitagliptin says met primary endpoint,https://www.benzinga.com/news/15/04/5447506/merck-offers-results-of-trial-evaluating-cv-outcomes-with-sitagliptin-says-met-pr,Paul Quintaro,2015-04-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852546,merck earnings the street and the crowd expect a doubledigit yearoveryear decline,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5445861/merck-earnings-the-street-and-the-crowd-expect-a-double-,Javier Hasse,2015-04-27 00:00:00,MRK,1,2,1,1,0,1,1,0,1,0.5
852547,does apple hide more cash abroad than anyone,https://www.benzinga.com/news/15/04/5442326/does-apple-hide-more-cash-abroad-than-anyone,Kevin Riley,2015-04-26 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.41105
852548,us tech dollar health care etfs to watch this week,https://www.benzinga.com/etfs/sector-etfs/15/04/5443314/u-s-tech-dollar-health-care-etfs-to-watch-this-week,David Fabian,2015-04-26 00:00:00,MRK,1,2,0,1,0,0,1,1,0,0.74695
852549,apple other earnings expected to dominate the week of april ,https://www.benzinga.com/news/earnings/15/04/5443526/apple-other-earnings-expected-to-dominate-the-week-of-april-27,Nelson Hem,2015-04-26 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.436
852550,morgan stanley alert gilead investors dont have the whole story,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5440630/morgan-stanley-alert-gilead-investors-dont-have-the-whol,Monica Gerson,2015-04-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852551,analyst biogen will miss on tecfidera sales no threat to gileads harvoni,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5439272/analyst-biogen-will-miss-on-tecfidera-sales-no-threat-to,John Seward,2015-04-24 00:00:00,MRK,1,2,1,1,0,1,1,1,0,0.13245
852552,mercks pivotal phase cedge program evaluating grazoprevirelbasvir shows high sustained virologic responses across broad range of patients with chronic hepatitis c virus infection,https://www.benzinga.com/news/15/04/5439930/mercks-pivotal-phase-3-c-edge-program-evaluating-grazoprevirelbasvir-shows-high-s,Charles Gross,2015-04-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852553,fda sentinel study finds no association between venous thromboembolism gardasil vaccination reuters,https://www.benzinga.com/news/15/04/5437308/fda-sentinel-study-finds-no-association-between-venous-thromboembolism-gardasil-v,Charles Gross,2015-04-23 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.352
852554,merck announces of patients in phase study of grazoprevirelbasvir achieved sustained virologic response,https://www.benzinga.com/news/15/04/5434817/merck-announces-99-of-patients-in-phase-23-study-of-grazoprevirelbasvir-achieved-,Charles Gross,2015-04-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852555,goat plague ppr affecting herds in africa asia reuters,https://www.benzinga.com/news/15/04/5432590/goat-plague-ppr-affecting-herds-in-africa-asia-reuters,Charles Gross,2015-04-22 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852556,update organovo shares rise following announcement of deal with merck,https://www.benzinga.com/news/15/04/5431030/update-organovo-shares-rise-15-following-announcement-of-deal-with-merck,Charles Gross,2015-04-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852557,organovo announces multiyear research collaboration agreement with merck sharp dohme corp,https://www.benzinga.com/news/15/04/5431016/organovo-announces-multi-year-research-collaboration-agreement-with-merck-sharp-d,Charles Gross,2015-04-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
852558,morgan stanley awaits this merck data,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5427122/morgan-stanley-awaits-this-merck-data,Monica Gerson,2015-04-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5386
852559,cart therapy stocks hit hard following aacr data,https://www.benzinga.com/general/biotech/15/04/5423290/car-t-therapy-stocks-hit-hard-following-aacr-data,Wayne Duggan,2015-04-20 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.44865
852560,merck will file totality of data regarding hep c drugs to fda wont limit fda filing to breakthrough status according to phonecall with vp infectious diseases eliav barr,https://www.benzinga.com/news/15/04/5423052/merck-will-file-totality-of-data-regarding-hep-c-drugs-to-fda-wont-limit-fda-fili,Paul Quintaro,2015-04-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852561,morning market gainers,https://www.benzinga.com/news/15/04/5422311/morning-market-gainers,Lisa Levin,2015-04-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852562,tetralogic announces co merck will collaborate related to evaluation of birinapant in combo with keytruda in solid tumors,https://www.benzinga.com/news/15/04/5421566/tetralogic-announces-co-merck-will-collaborate-related-to-evaluation-of-birinapan,Paul Quintaro,2015-04-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.57655
852563,early findings with mercks pembrolizumab in patients with advanced pleural mesothelioma presented at aacr annual meeting,https://www.benzinga.com/news/15/04/5420405/early-findings-with-mercks-pembrolizumab-in-patients-with-advanced-pleural-mesoth,Charles Gross,2015-04-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
852564,merck announces new data on treatment of advanced nsclc with pembrolizumab presented at aacr annual meeting published in nejm,https://www.benzinga.com/news/15/04/5420394/merck-announces-new-data-on-treatment-of-advanced-nsclc-with-pembrolizumab-presen,Charles Gross,2015-04-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
852565,early findings with keytruda in patients with advanced pleural mesothelioma presented at aacr annual meeting,https://www.benzinga.com/news/15/04/5420391/early-findings-with-keytruda-in-patients-with-advanced-pleural-mesothelioma-prese,Charles Gross,2015-04-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
852566,merck submits sbla to fda for keytruda in advanced nonsmall cell lung cancer,https://www.benzinga.com/news/15/04/5420348/merck-submits-sbla-to-fda-keytruda-in-advanced-non-small-cell-lung-cancer,Charles Gross,2015-04-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.23665000000000003
852567,its a big weekend for biotech,https://www.benzinga.com/general/biotech/15/04/5419376/its-a-big-weekend-for-biotech,Wayne Duggan,2015-04-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852568,suntrusts latest comments on merck,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5411600/suntrusts-latest-comments-on-merck,Jayson Derrick,2015-04-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852569,canine flu outbreak reported in chicago area wall street journal,https://www.benzinga.com/news/15/04/5410955/canine-flu-outbreak-reported-in-chicago-area-wall-street-journal,Charles Gross,2015-04-15 00:00:00,MRK,1,1,0,1,1,0,1,1,1,0.30910000000000004
852570,morgan stanleys major pharma q preview,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5407829/morgan-stanleys-major-pharma-q1-preview,Kevin Riley,2015-04-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852571,update phase iii trial of the merck and newlink genetics investigational ebola vaccine initiated in sierra leone,https://www.benzinga.com/news/15/04/5407146/update-phase-iii-trial-of-the-merck-and-newlink-genetics-investigational-ebola-va,Eddie Staley,2015-04-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852572,ebola vaccine trial begins in sierra leone,https://www.benzinga.com/news/15/04/5406423/ebola-vaccine-trial-begins-in-sierra-leone,Charles Gross,2015-04-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852573,biotech investors nomura says to watch these dates,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5398379/biotech-investors-nomura-says-to-watch-these-dates,Kevin Riley,2015-04-10 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852574,the biotech stocks jmp is watching,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5396461/the-biotech-stocks-jmp-is-watching,Monica Gerson,2015-04-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852575,advaxis merck report initiation of enrollment in phase study of adxspsa in combo with antipd therapy,https://www.benzinga.com/news/15/04/5389937/advaxis-merck-report-initiation-of-enrollment-in-phase-12-study-of-adxs-psa-in-co,Paul Quintaro,2015-04-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852576,grazoprevirelbasvir mercks investigational chronic hepatitis c therapy granted fda breakthrough therapy designations new phase data in multiple hcv patient types will be presented at the international liver congress tm ,https://www.benzinga.com/news/15/04/5389789/grazoprevirelbasvir-mercks-investigational-chronic-hepatitis-c-therapy-granted-fd,Hal Lindon,2015-04-08 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.625
852577,sector etfs and earnings,https://www.benzinga.com/etfs/sector-etfs/15/04/5384249/sector-etfs-and-earnings,Matthew McCall,2015-04-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852578,arvinas in strategic rd collaboration with merck to study novel protein degradation technology,https://www.benzinga.com/news/15/04/5385996/arvinas-in-strategic-r-d-collaboration-with-merck-to-study-novel-protein-degradat,Charles Gross,2015-04-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3634
852579,gilead alert what deutsche bank is saying,https://www.benzinga.com/analyst-ratings/analyst-color/15/04/5384237/gilead-alert-what-deutsche-bank-is-saying,Kevin Riley,2015-04-06 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.648
852580,merck shares teetering on the brink of a further downside correction,https://www.benzinga.com/trading-ideas/short-ideas/15/04/5382577/merck-shares-teetering-on-the-brink-of-a-further-downside-co,James Mecir,2015-04-06 00:00:00,MRK,1,1,0,1,0,0,1,0,1,0.5258
852581,top largecap stocks in the drug manufacturers industry with the highest roe,https://www.benzinga.com/trading-ideas/15/04/5382766/top-4-large-cap-stocks-in-the-drug-manufacturers-industry-with-the-highe,Monica Gerson,2015-04-06 00:00:00,MRK,1,0,0,1,1,0,1,1,1,0.60115
852582,syndax and merck to partner on immunooncology study evaluating entinostat in combination with keytruda pembrolizumab in lung cancer and melanoma,https://www.benzinga.com/news/15/03/5370313/syndax-and-merck-to-partner-on-immuno-oncology-study-evaluating-entinostat-in-com,Hal Lindon,2015-03-31 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
852583,ema recommends approval of mercks gardasil vaccine,https://www.benzinga.com/news/15/03/5362524/ema-recommends-approval-of-mercks-gardasil-9-vaccine,Charles Gross,2015-03-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8062
852584,merck announces deal with american diabetes association for education of adults with diabetes,https://www.benzinga.com/news/15/03/5359006/merck-announces-deal-with-american-diabetes-association-for-education-of-adults-w,Paul Quintaro,2015-03-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852585,key catalysts are coming for merck analyst predicts,https://www.benzinga.com/analyst-ratings/analyst-color/15/03/5356881/key-catalysts-are-coming-for-merck-analyst-predicts,Monica Gerson,2015-03-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852586,merck announces new b share repurchase program,https://www.benzinga.com/news/15/03/5353753/merck-announces-new-10b-share-repurchase-program,Eddie Staley,2015-03-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852587,mercks pivotal keynote study in firstline treatment for advanced melanoma met coprimary endpoints will be stopped early,https://www.benzinga.com/news/15/03/5351503/mercks-pivotal-keynote-006-study-in-first-line-treatment-for-advanced-melanoma-me,Hal Lindon,2015-03-24 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5129
852588,suntrust names eli lilly merck bristolmyers as favorite pharma firms,https://www.benzinga.com/analyst-ratings/analyst-color/15/03/5348881/suntrust-names-eli-lilly-merck-bristol-myers-as-favorite,Mark Meadows,2015-03-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7294
852589,option alert merck mar call contract trade above ask now ,https://www.benzinga.com/markets/options/15/03/5341306/option-alert-merck-mar-57-5-call-4200-contract-trade-above-ask-0-25,Charles Gross,2015-03-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852590,merck announced results from investigational improveit study that shows vytorin reduced total cardiovascular events by vs simvastatin,https://www.benzinga.com/news/15/03/5330241/merck-announced-results-from-investigational-improve-it-study-that-shows-vytorin-,Paul Quintaro,2015-03-16 00:00:00,MRK,1,0,0,1,0,0,1,0,1,0.5
852591,merck provides regulatory update on sugammadex injection,https://www.benzinga.com/press-releases/15/03/5326161/merck-provides-regulatory-update-on-sugammadex-injection,Hal Lindon,2015-03-13 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852592,measles cases could double in w african countries due to stain on health systems from ebola outbreak inability to maintain child immunizations reuters,https://www.benzinga.com/news/15/03/5322631/measles-cases-could-double-in-w-african-countries-due-to-stain-on-health-systems-,Charles Gross,2015-03-12 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.29905000000000004
852593,us stock futures signal higher start on wall street,https://www.benzinga.com/news/15/03/5316359/us-stock-futures-signal-higher-start-on-wall-street,Monica Gerson,2015-03-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852594,merck announces keytruda is first medicine to be made available to patients through uk eams for advanced melanoma,https://www.benzinga.com/news/15/03/5315841/merck-announces-keytruda-is-first-medicine-to-be-made-available-to-patients-throu,Charles Gross,2015-03-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.625
852595, healthcare names cowen co are talking about,https://www.benzinga.com/analyst-ratings/analyst-color/15/03/5315206/8-healthcare-names-cowen-co-are-talking-about,Monica Gerson,2015-03-10 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852596,who reports phase iii trial of ebola vaccine being developed by merck newlink to begin march ,https://www.benzinga.com/news/15/03/5300199/who-reports-phase-iii-trial-of-ebola-vaccine-being-developed-by-merck-tekmira-to-,Charles Gross,2015-03-05 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852597,merck announces co eisai enter deal to explore novel combo regimens antipd therapy with rtk inhibitor microtubule dynamics inhibitor for cancers,https://www.benzinga.com/news/15/03/5299508/merck-announces-co-eisai-enter-deal-to-explore-novel-combo-regimens-anti-pd-1-the,Paul Quintaro,2015-03-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
852598,fast money picks for march ,https://www.benzinga.com/media/cnbc/15/03/5285906/fast-money-picks-for-march-2,Craig Jones,2015-03-01 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852599,merck hpv vaccine gardasil recommended by cdcs advisory committee on immunization practices for females aged and males aged ,https://www.benzinga.com/news/15/02/5279946/merck-hpv-vaccine-gardasil-9-recommended-by-cdcs-advisory-committee-on-immunizati,Hal Lindon,2015-02-26 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.60115
852600,heavy news day for several biotech stocks,https://www.benzinga.com/general/biotech/15/02/5275042/heavy-news-day-for-several-biotech-stocks,John Seward,2015-02-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852601,merck collaborates with medicines patent pool to expand access to pediatric formulations of raltegravir in developing countries,https://www.benzinga.com/news/15/02/5267019/merck-collaborates-with-medicines-patent-pool-to-expand-access-to-pediatric-formu,Charles Gross,2015-02-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
852602,evercore isi technical analysis the single best idea,https://www.benzinga.com/analyst-ratings/analyst-color/15/02/5263279/evercore-isi-technical-analysis-the-single-best-idea,Mark Meadows,2015-02-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.81845
852603,update merck to make upfront payment ngm of m acquire stake in ngm for m,https://www.benzinga.com/news/15/02/5263218/update-merck-to-make-upfront-payment-ngm-of-94m-acquire-15-stake-in-ngm-for-106m,Charles Gross,2015-02-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852604,merck ngm report broad strategic deal to discover develop commercialize novel biologic therpeutics,https://www.benzinga.com/news/15/02/5263200/merck-ngm-report-broad-strategic-deal-to-discover-develop-commercialize-novel-bio,Paul Quintaro,2015-02-23 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.6591
852605,newlink genetics announces m milestone payment from merck,https://www.benzinga.com/news/15/02/5255330/newlink-genetics-announces-20m-milestone-payment-from-merck,Hal Lindon,2015-02-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852606,after a blockbuster what will hold for pharmaceutical ma,https://www.benzinga.com/general/education/15/02/5220037/after-a-blockbuster-2014-what-will-2015-hold-for-pharmaceutical-m-a,Steve Sapletal,2015-02-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7997000000000001
852607,fast money halftime report final trade from february ,https://www.benzinga.com/media/cnbc/15/02/5217507/fast-money-halftime-report-final-trade-from-february-5,Craig Jones,2015-02-06 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852608,merck prices b debt offering,https://www.benzinga.com/news/15/02/5217481/merck-prices-8b-debt-offering,Charles Gross,2015-02-05 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.3194
852609,update merck posts upbeat q earnings sales decline,https://www.benzinga.com/news/earnings/15/02/5209004/update-merck-posts-upbeat-q4-earnings-sales-decline,Monica Gerson,2015-02-04 00:00:00,MRK,1,0,0,1,0,0,1,0,0,0.5
852610,merck sees fy adj eps including items sales bb including items,https://www.benzinga.com/news/15/02/5208658/merck-sees-fy15-adj-eps-3-32-3-47-including-items-sales-38-3b-39-8b-including-ite,Paul Quintaro,2015-02-04 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852611,merck co reports q adj eps vs est sales b vs est b,https://www.benzinga.com/news/earnings/15/02/5208647/merck-co-reports-q4-adj-eps-0-87-vs-est-0-86-sales-10-48b-vs-est-10-50b,Eddie Staley,2015-02-04 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852612,earning economic calendar for wednesday february ,https://www.benzinga.com/news/earnings/15/02/5208301/earning-economic-calendar-for-wednesday-february-4-2015,Charles Gross,2015-02-04 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852613,earnings scheduled for february ,https://www.benzinga.com/news/earnings/15/02/5208273/earnings-scheduled-for-february-4-2015,Monica Gerson,2015-02-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852614,keep an eye on these stocks for february ,https://www.benzinga.com/news/earnings/15/02/5208195/keep-an-eye-on-these-10-stocks-for-february-4-2015,Monica Gerson,2015-02-04 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852615,mercks insomnia medicine belsomra suvorexant civ the first and only orexin receptor antagonist now available in the united states,https://www.benzinga.com/news/15/02/5204288/mercks-insomnia-medicine-belsomra-suvorexant-c-iv-the-first-and-only-orexin-recep,Eddie Staley,2015-02-03 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.4871
852616,earnings expectations for the week of february disney exxon gm and more,https://www.benzinga.com/news/earnings/15/02/5198536/earnings-expectations-for-the-week-of-february-2-disney-exxon-gm-and-mor,Nelson Hem,2015-02-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852617,what investors are watching for in regulus therapeutics next data release,https://www.benzinga.com/analyst-ratings/analyst-color/15/01/5196774/what-investors-are-watching-for-in-regulus-therapeutics-,Kyle Dennis,2015-01-30 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
852618,premarket prep technical update merck lower,https://www.benzinga.com/general/movers-shakers/15/01/5192180/premarket-prep-technical-update-merck-lower,Hal Lindon,2015-01-29 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852619,fast money halftime report final trade from january ,https://www.benzinga.com/media/cnbc/15/01/5184304/fast-money-halftime-report-final-trade-from-january-27,Craig Jones,2015-01-27 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852620,white house budget to support biotech rally,https://www.benzinga.com/news/15/01/5180194/white-house-budget-to-support-biotech-rally,Laura Brodbeck,2015-01-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
852621,merck reports chmp positive opinion for investigational antibiotic sivextro,https://www.benzinga.com/news/15/01/5176860/merck-reports-chmp-positive-opinion-for-investigational-antibiotic-sivextro,Paul Quintaro,2015-01-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
852622,ema recommends mercks combination of lamivudineraltegravir for approval reuters,https://www.benzinga.com/news/15/01/5172437/ema-recommends-mercks-combination-of-lamivudineraltegravir-for-approval-reuters,Charles Gross,2015-01-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8062
852623,the best dow stocks so far in ,https://www.benzinga.com/general/education/15/01/5161823/the-5-best-dow-stocks-so-far-in-2015,Wayne Duggan,2015-01-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.81845
852624,premarket prep technical update merck lower,https://www.benzinga.com/general/movers-shakers/15/01/5161669/premarket-prep-technical-update-merck-lower,Hal Lindon,2015-01-20 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852625,barclays issues upgrades downgrade on pharma stocks,https://www.benzinga.com/general/health-care/15/01/5154669/barclays-issues-3-upgrades-1-downgrade-on-pharma-stocks,Javier Hasse,2015-01-16 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852626,merck acquires oncoethix,https://www.benzinga.com/news/15/01/5155019/merck-acquires-oncoethix,Eddie Staley,2015-01-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852627,barclays upgrades merck to equalweight,https://www.benzinga.com/news/15/01/5153398/barclays-upgrades-merck-to-equalweight,Paul Quintaro,2015-01-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852628,premarket prep technical update merck lower,https://www.benzinga.com/general/movers-shakers/15/01/5151626/premarket-prep-technical-update-merck-lower,Hal Lindon,2015-01-15 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852629,fast money halftime report final trade from january ,https://www.benzinga.com/media/cnbc/15/01/5148734/fast-money-halftime-report-final-trade-from-january-14,Craig Jones,2015-01-15 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852630,practice fusion announces positive results of population health vaccine initiative,https://www.benzinga.com/news/15/01/5146021/practice-fusion-announces-positive-results-of-population-health-vaccine-initiativ,Hal Lindon,2015-01-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
852631,notes from the street flashbackoil going to barrel,https://www.benzinga.com/opinion/15/01/5141858/notes-from-the-street-flashback-oil-going-to-200barrel,Kenny Polcari,2015-01-13 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852632,merck and eli lilly announce agreement for collaboration on cancer clinical trial,https://www.benzinga.com/news/15/01/5141737/merck-and-eli-lilly-announce-agreement-for-collaboration-on-cancer-clinical-trial,Paul Quintaro,2015-01-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.352
852633,biotechs presenting at the jp morgan healthcare conference day ,https://www.benzinga.com/trading-ideas/long-ideas/15/01/5136442/biotechs-presenting-at-the-j-p-morgan-healthcare-conference-d,Kyle Dennis,2015-01-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852634,wall streets hall of fame and hall of shame the best and worst analyst recommendations of ,https://www.benzinga.com/analyst-ratings/analyst-color/15/01/5135725/wall-streets-hall-of-fame-and-hall-of-shame-the-best-and,TipRanks,2015-01-12 00:00:00,MRK,1,2,1,0,0,1,1,1,1,0.4871
852635,fda has approved mercks request to supplement pneumovax bla will add d barcode on label,https://www.benzinga.com/news/15/01/5122671/fda-has-approved-mercks-request-to-supplement-pneumovax-bla-will-add-2d-barcode-o,Paul Quintaro,2015-01-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
852636,bernstein upgrades merck to outperform,https://www.benzinga.com/news/15/01/5117771/bernstein-upgrades-merck-to-outperform,Paul Quintaro,2015-01-05 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.5
852637,what investors should be watching in the antibiotic space,https://www.benzinga.com/trading-ideas/long-ideas/14/12/5113964/what-investors-should-be-watching-in-the-antibiotic-space,Kyle Dennis,2014-12-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852638, lesserknown biotech stocks with robust drug pipelines,https://www.benzinga.com/trading-ideas/long-ideas/14/12/5112601/19-lesser-known-biotech-stocks-with-robust-drug-pipelines,Tom White,2014-12-31 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.67
852639,us dept of health human services issues release hhs supports efforts to speed ebola vaccine delivery,https://www.benzinga.com/news/14/12/5104036/us-dept-of-health-human-services-issues-release-hhs-supports-efforts-to-speed-ebo,Paul Quintaro,2014-12-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6806
852640,health care and biotech sector looking sick,https://www.benzinga.com/general/health-care/14/12/5103257/health-care-and-biotech-sector-looking-sick,Joel Elconin,2014-12-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.4871
852641,ftc requests public comment on merck co incs application to approve sale of facilities,https://www.benzinga.com/news/14/12/5103767/ftc-requests-public-comment-on-merck-co-inc-s-application-to-approve-sale-of-faci,Paul Quintaro,2014-12-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852642,premarket prep technical update merck lower,https://www.benzinga.com/general/movers-shakers/14/12/5100623/premarket-prep-technical-update-merck-lower,Hal Lindon,2014-12-22 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852643,newlink genetics surges following ebola contract news,https://www.benzinga.com/news/14/12/5099612/newlink-genetics-surges-3-following-ebola-contract-news,Kevin Riley,2014-12-22 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852644,newlink genetics announces collaboration with merck for manufacture of ebola vaccine deal supported by m award,https://www.benzinga.com/news/14/12/5099167/newlink-genetics-announces-collaboration-with-merck-for-manufacture-of-ebola-vacc,Paul Quintaro,2014-12-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.85015
852645,merck begins tender offer to acquire cubist,https://www.benzinga.com/news/14/12/5095847/merck-begins-tender-offer-to-acquire-cubist,Hal Lindon,2014-12-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852646,merck reports acquisition of oncoethix for m upfront payment could pay added m in milestone payment,https://www.benzinga.com/news/14/12/5090431/merck-reports-acquisition-of-oncoethix-for-110m-upfront-payment-could-pay-added-2,Paul Quintaro,2014-12-18 00:00:00,MRK,1,2,0,1,0,0,1,0,1,0.44865
852647,market mixed amid plan to spend million on ebola vaccines,https://www.benzinga.com/news/14/12/5074907/market-mixed-amid-plan-to-spend-300-million-on-ebola-vaccines,John Seward,2014-12-11 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.5
852648,these charts highlight twitter sentiment for todays movers,https://www.benzinga.com/general/crowdsourcing/14/12/5074024/these-4-charts-highlight-twitter-sentiment-for-todays-movers,Garrett Cook,2014-12-11 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.67
852649,sky news newsdesk tweets reuters geneva university hospital suspends trials of ebola vaccine one week early as a measure of precaution,https://www.benzinga.com/news/14/12/5073431/sky-news-newsdesk-tweets-reuters-geneva-university-hospital-suspends-trials-of-eb,Paul Quintaro,2014-12-11 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.5
852650,global vaccines alliance gavi said thursday it was committing up to m to buy ebola vaccines reuters,https://www.benzinga.com/news/14/12/5073294/global-vaccines-alliance-gavi-said-thursday-it-was-committing-up-to-300m-to-buy-e,Charles Gross,2014-12-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5386
852651,fda approves gardasil for prevention of certain cancers caused by additional types of hpv,https://www.benzinga.com/news/14/12/5071633/fda-approves-gardasil-9-for-prevention-of-certain-cancers-caused-by-5-additional-,Charles Gross,2014-12-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.79295
852652,data investigating keytruda mercks antipd therapy in patients with advanced triplenegative breast cancer presented at san antonio breast cancer symposium,https://www.benzinga.com/news/14/12/5070401/data-investigating-keytruda-mercks-anti-pd-1-therapy-in-patients-with-advanced-tr,Eddie Staley,2014-12-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.0842
852653,zoetis inc spikes briefly on remarks from sanofi ceo,https://www.benzinga.com/news/14/12/5068374/zoetis-inc-spikes-briefly-on-remarks-from-sanofi-ceo,John Seward,2014-12-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852654,mizuho securities downgrades cubist pharmaceuticals post acquisition announcement,https://www.benzinga.com/analyst-ratings/analyst-color/14/12/5067916/mizuho-securities-downgrades-cubist-pharmaceuticals-post,Kevin Riley,2014-12-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.648
852655,premarket prep technical update merck lower,https://www.benzinga.com/general/movers-shakers/14/12/5067953/premarket-prep-technical-update-merck-lower,Hal Lindon,2014-12-09 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852656,hospira inc ticks up on favorable patent ruling vs cubist pharmaceuticals inc,https://www.benzinga.com/news/14/12/5067423/hospira-inc-ticks-up-on-favorable-patent-ruling-vs-cubist-pharmaceuticals-inc,John Seward,2014-12-09 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.7383500000000001
852657,merck co under pressure following patent ruling,https://www.benzinga.com/news/14/12/5066865/merck-co-under-pressure-following-patent-ruling,Kevin Riley,2014-12-09 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.352
852658,cellceutix corp shares rise on two catalysts,https://www.benzinga.com/news/14/12/5066860/cellceutix-corp-shares-rise-on-two-catalysts,Alex Furno,2014-12-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852659,merck issues statement regarding cubicin patent litigation reaffirms transaction to proceed as planned,https://www.benzinga.com/press-releases/14/12/5066660/merck-issues-statement-regarding-cubicin-patent-litigation-reaffirms-tr,Hal Lindon,2014-12-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.39885
852660,benzingas ma chatter for monday december ,https://www.benzinga.com/news/14/12/5065368/benzingas-m-a-chatter-for-monday-december-8-2014,Charles Gross,2014-12-08 00:00:00,MRK,1,2,1,0,1,0,1,1,1,0.5
852661, biotech etfs rally on merger news,https://www.benzinga.com/etfs/sector-etfs/14/12/5064123/3-biotech-etfs-rally-on-merger-news,Matthew McCall,2014-12-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852662,cubist shares fall almost afterhours,https://www.benzinga.com/news/14/12/5065154/cubist-shares-fall-almost-5-after-hours,Charles Gross,2014-12-08 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.648
852663,midafternoon market update dow slides over points oil futures down ,https://www.benzinga.com/news/earnings/14/12/5064663/mid-afternoon-market-update-dow-slides-over-100-points-oil-futures-down-,Garrett Cook,2014-12-08 00:00:00,MRK,1,1,0,1,0,0,1,1,0,0.5
852664,fitch says cubist acquisition will strengthen mercks growth opportunities particularly in nonuseuropean markets,https://www.benzinga.com/analyst-ratings/analyst-color/14/12/5064519/fitch-says-cubist-acquisition-will-strengthen-mercks-gro,Charles Gross,2014-12-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.87895
852665,midday market update mcdonalds drops on weak november sales acceleron pharma shares jump,https://www.benzinga.com/news/earnings/14/12/5064296/mid-day-market-update-mcdonalds-drops-on-weak-november-sales-acceleron-p,Garrett Cook,2014-12-08 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.41105
852666,mercks ceo doesnt think that valuations in the biotech industry are rich,https://www.benzinga.com/media/cnbc/14/12/5064191/mercks-ceo-doesnt-think-that-valuations-in-the-biotech-industry-are-rich,Ritesh Anan,2014-12-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7787
852667,midmorning market update markets mixed merck to buy cubist pharmaceuticals for share,https://www.benzinga.com/news/earnings/14/12/5063952/mid-morning-market-update-markets-mixed-merck-to-buy-cubist-pharmaceutic,Garrett Cook,2014-12-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852668,benzingas volume movers,https://www.benzinga.com/news/14/12/5063874/benzingas-volume-movers,Lisa Levin,2014-12-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852669,stocks hitting week highs,https://www.benzinga.com/news/14/12/5063819/stocks-hitting-52-week-highs,Lisa Levin,2014-12-08 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
852670,morning market movers,https://www.benzinga.com/news/14/12/5063692/morning-market-movers,Lisa Levin,2014-12-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852671,pharmaceutical stocks in play following merckcubist deal,https://www.benzinga.com/news/14/12/5063362/pharmaceutical-stocks-in-play-following-merckcubist-deal,Alex Furno,2014-12-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.67
852672,benzingas top premarket gainers,https://www.benzinga.com/news/14/12/5063153/benzingas-top-premarket-gainers,Monica Gerson,2014-12-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852673,advaxis announces fda acceptance of investigational nda to begin clinical trials of adxspsa in combo with mercks keytrudar,https://www.benzinga.com/news/14/12/5062935/advaxis-announces-fda-acceptance-of-investigational-nda-to-begin-clinical-trials-,Paul Quintaro,2014-12-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
852674,merck to acquire cubist pharmaceuticals for share in cash,https://www.benzinga.com/news/14/12/5062841/merck-to-acquire-cubist-pharmaceuticals-for-102share-in-cash,Charles Gross,2014-12-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852675,update merck says cubist deal includes b in net debt,https://www.benzinga.com/news/14/12/5062837/update-merck-says-cubist-deal-includes-1-1b-in-net-debt,Charles Gross,2014-12-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3194
852676,us stock futures point to lower open monday,https://www.benzinga.com/news/14/12/5062826/us-stock-futures-point-to-lower-open-monday,Monica Gerson,2014-12-08 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.352
852677,merck to acquire cubist pharmaceuticals for per share in cash,https://www.benzinga.com/news/14/12/5062822/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash,Charles Gross,2014-12-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852678,cubist shares bid higher premarket on rumor of merck share bid,https://www.benzinga.com/news/14/12/5062642/cubist-shares-bid-28-higher-premarket-on-rumor-of-merck-100share-bid,Charles Gross,2014-12-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.76335
852679,must watch stocks for december ,https://www.benzinga.com/news/earnings/14/12/5062574/must-watch-stocks-for-december-8-2014,Monica Gerson,2014-12-08 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852680,benzingas weekend ma chatter,https://www.benzinga.com/news/14/12/5062319/benzingas-weekend-m-a-chatter,Charles Gross,2014-12-07 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852681,merck announces antipd therapy keytruda achieves overall response rate of in classical hodgkin lymphoma study,https://www.benzinga.com/news/14/12/5062107/merck-announces-anti-pd-1-therapy-keytruda-achieves-overall-response-rate-of-66-i,Charles Gross,2014-12-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852682,merck in talks to acquire cubist for share,https://www.benzinga.com/news/14/12/5061873/merck-in-talks-to-acquire-cubist-for-100share,Charles Gross,2014-12-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852683,merck in talks to acquire cubist pharmaceuticals for more than b could be announced as early as next week nyt dealbook,https://www.benzinga.com/news/14/12/5061872/merck-in-talks-to-acquire-cubist-pharmaceuticals-for-more-than-7b-could-be-announ,Charles Gross,2014-12-05 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852684,markets marginally lower ahead of fridays jobs report,https://www.benzinga.com/news/14/12/5058987/markets-marginally-lower-ahead-of-fridays-jobs-report,Jayson Derrick,2014-12-04 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.386
852685,jefferies maintains hold on merck company inc raises pt to ,https://www.benzinga.com/news/14/12/5056744/jefferies-maintains-hold-on-merck-company-inc-raises-pt-to-65-00,Eddie Staley,2014-12-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852686,no serious side effects reported in early test of experimental ebola vaccine being develped by merck newlink reuters,https://www.benzinga.com/news/14/12/5048851/no-serious-side-effects-reported-in-early-test-of-experimental-ebola-vaccine-bein,Charles Gross,2014-12-02 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.3194
852687,k from gilead sciences shows uk court invalidated idenix patent trials will be held on mercks idenix patents in canada in jan,https://www.benzinga.com/news/14/12/5047514/8-k-from-gilead-sciences-shows-uk-court-invalidated-idenix-489-patent-trials-will,Paul Quintaro,2014-12-01 00:00:00,MRK,1,1,0,0,0,0,1,0,0,0.5
852688,merck announces increased quarterly dividend from to share,https://www.benzinga.com/news/14/11/5037596/merck-announces-increased-quarterly-dividend-from-0-44-to-0-45share,Hal Lindon,2014-11-25 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.7553000000000001
852689,premarket prep technical update merck trading lower,https://www.benzinga.com/general/movers-shakers/14/11/5034397/premarket-prep-technical-update-merck-trading-lower,Hal Lindon,2014-11-24 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852690,merck reports submission to japanese pharma medical devices agency for omarigliptin,https://www.benzinga.com/news/14/11/5032531/merck-reports-submission-to-japanese-pharma-medical-devices-agency-for-omariglipt,Paul Quintaro,2014-11-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852691,merck newlink genetics announce licensing and collaboration agreement for investigational ebola vaccine,https://www.benzinga.com/news/14/11/5032430/merck-newlink-genetics-announce-licensing-and-collaboration-agreement-for-investi,Charles Gross,2014-11-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
852692,merck newlink genetics report entering of licensing collaboration deal for investigational ebola vaccine,https://www.benzinga.com/news/14/11/5032414/merck-newlink-genetics-report-entering-of-licensing-collaboration-deal-for-invest,Paul Quintaro,2014-11-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852693,ema recommends mercks blood clot preventer vorapaxar,https://www.benzinga.com/news/14/11/5029188/ema-recommends-mercks-blood-clot-preventer-vorapaxar,Charles Gross,2014-11-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.61315
852694,hearing newlink merck working on producing ebola vaccine,https://www.benzinga.com/news/14/11/5028134/hearing-newlink-merck-working-on-producing-ebola-vaccine,Charles Gross,2014-11-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852695,merck announces its vytorin reduces heart disease risk by over statin alone,https://www.benzinga.com/news/14/11/5015584/merck-announces-its-vytorin-reduces-heart-disease-risk-by-6-4-over-statin-alone,Paul Quintaro,2014-11-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.26165
852696,merck announces that improveit achieved primary endpoint data to be presented at american heart association scientific sessions today,https://www.benzinga.com/news/14/11/5014472/merck-announces-that-improve-it-achieved-primary-endpoint-data-to-be-presented-at,Eddie Staley,2014-11-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852697,pfizer will study mercks pdl in combo with pfizer assets to start clinical dev programs with merck six registration programs,https://www.benzinga.com/news/14/11/5014402/pfizer-will-study-mercks-pdl-1-in-combo-with-pfizer-assets-to-start-20-clinical-d,Paul Quintaro,2014-11-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.58895
852698,merck announces positive study investigating use of keytruda compared to chemotherapy in patients with ipilimumabrefractory advanced melanoma,https://www.benzinga.com/news/14/11/5013335/merck-announces-positive-study-investigating-use-of-keytruda-compared-to-chemothe,Charles Gross,2014-11-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8404
852699,merck announces results from phase study of investigational chronic hepatitis c treatment grazoprevirelbasvir in genotype infected treatmentnaÃ¯ve and difficulttocure patients,https://www.benzinga.com/news/14/11/4998984/merck-announces-results-from-phase-2-study-of-investigational-chronic-hepatitis-c,Eddie Staley,2014-11-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.25305
852700,merck offers results of phase study of investigational chronic hep c treatment grazoprevirelbasvir first wave of phase enrolled co will submit nda app in ,https://www.benzinga.com/news/14/11/4998956/merck-offers-results-of-phase-2-study-of-investigational-chronic-hep-c-treatment-,Paul Quintaro,2014-11-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852701,merck shares may have hit a ceiling for the most recent upside move,https://www.benzinga.com/trading-ideas/short-ideas/14/11/4997625/merck-shares-may-have-hit-a-ceiling-for-the-most-recent-upsi,James Mecir,2014-11-10 00:00:00,MRK,1,1,0,1,0,0,1,0,1,0.648
852702,merck has said taking no impairment charge following results of cholesteroldrug study,https://www.benzinga.com/news/14/11/4996496/merck-has-said-taking-no-impairment-charge-following-results-of-cholesterol-drug-,Paul Quintaro,2014-11-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.352
852703,rbc sees weak merck data as positive for gilead,https://www.benzinga.com/analyst-ratings/analyst-color/14/11/4995430/rbc-sees-weak-merck-data-as-positive-for-gilead,Mike Butler,2014-11-10 00:00:00,MRK,1,0,1,1,1,1,1,1,0,0.58895
852704,interim data from cswift study of mercks investigational hepatitis c treatment grazoprevirelbasvir in combination with a nucleotide inhibitor presented at the liver meeting,https://www.benzinga.com/news/14/11/4994025/interim-data-from-c-swift-study-of-mercks-investigational-hepatitis-c-treatment-g,Charles Gross,2014-11-09 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.4614
852705,us stock futures edge lower ahead of earnings jobless claims,https://www.benzinga.com/news/14/11/4987200/us-stock-futures-edge-lower-ahead-of-earnings-jobless-claims,Monica Gerson,2014-11-06 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.352
852706,bind therapeutics announces joint research agreement with merck,https://www.benzinga.com/news/14/11/4987077/bind-therapeutics-announces-joint-research-agreement-with-merck,Charles Gross,2014-11-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
852707,merck animal health provides update on zilmax fivestep plan announces next steps,https://www.benzinga.com/news/14/11/4982980/merck-animal-health-provides-update-on-zilmax-five-step-plan-announces-next-steps,Hal Lindon,2014-11-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852708,merck reports data from week phase b study of investigational hiv therapy doravirine in treatmentnaive patients phase clinical trial enrollment scheduled to begin by end of ,https://www.benzinga.com/news/14/11/4973188/merck-reports-data-from-48-week-phase-2b-study-of-investigational-hiv-therapy-dor,Charles Gross,2014-11-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852709,premarket primer tuesday october cdc warns that involuntary quarantines could discourage progress on ebola,https://www.benzinga.com/news/earnings/14/10/4956392/premarket-primer-tuesday-october-28-cdc-warns-that-involuntary-quarantin,Laura Brodbeck,2014-10-28 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.44865
852710,fast money traders discuss merck garmin and sarepta therapeutics,https://www.benzinga.com/media/cnbc/14/10/4955781/fast-money-traders-discuss-merck-garmin-and-sarepta-therapeutics,Craig Jones,2014-10-27 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852711,markets virtually flat oil continues to decline following bearish outlook,https://www.benzinga.com/news/14/10/4955391/markets-virtually-flat-oil-continues-to-decline-following-bearish-outlook,Jayson Derrick,2014-10-27 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.5
852712,merck conference call highlights,https://www.benzinga.com/news/earnings/14/10/4954989/merck-conference-call-highlights,Shazir Mucklai,2014-10-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852713,midafternoon market update nq mobile climbs on sec filing huntsman shares slide,https://www.benzinga.com/news/earnings/14/10/4954963/mid-afternoon-market-update-nq-mobile-climbs-on-sec-filing-huntsman-shar,Garrett Cook,2014-10-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852714,premarket prep technical update merck trading lower,https://www.benzinga.com/general/movers-shakers/14/10/4954894/premarket-prep-technical-update-merck-trading-lower,Hal Lindon,2014-10-27 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852715,midday market update micron gains on buyback announcement sarepta shares dip,https://www.benzinga.com/news/earnings/14/10/4954596/mid-day-market-update-micron-gains-on-buyback-announcement-sarepta-share,Garrett Cook,2014-10-27 00:00:00,MRK,1,0,0,1,0,0,1,0,1,0.7787
852716,midmorning market update markets down merck posts upbeat earnings,https://www.benzinga.com/news/earnings/14/10/4954154/mid-morning-market-update-markets-down-merck-posts-upbeat-earnings,Garrett Cook,2014-10-27 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
852717,premarket primer monday october ecb stress tests inline with expectations,https://www.benzinga.com/news/earnings/14/10/4952697/premarket-primer-monday-october-27-ecb-stress-tests-in-line-with-expecta,Laura Brodbeck,2014-10-27 00:00:00,MRK,1,2,0,1,0,0,1,1,0,0.28925
852718,us stock futures down ahead of economic data,https://www.benzinga.com/news/14/10/4953126/us-stock-futures-down-ahead-of-economic-data,Monica Gerson,2014-10-27 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852719,update merck q earnings top street view,https://www.benzinga.com/news/earnings/14/10/4953070/update-merck-q3-earnings-top-street-view,Monica Gerson,2014-10-27 00:00:00,MRK,1,2,1,0,1,0,1,1,1,0.60115
852720,merck company inc narrows fy eps guidance from to vs est,https://www.benzinga.com/news/14/10/4953013/merck-company-inc-narrows-fy2014-eps-guidance-from-3-43-3-53-to-3-46-3-50-vs-3-47,Paul Quintaro,2014-10-27 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852721,merck company inc reports q eps of vs est revenue of b vs b est,https://www.benzinga.com/news/earnings/14/10/4952969/merck-company-inc-reports-q3-eps-of-0-31-vs-0-88-est-revenue-of-10-60b-v,Paul Quintaro,2014-10-27 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852722,merck receives fda breakthrough therapy designation for keytruda in advanced nsclc,https://www.benzinga.com/news/14/10/4952940/merck-receives-fda-breakthrough-therapy-designation-for-keytruda-in-advanced-nscl,Charles Gross,2014-10-27 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.625
852723,earnings scheduled for october ,https://www.benzinga.com/news/earnings/14/10/4952718/earnings-scheduled-for-october-27-2014,Monica Gerson,2014-10-27 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852724,keep an eye on these stocks for october ,https://www.benzinga.com/news/earnings/14/10/4952672/keep-an-eye-on-these-7-stocks-for-october-27-2014,Monica Gerson,2014-10-27 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852725,earnings expectations for the week of october facebook exxon pfizer and much more,https://www.benzinga.com/news/earnings/14/10/4952347/earnings-expectations-for-the-week-of-october-27-facebook-exxon-pfizer-a,Nelson Hem,2014-10-26 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852726,fast money halftime report final trade from october ,https://www.benzinga.com/media/cnbc/14/10/4951575/fast-money-halftime-report-final-trade-from-october-24,Craig Jones,2014-10-24 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852727,fast money picks for october ,https://www.benzinga.com/media/cnbc/14/10/4945384/fast-money-picks-for-october-23,Craig Jones,2014-10-23 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852728,drug etfs attractive buys on pullback,https://www.benzinga.com/etfs/sector-etfs/14/10/4936002/drug-etfs-attractive-buys-on-pullback,Matthew McCall,2014-10-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
852729,premarket technical update merck trading higher,https://www.benzinga.com/general/movers-shakers/14/10/4940587/premarket-technical-update-merck-trading-higher,Hal Lindon,2014-10-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852730,us fda accepts for review a biologics license application for merck and sanofi pasteurs investigational pediatric hexavalent vaccine,https://www.benzinga.com/news/14/10/4934637/us-fda-accepts-for-review-a-biologics-license-application-for-merck-and-sanofi-pa,Eddie Staley,2014-10-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6591
852731,will actavis win competition for allergans affection,https://www.benzinga.com/analyst-ratings/analyst-color/14/10/4926309/will-activis-win-competition-for-allergans-affection,Jim Probasco,2014-10-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.901
852732,merck announces final results of tender offers for eight series of notes,https://www.benzinga.com/news/14/10/4923379/merck-announces-final-results-of-tender-offers-for-eight-series-of-notes,Hal Lindon,2014-10-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852733,markets debut week on negative note sp falls through key level,https://www.benzinga.com/news/14/10/4918141/markets-debut-week-on-negative-note-s-p-500-falls-through-key-level,Jayson Derrick,2014-10-13 00:00:00,MRK,1,1,0,1,0,0,1,1,0,0.21405000000000002
852734,premarket prep technical update merck trading lower,https://www.benzinga.com/general/movers-shakers/14/10/4917807/premarket-prep-technical-update-merck-trading-lower,Hal Lindon,2014-10-13 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852735,jefferies maintains hold on merck company inc lowers pt to ,https://www.benzinga.com/news/14/10/4916744/jefferies-maintains-hold-on-merck-company-inc-lowers-pt-to-60-00,Eddie Staley,2014-10-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
852736, companies that could develop an enterovirus treatment,https://www.benzinga.com/top-stories/14/10/4915747/5-companies-that-could-develop-an-enterovirus-treatment,Nelson Hem,2014-10-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852737,premarket prep technical update merck trading sharply higher,https://www.benzinga.com/general/movers-shakers/14/10/4908412/premarket-prep-technical-update-merck-trading-sharply-higher,Hal Lindon,2014-10-08 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
852738,merck prices b debt offering,https://www.benzinga.com/news/14/10/4900940/merck-prices-3-1b-debt-offering,Hal Lindon,2014-10-06 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.3194
852739, mutual funds holding hospital stocks,https://www.benzinga.com/general/health-care/14/10/4898850/2-mutual-funds-holding-hospital-stocks,Kate Stalter,2014-10-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852740,merck commencestender offers for eight series of notes,https://www.benzinga.com/news/14/10/4899193/merck-commencestender-offers-for-eight-series-of-notes,Charles Gross,2014-10-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852741,merck commences public debt offering,https://www.benzinga.com/news/14/10/4899190/merck-commences-public-debt-offering,Charles Gross,2014-10-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3194
852742,premarket prep technical update merck trading higher,https://www.benzinga.com/general/movers-shakers/14/10/4897898/premarket-prep-technical-update-merck-trading-higher,Hal Lindon,2014-10-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852743,markets little changed ahead of fridays jobs report,https://www.benzinga.com/news/earnings/14/10/4895753/markets-little-changed-ahead-of-fridays-jobs-report,Jayson Derrick,2014-10-02 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852744,guggenheim securities initiates coverage on merck company inc at neutral announces pt,https://www.benzinga.com/news/14/10/4893391/guggenheim-securities-initiates-coverage-on-merck-company-inc-at-neutral-announce,Paul Quintaro,2014-10-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852745,merck co inc stock still holding its position as a bigpharma leader,https://www.benzinga.com/trading-ideas/long-ideas/14/09/4883013/merck-co-inc-stock-still-holding-its-position-as-a-big-pharma,Tim Thielen,2014-09-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852746,merck presents early data on investigational use of keytruda in patients with advanced bladder cancer at esmo ,https://www.benzinga.com/news/14/09/4881220/merck-presents-early-data-on-investigational-use-of-keytruda-in-patients-with-adv,Charles Gross,2014-09-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.23665000000000003
852747,fast money halftime report final trade from september merck co inc ncr corporation and bp plc,https://www.benzinga.com/media/cnbc/14/09/4879863/fast-money-halftime-report-final-trade-from-september-26-merck-co-inc-ncr-c,Craig Jones,2014-09-26 00:00:00,MRK,1,2,0,0,1,0,1,1,1,0.5
852748,citigroup inc hertz global holdings inc highlight fast money halftime report final trade from september ,https://www.benzinga.com/media/cnbc/14/09/4866937/citigroup-inc-hertz-global-holdings-inc-highlight-fast-money-halftime-repor,Craig Jones,2014-09-22 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.67
852749,merck reports entered into license deal with sun pharma for tildrakizumab,https://www.benzinga.com/news/14/09/4857207/merck-reports-entered-into-license-deal-with-sun-pharma-for-tildrakizumab,Paul Quintaro,2014-09-17 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.5
852750,merck presents first phase data in japanese patients for omarigliptin an investigational onceweekly dpp inhibitor for type diabetes,https://www.benzinga.com/news/14/09/4856342/merck-presents-first-phase-3-data-in-japanese-patients-for-omarigliptin-an-invest,Eddie Staley,2014-09-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.4614
852751,sun pharma and merck enter into licensing agreement for tildrakizumab,https://www.benzinga.com/news/14/09/4855932/sun-pharma-and-merck-enter-into-licensing-agreement-for-tildrakizumab,Hal Lindon,2014-09-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
852752,premarket prep technical update merck trading higher,https://www.benzinga.com/general/movers-shakers/14/09/4854183/premarket-prep-technical-update-merck-trading-higher,Hal Lindon,2014-09-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852753,merck announces data from pivotal phase fracture outcomes study for odanacatib expects to submit nda to fda in ,https://www.benzinga.com/news/14/09/4850040/merck-announces-data-from-pivotal-phase-3-fracture-outcomes-study-for-odanacatib-,Charles Gross,2014-09-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852754,premarket prep technical update merck trading lower,https://www.benzinga.com/general/movers-shakers/14/09/4846751/premarket-prep-technical-update-merck-trading-lower,Hal Lindon,2014-09-12 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852755,is merck co inc a leader in a red hot market,https://www.benzinga.com/trading-ideas/technicals/14/09/4840330/is-merck-co-inc-a-leader-in-a-red-hot-market,Tim Thielen,2014-09-10 00:00:00,MRK,1,0,0,1,1,0,1,1,1,0.5
852756,option alert merck jan call traded vs oi currently ,https://www.benzinga.com/markets/options/14/09/4840460/option-alert-merck-jan-15-50-call-32-105-traded-vs-12-719-oi-currently,Hal Lindon,2014-09-10 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.648
852757,merck ceo says tax inversion deals would not fit corporate strategy reuters,https://www.benzinga.com/news/14/09/4835152/merck-ceo-says-tax-inversion-deals-would-not-fit-corporate-strategy-reuters,Charles Gross,2014-09-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.36224999999999996
852758,bristolmyers squibb co in patent suit vs merck co inc over skin cancer drug,https://www.benzinga.com/news/14/09/4829572/bristol-myers-squibb-co-in-patent-suit-vs-merck-co-inc-over-skin-cancer-drug,John Seward,2014-09-05 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.17015000000000002
852759,shares of bristolmyers edge off session lows as bloomberg reporting co has filed suit against merck related to patent for immunotherapy drugs,https://www.benzinga.com/news/14/09/4828882/shares-of-bristol-myers-edge-off-session-lows-as-bloomberg-reporting-co-has-filed,Paul Quintaro,2014-09-05 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.55135
852760,merck wins fda approval for pembrolizumab in melanoma,https://www.benzinga.com/news/14/09/4826725/merck-wins-fda-approval-for-pembrolizumab-in-melanoma,Paul Quintaro,2014-09-04 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.88915
852761,merck co mk gets fast track designation from fda,https://www.benzinga.com/news/14/09/4825436/merck-co-mk-7655-gets-fast-track-designation-from-fda,Paul Quintaro,2014-09-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852762,markets little changed in low volume and slow news ahead of long weekend,https://www.benzinga.com/news/earnings/14/08/4809313/markets-little-changed-in-low-volume-and-slow-news-ahead-of-long-weekend,Jayson Derrick,2014-08-27 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.39444999999999997
852763,biotech etfs hitting new highs on takeover news fbt pbe itmn,https://www.benzinga.com/etfs/sector-etfs/14/08/4804182/biotech-etfs-hitting-new-highs-on-takeover-news-fbt-pbe-itmn,Matthew McCall,2014-08-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852764,deutsche bank starts pfizer lilly at buy merck bristolmyers at hold,https://www.benzinga.com/news/14/08/4808624/deutsche-bank-starts-pfizer-lilly-at-buy-merck-bristol-myers-at-hold,Paul Quintaro,2014-08-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852765,update deutsche bank initiates coverage on merck,https://www.benzinga.com/analyst-ratings/analyst-color/14/08/4807798/update-deutsche-bank-initiates-coverage-on-merck,Alex Furno,2014-08-27 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
852766,deutsche bank initiates coverage on merck company inc at hold announces pt,https://www.benzinga.com/news/14/08/4807107/deutsche-bank-initiates-coverage-on-merck-company-inc-at-hold-announces-63-00-pt,Paul Quintaro,2014-08-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852767,sp closes above dow hits new alltime high as markets continue to rally,https://www.benzinga.com/news/14/08/4806010/s-p-500-closes-above-2-000-dow-hits-new-all-time-high-as-markets-continue-to-rall,Jayson Derrick,2014-08-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852768,fast money halftime report final trade from august ,https://www.benzinga.com/media/cnbc/14/08/4805499/fast-money-halftime-report-final-trade-from-august-26,Craig Jones,2014-08-26 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852769,pfizer merck report collaboration on study evaluating novel anticancer combo regimen,https://www.benzinga.com/news/14/08/4803932/pfizer-merck-report-collaboration-on-study-evaluating-novel-anti-cancer-combo-reg,Paul Quintaro,2014-08-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6591
852770,premarket prep technical update merck approaches ,https://www.benzinga.com/general/movers-shakers/14/08/4802157/premarket-prep-technical-update-merck-approaches-60-00,Hal Lindon,2014-08-25 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852771,us stock futures rise ahead of economic data,https://www.benzinga.com/news/14/08/4800726/us-stock-futures-rise-ahead-of-economic-data,Monica Gerson,2014-08-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852772,us regulators have approved mercks pembrolizumab soon reuters,https://www.benzinga.com/news/14/08/4800723/us-regulators-have-approved-mercks-pembrolizumab-soon-reuters,Paul Quintaro,2014-08-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
852773,advaxis merck to collaborate on investigational combination of two novel immunotherapy candidates for advanced prostate cancer,https://www.benzinga.com/news/14/08/4800467/advaxis-merck-to-collaborate-on-investigational-combination-of-two-novel-immunoth,Charles Gross,2014-08-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3634
852774,merck issues statement related to role of pneumovax in updated acip recommendations,https://www.benzinga.com/news/14/08/4779270/merck-issues-statement-related-to-role-of-pneumovax-23-in-updated-acip-recommenda,Paul Quintaro,2014-08-13 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852775,update fda approves belsomra tablets for use as sleep aid,https://www.benzinga.com/news/14/08/4779034/update-fda-approves-belsomra-tablets-for-use-as-sleep-aid,Eddie Staley,2014-08-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
852776,fda approves belsomra tablets for use as sleep aid,https://www.benzinga.com/news/14/08/4778682/fda-approves-belsomra-tablets-for-use-as-sleep-aid,Charles Gross,2014-08-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
852777,medicare spokesperson tells cdc vaccine advisory panel medicare would need to change current policy to cover pfizers prevnar for elderly previously vaccinated with mercks pneumovax reuters,https://www.benzinga.com/news/14/08/4778653/medicare-spokesperson-tells-cdc-vaccine-advisory-panel-medicare-would-need-to-cha,Charles Gross,2014-08-13 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
852778,markets marginally higher on light volume and encouraging geopolitical developments,https://www.benzinga.com/news/earnings/14/08/4772254/markets-marginally-higher-on-light-volume-and-encouraging-geopolitical-d,Jayson Derrick,2014-08-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.76335
852779,ukraine tension prominent as dow suffers triple digit loss sp nasdaq also lower,https://www.benzinga.com/news/earnings/14/08/4758363/ukraine-tension-prominent-as-dow-suffers-triple-digit-loss-s-p-500-nasda,Jayson Derrick,2014-08-05 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.1175
852780,premarket prep technical update merck trading sharply lower,https://www.benzinga.com/general/movers-shakers/14/08/4757823/premarket-prep-technical-update-merck-trading-sharply-lower,Hal Lindon,2014-08-05 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.352
852781,merck says on july was advised by british columbia medical beneficiary and pharmaceutical services division of delisting of sitagliptin products,https://www.benzinga.com/news/14/08/4757143/merck-says-on-july-30-was-advised-by-british-columbia-medical-beneficiary-and-pha,Charles Gross,2014-08-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
852782,merck successfully completes tender offer to acquire idenix for share,https://www.benzinga.com/news/14/08/4755390/merck-successfully-completes-tender-offer-to-acquire-idenix-for-24-50share,Charles Gross,2014-08-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.82985
852783,glaxo sanofi trend up on potential deal for established brands,https://www.benzinga.com/news/14/08/4753602/glaxo-sanofi-trend-up-on-potential-deal-for-established-brands,John Seward,2014-08-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852784, reasons to buy merck for the long term,https://www.benzinga.com/trading-ideas/long-ideas/14/07/4742113/3-reasons-to-buy-merck-for-the-long-term,Jonathan Yates,2014-07-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852785,stocks lower as earnings season takes back seat to geopolitical uncertainties,https://www.benzinga.com/news/earnings/14/07/4739183/stocks-lower-as-earnings-season-takes-back-seat-to-geopolitical-uncertai,Jayson Derrick,2014-07-29 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.2213
852786,pharmaceutical etfs are health care sector standouts,https://www.benzinga.com/etfs/sector-etfs/14/07/4738477/pharmaceutical-etfs-are-health-care-sector-standouts,David Fabian,2014-07-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
852787,indices remain mixed merck beats expectations,https://www.benzinga.com/news/earnings/14/07/4738720/indices-remain-mixed-merck-beats-expectations,Garrett Cook,2014-07-29 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
852788,tuesday morning earnings releases,https://www.benzinga.com/news/earnings/14/07/4737858/tuesday-morning-earnings-releases,Ali Berri,2014-07-29 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852789,premarket prep technical update merck trading higher,https://www.benzinga.com/general/movers-shakers/14/07/4738623/premarket-prep-technical-update-merck-trading-higher,Hal Lindon,2014-07-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852790,herbalife falls on downbeat results windstream shares spike higher,https://www.benzinga.com/news/earnings/14/07/4738398/herbalife-falls-on-downbeat-results-windstream-shares-spike-higher,Garrett Cook,2014-07-29 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.648
852791,markets open higher merck posts upbeat profit,https://www.benzinga.com/news/14/07/4737790/markets-open-higher-merck-posts-upbeat-profit,Garrett Cook,2014-07-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
852792,us stock futures rise ahead of earnings consumer confidence data,https://www.benzinga.com/news/14/07/4736669/us-stock-futures-rise-ahead-of-earnings-consumer-confidence-data,Monica Gerson,2014-07-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
852793,update merck q profit beats street view shares rise,https://www.benzinga.com/news/earnings/14/07/4736612/update-merck-q2-profit-beats-street-view-shares-rise,Monica Gerson,2014-07-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.81245
852794,merck company inc raises fy eps guidance from to vs est reaffirms sales outlook,https://www.benzinga.com/news/14/07/4736391/merck-company-inc-raises-fy2014-eps-guidance-from-3-35-3-53-to-3-43-3-53-vs-3-48-,Paul Quintaro,2014-07-29 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852795,merck company inc reports q eps of vs est revenue of b vs b est,https://www.benzinga.com/news/earnings/14/07/4736390/merck-company-inc-reports-q2-eps-of-0-85-vs-0-80-est-revenue-of-10-93b-v,Paul Quintaro,2014-07-29 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852796,earnings scheduled for july ,https://www.benzinga.com/news/earnings/14/07/4736154/earnings-scheduled-for-july-29-2014,Monica Gerson,2014-07-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852797,stocks to watch for july ,https://www.benzinga.com/news/earnings/14/07/4736050/stocks-to-watch-for-july-29-2014,Monica Gerson,2014-07-29 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852798,markets little changed ahead of the federal reserves policy decision,https://www.benzinga.com/news/earnings/14/07/4735043/markets-little-changed-ahead-of-the-federal-reserves-policy-decision,Jayson Derrick,2014-07-28 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852799,earnings expectations for the week of july exxon pfizer twitter and much more,https://www.benzinga.com/news/earnings/14/07/4732297/earnings-expectations-for-the-week-of-july-28-exxon-pfizer-twitter-and-m,Nelson Hem,2014-07-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852800,benzinga weekly preview fomc in focus as earnings season progresses,https://www.benzinga.com/news/earnings/14/07/4731269/benzinga-weekly-preview-fomc-in-focus-as-earnings-season-progresses,Laura Brodbeck,2014-07-26 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852801,merck announces initiation of phase for letermovir,https://www.benzinga.com/news/14/07/4726906/merck-announces-initiation-of-phase-3-for-letermovir,Hal Lindon,2014-07-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852802,idenix pharma shares spiking higher following sec filing showing hsr approval of purchase by merck,https://www.benzinga.com/news/14/07/4716497/idenix-pharma-shares-spiking-higher-following-sec-filing-showing-hsr-approval-of-,Paul Quintaro,2014-07-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8243
852803,markets marginally lower ahead of earnings season,https://www.benzinga.com/news/earnings/14/07/4684847/markets-marginally-lower-ahead-of-earnings-season,Jayson Derrick,2014-07-07 00:00:00,MRK,0,1,0,0,1,0,0,0,0,0.386
852804,premarket prep technical update merck trading lower,https://www.benzinga.com/general/movers-shakers/14/07/4684558/premarket-prep-technical-update-merck-trading-lower,Hal Lindon,2014-07-07 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852805,exclusive enanta pharmaceuticals ceo jay luly discusses hep c pipeline,https://www.benzinga.com/general/health-care/14/07/4678460/exclusive-enanta-pharmaceuticals-ceo-jay-luly-discusses-hep-c-pipe,Luke Jacobi,2014-07-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5640000000000001
852806,markets little changed ahead of th of july break,https://www.benzinga.com/news/earnings/14/07/4678705/markets-little-changed-ahead-of-4th-of-july-break,Jayson Derrick,2014-07-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852807,barclays downgrades pharmaceutical sector,https://www.benzinga.com/analyst-ratings/analyst-color/14/07/4678189/barclays-downgrades-pharmaceutical-sector,John Seward,2014-07-02 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.5
852808,bayer could keep scholls coppertone brands from merck reuters,https://www.benzinga.com/news/14/07/4674018/bayer-could-keep-scholls-coppertone-brands-from-merck-reuters,Paul Quintaro,2014-07-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852809,merck announces investigational data from phase emend,https://www.benzinga.com/news/14/06/4669838/merck-announces-investigational-data-from-phase-3-emend,Paul Quintaro,2014-06-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852810,us stock futures fall ahead of home sales report,https://www.benzinga.com/news/14/06/4669632/us-stock-futures-fall-ahead-of-home-sales-report,Monica Gerson,2014-06-30 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.5
852811,mercks investigational antipd antibody pembrolizumab under regulatory review by ema for treatment of advanced melanoma,https://www.benzinga.com/news/14/06/4669457/mercks-investigational-anti-pd-1-antibody-pembrolizumab-under-regulatory-review-b,Charles Gross,2014-06-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
852812,exclusive hepatitis c stock valuation with enanta ceo jay luly,https://www.benzinga.com/news/14/06/4667085/exclusive-hepatitis-c-stock-valuation-with-enanta-ceo-jay-luly,Luke Jacobi,2014-06-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5640000000000001
852813,premarket prep technical update merck trading lower,https://www.benzinga.com/general/movers-shakers/14/06/4664627/premarket-prep-technical-update-merck-trading-lower,Hal Lindon,2014-06-26 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852814,market wrap for june yet again dow and sp indices hit new highs,https://www.benzinga.com/news/earnings/14/06/4650335/market-wrap-for-june-20-yet-again-dow-and-s-p-500-indices-hit-new-highs,Jayson Derrick,2014-06-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852815,star biotech stock watch synta pharmaceuticals,https://www.benzinga.com/general/education/14/06/4643303/5-star-biotech-stock-watch-synta-pharmaceuticals,Christian Tharp CMT,2014-06-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852816,update merck research head says company aims to capture big share of hep c market selling best drugs at fair cost,https://www.benzinga.com/news/14/06/4629464/update-merck-research-head-says-company-aims-to-capture-big-share-of-hep-c-market,Charles Gross,2014-06-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.91355
852817,merck research head says company open to big acquisition for biotech products reuters,https://www.benzinga.com/news/14/06/4629385/merck-research-head-says-company-open-to-big-acquisition-for-biotech-products-reu,Charles Gross,2014-06-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852818,update bank of america reiterates on merck co on higher sales estimates,https://www.benzinga.com/analyst-ratings/analyst-color/14/06/4628321/update-bank-of-america-reiterates-on-merck-co-on-higher-,Dwight Einhorn,2014-06-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852819,takeover whispers add to achillion pharmaceuticals momentum,https://www.benzinga.com/news/earnings/14/06/4626233/when-news-and-rumors-add-to-a-stocks-momentum,Joel Elconin,2014-06-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852820,etf outlook for tuesday june iat fxe pbe hyhg idix mrk,https://www.benzinga.com/etfs/sector-etfs/14/06/4621598/etf-outlook-for-tuesday-june-10-2014-iat-fxe-pbe-hyhg-idix-mrk,Matthew McCall,2014-06-10 00:00:00,MRK,1,2,0,1,0,1,1,1,1,0.5
852821,benzingas ma chatter for monday june ,https://www.benzinga.com/news/14/06/4620057/benzingas-m-a-chatter-for-monday-june-9-2014,Charles Gross,2014-06-09 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852822,market wrap for june markets higher on st louis fed comments low volume,https://www.benzinga.com/news/earnings/14/06/4619787/market-wrap-for-june-9-markets-higher-on-st-louis-fed-comments-low-volum,Jayson Derrick,2014-06-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.3634
852823,midafternoon market update icahns stake in family dollar tyson foods wins bid for hillshire brands,https://www.benzinga.com/news/earnings/14/06/4619464/mid-afternoon-market-update-icahns-9-stake-in-family-dollar-tyson-foods-,Garrett Cook,2014-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,0,0.7859499999999999
852824,are gilead shares overreacting to mercks idenix acquisition,https://www.benzinga.com/analyst-ratings/analyst-color/14/06/4619268/are-gilead-shares-overreacting-to-mercks-idenix-acquisit,Erika Janowicz,2014-06-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.648
852825,midday market update idenix pharma surges on merck buyout pilgrims pride shares slide,https://www.benzinga.com/news/14/06/4619076/mid-day-market-update-idenix-pharma-surges-on-merck-buyout-pilgrims-pride-shares-,Garrett Cook,2014-06-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.7787
852826,benzingas volume movers,https://www.benzinga.com/news/14/06/4618606/benzingas-volume-movers,Lisa Levin,2014-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852827,stocks hitting week highs,https://www.benzinga.com/news/14/06/4618580/stocks-hitting-52-week-highs,Lisa Levin,2014-06-09 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
852828,midmorning market update markets edge higher tyson wins bidding battle to buy hillshire brands for share,https://www.benzinga.com/news/earnings/14/06/4618511/mid-morning-market-update-markets-edge-higher-tyson-wins-bidding-battle-,Garrett Cook,2014-06-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
852829,morning market movers,https://www.benzinga.com/news/14/06/4618403/morning-market-movers,Monica Gerson,2014-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852830,update merck says dual therapy of mk mk cures high s of patients in weeks triple therapy could be more effective faster,https://www.benzinga.com/news/14/06/4618070/update-merck-says-dual-therapy-of-mk-5172-mk-8742-cures-high-90s-of-patients-in-1,Charles Gross,2014-06-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7627999999999999
852831,hepatitis c stocks move after idenix rockets up ,https://www.benzinga.com/news/14/06/4618012/hepatitis-c-stocks-move-after-idenix-rockets-up-235,Luke Jacobi,2014-06-09 00:00:00,MRK,1,1,1,0,1,1,1,1,1,0.5
852832,merck research head says combination of idenix nucleotide inhibitor idx plus leading two experimental merck drugs could produce cures in weeks,https://www.benzinga.com/news/14/06/4618025/merck-research-head-says-combination-of-idenix-nucleotide-inhibitor-idx21437-plus,Charles Gross,2014-06-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.4614
852833,benzingas top premarket losers,https://www.benzinga.com/news/14/06/4617783/benzingas-top-premarket-losers,Monica Gerson,2014-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.30910000000000004
852834,benzingas top premarket gainers,https://www.benzinga.com/news/14/06/4617746/benzingas-top-premarket-gainers,Monica Gerson,2014-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852835,achillion pharmaceuticals shares rise premarket on news of merckidenix deal,https://www.benzinga.com/news/14/06/4617634/achillion-pharmaceuticals-shares-rise-38-premarket-on-news-of-merck-idenix-deal,Charles Gross,2014-06-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
852836,shares of idenix pharma now up to ,https://www.benzinga.com/movers/14/06/4617625/shares-of-idenix-pharma-now-up-200-to-22,Paul Quintaro,2014-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852837,update merck announces will purchase idenix for bn,https://www.benzinga.com/news/14/06/4617619/update-merck-announces-will-purchase-idenix-for-3-85bn,Hal Lindon,2014-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852838,merck announces will purchase idenix for share,https://www.benzinga.com/news/14/06/4617595/merck-announces-will-purchase-idenix-for-24-50share,Paul Quintaro,2014-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852839,premarket prep technical update merck trading lower,https://www.benzinga.com/trading-ideas/technicals/14/06/4615506/premarket-prep-technical-update-merck-trading-lower,Hal Lindon,2014-06-06 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852840,merck announces will present new clinical data on januvia at ssada,https://www.benzinga.com/news/14/06/4614713/merck-announces-will-present-new-clinical-data-on-januvia-at-ssada,Paul Quintaro,2014-06-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852841,merck announces first patient in phase trial of isentress enrolled,https://www.benzinga.com/news/14/06/4613714/merck-announces-first-patient-in-phase-3-trial-of-isentress-enrolled,Paul Quintaro,2014-06-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852842,premarket prep technical update merck trading higher,https://www.benzinga.com/general/movers-shakers/14/06/4612899/premarket-prep-technical-update-merck-trading-higher,Hal Lindon,2014-06-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852843,asco meeting day risks and rewards of immunotherapy,https://www.benzinga.com/news/14/06/4606517/asco-meeting-day-4-risks-and-rewards-of-immunotherapy,Erika Janowicz,2014-06-04 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.625
852844,merck presents early data for pembrolizumab in patients with pdl positive advanced head and neck cancer at asco,https://www.benzinga.com/news/14/06/4599565/merck-presents-early-data-for-pembrolizumab-in-patients-with-pd-l1-positive-advan,Charles Gross,2014-06-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5258
852845,merck announces generic name for mk pembrolizumab,https://www.benzinga.com/news/14/05/4596723/merck-announces-generic-name-for-mk-3475-pembrolizumab,Paul Quintaro,2014-05-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852846,premarket prep technical update merck trading higher,https://www.benzinga.com/general/movers-shakers/14/05/4593725/premarket-prep-technical-update-merck-trading-higher,Hal Lindon,2014-05-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852847,premarket technical update merck trading higher,https://www.benzinga.com/general/movers-shakers/14/05/4581603/premarket-technical-update-merck-trading-higher,Hal Lindon,2014-05-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852848,merck reports animal health has announced fda approval of bravecto,https://www.benzinga.com/news/14/05/4569316/merck-reports-animal-health-has-announced-fda-approval-of-bravecto,Paul Quintaro,2014-05-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
852849,merck endocyte report withrdrawal of conditional marketing authorization for vintafolide companion imaging from ema,https://www.benzinga.com/news/14/05/4567753/merck-endocyte-report-withrdrawal-of-conditional-marketing-authorization-for-vint,Paul Quintaro,2014-05-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852850,chimerix announces has regained worldwide rights to cmx from merck says co will no longer pursue development,https://www.benzinga.com/news/14/05/4562426/chimerix-announces-has-regained-worldwide-rights-to-cmx157-from-merck-says-co-wil,Paul Quintaro,2014-05-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.352
852851,merck vp schechter sells shares share form ,https://www.benzinga.com/news/14/05/4556226/merck-vp-schechter-sells-10-527-shares-55-91share-form-4,Charles Gross,2014-05-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.76335
852852,rd tax credit passed in the house faces challenges ahead,https://www.benzinga.com/general/politics/14/05/4551473/r-d-tax-credit-passed-in-the-house-faces-challenges-ahead,Spencer Schredder,2014-05-14 00:00:00,MRK,1,1,0,0,0,0,1,0,0,0.7202
852853,the most overvalued dow stocks,https://www.benzinga.com/general/education/14/05/4554554/the-5-most-overvalued-dow-stocks,Charley Blaine,2014-05-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852854,new data on mercks investigational antipd antibody mk to be presented at asco ,https://www.benzinga.com/news/14/05/4554412/new-data-on-mercks-investigational-anti-pd1-antibody-mk-3475-to-be-presented-at-a,Charles Gross,2014-05-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852855,us stock futures up ahead of retail sales report,https://www.benzinga.com/news/14/05/4549963/us-stock-futures-up-ahead-of-retail-sales-report,Monica Gerson,2014-05-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852856,merck to sell ophthalmology products in japan key markets in europe and asia pacific to santen for m upfront payment,https://www.benzinga.com/news/14/05/4549543/merck-to-sell-ophthalmology-products-in-japan-key-markets-in-europe-and-asia-paci,Charles Gross,2014-05-13 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852857,update merck reports fda okay of zontivity,https://www.benzinga.com/news/14/05/4545837/update-merck-reports-fda-okay-of-zontivity,Hal Lindon,2014-05-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.61315
852858,merck reports fda okay o f zontivity,https://www.benzinga.com/news/14/05/4545822/merck-reports-fda-okay-o-f-zontivity,Paul Quintaro,2014-05-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.61315
852859,premarket prep technical update merck trading lower again,https://www.benzinga.com/general/movers-shakers/14/05/4540216/premarket-prep-technical-update-merck-trading-lower-again,Hal Lindon,2014-05-08 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.352
852860,this morning bmo capital downgraded merck company to market perform lowered pt to ,https://www.benzinga.com/news/14/05/4539096/this-morning-bmo-capital-downgraded-merck-company-to-market-perform-lowered-pt-to,Hal Lindon,2014-05-08 00:00:00,MRK,1,1,0,1,0,0,1,0,0,0.436
852861,merck announces results show letermovir in cmvseropositive allogeneic human blood precursor cell recipients met studys two primary efficacy endpoints,https://www.benzinga.com/news/14/05/4538810/merck-announces-results-show-letermovir-in-cmv-seropositive-allogeneic-human-bloo,Charles Gross,2014-05-08 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.5
852862,market wrap for may dow banks tripledigit point gain while nasdaq closes lower,https://www.benzinga.com/news/earnings/14/05/4536119/market-wrap-for-may-7-dow-banks-triple-digit-point-gain-while-nasdaq-clo,Jayson Derrick,2014-05-07 00:00:00,MRK,0,0,0,1,0,0,0,0,0,0.648
852863,premarket technical update merck trading lower,https://www.benzinga.com/general/movers-shakers/14/05/4535556/premarket-technical-update-merck-trading-lower,Hal Lindon,2014-05-07 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852864,merck shares tumble following morgan stanley downgrade,https://www.benzinga.com/news/14/05/4534599/merck-shares-tumble-2-following-morgan-stanley-downgrade,Paul Quintaro,2014-05-07 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.648
852865,market wrap for may dow suffers tripledigit point loss nasdaq underperforms once again,https://www.benzinga.com/news/earnings/14/05/4531649/market-wrap-for-may-6-dow-suffers-triple-digit-point-loss-nasdaq-underpe,Jayson Derrick,2014-05-06 00:00:00,MRK,0,1,0,1,0,0,1,1,1,0.17015000000000002
852866,premarket prep technical update merck trading sharply lower,https://www.benzinga.com/general/movers-shakers/14/05/4531230/premarket-prep-technical-update-merck-trading-sharply-lower,Hal Lindon,2014-05-06 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.352
852867,fitch says merck consumer business sale improves its core focus,https://www.benzinga.com/analyst-ratings/analyst-color/14/05/4531065/fitch-says-merck-consumer-business-sale-improves-its-cor,Charles Gross,2014-05-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
852868,merck says global cancer sales could reach b by ,https://www.benzinga.com/news/14/05/4530687/merck-says-global-cancer-sales-could-reach-120b-by-2020,Charles Gross,2014-05-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17570000000000002
852869,merck ceo says would be interested in acquiring animal health brands with the right products at the right price reuters,https://www.benzinga.com/news/14/05/4530673/merck-ceo-says-would-be-interested-in-acquiring-animal-health-brands-with-the-rig,Charles Gross,2014-05-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
852870,merck says may look to ma for biotech expansion bloomberg,https://www.benzinga.com/news/14/05/4530631/merck-says-may-look-to-m-a-for-biotech-expansion-bloomberg,Paul Quintaro,2014-05-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852871,update merck highlights strategic initiative,https://www.benzinga.com/news/14/05/4529503/update-merck-highlights-strategic-initiative,Hal Lindon,2014-05-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852872,merck offers details of plans to file odanacatib for osteoporoisis in h will continue to explore ways to augment animal health unit,https://www.benzinga.com/news/14/05/4529430/merck-offers-details-of-plans-to-file-odanacatib-for-osteoporoisis-in-2h-will-con,Paul Quintaro,2014-05-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852873,merck announces fda acceptance for review of mk,https://www.benzinga.com/news/14/05/4529354/merck-announces-fda-acceptance-for-review-of-mk-3475,Hal Lindon,2014-05-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7294
852874,us stock futures flat ahead of international trade data,https://www.benzinga.com/news/14/05/4528761/us-stock-futures-flat-ahead-of-international-trade-data,Monica Gerson,2014-05-06 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852875,merck announces sale of consumer care business to bayer for b,https://www.benzinga.com/news/14/05/4528422/merck-announces-sale-of-consumer-care-business-to-bayer-for-14-2b,Charles Gross,2014-05-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
852876,bayer to buy merck consumer care ops for b,https://www.benzinga.com/news/14/05/4528415/bayer-to-buy-merck-consumer-care-ops-for-14-2b,Charles Gross,2014-05-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
852877,etf outlook for the week of may nge xlu usmv jjn,https://www.benzinga.com/etfs/sector-etfs/14/05/4524028/etf-outlook-for-the-week-of-may-5-2014-nge-xlu-usmv-jjn,Matthew McCall,2014-05-05 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852878,market wrap for may markets slip on ukraine tensions despite positive jobs data,https://www.benzinga.com/news/earnings/14/05/4523065/market-wrap-for-may-2-markets-slip-on-ukraine-tensions-despite-positive-,Jayson Derrick,2014-05-02 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.15839999999999999
852879,sanofi merck rumored to each weigh sale of maturedrug portfolios bloomberg,https://www.benzinga.com/news/14/05/4522825/sanofi-merck-rumored-to-each-weigh-sale-of-mature-drug-portfolios-bloomberg,Paul Quintaro,2014-05-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852880,premarket preo technical update merck trading lower,https://www.benzinga.com/general/movers-shakers/14/05/4522237/premarket-preo-technical-update-merck-trading-lower,Hal Lindon,2014-05-02 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852881,endocyte to resume trading at am et,https://www.benzinga.com/news/earnings/14/05/4521498/endocyte-to-resume-trading-at-8-30-am-et,Charles Gross,2014-05-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852882,merck endocyte announce independent dsmb recommends vintafolide proceed phase trial be stopped for futility following interim analysis,https://www.benzinga.com/news/14/05/4521485/merck-endocyte-announce-independent-dsmb-recommends-vintafolide-proceed-phase-3-t,Charles Gross,2014-05-02 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
852883,merck endocyte report dsmb has recommended vintafolide trial be suspended cites trial not showing efficacy,https://www.benzinga.com/news/14/05/4521464/merck-endocyte-report-dsmb-has-recommended-vintafolide-trial-be-suspended-cites-t,Paul Quintaro,2014-05-02 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.3409
852884,benzingas ma chatter for thursday may ,https://www.benzinga.com/news/14/05/4520419/benzingas-m-a-chatter-for-thursday-may-1-2014,Charles Gross,2014-05-01 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852885,bayer could be preparing b bid for mercks consumer unit bloomberg,https://www.benzinga.com/news/14/05/4519195/bayer-could-be-preparing-14b-bid-for-mercks-consumer-unit-bloomberg,Paul Quintaro,2014-05-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852886,premarket prep technical update merck trading lower,https://www.benzinga.com/trading-ideas/technicals/14/04/4513927/premarket-prep-technical-update-merck-trading-lower,Hal Lindon,2014-04-30 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852887,reckitt benckiser confirms it is no longer in talks with merck regarding bid for consumer health business,https://www.benzinga.com/news/14/04/4513536/update-reckitt-benckiser-confirms-it-is-no-longer-in-talks-with-merck-regarding-b,Charles Gross,2014-04-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.352
852888,premarket primer wednesday april no boj stimulus on the horizon,https://www.benzinga.com/news/earnings/14/04/4510542/premarket-primer-wednesday-april-30-no-boj-stimulus-on-the-horizon,Laura Brodbeck,2014-04-30 00:00:00,MRK,1,2,0,0,0,1,1,1,0,0.352
852889,market wrap for april dow approaches record highs despite ongoing ukraine tension and upcoming fed meeting,https://www.benzinga.com/news/14/04/4509591/market-wrap-for-april-29-dow-approaches-record-highs-despite-ongoing-ukraine-tens,Jayson Derrick,2014-04-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.62055
852890,midafternoon market update markets show strength as prothena shares plummet,https://www.benzinga.com/news/earnings/14/04/4509097/mid-afternoon-market-update-markets-show-strength-as-prothena-shares-plu,Jake L'Ecuyer,2014-04-29 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.82985
852891,bids for merck consumerhealth unit said to be over b bayer looking to weigh jv with merck as part of offer bloomberg,https://www.benzinga.com/news/14/04/4509115/bids-for-merck-consumer-health-unit-said-to-be-over-14b-bayer-looking-to-weigh-jv,Paul Quintaro,2014-04-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852892,premarket technical update merck trading higher,https://www.benzinga.com/general/movers-shakers/14/04/4508744/premarket-technical-update-merck-trading-higher,Hal Lindon,2014-04-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852893,midday market update coach slips after q results orbital shares spike higher,https://www.benzinga.com/news/earnings/14/04/4508528/mid-day-market-update-coach-slips-after-q3-results-orbital-shares-spike-,Jake L'Ecuyer,2014-04-29 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.648
852894,midmorning market update markets rise merck earnings beat street view,https://www.benzinga.com/news/earnings/14/04/4507854/mid-morning-market-update-markets-rise-merck-earnings-beat-street-view,Jake L'Ecuyer,2014-04-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852895,update merck posts upbeat q profit,https://www.benzinga.com/news/earnings/14/04/4506653/update-merck-posts-upbeat-q1-profit,Monica Gerson,2014-04-29 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.7202
852896,premarket primer tuesday april us steps up sanctions against russia,https://www.benzinga.com/news/earnings/14/04/4505523/premarket-primer-tuesday-april-29-us-steps-up-sanctions-against-russia,Laura Brodbeck,2014-04-29 00:00:00,MRK,1,0,0,1,0,0,1,1,0,0.5
852897,merck company inc reports q eps of vs est revenue of b vs b est reaffirms outlook,https://www.benzinga.com/news/earnings/14/04/4506416/merck-company-inc-reports-q1-eps-of-0-88-vs-0-79-est-revenue-of-10-30b-v,Paul Quintaro,2014-04-29 00:00:00,MRK,1,0,1,0,0,0,1,1,1,0.5
852898,market wrap for april apple hits new week highs in a volatile start to the trading week,https://www.benzinga.com/news/earnings/14/04/4504768/market-wrap-for-april-28-apple-hits-new-52-week-highs-in-a-volatile-star,Jayson Derrick,2014-04-28 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
852899,reckitt benckiser confirms talks with merck regarding bid for consumer health business bayer also rumored bidder,https://www.benzinga.com/news/14/04/4503938/reckitt-benckiser-confirms-talks-with-merck-regarding-bid-for-consumer-health-bus,Charles Gross,2014-04-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852900,agenus announces license deal with merck related to novel checkpoint antibodybased cancer immunotherapies eligible for m in milestone payments,https://www.benzinga.com/news/14/04/4502360/agenus-announces-license-deal-with-merck-related-to-novel-checkpoint-antibody-bas,Paul Quintaro,2014-04-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.26165
852901,benzingas weekend ma chatter,https://www.benzinga.com/news/14/04/4501544/benzingas-weekend-m-a-chatter,Charles Gross,2014-04-27 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
852902,earnings expectations for the week of april big oil big pharma and more,https://www.benzinga.com/news/earnings/14/04/4501471/earnings-expectations-for-the-week-of-april-28-big-oil-big-pharma-and-mo,Nelson Hem,2014-04-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852903,reuters reports merck in talks to sell consumer health unit to bayer reckitt benckiser for approximately b according to sources,https://www.benzinga.com/news/14/04/4501241/reuters-reports-merck-in-talks-to-sell-consumer-health-unit-to-bayer-reckitt-benc,Charles Gross,2014-04-26 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852904,benzinga weekly preview earnings season continues as biotech pharmaceutical companies report,https://www.benzinga.com/news/earnings/14/04/4500268/benzinga-weekly-preview-earnings-season-continues-as-biotech-pharmaceuti,Laura Brodbeck,2014-04-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852905, ways to profit from merger activity in the pharmaceutical sector,https://www.benzinga.com/trading-ideas/long-ideas/14/04/4492163/3-ways-to-profit-from-merger-activity-in-the-pharmaceutical-s,Jonathan Yates,2014-04-25 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.7202
852906,market wrap for april apples smashing earnings overshadowed by ukraine concerns,https://www.benzinga.com/news/14/04/4497474/market-wrap-for-april-24-apples-smashing-earnings-overshadowed-by-ukraine-concern,Jayson Derrick,2014-04-24 00:00:00,MRK,1,1,0,0,0,0,1,1,1,0.5
852907,fitch affirms mercks lt idr at a outlook negative,https://www.benzinga.com/news/14/04/4496676/fitch-affirms-mercks-lt-idr-at-a-outlook-negative,Paul Quintaro,2014-04-24 00:00:00,MRK,1,2,0,1,0,0,1,0,0,0.21405000000000002
852908,bank of america maintains buy on merck company inc raises pt to ,https://www.benzinga.com/news/14/04/4494394/bank-of-america-maintains-buy-on-merck-company-inc-raises-pt-to-62-00,Juan Lopez,2014-04-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852909,premarket technical update merck trading lower,https://www.benzinga.com/trading-ideas/technicals/14/04/4492390/premarket-technical-update-merck-trading-lower,Hal Lindon,2014-04-23 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.352
852910,bill ackman talks partnership with valeant for allergan deal,https://www.benzinga.com/media/cnbc/14/04/4491177/bill-ackman-talks-partnership-with-valeant-for-allergan-deal,Jason Papallo,2014-04-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852911,the top africanamerican ceos in business,https://www.benzinga.com/general/entrepreneurship/14/04/4440816/the-top-21-african-american-ceos-in-business,Jason Shubnell,2014-04-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852912,fda clears mercks ragwitek,https://www.benzinga.com/news/14/04/4479947/fda-clears-mercks-ragwitek,Paul Quintaro,2014-04-17 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5386
852913,merck announces fda has approved grastek sublingual tablet for treatment of grass polleninduced allergic rhinitis,https://www.benzinga.com/news/14/04/4469568/merck-announces-fda-has-approved-grastek-sublingual-tablet-for-treatment-of-grass,Paul Quintaro,2014-04-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.57655
852914,market wrap for april markets surge on positive retail data citi earnings,https://www.benzinga.com/news/14/04/4469346/market-wrap-for-april-14-markets-surge-on-positive-retail-data-citi-earnings,Jayson Derrick,2014-04-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
852915,markets falling get your defense ready,https://www.benzinga.com/news/14/04/4465712/markets-falling-get-your-defense-ready,Charley Blaine,2014-04-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.67
852916,no legwork mondays merck and vioxx,https://www.benzinga.com/markets/14/04/4463942/no-legwork-mondays-merck-and-vioxx,Tabitha Jean Naylor,2014-04-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.352
852917,top upcoming earnings releases,https://www.benzinga.com/news/earnings/14/04/4463056/top-40-upcoming-earnings-releases,Erika Janowicz,2014-04-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852918,google honors chemist percy julian his contributions,https://www.benzinga.com/news/14/04/4464959/google-honors-chemist-percy-julian-his-contributions,Erika Janowicz,2014-04-11 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.7553000000000001
852919,us stock futures slip ahead of consumer sentiment report,https://www.benzinga.com/news/14/04/4464100/us-stock-futures-slip-ahead-of-consumer-sentiment-report,Monica Gerson,2014-04-11 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
852920,phase trial of mercks investigational chronic hepatitis c combination therapy mkmk demonstrates antiviral activity,https://www.benzinga.com/news/14/04/4463875/phase-2-trial-of-mercks-investigational-chronic-hepatitis-c-combination-therapy-m,Charles Gross,2014-04-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852921,when it comes to drug stocks do not always buy the news,https://www.benzinga.com/general/movers-shakers/14/04/4461950/when-it-comes-to-drug-stocks-do-not-always-buy-the-news,Joel Elconin,2014-04-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852922,us stock futures edge lower ahead of jobless claims data,https://www.benzinga.com/news/14/04/4460722/us-stock-futures-edge-lower-ahead-of-jobless-claims-data,Monica Gerson,2014-04-10 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.352
852923,merck announces results from studies evaluating mk and mk investigational hepatitis c treatments,https://www.benzinga.com/news/14/04/4460429/merck-announces-results-from-studies-evaluating-mk-5172-and-mk-8742-investigation,Charles Gross,2014-04-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852924,biotechs struggling to find a bottom,https://www.benzinga.com/news/14/04/4454025/biotechs-struggling-to-find-a-bottom,Charley Blaine,2014-04-08 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.28925
852925,express scripts reports spending on hepatitis c medications in us to rise by ,https://www.benzinga.com/news/14/04/4453501/express-scripts-reports-spending-on-hepatitis-c-medications-in-us-to-rise-1-800-b,Charles Gross,2014-04-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852926,merck presents early findings from mk treatment at aarc ,https://www.benzinga.com/news/14/04/4449062/merck-presents-early-findings-from-mk-3475-treatment-at-aarc-2014,Charles Gross,2014-04-06 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852927,merck shares volatile this afternoon reuters earlier reported co is seeing resistance from beef industry for test of zilmax on k cattle,https://www.benzinga.com/news/14/04/4447753/merck-shares-volatile-this-afternoon-reuters-earlier-reported-co-is-seeing-resist,Paul Quintaro,2014-04-04 00:00:00,MRK,1,0,0,1,0,0,1,1,1,0.648
852928,merck announces appointment of robert m davis as chief financial officer succeeds peter n kellogg who has served in the role since ,https://www.benzinga.com/news/14/03/4423626/merck-announces-appointment-of-robert-m-davis-as-chief-financial-officer-succeeds,Eddie Staley,2014-03-27 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.74695
852929,merck names robert davis as cfo succeeding peter kellogg,https://www.benzinga.com/news/14/03/4423623/merck-names-robert-davis-as-cfo-succeeding-peter-kellogg,Paul Quintaro,2014-03-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
852930,nanobio announces licensing agreement with unit of merck for use of its nanoemulsion adjuvant technology,https://www.benzinga.com/news/14/03/4420686/nanobio-announces-licensing-agreement-with-unit-of-merck-for-use-of-its-nanoemuls,Charles Gross,2014-03-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
852931,nanobio announces licensing agreement with unit of merck for use of its nanoemulsion adjuvant technology,https://www.benzinga.com/news/14/03/4420687/nanobio-announces-licensing-agreement-with-unit-of-merck-for-use-of-its-nanoemuls,Charles Gross,2014-03-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
852932,reckitt benckiser a frontrunner for mercks otc segment sanofi rumored to join bidders final bids are due next week bloomberg,https://www.benzinga.com/news/14/03/4414254/reckitt-benckiser-a-frontrunner-for-mercks-otc-segment-sanofi-rumored-to-join-bid,Paul Quintaro,2014-03-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852933,google honors activist dorothy height her contributions,https://www.benzinga.com/news/14/03/4413835/google-honors-activist-dorothy-height-her-contributions,Erika Janowicz,2014-03-24 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.7553000000000001
852934,midday market update nike drops on cautious forecast endocyte shares spike higher,https://www.benzinga.com/news/earnings/14/03/4409945/mid-day-market-update-nike-drops-on-cautious-forecast-endocyte-shares-sp,Jake L'Ecuyer,2014-03-21 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.60115
852935,premarket prep technical update merck trading lower after higher open,https://www.benzinga.com/general/movers-shakers/14/03/4409714/premarket-prep-technical-update-merck-trading-lower-after-highe,Hal Lindon,2014-03-21 00:00:00,MRK,0,1,0,1,1,0,0,0,0,0.352
852936,midmorning market update markets open higher tiffany posts downbeat earnings,https://www.benzinga.com/news/earnings/14/03/4409603/mid-morning-market-update-markets-open-higher-tiffany-posts-downbeat-ear,Jake L'Ecuyer,2014-03-21 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852937,benzingas volume movers,https://www.benzinga.com/news/14/03/4409602/benzingas-volume-movers,Lisa Levin,2014-03-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852938,update endocyte shares rise ,https://www.benzinga.com/news/14/03/4409189/update-endocyte-shares-rise-158,Charles Gross,2014-03-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
852939,update endocyte shares rise on european chmp positive opinions for vynfinit,https://www.benzinga.com/news/14/03/4409114/update-endocyte-shares-rise-91-on-european-chmp-positive-opinions-for-vynfinit,Charles Gross,2014-03-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.85015
852940,preview endocyte to resume trading at am et,https://www.benzinga.com/news/14/03/4409031/preview-endocyte-to-resume-trading-at-8-30am-et,Charles Gross,2014-03-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852941,benzingas top premarket gainers,https://www.benzinga.com/news/14/03/4409027/benzingas-top-premarket-gainers,Monica Gerson,2014-03-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852942,merck endocyte announce european chmp positive opinions for vynfinit companion agents folcepri neocepri,https://www.benzinga.com/news/14/03/4409007/merck-endocyte-announce-european-chmp-positive-opinions-for-vynfinit-companion-ag,Paul Quintaro,2014-03-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
852943,ligand pharma announces m milestone payment triggered following fda approval of mercks noxafil,https://www.benzinga.com/news/14/03/4394813/ligand-pharma-announces-1m-milestone-payment-triggered-following-fda-approval-of-,Paul Quintaro,2014-03-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
852944,update fda approves merck noxafi injection for iv use,https://www.benzinga.com/news/14/03/4392406/update-fda-approves-merck-noxafi-injection-for-iv-use,Paul Quintaro,2014-03-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
852945,fda approves merck noxafi injection for intravenous use,https://www.benzinga.com/news/14/03/4392402/fda-approves-merck-noxafi-injection-for-intravenous-use,Charles Gross,2014-03-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
852946,merck unchanged,https://www.benzinga.com/trading-ideas/technicals/14/03/4386061/merck-unchanged,Hal Lindon,2014-03-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852947,merck trading higher,https://www.benzinga.com/trading-ideas/technicals/14/03/4371565/merck-trading-higher,Hal Lindon,2014-03-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852948,merck announces mk shows antiviral activity in phase b trial co planning to initiate phase development program during h,https://www.benzinga.com/news/14/03/4367440/merck-announces-mk-1439-shows-antiviral-activity-in-phase-2b-trial-co-planning-to,Paul Quintaro,2014-03-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852949,update merck plans to initiate phase clinical development program in second half of ,https://www.benzinga.com/news/14/03/4367439/update-merck-plans-to-initiate-phase-3-clinical-development-program-in-second-hal,Charles Gross,2014-03-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852950,mercks investigational hiv therapy doravirine mk demonstrates antiviral activity in phase b study of treatmentnaÃ¯ve adults,https://www.benzinga.com/news/14/03/4367435/mercks-investigational-hiv-therapy-doravirine-mk-1439-demonstrates-antiviral-acti,Charles Gross,2014-03-05 00:00:00,MRK,1,0,1,0,0,1,1,1,1,0.5
852951,merck issues results from phase b study of mk says secondary efficacy endpoints average tnss du made significant dose time dependent reduction,https://www.benzinga.com/news/14/03/4364769/merck-issues-results-from-phase-2b-study-of-mk-8237-says-secondary-efficacy-endpo,Paul Quintaro,2014-03-04 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.60115
852952,biotechs vs pharmaceuticals whats the difference,https://www.benzinga.com/general/education/14/03/4361845/biotechs-vs-pharmaceuticals-whats-the-difference,Tim Parker,2014-03-04 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852953,the top five dow stocks in february,https://www.benzinga.com/trading-ideas/14/03/4356938/the-top-five-dow-stocks-in-february,Nelson Hem,2014-03-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852954,overvaluing liquidity invest for the future not for today,https://www.benzinga.com/general/education/14/02/4355220/overvaluing-liquidity-invest-for-the-future-not-for-today,Tim Melvin,2014-02-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852955,chmp issues positive opinion for tablet formulation of mercks noxafil,https://www.benzinga.com/news/14/02/4354299/chmp-issues-positive-opinion-for-tablet-formulation-of-mercks-noxafil,Charles Gross,2014-02-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
852956,hb reporting via bloomberg merck is still interested in more purchases in the pharma group,https://www.benzinga.com/news/14/02/4325761/hb-reporting-via-bloomberg-merck-is-still-interested-in-more-purchases-in-the-pha,Paul Quintaro,2014-02-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
852957,merck testing multiyear highs,https://www.benzinga.com/trading-ideas/technicals/14/02/4325698/merck-testing-multi-year-highs,Hal Lindon,2014-02-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852958,merck reports fda acceptance for review of bla for v,https://www.benzinga.com/news/14/02/4324134/merck-reports-fda-acceptance-for-review-of-bla-for-v503,Paul Quintaro,2014-02-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
852959,fda accepts for review mercks biologics license application for v investigational valent human papillomavirus vaccine,https://www.benzinga.com/news/14/02/4324132/fda-accepts-for-review-mercks-biologics-license-application-for-v503-investigatio,Eddie Staley,2014-02-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6591
852960,merck finds resistance,https://www.benzinga.com/general/movers-shakers/14/02/4304611/merck-finds-resistance,Hal Lindon,2014-02-12 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852961,three etfs to buy on the pullback pjp skyy spy,https://www.benzinga.com/etfs/sector-etfs/14/02/4292008/three-etfs-to-buy-on-the-pullback-pjp-skyy-spy,Matthew McCall,2014-02-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852962,merck samsung bioepis announce deal to develop insulin glargine candidate,https://www.benzinga.com/news/14/02/4294650/merck-samsung-bioepis-announce-deal-to-develop-insulin-glargine-candidate,Paul Quintaro,2014-02-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
852963,market wrap for february jobs report not great but not too bad,https://www.benzinga.com/news/14/02/4292345/market-wrap-for-february-7-jobs-report-not-great-but-not-too-bad,Jayson Derrick,2014-02-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.69375
852964,bloomberg reporting merck has reached agreement in principle to resolve suits related to nuvaring,https://www.benzinga.com/news/14/02/4291274/bloomberg-reporting-merck-has-reached-agreement-in-principle-to-resolve-suits-rel,Paul Quintaro,2014-02-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.86755
852965,bloomberg reporting merck said to agree to pay m related to nuvaring settlement,https://www.benzinga.com/news/14/02/4288968/bloomberg-reporting-merck-said-to-agree-to-pay-100m-related-to-nuvaring-settlemen,Paul Quintaro,2014-02-06 00:00:00,MRK,1,0,0,1,0,0,1,1,1,0.6366
852966,premarket primer thursday february markets taking a breather after twitter earnings,https://www.benzinga.com/news/earnings/14/02/4286643/premarket-primer-thursday-february-6-markets-taking-a-breather-after-twi,Tim Parker,2014-02-06 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852967,market wrap for february markets unsure of which direction to take,https://www.benzinga.com/news/14/02/4285207/market-wrap-for-february-5-markets-unsure-of-which-direction-to-take,Jayson Derrick,2014-02-05 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.375
852968,merck retreats from highs,https://www.benzinga.com/general/movers-shakers/14/02/4284722/merck-retreats-from-highs,Hal Lindon,2014-02-05 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852969,top trending tickers on stocktwits for february ,https://www.benzinga.com/news/14/02/4283338/top-trending-tickers-on-stocktwits-for-february-5,Jayson Derrick,2014-02-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852970,stocks hitting week highs,https://www.benzinga.com/news/14/02/4283918/stocks-hitting-52-week-highs,Lisa Levin,2014-02-05 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
852971,benzingas top premarket gainers,https://www.benzinga.com/news/14/02/4283138/benzingas-top-premarket-gainers,Monica Gerson,2014-02-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
852972,update merck posts drop in q profit,https://www.benzinga.com/news/earnings/14/02/4282886/update-merck-posts-drop-in-q4-profit,Monica Gerson,2014-02-05 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.60115
852973,merck company inc sees fy eps vs est sees sales bb vs b est,https://www.benzinga.com/news/14/02/4282811/merck-company-inc-sees-fy2014-eps-3-35-3-53-vs-3-47-est-sees-sales-42-40b-43-20b-,Paul Quintaro,2014-02-05 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
852974,us stock futures flat all eyes on adp report,https://www.benzinga.com/news/14/02/4282808/us-stock-futures-flat-all-eyes-on-adp-report,Monica Gerson,2014-02-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852975,merck company inc reports q adjusted eps of inline revenue of b vs b est,https://www.benzinga.com/news/earnings/14/02/4282777/merck-company-inc-reports-q4-adjusted-eps-of-0-88-inline-revenue-of-11-3,Charles Gross,2014-02-05 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
852976,pfizer confirms collaboration with merck on innovative anticancer combination studies,https://www.benzinga.com/news/14/02/4282710/pfizer-confirms-collaboration-with-merck-on-innovative-anti-cancer-combination-st,Charles Gross,2014-02-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
852977,incyte confirms clinical trial collaboration with merck to evaluate combination of two novel immunotherapies,https://www.benzinga.com/news/14/02/4282709/incyte-confirms-clinical-trial-collaboration-with-merck-to-evaluate-combination-o,Charles Gross,2014-02-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
852978,merck confirms collaborations with amgen incyte and pfizer to evaluate novel combination anticancer regimens with mk,https://www.benzinga.com/news/14/02/4282684/merck-confirms-collaborations-with-amgen-incyte-and-pfizer-to-evaluate-novel-comb,Charles Gross,2014-02-05 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.6591
852979,amgenmerck announce collaboration to evaluate investigational combination treatment for advanced melanoma,https://www.benzinga.com/news/14/02/4282630/amgen-merck-announce-collaboration-to-evaluate-investigational-combination-treatm,Charles Gross,2014-02-05 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.625
852980,earnings scheduled for february ,https://www.benzinga.com/news/earnings/14/02/4282435/earnings-scheduled-for-february-5-2014,Monica Gerson,2014-02-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852981,stocks to watch for february ,https://www.benzinga.com/news/earnings/14/02/4282418/stocks-to-watch-for-february-5-2014,Monica Gerson,2014-02-05 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
852982,merck rallies back,https://www.benzinga.com/trading-ideas/technicals/14/02/4280721/merck-rallies-back,Hal Lindon,2014-02-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852983,suntrust robinson humphrey upgrades merck company inc to buy,https://www.benzinga.com/news/14/02/4278606/suntrust-robinson-humphrey-upgrades-merck-company-inc-to-buy,Paul Quintaro,2014-02-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852984,merck receives canadian approval of grastek,https://www.benzinga.com/news/14/02/4274965/merck-receives-canadian-approval-of-grastek,Paul Quintaro,2014-02-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
852985,earnings expectations for the week of february gm twitter disney and more,https://www.benzinga.com/news/earnings/14/02/4273611/earnings-expectations-for-the-week-of-february-3-gm-twitter-disney-and-m,Nelson Hem,2014-02-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
852986,market wrap for january markets end january on sour note,https://www.benzinga.com/news/14/01/4272196/market-wrap-for-january-31-markets-end-january-on-sour-note,Jayson Derrick,2014-01-31 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
852987,reuters reporting merck consumer health unit could get b in sale,https://www.benzinga.com/news/14/01/4271822/reuters-reporting-merck-consumer-health-unit-could-get-8-10b-in-sale,Paul Quintaro,2014-01-31 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
852988,market wrap for january china concerns declining home sales tomorrows fed meeting and obamas speech keep markets lower,https://www.benzinga.com/news/14/01/4255280/market-wrap-for-january-27-china-concerns-declining-home-sales-tomorrows-fed-meet,Jayson Derrick,2014-01-27 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.352
852989,winters stock knockdown may give way to a spring thaw,https://www.benzinga.com/news/14/01/4253896/winters-stock-knockdown-may-give-way-to-a-spring-thaw,Charley Blaine,2014-01-27 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
852990,update merck upgraded by morgan stanley on oncology optimism,https://www.benzinga.com/news/14/01/4254178/update-merck-upgraded-by-morgan-stanley-on-oncology-optimism,Victor Nguyen,2014-01-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.77115
852991,stocks hitting week highs,https://www.benzinga.com/news/14/01/4254172/stocks-hitting-52-week-highs,Monica Gerson,2014-01-27 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
852992,benzingas top upgrades,https://www.benzinga.com/analyst-ratings/upgrades/14/01/4253209/benzingas-top-upgrades,Monica Gerson,2014-01-27 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.60115
852993,us stock futures gain ahead of homesales data,https://www.benzinga.com/news/14/01/4253119/us-stock-futures-gain-ahead-of-home-sales-data,Monica Gerson,2014-01-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.76335
852994,morgan stanley upgrades merck company inc to overweight announces pt,https://www.benzinga.com/news/14/01/4252912/morgan-stanley-upgrades-merck-company-inc-to-overweight-announces-60-00-pt,Juan Lopez,2014-01-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3194
852995,merck shares higher following bristolmyers phase disappointment,https://www.benzinga.com/analyst-ratings/analyst-color/14/01/4250852/merck-shares-higher-following-bristol-myers-phase-3-disa,Erika Janowicz,2014-01-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.3634
852996,merck pleased with fda advisory committee recommendation for approval of vorapaxar,https://www.benzinga.com/news/14/01/4227122/merck-pleased-with-fda-advisory-committee-recommendation-for-approval-of-vorapaxa,Charles Gross,2014-01-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8592
852997,market wrap for january bulls take over as economic growth remains healthy,https://www.benzinga.com/news/earnings/14/01/4226775/market-wrap-for-january-15-bulls-take-over-as-economic-growth-remains-he,Jayson Derrick,2014-01-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8243
852998,bloomberg first word reporting merck has won fda advisory panel support for vorapaxar,https://www.benzinga.com/news/14/01/4226600/bloomberg-first-word-reporting-merck-has-won-fda-advisory-panel-support-for-vorap,Paul Quintaro,2014-01-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8753
852999,merck voluntarily recalls all lots of liptruzet cites packaging defects,https://www.benzinga.com/news/14/01/4221303/merck-voluntarily-recalls-all-lots-of-liptruzet-cites-packaging-defects,Paul Quintaro,2014-01-14 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.29905000000000004
853000,benzingas ma chatter for monday january ,https://www.benzinga.com/news/14/01/4219291/benzingas-m-a-chatter-for-monday-january-13-2014,Charles Gross,2014-01-13 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853001,market wrap for january markets showing weakness ahead of major earning releases,https://www.benzinga.com/news/14/01/4219057/market-wrap-for-january-13-markets-showing-weakness-ahead-of-major-earning-releas,Jayson Derrick,2014-01-13 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.28925
853002,midafternoon market update markets dip despite large amount of ma,https://www.benzinga.com/news/earnings/14/01/4218866/mid-afternoon-market-update-markets-dip-despite-large-amount-of-m-a,Jake L'Ecuyer,2014-01-13 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853003,midday market update sodastream drops after weak outlook beam shares spike higher,https://www.benzinga.com/news/earnings/14/01/4218359/mid-day-market-update-sodastream-drops-after-weak-outlook-beam-shares-sp,Jake L'Ecuyer,2014-01-13 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.41105
853004,midmorning market update markets open lower lululemon lowers q outlook,https://www.benzinga.com/news/earnings/14/01/4217874/mid-morning-market-update-markets-open-lower-lululemon-lowers-q4-outlook,Jake L'Ecuyer,2014-01-13 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.29905000000000004
853005,morning market movers,https://www.benzinga.com/news/14/01/4217817/morning-market-movers,Lisa Levin,2014-01-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853006,merck initiates rolling submission to fda of us biologics license application for mk,https://www.benzinga.com/news/14/01/4217391/merck-initiates-rolling-submission-to-fda-of-us-biologics-license-application-for,Charles Gross,2014-01-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853007,merck begins enrollment of bla for mk sees completing application in h,https://www.benzinga.com/news/14/01/4217345/merck-begins-enrollment-of-bla-for-mk-3475-sees-completing-application-in-1h14,Paul Quintaro,2014-01-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853008,benzingas top premarket gainers,https://www.benzinga.com/news/14/01/4217204/benzingas-top-premarket-gainers,Monica Gerson,2014-01-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
853009,update novartis could swap its animalhealth human vaccines units for mercks otc healthproducts unit,https://www.benzinga.com/news/14/01/4203453/update-novartis-could-swap-its-animal-health-human-vaccines-units-for-mercks-otc-,Paul Quintaro,2014-01-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853010,bloomberg reporting novartis said to be in talks with merck on b unit swap,https://www.benzinga.com/news/14/01/4203452/bloomberg-reporting-novartis-said-to-be-in-talks-with-merck-on-5b-unit-swap,Paul Quintaro,2014-01-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853011,merck receives fda approval for isentress for pediatric,https://www.benzinga.com/news/14/01/4202001/merck-receives-fda-approval-for-isentress-for-pediatric,Paul Quintaro,2014-01-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
853012,wsj reporting merck on radically reshaping rd,https://www.benzinga.com/news/13/12/4182360/wsj-reporting-merck-on-radically-reshaping-r-d,Paul Quintaro,2013-12-27 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853013,alk reports fda panel will revie ragweed tablet,https://www.benzinga.com/news/13/12/4180834/alk-reports-fda-panel-will-revie-ragweed-tablet,Paul Quintaro,2013-12-26 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853014,merck sues to stop generic nuvaring,https://www.benzinga.com/trading-ideas/long-ideas/13/12/4180646/merck-sues-to-stop-generic-nuvaring,Daniel Jennings,2013-12-26 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.352
853015,merck spikes higher on positive jim cramermad money comments,https://www.benzinga.com/media/cnbc/13/12/4167252/merck-spikes-higher-on-positive-jim-cramermad-money-comments,Charles Gross,2013-12-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
853016,merck collaborates with glaxosmithkline on mk,https://www.benzinga.com/news/13/12/4164741/merck-collaborates-with-glaxosmithkline-on-mk-3475,Charles Gross,2013-12-18 00:00:00,MRK,1,2,1,0,0,1,1,1,1,0.5
853017,merck says vintafolide has won orphan drug designation for ovarian cancer,https://www.benzinga.com/news/13/12/4163486/merck-says-vintafolide-has-won-orphan-drug-designation-for-ovarian-cancer,Paul Quintaro,2013-12-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.41105
853018,ema says will discuss extension of indication for mercks noxafil isentress pfizers vfend amgens xgeva vertex pharmas kalydeco,https://www.benzinga.com/news/13/12/4162251/ema-says-will-discuss-extension-of-indication-for-mercks-noxafil-isentress-pfizer,Paul Quintaro,2013-12-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853019,fda reviewing mercks bid for grastek panel recommends approval of grastek,https://www.benzinga.com/news/13/12/4152281/fda-reviewing-mercks-bid-for-grastek-panel-recommends-approval-of-grastek,Paul Quintaro,2013-12-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8062
853020,premarket primer thursday december us budget deal gaining momentum,https://www.benzinga.com/markets/bonds/13/12/4149958/premarket-primer-thursday-december-12-us-budget-deal-gaining-momentum,Laura Brodbeck,2013-12-12 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.71075
853021,merck says data monitoring committee recommending continuation of phase iiiii epoch study for mk,https://www.benzinga.com/news/13/12/4142743/merck-says-data-monitoring-committee-recommending-continuation-of-phase-iiiii-epo,Paul Quintaro,2013-12-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853022,merck agrees to settle litigation over jaw injuries caused by fosamax reuters,https://www.benzinga.com/news/13/12/4140862/merck-agrees-to-settle-litigation-over-jaw-injuries-caused-by-fosamax-reuters,Charles Gross,2013-12-09 00:00:00,MRK,1,0,0,0,0,0,1,1,1,0.5
853023,bloomberg reporting merck eli lilly rumored to be interested in novartis veterinary unit,https://www.benzinga.com/news/13/12/4125553/bloomberg-reporting-merck-eli-lilly-rumored-to-be-interested-in-novartis-veterina,Paul Quintaro,2013-12-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
853024,merck raises quarterly dividend to from ,https://www.benzinga.com/news/13/11/4111053/merck-raises-quarterly-dividend-to-0-44-from-0-43,Charles Gross,2013-11-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853025,fda okays mercks noxafil dr tablets,https://www.benzinga.com/news/13/11/4109957/fda-okays-mercks-noxafil-dr-tablets,Paul Quintaro,2013-11-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
853026,merck announces position opinion from chmp on update for erbitux metastatic colorectal cancer labeling,https://www.benzinga.com/news/13/11/4103302/merck-announces-position-opinion-from-chmp-on-update-for-erbitux-metastatic-color,Paul Quintaro,2013-11-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
853027,investing in companies developing promising immunotherapy drugs for melanoma,https://www.benzinga.com/markets/13/11/4088353/investing-in-companies-developing-promising-immunotherapy-drugs-for-melanoma,GlenWoods,2013-11-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
853028,mercks nda for noxafil wins fda priority review,https://www.benzinga.com/news/13/11/4087690/mercks-nda-for-noxafil-wins-fda-priority-review,Paul Quintaro,2013-11-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7859499999999999
853029,mercks mk significantly reduced allergy symptoms in adults and children in pivotal phase iii study,https://www.benzinga.com/news/13/11/4066759/mercks-mk-7243-significantly-reduced-allergy-symptoms-in-adults-and-children-in-p,Charles Gross,2013-11-09 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
853030,job cuts higher in october pharmaceutical financial sectors took biggest hits,https://www.benzinga.com/news/13/11/4057611/job-cuts-higher-in-october-pharmaceutical-financial-sectors-took-biggest-hits,Bruce Kennedy,2013-11-06 00:00:00,MRK,1,1,0,1,0,0,1,1,0,0.352
853031,analysts comment on mercks hep c regiment advances,https://www.benzinga.com/analyst-ratings/analyst-color/13/11/4048183/analysts-comment-on-mercks-hep-c-regiment-advances,Erika Janowicz,2013-11-04 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853032,merck says investigational v prevented of cervical vaginal vulvar precancers caused by five added hpv types,https://www.benzinga.com/news/13/11/4047211/merck-says-investigational-v503-prevented-97-of-cervical-vaginal-vulvar-pre-cance,Paul Quintaro,2013-11-04 00:00:00,MRK,1,1,1,0,0,1,1,1,1,0.5129
853033,bmo capital upgrades merck company inc to outperform,https://www.benzinga.com/news/13/11/4044361/bmo-capital-upgrades-merck-company-inc-to-outperform,Paul Quintaro,2013-11-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853034,market wrap for october fed worries pull stocks lower,https://www.benzinga.com/markets/bonds/13/10/4041967/market-wrap-for-october-31-fed-worries-pull-stocks-lower,Charley Blaine,2013-10-31 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.19379999999999997
853035,us stock futures flat ahead of fed,https://www.benzinga.com/news/13/10/4029996/us-stock-futures-flat-ahead-of-fed,Monica Gerson,2013-10-29 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853036,premarket primer tuesday october fed meeting likely uneventful,https://www.benzinga.com/news/earnings/13/10/4029417/premarket-primer-tuesday-october-29-fed-meeting-likely-uneventful,Laura Brodbeck,2013-10-29 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853037,merck presents interim data from phase b study of mk at th world conference on lung cancer,https://www.benzinga.com/news/13/10/4029607/merck-presents-interim-data-from-phase-1b-study-of-mk-3475-at-15th-world-conferen,Charles Gross,2013-10-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
853038,think silver top stocks catering to seniors,https://www.benzinga.com/general/travel/13/10/4024406/think-silver-top-stocks-catering-to-seniors,Tabitha Jean Naylor,2013-10-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
853039,midafternoon market update markets mixed as jc penney rises,https://www.benzinga.com/news/earnings/13/10/4027987/mid-afternoon-market-update-markets-mixed-as-jc-penney-rises,Jake L'Ecuyer,2013-10-28 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853040,midday market update burger king surges on upbeat earnings sohu shares dip,https://www.benzinga.com/news/earnings/13/10/4027500/mid-day-market-update-burger-king-surges-on-upbeat-earnings-sohu-shares-,Jake L'Ecuyer,2013-10-28 00:00:00,MRK,1,0,0,1,1,0,1,1,1,0.648
853041,midmorning market update markets mixed merck profit beats estimates,https://www.benzinga.com/news/earnings/13/10/4027018/mid-morning-market-update-markets-mixed-merck-profit-beats-estimates,Jake L'Ecuyer,2013-10-28 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.7202
853042,mercks q call just beginning,https://www.benzinga.com/news/13/10/4026364/mercks-q3-call-just-beginning,Paul Quintaro,2013-10-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853043,update merck posts upbeat q profit,https://www.benzinga.com/news/earnings/13/10/4026030/update-merck-posts-upbeat-q3-profit,Monica Gerson,2013-10-28 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.7202
853044,merck company inc narrows fy eps guidance from to vs est,https://www.benzinga.com/news/13/10/4025940/merck-company-inc-narrows-fy2013-eps-guidance-from-3-45-3-55-to-3-48-3-52-vs-3-47,Paul Quintaro,2013-10-28 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853045,merck company inc reports q eps of vs est revenue of b vs b est,https://www.benzinga.com/news/earnings/13/10/4025935/merck-company-inc-reports-q3-eps-of-0-92-vs-0-88-est-revenue-of-11-03b-v,Paul Quintaro,2013-10-28 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853046,premarket primer monday october all eyes on apple,https://www.benzinga.com/news/earnings/13/10/4025845/premarket-primer-monday-october-28-all-eyes-on-apple,Laura Brodbeck,2013-10-28 00:00:00,MRK,1,2,1,0,0,0,1,1,1,0.5
853047,earnings scheduled for october ,https://www.benzinga.com/news/earnings/13/10/4025722/earnings-scheduled-for-october-28-2013,Monica Gerson,2013-10-28 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853048,stocks to watch for october ,https://www.benzinga.com/news/earnings/13/10/4025710/stocks-to-watch-for-october-28-2013,Monica Gerson,2013-10-28 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853049,earnings expectations for the week of october apple facebook gm and more,https://www.benzinga.com/news/earnings/13/10/4025169/earnings-expectations-for-the-week-of-october-28-apple-facebook-gm-and-m,Nelson Hem,2013-10-27 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853050,benzinga weekly preview fomc meeting closely watched,https://www.benzinga.com/news/13/10/4023784/benzinga-weekly-preview-fomc-meeting-closely-watched,Laura Brodbeck,2013-10-25 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853051,short sellers retreat from biogen idec move on pharmacyclics biib bmrn pcyc,https://www.benzinga.com/trading-ideas/short-ideas/13/10/4023493/short-sellers-retreat-from-biogen-idec-move-on-pharmacyclics,Nelson Hem,2013-10-25 00:00:00,MRK,0,2,0,0,0,0,0,0,0,0.60115
853052,merck says primary endpoints met for investigational valent hpv vaccine expecting to submit bla for v in ,https://www.benzinga.com/news/13/10/4019525/merck-says-primary-endpoints-met-for-investigational-9-valent-hpv-vaccine-expecti,Paul Quintaro,2013-10-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853053,merck says primary endpoints met for investigational valent hpv vaccine expecting to submit bla for v in ,https://www.benzinga.com/news/13/10/4019524/merck-says-primary-endpoints-met-for-investigational-9-valent-hpv-vaccine-expecti,Paul Quintaro,2013-10-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853054,how investors can play the losers in blue chips,https://www.benzinga.com/markets/13/10/4015334/how-investors-can-play-the-losers-in-blue-chips,investmentcontrarians,2013-10-23 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.375
853055,mercks mkmk receives breakthrough therapy designation from fda,https://www.benzinga.com/news/13/10/4012613/mercks-mk-5172mk-8742-receives-breakthrough-therapy-designation-from-fda,Paul Quintaro,2013-10-22 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.5
853056,merck confirms development of investigational dosing isentress will begin phase iii trial early ,https://www.benzinga.com/news/13/10/3995675/merck-confirms-development-of-investigational-dosing-isentress-will-begin-phase-i,Paul Quintaro,2013-10-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853057,merck endocyte report vintafolidepld generaly well tolerated showed median pfs of five months,https://www.benzinga.com/news/13/10/3989717/merck-endocyte-report-vintafolide-pld-generaly-well-tolerated-showed-median-pfs-o,Paul Quintaro,2013-10-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6366
853058,update bernstein downgrades merck co on negative outlook,https://www.benzinga.com/analyst-ratings/analyst-color/13/10/3988673/update-bernstein-downgrades-merck-co-on-negative-outlook,Dwight Einhorn,2013-10-14 00:00:00,MRK,1,1,0,1,0,0,1,0,0,0.21405000000000002
853059,barclays downgrades merck company inc to equalweight,https://www.benzinga.com/news/13/10/3988736/barclays-downgrades-merck-company-inc-to-equalweight,Paul Quintaro,2013-10-14 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.5
853060,benzingas top downgrades,https://www.benzinga.com/analyst-ratings/downgrades/13/10/3988190/benzingas-top-downgrades,Monica Gerson,2013-10-14 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.60115
853061,bernstein downgrades merck company inc to market perform lowers pt to ,https://www.benzinga.com/news/13/10/3988040/bernstein-downgrades-merck-company-inc-to-market-perform-lowers-pt-to-50-00,Paul Quintaro,2013-10-14 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.436
853062,short sellers move on amgen vertex amgn pcyc vrtx,https://www.benzinga.com/trading-ideas/short-ideas/13/10/3985717/short-sellers-move-on-amgen-vertex-amgn-pcyc-vrtx,Nelson Hem,2013-10-11 00:00:00,MRK,0,2,0,0,0,0,0,0,0,0.5
853063,jefferies downgrades merck company inc to hold lowers pt to ,https://www.benzinga.com/news/13/10/3984955/jefferies-downgrades-merck-company-inc-to-hold-lowers-pt-to-50-00,Paul Quintaro,2013-10-11 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.436
853064,credit suisse starts pfizer bristolmyers abbvie allergan at outperform merck eli lilly forest labs at neutral,https://www.benzinga.com/analyst-ratings/price-target/13/10/3976494/credit-suisse-starts-pfizer-bristol-myers-abbvie-allergan,Paul Quintaro,2013-10-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6909
853065,fda postpones advisory committee meeting for grass ait tablet due to us government shutdown,https://www.benzinga.com/news/13/10/3975619/fda-postpones-advisory-committee-meeting-for-grass-ait-tablet-due-to-us-governmen,Charles Gross,2013-10-08 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.3634
853066,merck says data shows cognigram as sensitive assessment,https://www.benzinga.com/news/13/10/3970742/merck-says-data-shows-cognigram-as-sensitive-assessment,Paul Quintaro,2013-10-07 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853067,pharmaceutical industry expected to collect billions from obamacare,https://www.benzinga.com/trading-ideas/long-ideas/13/10/3959811/pharmaceutical-industry-expected-to-collect-billions-from-oba,James Ha,2013-10-02 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853068,merck shares soar after announcing more job cuts,https://www.benzinga.com/news/13/10/3958346/merck-shares-soar-after-announcing-more-job-cuts,Chris Freeman,2013-10-01 00:00:00,MRK,1,1,0,1,0,0,1,0,0,0.46415
853069,merck says interim data for mk to be presented at th world conference on lung cancer,https://www.benzinga.com/news/13/10/3958076/merck-says-interim-data-for-mk-3475-to-be-presented-at-15th-world-conference-on-l,Paul Quintaro,2013-10-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
853070,premarket info recap for october government shutdown gives markets a boost,https://www.benzinga.com/markets/commodities/13/10/3956960/premarket-info-recap-for-october-1-2013-government-shutdown-gives-,PreMarketInfo,2013-10-01 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.70095
853071,merck says will close summit campus will move global hq to kenilworth,https://www.benzinga.com/news/13/10/3956564/merck-says-will-close-summit-campus-will-move-global-hq-to-kenilworth,Paul Quintaro,2013-10-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853072,update merck announces global initiative to sharpen commercial and rd focus cutting jobs affirms fy target,https://www.benzinga.com/news/13/10/3956170/update-merck-announces-global-initiative-to-sharpen-commercial-and-r-d-focus-cutt,Eddie Staley,2013-10-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.436
853073,merck cutting jobs related to global initiative to sharpen commercial rd focus sees pretax charge b reaffirms fy outlook,https://www.benzinga.com/news/13/10/3956165/merck-cutting-8-500-jobs-related-to-global-initiative-to-sharpen-commercial-r-d-f,Paul Quintaro,2013-10-01 00:00:00,MRK,1,1,0,1,0,0,1,1,0,0.436
853074,merck receives crl for investigational medicine sugammadex sodium injection,https://www.benzinga.com/news/13/09/3933088/merck-receives-crl-for-investigational-medicine-sugammadex-sodium-injection,Paul Quintaro,2013-09-23 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
853075,write a prescription for health care etfs,https://www.benzinga.com/analyst-ratings/analyst-color/13/09/3925530/write-a-prescription-for-health-care-etfs,ETF Professor,2013-09-19 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.74695
853076,alexion pharmacyclics buck trend in biotech short interest alxn celg pcyc,https://www.benzinga.com/trading-ideas/short-ideas/13/09/3913320/alexion-pharmacyclics-buck-trend-in-biotech-short-interest-a,Nelson Hem,2013-09-14 00:00:00,MRK,0,2,0,1,1,0,0,0,0,0.7294
853077,watch shares of caterpillar deere devon merck and oracle to the downside on a bearish article from jim cramer tweeted out by carl icahn,https://www.benzinga.com/news/13/09/3909895/watch-shares-of-caterpillar-deere-devon-merck-and-oracle-to-the-downside-on-a-bea,Eddie Staley,2013-09-12 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.5258
853078,us stock futures flat apple shares drop in premarket trading,https://www.benzinga.com/news/13/09/3904076/us-stock-futures-flat-apple-shares-drop-in-pre-market-trading,Monica Gerson,2013-09-11 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.5129
853079,merck astrazeneca announce license agreement for mk,https://www.benzinga.com/news/13/09/3903860/merck-astrazeneca-announce-license-agreement-for-mk-1775,Charles Gross,2013-09-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
853080,usa td ameritrades investor movement index for aug vs prior,https://www.benzinga.com/news/13/09/3897492/usa-td-ameritrades-investor-movement-index-for-aug-5-16-vs-4-87-prior,Paul Quintaro,2013-09-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853081,merck reports fda acceptance of nda for investigational fertility treatment,https://www.benzinga.com/news/13/09/3896301/merck-reports-fda-acceptance-of-nda-for-investigational-fertility-treatment,Paul Quintaro,2013-09-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
853082,mercks durham site receives us fda license for varicella bulk,https://www.benzinga.com/news/13/09/3887444/mercks-durham-site-receives-us-fda-license-for-varicella-bulk,Paul Quintaro,2013-09-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853083,plenty of etfs with favorable risk traits,https://www.benzinga.com/analyst-ratings/analyst-color/13/08/3876854/plenty-of-etfs-with-favorable-risk-traits,ETF Professor,2013-08-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
853084,short interest in celgene onyx continues to shrink celg onxx vrtx,https://www.benzinga.com/trading-ideas/short-ideas/13/08/3867159/short-interest-in-celgene-onyx-continues-to-shrink-celg-onxx,Nelson Hem,2013-08-27 00:00:00,MRK,0,1,0,1,1,0,0,0,0,0.7294
853085,chicago tribune running story cargill to stop buying cows fed with questionable growth drug related to mercks zillmax,https://www.benzinga.com/news/13/08/3865059/chicago-tribune-running-story-cargill-to-stop-buying-cows-fed-with-questionable-g,Paul Quintaro,2013-08-26 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.39885
853086,merck shares down today but have been relatively quietrangebound all day traders seemed to shrug at earlier report co to temporarily halt zilmax sales,https://www.benzinga.com/news/13/08/3845384/merck-shares-down-0-75-today-but-have-been-relatively-quietrangebound-all-day-tra,Paul Quintaro,2013-08-16 00:00:00,MRK,1,1,0,1,0,1,1,0,0,0.57655
853087,f from leon coopermans omega advisors shows new stakes in thermofisher mckesson liquidated stakes in freeportmcmoran facebook covidien raised stakes in dish citi lowered stakes in merck aig polycom,https://www.benzinga.com/news/13/08/3838598/13f-from-leon-coopermans-omega-advisors-shows-new-stakes-in-thermo-fisher-mckesso,Paul Quintaro,2013-08-14 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.436
853088,midafternoon market update apple rises sharply on icahn stake nasdaq pulled upward,https://www.benzinga.com/news/earnings/13/08/3835738/mid-afternoon-market-update-apple-rises-sharply-on-icahn-stake-nasdaq-pu,Jake L'Ecuyer,2013-08-13 00:00:00,MRK,1,1,1,0,1,1,1,1,1,0.5
853089,midday market update us stocks edge higher valspar shares decline on downbeat results,https://www.benzinga.com/news/earnings/13/08/3835348/mid-day-market-update-us-stocks-edge-higher-valspar-shares-decline-on-do,Jake L'Ecuyer,2013-08-13 00:00:00,MRK,1,1,1,1,0,1,1,1,0,0.648
853090,midmorning market update markets drop yum china samestore sales down ,https://www.benzinga.com/news/earnings/13/08/3834922/mid-morning-market-update-markets-drop-yum-china-same-store-sales-down-1,Jake L'Ecuyer,2013-08-13 00:00:00,MRK,1,1,0,1,1,0,0,0,0,0.3634
853091,benzingas top premarket gainers,https://www.benzinga.com/news/13/08/3834072/benzingas-top-pre-market-gainers,Lisa Levin,2013-08-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
853092,avanir pharmaceuticals announces diabetes copromotion agreement with merck,https://www.benzinga.com/news/13/08/3832130/avanir-pharmaceuticals-announces-diabetes-co-promotion-agreement-with-merck,James Hunt,2013-08-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
853093,hearing unconfirmed takeover chatter in inovio,https://www.benzinga.com/news/13/08/3812855/hearing-unconfirmed-takeover-chatter-in-inovio,Charles Gross,2013-08-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
853094,apple walmart and other companies with monster share buyback aapl wmt,https://www.benzinga.com/news/buybacks/13/08/3812457/apple-wal-mart-and-other-companies-with-monster-share-buyback-aapl-wmt,Nelson Hem,2013-08-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
853095,sp heaping praise for some health care etfs,https://www.benzinga.com/analyst-ratings/analyst-color/13/08/3809455/s-p-heaping-praise-for-some-health-care-etfs,ETF Professor,2013-08-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.88915
853096,three soaring but overlooked health care etfs,https://www.benzinga.com/trading-ideas/long-ideas/13/08/3809192/three-soaring-but-overlooked-health-care-etfs,ETF Professor,2013-08-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8155
853097,bionomics signs option and license agreement with merck,https://www.benzinga.com/news/13/07/3798765/bionomics-signs-option-and-license-agreement-with-merck,Charles Gross,2013-07-31 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
853098,benzinga market primer wednesday july futures higher heading into fomc decision,https://www.benzinga.com/markets/bonds/13/07/3798536/benzinga-market-primer-wednesday-july-31-futures-higher-heading-into-fom,Matthew Kanterman,2013-07-31 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853099,slideshow stocks to benefit from a repatriation deal in congress,https://www.benzinga.com/news/13/07/3795770/slideshow-8-stocks-to-benefit-from-a-repatriation-deal-in-congress,Matthew Kanterman,2013-07-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
853100,benzingas premarket info recap for july potash smash,https://www.benzinga.com/pre-market-outlook/13/07/3795113/benzingas-premarket-info-recap-for-july-30-2013-potash-smash,PreMarketInfo,2013-07-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853101,update merck posts drop in q profit,https://www.benzinga.com/news/earnings/13/07/3794387/update-merck-posts-drop-in-q2-profit,Lisa Levin,2013-07-30 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.60115
853102,merck company inc reports q eps of vs est revenue of b vs b est,https://www.benzinga.com/news/earnings/13/07/3794056/merck-company-inc-reports-q2-eps-of-0-84-vs-0-83-est-revenue-of-11-0b-vs,Paul Quintaro,2013-07-30 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853103,benzinga market primer wednesday july futures higher after asia turnaround,https://www.benzinga.com/markets/bonds/13/07/3793814/benzinga-market-primer-wednesday-july-30-futures-higher-after-asia-turna,Matthew Kanterman,2013-07-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853104,earnings expectations for the week of july ,https://www.benzinga.com/news/earnings/13/07/3789215/earnings-expectations-for-the-week-of-july-29,Nelson Hem,2013-07-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853105,weekly preview earnings season continues fed in focus economic maelstrom expected,https://www.benzinga.com/analyst-ratings/analyst-color/13/07/3787751/weekly-preview-earnings-season-continues-fed-in-focus-ec,Matthew Kanterman,2013-07-26 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853106,short interest in pharmacyclics plunges amgn onxx pcyc,https://www.benzinga.com/trading-ideas/short-ideas/13/07/3786501/short-interest-in-pharmacyclics-plunges-amgn-onxx-pcyc,Nelson Hem,2013-07-26 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.7294
853107,merck statement regarding chmp review of incretinbased therapies for type diabetes including sitagliptin,https://www.benzinga.com/news/13/07/3787088/merck-statement-regarding-chmp-review-of-incretin-based-therapies-for-type-2-diab,James Hunt,2013-07-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853108,update merck announces fda acceptance of new drug application for vorapaxar investigational antithrombotic medicine,https://www.benzinga.com/news/13/07/3778459/update-merck-announces-fda-acceptance-of-new-drug-application-for-vorapaxar-inves,James Hunt,2013-07-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
853109,merck announces fda acceptance of nda for vorapaxar,https://www.benzinga.com/news/13/07/3778379/merck-announces-fda-acceptance-of-nda-for-vorapaxar,Paul Quintaro,2013-07-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
853110,bmo capital downgrades merck company inc to market perform,https://www.benzinga.com/news/13/07/3763291/bmo-capital-downgrades-merck-company-inc-to-market-perform,Paul Quintaro,2013-07-18 00:00:00,MRK,1,1,0,1,1,0,1,1,1,0.5
853111,merck in talks with fda to identify steps needed for review of sugammadex sodium injection,https://www.benzinga.com/news/13/07/3756902/merck-in-talks-with-fda-to-identify-steps-needed-for-review-of-sugammadex-sodium-,Paul Quintaro,2013-07-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853112,eli lilly tries again with alzheimers drug as the race for a cure continues lly,https://www.benzinga.com/analyst-ratings/analyst-color/13/07/3756698/eli-lilly-tries-again-with-alzheimers-drug-as-the-race-f,Jim Probasco,2013-07-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853113,life technologies to collaborate with merck serono for companion diagnostics development and commercialization,https://www.benzinga.com/news/13/07/3755596/life-technologies-to-collaborate-with-merck-serono-for-companion-diagnostics-deve,James Hunt,2013-07-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853114,health care etfs looking healthy ahead of earnings,https://www.benzinga.com/analyst-ratings/analyst-color/13/07/3753598/health-care-etfs-looking-healthy-ahead-of-earnings,ETF Professor,2013-07-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8548
853115,sanofi pasteur vaccine suspended as precautionionary measury who citing quality problem,https://www.benzinga.com/news/13/07/3748974/sanofi-pasteur-vaccine-suspended-as-precautionionary-measury-who-citing-quality-p,Paul Quintaro,2013-07-12 00:00:00,MRK,1,1,1,0,1,1,1,1,1,0.14984999999999998
853116,update jefferies lowers pt on merck on challenges ahead,https://www.benzinga.com/analyst-ratings/analyst-color/13/07/3748686/update-jefferies-lowers-pt-on-merck-on-challenges-ahead,Dwight Einhorn,2013-07-12 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.4742
853117,jefferies maintains buy on merck company inc lowers pt to ,https://www.benzinga.com/news/13/07/3748358/jefferies-maintains-buy-on-merck-company-inc-lowers-pt-to-54-00,Juan Lopez,2013-07-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
853118,short interest rises in gilead sciences onyx pharmaceuticals biib gild onxx,https://www.benzinga.com/trading-ideas/short-ideas/13/07/3746399/short-interest-rises-in-gilead-sciences-onyx-pharmaceuticals,Nelson Hem,2013-07-11 00:00:00,MRK,0,0,1,0,0,1,0,0,0,0.7294
853119,financial times reporting that china is investigating foreign pharmaceutical companies for pricing irregularities,https://www.benzinga.com/news/13/07/3729718/financial-times-reporting-that-china-is-investigating-33-foreign-pharmaceutical-c,James Hunt,2013-07-04 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853120,pfizer and novartis could be eyeing onyx pfe nvs onxx,https://www.benzinga.com/analyst-ratings/analyst-color/13/07/3723726/pfizer-and-novartis-could-be-eyeing-onyx-pfe-nvs-onxx,Jim Probasco,2013-07-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853121,fda approves new us labeling for isentress raltegravir to include week results from startmrk study of isentress containing regimen in previously untreated hiv infected adult patients,https://www.benzinga.com/news/13/07/3722247/fda-approves-new-u-s-labeling-for-isentress-raltegravir-to-include-240-week-resul,James Hunt,2013-07-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.436
853122,merck receives complete response letter for suvorexant mercks investigational medicine for insomnia fda says data does not support approval of suvorexant mg and mg,https://www.benzinga.com/news/13/07/3720216/merck-receives-complete-response-letter-for-suvorexant-mercks-investigational-med,Eddie Staley,2013-07-01 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.20625
853123,merck receives crl for suvorexant,https://www.benzinga.com/news/13/07/3720201/merck-receives-crl-for-suvorexant,Paul Quintaro,2013-07-01 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
853124,aspen pharmacare to acquire netherlands plant portfolio of drug brands from merck for b reuters,https://www.benzinga.com/news/13/06/3711271/aspen-pharmacare-to-acquire-netherlands-plant-portfolio-of-11-drug-brands-from-me,Charles Gross,2013-06-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853125,short interest in biogen idec and vertex shrinks biib celg vrtx,https://www.benzinga.com/trading-ideas/short-ideas/13/06/3708852/short-interest-in-biogen-idec-and-vertex-shrinks-biib-celg-v,Nelson Hem,2013-06-26 00:00:00,MRK,0,2,0,1,1,0,0,0,0,0.7294
853126,update bmo capital markets lowers pt on merck following new sglt data,https://www.benzinga.com/analyst-ratings/analyst-color/13/06/3699314/update-bmo-capital-markets-lowers-pt-on-merck-following-,Dwight Einhorn,2013-06-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
853127,bmo capital maintains outperform on merck company inc lowers pt to ,https://www.benzinga.com/news/13/06/3699049/bmo-capital-maintains-outperform-on-merck-company-inc-lowers-pt-to-52-00,Juan Lopez,2013-06-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.436
853128,interesting similarities among s topperforming etfs,https://www.benzinga.com/trading-ideas/long-ideas/13/06/3686609/interesting-similarities-among-2013s-top-performing-etfs,ETF Professor,2013-06-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
853129,mylan being sued by pfizer merck want blockage of proposed copy of azasite,https://www.benzinga.com/news/13/06/3681630/mylan-being-sued-by-pfizer-merck-want-blockage-of-proposed-copy-of-azasite,Paul Quintaro,2013-06-17 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5386
853130,dow jones reporting merck to cut jobs change organizational structure of rd unit,https://www.benzinga.com/news/13/06/3677677/dow-jones-reporting-merck-to-cut-jobs-change-organizational-structure-of-r-d-unit,Paul Quintaro,2013-06-14 00:00:00,MRK,1,1,0,0,0,0,0,0,0,0.3634
853131,short interest falls in vertex rises in biogen idec vrtx biib,https://www.benzinga.com/trading-ideas/short-ideas/13/06/3670486/short-interest-in-vertex-falls-in-biogen-idec-rises,Nelson Hem,2013-06-12 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.7294
853132,fda says considering new study of incretin mimetic diabetes drug says may need to look for cancerlink patterns,https://www.benzinga.com/news/13/06/3669246/fda-says-considering-new-study-of-incretin-mimetic-diabetes-drug-says-may-need-to,Paul Quintaro,2013-06-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853133,merck loses us appeal of apotex patent win over nasonex,https://www.benzinga.com/news/13/06/3662242/merck-loses-us-appeal-of-apotex-patent-win-over-nasonex,Paul Quintaro,2013-06-10 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.6806
853134,update jefferies raises pt on merck co following global pharma review,https://www.benzinga.com/analyst-ratings/analyst-color/13/06/3657849/update-jefferies-raises-pt-on-merck-co-following-global-,Dwight Einhorn,2013-06-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853135,jefferies maintains buy on merck company inc raises pt to ,https://www.benzinga.com/news/13/06/3657173/jefferies-maintains-buy-on-merck-company-inc-raises-pt-to-56-00,Juan Lopez,2013-06-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853136,with bond yields so low reluctant investors are now making the move into these stocks,https://www.benzinga.com/markets/bonds/13/06/3646194/with-bond-yields-so-low-reluctant-investors-are-now-making-the-move-into,investmentcontrarians,2013-06-04 00:00:00,MRK,1,2,0,1,0,0,1,0,1,0.19255
853137,ism manufacturing index drops in may shows contraction,https://www.benzinga.com/markets/bonds/13/06/3642056/ism-manufacturing-index-drops-in-may-shows-contraction,Matthew Kanterman,2013-06-03 00:00:00,MRK,1,1,0,1,0,0,1,0,1,0.5
853138,benzingas top premarket gainers,https://www.benzinga.com/news/13/06/3641148/benzingas-top-pre-market-gainers,Lisa Levin,2013-06-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
853139,suntrust robinson humphrey initiates coverage on merck company inc at neutral announces pt,https://www.benzinga.com/news/13/05/3630597/suntrust-robinson-humphrey-initiates-coverage-on-merck-company-inc-at-neutral-ann,Paul Quintaro,2013-05-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853140,short interest in vertex rises in biogen idec falls,https://www.benzinga.com/trading-ideas/short-ideas/13/05/3629538/short-interest-in-vertex-rises-in-biogen-idec-falls,Nelson Hem,2013-05-29 00:00:00,MRK,0,2,0,0,0,0,0,0,0,0.7294
853141,update jefferies upgrades merck to buy raises pt following sotp analysis,https://www.benzinga.com/analyst-ratings/analyst-color/13/05/3624639/update-jefferies-upgrades-merck-to-buy-raises-pt-followi,Dwight Einhorn,2013-05-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853142,premarket info recap for may ,https://www.benzinga.com/news/earnings/13/05/3624297/premarket-info-recap-for-may-28-2013,PreMarketInfo,2013-05-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853143,jefferies upgrades merck company inc to buy raises pt to ,https://www.benzinga.com/news/13/05/3623664/jefferies-upgrades-merck-company-inc-to-buy-raises-pt-to-54-00,Juan Lopez,2013-05-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853144,merck issues update on phase iii trial for preladenant,https://www.benzinga.com/news/13/05/3617569/merck-issues-update-on-phase-iii-trial-for-preladenant,Paul Quintaro,2013-05-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853145,merck issues statement on fda advisory committee meeting results for suvorexant,https://www.benzinga.com/news/13/05/3613926/merck-issues-statement-on-fda-advisory-committee-meeting-results-for-suvorexant,Charles Gross,2013-05-22 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853146,fda panel votes mercks suvorexant unsafe in higher doses,https://www.benzinga.com/news/13/05/3613432/fda-panel-votes-8-7-mercks-suvorexant-unsafe-in-higher-doses,Paul Quintaro,2013-05-22 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853147,fda panel votes mercks suvorexant is safe in low doses,https://www.benzinga.com/news/13/05/3613366/fda-panel-votes-13-3-mercks-suvorexant-is-safe-in-low-doses,Paul Quintaro,2013-05-22 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.60115
853148,fda panel finds merck doesnt need to study mg suvorexant,https://www.benzinga.com/news/13/05/3613112/fda-panel-finds-merck-doesnt-need-to-study-10mg-suvorexant,Paul Quintaro,2013-05-22 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853149,fda says merck insomnia drug helps patients stay asleep bloomberg,https://www.benzinga.com/news/13/05/3613026/fda-says-merck-insomnia-drug-helps-patients-stay-asleep-bloomberg,Paul Quintaro,2013-05-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
853150,fda panel votes yes no on effectiveness of merck insomnia drug,https://www.benzinga.com/news/13/05/3613022/fda-panel-votes-12-yes-4-no-on-effectiveness-of-merck-insomnia-drug,Charles Gross,2013-05-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5640000000000001
853151,premarket info recap for may ,https://www.benzinga.com/news/13/05/3611571/premarket-info-recap-for-may-22-2013,PreMarketInfo,2013-05-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853152,merck fda advisory committee meeting for insomnia drug suvorexant begins at am et,https://www.benzinga.com/news/13/05/3610937/merck-fda-advisory-committee-meeting-for-insomnia-drug-suvorexant-begins-at-8-am-,Charles Gross,2013-05-22 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853153,merck to take initial delivery of m shares,https://www.benzinga.com/news/13/05/3609410/merck-to-take-initial-delivery-of-99-5m-shares,Paul Quintaro,2013-05-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
853154,merck announces b accelerated buyback plan,https://www.benzinga.com/news/13/05/3609393/merck-announces-5b-accelerated-buyback-plan,Paul Quintaro,2013-05-21 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853155,isi suggesting the fda report on merck points to some risk from panel,https://www.benzinga.com/analyst-ratings/analyst-color/13/05/3603751/isi-suggesting-the-fda-report-on-merck-points-to-some-ri,Paul Quintaro,2013-05-20 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.3634
853156,merck prices b debt offering,https://www.benzinga.com/news/13/05/3594201/merck-prices-6-5b-debt-offering,Paul Quintaro,2013-05-15 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.3194
853157,moodys downgrades mercks guaranteed senior unsecured rating from aa to a,https://www.benzinga.com/news/13/05/3589516/moodys-downgrades-mercks-guaranteed-senior-unsecured-rating-from-aa3-to-a1,Paul Quintaro,2013-05-14 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.30910000000000004
853158,short interest in vertex rises in celgene falls,https://www.benzinga.com/trading-ideas/short-ideas/13/05/3581061/short-interest-in-vertex-rises-in-celgene-falls,Nelson Hem,2013-05-11 00:00:00,MRK,0,2,0,0,0,0,0,0,0,0.7294
853159,merck glaxo reduce prices for hpv vaccine in poor nations,https://www.benzinga.com/news/13/05/3574149/merck-glaxo-reduce-prices-95-for-hpv-vaccine-in-poor-nations,Paul Quintaro,2013-05-09 00:00:00,MRK,1,0,0,1,0,0,1,1,1,0.26165
853160,merck announces fda acceptance of biologics license application for investigational ragweed pollen sublingual allergy immunotherapy tablet,https://www.benzinga.com/news/13/05/3570135/merck-announces-fda-acceptance-of-biologics-license-application-for-investigation,Paul Quintaro,2013-05-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
853161,barrons recap apple tops the barrons ,https://www.benzinga.com/media/barrons/13/05/3559462/barrons-recap-apple-tops-the-barrons-500,Nelson Hem,2013-05-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7553000000000001
853162,fda approves mercks liptruzet for hyperlipidemia treatment,https://www.benzinga.com/news/13/05/3558161/fda-approves-mercks-liptruzet-for-hyperlipidemia-treatment,Paul Quintaro,2013-05-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
853163,update fitch affirms ratings on merck outlook lowered from positive to negative,https://www.benzinga.com/news/13/05/3557328/update-fitch-affirms-ratings-on-merck-outlook-lowered-from-positive-to-negative,Paul Quintaro,2013-05-03 00:00:00,MRK,1,1,0,1,0,1,0,1,0,0.42345
853164,fitch affirms ratings on merck outlook lowered from positive to negative,https://www.benzinga.com/news/13/05/3557304/fitch-affirms-ratings-on-merck-outlook-lowered-from-positive-to-negative,Paul Quintaro,2013-05-03 00:00:00,MRK,1,1,0,1,0,1,0,1,0,0.42345
853165,earnings trigger volume spike in pharma etf,https://www.benzinga.com/news/earnings/13/05/3549321/earnings-trigger-volume-spike-in-pharma-etf,ETF Professor,2013-05-01 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853166,may st watchlist,https://www.benzinga.com/markets/options/13/05/3548193/may-1st-watchlist,Sang Lucci,2013-05-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853167,merck cc rd chief calls erosion on singulair sales faster than expected says victrelis sales harmed in us france germany,https://www.benzinga.com/news/13/05/3547579/merck-cc-r-d-chief-calls-erosion-on-singulair-sales-faster-than-expected-says-vic,Paul Quintaro,2013-05-01 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.26165
853168,from merck conference call q results not indicative of the future,https://www.benzinga.com/news/13/05/3547553/from-merck-conference-call-q1-results-not-indicative-of-the-future,Paul Quintaro,2013-05-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853169,update merck posts drop in q profit lowers forecast,https://www.benzinga.com/news/earnings/13/05/3547235/update-merck-posts-8-3-drop-in-q1-profit-lowers-forecast,Lisa Levin,2013-05-01 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.5386
853170,merck announces new b buyback plan,https://www.benzinga.com/news/13/05/3547124/merck-announces-new-15b-buyback-plan,Paul Quintaro,2013-05-01 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853171,merck company inc lowers fy eps guidance from to vs est,https://www.benzinga.com/news/13/05/3547123/merck-company-inc-lowers-fy2013-eps-guidance-from-3-60-3-70-to-3-45-3-55-vs-3-63-,Paul Quintaro,2013-05-01 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.436
853172,merck company inc reports q eps of vs est revenue of b vs b est,https://www.benzinga.com/news/earnings/13/05/3547049/merck-company-inc-reports-q1-eps-of-0-85-vs-0-79-est-revenue-of-10-70b-v,Charles Gross,2013-05-01 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853173,merck announces new b share repurchase program,https://www.benzinga.com/news/13/05/3546979/merck-announces-new-15b-share-repurchase-program,Charles Gross,2013-05-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
853174,pfizer tanks on earnings unhealthy guidance,https://www.benzinga.com/news/earnings/13/04/3542519/pfizer-tanks-on-earnings-unhealthy-guidance,Clay Wyatt,2013-04-30 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.23665000000000003
853175,merck wins fosamax federal bellwether trial involving atypical femur fracture claims,https://www.benzinga.com/news/13/04/3539713/merck-wins-fosamax-federal-bellwether-trial-involving-atypical-femur-fracture-cla,Eddie Staley,2013-04-29 00:00:00,MRK,1,0,0,1,1,0,1,0,1,0.7859499999999999
853176,market wrap for monday april stocks start week with a rally,https://www.benzinga.com/markets/bonds/13/04/3539436/market-wrap-for-monday-april-29-stocks-start-week-with-a-rally,Scott Rubin,2013-04-29 00:00:00,MRK,1,0,0,1,0,0,1,1,1,0.5
853177,merck pfizer announce worldwide collaboration deal for development commercialization of ertugliflozin,https://www.benzinga.com/news/13/04/3537028/merck-pfizer-announce-worldwide-collaboration-deal-for-development-commercializat,Paul Quintaro,2013-04-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853178,earnings expectations for the week of april ,https://www.benzinga.com/news/earnings/13/04/3536001/earnings-expectations-for-the-week-of-april-29,Nelson Hem,2013-04-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853179,a look ahead this weeks etfs to watch,https://www.benzinga.com/news/earnings/13/04/3536045/a-look-ahead-this-weeks-etfs-to-watch,ETF Professor,2013-04-28 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853180,weekly preview focus shifts from earnings to economy,https://www.benzinga.com/analyst-ratings/analyst-color/13/04/3534363/weekly-preview-focus-shifts-from-earnings-to-economy,Matthew Kanterman,2013-04-26 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853181,short sellers move into celgene regeneron,https://www.benzinga.com/trading-ideas/short-ideas/13/04/3534019/short-sellers-move-into-celgene-regeneron,Nelson Hem,2013-04-26 00:00:00,MRK,0,2,0,0,0,0,0,0,0,0.5
853182,stocks to watch for april ,https://www.benzinga.com/trading-ideas/technicals/13/04/3527163/stocks-to-watch-for-april-25-2013,AntÃ³nio Costa,2013-04-25 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853183,merck co currently up to away from week and multiyear high,https://www.benzinga.com/trading-ideas/technicals/13/04/3517049/merck-co-currently-up-0-33-to-47-82-0-17-away-from-52-week-an,bret.kenwell@benzinga.com,2013-04-22 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853184,update bmo capital markets raises pt on merck co on q preview longterm outlook,https://www.benzinga.com/analyst-ratings/analyst-color/13/04/3511375/update-bmo-capital-markets-raises-pt-on-merck-co-on-1q13,Dwight Einhorn,2013-04-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853185,bmo capital maintains outperform on merck company inc raises pt to ,https://www.benzinga.com/news/13/04/3510776/bmo-capital-maintains-outperform-on-merck-company-inc-raises-pt-to-51-00,Juan Lopez,2013-04-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853186,merck sees odanacatib us eu filing in ,https://www.benzinga.com/news/13/04/3493239/merck-sees-odanacatib-us-eu-filing-in-2014,Paul Quintaro,2013-04-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853187,benzinga market primer friday april ,https://www.benzinga.com/markets/bonds/13/04/3492301/benzinga-market-primer-friday-april-12,Matthew Kanterman,2013-04-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853188,etf showdown a pharma fight,https://www.benzinga.com/trading-ideas/long-ideas/13/04/3491090/etf-showdown-a-pharma-fight,ETF Professor,2013-04-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.30910000000000004
853189,court says merck victory upholding vytorin patents will stand says mylan cant sell copies of vytorin zetia before apr ,https://www.benzinga.com/news/13/04/3490164/court-says-merck-victory-upholding-vytorin-patents-will-stand-says-mylan-cant-sel,Paul Quintaro,2013-04-11 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853190,short sellers move out of amgen celgene pharmacyclics,https://www.benzinga.com/trading-ideas/short-ideas/13/04/3486909/short-sellers-move-out-of-amgen-celgene-pharmacyclics,Nelson Hem,2013-04-10 00:00:00,MRK,0,2,0,0,0,0,0,0,0,0.5
853191,update jefferies raises pt on merck co on positive outlook,https://www.benzinga.com/analyst-ratings/analyst-color/13/04/3486710/update-jefferies-raises-pt-on-merck-co-on-positive-outlo,Dwight Einhorn,2013-04-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
853192,merck announces fda acceptance of nda for noxafil investigational tablet formulation,https://www.benzinga.com/news/13/04/3485662/merck-announces-fda-acceptance-of-nda-for-noxafil-investigational-tablet-formulat,Paul Quintaro,2013-04-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
853193,jefferies maintains hold on merck company inc raises pt to ,https://www.benzinga.com/news/13/04/3485540/jefferies-maintains-hold-on-merck-company-inc-raises-pt-to-48-00,Juan Lopez,2013-04-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853194,merck receives positive mad moneyjim cramer mention cnbc,https://www.benzinga.com/media/cnbc/13/04/3484140/merck-receives-positive-mad-moneyjim-cramer-mention-cnbc,Charles Gross,2013-04-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.55135
853195,golden crosses over the past trading week sma cross above sma cmg lo mrk prgo so wmt yum,https://www.benzinga.com/trading-ideas/long-ideas/13/04/3479353/golden-crosses-over-the-past-trading-week-50-sma-cross-above-,Zack Armstrong,2013-04-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853196,cheap does not always mean buy,https://www.benzinga.com/markets/13/04/3477984/cheap-does-not-always-mean-buy,Bob Lang,2013-04-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853197, new dividend etfs to consider,https://www.benzinga.com/news/13/04/3472831/2-new-dividend-etfs-to-consider,ETF Professor,2013-04-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853198,golden crosses over the past trading week sma cross above sma,https://www.benzinga.com/trading-ideas/long-ideas/13/04/3468624/golden-crosses-over-the-past-trading-week-50-sma-cross-above-,Zack Armstrong,2013-04-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853199,merck announces fda acceptance of biologics license app for investigational grass pollen allergy immunotherapy tablet,https://www.benzinga.com/news/13/03/3450417/merck-announces-fda-acceptance-of-biologics-license-app-for-investigational-grass,Paul Quintaro,2013-03-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
853200,the supreme court is about to stick it to big pharma,https://www.benzinga.com/news/13/03/3447519/the-supreme-court-is-about-to-stick-it-to-big-pharma,Tim Parker,2013-03-26 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.7787
853201,risk on rally these etfs say no,https://www.benzinga.com/trading-ideas/long-ideas/13/03/3447304/risk-on-rally-these-etfs-say-no,ETF Professor,2013-03-26 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.24469999999999997
853202,ema investigating pancreatic risks with glp diabetes drugs,https://www.benzinga.com/news/13/03/3447431/ema-investigating-pancreatic-risks-with-glp-1-diabetes-drugs,Paul Quintaro,2013-03-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3634
853203,bank of america reiterates buy rating pt on merck co ahead of potential approvals,https://www.benzinga.com/analyst-ratings/analyst-color/13/03/3442867/bank-of-america-reiterates-buy-rating-47-pt-on-merck-co-,Dwight Einhorn,2013-03-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853204,golden crosses over the past trading week sma cross above sma,https://www.benzinga.com/trading-ideas/long-ideas/13/03/3425125/golden-crosses-over-the-past-trading-week-50-sma-cross-above-,Zack Armstrong,2013-03-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853205,reuters reporting merck saying fda extended review of sugammadex,https://www.benzinga.com/news/13/03/3420308/reuters-reporting-merck-saying-fda-extended-review-of-sugammadex,Paul Quintaro,2013-03-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853206,embrace these new etfs,https://www.benzinga.com/markets/bonds/13/03/3417752/embrace-these-new-etfs,ETF Professor,2013-03-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6591
853207,the top africanamerican ceos in business today,https://www.benzinga.com/general/entrepreneurship/13/03/3413569/the-top-20-african-american-ceos-in-business-today,Alex Biles,2013-03-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
853208,bank of america reiterates buy rating pt on merck co following improveit trial review,https://www.benzinga.com/analyst-ratings/analyst-color/13/03/3412207/bank-of-america-reiterates-buy-rating-47-pt-on-merck-co-,Dwight Einhorn,2013-03-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853209,unusual options alert merck co continues to do extremely heavy volume,https://www.benzinga.com/markets/options/13/03/3409512/unusual-options-alert-merck-co-continues-to-do-extremely-heavy-volume,bret.kenwell@benzinga.com,2013-03-12 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.648
853210,short interest swings in biotech stocks amgn celg pcyc,https://www.benzinga.com/trading-ideas/long-ideas/13/03/3409383/short-interest-swings-in-biotech-stocks-amgn-celg-pcyc,Nelson Hem,2013-03-12 00:00:00,MRK,0,2,0,0,0,0,0,0,0,0.7294
853211,lawyer tells jury in merck case over fosamax co hid products boneweakening risks,https://www.benzinga.com/news/13/03/3409400/lawyer-tells-jury-in-merck-case-over-fosamax-co-hid-products-bone-weakening-risks,Paul Quintaro,2013-03-12 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.3194
853212,merck issues update on improveit trial says dsmb recommend study to continue,https://www.benzinga.com/news/13/03/3407908/merck-issues-update-on-improve-it-trial-says-dsmb-recommend-study-to-continue,Paul Quintaro,2013-03-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6806
853213,death crosses over the past trading week sma cross below sma,https://www.benzinga.com/trading-ideas/short-ideas/13/03/3405688/death-crosses-over-the-past-trading-week-50-sma-cross-below-,Zack Armstrong,2013-03-11 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.20029999999999998
853214,top nyse stocks in the drug manufacturersmajor industry with the highest dividend yield,https://www.benzinga.com/trading-ideas/dividends/13/03/3399412/top-4-nyse-stocks-in-the-drug-manufacturers-major-industry-wit,Monica Gerson,2013-03-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.60115
853215,merck announces appointment of roger m perlmutter md phd as president of merck research laboratories peter s kim phd to retire,https://www.benzinga.com/news/13/03/3396634/merck-announces-appointment-of-roger-m-perlmutter-m-d-ph-d-as-president-of-merck-,Eddie Staley,2013-03-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853216, sector etfs outpacing larger rivals,https://www.benzinga.com/trading-ideas/long-ideas/13/03/3395530/3-sector-etfs-outpacing-larger-rivals,ETF Professor,2013-03-06 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853217,from merck presentation for cowen healthcare conference sees v for cancer endpoint driven trial filing this year v filing for hct v pediatric combo vaccine filing next year,https://www.benzinga.com/news/13/03/3394880/from-merck-presentation-for-cowen-healthcare-conference-sees-v503-for-cancer-endp,Paul Quintaro,2013-03-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
853218,hedging the dow at its alltime high,https://www.benzinga.com/markets/options/13/03/3394235/hedging-the-dow-at-its-all-time-high,David Pinsen,2013-03-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853219,death crosses over the past trading week sma crossed below sma,https://www.benzinga.com/trading-ideas/technicals/13/03/3391528/death-crosses-over-the-past-trading-week-50-sma-crossed-below,Zack Armstrong,2013-03-05 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.20029999999999998
853220,an hiv cure is great news for these drug manufacturers,https://www.benzinga.com/news/13/03/3387279/the-news-of-an-hiv-cure-is-great-news-for-these-publicly-traded-companies,Alex Biles,2013-03-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81245
853221,cardiome ends line of credit merck to buy added m of vernakalant iv inventory,https://www.benzinga.com/news/13/03/3385911/cardiome-ends-line-of-credit-merck-to-buy-added-3m-of-vernakalant-iv-inventory,Paul Quintaro,2013-03-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
853222,update bank of america upgrades merck to buy pullback creates meaningful upside potential,https://www.benzinga.com/analyst-ratings/analyst-color/13/03/3385142/update-bank-of-america-upgrades-merck-to-buy-pullback-cr,David Johnson,2013-03-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.76335
853223,bank of america upgrades merck company inc to buy maintains po,https://www.benzinga.com/news/13/03/3385120/bank-of-america-upgrades-merck-company-inc-to-buy-maintains-47-00-po,Juan Lopez,2013-03-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.2213
853224,if the market falls try these low beta etfs,https://www.benzinga.com/trading-ideas/long-ideas/13/02/3379576/if-the-market-falls-try-these-low-beta-etfs,ETF Professor,2013-02-28 00:00:00,MRK,1,1,0,1,0,0,1,0,1,0.3634
853225,still no herbalife in f etfs,https://www.benzinga.com/trading-ideas/long-ideas/13/02/3373262/still-no-herbalife-in-13f-etfs,ETF Professor,2013-02-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.352
853226,update jefferies reiterates hold rating lowers pt on merck co on improveit overhang removal,https://www.benzinga.com/analyst-ratings/analyst-color/13/02/3362871/update-jefferies-reiterates-hold-rating-lowers-pt-on-mer,Dwight Einhorn,2013-02-25 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.436
853227,jefferies maintains hold on merck company inc lowers pt to ,https://www.benzinga.com/news/13/02/3361658/jefferies-maintains-hold-on-merck-company-inc-lowers-pt-to-46-00,Juan Lopez,2013-02-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
853228,bmo capital maintains outperform on merck company inc lowers pt to ,https://www.benzinga.com/news/13/02/3337114/bmo-capital-maintains-outperform-on-merck-company-inc-lowers-pt-to-47-00,Juan Lopez,2013-02-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.436
853229,merck resolves securities classaction suit related to enhance to record m charge,https://www.benzinga.com/news/13/02/3334113/merck-resolves-securities-class-action-suit-related-to-enhance-to-record-493m-cha,Paul Quintaro,2013-02-14 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.7202
853230,merck shares down premarket following outlook update,https://www.benzinga.com/movers/13/02/3330094/merck-shares-down-0-6-premarket-following-outlook-update,Paul Quintaro,2013-02-13 00:00:00,MRK,1,1,0,1,0,0,1,0,0,0.648
853231,merck sees q adjeps vs est,https://www.benzinga.com/news/13/02/3329985/merck-sees-q1-adj-eps-0-76-0-78-vs-0-86-est,Paul Quintaro,2013-02-13 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
853232,merck reaffirms outlook,https://www.benzinga.com/news/13/02/3329963/merck-reaffirms-outlook,Paul Quintaro,2013-02-13 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853233,short interest swings in biotech stocks amgn celg onxx,https://www.benzinga.com/trading-ideas/long-ideas/13/02/3326974/short-interest-swings-in-biotech-stocks-amgn-celg-onxx,Nelson Hem,2013-02-12 00:00:00,MRK,0,2,0,0,0,0,0,0,0,0.7294
853234,mylan loses appeals court bid to invalidate zetia patents,https://www.benzinga.com/news/13/02/3314426/mylan-loses-appeals-court-bid-to-invalidate-zetia-patents,Paul Quintaro,2013-02-07 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.3409
853235,merck serono opexa therapeutics enter option license agreement for development of tcelna,https://www.benzinga.com/news/13/02/3304078/merck-serono-opexa-therapeutics-enter-option-license-agreement-for-development-of,Paul Quintaro,2013-02-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
853236,update bmo capital markets reiterates outperform rating lowers pt on merck co,https://www.benzinga.com/analyst-ratings/analyst-color/13/02/3300276/update-bmo-capital-markets-reiterates-outperform-rating-,Dwight Einhorn,2013-02-04 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.436
853237,update morgan stanley downgrades merck to underweight ahead of key march trial,https://www.benzinga.com/analyst-ratings/analyst-color/13/02/3300233/update-morgan-stanley-downgrades-merck-to-underweight-ah,David Johnson,2013-02-04 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.5
853238,leerink swann downgrades merck company inc to market perform,https://www.benzinga.com/news/13/02/3300355/leerink-swann-downgrades-merck-company-inc-to-market-perform,Juan Lopez,2013-02-04 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
853239,morgan stanley downgrades merck company inc to underweight removes pt,https://www.benzinga.com/news/13/02/3299651/morgan-stanley-downgrades-merck-company-inc-to-underweight-removes-43-00-pt,Juan Lopez,2013-02-04 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
853240,hearing merck defded at credit suisse,https://www.benzinga.com/analyst-ratings/analyst-color/13/02/3296826/hearing-merck-defded-at-credit-suisse,Charles Gross,2013-02-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
853241,merck company inc reports q eps of vs est revenue of b vs b est,https://www.benzinga.com/news/earnings/13/02/3296044/merck-company-inc-reports-q4-eps-of-0-83-vs-0-81-est-revenue-of-11-74b-v,Charles Gross,2013-02-01 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853242,us stock futures up all eyes on payroll data,https://www.benzinga.com/news/13/02/3295859/us-stock-futures-up-all-eyes-on-payroll-data,Monica Gerson,2013-02-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853243,earnings scheduled for february ,https://www.benzinga.com/news/earnings/13/02/3295723/earnings-scheduled-for-february-1-2013,Monica Gerson,2013-02-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853244,stocks to watch for february ,https://www.benzinga.com/news/earnings/13/02/3295376/stocks-to-watch-for-february-1-2013,Monica Gerson,2013-02-01 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853245,isis and sanofis drug okd to treat inherited cholesterol disease,https://www.benzinga.com/news/13/01/3288938/isis-and-sanofis-drug-okd-to-treat-inherited-cholesterol-disease,Minyanville,2013-01-30 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.70095
853246,fda approves oxytrol for women,https://www.benzinga.com/news/13/01/3274993/fda-approves-oxytrol-for-women,Paul Quintaro,2013-01-25 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.70095
853247,update jefferies company reiterates hold rating lowers pt on merck co,https://www.benzinga.com/analyst-ratings/analyst-color/13/01/3248063/update-jefferies-company-reiterates-hold-rating-lowers-p,Dwight Einhorn,2013-01-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
853248,jefferies maintains hold on merck company inc lowers pt to ,https://www.benzinga.com/news/13/01/3247861/jefferies-maintains-hold-on-merck-company-inc-lowers-pt-to-47-00,Juan Lopez,2013-01-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
853249,three stocks to buy for flu season,https://www.benzinga.com/trading-ideas/long-ideas/13/01/3236238/three-stocks-to-buy-for-flu-season,Clay Wyatt,2013-01-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.30910000000000004
853250,merck to suspend availability of tredaptive worldwide,https://www.benzinga.com/news/13/01/3234999/merck-to-suspend-availability-of-tredaptive-worldwide,Charles Gross,2013-01-11 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.3409
853251,microbiotix merck announce licensing pact for hcv nsb,https://www.benzinga.com/news/13/01/3228411/microbiotix-merck-announce-licensing-pact-for-hcv-ns5b,Paul Quintaro,2013-01-09 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853252, health care etfs your broker forgot to mention,https://www.benzinga.com/trading-ideas/long-ideas/13/01/3221049/4-health-care-etfs-your-broker-forgot-to-mention,ETF Professor,2013-01-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
853253,merck receives fda acceptance of resubmission of nda for sugammadex sodium injection,https://www.benzinga.com/news/13/01/3218835/merck-receives-fda-acceptance-of-resubmission-of-nda-for-sugammadex-sodium-inject,Paul Quintaro,2013-01-07 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.7294
853254,merck pfizer abbott jj sanofi said to show interest in bausch lomb bid bloomberg,https://www.benzinga.com/news/13/01/3213668/merck-pfizer-abbott-j-j-sanofi-said-to-show-interest-in-bausch-lomb-bid-bloomberg,Paul Quintaro,2013-01-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8062
853255,merck says fda acknowledged resubmission of nda for ezetimibe atorvastatin tablets,https://www.benzinga.com/news/13/01/3210428/merck-says-fda-acknowledged-resubmission-of-nda-for-ezetimibe-atorvastatin-tablet,Paul Quintaro,2013-01-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853256,merck sends dear doctor letter related to tredaptives failed study says side effects include muscle skin blood damage,https://www.benzinga.com/news/12/12/3203544/merck-sends-dear-doctor-letter-related-to-tredaptives-failed-study-says-side-effe,Paul Quintaro,2012-12-28 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.20029999999999998
853257,option alert merck january call block trade contracts currently ,https://www.benzinga.com/markets/options/12/12/3199709/option-alert-merck-january-45-call-block-trade-7-000-contracts-0-03-cu,Charles Gross,2012-12-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.41105
853258,goldman sachs maintains neutral on merck company inc lowers pt to ,https://www.benzinga.com/news/12/12/3191111/goldman-sachs-maintains-neutral-on-merck-company-inc-lowers-pt-to-47-00,Juan Lopez,2012-12-20 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.436
853259,midmorning market update rite aid rallies new york stock exchange acquired by ice,https://www.benzinga.com/news/earnings/12/12/3190606/mid-morning-market-update-rite-aid-rallies-new-york-stock-exchange-acqui,Jake L'Ecuyer,2012-12-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853260,merck says hpsthrive study of tredaptive did not achieve primary endpoint,https://www.benzinga.com/news/12/12/3189993/merck-says-hps2-thrive-study-of-tredaptive-did-not-achieve-primary-endpoint,Paul Quintaro,2012-12-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853261,merck ge healthcare announce collaboration on use of imaging biomarkers for investigational bace inhibitor program,https://www.benzinga.com/news/12/12/3181644/merck-ge-healthcare-announce-collaboration-on-use-of-imaging-biomarkers-for-inves,Paul Quintaro,2012-12-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.4614
853262,these dow laggards could rebound in ,https://www.benzinga.com/trading-ideas/long-ideas/12/12/3176708/these-2-dow-laggards-could-rebound-in-2013,Gordon Wilcox,2012-12-16 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
853263,benzingas small cap movers for tuesday december ,https://www.benzinga.com/trading-ideas/long-ideas/12/12/3165040/benzingas-small-cap-movers-for-tuesday-december-11-2012,Charles Gross,2012-12-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853264,benzingas ma chatter for tuesday december ,https://www.benzinga.com/trading-ideas/long-ideas/12/12/3164833/benzingas-m-a-chatter-for-tuesday-december-11-2012,Charles Gross,2012-12-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853265,warburg pincus said to hire goldman sachs to sell bausch lomb seeking at least b abbott glaxo merck sanofi said to be contacted bloomberg,https://www.benzinga.com/news/12/12/3164699/warburg-pincus-said-to-hire-goldman-sachs-to-sell-bausch-lomb-seeking-at-least-10,Paul Quintaro,2012-12-11 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853266,cardiome reaches deal with merck to retire debtclose line of credit will pay merck m,https://www.benzinga.com/news/12/12/3162245/cardiome-reaches-deal-with-merck-to-retire-debtclose-line-of-credit-will-pay-merc,Paul Quintaro,2012-12-11 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.67
853267,three more defensive stock picks for lly pfe vtr,https://www.benzinga.com/trading-ideas/long-ideas/12/12/3159940/three-more-defensive-stock-picks-for-2013-lly-pfe-vtr,Nelson Hem,2012-12-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5505
853268,barrons recap ten stock picks for ,https://www.benzinga.com/media/barrons/12/12/3157009/barrons-recap-12812-ten-stock-picks-for-2013,Nelson Hem,2012-12-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853269,merck files debt securities shelf,https://www.benzinga.com/news/12/12/3140808/merck-files-debt-securities-shelf,Paul Quintaro,2012-12-03 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.4614
853270,merck begins phase iiiii study of investigational bace inhibitor mk,https://www.benzinga.com/news/12/12/3138220/merck-begins-phase-iiiii-study-of-investigational-bace-inhibitor-mk-8931,Paul Quintaro,2012-12-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.4614
853271,citigroup initiates coverage on merck company inc at neutral announces pt,https://www.benzinga.com/news/12/11/3135459/citigroup-initiates-coverage-on-merck-company-inc-at-neutral-announces-44-00-pt,Paul Quintaro,2012-11-30 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853272,merck increases dividend to from ,https://www.benzinga.com/news/12/11/3123494/merck-increases-dividend-to-0-43-from-0-42,Paul Quintaro,2012-11-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853273,merck receives fda orphan status for melanoma treatment,https://www.benzinga.com/news/12/11/3107883/merck-receives-fda-orphan-status-for-melanoma-treatment,Paul Quintaro,2012-11-20 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.5
853274,mkm partners upgrades merck from neutral to buy raises pt from to ,https://www.benzinga.com/analyst-ratings/upgrades/12/11/3107656/mkm-partners-upgrades-merck-from-neutral-to-buy-raises-pt-fro,Paul Quintaro,2012-11-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853275,benzingas top upgrades,https://www.benzinga.com/analyst-ratings/upgrades/12/11/3106640/benzingas-top-upgrades,Lisa Levin,2012-11-20 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.60115
853276,sp reiterates bullish view on health care etfs,https://www.benzinga.com/analyst-ratings/analyst-color/12/11/3098876/s-p-reiterates-bullish-view-on-health-care-etfs,ETF Professor,2012-11-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
853277,these etfs offer solid yield in uncertain times,https://www.benzinga.com/markets/bonds/12/11/3088634/these-etfs-offer-solid-yield-in-uncertain-times,Ken Shreve,2012-11-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
853278,short interest swings in biotech stocks amgn biib vrtx,https://www.benzinga.com/trading-ideas/long-ideas/12/11/3081035/short-interest-swings-in-biotech-stocks-amgn-biib-vrtx,Nelson Hem,2012-11-12 00:00:00,MRK,0,2,0,0,0,0,0,0,0,0.7294
853279,update bmo capital markets upgrades merck co to outperform reiterates pt,https://www.benzinga.com/analyst-ratings/analyst-color/12/11/3080601/update-bmo-capital-markets-upgrades-merck-co-to-outperfo,Dwight Einhorn,2012-11-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853280,bmo capital markets upgrades merck from market perform to outperform maintains pt at ,https://www.benzinga.com/analyst-ratings/upgrades/12/11/3079434/bmo-capital-markets-upgrades-merck-from-market-perform-to-out,Juan Lopez,2012-11-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853281,merck presents earlystage interim data for mk study for treatment of advanced melanoma,https://www.benzinga.com/news/12/11/3079059/merck-presents-early-stage-interim-data-for-mk-3475-study-for-treatment-of-advanc,Charles Gross,2012-11-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
853282,futures flat euro falls ahead of central banks,https://www.benzinga.com/markets/bonds/12/11/3069015/futures-flat-euro-falls-ahead-of-central-banks,Matthew Kanterman,2012-11-08 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853283,moves in smaller health care stocks gmed sem uam vrtx,https://www.benzinga.com/trading-ideas/long-ideas/12/11/3053876/moves-in-smaller-health-care-stocks-gmed-sem-uam-vrtx,Nelson Hem,2012-11-03 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.74695
853284,more equalweight etfs your broker forgot to mention,https://www.benzinga.com/trading-ideas/long-ideas/12/10/3039328/more-equal-weight-etfs-your-broker-forgot-to-mention,ETF Professor,2012-10-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853285,update bmo capital markets reiterates market perform rating raises pt on merck co,https://www.benzinga.com/analyst-ratings/analyst-color/12/10/3035564/update-bmo-capital-markets-reiterates-market-perform-rat,Dwight Einhorn,2012-10-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853286,bmo capital markets maintains merck at market perform raises pt from to ,https://www.benzinga.com/analyst-ratings/price-target/12/10/3034618/bmo-capital-markets-maintains-merck-at-market-perform-rai,Juan Lopez,2012-10-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853287,merck begins earnings call,https://www.benzinga.com/news/earnings/12/10/3030227/merck-begins-earnings-call,Paul Quintaro,2012-10-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853288,sp bullish on select dividend etfs,https://www.benzinga.com/analyst-ratings/analyst-color/12/10/3028115/s-p-bullish-on-select-dividend-etfs,ETF Professor,2012-10-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853289,merck reports q eps vs est revenues b vs b est,https://www.benzinga.com/news/earnings/12/10/3029847/merck-reports-q3-eps-0-92-vs-0-92-est-revenues-11-49b-vs-11-57b-est,Allie Wickman,2012-10-26 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
853290,benzinga market primer friday october ,https://www.benzinga.com/markets/bonds/12/10/3029602/benzinga-market-primer-friday-october-26,Matthew Kanterman,2012-10-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853291,us stock futures down after apple earnings,https://www.benzinga.com/news/12/10/3029673/us-stock-futures-down-after-apple-earnings,Monica Gerson,2012-10-26 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853292,earnings scheduled for october ,https://www.benzinga.com/news/earnings/12/10/3029167/earnings-scheduled-for-october-26-2012,Monica Gerson,2012-10-26 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853293,stocks to watch for october ,https://www.benzinga.com/news/earnings/12/10/3029097/stocks-to-watch-for-october-26-2012,Monica Gerson,2012-10-26 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853294,stocks to watch for october ,https://www.benzinga.com/news/earnings/12/10/3029098/stocks-to-watch-for-october-26-2012,Monica Gerson,2012-10-26 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853295,sp likes a trio of biotech etfs,https://www.benzinga.com/analyst-ratings/analyst-color/12/10/3023221/s-p-likes-a-trio-of-biotech-etfs,ETF Professor,2012-10-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
853296,earnings expectations for the week of october ,https://www.benzinga.com/news/earnings/12/10/3012252/earnings-expectations-for-the-week-of-october-22,Nelson Hem,2012-10-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853297,barclays maintains merck at overweight raises pt from to ,https://www.benzinga.com/analyst-ratings/price-target/12/10/2994491/barclays-maintains-merck-at-overweight-raises-pt-from-46-,Juan Lopez,2012-10-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3194
853298,a peek into the market before the trading starts,https://www.benzinga.com/news/12/10/2993115/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,2012-10-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853299,aicuris merck enter exclusive worldwide license agreement,https://www.benzinga.com/news/12/10/2992974/aicuris-merck-enter-exclusive-worldwide-license-agreement,Charles Gross,2012-10-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7859499999999999
853300,merck bmd data from a phase ii study of odanacatib shows significantly increased bone mineral density,https://www.benzinga.com/news/12/10/2991906/merck-bmd-data-from-a-phase-ii-study-of-odanacatib-shows-significantly-increased-,Charles Gross,2012-10-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6366
853301,jefferies company maintains merck at hold raises pt from to ,https://www.benzinga.com/analyst-ratings/price-target/12/10/2989411/jefferies-company-maintains-merck-at-hold-raises-pt-from-,Juan Lopez,2012-10-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853302,part i must know etfs for q earnings,https://www.benzinga.com/markets/bonds/12/10/2979411/part-i-must-know-etfs-for-q3-earnings,ETF Professor,2012-10-09 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
853303,merck to move global headquarters within new jersey,https://www.benzinga.com/news/12/10/2977761/merck-to-move-global-headquarters-within-new-jersey,Eddie Staley,2012-10-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853304,delphi genetics grants merck license for the use of the stabyexpress system,https://www.benzinga.com/news/12/10/2974175/delphi-genetics-grants-merck-license-for-the-use-of-the-stabyexpress-system,Paul Quintaro,2012-10-08 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.61315
853305,deutsche bank suspends coverage on merck ,https://www.benzinga.com/analyst-ratings/price-target/12/10/2956765/deutsche-bank-suspends-coverage-on-merck,Juan Lopez,2012-10-01 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.5
853306,merck hpv vaccine shown to be safe in a kaiser study,https://www.benzinga.com/news/12/10/2956623/merck-hpv-vaccine-shown-to-be-safe-in-a-kaiser-study,Paul Quintaro,2012-10-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
853307,merck returns rights for vernakalant to cardiome,https://www.benzinga.com/news/12/09/2941303/merck-returns-rights-for-vernakalant-to-cardiome,Paul Quintaro,2012-09-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853308,sp highlights election etfs,https://www.benzinga.com/analyst-ratings/analyst-color/12/09/2939541/s-p-highlights-election-etfs,ETF Professor,2012-09-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853309,pfizer merck set up chinese joint ventures for generic drugs wantchinatimes,https://www.benzinga.com/news/12/09/2922827/pfizer-merck-set-up-chinese-joint-ventures-for-generic-drugs-wantchinatimes,Charles Gross,2012-09-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853310,simcere pharmaceutical group announces appointment of new chief executive officer,https://www.benzinga.com/news/12/09/2907264/simcere-pharmaceutical-group-announces-appointment-of-new-chief-executive-officer,Charles Gross,2012-09-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853311,merck announces new phase iii data for suvorexant says patients normal sleep patterns return after stopping use,https://www.benzinga.com/news/12/09/2895740/merck-announces-new-phase-iii-data-for-suvorexant-says-patients-normal-sleep-patt,Eddie Staley,2012-09-10 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.42345
853312,merck provides update on cardiovascular development programs,https://www.benzinga.com/news/12/08/2859806/merck-provides-update-on-cardiovascular-development-programs,Charles Gross,2012-08-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853313,update bank of america merrill lynch downgrades merck to neutral reiterates pt,https://www.benzinga.com/analyst-ratings/analyst-color/12/08/2858344/update-bank-of-america-merrill-lynch-downgrades-merck-to,Dwight Einhorn,2012-08-24 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853314,bank of america downgrades merck from buy to neutral announces po of ,https://www.benzinga.com/analyst-ratings/downgrades/12/08/2857588/bank-of-america-downgrades-merck-from-buy-to-neutral-announ,Juan Lopez,2012-08-24 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.2213
853315,sp still bullish on health care etfs,https://www.benzinga.com/analyst-ratings/analyst-color/12/08/2839847/s-p-still-bullish-on-health-care-etfs,ETF Professor,2012-08-16 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.74695
853316,jefferies company maintains merck co at hold raises pt from to ,https://www.benzinga.com/analyst-ratings/price-target/12/08/2826335/jefferies-company-maintains-merck-co-at-hold-raises-pt-fr,Juan Lopez,2012-08-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853317,top nyse stocks in the drug manufacturersmajor industry with the highest dividend yield,https://www.benzinga.com/trading-ideas/dividends/12/08/2825817/top-4-nyse-stocks-in-the-drug-manufacturers-major-industry-wit,Monica Gerson,2012-08-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.60115
853318,under the hood tempting technicals and a dividend,https://www.benzinga.com/trading-ideas/long-ideas/12/08/2818385/under-the-hood-tempting-technicals-and-a-dividend,ETF Professor,2012-08-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853319,credit suisse maintains merck at outperform lowers pt from to ,https://www.benzinga.com/analyst-ratings/price-target/12/08/2819029/credit-suisse-maintains-merck-at-outperform-lowers-pt-fro,Juan Lopez,2012-08-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6366
853320,ubs maintains merck at buy raises pt from to ,https://www.benzinga.com/analyst-ratings/price-target/12/07/2786994/ubs-maintains-merck-at-buy-raises-pt-from-45-to-50,Juan Lopez,2012-07-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853321,bmo capital markets maitnains merck at market perform raises pt from to ,https://www.benzinga.com/analyst-ratings/price-target/12/07/2785770/bmo-capital-markets-maitnains-merck-at-market-perform-rai,Juan Lopez,2012-07-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853322,benzinga market primer monday july ,https://www.benzinga.com/analyst-ratings/analyst-color/12/07/2785522/benzinga-market-primer-monday-july-30,Matthew Kanterman,2012-07-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853323,merck on call says expecting multiple generic singulair entrants on day one,https://www.benzinga.com/news/12/07/2782078/merck-on-call-says-expecting-multiple-generic-singulair-entrants-on-day-one,Paul Quintaro,2012-07-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853324,update merck beats eps estimates by and beats revenues estimates while reaffirming fy guidance,https://www.benzinga.com/news/earnings/12/07/2781696/update-merck-beats-eps-estimates-by-0-03-and-beats-revenues-estimates-wh,Patrick Henderson,2012-07-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853325,merck reports q vytorin sales m vs m est q remicade sales m vs m est,https://www.benzinga.com/news/12/07/2781770/merck-reports-q2-vytorin-sales-445m-vs-432-3m-est-q2-remicade-sales-518m-vs-545m-,Paul Quintaro,2012-07-27 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853326,benzinga market primer friday july ,https://www.benzinga.com/markets/bonds/12/07/2781594/benzinga-market-primer-friday-july-27,Matthew Kanterman,2012-07-27 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853327,merck says suvorexant odanacatib filings on track,https://www.benzinga.com/news/12/07/2781767/merck-says-suvorexant-odanacatib-filings-on-track,Paul Quintaro,2012-07-27 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853328,merck reports q eps vs est revenues b vs b est,https://www.benzinga.com/news/earnings/12/07/2781650/merck-reports-q2-eps-1-05-vs-1-01-est-revenues-12-2b-vs-12-15b-est,Eddie Staley,2012-07-27 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
853329,us stock futures up gdp data in focus,https://www.benzinga.com/news/12/07/2781576/us-stock-futures-up-gdp-data-in-focus,Monica Gerson,2012-07-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853330,earnings scheduled for july ,https://www.benzinga.com/news/earnings/12/07/2781020/earnings-scheduled-for-july-27,Monica Gerson,2012-07-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853331,stocks to watch for july ,https://www.benzinga.com/news/earnings/12/07/2781019/stocks-to-watch-for-july-27,Monica Gerson,2012-07-27 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853332,from earlier merck isentress in combination therapy demonstrated longterm efficacy safety and tolerability in previously untreated adult patients with hiv for up to weeks,https://www.benzinga.com/news/12/07/2764555/from-earlier-merck-isentress-in-combination-therapy-demonstrated-long-term-effica,Eddie Staley,2012-07-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
853333,earnings expectations for the week of july ,https://www.benzinga.com/news/earnings/12/07/2763770/earnings-expectations-for-the-week-of-july-23,Nelson Hem,2012-07-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853334,isentress in combination therapy demonstrated longterm efficacy safety and tolerability in previously untreated adult patients with hiv,https://www.benzinga.com/news/12/07/2763837/isentress-in-combination-therapy-demonstrated-long-term-efficacy-safety-and-toler,Charles Gross,2012-07-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
853335,alnylam in talks on cholesterol drug partnership ceo says has completed phase i clinical trial of drug,https://www.benzinga.com/news/12/07/2758741/alnylam-in-talks-on-cholesterol-drug-partnership-ceo-says-has-completed-phase-i-c,Paul Quintaro,2012-07-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853336,kapito we like att vz mrk jnj for yields,https://www.benzinga.com/media/cnbc/12/07/2754928/kapito-we-like-att-vz-mrk-jnj-for-yields,Charles Gross,2012-07-18 00:00:00,MRK,1,2,0,0,0,0,1,1,1,0.6806
853337,morgan stanley maintains merck co at equalweight raises pt from to ,https://www.benzinga.com/analyst-ratings/price-target/12/07/2752834/morgan-stanley-maintains-merck-co-at-equal-weight-raises-,Juan Lopez,2012-07-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853338,merck says court approves proposed erisa settlement,https://www.benzinga.com/news/12/07/2750461/merck-says-court-approves-proposed-erisa-settlement,Paul Quintaro,2012-07-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
853339,popular drug manufacturing stocks among hedge funds,https://www.benzinga.com/trading-ideas/long-ideas/12/07/2746905/popular-drug-manufacturing-stocks-among-hedge-funds,Viktor Puskorius,2012-07-17 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.71075
853340,low volume high returns for these etfs bib fhc drw,https://www.benzinga.com/trading-ideas/long-ideas/12/07/2742958/low-volume-high-returns-for-these-etfs-bib-fhc-drw,ETF Professor,2012-07-13 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.3634
853341, marketbased etfs your broker forgot to mention hdiv off pdp,https://www.benzinga.com/trading-ideas/long-ideas/12/07/2742714/5-market-based-etfs-your-broker-forgot-to-mention-hdiv-off-pd,ETF Professor,2012-07-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853342,social media outlook friday july ,https://www.benzinga.com/analyst-ratings/12/07/2742309/social-media-outlook-friday-july-13,Matthew Kanterman,2012-07-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853343,jefferies company maintains merck co at hold raises pt from to ,https://www.benzinga.com/analyst-ratings/price-target/12/07/2741556/jefferies-company-maintains-merck-co-at-hold-raises-pt-fr,Juan Lopez,2012-07-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853344,merck hits year high thursday on positive phase osteoporosis drug data ibd,https://www.benzinga.com/trading-ideas/long-ideas/12/07/2739385/merck-hits-4-year-high-thursday-on-positive-phase-3-osteoporo,Charles Gross,2012-07-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
853345,thursday market movers,https://www.benzinga.com/news/earnings/12/07/2739162/thursday-market-movers,Viktor Puskorius,2012-07-12 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853346,update citigroup upgrades merck raises pt,https://www.benzinga.com/analyst-ratings/analyst-color/12/07/2739168/update-citigroup-upgrades-merck-raises-pt,Delores Land,2012-07-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853347,from earlier update on phase iii trial for odanacatib mercks investigational catk inhibitor for osteoporosis,https://www.benzinga.com/news/12/07/2738502/from-earlier-update-on-phase-iii-trial-for-odanacatib-mercks-investigational-cat-,Eddie Staley,2012-07-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.4614
853348,benzingas top premarket gainers,https://www.benzinga.com/news/12/07/2738335/benzingas-top-pre-market-gainers,Lisa Levin,2012-07-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
853349,goldman sachs maintains merck co at neutral raises pt from to ,https://www.benzinga.com/analyst-ratings/price-target/12/07/2738152/goldman-sachs-maintains-merck-co-at-neutral-raises-pt-fro,Juan Lopez,2012-07-12 00:00:00,MRK,1,2,1,0,0,1,1,1,1,0.5
853350,benzingas top upgrades,https://www.benzinga.com/analyst-ratings/upgrades/12/07/2738021/benzingas-top-upgrades,Lisa Levin,2012-07-12 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.60115
853351,citigroup upgrades merck from neutral to buy raises pt from to ,https://www.benzinga.com/analyst-ratings/upgrades/12/07/2737690/citigroup-upgrades-merck-from-neutral-to-buy-raises-pt-from-3,Juan Lopez,2012-07-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853352,study for mercks investigational catk inhibitor for osteoporosis meets outcomes and is concluded early,https://www.benzinga.com/news/12/07/2736655/study-for-mercks-investigational-cat-k-inhibitor-for-osteoporosis-meets-outcomes-,Allie Wickman,2012-07-11 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.4614
853353,merck announces collaboration to improve maternal health through expanded access to family planning,https://www.benzinga.com/news/12/07/2735248/merck-announces-collaboration-to-improve-maternal-health-through-expanded-access-,Allie Wickman,2012-07-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
853354,deutsche bank maintains merck at buy raises pt from to ,https://www.benzinga.com/analyst-ratings/price-target/12/07/2732487/deutsche-bank-maintains-merck-at-buy-raises-pt-from-43-to,Juan Lopez,2012-07-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853355,dendreon pharmacyclics and other biotech takeover targets,https://www.benzinga.com/trading-ideas/long-ideas/12/07/2731671/dendreon-pharmacyclics-and-other-biotech-takeover-targets,Nelson Hem,2012-07-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853356,alps unveils dogs of the dow etf,https://www.benzinga.com/trading-ideas/long-ideas/12/06/2709715/alps-unveils-dogs-of-the-dow-etf,ETF Professor,2012-06-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853357,ultimate stock watch list for the supreme courts health care ruling,https://www.benzinga.com/trading-ideas/long-ideas/12/06/2705465/ultimate-stock-watch-list-for-the-supreme-courts-health-care-,Matt Jackson,2012-06-28 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.88915
853358,a peek into the market before the trading starts,https://www.benzinga.com/news/12/06/2700668/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,2012-06-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853359,merck and astrazeneca agree to amend partnership,https://www.benzinga.com/news/12/06/2700601/merck-and-astrazeneca-agree-to-amend-partnership,Eddie Staley,2012-06-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6806
853360,leveraged etfs for the obamacare ruling,https://www.benzinga.com/trading-ideas/long-ideas/12/06/2699379/leveraged-etfs-for-the-obamacare-ruling,ETF Professor,2012-06-26 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853361,benzingas ma chatter for tuesday june ,https://www.benzinga.com/trading-ideas/long-ideas/12/06/2699375/benzingas-m-a-chatter-for-tuesday-june-26-2012,Charles Gross,2012-06-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853362,spokesperson for amylin pharmaceuticals wont comment on rumor of bids from pharma companies,https://www.benzinga.com/news/12/06/2698581/spokesperson-for-amylin-pharmaceuticals-wont-comment-on-rumor-of-bids-from-pharma,Charles Gross,2012-06-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853363,amylin pharmaceuticals spiking to highs on earlier bid reports,https://www.benzinga.com/news/12/06/2698303/amylin-pharmaceuticals-spiking-to-highs-on-earlier-bid-reports,Charles Gross,2012-06-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853364,novartis sanofi merck bristol astrazeneca weigh amylin final bids amylin expects final bids starting end of the week reuters,https://www.benzinga.com/news/12/06/2698236/novartis-sanofi-merck-bristol-astrazeneca-weigh-amylin-final-bids-amylin-expects-,Eddie Staley,2012-06-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853365,ahead of obamacare ruling sp likes health care spdr,https://www.benzinga.com/analyst-ratings/analyst-color/12/06/2694761/ahead-of-obamacare-ruling-s-p-likes-health-care-spdr,ETF Professor,2012-06-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8592
853366,merck spikes to new week high on heavy volume ,https://www.benzinga.com/news/12/06/2690507/merck-spikes-to-new-52-week-high-on-heavy-volume-40-18,Charles Gross,2012-06-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853367,merck statement on cdc advisory committee on immunization practices recommendation for pneumococcal vaccination in immunocompromised adults,https://www.benzinga.com/news/12/06/2684418/merck-statement-on-cdc-advisory-committee-on-immunization-practices-recommendatio,Eddie Staley,2012-06-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853368,geisinger and merck to collaborate on multiyear effort to improve patient adherence engagement and care delivery,https://www.benzinga.com/news/12/06/2675051/geisinger-and-merck-to-collaborate-on-multi-year-effort-to-improve-patient-adhere,Allie Wickman,2012-06-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.9220999999999999
853369,from earlier us district court rules against merck in nasonex patent lawsuit,https://www.benzinga.com/news/12/06/2674918/from-earlier-u-s-district-court-rules-against-merck-in-nasonex-patent-lawsuit,Eddie Staley,2012-06-18 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.38685
853370,us district court rules against merck in nasonex patent lawsuit,https://www.benzinga.com/news/12/06/2673195/us-district-court-rules-against-merck-in-nasonex-patent-lawsuit,Charles Gross,2012-06-15 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.38685
853371,believe in the rally try these etfs hdv iyz hyd,https://www.benzinga.com/markets/bonds/12/06/2670188/believe-in-the-rally-try-these-etfs-hdv-iyz-hyd,ETF Professor,2012-06-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853372,johnson johnson to complete synthes acquisition,https://www.benzinga.com/news/12/06/2668536/johnson-johnson-to-complete-synthes-acquisition,Brett Callwood,2012-06-14 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853373,merck announces new phase iii data showed mercks investigational insomnia medicine suvorexant improved patients ability to fall asleep and stay asleep,https://www.benzinga.com/news/12/06/2664822/merck-announces-new-phase-iii-data-showed-mercks-investigational-insomnia-medicin,Eddie Staley,2012-06-13 00:00:00,MRK,0,0,1,1,1,1,1,1,0,0.82985
853374,pfizer plans to ipo part of its animal health segment,https://www.benzinga.com/news/12/06/2652144/pfizer-plans-to-ipo-part-of-its-animal-health-segment,Viktor Puskorius,2012-06-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853375,merck sues sandoz accord healthcare on proposed emend copy claims infringement of patents expiring in and ,https://www.benzinga.com/news/12/06/2645061/merck-sues-sandoz-accord-healthcare-on-proposed-emend-copy-claims-infringement-of,Paul Quintaro,2012-06-05 00:00:00,MRK,1,1,1,1,0,1,1,0,1,0.26165
853376,merck gets response letter for ridaforolimus says added clinical trials would need to be conducted in talks with eu health authorities bloomberg,https://www.benzinga.com/news/12/06/2645002/merck-gets-response-letter-for-ridaforolimus-says-added-clinical-trials-would-nee,Paul Quintaro,2012-06-05 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853377,the us economy and the united nations bold strategies needed tax reform and benefits reform,https://www.benzinga.com/personal-finance/financial-advisors/12/06/2637998/the-us-economy-and-the-united-nations-bold-strateg,George Mentz,2012-06-04 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.8953
853378,benzingas ma chatter for friday june ,https://www.benzinga.com/trading-ideas/long-ideas/12/06/2637924/benzingas-m-a-chatter-for-friday-june-1-2012,Charles Gross,2012-06-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853379,amylin pharmaceuticals spokesperson declines comment on renewed takeover chatter,https://www.benzinga.com/news/12/06/2636706/amylin-pharmaceuticals-spokesperson-declines-comment-on-renewed-takeover-chatter,Charles Gross,2012-06-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853380,hearing renewed takeover chatter in amylin pharmaceuticals,https://www.benzinga.com/news/12/06/2636473/hearing-renewed-takeover-chatter-in-amylin-pharmaceuticals,Charles Gross,2012-06-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853381, great stocks with great yield,https://www.benzinga.com/trading-ideas/dividends/12/05/2633305/15-great-stocks-with-great-yield,Matthew Kanterman,2012-05-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.92405
853382,merck ceo says he isnt interested in breaking up the company bloomberg,https://www.benzinga.com/news/12/05/2631371/merck-ceo-says-he-isnt-interested-in-breaking-up-the-company-bloomberg,Paul Quintaro,2012-05-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.34555
853383,benzingas ma chatter for wednesday may ,https://www.benzinga.com/trading-ideas/long-ideas/12/05/2629184/benzingas-m-a-chatter-for-wednesday-may-30-2012,Charles Gross,2012-05-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853384, healthcare stocks with the highest cash,https://www.benzinga.com/trading-ideas/12/05/2622809/5-healthcare-stocks-with-the-highest-cash,Lisa Levin,2012-05-29 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853385,benzingas ma chatter for friday may ,https://www.benzinga.com/trading-ideas/long-ideas/12/05/2620944/benzingas-m-a-chatter-for-friday-may-25-2012,Charles Gross,2012-05-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853386,amylin shares jump as sanofi merck sumbit bids,https://www.benzinga.com/news/12/05/2619961/amylin-shares-jump-as-sanofi-merck-sumbit-bids,Scott Rubin,2012-05-25 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.648
853387,merck spokesperson would not comment on reports of bid for amylin,https://www.benzinga.com/news/12/05/2619898/merck-spokesperson-would-not-comment-on-reports-of-bid-for-amylin,Charles Gross,2012-05-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853388,amylin spokesperson would not comment on bloomberg report of bids from merck and sanofi,https://www.benzinga.com/news/12/05/2619892/amylin-spokesperson-would-not-comment-on-bloomberg-report-of-bids-from-merck-and-,Charles Gross,2012-05-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853389,amylin said to get firstround bids from sanofi merck bloomberg,https://www.benzinga.com/news/12/05/2619861/amylin-said-to-get-first-round-bids-from-sanofi-merck-bloomberg,Paul Quintaro,2012-05-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853390,government of rwanda introduces mercks rotateq,https://www.benzinga.com/news/12/05/2618675/government-of-rwanda-introduces-mercks-rotateq,Eddie Staley,2012-05-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853391,health care spdr in focus ahead of obamacare decision,https://www.benzinga.com/analyst-ratings/analyst-color/12/05/2606901/health-care-spdr-in-focus-ahead-of-obamacare-decision,ETF Professor,2012-05-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
853392,merck fda approves new labeling for isentress to include week data demonstrating longterm efficacy safety and tolerability,https://www.benzinga.com/news/12/05/2603557/merck-fda-approves-new-labeling-for-isentress-to-include-156-week-data-demonstrat,Allie Wickman,2012-05-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.83525
853393,bmo capital markets initiates coverage on merck at market perform announces pt of ,https://www.benzinga.com/analyst-ratings/price-target/12/05/2600594/bmo-capital-markets-initiates-coverage-on-merck-at-market,webmaster,2012-05-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853394,sp bullish on biotech etfs fbt ibb xbi,https://www.benzinga.com/analyst-ratings/analyst-color/12/05/2590458/s-p-bullish-on-biotech-etfs-fbt-ibb-xbi,ETF Professor,2012-05-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853395,the shorts report megacaps with increased short selling,https://www.benzinga.com/news/earnings/12/05/2581169/the-shorts-report-10-mega-caps-with-increased-short-selling,Jake Mann,2012-05-11 00:00:00,MRK,0,1,1,1,0,1,1,1,0,0.6366
853396,jp morgan reiterates overweight rating for merck,https://www.benzinga.com/analyst-ratings/analyst-color/12/05/2564793/j-p-morgan-reiterates-overweight-rating-for-merck,Dwight Einhorn,2012-05-07 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.41105
853397,goldman sachs reiterates neutral rating for merck,https://www.benzinga.com/analyst-ratings/analyst-color/12/05/2564230/goldman-sachs-reiterates-neutral-rating-for-merck,Dwight Einhorn,2012-05-07 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853398,pfizer merck pulled into expanded congressional investigation republicans seeking documents over obama deal bloomberg,https://www.benzinga.com/news/12/05/2559933/pfizer-merck-pulled-into-expanded-congressional-investigation-republicans-seeking,Paul Quintaro,2012-05-04 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853399,new kids do these new etfs have the right stuff,https://www.benzinga.com/markets/bonds/12/04/2542144/new-kids-do-these-new-etfs-have-the-right-stuff,ETF Professor,2012-04-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853400,fda considering letting patients purchase drugs without prescriptions,https://www.benzinga.com/news/12/04/2541492/fda-considering-letting-patients-purchase-drugs-without-prescriptions,Marco Rabinowitz,2012-04-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853401,merck amp reports q eps vs est revenues b vs b est,https://www.benzinga.com/news/earnings/12/04/2535750/merck-amp-reports-q1-eps-0-99-vs-0-98-est-revenues-11-7b-vs-11-82b-est,webmaster,2012-04-27 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853402,us stock futures flat gdp data in focus,https://www.benzinga.com/news/12/04/2535635/us-stock-futures-flat-gdp-data-in-focus,Lisa Levin,2012-04-27 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853403,earnings scheduled for april ,https://www.benzinga.com/news/earnings/12/04/2535133/earnings-scheduled-for-april-27,Monica Gerson,2012-04-27 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853404,earnings expectations for the week of april aapl xom ups,https://www.benzinga.com/news/earnings/12/04/2517141/earnings-expectations-for-the-week-of-april-23-aapl-xom-ups,Nelson Hem,2012-04-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853405,sp bullish on pharma etfs longterm,https://www.benzinga.com/analyst-ratings/analyst-color/12/04/2512735/s-p-bullish-on-pharma-etfs-long-term,ETF Professor,2012-04-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853406,merck reports phase iii study results evaluating anaemia management strategies used with victrelis boceprevir combination therapy,https://www.benzinga.com/news/12/04/2510311/merck-reports-phase-iii-study-results-evaluating-anaemia-management-strategies-us,Eddie Staley,2012-04-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853407,merck wins another fosamax state court trial,https://www.benzinga.com/news/12/04/2508766/merck-wins-another-fosamax-state-court-trial,Eddie Staley,2012-04-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7859499999999999
853408,benzingas microcap movers for monday april ,https://www.benzinga.com/trading-ideas/long-ideas/12/04/2502818/benzingas-microcap-movers-for-monday-april-16-2012,Charles Gross,2012-04-17 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853409,benzingas top premarket gainers,https://www.benzinga.com/news/12/04/2502530/benzingas-top-pre-market-gainers,Lisa Levin,2012-04-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
853410,option alert endocyte call volume at of average on merck deal,https://www.benzinga.com/news/12/04/2499426/option-alert-endocyte-call-volume-at-818-of-average-on-merck-deal,Charles Gross,2012-04-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
853411,morning market movers,https://www.benzinga.com/news/12/04/2499157/morning-market-movers,Lisa Levin,2012-04-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853412,benzingas top premarket gainers,https://www.benzinga.com/news/12/04/2498060/benzingas-top-pre-market-gainers,Lisa Levin,2012-04-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
853413,endocyte rises premarket on merck deal,https://www.benzinga.com/news/12/04/2497729/endocyte-rises-100-pre-market-on-merck-deal,Charles Gross,2012-04-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853414,financial breakfast morning news summary for april ,https://www.benzinga.com/news/earnings/12/04/2497725/financial-breakfast-morning-news-summary-for-april-16-2012,Allie Wickman,2012-04-16 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853415,endocyte resumes trading,https://www.benzinga.com/news/12/04/2497706/endocyte-resumes-trading,Charles Gross,2012-04-16 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853416,preview endocyte to resume trading at am,https://www.benzinga.com/news/12/04/2497647/preview-endocyte-to-resume-trading-at-7-30am,Charles Gross,2012-04-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853417,merck and endocyte enter exclusive worldwide agreement to develop and commercialize phase iii cancer candidate vintafolide,https://www.benzinga.com/news/12/04/2497636/merck-and-endocyte-enter-exclusive-worldwide-agreement-to-develop-and-commerciali,Eddie Staley,2012-04-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.41105
853418,decoding wall st express scripts and medco merger is no joke,https://www.benzinga.com/news/global/12/04/2471840/decoding-wall-st-express-scripts-and-medco-merger-is-no-joke,BrianSozzi,2012-04-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853419,merck,https://www.benzinga.com/trading-ideas/12/04/2470794/merck,Investor's Business Daily,2012-04-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853420,codexis and merck develop prototype enzymebased method for production of boceprevir,https://www.benzinga.com/news/12/04/2470274/codexis-and-merck-develop-prototype-enzyme-based-method-for-production-of-bocepre,Eddie Staley,2012-04-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853421,benzingas ma chatter for tuesday march ,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2450204/benzingas-m-a-chatter-for-tuesday-march-27-2012,Charles Gross,2012-03-27 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853422,merck spokesperson responding to chatter of offer for amarin says company policy is not to respond to rumors regarding business development deals,https://www.benzinga.com/news/12/03/2449339/merck-spokesperson-responding-to-chatter-of-26-offer-for-amarin-says-company-poli,Charles Gross,2012-03-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853423,hearing chatter merck making share bid for amarin,https://www.benzinga.com/news/12/03/2449128/hearing-chatter-merck-making-26share-bid-for-amarin,Charles Gross,2012-03-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
853424,victrelis available for eligible patients in british columbia,https://www.benzinga.com/news/12/03/2447784/victrelis-available-for-eligible-patients-in-british-columbia,Paul Quintaro,2012-03-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853425,merck reports cm investment and start of merck lumira fund,https://www.benzinga.com/news/12/03/2447055/merck-reports-c-35m-investment-and-start-of-merck-lumira-fund,Paul Quintaro,2012-03-26 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853426,adding mercks vorapaxar to standard of care significantly reduced the risk of cardiovascular events,https://www.benzinga.com/news/12/03/2445874/adding-mercks-vorapaxar-to-standard-of-care-significantly-reduced-the-risk-of-car,Charles Gross,2012-03-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6366
853427,update merck and ariad pharmaceuticals provide update on fda advisory committee vote voted to against the use of ridaforolimus,https://www.benzinga.com/news/12/03/2440609/update-merck-and-ariad-pharmaceuticals-provide-update-on-fda-advisory-committee-v,Allie Wickman,2012-03-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853428,ariad pharmaceuticals falls on fda panel vote,https://www.benzinga.com/news/12/03/2439094/ariad-pharmaceuticals-falls-5-on-fda-panel-vote,Charles Gross,2012-03-20 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853429,fda panel votes against recommending taltorvic as maintenance treatment for softtissue and bone sarcoma reuters,https://www.benzinga.com/news/12/03/2439091/fda-panel-votes-13-1-against-recommending-taltorvic-as-maintenance-treatment-for-,Eddie Staley,2012-03-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853430,etf showdown dividend dilemma hdv hdiv jnj,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2430857/etf-showdown-dividend-dilemma-hdv-hdiv-jnj,ETF Professor,2012-03-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.41105
853431,briefing information for the march meeting of the oncologic drugs advisory committee,https://www.benzinga.com/news/12/03/2429594/briefing-information-for-the-march-20-2012-meeting-of-the-oncologic-drugs-advisor,Charles Gross,2012-03-16 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853432,a look at the new russell high yield etf hdiv abt kft,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2427762/a-look-at-the-new-russell-high-yield-etf-hdiv-abt-kft,ETF Professor,2012-03-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853433,benzingas ma chatter for monday march ,https://www.benzinga.com/trading-ideas/long-ideas/12/03/2416916/benzingas-m-a-chatter-for-monday-march-12-2012,Charles Gross,2012-03-12 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853434,merck repeats forecast in presentation slides bloomberg,https://www.benzinga.com/news/12/03/2416301/merck-repeats-2012-forecast-in-presentation-slides-bloomberg,Matthew Kennedy,2012-03-12 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853435,merck spokesperson would not comment on earlier speculation of idenix pharmaceuticals takeover bid,https://www.benzinga.com/news/12/03/2416279/merck-spokesperson-would-not-comment-on-earlier-speculation-of-idenix-pharmaceuti,Charles Gross,2012-03-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853436,hearing renewed takeover chatter in idenix pharmaceuticals merck rumored buyer,https://www.benzinga.com/news/12/03/2415990/hearing-renewed-takeover-chatter-in-idenix-pharmaceuticals-merck-rumored-buyer,Charles Gross,2012-03-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853437,positive rumors circulate about idenix pharmaceuticals,https://www.benzinga.com/news/rumors/12/03/2415989/positive-rumors-circulate-about-idenix-pharmaceuticals,webmaster,2012-03-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
853438,merck gives weak q outlook,https://www.benzinga.com/news/12/03/2404000/merck-gives-weak-q1-outlook,Investor's Business Daily,2012-03-07 00:00:00,MRK,1,1,0,0,0,0,0,0,0,0.2798
853439,from earlier merck announces results from investigational studies with victrelis presented at the conference on retroviruses and opportunistic infections to understand potential use in patients coinfected with chronic hepatitis c and hiv,https://www.benzinga.com/news/12/03/2403365/from-earlier-merck-announces-results-from-investigational-studies-with-victrelis-,Eddie Staley,2012-03-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.4871
853440,oncothyreon analyst stimulax continuation was expected as likely outcome for trial to be completed rather than stop early for positive efficacy or futility,https://www.benzinga.com/news/12/03/2401566/oncothyreon-analyst-stimulax-continuation-was-expected-as-likely-outcome-for-tria,Matthew Kennedy,2012-03-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.67
853441,merck down after reaffirming guidance,https://www.benzinga.com/news/12/03/2401100/merck-down-2-after-reaffirming-2012-guidance,Matthew Kennedy,2012-03-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853442,abbott and merck collaborate to develop companion diagnostic test for investigational cancer therapy,https://www.benzinga.com/news/12/03/2399924/abbott-and-merck-collaborate-to-develop-companion-diagnostic-test-for-investigati,Eddie Staley,2012-03-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.17015000000000002
853443,merck issues q profit forecast,https://www.benzinga.com/news/earnings/12/03/2399621/merck-issues-q1-profit-forecast,Lisa Levin,2012-03-06 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.7202
853444,update merck confirms fullyear guidance,https://www.benzinga.com/news/12/03/2399424/update-merck-confirms-2012-full-year-guidance,Matthew Kennedy,2012-03-06 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853445,merck guides q eps vs est confirms guidance,https://www.benzinga.com/news/12/03/2399423/merck-guides-q1-eps-0-95-0-98-vs-1-01-est-confirms-2012-guidance,Matthew Kennedy,2012-03-06 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853446,oncothyreon falls premarket on stimuvax report,https://www.benzinga.com/news/12/03/2399193/oncothyreon-falls-47-pre-market-on-stimuvax-report,Charles Gross,2012-03-06 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853447,update merck says stimuvax trial to continue to final analysis says final result expected in ,https://www.benzinga.com/news/12/03/2399185/update-merck-says-stimuvax-trial-to-continue-to-final-analysis-says-final-result-,Matthew Kennedy,2012-03-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853448,merck says fda declines to approve its new drug application for ezetimibe and atorvastatin tablets reuters,https://www.benzinga.com/news/12/03/2397389/merck-says-fda-declines-to-approve-its-new-drug-application-for-ezetimibe-and-ato,Eddie Staley,2012-03-05 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853449,mercks investigational allergy immunotherapy tablet significantly reduced the combination of ragweed allergy symptoms,https://www.benzinga.com/news/12/03/2395719/mercks-investigational-allergy-immunotherapy-tablet-significantly-reduced-the-com,Matthew Kennedy,2012-03-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853450,merck says fda says added data needed on ezetimibeatorvastatin bloomberg,https://www.benzinga.com/news/12/03/2395568/merck-says-fda-says-added-data-needed-on-ezetimibeatorvastatin-bloomberg,Matthew Kennedy,2012-03-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853451,the rick santorum etf portfolio kol pbs iyz,https://www.benzinga.com/trading-ideas/long-ideas/12/02/2381159/the-rick-santorum-etf-portfolio-kol-pbs-iyz,ETF Professor,2012-02-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853452,fda approves important safety label changes for the class of cholesterollowering drugs known as statins reuters,https://www.benzinga.com/news/12/02/2380403/fda-approves-important-safety-label-changes-for-the-class-of-cholesterol-lowering,Eddie Staley,2012-02-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8714999999999999
853453,viva vivus but not in etfs vvus ibb pjp,https://www.benzinga.com/trading-ideas/long-ideas/12/02/2365365/viva-vivus-but-not-in-etfs-vvus-ibb-pjp,ETF Professor,2012-02-22 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853454,merck establishes joint venture with supera farma to commercialize innovative pharmaceutical products and branded generics in brazil,https://www.benzinga.com/news/12/02/2345788/merck-establishes-joint-venture-with-supera-farma-to-commercialize-innovative-pha,Eddie Staley,2012-02-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
853455,fda approves zioptan mercks oncedaily preservativefree ophthalmic medication,https://www.benzinga.com/news/12/02/2339085/fda-approves-zioptan-mercks-once-daily-preservative-free-ophthalmic-medication,Matthew Kennedy,2012-02-13 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.70095
853456,update morgan stanley raises pt to on merck,https://www.benzinga.com/analyst-ratings/analyst-color/12/02/2338000/update-morgan-stanley-raises-pt-to-37-on-merck,David Johnson,2012-02-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853457,grandpas etf portfolio,https://www.benzinga.com/trading-ideas/long-ideas/12/02/2335968/grandpas-2012-etf-portfolio,ETF Professor,2012-02-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853458,merck analyst effectiveness of vorapaxar was surprise but ability to reach market is limited due to bleeding risk,https://www.benzinga.com/news/12/02/2324030/merck-analyst-effectiveness-of-vorapaxar-was-surprise-but-ability-to-reach-market,Matthew Kennedy,2012-02-07 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.455
853459,merck announces topline results of trap study of vorapaxar,https://www.benzinga.com/news/12/02/2322806/merck-announces-top-line-results-of-tra-2p-study-of-vorapaxar,Matthew Kennedy,2012-02-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3409
853460,benzingas ma chatter for monday february ,https://www.benzinga.com/trading-ideas/long-ideas/12/02/2321339/benzingas-m-a-chatter-for-monday-february-6-2012,Charles Gross,2012-02-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853461,idenix pharmaceuticals spokesperson has no comment on renewed merck takeover chatter,https://www.benzinga.com/news/12/02/2320157/idenix-pharmaceuticals-spokesperson-has-no-comment-on-renewed-merck-takeover-chat,Charles Gross,2012-02-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.352
853462,update idenix pharmaceuticals spiking higher on renewed takeover chatter merck rumored buyer,https://www.benzinga.com/news/12/02/2320093/update-idenix-pharmaceuticals-spiking-higher-on-renewed-takeover-chatter-merck-ru,Charles Gross,2012-02-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853463,merck confirms plans to file nda for suvorexant in ,https://www.benzinga.com/news/12/02/2318985/merck-confirms-plans-to-file-nda-for-suvorexant-in-2012,Eddie Staley,2012-02-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853464,candlesticks bears appeared on merck,https://www.benzinga.com/news/earnings/12/02/2316337/candlesticks-bears-appeared-on-merck,Traders Huddle,2012-02-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853465,from earlier threshold pharmaceuticals and merck kgaa announce global agreement to codevelop and commercialize phase hypoxiatargeted drug th,https://www.benzinga.com/news/12/02/2315028/from-earlier-threshold-pharmaceuticals-and-merck-kgaa-announce-global-agreement-t,Eddie Staley,2012-02-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
853466,fda approves janumet xr for type diabetes,https://www.benzinga.com/news/12/02/2313255/fda-approves-janumet-xr-for-type-2-diabetes,Matthew Kennedy,2012-02-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
853467,update merck swings to q profit,https://www.benzinga.com/news/earnings/12/02/2312747/update-merck-swings-to-q4-profit,Lisa Levin,2012-02-02 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.7202
853468,mercks earnings are up but a huge drop may be coming,https://www.benzinga.com/news/earnings/12/02/2311149/mercks-earnings-are-up-but-a-huge-drop-may-be-coming,Michael R Foster,2012-02-02 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.5386
853469,financial breakfast morning news summary for february ,https://www.benzinga.com/news/earnings/12/02/2311121/financial-breakfast-morning-news-summary-for-february-2-2012,Allie Wickman,2012-02-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853470,merck reports q eps vs est revenues b vs b est,https://www.benzinga.com/news/earnings/12/02/2310962/merck-reports-q4-eps-0-97-vs-0-95-est-revenues-12-30b-vs-12-53b-est,Matthew Kennedy,2012-02-02 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
853471,earnings scheduled for february ,https://www.benzinga.com/news/earnings/12/02/2310628/earnings-scheduled-for-february-2,Monica Gerson,2012-02-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853472,merck wins patent ruling over sandoz version of cancidas bloomberg,https://www.benzinga.com/news/12/01/2305393/merck-wins-patent-ruling-over-sandoz-version-of-cancidas-bloomberg,Matthew Kennedy,2012-01-31 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.7859499999999999
853473,earnings expectations for the week of january ,https://www.benzinga.com/news/earnings/12/01/2297577/earnings-expectations-for-the-week-of-january-30,Nelson Hem,2012-01-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853474,benzingas ma chatter for thursday january ,https://www.benzinga.com/trading-ideas/long-ideas/12/01/2291823/benzingas-m-a-chatter-for-thursday-january-26-2012,Charles Gross,2012-01-26 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853475,seattle genetics spokesperson would not comment on earlier merck takeover rumor,https://www.benzinga.com/news/12/01/2291534/seattle-genetics-spokesperson-would-not-comment-on-earlier-merck-takeover-rumor,Charles Gross,2012-01-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853476,benzingas ma chatter for wednesday january ,https://www.benzinga.com/trading-ideas/long-ideas/12/01/2290441/benzingas-m-a-chatter-for-wednesday-january-25-2012,Charles Gross,2012-01-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853477,merck spokesperson would not comment on earlier speculation of idenix pharmaceuticals takeover,https://www.benzinga.com/news/12/01/2290229/merck-spokesperson-would-not-comment-on-earlier-speculation-of-idenix-pharmaceuti,Charles Gross,2012-01-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853478,idenix pharmaceuticals spokesperson has no comment on earlier merck takeover chatter,https://www.benzinga.com/news/12/01/2289418/idenix-pharmaceuticals-spokesperson-has-no-comment-on-earlier-merck-takeover-chat,Charles Gross,2012-01-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.352
853479,idenix pharmaceuticals spiking higher on renewed takeover chatter merck rumored buyer,https://www.benzinga.com/news/12/01/2288361/idenix-pharmaceuticals-spiking-higher-on-renewed-takeover-chatter-merck-rumored-b,Charles Gross,2012-01-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853480,update merck fda did not approve new indication for vytorin because of study design,https://www.benzinga.com/news/12/01/2287889/update-merck-fda-did-not-approve-new-indication-for-vytorin-because-of-study-desi,Allie Wickman,2012-01-25 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853481,merck announces new fda approved labeling for vytorin includes results from the study of heart and renal protection in patients with moderate to severe chronic kidney disease,https://www.benzinga.com/news/12/01/2287867/merck-announces-new-fda-approved-labeling-for-vytorin-includes-results-from-the-s,Eddie Staley,2012-01-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5258
853482,update isi group initiates buy on merck,https://www.benzinga.com/analyst-ratings/analyst-color/12/01/2284593/update-isi-group-initiates-buy-45-on-merck,David Johnson,2012-01-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853483,merck receives positive mad moneyjim cramer mention cnbc,https://www.benzinga.com/media/cnbc/12/01/2282228/merck-receives-positive-mad-moneyjim-cramer-mention-cnbc,Charles Gross,2012-01-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.55135
853484,merck announces remicade receives positive opinion from chmp in europe for treatment of ulcerative colitis in pediatric patients,https://www.benzinga.com/news/12/01/2277479/merck-announces-remicade-receives-positive-opinion-from-chmp-in-europe-for-treatm,Eddie Staley,2012-01-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
853485,whats the future like for health care,https://www.benzinga.com/news/12/01/2277200/whats-the-future-like-for-health-care,Abhi Rao,2012-01-20 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.8453999999999999
853486,merck hits week high of ,https://www.benzinga.com/intraday-update/12/01/2271927/merck-hits-52-week-high-of-39-01,Benzinga Staff,2012-01-19 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
853487,benzingas ma chatter for wednesday january ,https://www.benzinga.com/trading-ideas/long-ideas/12/01/2271061/benzingas-m-a-chatter-for-wednesday-january-18-2012,Charles Gross,2012-01-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853488,positive rumors circulate about vertex pharmaceuticals,https://www.benzinga.com/news/rumors/12/01/2269987/positive-rumors-circulate-about-vertex-pharmaceuticals,webmaster,2012-01-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
853489,hearing wedbush says idenix pharmaceuticals takeover target of merck johnson johnson abbott labs share,https://www.benzinga.com/analyst-ratings/analyst-color/12/01/2269520/hearing-wedbush-says-idenix-pharmaceuticals-takeover-tar,Charles Gross,2012-01-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
853490,how to trade biotechs based on the jp morgan health care conference,https://www.benzinga.com/analyst-ratings/analyst-color/12/01/2257543/how-to-trade-biotechs-based-on-the-jp-morgan-health-care,Abhi Rao,2012-01-11 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.8062
853491,going nuclear on hepatitis c is idenix the next target,https://www.benzinga.com/trading-ideas/long-ideas/12/01/2254086/going-nuc-lear-on-hepatitis-c-is-idenix-the-next-target,Ilir Shkurti,2012-01-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853492,feuerstein merck for idenix pharma was just a prediction not a rumor,https://www.benzinga.com/news/12/01/2254050/feuerstein-merck-for-idenix-pharma-was-just-a-prediction-not-a-rumor,Allie Wickman,2012-01-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853493,jefferies downgrades merck company to hold,https://www.benzinga.com/analyst-ratings/downgrades/12/01/2248026/jefferies-downgrades-merck-company-to-hold,Juan Lopez,2012-01-09 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
853494,merck says fda approves isentress for children in ages up bloomberg,https://www.benzinga.com/news/12/01/2246274/merck-says-fda-approves-isentress-for-children-in-ages-2-up-bloomberg,Matthew Kennedy,2012-01-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.70095
853495,merck hits week high of ,https://www.benzinga.com/intraday-update/12/01/2242037/merck-hits-52-week-high-of-38-57,Benzinga Staff,2012-01-05 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
853496,will alnylams prospective obesity drug change the world forever,https://www.benzinga.com/trading-ideas/long-ideas/12/01/2240367/will-alnylams-prospective-obesity-drug-change-the-world-forev,Abhi Rao,2012-01-04 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853497,bark at the dows dogs with these etfs,https://www.benzinga.com/trading-ideas/long-ideas/12/01/2240195/bark-at-the-dows-dogs-with-these-etfs,ETF Professor,2012-01-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853498,merck hits week high of ,https://www.benzinga.com/intraday-update/12/01/2236252/merck-hits-52-week-high-of-37-98,Benzinga Staff,2012-01-03 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
853499,can germanys employers turn europe around,https://www.benzinga.com/news/12/01/2235738/can-germanys-employers-turn-europe-around,Abhi Rao,2012-01-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853500,etf showdown fun with pharma,https://www.benzinga.com/trading-ideas/long-ideas/11/12/2233813/etf-showdown-fun-with-pharma,ETF Professor,2011-12-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7553000000000001
853501,inside s best value investment,https://www.benzinga.com/analyst-ratings/analyst-color/11/12/2229860/inside-2012s-best-value-investment,Abhi Rao,2011-12-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8825000000000001
853502,merck hits week high of ,https://www.benzinga.com/intraday-update/11/12/2227147/merck-hits-52-week-high-of-37-76,Benzinga Staff,2011-12-23 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
853503,merck hits week high of ,https://www.benzinga.com/intraday-update/11/12/2225283/merck-hits-52-week-high-of-37-66,Benzinga Staff,2011-12-22 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
853504,exelixis trading higher after licensing agreement with merck,https://www.benzinga.com/trading-ideas/long-ideas/11/12/2222764/exelixis-trading-higher-after-licensing-agreement-with-merck,Eddie Staley,2011-12-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
853505,merck and the adap crisis task force announce new agreement to improve access and care for people with hiv,https://www.benzinga.com/news/11/12/2222404/merck-and-the-adap-crisis-task-force-announce-new-agreement-to-improve-access-and,Eddie Staley,2011-12-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81845
853506,exelixis licenses pikdelta program to merck,https://www.benzinga.com/news/11/12/2221330/exelixis-licenses-pi3k-delta-program-to-merck,Allie Wickman,2011-12-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853507,can a picture of the ceo predict stock performance,https://www.benzinga.com/trading-ideas/long-ideas/11/12/2215116/can-a-picture-of-the-ceo-predict-stock-performance,Tuomo Kallio,2011-12-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853508,benzingas top premarket losers,https://www.benzinga.com/news/11/12/2200124/benzingas-top-pre-market-losers,Lisa Levin,2011-12-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.30910000000000004
853509,are you guaranteed profits if these rumors are true,https://www.benzinga.com/trading-ideas/long-ideas/11/12/2193522/are-you-guaranteed-profits-if-these-rumors-are-true,Abe Raymond,2011-12-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8453999999999999
853510,five biotech stocks to watch going into big doctors meeting,https://www.benzinga.com/markets/11/12/2193320/five-biotech-stocks-to-watch-going-into-big-doctors-meeting,Minyanville,2011-12-09 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853511,are the samsung ma rumors true,https://www.benzinga.com/analyst-ratings/analyst-color/11/12/2169040/are-the-samsung-m-a-rumors-true,Abe Raymond,2011-12-01 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.71075
853512,these stocks may be better than their dow equivalents,https://www.benzinga.com/trading-ideas/long-ideas/11/12/2165707/these-stocks-may-be-better-than-their-dow-equivalents,Gordon Wilcox,2011-12-01 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.7202
853513,is arena pharma going to cure obesity,https://www.benzinga.com/news/11/11/2156318/is-arena-pharma-going-to-cure-obesity,Abe Raymond,2011-11-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853514,merck kgaa says merck co has taken over its facecbook page asks court to order facebook to give information,https://www.benzinga.com/news/11/11/2147077/merck-kgaa-says-merck-co-has-taken-over-its-facecbook-page-asks-court-to-order-fa,Matthew Kennedy,2011-11-22 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853515,endofday market summary for november ,https://www.benzinga.com/news/11/11/2146830/end-of-day-market-summary-for-november-22-2011,Abe Raymond,2011-11-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853516,update merck resolves previously disclosed sevenyear investigation led by us attorneys office for the district of massachusetts related to vioxx,https://www.benzinga.com/news/11/11/2146626/update-merck-resolves-previously-disclosed-seven-year-investigation-led-by-u-s-at,Eddie Staley,2011-11-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.58895
853517,merck will pay m to settle government vioxx probe,https://www.benzinga.com/news/11/11/2146542/merck-will-pay-950m-to-settle-government-vioxx-probe,Matthew Kennedy,2011-11-22 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.44865
853518,merck settles vioxx suits from ny florida s carolina reuters,https://www.benzinga.com/news/11/11/2130494/merck-settles-vioxx-suits-from-ny-florida-s-carolina-reuters,Allie Wickman,2011-11-15 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
853519,appaloosa took stakes in etrade bp and dana holding in q exited pfizer bank of america hewlettpackard wells fargo merck unitedhealth group and metlife in q,https://www.benzinga.com/news/11/11/2125838/appaloosa-took-stakes-in-etrade-bp-and-dana-holding-in-q3-exited-pfizer-bank-of-a,Paul Quintaro,2011-11-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
853520,morgan stanley maintains equalweight rating and pt on merck co,https://www.benzinga.com/analyst-ratings/analyst-color/11/11/2119111/morgan-stanley-maintains-equal-weight-rating-and-34-pt-o,Phil Marsh,2011-11-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853521,merk ceo saying will not make disproportionate changes to rd spending,https://www.benzinga.com/news/11/11/2116596/merk-ceo-saying-will-not-make-disproportionate-changes-to-r-d-spending,Eddie Staley,2011-11-10 00:00:00,MRK,1,2,0,1,0,0,1,0,1,0.5
853522,merck increase quarterly dividend by ,https://www.benzinga.com/news/11/11/2115097/merck-increase-quarterly-dividend-by-11,Matthew Kennedy,2011-11-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6591
853523,citi maintains neutral rating and pt on merck,https://www.benzinga.com/analyst-ratings/analyst-color/11/11/2115040/citi-maintains-neutral-rating-and-34-pt-on-merck,Phil Marsh,2011-11-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853524,update merck to pay m to settle certain vioxxrelated lawsuits,https://www.benzinga.com/news/11/11/2111415/update-merck-to-pay-49-5m-to-settle-certain-vioxx-related-lawsuits,Allie Wickman,2011-11-09 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5129
853525,merck gets justice dept requests for information on drug marketing relate to marketing of integrilin avelox and azasite,https://www.benzinga.com/news/11/11/2111413/merck-gets-justice-dept-requests-for-information-on-drug-marketing-relate-to-mark,Allie Wickman,2011-11-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.76335
853526,merck fda declines to approve merck eyedisease drug tafluprost dj,https://www.benzinga.com/news/11/11/2110534/merck-fda-declines-to-approve-merck-eye-disease-drug-tafluprost-dj,Allie Wickman,2011-11-09 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853527,merck launches nexplanon mg in the united states,https://www.benzinga.com/news/11/11/2110010/merck-launches-nexplanon-68-mg-in-the-united-states,Matthew Kennedy,2011-11-09 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.71075
853528,jp morgan maintains overweight rating and pt on merck co,https://www.benzinga.com/analyst-ratings/analyst-color/11/11/2101197/jp-morgan-maintains-overweight-rating-and-44-pt-on-merck,Joe Young,2011-11-07 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.41105
853530,fda advisory committee unanimously recommends approval of mercks vytorin for use in patients with predialysis chronic kidney disease,https://www.benzinga.com/news/11/11/2089172/fda-advisory-committee-unanimously-recommends-approval-of-mercks-vytorin-for-use-,Matthew Kennedy,2011-11-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.8062
853531,fda advisers vote efficacy safety data support approval of mercks vytorin,https://www.benzinga.com/news/11/11/2088298/fda-advisers-vote-16-0-efficacy-safety-data-support-approval-of-mercks-vytorin,Eddie Staley,2011-11-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.91125
853532,are upcoming study results spurring insider buying at ligand pharmaceuticals,https://www.benzinga.com/general/topics/11/11/2085693/are-upcoming-study-results-spurring-insider-buying-at-ligand-pharmaceut,M.E. Garza,2011-11-02 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853533,which pharma stock should you short,https://www.benzinga.com/news/11/11/2083990/which-pharma-stock-should-you-short,Abe Raymond,2011-11-01 00:00:00,MRK,0,2,0,0,1,0,0,0,0,0.5
853534,one pill makes you stronger pfizer earnings are the white knight,https://www.benzinga.com/news/earnings/11/11/2083327/one-pill-makes-you-stronger-pfizer-earnings-are-the-white-knight,Jonathan Chen,2011-11-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
853535,a look at the new drgs etn,https://www.benzinga.com/trading-ideas/long-ideas/11/10/2078940/a-look-at-the-new-drgs-etn,ETF Professor,2011-10-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853536,merck can block teva on generic temodar as court rejects appeal bloomberg,https://www.benzinga.com/news/11/10/2077788/merck-can-block-teva-on-generic-temodar-as-court-rejects-appeal-bloomberg,Matthew Kennedy,2011-10-31 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.13655
853537,citi maintains neutral rating and pt on merck,https://www.benzinga.com/analyst-ratings/analyst-color/11/10/2077078/citi-maintains-neutral-rating-and-34-pt-on-merck,Joe Young,2011-10-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853538,merck announces increased earnings,https://www.benzinga.com/news/earnings/11/10/2022144/merck-announces-increased-earnings,Benzinga Staff Writer,2011-10-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6366
853539,financial breakfast morning news summary for october ,https://www.benzinga.com/news/earnings/11/10/2021852/financial-breakfast-morning-news-summary-for-october-28-2011,Allie Wickman,2011-10-28 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853540,merck co reports q eps vs est revenues b vs b est,https://www.benzinga.com/news/earnings/11/10/2021665/merck-co-reports-q3-eps-0-94-vs-0-91-est-revenues-12-02b-vs-11-61b-est,Matthew Kennedy,2011-10-28 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
853541,us stock futures signal lower start on wall street,https://www.benzinga.com/news/11/10/2021618/us-stock-futures-signal-lower-start-on-wall-street,Monica Gerson,2011-10-28 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.352
853542,earnings scheduled for october ,https://www.benzinga.com/news/earnings/11/10/2021225/earnings-scheduled-for-october-28,Monica Gerson,2011-10-28 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853543,deutsche bank maintains buy rating on merck co,https://www.benzinga.com/analyst-ratings/analyst-color/11/10/2013787/deutsche-bank-maintains-buy-rating-on-merck-co,Steven Anfield,2011-10-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853544,merck announces cdc advisory committee on immunization practices votes for expanded use of gardasil in boys and young men,https://www.benzinga.com/news/11/10/2011845/merck-announces-cdc-advisory-committee-on-immunization-practices-votes-for-expand,Eddie Staley,2011-10-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853545,what does novartis earnings release really mean for the company,https://www.benzinga.com/news/earnings/11/10/2011837/what-does-novartis-earnings-release-really-mean-for-the-company,Abe Raymond,2011-10-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853546,merck earnings preview analysts expect higher eps revenue,https://www.benzinga.com/news/earnings/11/10/2011512/merck-earnings-preview-analysts-expect-higher-eps-revenue,Benzinga Staff Writer,2011-10-25 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.5
853547,merck announces presentation of phase iii investigational studies evaluating dulera inhalation aerosol in chronic obstructive pulmonary disease,https://www.benzinga.com/news/11/10/2008583/merck-announces-presentation-of-phase-iii-investigational-studies-evaluating-dule,Allie Wickman,2011-10-24 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853548,earnings expectations for the week of october ,https://www.benzinga.com/news/earnings/11/10/2005743/earnings-expectations-for-the-week-of-october-24,Nelson Hem,2011-10-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853549,mylan laboratories earnings preview analysts expect higher eps revenue,https://www.benzinga.com/news/earnings/11/10/2004815/mylan-laboratories-earnings-preview-analysts-expect-higher-eps-revenue,Benzinga Staff Writer,2011-10-21 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.5
853550,top stocks in the drug manufacturersmajor industry with the highest dividend yield,https://www.benzinga.com/trading-ideas/dividends/11/10/1985660/top-4-stocks-in-the-drug-manufacturers-major-industry-with-the,Monica Gerson,2011-10-14 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.60115
853551,under the hood emerging markets health care,https://www.benzinga.com/news/11/10/1984778/under-the-hood-emerging-markets-health-care,ETF Professor,2011-10-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
853552,merck announces retirement of chairman and former ceo richard t clark,https://www.benzinga.com/news/11/10/1970188/merck-announces-retirement-of-chairman-and-former-ceo-richard-t-clark,Eddie Staley,2011-10-06 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853553,bristolmyers and quidel to open near week highs,https://www.benzinga.com/trading-ideas/long-ideas/11/10/1969308/bristol-myers-and-quidel-to-open-near-52-week-highs,Nelson Hem,2011-10-06 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853554,fda accepts new drug application filing for ridaforolimus investigational mtor inhibitor,https://www.benzinga.com/news/11/10/1965969/fda-accepts-new-drug-application-filing-for-ridaforolimus-investigational-mtor-in,Eddie Staley,2011-10-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
853555,merck wins another federal bellwether trial regarding fosamax,https://www.benzinga.com/news/11/10/1960726/merck-wins-another-federal-bellwether-trial-regarding-fosamax,Eddie Staley,2011-10-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7859499999999999
853556,merck announces new data analyses for victrelis will be presented at the american association for the study of liver diseases annual meeting,https://www.benzinga.com/news/11/09/1956221/merck-announces-new-data-analyses-for-victrelis-will-be-presented-at-the-american,Eddie Staley,2011-09-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853557,merck sells its interest in johnson johnsonmerck consumer pharmaceuticals for m,https://www.benzinga.com/news/11/09/1951285/merck-sells-its-interest-in-johnson-johnson-merck-consumer-pharmaceuticals-for-17,Eddie Staley,2011-09-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7294
853558,merck names cuong viet do as chief strategy officer,https://www.benzinga.com/news/11/09/1946941/merck-names-cuong-viet-do-as-chief-strategy-officer,Matthew Kennedy,2011-09-27 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853559,mercks issentress combo showed efficacy tolerability,https://www.benzinga.com/news/11/09/1925844/mercks-iss-entress-combo-showed-efficacy-tolerability,Matthew Kennedy,2011-09-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853560,sp likes three health care etfs,https://www.benzinga.com/analyst-ratings/analyst-color/11/09/1917987/s-p-likes-three-health-care-etfs,ETF Professor,2011-09-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8592
853561,bounceback kings stocks up more than in the past month,https://www.benzinga.com/trading-ideas/long-ideas/11/09/1916754/bounce-back-kings-9-stocks-up-more-than-30-in-the-past-month,Nelson Hem,2011-09-14 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
853563,a peek into the market before the trading starts,https://www.benzinga.com/news/11/09/1914222/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,2011-09-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853564,merck and bgi establish strategic collaboration focused on biomarkers and genomic technologies,https://www.benzinga.com/news/11/09/1913990/merck-and-bgi-establish-strategic-collaboration-focused-on-biomarkers-and-genomic,Eddie Staley,2011-09-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6909
853565,bank of america merrill lynch maintains buy on merck co,https://www.benzinga.com/analyst-ratings/analyst-color/11/09/1906513/bank-of-america-merrill-lynch-maintains-buy-on-merck-co,BenzingaStaffJ,2011-09-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853566,stocks going ex dividend the third week of september,https://www.benzinga.com/trading-ideas/long-ideas/11/09/1906067/stocks-going-ex-dividend-the-third-week-of-september,Fred Fuld,2011-09-07 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853567,merck millipore strengthens bioscience business by acquiring amnis corporation,https://www.benzinga.com/news/11/08/1890301/merck-millipore-strengthens-bioscience-business-by-acquiring-amnis-corporation,Matthew Kennedy,2011-08-30 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.7294
853568,zymeworks announces collaboration with merck to develop bispecific antibody therapeutics,https://www.benzinga.com/news/11/08/1888323/zymeworks-announces-collaboration-with-merck-to-develop-bi-specific-antibody-ther,Matthew Kennedy,2011-08-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853570, most popular healthcare stocks among hedge funds,https://www.benzinga.com/trading-ideas/long-ideas/11/08/1884640/12-most-popular-healthcare-stocks-among-hedge-funds,Insider Monkey,2011-08-25 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.7377
853571, most popular healthcare stocks among hedge funds,https://www.benzinga.com/trading-ideas/long-ideas/11/08/1883734/12-most-popular-healthcare-stocks-among-hedge-funds,Insider Monkey,2011-08-25 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.7377
853572,merck and ariad announce european medicines agency accepts marketing authorization application for ridaforolimus,https://www.benzinga.com/news/11/08/1866276/merck-and-ariad-announce-european-medicines-agency-accepts-marketing-authorizatio,Eddie Staley,2011-08-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
853573,merck and ariad announce european medicines agency accepts marketing authorization application for ridaforolimus,https://www.benzinga.com/news/11/08/1866271/merck-and-ariad-announce-european-medicines-agency-accepts-marketing-authorizatio,Abe Raymond,2011-08-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
853574,mad money lightning round cramer likes cummins,https://www.benzinga.com/media/cnbc/11/08/1850200/mad-money-lightning-round-cramer-likes-cummins,Lisa Levin,2011-08-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.44865
853575,update jefferies upgrades merck co to buy,https://www.benzinga.com/analyst-ratings/analyst-color/11/08/1844328/update-jefferies-upgrades-merck-co-to-buy,BenzingaStaffB,2011-08-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853576,news summary for august ,https://www.benzinga.com/etfs/commodities/11/08/1844189/news-summary-for-august-9-2011,Allie Wickman,2011-08-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853577,benzingas top upgrades,https://www.benzinga.com/analyst-ratings/upgrades/11/08/1844172/benzingas-top-upgrades,Monica Gerson,2011-08-09 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.60115
853578,jefferies upgrades merck co to buy lowers pt to ,https://www.benzinga.com/analyst-ratings/upgrades/11/08/1843818/jefferies-upgrades-merck-co-to-buy-lowers-pt-to-37,Joe Young,2011-08-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
853579,merck and serum institute announce collaboration to develop and expand global access to pneumococcal conjugate vaccine,https://www.benzinga.com/news/11/08/1829259/merck-and-serum-institute-announce-collaboration-to-develop-and-expand-global-acc,Eddie Staley,2011-08-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
853580,aw snap is market gonna crackle or pop,https://www.benzinga.com/11/08/1827337/aw-snap-is-market-gonna-crackle-or-pop,optionsXpress,2011-08-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853581,weak data in focus ,https://www.benzinga.com/11/08/1822652/weak-data-in-focus-08-01-2011,optionsXpress,2011-08-01 00:00:00,MRK,1,1,0,1,1,0,0,0,0,0.2798
853582,merck to close mission bay research center,https://www.benzinga.com/success-stories/11/08/1822528/merck-to-close-mission-bay-research-center,Steven Anfield,2011-08-01 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853583,jp morgan maintains overweight rating on merck co,https://www.benzinga.com/analyst-ratings/analyst-color/11/08/1821226/j-p-morgan-maintains-overweight-rating-on-merck-co,BenzingaStaffB,2011-08-01 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.41105
853584,ariad announces that merck has submitted for approval of ridaforolimus an investigational mtor inhibitor in the eu,https://www.benzinga.com/news/11/08/1820932/ariad-announces-that-merck-has-submitted-for-approval-of-ridaforolimus-an-investi,Eddie Staley,2011-08-01 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
853585,deutsche bank updates ,https://www.benzinga.com/analyst-ratings/price-target/11/08/1820913/deutsche-bank-updates-81,Emily Austin,2011-08-01 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
853598,merck cites brand and emerging market investment for higher quarter costs,https://www.benzinga.com/news/11/07/1816631/merck-cites-brand-and-emerging-market-investment-for-higher-quarter-costs,Paul Quintaro,2011-07-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853599,merck doubles profits in second quarter,https://www.benzinga.com/news/earnings/11/07/1816419/merck-doubles-profits-in-second-quarter,Benzinga Staff Writer,2011-07-29 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.7202
853600,news summary for july ,https://www.benzinga.com/etfs/commodities/11/07/1816218/news-summary-for-july-29-2011,Allie Wickman,2011-07-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853601,merck fda accepts sndas for vytorin zetia indications for review,https://www.benzinga.com/news/11/07/1816188/merck-fda-accepts-sndas-for-vytorin-zetia-indications-for-review,Allie Wickman,2011-07-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6591
853602,merck to cut workforce by added from levels,https://www.benzinga.com/news/11/07/1816080/merck-to-cut-workforce-by-added-12-13-from-2009-levels,Paul Quintaro,2011-07-29 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.3634
853603,merck guides fy eps vs est,https://www.benzinga.com/news/earnings/11/07/1816045/merck-guides-fy-2011-eps-3-68-3-76-vs-3-74-est,Allie Wickman,2011-07-29 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853604,merck reports q eps vs est revenues b vs b est,https://www.benzinga.com/news/earnings/11/07/1816015/merck-reports-q2-eps-0-95-vs-0-95-est-revenues-12-15b-vs-11-78b-est,Allie Wickman,2011-07-29 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
853605,us stock futures down on debt worries,https://www.benzinga.com/news/11/07/1815907/us-stock-futures-down-on-debt-worries,Monica Gerson,2011-07-29 00:00:00,MRK,1,1,0,1,0,0,1,1,0,0.17570000000000002
853606,earnings scheduled for july ,https://www.benzinga.com/news/earnings/11/07/1815758/earnings-scheduled-for-july-29,Monica Gerson,2011-07-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853607,stocks to watch for july ,https://www.benzinga.com/news/earnings/11/07/1815618/stocks-to-watch-for-july-29,Monica Gerson,2011-07-29 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853608,high yield birth control stocks,https://www.benzinga.com/11/07/1815431/high-yield-birth-control-stocks,Fred Fuld,2011-07-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853609,how to profit from exploding government healthcare costs,https://www.benzinga.com/trading-ideas/long-ideas/11/07/1812394/how-to-profit-from-exploding-government-healthcare-costs,Daniel Hayden IV,2011-07-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7202
853610,hearing supreme court asked to overturn obamas health care reform,https://www.benzinga.com/news/11/07/1809176/hearing-supreme-court-asked-to-overturn-obamas-health-care-reform,Paul Quintaro,2011-07-27 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.88915
853611,earnings preview merck eps revenue expected to rise from previous quarter,https://www.benzinga.com/news/earnings/11/07/1803995/earnings-preview-merck-eps-revenue-expected-to-rise-from-previous-quarte,Benzinga Staff Writer,2011-07-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853612,merck to acquire rights to vernakalant iv in canada mexico and the united states from astellas,https://www.benzinga.com/news/11/07/1801899/merck-to-acquire-rights-to-vernakalant-i-v-in-canada-mexico-and-the-united-states,Allie Wickman,2011-07-26 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.71075
853613,ratchet back the risk with these etfs,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1799138/ratchet-back-the-risk-with-these-etfs,ETF Professor,2011-07-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3634
853614,earnings expectations for the week of july ,https://www.benzinga.com/news/earnings/11/07/1795657/earnings-expectations-for-the-week-of-july-25,Nelson Hem,2011-07-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853615,earnings preview mylan laboratories eps revenue expected to rise from previous quarter,https://www.benzinga.com/news/earnings/11/07/1793625/earnings-preview-mylan-laboratories-eps-revenue-expected-to-rise-from-pr,Benzinga Staff Writer,2011-07-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853616,fifteen health care etfs trading near week highs,https://www.benzinga.com/trading-ideas/long-ideas/11/07/1790212/fifteen-health-care-etfs-trading-near-52-week-highs,Nelson Hem,2011-07-21 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.74695
853617,earnings preview gilead sciences eps revenue expected to rise from previous quarter,https://www.benzinga.com/news/earnings/11/07/1789923/earnings-preview-gilead-sciences-eps-revenue-expected-to-rise-from-previ,Benzinga Staff Writer,2011-07-21 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853618,merck and roche expand agreement in fight against chronic hepatitis c,https://www.benzinga.com/news/11/07/1782635/merck-and-roche-expand-agreement-in-fight-against-chronic-hepatitis-c,Paul Quintaro,2011-07-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
853619,dow jones industrial average companies increase expected dividend distribution by from a year ago,https://www.benzinga.com/news/11/07/1778743/dow-jones-industrial-average-companies-increase-expected-dividend-distribution-by,Allie Wickman,2011-07-19 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6591
853620,merck announces victrelis firstinclass oral hepatitis c virus protease inhibitor approved in the eu for treatment of chronic hepatitis c,https://www.benzinga.com/news/11/07/1774306/merck-announces-victrelis-first-in-class-oral-hepatitis-c-virus-protease-inhibito,Eddie Staley,2011-07-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6806
853621,deutsche bank provides color on pharmaceuticals,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1773162/deutsche-bank-provides-color-on-pharmaceuticals,Emily Austin,2011-07-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853622,mercks isentress in combination therapy demonstrated efficacy in a phase ii study extending to nearly five years in previously untreated adults with hiv,https://www.benzinga.com/news/11/07/1773038/mercks-isentress-in-combination-therapy-demonstrated-efficacy-in-a-phase-ii-study,Allie Wickman,2011-07-18 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.5
853623, high dividend names for sound sleeping,https://www.benzinga.com/trading-ideas/long-ideas/11/07/1766669/5-high-dividend-names-for-sound-sleeping,Jonathan Chen,2011-07-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853624,twelve health care etfs trading near week highs,https://www.benzinga.com/trading-ideas/long-ideas/11/07/1761358/twelve-health-care-etfs-trading-near-52-week-highs,Nelson Hem,2011-07-13 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.74695
853625,twelve etfs trading near week highs,https://www.benzinga.com/trading-ideas/long-ideas/11/07/1756935/twelve-etfs-trading-near-52-week-highs,Nelson Hem,2011-07-12 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853626,merck to participate in new research efforts to eradicate hiv,https://www.benzinga.com/news/11/07/1754571/merck-to-participate-in-new-research-efforts-to-eradicate-hiv,Eddie Staley,2011-07-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853627,hottest and coldest sectors for friday ,https://www.benzinga.com/trading-ideas/long-ideas/11/07/1750479/hottest-and-coldest-sectors-for-friday-7811,Benjamin Lee,2011-07-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853628,teva and merck settle patent dispute over generic vytorin teva will not sell generic until ,https://www.benzinga.com/news/11/07/1750347/teva-and-merck-settle-patent-dispute-over-generic-vytorin-teva-will-not-sell-gene,Paul Quintaro,2011-07-08 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.29905000000000004
853629,goldman sachs suggests buying calls on merck co,https://www.benzinga.com/analyst-ratings/analyst-color/11/07/1744650/goldman-sachs-suggests-buying-calls-on-merck-co,Michael J. Zerinskas,2011-07-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853630,merck receives approval to market gardasil zolinza and cubicin in japan,https://www.benzinga.com/news/11/07/1219599/merck-receives-approval-to-market-gardasil-zolinza-and-cubicin-in-japan,Paul Quintaro,2011-07-01 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.7383500000000001
853631,a peek into the market before the trading starts,https://www.benzinga.com/news/11/06/1206249/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,2011-06-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853632,ups and merck expand their distribution and logistics agreement,https://www.benzinga.com/news/11/06/1206168/ups-and-merck-expand-their-distribution-and-logistics-agreement,Paul Quintaro,2011-06-28 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.83525
853633,stocks shrug off greece deficit uncertainty,https://www.benzinga.com/news/11/06/1204080/stocks-shrug-off-greece-deficit-uncertainty,BenzingaStaffB,2011-06-27 00:00:00,MRK,1,1,1,0,0,1,1,1,1,0.18755
853634,morgan stanley reiterates equalweight on merck,https://www.benzinga.com/analyst-ratings/reiteration/11/06/1197776/morgan-stanley-reiterates-equal-weight-on-merck,Emily Austin,2011-06-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853635,high yield big pharmaceutical stocks,https://www.benzinga.com/11/06/1198305/high-yield-big-pharmaceutical-stocks,Fred Fuld,2011-06-24 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853636,ligand enters into captisol commercial supply agreement with merck,https://www.benzinga.com/news/11/06/1182465/ligand-enters-into-captisol-commercial-supply-agreement-with-merck,Benzinga Staff,2011-06-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.74695
853637,build a wealthy portfolio with these economic moats,https://www.benzinga.com/general/11/06/1164308/build-a-wealthy-portfolio-with-these-economic-moats,Jae Jun,2011-06-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6806
853638,fda urges limits on dosages of zocor wsj,https://www.benzinga.com/media/wall-street-journal/11/06/1155050/fda-urges-limits-on-dosages-of-zocor-wsj,Allie Wickman,2011-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853639,alpha reductase inhibitors may increase risk of prostate cancer fda,https://www.benzinga.com/news/fda/11/06/1154416/5-alpha-reductase-inhibitors-may-increase-risk-of-prostate-cancer-fda,Theo Kratz,2011-06-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.13245
853640,merck announces us prescribing information for simvastatin revised to include new limits on the use of the highest dose and updated drug interaction information,https://www.benzinga.com/news/fda/11/06/1150874/merck-announces-u-s-prescribing-information-for-simvastatin-revised-to-includ,Benzinga Staff,2011-06-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853641,update merck and intercell ag announce termination of phase iiiii clinical trial of investigational staphylococcus aureus vaccine v,https://www.benzinga.com/news/fda/11/06/1148503/update-merck-and-intercell-ag-announce-termination-of-phase-iiiii-clinical-tr,Allie Wickman,2011-06-08 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
853642,bank of america merrill lynch maintains buy on merck co,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1144476/bank-of-america-merrill-lynch-maintains-buy-on-merck-co,BenzingaStaffJ,2011-06-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853643,roche and merck collaborate to develop diagnostic tests for mercks investigational cancer therapies,https://www.benzinga.com/news/contracts/11/06/1144245/roche-and-merck-collaborate-to-develop-diagnostic-tests-for-mercks-inve,Benzinga Staff,2011-06-07 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
853644,merck and ariad announce presentation of results of phase iii succeed trial at american society of clinical oncology annual meeting,https://www.benzinga.com/news/fda/11/06/1140071/merck-and-ariad-announce-presentation-of-results-of-phase-iii-succeed-trial-a,Allie Wickman,2011-06-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
853645,hepatitis c virus hcv updates from biotechpharma stocks,https://www.benzinga.com/markets/11/06/1137089/hepatitis-c-virus-hcv-updates-from-biotechpharma-stocks,Investor Ideas,2011-06-03 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853646,pimcos gross likes pg and merck offer better yields and conservative bloomberg,https://www.benzinga.com/news/11/06/1136582/pimcos-gross-likes-p-g-and-merck-offer-better-yields-and-conservative-bloomberg,Theo Kratz,2011-06-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6909
853647,pimcos gross says procter gamble and merck are relatively attractive to savers bloomberg,https://www.benzinga.com/news/11/06/1136387/pimcos-gross-says-procter-gamble-and-merck-are-relatively-attractive-to-savers-bl,Theo Kratz,2011-06-03 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.4742
853648,my top defensive stock plays,https://www.benzinga.com/11/06/1133837/my-top-20-defensive-stock-plays,Ryan Mallory,2011-06-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7202
853649,fda treatment with angiotensin receptor blockers for high blood pressure does not increase risk of cancer,https://www.benzinga.com/news/fda/11/06/1133546/fda-treatment-with-angiotensin-receptor-blockers-for-high-blood-pressure-does,Theo Kratz,2011-06-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.11254999999999998
853650,fda says that high blood pressure drugs do not increase cancer risk bloomberg,https://www.benzinga.com/news/fda/11/06/1132726/fda-says-that-high-blood-pressure-drugs-do-not-increase-cancer-risk-bloomberg,Theo Kratz,2011-06-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.64435
853651,hapoalim securities terminates healthcare coverage including bristolmyers eli lilly merck and pfizer,https://www.benzinga.com/analyst-ratings/11/06/1128490/hapoalim-securities-terminates-healthcare-coverage-including-bristol-m,BenzingaStaffL,2011-06-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
853652,hapoalim cutting ocverage on multitude of names,https://www.benzinga.com/analyst-ratings/analyst-color/11/06/1128380/hapoalim-cutting-ocverage-on-multitude-of-names,Jonathan Chen,2011-06-01 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.436
853653,health canada approves gardasil to prevent anal cancer,https://www.benzinga.com/generallifemisc/11/05/1122875/health-canada-approves-gardasil-to-prevent-anal-cancer,Theo Kratz,2011-05-31 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.30910000000000004
853654,morgan stanley reports on merck,https://www.benzinga.com/analyst-ratings/analyst-color/11/05/1117552/morgan-stanley-reports-on-merck,Paul Quintaro,2011-05-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853655,insite vision announces joint patent infringement lawsuit with merck against sandoz,https://www.benzinga.com/news/legal/11/05/1116250/insite-vision-announces-joint-patent-infringement-lawsuit-with-merck-agains,Benzinga Staff,2011-05-26 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.2706
853656,joel greenblatt one bubble after another,https://www.benzinga.com/trading-ideas/long-ideas/11/05/1114680/joel-greenblatt-one-bubble-after-another,Jonathan Chen,2011-05-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853657,ftc files amicus brief in kdur antitrust litigation bloomberg,https://www.benzinga.com/news/legal/11/05/1108639/ftc-files-amicus-brief-in-k-dur-antitrust-litigation-bloomberg,Theo Kratz,2011-05-24 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.39885
853658,europes sovereigndebt crisis effects on drug stocks,https://www.benzinga.com/11/05/1105822/europes-sovereign-debt-crisis-effects-on-drug-stocks,CEO World,2011-05-23 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.18755
853659,vertex hepatitis c drug approved by the fda bloomberg,https://www.benzinga.com/news/fda/11/05/1104683/vertex-hepatitis-c-drug-approved-by-the-fda-bloomberg,Allie Wickman,2011-05-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
853660,top healthcare and major drugs stocks to watch sector performance,https://www.benzinga.com/11/05/1103086/top-healthcare-and-major-drugs-stocks-to-watch-sector-performance,CEO World,2011-05-22 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.60115
853661,chmp issues positive opinion for mercks victrelistm oral hepatitis c virus protease inhibitor,https://www.benzinga.com/news/fda/11/05/1100170/chmp-issues-positive-opinion-for-mercks-victrelistm-oral-hepatitis-c-virus-pr,Benzinga Staff,2011-05-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
853662,exclusive merck talks to benzinga about collaboration with roche mrk,https://www.benzinga.com/news/fda/11/05/1097376/exclusive-%E2%80%93-merck-talks-to-benzinga-about-collaboration-with-roche-mrk,Steven Anfield,2011-05-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5640000000000001
853663,deutsche bank comments on merck and roche collaboration,https://www.benzinga.com/analyst-ratings/analyst-color/11/05/1096578/deutsche-bank-comments-on-merck-and-roche-collaboration,BenzingaStaffB,2011-05-19 00:00:00,MRK,1,2,1,0,1,0,1,1,1,0.5
853664,biotechpharma stocks news alert hepatitis c virus hcv fda news from aethlon medical vertex pharmaceuticals merck company,https://www.benzinga.com/markets/11/05/1090632/biotechpharma-stocks-news-alert-hepatitis-c-virus-hcv-fda-news-from-aethlon-me,Investor Ideas,2011-05-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
853665,merck and roche establish strategic agreements in fight against chronic hepatitis c,https://www.benzinga.com/news/contracts/11/05/1090573/merck-and-roche-establish-strategic-agreements-in-fight-against-chronic,Benzinga Staff,2011-05-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.436
853666,biotechpharma stocks alert hepatitis c virus hcv fda news from otcbb aemd nyse mrk vrtx,https://www.benzinga.com/11/05/1090087/biotechpharma-stocks-alert-hepatitis-c-virus-hcv-fda-news-from-otcbb-aemd-nyse-mrk-vrt,Investor Ideas,2011-05-17 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.648
853667,biotechpharma stocks alert hepatitis c virus hcv fda news from otcbb aemd nyse mrk vrtx,https://www.benzinga.com/11/05/1090083/biotechpharma-stocks-alert-hepatitis-c-virus-hcv-fda-news-from-otcbb-aemd-nyse-mrk-vrt,Investor Ideas,2011-05-17 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.648
853668,piper jaffray discontinues coverage on isph,https://www.benzinga.com/analyst-ratings/analyst-color/11/05/1089442/piper-jaffray-discontinues-coverage-on-isph,BenzingaStaffT,2011-05-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853669,goldman sachs reports on merck co mrk,https://www.benzinga.com/analyst-ratings/analyst-color/11/05/1085857/goldman-sachs-reports-on-merck-co-mrk,BenzingaStaffK,2011-05-16 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853670,deutsche bank comments on victrelis fda approval,https://www.benzinga.com/analyst-ratings/11/05/1085846/deutsche-bank-comments-on-victrelis-fda-approval,BenzingaStaffL,2011-05-16 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.7383500000000001
853671,jp morgan calls merck cos hep c treatment a modest positive,https://www.benzinga.com/analyst-ratings/analyst-color/11/05/1085573/j-p-morgan-calls-merck-cos-hep-c-treatment-a-modest-posi,BenzingaStaffB,2011-05-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.82985
853672,bank of america raises pt to on mrk,https://www.benzinga.com/analyst-ratings/analyst-color/11/05/1085540/bank-of-america-raises-pt-to-29-on-mrk,BenzingaStaffT,2011-05-16 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853673,biotechpharma stock news alert otcbb aemd nyse mrk vrtx progress on potential new treatments for hepatitis c virus hcv,https://www.benzinga.com/markets/11/05/1083163/biotechpharma-stock-news-alert-otcbb-aemd-nyse-mrk-vrtx-progress-on-potential-,Investor Ideas,2011-05-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8062
853674,biotechpharma stocks otcbb aemd nyse mrk vrtx progress on potential new treatments for hepatitis c virus hcv,https://www.benzinga.com/11/05/1082960/biotechpharma-stocks-otcbb-aemd-nyse-mrk-vrtx-progress-on-potential-new-treatments-for,Investor Ideas,2011-05-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
853675,biotechpharma stocks otcbb aemd nyse mrk vrtx progress on potential new treatments for hepatitis c virus hcv,https://www.benzinga.com/11/05/1082959/biotechpharma-stocks-otcbb-aemd-nyse-mrk-vrtx-progress-on-potential-new-treatments-for,Investor Ideas,2011-05-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
853676,the father of growth investing t rowe price screen,https://www.benzinga.com/11/05/1077303/the-father-of-growth-investing-t-rowe-price-screen,Stockopedia,2011-05-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
853677,update fda approves new treatment for rare type of pancreatic cancer pfe mrk gsk,https://www.benzinga.com/news/fda/11/05/1063574/update-fda-approves-new-treatment-for-rare-type-of-pancreatic-cancer-pfe-mrk-,Benzinga Staff,2011-05-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.29905000000000004
853678,may catalysts for biotech and drug stocks,https://www.benzinga.com/trading-ideas/long-ideas/11/05/1056879/may-catalysts-for-biotech-and-drug-stocks,Minyanville,2011-05-04 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853679,morning news summary for may ,https://www.benzinga.com/markets/11/05/1052203/morning-news-summary-for-may-3-2011,Gary Cassady,2011-05-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853680,earnings preview for allergan agn mrk isph vrx ceph,https://www.benzinga.com/news/earnings/11/05/1050910/earnings-preview-for-allergan-agn-mrk-isph-vrx-ceph,Emily Austin,2011-05-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853681,top largecap stocks in the drug manufacturersmajor industry with the lowest peg ratio gsk abt mrk jnj,https://www.benzinga.com/markets/11/05/1050590/top-4-large-cap-stocks-in-the-drug-manufacturers-major-industry-with-the-lowes,Lisa Levin,2011-05-02 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.39885
853682,update jp morgan raises pt on merck co to mrk,https://www.benzinga.com/analyst-ratings/analyst-color/11/05/1047250/update-j-p-morgan-raises-pt-on-merck-co-to-44-mrk,BenzingaStaffJ,2011-05-02 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.60115
853683,citi updates fy estimates on merck after reporting solid earnings,https://www.benzinga.com/analyst-ratings/analyst-color/11/05/1047235/citi-updates-fy-estimates-on-merck-after-reporting-solid,Benzinga Staff,2011-05-02 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.57655
853684,jp morgan raises pt on merck company to ,https://www.benzinga.com/analyst-ratings/11/05/1046847/jp-morgan-raises-pt-on-merck-company-to-44,Joe Young,2011-05-02 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.60115
853685,ceoworld top analyst calls of the week dndn insp mcp siri vicl,https://www.benzinga.com/11/05/1046732/ceoworld-top-5-analyst-calls-of-the-week-dndn-insp-mcp-siri-vicl,CEO World,2011-05-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
853686,royal putz not to be confused with married putz ,https://www.benzinga.com/11/04/1045636/royal-put-z-not-to-be-confused-with-married-put-z-04-29-2011,optionsXpress,2011-04-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.62055
853687,married putz ,https://www.benzinga.com/11/04/1045102/married-put-z-04-29-2011,optionsXpress,2011-04-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853688,merck up on strong earnings today mrk,https://www.benzinga.com/news/earnings/11/04/1044819/merck-up-on-strong-earnings-today-mrk,Jonathan Chen,2011-04-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
853689,citi reports strong q results for merck,https://www.benzinga.com/analyst-ratings/analyst-color/11/04/1044401/citi-reports-strong-1q11-results-for-merck,BenzingaStaffB,2011-04-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
853690,friday morning market summary ,https://www.benzinga.com/news/earnings/11/04/1043893/friday-morning-market-summary-4292011,Gary Cassady,2011-04-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853691,a peek into the market before the trading starts,https://www.benzinga.com/markets/futures/11/04/1043548/a-peek-into-the-market-before-the-trading-starts,Monica Gerson,2011-04-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853692,update merck reports upbeat q earnings shares rise in premarket trading,https://www.benzinga.com/news/earnings/11/04/1043525/update-merck-reports-upbeat-q1-earnings-shares-rise-in-pre-market-tradin,Monica Gerson,2011-04-29 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
853693,merck announces first quarter financial results,https://www.benzinga.com/news/earnings/11/04/1043409/merck-announces-first-quarter-2011-financial-results,Benzinga Staff,2011-04-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853694,merck guides fy eps vs est mrk,https://www.benzinga.com/news/guidance/11/04/1043408/merck-guides-fy-2011-eps-3-66-3-76-vs-3-69-est-mrk,Benzinga Staff,2011-04-29 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853695,merck reports eps of vs estimate revenues b vs b estimate,https://www.benzinga.com/news/earnings/11/04/1043391/merck-reports-eps-of-0-92-vs-0-84-estimate-revenues-11-58b-vs-11-37b-est,Theo Kratz,2011-04-29 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853696,us stock futures mixed as investors await economic data earnings reports research in motion shares decline in premarket trading,https://www.benzinga.com/markets/futures/11/04/1043224/us-stock-futures-mixed-as-investors-await-economic-data-earnings-repor,Monica Gerson,2011-04-29 00:00:00,MRK,1,1,0,1,0,0,1,0,0,0.6909
853697,earnings scheduled for april wy axl nwl itt mrk pbi mi cpn gt cat agp nee cvx ppc dhi etr vfc,https://www.benzinga.com/news/earnings/11/04/1042791/earnings-scheduled-for-april-29-wy-axl-nwl-itt-mrk-pbi-mi-cpn-gt-cat-agp,Lisa Levin,2011-04-29 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.6366
853698,stocks to watch for april cvx rimm cat msft mrk,https://www.benzinga.com/news/earnings/11/04/1042749/stocks-to-watch-for-april-29-cvx-rimm-cat-msft-mrk,Lisa Levin,2011-04-29 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853699,merck and inspire announce expiration of hartscottrodino act waiting period relating to tender offer for shares of inspire isph mrk,https://www.benzinga.com/news/11/04/1040069/merck-and-inspire-announce-expiration-of-hart-scott-rodino-act-waiting-period-rel,Theo Kratz,2011-04-28 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.93125
853700,victrelis unanimously recommended for approval by fda advisory committee mrk,https://www.benzinga.com/news/fda/11/04/1038159/victrelis%E2%84%A2-unanimously-recommended-for-approval-by-fda-advisory-committee-mrk,Theo Kratz,2011-04-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7997000000000001
853701,victrelis unanimously recommended for approval by fda advisory committee for treatment of chronic hcv genotype infection,https://www.benzinga.com/news/fda/11/04/1038156/victrelis-unanimously-recommended-for-approval-by-fda-advisory-committee-for-,Benzinga Staff,2011-04-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7997000000000001
853702,hepatitis treatment wins over the us fda panel bloomberg mrk,https://www.benzinga.com/news/fda/11/04/1037798/hepatitis-treatment-wins-over-the-u-s-fda-panel-bloomberg-mrk,Theo Kratz,2011-04-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7859499999999999
853703,deutsche bank to hold th annual healthcare conference next week,https://www.benzinga.com/analyst-ratings/analyst-color/11/04/1035827/deutsche-bank-to-hold-36th-annual-healthcare-conference-,BenzingaStaffT,2011-04-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853704,merck announces new billion share repurchase program mrk,https://www.benzinga.com/news/buybacks/11/04/1035758/merck-announces-new-5-billion-share-repurchase-program-mrk,Theo Kratz,2011-04-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
853705,vertex stock booms after fda reports new drug is effective vrtx,https://www.benzinga.com/news/fda/11/04/1033394/vertex-stock-booms-after-fda-reports-new-drug-is-effective-vrtx,Luci Morland,2011-04-26 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
853706,rwanda merck and qiagen launch africas first comprehensive cervical cancer prevention program incorporating both hpv vaccination and hpv testing,https://www.benzinga.com/news/11/04/1028065/rwanda-merck-and-qiagen-launch-africas-first-comprehensive-cervical-cancer-preven,Benzinga Staff,2011-04-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.23665000000000003
853707,mercks hepatitis c drug increases anemia risk fda staff says bloomberg mrk,https://www.benzinga.com/news/11/04/1027941/mercks-hepatitis-c-drug-increases-anemia-risk-fda-staff-says-bloomberg-mrk,Benzinga Staff,2011-04-25 00:00:00,MRK,0,2,0,1,0,1,0,1,0,0.3634
853708,merck and sanofi pasteur initiate phase iii study in the united states of pediatric combination vaccine to help prevent six infectious diseases,https://www.benzinga.com/news/11/04/1022754/merck-and-sanofi-pasteur-initiate-phase-iii-study-in-the-united-states-of-pediatr,Benzinga Staff,2011-04-21 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.8404
853709,dont fall for the defensive portfolio hype,https://www.benzinga.com/news/11/04/1012738/dont-fall-for-the-defensive-portfolio-hype,Benzinga Staff,2011-04-18 00:00:00,MRK,0,2,0,1,0,0,0,0,0,0.5129
853710,jp morgan adjusting estimates on merck co,https://www.benzinga.com/analyst-ratings/analyst-color/11/04/1010223/j-p-morgan-adjusting-estimates-on-merck-co,BenzingaStaffB,2011-04-18 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.60115
853711,weird dynamic at play ,https://www.benzinga.com/11/04/1008477/weird-dynamic-at-play-04-15-2011,optionsXpress,2011-04-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7553000000000001
853712,merck commences tender offer for inspire pharmaceuticals at per share,https://www.benzinga.com/news/11/04/1006935/merck-commences-tender-offer-for-inspire-pharmaceuticals-at-5-00-per-share,Benzinga Staff,2011-04-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8548
853713,a peek into the market before the trading starts,https://www.benzinga.com/markets/futures/11/04/1006560/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,2011-04-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853714,merck reaffirms nongaap eps target of to ,https://www.benzinga.com/news/11/04/1006536/merck-reaffirms-2011-non-gaap-eps-target-of-3-64-to-3-76,Benzinga Staff,2011-04-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853715,johnson johnson provides additional information regarding amended agreement with merck jnj mrk,https://www.benzinga.com/news/11/04/1006534/johnson-johnson-provides-additional-information-regarding-amended-agreement-with-,Franklin Price,2011-04-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
853716,merck and johnson johnson reach agreement on distribution rights for remicade and simponi mrk jnj,https://www.benzinga.com/news/11/04/1006445/merck-and-johnson-johnson-reach-agreement-on-distribution-rights-for-remicade%C2%AE-an,Franklin Price,2011-04-15 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7553000000000001
853717,inspire pharmaceuticals shareholder sues over merck deal mrk isph,https://www.benzinga.com/news/11/04/997399/inspire-pharmaceuticals-shareholder-sues-over-merck-deal-mrk-isph,Gary Cassady,2011-04-12 00:00:00,MRK,1,1,1,0,0,1,1,1,1,0.7859499999999999
853718,fda approves mercks sylatron for injection a new adjuvant treatment for melanoma with microscopic or gross nodal involvement,https://www.benzinga.com/news/11/04/995068/fda-approves-mercks-sylatron-for-injection-a-new-adjuvant-treatment-for-melanoma-w,Benzinga Staff,2011-04-11 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.44865
853719,merck co and sun pharma establish joint venture mrk,https://www.benzinga.com/news/11/04/992863/merck-co-and-sun-pharma-establish-joint-venture-mrk,Benzinga Staff,2011-04-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853720,merck loses uk appeal against teva to reinstate cosopt patent mrk,https://www.benzinga.com/news/11/04/989386/merck-loses-u-k-appeal-against-teva-to-reinstate-cosopt-patent-mrk,Benzinga Staff,2011-04-08 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.3409
853721,lifetech capital comments on merck acquisition mrk isph,https://www.benzinga.com/analyst-ratings/11/04/986286/lifetech-capital-comments-on-merck-acquisition-mrk-isph,BenzingaStaffL,2011-04-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853722,experts think mercks gardasil could be widely distributed mrk,https://www.benzinga.com/trading-ideas/long-ideas/11/04/983544/experts-think-mercks-gardasil-could-be-widely-distributed-mrk,Roger Nachman,2011-04-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853723,mid afternoon top and bottom percentage gainers nsm isph mrk qcor pk aau dgw leds meru wmgi zstn,https://www.benzinga.com/trading-ideas/long-ideas/11/04/980005/mid-afternoon-top-5-and-bottom-5-percentage-gainers-nsm-isph-m,Gary Cassady,2011-04-05 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.60115
853724,merck to acquire inspire pharmaceuticals inc for per share totaling m,https://www.benzinga.com/news/11/04/978649/merck-to-acquire-inspire-pharmaceuticals-inc-for-5-00-totaling-430m,Benzinga Staff,2011-04-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8548
853725,biotechpharma stocks merck nysemrk to acquire inspire pharmaceuticals inc nasdaqisph,https://www.benzinga.com/11/04/979308/biotechpharma-stocks-merck-nyse-mrk-to-acquire-inspire-pharmaceuticals-inc-nasdaq-isph,Investor Ideas,2011-04-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7859499999999999
853726,biotechpharma stocks merck nysemrk to acquire inspire pharmaceuticals inc nasdaqisph,https://www.benzinga.com/11/04/979307/biotechpharma-stocks-merck-nyse-mrk-to-acquire-inspire-pharmaceuticals-inc-nasdaq-isph,Investor Ideas,2011-04-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7859499999999999
853727,april catalysts for biotech and drug stocks,https://www.benzinga.com/life/politics/11/04/971272/april-catalysts-for-biotech-and-drug-stocks,Minyanville,2011-04-01 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853728,victrelis mercks investigational medicine added to peginterferon alfaa and ribavirin achieved significantly higher svr rates in treatmentfailure patients with chronic hcv genotype compared to control,https://www.benzinga.com/news/11/03/966391/victrelis-mercks-investigational-medicine-added-to-peginterferon-alfa-2a-and-ribav,Benzinga Staff,2011-03-31 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853729,mad money lightning round cramer likes alcoa health care reit aa sppi panl pfe gild celg mrk abt agnc nly hcn,https://www.benzinga.com/media/cnbc/11/03/954983/mad-money-lightning-round-cramer-likes-alcoa-health-care-reit-aa-sppi-panl-p,Lisa Levin,2011-03-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
853730,march market madness merck mrk,https://www.benzinga.com/11/03/953692/march-market-madness-merck-mrk,The Disciplined Investor,2011-03-25 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.2798
853731,citi comments on mrks return of betrixaban maintains eps estimate,https://www.benzinga.com/analyst-ratings/11/03/951920/citi-comments-on-mrks-return-of-betrixaban-maintains-eps-estimate,BenzingaStaffL,2011-03-25 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853732,merck announces fda approves zostavax vaccine to prevent shingles in individuals to years of age,https://www.benzinga.com/news/11/03/950758/merck-announces-fda-approves-zostavax-vaccine-to-prevent-shingles-in-individuals-5,Benzinga Staff,2011-03-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
853733,portola pharmaceuticals to regain global rights for investigational medicine betrixaban from merck,https://www.benzinga.com/news/11/03/949036/portola-pharmaceuticals-to-regain-global-rights-for-investigational-medicine-betri,Benzinga Staff,2011-03-24 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853734,zings of the day sny mrk aapl amzn,https://www.benzinga.com/news/11/03/944018/zings-of-the-day-sny-mrk-aapl-amzn,Jonathan Chen,2011-03-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853735,committee for medicinal products for human use chmp issues positive opinion for new contraception offering,https://www.benzinga.com/news/11/03/935674/committee-for-medicinal-products-for-human-use-chmp-issues-positive-opinion-for-ne,Benzinga Staff,2011-03-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
853736,ariad announces election to copromote ridaforolimus in sarcoma indication in us upon approval,https://www.benzinga.com/news/11/03/932531/ariad-announces-election-to-co-promote-ridaforolimus-in-sarcoma-indication-in-u-s-,Benzinga Staff,2011-03-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
853737,some high dividend paying stocks for a weak market mo mrk jnj nly,https://www.benzinga.com/trading-ideas/long-ideas/11/03/931282/some-high-dividend-paying-stocks-for-a-weak-market-mo-mrk-jnj-,Jonathan Chen,2011-03-16 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.2798
853738,health insurers triple sp returns,https://www.benzinga.com/trading-ideas/long-ideas/11/03/917642/health-insurers-triple-s-p-500-returns,Minyanville,2011-03-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853739,merck announces new data analyses for victrelis will be presented at the international liver congress,https://www.benzinga.com/news/11/03/907623/merck-announces-new-data-analyses-for-victrelis-will-be-presented-at-the-internati,Benzinga Staff,2011-03-07 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853740,merck wins first fosamax state court trial,https://www.benzinga.com/news/11/02/858592/merck-wins-first-fosamax-state-court-trial,Benzinga Staff,2011-02-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7859499999999999
853741,jefferies raises pt on merck company to ,https://www.benzinga.com/analyst-ratings/price-target/11/02/857509/jefferies-raises-pt-on-merck-company-to-34-50,Joe Young,2011-02-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853742,two etfs for the recovery in big pharma,https://www.benzinga.com/trading-ideas/long-ideas/11/02/855024/two-etfs-for-the-recovery-in-big-pharma,Charles Lewis Sizemore CFA,2011-02-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853743,value in valspar val,https://www.benzinga.com/trading-ideas/long-ideas/11/02/836608/value-in-valspar-val,Jonathan Chen,2011-02-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.67
853744,ubs price target research summary,https://www.benzinga.com/analyst-ratings/analyst-color/11/02/835468/ubs-price-target-research-summary,Benzinga Staff,2011-02-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853745,merck beats but guides lower analyst blog,https://www.benzinga.com/11/02/832517/merck-beats-but-guides-lower-analyst-blog,Zacks,2011-02-03 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.28925
853746,merck beats but guides lower analyst blog,https://www.benzinga.com/11/02/832566/merck-beats-but-guides-lower-analyst-blog,webmaster,2011-02-03 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.28925
853747,a peek into the market before the trading starts,https://www.benzinga.com/analyst-ratings/analyst-color/11/02/831035/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,2011-02-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853748,merck reports q eps of ,https://www.benzinga.com/news/11/02/830846/merck-reports-q4-eps-of-0-88,Lisa Levin,2011-02-03 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853749,us stock futures mixed as investors await earnings reports economic data merck earnings in focus,https://www.benzinga.com/news/11/02/830781/us-stock-futures-mixed-as-investors-await-earnings-reports-economic-data-merck-ear,Lisa Levin,2011-02-03 00:00:00,MRK,1,1,0,0,0,0,1,1,1,0.55135
853750,us stock futures mixed as investors await earnings reports economic data merck earnings in focus,https://www.benzinga.com/news/11/02/830780/us-stock-futures-mixed-as-investors-await-earnings-reports-economic-data-merck-ear,Lisa Levin,2011-02-03 00:00:00,MRK,1,1,0,0,0,0,1,1,1,0.55135
853751,earnings scheduled for february k ma ci itt sun cah mrk nyt dow bx lvs do cstr cme ip gr mco hot,https://www.benzinga.com/news/earnings/11/02/830277/earnings-scheduled-for-february-3-k-ma-ci-itt-sun-cah-mrk-nyt-dow-bx-lvs-,Lisa Levin,2011-02-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853752,busy earnings week ahead earnings preview,https://www.benzinga.com/11/01/817197/busy-earnings-week-ahead-earnings-preview,Zacks,2011-01-28 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
853753,astrazeneca revenues disappoint analyst blog,https://www.benzinga.com/11/01/816652/astrazeneca-revenues-disappoint-analyst-blog,Zacks,2011-01-28 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.29905000000000004
853754,astrazeneca revenues disappoint analyst blog,https://www.benzinga.com/11/01/816657/astrazeneca-revenues-disappoint-analyst-blog,webmaster,2011-01-28 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.29905000000000004
853755,busy earnings week ahead earnings preview,https://www.benzinga.com/11/01/817219/busy-earnings-week-ahead-earnings-preview,webmaster,2011-01-27 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
853756,earnings preview eli lilly analyst blog,https://www.benzinga.com/11/01/805010/earnings-preview-eli-lilly-analyst-blog,Zacks,2011-01-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853757,earnings preview eli lilly analyst blog,https://www.benzinga.com/11/01/805014/earnings-preview-eli-lilly-analyst-blog,webmaster,2011-01-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853758,priority review for vertex hcv drug analyst blog,https://www.benzinga.com/11/01/799321/priority-review-for-vertex-hcv-drug-analyst-blog,Zacks,2011-01-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853759,priority review for vertex hcv drug analyst blog,https://www.benzinga.com/11/01/799331/priority-review-for-vertex-hcv-drug-analyst-blog,webmaster,2011-01-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853760,deutsche bank lowers mrk target to reiterates buy rating,https://www.benzinga.com/analyst-ratings/11/01/797230/deutsche-bank-lowers-mrk-target-to-43-reiterates-buy-rating,BenzingaStaffL,2011-01-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
853761,deutsche bank lowers pt on merck co,https://www.benzinga.com/analyst-ratings/price-target/11/01/797153/deutsche-bank-lowers-pt-on-merck-co,Joe Young,2011-01-21 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.436
853762,bleeding risk with mrks candidate analyst blog,https://www.benzinga.com/11/01/794495/bleeding-risk-with-mrks-candidate-analyst-blog,Zacks,2011-01-20 00:00:00,MRK,1,2,1,0,0,1,1,1,1,0.3634
853763,bleeding risk with mrks candidate analyst blog,https://www.benzinga.com/11/01/794579/bleeding-risk-with-mrks-candidate-analyst-blog,webmaster,2011-01-20 00:00:00,MRK,1,2,1,0,0,1,1,1,1,0.3634
853764, drug stocks poised to stage comeback,https://www.benzinga.com/11/01/793318/4-drug-stocks-poised-to-stage-comeback,webmaster,2011-01-20 00:00:00,MRK,1,0,1,0,1,1,1,1,1,0.625
853765,merck says additional information provided to investigators in clinical study of vorapaxar mrk,https://www.benzinga.com/news/11/01/791757/merck-says-additional-information-provided-to-investigators-in-clinical-study-of-v,Benzinga Staff,2011-01-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853766,ariad scores with succeed analyst blog,https://www.benzinga.com/11/01/790933/ariad-scores-with-succeed-analyst-blog,Zacks,2011-01-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
853767,ariad scores with succeed analyst blog,https://www.benzinga.com/11/01/790974/ariad-scores-with-succeed-analyst-blog,webmaster,2011-01-19 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
853768,ariad pharmaceuticals skyrocketing aria,https://www.benzinga.com/movers/11/01/786970/ariad-pharmaceuticals-skyrocketing-aria,Jonathan Chen,2011-01-18 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853769,ariad sarcoma drug delays progression,https://www.benzinga.com/11/01/785536/ariad-sarcoma-drug-delays-progression,webmaster,2011-01-18 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
853770,company news for january corporate summary,https://www.benzinga.com/11/01/784026/company-news-for-january-17-2011-corporate-summary,Zacks,2011-01-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853771,company news for january corporate summary,https://www.benzinga.com/11/01/784062/company-news-for-january-17-2011-corporate-summary,webmaster,2011-01-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853772,mercks blood thinner in trouble analyst blog,https://www.benzinga.com/11/01/781769/mercks-blood-thinner-in-trouble-analyst-blog,Zacks,2011-01-14 00:00:00,MRK,1,1,1,1,0,1,1,0,0,0.29905000000000004
853773,mercks blood thinner in trouble analyst blog,https://www.benzinga.com/11/01/781796/mercks-blood-thinner-in-trouble-analyst-blog,webmaster,2011-01-14 00:00:00,MRK,1,1,1,1,0,1,1,0,0,0.29905000000000004
853774,stock market news for jan market news,https://www.benzinga.com/11/01/780375/stock-market-news-for-jan-14-2011-market-news,Zacks,2011-01-14 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853775,stock market news for jan market news,https://www.benzinga.com/11/01/780424/stock-market-news-for-jan-14-2011-market-news,webmaster,2011-01-14 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853776,merck analysts upgrades downgrades,https://www.benzinga.com/11/01/780230/merck-analysts-upgrades-downgrades,webmaster,2011-01-14 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853777,jefferies cuts price target on merck mrk,https://www.benzinga.com/analyst-ratings/analyst-color/11/01/779925/jefferies-cuts-price-target-on-merck-mrk,Roger Nachman,2011-01-14 00:00:00,MRK,1,2,0,1,0,0,1,0,0,0.352
853778,jefferies lowers pt on merck co,https://www.benzinga.com/analyst-ratings/price-target/11/01/779820/jefferies-lowers-pt-on-merck-co,Joe Young,2011-01-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.436
853779,the fed takes credit daves daily,https://www.benzinga.com/11/01/778816/the-fed-takes-credit-daves-daily,webmaster,2011-01-13 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.6909
853780,two biggies due to report earnings ,https://www.benzinga.com/11/01/778028/two-biggies-due-to-report-earnings-01-13-2011,optionsXpress,2011-01-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853781,merck pipeline setback big pharma losers,https://www.benzinga.com/11/01/777561/merck-pipeline-setback-big-pharma-losers,webmaster,2011-01-13 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.23665000000000003
853782,merck parexel enter pact analyst blog,https://www.benzinga.com/11/01/776940/merck-parexel-enter-pact-analyst-blog,Zacks,2011-01-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853783,merck parexel enter pact analyst blog,https://www.benzinga.com/11/01/777053/merck-parexel-enter-pact-analyst-blog,webmaster,2011-01-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853784,merck announces fda acceptance of new drug application for janumet,https://www.benzinga.com/news/11/01/769288/merck-announces-fda-acceptance-of-new-drug-application-for-janumet%C2%AE,Benzinga Staff,2011-01-11 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7294
853785,priority review for mercks hcv drug analyst blog,https://www.benzinga.com/11/01/762136/priority-review-for-mercks-hcv-drug-analyst-blog,Zacks,2011-01-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853786,priority review for mercks hcv drug analyst blog,https://www.benzinga.com/11/01/762138/priority-review-for-mercks-hcv-drug-analyst-blog,webmaster,2011-01-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853787,enzon pharm upped to neutral analyst blog,https://www.benzinga.com/11/01/759843/enzon-pharm-upped-to-neutral-analyst-blog,Zacks,2011-01-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853788,enzon pharm upped to neutral analyst blog,https://www.benzinga.com/11/01/759861/enzon-pharm-upped-to-neutral-analyst-blog,webmaster,2011-01-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853789,goldman sachs healthcare ceos conference bmy mrk celg,https://www.benzinga.com/movers/11/01/758148/goldman-sachs-healthcare-ceos-conference-bmy-mrk-celg,Roger Nachman,2011-01-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853790,mutts of the dow have no bite,https://www.benzinga.com/11/01/753103/mutts-of-the-dow-have-no-bite,webmaster,2011-01-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.352
853791,cramers mad money recap stellar year for stocks update ,https://www.benzinga.com/11/01/748367/cramers-mad-money-recap-stellar-year-for-stocks-update-1,webmaster,2011-01-03 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.25305
853792,xoma shares climb xoma nvg mrk,https://www.benzinga.com/market-update/10/12/741507/xoma-shares-climb-8-6-xoma-nvg-mrk,Daniel Hayden IV,2010-12-30 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
853793, best worst performers in the dow aa mrk bac dis trv,https://www.benzinga.com/movers/10/12/729301/5-best-worst-performers-in-the-dow-aa-mrk-bac-dis-trv,Roger Nachman,2010-12-23 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5129
853794,fdas approves gardasil to prevent anal cancer,https://www.benzinga.com/news/10/12/726547/fdas-approves-gardasil-to-prevent-anal-cancer,Benzinga Staff,2010-12-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.30910000000000004
853795,world stock markets daily report december ,https://www.benzinga.com/market-update/10/12/716506/world-stock-markets-daily-report-december-20-2010,Benzinga Staff,2010-12-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853796,cpi inflation still tame analyst blog,https://www.benzinga.com/10/12/703972/cpi-inflation-still-tame-analyst-blog,Zacks,2010-12-15 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853797,cpi inflation still tame analyst blog,https://www.benzinga.com/10/12/704061/cpi-inflation-still-tame-analyst-blog,webmaster,2010-12-15 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853798, best dow dividend stocks for ,https://www.benzinga.com/10/12/691945/10-best-dow-dividend-stocks-for-2011,webmaster,2010-12-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.81845
853799,merck closes on billion notes sale,https://www.benzinga.com/10/12/690282/merck-closes-on-2-billion-notes-sale,webmaster,2010-12-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853800,mad money lightning round cramer advises investors to buy blackrock lly deck cmi oxps axp v mrk abt blk,https://www.benzinga.com/media/cnbc/10/12/686930/mad-money-lightning-round-cramer-advises-investors-to-buy-blackrock-lly-deck,Lisa Levin,2010-12-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.25305
853801,mad money lightning round go for blackrock,https://www.benzinga.com/10/12/686549/mad-money-lightning-round-go-for-blackrock,webmaster,2010-12-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.25305
853802,best stocks for creating a passive income stream,https://www.benzinga.com/10/12/686102/best-stocks-for-creating-a-passive-income-stream,Mark Riddix,2010-12-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.901
853803,positive data on roches drug analyst blog,https://www.benzinga.com/10/12/675336/positive-data-on-roches-drug-analyst-blog,Zacks,2010-12-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7787
853804,positive data on roches drug analyst blog,https://www.benzinga.com/10/12/675537/positive-data-on-roches-drug-analyst-blog,webmaster,2010-12-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7787
853805,etfs for biotech ma mania,https://www.benzinga.com/trading-ideas/long-ideas/10/12/671590/etfs-for-biotech-m-a-mania,ETF Professor,2010-12-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853806,change at pfizers helm analyst blog,https://www.benzinga.com/10/12/671174/change-at-pfizers-helm-analyst-blog,Zacks,2010-12-06 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853807,change at pfizers helm analyst blog,https://www.benzinga.com/10/12/671958/change-at-pfizers-helm-analyst-blog,webmaster,2010-12-06 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853808,goldman recommends stocks for ,https://www.benzinga.com/trading-ideas/long-ideas/10/12/670650/goldman-recommends-stocks-for-2011,Roger Nachman,2010-12-06 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.61315
853809,cbsts fastinjection cubicin okd analyst blog,https://www.benzinga.com/10/12/667408/cbsts-fast-injection-cubicin-okd-analyst-blog,Zacks,2010-12-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853810,cbsts fastinjection cubicin okd analyst blog,https://www.benzinga.com/10/12/667491/cbsts-fast-injection-cubicin-okd-analyst-blog,webmaster,2010-12-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853811,merck strikes deal with smartcells analyst blog,https://www.benzinga.com/10/12/666201/merck-strikes-deal-with-smartcells-analyst-blog,Zacks,2010-12-03 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.3194
853812,merck strikes deal with smartcells analyst blog,https://www.benzinga.com/10/12/666755/merck-strikes-deal-with-smartcells-analyst-blog,webmaster,2010-12-03 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.3194
853813,jj merck recall mylanta alternagel,https://www.benzinga.com/10/12/662055/j-j-merck-recall-mylanta-alternagel,webmaster,2010-12-02 00:00:00,MRK,1,2,0,1,0,0,1,1,0,0.625
853814,a peek into the market before the trading starts,https://www.benzinga.com/analyst-ratings/analyst-color/10/12/661508/a-peek-into-the-market-before-the-trading-starts,Lisa Levin,2010-12-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853815,merck to acquire smartcells inc transaction may exceed m,https://www.benzinga.com/news/10/12/661248/merck-to-acquire-smartcells-inc-transaction-may-exceed-500m,Benzinga Staff,2010-12-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853816,merck may buy biotech firm smartcells,https://www.benzinga.com/10/12/660606/merck-may-buy-biotech-firm-smartcells,webmaster,2010-12-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853817,surmodics cut to underperform analyst blog,https://www.benzinga.com/10/12/658621/surmodics-cut-to-underperform-analyst-blog,Zacks,2010-12-01 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.3634
853818,surmodics cut to underperform analyst blog,https://www.benzinga.com/10/12/658667/surmodics-cut-to-underperform-analyst-blog,webmaster,2010-12-01 00:00:00,MRK,1,1,0,1,0,0,0,0,0,0.3634
853819,merck down slightly on new ceo mrk,https://www.benzinga.com/movers/10/11/653844/merck-down-slightly-on-new-ceo-mrk,Roger Nachman,2010-11-30 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853820,merck halts isentress study analyst blog,https://www.benzinga.com/10/11/652614/merck-halts-isentress-study-analyst-blog,Zacks,2010-11-30 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853821,news summary,https://www.benzinga.com/markets/futures/10/11/652523/news-summary,Monica Gerson,2010-11-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853822,bootstrap like spanx to start a business,https://www.benzinga.com/10/11/651986/bootstrap-like-spanx-to-start-a-business,webmaster,2010-11-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6806
853823,merck names kenneth frazier as ceo,https://www.benzinga.com/10/11/651798/merck-names-kenneth-frazier-as-ceo,webmaster,2010-11-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853824,merck board elects kenneth c frazier as next ceo,https://www.benzinga.com/news/10/11/651712/merck-board-elects-kenneth-c-frazier-as-next-ceo,Benzinga Staff,2010-11-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853825,merck halts isentress study analyst blog,https://www.benzinga.com/10/11/652619/merck-halts-isentress-study-analyst-blog,webmaster,2010-11-30 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853826,vertex eyes telaprevir approval analyst blog,https://www.benzinga.com/10/11/642656/vertex-eyes-telaprevir-approval-analyst-blog,Zacks,2010-11-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
853827,vertex eyes telaprevir approval analyst blog,https://www.benzinga.com/10/11/642829/vertex-eyes-telaprevir-approval-analyst-blog,webmaster,2010-11-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
853828,stock market news for november market news,https://www.benzinga.com/10/11/640699/stock-market-news-for-november-24-2010-market-news,Zacks,2010-11-24 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853829,stock market news for november market news,https://www.benzinga.com/10/11/640739/stock-market-news-for-november-24-2010-market-news,webmaster,2010-11-24 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853830,top wellington positions,https://www.benzinga.com/life/movers-shakers/10/11/637915/top-5-wellington-positions,Roger Nachman,2010-11-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
853831,vertex files for hep c drug approval,https://www.benzinga.com/10/11/636405/vertex-files-for-hep-c-drug-approval,webmaster,2010-11-23 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.7383500000000001
853832,positive data on mercks vytorin analyst blog,https://www.benzinga.com/10/11/633621/positive-data-on-mercks-vytorin-analyst-blog,Zacks,2010-11-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
853833,positive data on mercks vytorin analyst blog,https://www.benzinga.com/10/11/633682/positive-data-on-mercks-vytorin-analyst-blog,webmaster,2010-11-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7787
853834,goldman sachs comments on mercks sharp results,https://www.benzinga.com/analyst-ratings/analyst-color/10/11/631715/goldman-sachs-comments-on-mercks-sharp-results,Benzinga Staff,2010-11-22 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.5
853835,merck stabilizes after sharp results mrk,https://www.benzinga.com/analyst-ratings/analyst-color/10/11/631272/merck-stabilizes-after-sharp-results,Joe Young,2010-11-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853836,study merck drug helps kidney patients,https://www.benzinga.com/10/11/630182/study-merck-drug-helps-kidney-patients,webmaster,2010-11-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
853837,mercks candidate impresses analyst blog,https://www.benzinga.com/10/11/623098/mercks-candidate-impresses-analyst-blog,Zacks,2010-11-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
853838,mercks candidate impresses analyst blog,https://www.benzinga.com/10/11/624474/mercks-candidate-impresses-analyst-blog,webmaster,2010-11-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7383500000000001
853839,consumer price index tame analyst blog,https://www.benzinga.com/10/11/620114/consumer-price-index-tame-analyst-blog,Zacks,2010-11-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853840,merck adding to its list of late stage revenue generating assets citigroup reports,https://www.benzinga.com/analyst-ratings/10/11/619359/merck-adding-to-its-list-of-late-stage-revenue-generating-assets-citigr,BenzingaStaffL,2010-11-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.58895
853841,consumer price index tame analyst blog,https://www.benzinga.com/10/11/624525/consumer-price-index-tame-analyst-blog,webmaster,2010-11-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853842,goldman sachs adjusts mhs and esrx estimates,https://www.benzinga.com/analyst-ratings/10/11/614143/goldman-sachs-adjusts-mhs-and-esrx-estimates,BenzingaStaffL,2010-11-16 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853851,jefferies company adjusts merck estimates,https://www.benzinga.com/analyst-ratings/10/11/609206/jefferies-company-adjusts-merck-estimates,BenzingaStaffL,2010-11-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853852,stocks to watch for november jwn low urbn mrk gymb,https://www.benzinga.com/market-update/10/11/608318/stocks-to-watch-for-november-15-jwn-low-urbn-mrk-gymb,Lisa Levin,2010-11-15 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.3634
853853,rolls for breakfast ,https://www.benzinga.com/10/11/599981/rolls-for-breakfast-11-10-2010,optionsXpress,2010-11-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853854,pharma biotech industry outlook nov zacks analyst interviews,https://www.benzinga.com/10/11/596175/pharma-biotech-industry-outlook-nov-2010-zacks-analyst-interviews,Zacks,2010-11-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853855,pharma biotech industry outlook nov industry outlook,https://www.benzinga.com/10/11/596174/pharma-biotech-industry-outlook-nov-2010-industry-outlook,Zacks,2010-11-09 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853856,merck wins temodar patent infringement lawsuit,https://www.benzinga.com/news/10/11/595410/merck-wins-temodar-patent-infringement-lawsuit,Benzinga Staff,2010-11-09 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.4614
853857, high paying dividend stocks to consider,https://www.benzinga.com/trading-ideas/long-ideas/10/11/576816/3-high-paying-dividend-stocks-to-consider,Roger Nachman,2010-11-03 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
853858,sectors to benefit from republican victory oil services healthcare mrk pfe do rig,https://www.benzinga.com/trading-ideas/long-ideas/10/11/572246/sectors-to-benefit-from-republican-victory-oil-services-health,Scott Rubin,2010-11-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6806
853859,zacks analyst blog highlights monster worldwide yahoo merck co johnson johnson and verisign press releases,https://www.benzinga.com/10/11/571533/zacks-analyst-blog-highlights-monster-worldwide-yahoo-merck-co-johnson-johnson-and-veri,Zacks,2010-11-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853860,citigroup reiterates buy rating on merck mrk,https://www.benzinga.com/analyst-ratings/analyst-color/10/11/567689/citigroup-reiterates-buy-rating-on-merck-mrk,Michael J. Zerinskas,2010-11-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853861,steve grassos health care trades unh ci aet agp hs pfe mrk wlp,https://www.benzinga.com/media/cnbc/10/10/566001/steve-grassos-health-care-trades-unh-ci-aet-agp-hs-pfe-mrk-wlp,Craig Jones,2010-10-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
853862,markets yawn at data earnings deluge,https://www.benzinga.com/market-update/10/10/564610/markets-yawn-at-data-earnings-deluge,Benzinga Staff,2010-10-29 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853863,stock market news for october market news,https://www.benzinga.com/10/10/563853/stock-market-news-for-october-29-2010-market-news,Zacks,2010-10-29 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853864,company news for october corporate summary,https://www.benzinga.com/10/10/563852/company-news-for-october-29-2010-corporate-summary,Zacks,2010-10-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853865,news summary,https://www.benzinga.com/market-update/10/10/563757/news-summary,Lisa Levin,2010-10-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853866,merck beats on eps misses on revs analyst blog,https://www.benzinga.com/10/10/563587/merck-beats-on-eps-misses-on-revs-analyst-blog,Zacks,2010-10-29 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.38685
853867,us stock futures down as investors await q gdp data,https://www.benzinga.com/trading-ideas/long-ideas/10/10/562936/us-stock-futures-down-as-investors-await-q3-gdp-data,Lisa Levin,2010-10-29 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.55135
853868,earnings scheduled for october cvx pom ceg mrk pgn nee sne d el itt ci wy eix lnt,https://www.benzinga.com/market-update/10/10/562628/earnings-scheduled-for-october-29-cvx-pom-ceg-mrk-pgn-nee-sne-d-el-itt-ci,Lisa Levin,2010-10-29 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
853869,stocks to watch for october msft mrk expe cvx mxim,https://www.benzinga.com/market-update/10/10/562626/stocks-to-watch-for-october-29-msft-mrk-expe-cvx-mxim,Lisa Levin,2010-10-29 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853870,merck in talks to acquire intermune mrk itmn,https://www.benzinga.com/news/10/10/555756/merck-in-talks-to-acquire-intermune-mrk-itmn,Roger Nachman,2010-10-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853871,stock market news for october market news,https://www.benzinga.com/10/10/548921/stock-market-news-for-october-25-2010-market-news,Zacks,2010-10-25 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853872,citi says merger should help merck mrk,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/547808/citi-says-merger-should-help-merck-mrk,Roger Nachman,2010-10-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.70095
853873,viagra treatment for muscular dystrophy,https://www.benzinga.com/10/10/535843/viagra-treatment-for-muscular-dystrophy,Fred Fuld,2010-10-20 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853874,cpi tame in september analyst blog,https://www.benzinga.com/10/10/530042/cpi-tame-in-september-analyst-blog,Zacks,2010-10-18 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853875,zacks analyst blog highlights krtbtpfemrkgci press releases,https://www.benzinga.com/10/10/529103/zacks-analyst-blog-highlights-kr-tbt-pfe-mrk-gci-press-releases,Zacks,2010-10-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853876,citigroup expects big things from mercks new osteoporosis medication,https://www.benzinga.com/analyst-ratings/10/10/528180/citigroup-expects-big-things-from-mercks-new-osteoporosis-medication,BenzingaStaffL,2010-10-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853877,highest yielding dow jones industrial average stocks,https://www.benzinga.com/10/10/527599/highest-yielding-dow-jones-industrial-average-stocks,Fred Fuld,2010-10-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853878,goldman buying hedges on merck mrk,https://www.benzinga.com/analyst-ratings/analyst-color/10/10/511315/goldman-buying-hedges-on-merck-mrk,Michael J. Zerinskas,2010-10-06 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853879, dow dividend stocks for weary investors,https://www.benzinga.com/trading-ideas/10/10/508088/10-dow-dividend-stocks-for-weary-investors,Benzinga Staff,2010-10-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3634
853880,jjgalapagos in anticancer deal analyst blog,https://www.benzinga.com/10/10/507625/j-j-galapagos-in-anti-cancer-deal-analyst-blog,Zacks,2010-10-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853881,male menopause another treatment for pharmaceutical companies,https://www.benzinga.com/10/10/507557/male-menopause-another-treatment-for-pharmaceutical-companies,Fred Fuld,2010-10-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853882,merck to appeal reduced jury verdict in federal fosamax case,https://www.benzinga.com/news/10/10/507226/merck-to-appeal-reduced-jury-verdict-in-federal-fosamax-case,Benzinga Staff,2010-10-04 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.57655
853883,structured notes the retail brokers own little synthetic cdo,https://www.benzinga.com/10/10/505157/structured-notes-the-retail-brokers-own-little-synthetic-cdo,Joshua Brown,2010-10-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853884,merck announces pivotal phase iii data for boceprevir will be presented at liver diseases meeting,https://www.benzinga.com/news/10/10/503603/merck-announces-pivotal-phase-iii-data-for-boceprevir-will-be-presented-at-liver-d,Benzinga Staff,2010-10-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853885,fda restricts use of glaxo drug analyst blog,https://www.benzinga.com/10/09/492500/fda-restricts-use-of-glaxo-drug-analyst-blog,Zacks,2010-09-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3409
853886,the rapid growth of layoffs in pharma as industry despairs of its future bmy abt pfe mrk,https://www.benzinga.com/general/10/09/490080/the-rapid-growth-of-layoffs-in-pharma-as-industry-despairs-of-its-future-bmy-ab,Benzinga Staff,2010-09-24 00:00:00,MRK,0,1,1,1,1,1,0,0,0,0.3634
853887,travelers mad as hell,https://www.benzinga.com/general/10/09/488900/travelers-mad-as-hell,Benzinga Staff,2010-09-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.0842
853888,bmys diabetes candidate encourages analyst blog,https://www.benzinga.com/10/09/485972/bmys-diabetes-candidate-encourages-analyst-blog,Zacks,2010-09-21 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.7202
853889,zacks analyst blog highlights proshares ultrashort year etf pfizer merck ford and carmax press releases,https://www.benzinga.com/10/09/484453/zacks-analyst-blog-highlights-proshares-ultrashort-20-year-etf-pfizer-merck-ford-and-ca,Zacks,2010-09-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853890,zacks analyst blog highlights johnson johnson crucell nv glaxosmithkline merck and sanofiaventis press releases,https://www.benzinga.com/10/09/484362/zacks-analyst-blog-highlights-johnson-johnson-crucell-nv-glaxosmithkline-merck-and-sano,Zacks,2010-09-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853891,under the hood wisdomtree largecap dividend fund,https://www.benzinga.com/trading-ideas/long-ideas/10/09/484089/under-the-hood-wisdomtree-largecap-dividend-fund,ETF Professor,2010-09-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853892,jj makes a pitch for crucell analyst blog,https://www.benzinga.com/10/09/480731/j-j-makes-a-pitch-for-crucell-analyst-blog,Zacks,2010-09-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.625
853893,unconfirmed chatter that merck co inc mrk will buy medicines co mdco at a share,https://www.benzinga.com/news/10/09/477384/unconfirmed-chatter-that-merck-co-inc-mrk-will-buy-medicines-co-mdco-at-23-00-a-sh,Franklin Price,2010-09-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.58895
853894,jefferies initiates hold rating on merck mrk,https://www.benzinga.com/analyst-ratings/analyst-color/10/09/477184/jefferies-initiates-hold-rating-on-merck-mrk,Michael J. Zerinskas,2010-09-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853895,surmodics stays neutral analyst blog,https://www.benzinga.com/10/09/471116/surmodics-stays-neutral-analyst-blog,Zacks,2010-09-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853896,top buyrated stocks under ,https://www.benzinga.com/news/10/09/464411/top-10-buy-rated-stocks-under-5,Benzinga Staff,2010-09-09 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.60115
853897,goldman sachs buy mrk puts as hedge,https://www.benzinga.com/trading-ideas/short-ideas/10/09/462615/goldman-sachs-buy-mrk-puts-as-hedge,Benzinga Staff,2010-09-08 00:00:00,MRK,1,2,1,1,0,0,1,1,0,0.5
853898,youd have to be sick to touch this drug stock pfe,https://www.benzinga.com/trading-ideas/short-ideas/10/08/450395/youd-have-to-be-sick-to-touch-this-drug-stock-pfe,Roger Nachman,2010-08-31 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.24469999999999997
853899,goldman sachs introduces and adjusts estimates for major pharmaceuticals,https://www.benzinga.com/analyst-ratings/analyst-color/10/08/448162/goldman-sachs-introduces-and-adjusts-estimates-for-major-,Monica Gerson,2010-08-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853900,sunday morning coffee,https://www.benzinga.com/10/08/447188/sunday-morning-coffee,Roger Nusbaum,2010-08-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853901,birth control stocks a recession play,https://www.benzinga.com/10/08/446978/birth-control-stocks-a-recession-play,Fred Fuld,2010-08-27 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.44865
853902,a new round of corporate layoffs,https://www.benzinga.com/markets/company-news/10/08/444204/a-new-round-of-corporate-layoffs,Benzinga Staff,2010-08-26 00:00:00,MRK,0,1,1,1,1,1,1,0,1,0.5
853903,generic risk for gileads hepsera analyst blog,https://www.benzinga.com/10/08/438778/generic-risk-for-gileads-hepsera-analyst-blog,Zacks,2010-08-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.3634
853904, highestrated dow dividend stocks,https://www.benzinga.com/trading-ideas/long-ideas/10/08/433391/10-highest-rated-dow-dividend-stocks,Benzinga Staff,2010-08-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853905,oppenheimer remains buyer of vrtx,https://www.benzinga.com/analyst-ratings/analyst-color/10/08/431757/oppenheimer-remains-buyer-of-vrtx,Monica Gerson,2010-08-17 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853906,all is not well in the pharmaceutical industry,https://www.benzinga.com/markets/company-news/10/08/427658/all-is-not-well-in-the-pharmaceutical-industry,Monica Gerson,2010-08-13 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.39715
853907,us probing pharmaceutical corruption gsk pfe bmy lly,https://www.benzinga.com/markets/company-news/10/08/427275/u-s-probing-pharmaceutical-corruption-gsk-pfe-bmy-lly,Ronald Weisenstein,2010-08-13 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853908,merck announces mandatory conversion of its mandatory convertible preferred stock,https://www.benzinga.com/markets/company-news/10/08/425955/merck-announces-mandatory-conversion-of-its-6-00-mandatory-convert,Benzinga Staff,2010-08-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.57655
853909,dogs of the dow highest yielding dow stocks mrk pfe pg t vz,https://www.benzinga.com/trading-ideas/long-ideas/10/08/423264/dogs-of-the-dow-5-highest-yielding-dow-stocks-mrk-pfe-pg-t-vz,Roger Nachman,2010-08-11 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853910,cost reduction lowers enzn loss analyst blog,https://www.benzinga.com/10/08/419704/cost-reduction-lowers-enzn-loss-analyst-blog,Zacks,2010-08-09 00:00:00,MRK,0,0,0,1,0,0,1,0,1,0.28925
853911,finally there is a cure for tobacco addiction cigx,https://www.benzinga.com/markets/company-news/10/08/418540/finally-there-is-a-cure-for-tobacco-addiction-cigx,Monica Gerson,2010-08-09 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853912,best stocks for a deflationary environment nem abx gg dltr fdo mrk jnj,https://www.benzinga.com/trading-ideas/long-ideas/10/08/416959/best-stocks-for-a-deflationary-environment-nem-abx-gg-dltr-fdo,Jason Raznick,2010-08-06 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.8753
853913,oncothyreon phase breast cancer trial shut down,https://www.benzinga.com/markets/company-news/10/08/416251/oncothyreon-phase-3-breast-cancer-trial-shut-down,Benzinga Staff,2010-08-06 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.17015000000000002
853914,vertex loss narrows reaffirms guidance analyst blog,https://www.benzinga.com/10/08/412373/vertex-loss-narrows-reaffirms-guidance-analyst-blog,Zacks,2010-08-04 00:00:00,MRK,0,1,1,1,1,1,1,1,1,0.3409
853915,santarus beats on higher revs analyst blog,https://www.benzinga.com/10/08/411640/santarus-beats-on-higher-revs-analyst-blog,Zacks,2010-08-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853916,zacks analyst blog highlights the clorox astrazeneca merck dean foods and coach press releases,https://www.benzinga.com/10/08/410889/zacks-analyst-blog-highlights-the-clorox-astrazeneca-merck-dean-foods-and-coach-press-r,Zacks,2010-08-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853917,astrazeneca eps beats ups analyst blog,https://www.benzinga.com/10/08/409081/astrazeneca-eps-beats-ups-analyst-blog,Zacks,2010-08-03 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853918,top nyse stocks in the healthcare sector with the highest free cash flow pfe jnj mrk lly,https://www.benzinga.com/trading-ideas/long-ideas/10/08/405780/top-4-nyse-stocks-in-the-healthcare-sector-with-the-highest-fr,Monica Gerson,2010-08-02 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81245
853919,hapoalim securities downgrades merck to hold from buy mrk,https://www.benzinga.com/analyst-ratings/analyst-color/10/07/404437/hapoalim-securities-downgrades-merck-to-hold-from-buy-mrk,Michael J. Zerinskas,2010-07-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.648
853920,company news for july corporate summary,https://www.benzinga.com/10/07/403886/company-news-for-july-30-2010-corporate-summary,Zacks,2010-07-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853921,us stock futures point to weak day today,https://www.benzinga.com/markets/company-news/10/07/403759/us-stock-futures-point-to-weak-day-today,Monica Gerson,2010-07-30 00:00:00,MRK,1,1,0,1,0,1,0,0,0,0.2798
853922,merck posts mixed results mrk,https://www.benzinga.com/markets/company-news/10/07/403496/merck-posts-mixed-results-mrk,Daniel Hayden IV,2010-07-30 00:00:00,MRK,1,1,1,0,0,1,1,1,1,0.5
853923,etfs to watch july hao pph ycs pall,https://www.benzinga.com/markets/company-news/10/07/403425/etfs-to-watch-july-30-2010-hao-pph-ycs-pall,ETF Professor,2010-07-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853924,mercks q earnings beat targets revenue misses,https://www.benzinga.com/markets/company-news/10/07/403404/merck%E2%80%99s-q2-earnings-beat-targets-revenue-misses,Monica Gerson,2010-07-30 00:00:00,MRK,1,0,1,1,0,0,1,1,1,0.38685
853925,earnings scheduled for july mrk aon cvx cvh wy ppc,https://www.benzinga.com/markets/company-news/10/07/403374/earnings-scheduled-for-july-30-mrk-aon-cvx-cvh-wy-ppc,Monica Gerson,2010-07-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853926,stocks to watch for july fslr mrk cvx aon cstr,https://www.benzinga.com/markets/company-news/10/07/403358/stocks-to-watch-for-july-30-fslr-mrk-cvx-aon-cstr,Monica Gerson,2010-07-30 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853927,fast money leerink swann is a buyer of merck mrk,https://www.benzinga.com/media/cnbc/10/07/400402/fast-money-360-leerink-swann-is-a-buyer-of-merck-mrk,Craig Jones,2010-07-28 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853928,huge call purchase on merck co mrk,https://www.benzinga.com/trading-ideas/long-ideas/10/07/396704/huge-call-purchase-on-merck-co-mrk,Michael J. Zerinskas,2010-07-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6591
853929,a peek into the market at the start of the trading day,https://www.benzinga.com/analyst-ratings/analyst-color/10/07/396189/a-peek-into-the-market-at-the-start-of-the-trading-day,Monica Gerson,2010-07-27 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
853930,sanofiaventis and merck appoint ceo for joint venture,https://www.benzinga.com/markets/company-news/10/07/396002/sanofi-aventis-and-merck-appoint-ceo-for-joint-venture,Benzinga Staff,2010-07-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853931,merk and sinopharm sign statement of mutual intent,https://www.benzinga.com/markets/company-news/10/07/395979/merk-and-sinopharm-sign-statement-of-mutual-intent,Benzinga Staff,2010-07-27 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853932,corporate catalysts for the week starting july ,https://www.benzinga.com/markets/company-news/10/07/393588/corporate-catalysts-for-the-week-starting-july-26,Monica Gerson,2010-07-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853933,ryan recommends bristolmyers and merck bmy mrk pfe,https://www.benzinga.com/analyst-ratings/analyst-color/10/07/376200/ryan-recommends-bristol-myers-and-merck-bmy-mrk-pfe,Alex Furno,2010-07-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.61315
853934, firms expecting clinical trial results,https://www.benzinga.com/markets/company-news/10/07/374730/10-firms-expecting-clinical-trial-results,Benzinga Staff,2010-07-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853935,miller tabak likes bristol myers squibb bmy novartis nvs and merck mrk,https://www.benzinga.com/media/cnbc/10/07/373527/miller-tabak-likes-bristol-myers-squibb-bmy-novartis-nvs-and-merck-mrk,Craig Jones,2010-07-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
853936,glaxosmithkline another drug company runs afoul of the truth,https://www.benzinga.com/markets/company-news/10/07/372363/glaxosmithkline-another-drug-company-runs-afoul-of-the-truth,Benzinga Staff,2010-07-13 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.6591
853937,late market roundup,https://www.benzinga.com/markets/company-news/10/07/367706/late-market-roundup,Monica Gerson,2010-07-08 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853938,news summary hrb bp mrk,https://www.benzinga.com/markets/company-news/10/07/367091/news-summary-hrb-bp-mrk,Monica Gerson,2010-07-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853939,merck details global restructuring program,https://www.benzinga.com/markets/company-news/10/07/366715/merck-details-global-restructuring-program,Benzinga Staff,2010-07-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853940,top yielding big pharmaceutical stocks,https://www.benzinga.com/10/07/366052/top-yielding-big-pharmaceutical-stocks,Fred Fuld,2010-07-07 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.60115
853941,puts purchased on millipore corp mil,https://www.benzinga.com/trading-ideas/technicals/10/07/365713/puts-purchased-on-millipore-corp-mil,Michael J. Zerinskas,2010-07-07 00:00:00,MRK,1,2,0,0,0,0,1,0,0,0.5
853942,stock market news for july market news,https://www.benzinga.com/10/07/364622/stock-market-news-for-july-7-2010-market-news,Zacks,2010-07-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853943,stock market news for july market news,https://www.benzinga.com/10/07/360084/stock-market-news-for-july-2-2010-market-news,Zacks,2010-07-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853944,pharmaceutical etfs on the rise,https://www.benzinga.com/etfs/sector-etfs/10/06/357267/pharmaceutical-etfs-on-the-rise,Benzinga Staff,2010-06-30 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853945,good news for nvos victoza analyst blog,https://www.benzinga.com/10/06/355285/good-news-for-nvo-s-victoza-analyst-blog,Zacks,2010-06-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7202
853946,soleil initiates mrk with hold,https://www.benzinga.com/analyst-ratings/new-coverage/10/06/353499/soleil-initiates-mrk-with-hold,Monica Gerson,2010-06-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853947,citi c has a price target of for bristol myers squibb bmy,https://www.benzinga.com/analyst-ratings/analyst-color/10/06/352671/citi-c-has-a-price-target-of-30-for-bristol-myers-squibb-,Craig Jones,2010-06-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853948,late market roundup,https://www.benzinga.com/markets/company-news/10/06/344738/late-market-roundup,Monica Gerson,2010-06-22 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
853949,dorfman recommends merck calmaine foods and paycheck mrk calm payx,https://www.benzinga.com/analyst-ratings/analyst-color/10/06/333144/dorfman-recommends-merck-cal-maine-foods-and-paycheck-mrk,Alex Furno,2010-06-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
853950,fast money halftime recommendations oxy cvx abt pfe mrk axp c bac jpm,https://www.benzinga.com/media/cnbc/10/05/306468/fast-money-halftime-recommendations-oxy-cvx-abt-pfe-mrk-axp-c-bac-jpm,Craig Jones,2010-05-28 00:00:00,MRK,1,2,0,1,0,1,1,1,0,0.5
853951,citigroup outlook for us major pharmaceuticals mrk pfe bmy,https://www.benzinga.com/analyst-ratings/analyst-color/10/05/304185/citigroup-outlook-for-u-s-major-pharmaceuticals-mrk-pfe-b,Bud Fox,2010-05-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853952,deutsche bank sees a brighter future for drug stocks mrk pfe,https://www.benzinga.com/analyst-ratings/analyst-color/10/05/303984/deutsche-bank-sees-a-brighter-future-for-drug-stocks-mrk-,Alex Furno,2010-05-27 00:00:00,MRK,1,0,1,1,1,0,1,1,1,0.6909
853953,bill smead likes merck and disney mrk dis,https://www.benzinga.com/media/cnbc/10/05/300868/bill-smead-likes-merck-and-disney-mrk-dis,Benzinga Staff 5,2010-05-26 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
853954,citi says dmards not immune to tough economy jnj mrk bmy amgn abt,https://www.benzinga.com/analyst-ratings/analyst-color/10/05/297169/citi-says-dmards-not-immune-to-tough-economy-jnj-mrk-bmy-,Alex Furno,2010-05-24 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.4337
853955,all dow components in the red mrk ge,https://www.benzinga.com/general/10/05/292680/all-30-dow-components-in-the-red-mrk-ge,Swing Trader,2010-05-20 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853956,us stocks end lower yesterday after soaring on monday dow and sp down nasdaq bucks trend,https://www.benzinga.com/markets/company-news/10/05/276833/us-stocks-end-lower-yesterday-after-soaring-on-monday-dow-and-s-p-,Monica Gerson,2010-05-12 00:00:00,MRK,0,1,0,0,0,0,0,0,0,0.352
853957,five new drugs on cards for merck mrk,https://www.benzinga.com/markets/company-news/10/05/273513/five-new-drugs-on-cards-for-merck-mrk,Benzinga Staff 5,2010-05-11 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853958,citi gives thoughts on mrks annual briefing and its price target,https://www.benzinga.com/analyst-ratings/analyst-color/269747/citi-gives-thoughts-on-mrk%E2%80%99s-2010-annual-briefing-and-its-45-00,Junior Analyst,2010-05-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853959,merck and ariad rewrite ridaforolimus contract mrk aria,https://www.benzinga.com/markets/company-news/263379/merck-and-ariad-re-write-ridaforolimus-contract-mrk-aria,Benzinga Staff 5,2010-05-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853960,stock market news for may market news,https://www.benzinga.com/262626/stock-market-news-for-may-5-2010-market-news,Zacks,2010-05-05 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853961,company news for may corporate summary,https://www.benzinga.com/262625/company-news-for-may-5-2010-corporate-summary,Zacks,2010-05-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853962,benzingas top premarket gainers ammd hnsn acas aria erts,https://www.benzinga.com/markets/company-news/262530/benzinga%E2%80%99s-top-pre-market-gainers-ammd-hnsn-acas-aria-erts,Monica Gerson,2010-05-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
853963,goldman downgrades mrk to neutral,https://www.benzinga.com/analyst-ratings/downgrades/262297/goldman-downgrades-mrk-to-neutral,Monica Gerson,2010-05-05 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.5
853964,forex commodities stocks outlook may th special eu crisis market correction gmt,https://www.benzinga.com/263867/forex-commodities-stocks-outlook-may-5th-special-eu-crisis-market-correction-10-30-gmt,Cliff Wachtel,2010-05-05 00:00:00,MRK,1,1,0,1,0,0,1,0,0,0.32999999999999996
853965,us stocks dive hit by europe crisis investors take refuge in dollar bonds,https://www.benzinga.com/markets/company-news/261930/us-stocks-dive-deep-hit-by-europe-crisis-investors-take-refuge-in-dollar,Monica Gerson,2010-05-05 00:00:00,MRK,1,1,0,1,0,0,1,0,0,0.18755
853966,jim cramers short term plays,https://www.benzinga.com/media/cnbc/260690/jim-cramer%E2%80%99s-short-term-plays,Michael J. Zerinskas,2010-05-04 00:00:00,MRK,1,2,0,1,0,0,1,1,0,0.625
853967,pfizer pfe breaches above its day ma,https://www.benzinga.com/trading-ideas/long-ideas/260420/pfizer-pfe-breaches-above-its-50-day-ma,Mark Moneymaster,2010-05-04 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
853968,us stock futures fall on greece worries,https://www.benzinga.com/markets/futures/260085/us-stock-futures-fall-on-greece-worries,Monica Gerson,2010-05-04 00:00:00,MRK,0,1,0,1,0,0,0,0,0,0.28925
853969,mrk shares rise as q profits sales exceeds expectations,https://www.benzinga.com/markets/company-news/259968/mrk-shares-rise-as-q1-profits-sales-exceeds-expectations,Monica Gerson,2010-05-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81245
853970,stock market news for may market news,https://www.benzinga.com/259771/stock-market-news-for-may-4-2010-market-news,Zacks,2010-05-04 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853971,company news for may corporate summary,https://www.benzinga.com/259770/company-news-for-may-4-2010-corporate-summary,Zacks,2010-05-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853972,merck cos mrk firstquarter profit down by ,https://www.benzinga.com/markets/company-news/259252/merck-co-%E2%80%99s-mrk-first-quarter-profit-down-by-77,Benzinga Staff 5,2010-05-04 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.7202
853973,jims game plan for this week smg clne cpno jdsu apa dvn rig mrk pfe shoo sba amt vmc syy,https://www.benzinga.com/media/cnbc/257127/jim%E2%80%99s-game-plan-for-this-week-smg-clne-cpno-jdsu-apa-dvn-rig-mrk-pfe-shoo-sba-amt-,Monica Gerson,2010-05-03 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.436
853974,stock market news for may market news,https://www.benzinga.com/257076/stock-market-news-for-may-3-2010-market-news,Zacks,2010-05-03 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853975,dow gains the highest since march led by q gains,https://www.benzinga.com/markets/company-news/254789/dow-gains-the-highest-since-march-5-led-by-q1-gains,Monica Gerson,2010-04-30 00:00:00,MRK,1,0,0,1,0,0,1,1,1,0.79295
853976,fast money picks for april th mrk rig glw xom,https://www.benzinga.com/media/cnbc/254454/fast-money-picks-for-april-30th-mrk-rig-glw-xom,Craig Jones,2010-04-29 00:00:00,MRK,1,2,0,1,0,0,1,1,0,0.436
853977,afternoon market update goldman sachs nyse gs merck nyse mrk astrazeneca nyse azn,https://www.benzinga.com/markets/company-news/250908/afternoon-market-update-goldman-sachs-nyse-gs-merck-nyse-mrk-astrazeneca,Monica Gerson,2010-04-28 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
853978,investors allowed to sue merck over vioxx mrk,https://www.benzinga.com/markets/company-news/250372/investors-allowed-to-sue-merck-over-vioxx-mrk,Bud Fox,2010-04-28 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.5
853979,merck to lose million in revenue mrk,https://www.benzinga.com/analyst-ratings/analyst-color/242477/merck-to-lose-170-million-in-revenue-mrk,Bud Fox,2010-04-23 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.29905000000000004
853980,merck co mrk says us healthcare legislation to reduce revenue by million,https://www.benzinga.com/markets/company-news/242437/merck-co-mrk-says-u-s-health-care-legislation-to-reduce-2010-revenue-by-,Benzinga Staff 5,2010-04-23 00:00:00,MRK,1,1,1,1,1,0,1,1,1,0.5
853981,market roundup ms c hls ubs hbc usb mrk,https://www.benzinga.com/markets/company-news/242131/market-roundup-ms-c-hls-ubs-hbc-usb-mrk,Monica Gerson,2010-04-23 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
853982,us stock ended in positive territory after losing points,https://www.benzinga.com/markets/company-news/240812/us-stock-ended-in-positive-territory-after-losing-100-points,Monica Gerson,2010-04-23 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.625
853983,stock market news for april market news,https://www.benzinga.com/238669/stock-market-news-for-april-22-2010-market-news,Zacks,2010-04-22 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853984,top stocks of new jersey,https://www.benzinga.com/237008/top-stocks-of-new-jersey,Fred Fuld,2010-04-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
853985,mad money lightning round jim likes amd apc armh imax yhoo exc mur,https://www.benzinga.com/media/cnbc/225008/mad-money-lightning-round-jim-likes-amd-apc-armh-imax-yhoo-exc-mur,Monica Gerson,2010-04-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.44865
853986,stock market news for april market news,https://www.benzinga.com/213441/stock-market-news-for-april-8-2010-market-news,Zacks,2010-04-08 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
853987,us equity market preview aapl exc hsp itmn mrk,https://www.benzinga.com/pre-market-outlook/205896/u-s-equity-market-preview-aapl-exc-hsp-itmn-mrk,Benzinga Staff 5,2010-04-05 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853988,top five dow stocks with high yields dd mrk pfe t vz,https://www.benzinga.com/trading-ideas/long-ideas/191229/top-five-dow-stocks-with-high-yields,Monica Gerson,2010-03-25 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.60115
853989,the high yielders of the dow,https://www.benzinga.com/191028/the-high-yielders-of-the-dow,Fred Fuld,2010-03-25 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853990,before jumping into a single health care stock consider this etf,https://www.benzinga.com/188732/before-jumping-into-a-single-health-care-stock-consider-this-etf,David Bettencourt,2010-03-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
853991,fast money picks for march th mpel apa pll bac,https://www.benzinga.com/media/cnbc/188594/fast-money-picks-for-march-24th-mpel-apa-pll-bac,Craig Jones,2010-03-23 00:00:00,MRK,1,2,0,1,0,0,1,1,0,0.5
853992,investors flock to healthcare etfs on historic reform,https://www.benzinga.com/185428/investors-flock-to-healthcare-etfs-on-historic-reform,David Bettencourt,2010-03-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853993,us stocks jump up rally driven by health pharma stocks axp dd mrk pfe mrk thc hma,https://www.benzinga.com/trading-ideas/long-ideas/185319/us-stocks-jump-up-rally-driven-by-health-pharma-stocks-axp-dd-mrk-pf,Monica Gerson,2010-03-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853994,fda asks doctors to suspend use of glaxosmithkline gsk rotavirus vaccine,https://www.benzinga.com/markets/company-news/185292/fda-asks-doctors-to-suspend-use-of-glaxosmithkline-gsk-rotavirus-vaccine,Daniel Hayden IV,2010-03-22 00:00:00,MRK,1,1,1,1,0,0,1,1,1,0.3409
853995,pfizer pfe and merck mrk advance following approval of healthcare legislation,https://www.benzinga.com/trading-ideas/long-ideas/184983/pfizer-pfe-and-merck-mrk-advance-following-approval-of-healthcare-le,Mark Moneymaster,2010-03-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7383500000000001
853996,this healthcare etf xlv is seeing above average call buying,https://www.benzinga.com/178858/this-healthcare-etf-xlv-is-seeing-above-average-call-buying,David Bettencourt,2010-03-17 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
853997,benzingas news roundup pep alks mrk,https://www.benzinga.com/markets/company-news/173095/benzinga%E2%80%99s-news-roundup-pep-alks-mrk,BenzingaStaff3,2010-03-15 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853998,merck to continue its ma spree mrk mil,https://www.benzinga.com/markets/company-news/171829/merck-to-continue-its-m-a-spree-mrk-mil,Bud Fox,2010-03-12 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
853999,overhang on merck company mrk lifted by improveit update,https://www.benzinga.com/analyst-ratings/analyst-color/170837/overhang-on-merck-company-mrk-lifted-by-improve-it-update,Monica Gerson,2010-03-12 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
854000,stock market news for march market news,https://www.benzinga.com/170673/stock-market-news-for-march-12-2010-market-news,Zacks,2010-03-12 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
854001,sonofimerck mrk deal positive,https://www.benzinga.com/markets/company-news/165022/sonofi-merck-mrk-deal-positive,Monica Gerson,2010-03-09 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7787
854002,thinkequity reiterates buy on orasure technologies osur mrk pfe,https://www.benzinga.com/analyst-ratings/analyst-color/162626/thinkequity-reiterates-buy-on-orasure-technologies-osur-mrk-pfe,Benzinga Staff,2010-03-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854003,simple quantitative view of goldmans vip list generates some other long ideas,https://www.benzinga.com/182850/simple-quantitative-view-of-goldman-s-vip-list-generates-some-other-long-ideas,Stephen Castellano,2010-03-08 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7553000000000001
854004,goldman sachs gs vip list of top hedge fund holdings,https://www.benzinga.com/160134/goldman-sachs-gs-vip-list-of-top-hedge-fund-holdings,tradermark,2010-03-05 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.81245
854005,karen finerman thinks there might be other bidders for mil,https://www.benzinga.com/media/cnbc/150974/karen-finerman-thinks-there-might-be-other-bidders-for-mil,Craig Jones,2010-03-01 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854006,eli lilly banks on its restructured development process to offset sales loss lly,https://www.benzinga.com/markets/company-news/144430/eli-lilly-banks-on-its-restructured-development-process-to-offset-sales-,Benzinga Staff 5,2010-02-25 00:00:00,MRK,0,0,1,1,1,1,1,1,1,0.3409
854007,large hacking instance detected mrk cah,https://www.benzinga.com/general/132567/large-hacking-instance-detected-mrk-cah,Benzinga Staff 5,2010-02-18 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
854008,john paulson sells merck mrk buys bank of america bac,https://www.benzinga.com/media/cnbc/129649/john-paulson-sells-merck-mrk-buys-bank-of-america-bac,Craig Jones,2010-02-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854009,movement expected in the shares of these companies amid significant events brkb bx jpm orclyhoo,https://www.benzinga.com/market-update/129360/movement-expected-in-the-shares-of-these-companies-amid-significant-events-brk-,Benzinga Staff 5,2010-02-16 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.7294
854010,merck co mrk reports bigger profit helped by scheringploug deal,https://www.benzinga.com/markets/company-news/129222/merck-co-mrk-reports-bigger-profit-helped-by-schering-ploug-deal,Benzinga Staff 5,2010-02-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
854011,merck posts bigger profit mrk,https://www.benzinga.com/markets/company-news/128122/merck-posts-bigger-profit-mrk,Bud Fox,2010-02-16 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.7202
854012,company news for february corporate summary,https://www.benzinga.com/128604/company-news-for-february-16-2010-corporate-summary,Zacks,2010-02-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854013,mrk shares up as q earnings match expectations,https://www.benzinga.com/markets/company-news/128029/mrk-shares-up-as-4q-earnings-match-expectations,Monica Gerson,2010-02-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.648
854014,stock market news for february market news,https://www.benzinga.com/128606/stock-market-news-for-february-16-2010-market-news,Zacks,2010-02-16 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
854015,merck co mrk reports schering fueled profit jump,https://www.benzinga.com/markets/company-news/127681/merck-co-mrk-reports-schering-fueled-profit-jump,Daniel Hayden IV,2010-02-16 00:00:00,MRK,1,1,1,1,0,1,1,1,1,0.7202
854016,merck reports inline stock off to good start in premarket mrk,https://www.benzinga.com/markets/company-news/127626/merck-reports-inline-stock-off-to-good-start-in-premarket-mrk,chenry4287,2010-02-16 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.7202
854017,top large cap growth stocks esrx mrk vale aapl bhp,https://www.benzinga.com/trading-ideas/long-ideas/127478/top-5-large-cap-growth-stocks-esrx-mrk-vale-aapl-bhp,Monica Gerson,2010-02-16 00:00:00,MRK,1,2,1,0,0,1,1,1,1,0.76335
854018,credit suisse lowers estimates price targets on merck pfizer,https://www.benzinga.com/analyst-ratings/analyst-color/123926/credit-suisse-lowers-estimates-price-targets-on-merck-pfizer,Gordon Wilcox,2010-02-11 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.6366
854019,merck co to change safety procedures mrk,https://www.benzinga.com/markets/company-news/121913/merck-co-to-change-safety-procedures-mrk,Bud Fox,2010-02-10 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.71075
854020,merck co mrk agrees to changes in vioxx settlement,https://www.benzinga.com/markets/company-news/121869/merck-co-mrk-agrees-to-changes-in-vioxx-settlement,Daniel Hayden IV,2010-02-10 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.60115
854021,market roundup aapl mrk fitb pnc ttwo goog,https://www.benzinga.com/markets/company-news/121712/market-roundup-aapl-mrk-fitb-pnc-ttwo-goog,Monica Gerson,2010-02-10 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
854022,market roundup ubs goog aapl mot pg pfe mrk lly cvs wag,https://www.benzinga.com/markets/company-news/115676/market-round-up-ubs-goog%C2%B8-aapl-mot%C2%B8-pg-pfe-mrk-lly-cvs-wag,Monica Gerson,2010-02-05 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.4742
854023,merck mrk is a frontrunner among pharma stocks,https://www.benzinga.com/media/cnbc/110750/merck-mrk-is-a-frontrunner-among-pharma-stocks,Benzinga Staff 5,2010-02-04 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
854024,mad money lightning round jim prefers mrk syk intc aapl to coms zmh ebix msft mot,https://www.benzinga.com/media/cnbc/109830/mad-money-lightning-round-jim-likes-syk-intc-aapl,Monica Gerson,2010-02-03 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.25305
854025,invest in high quality stocks like merck mrk analyst says on cnbc,https://www.benzinga.com/media/cnbc/104439/invest-in-high-quality-stocks-like-merck-mrk-analyst-says-on-cnbc,Benzinga Staff 5,2010-01-29 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6806
854026,merck mrk doing well but becoming more transparent,https://www.benzinga.com/media/cnbc/97425/merck-mrk-doing-good-but-becoming-more-transparent,Benzinga Staff 5,2010-01-25 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5703
854027,big pharma will trade on the following fundamentals morningstar says big pharma well positioned,https://www.benzinga.com/trading-ideas/long-ideas/96601/big-pharma-will-trade-on-the-following-fundamentals-morningstar-says-,strichie,2010-01-22 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6366
854028,stock market news for january market news,https://www.benzinga.com/93336/stock-market-news-for-january-20-2010-market-news,Zacks,2010-01-20 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
854029,merck has the best pharma bet mrk,https://www.benzinga.com/analyst-ratings/analyst-color/90356/merck-has-the-best-pharma-bet-mrk,Benzinga Staff 5,2010-01-18 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.81845
854030,pete najarian sees an opportunity in pharma xlv wlp aet unh hum mrk pfe jnj,https://www.benzinga.com/media/cnbc/88478/pete-najarian-sees-an-opportunity-in-pharma-xlv-wlp-aet-unh-hum-mrk-pfe-jnj,Craig Jones,2010-01-14 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.71075
854031,merck co mrk submits new data to fda to widen gardasil use,https://www.benzinga.com/markets/company-news/88253/merck-co-mrk-submits-new-data-to-fda-to-widen-gardasil-use,Benzinga Staff 5,2010-01-14 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854032,stock market news for january market news,https://www.benzinga.com/87736/stock-market-news-for-january-14-2010-market-news,Zacks,2010-01-14 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
854033,top largecap stocks in the healthcare sector with the highest roe gsk gild azn acl mrk,https://www.benzinga.com/trading-ideas/long-ideas/87398/top-5-large-cap-stocks-in-the-healthcare-sector-with-the-highest-roe-,Monica Gerson,2010-01-14 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.60115
854034,merck leads drug stocks up,https://www.benzinga.com/general/86566/merck-leads-drug-stocks-up,Daniel Hayden IV,2010-01-13 00:00:00,MRK,1,2,1,1,0,0,1,1,1,0.5
854035,merck co mrk soars on upgrade by credit suisse,https://www.benzinga.com/trading-ideas/long-ideas/86362/merck-co-mrk-soars-on-upgrade-by-credit-suisse,Mark Moneymaster,2010-01-13 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6909
854036,merck upgraded at credit suisse mrk,https://www.benzinga.com/global/86270/merck-upgraded-at-credit-suisse-mrk,Bud Fox,2010-01-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.6909
854037,benzingas top upgrades bidu mrk ntap ups aaww,https://www.benzinga.com/analyst-ratings/analyst-color/86104/benzinga%E2%80%99s-top-upgrades-bidu-mrk-ntap-ups-aaww,BenzingaStaff3,2010-01-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.60115
854038,company news for january corporate summary,https://www.benzinga.com/86099/company-news-for-january-13-2010-corporate-summary,Zacks,2010-01-13 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854039,investment mantra be bullish on mega caps in the dogs of the dow xom wfc ba cvx du mcd mrk pfe,https://www.benzinga.com/trading-ideas/long-ideas/81558/investment-mantra-2010-be-bullish-on-mega-caps-in-%E2%80%98the-dogs-of-the-do,Benzinga Staff 5,2010-01-08 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
854040,drug pipeline targeting high growth markets may boost merck prospects mrk c,https://www.benzinga.com/analyst-ratings/analyst-color/76045/drug-pipeline-targeting-high-growth-markets-may-boost-merck-pros,Benzinga Staff 5,2010-01-05 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.87895
854041,biotech listings to form a major chunk of ipo market jnj pfe mrk cdxstngn mbgi,https://www.benzinga.com/markets/company-news/75225/biotech-listings-to-form-a-major-chunk-of-ipo-market-jnj-pfe-mrk-cdxs-tng,Benzinga Staff 5,2010-01-04 00:00:00,MRK,1,2,1,0,1,1,1,1,1,0.5
854042,the worlds largest ma deals in pfe wla gm sgp mrk,https://www.benzinga.com/markets/company-news/72484/the-world-s-10-largest-m-a-deals-in-2009-pfe-wla-gm-sgp-mrk,Benzinga Staff 5,2009-12-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854043,merck decides to discontinue its collaboration with arna for dyslipidemia,https://www.benzinga.com/analyst-ratings/analyst-color/71878/merck-decides-to-discontinue-its-collaboration-with-arna-for-dys,Monica Gerson,2009-12-24 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854044,above average eps growth projected for mrk,https://www.benzinga.com/analyst-ratings/analyst-color/71211/above-average-eps-growth-projected-for-mrk,Monica Gerson,2009-12-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.6909
854045,fda indicates role of vytorin and zetia in increased cancer risk unlikely,https://www.benzinga.com/general/71206/fda-indicates-role-of-vytorin-and-zetia-in-increased-cancer-risk-unlikely,Monica Gerson,2009-12-23 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.17015000000000002
854046,merck co inc mrk gets a hold rating,https://www.benzinga.com/markets/company-news/71168/merck-co-inc-mrk-gets-a-hold-rating,Benzinga Staff 5,2009-12-23 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854047,walmart wmt and comcast cmcsa for ,https://www.benzinga.com/media/cnbc/70284/walmart-wmt-and-comcast-cmcsa-for-2010,Benzinga Staff 5,2009-12-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854048,buying value for ,https://www.benzinga.com/69638/buying-value-for-2010,Invest With An Edge,2009-12-22 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.67
854049,health brings wealth to the street pfe mrk aet unh sny chtt,https://www.benzinga.com/markets/company-news/69218/health-brings-wealth-to-the-street-pfe-mrk-aet-unh-sny-chtt,Benzinga Staff 5,2009-12-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.74695
854050,new pbm president good for caremark cvs,https://www.benzinga.com/analyst-ratings/price-target/69130/new-pbm-president-good-for-caremark-cvs,Benzinga Staff 5,2009-12-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7202
854051, dogs of the dow,https://www.benzinga.com/markets/68868/2010-dogs-of-the-dow,Bud Fox,2009-12-21 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854052,peak sales of mrks isentress may touch billion,https://www.benzinga.com/analyst-ratings/analyst-color/67677/peak-sales-of-mrk%E2%80%99s-isentress-may-touch-2-billion,Monica Gerson,2009-12-18 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
854053,top largecap stocks with highest sales growth estimate for next year tm su mrk esrx pot,https://www.benzinga.com/trading-ideas/long-ideas/64208/top-5-large-cap-stocks-with-highest-sales-growth-estimate-for-next-ye,Monica Gerson,2009-12-16 00:00:00,MRK,1,0,1,1,0,1,1,1,1,0.76335
854054,large caps breaking out johnson johnson jnj coke ko ibm ibm merck mrk verizon vz disney dis m mmm,https://www.benzinga.com/61392/large-caps-breaking-out-johnson-johnson-jnj-coke-ko-ibm-ibm-merck-mrk-verizon-vz-disney-dis-3m,tradermark,2009-12-14 00:00:00,MRK,1,2,0,1,0,0,1,1,1,0.5
854055,sec on trail of insider trading transactions,https://www.benzinga.com/markets/company-news/58782/sec-on-trail-of-insider-trading-transactions,Benzinga Staff 5,2009-12-10 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
854056,stock market news for december market news,https://www.benzinga.com/55846/stock-market-news-for-december-08-2009-market-news,Zacks,2009-12-08 00:00:00,MRK,1,2,0,1,1,0,1,1,1,0.5
854057,cowen stays neutral on santarus snts cites litigation concerns prx mrk azn nvs,https://www.benzinga.com/markets/analyst-research/50592/cowen-stays-neutral-on-santarus-snts-cites-litigation-concerns-prx-mr,Benzinga Staff 5,2009-12-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.39885
854058,googles most popular stock searches today snts mrk itvi dyax snda,https://www.benzinga.com/general/50208/google-s-most-popular-stock-searches-today-snts-mrk-itvi-dyax-snda,Benzinga Staff 5,2009-12-02 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7377
854059,taking a look at two pharma etfs ihe pph,https://www.benzinga.com/trading-ideas/long-ideas/46529/taking-a-look-at-two-pharma-etfs-ihe-pph,ETF Professor,2009-11-28 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854060,stocks that will continue to achieve new highs bby sjm agu ko tra mrk ctl,https://www.benzinga.com/movers/43859/stocks-that-will-continue-to-achieve-new-highs-bby-sjm-agu-ko-tra-mrk-ctl,Craig Jones,2009-11-20 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
854061,jpmorgan likes abbott abt because of niaspan,https://www.benzinga.com/markets/analyst-research/analyst-color/41527/jpmorgan-likes-abbott-abt-because-of-niaspan,Benzinga Staff,2009-11-16 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.71075
854062,merck sends letter to nyt editor about arbiter story,https://www.benzinga.com/markets/company-news/41409/merck-sends-letter-to-nyt-editor-about-arbiter-story,Benzinga Staff,2009-11-14 00:00:00,MRK,1,2,1,1,0,1,1,1,1,0.5
854063,merck mrk drugs under scanner of cholesterol study,https://www.benzinga.com/markets/company-news/41131/merck-mrk-drugs-under-scanner-of-cholesterol-study,Benzinga Staff 5,2009-11-13 00:00:00,MRK,1,1,1,1,1,1,1,1,1,0.5
854064,leerink swann upgrades merck to outperform,https://www.benzinga.com/market-update/37739/leerink-swann-upgrades-merck-to-outpeform,BenzingaStaff3,2009-11-09 00:00:00,MRK,1,0,1,1,1,1,1,1,1,0.5
854065,the etf professor told you to watch this healthcare etf xlv,https://www.benzinga.com/trading-ideas/long-ideas/37389/the-etf-professor-told-you-to-watch-this-healthcare-etf-xlv,ETF Professor,2009-11-06 00:00:00,MRK,1,2,1,1,1,0,1,1,1,0.5
854066,merck says it wont seek another larger merger,https://www.benzinga.com/markets/company-news/35781/merck-says-it-won-t-seek-another-larger-merger,Benzinga Staff,2009-11-04 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854067,fitch downgrades merck outlook stable,https://www.benzinga.com/markets/analyst-research/35748/fitch-downgrades-merck-outlook-stable,Benzinga Staff,2009-11-04 00:00:00,MRK,1,1,0,1,0,0,1,1,1,0.648
854068,sanofiaventis sny completes acquisition of merial,https://www.benzinga.com/benzingastaff1/2009/9/18/sanofi-aventis-sny-completes-acquisition-of-merial,BenzingaStaff1,2009-09-18 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.5
854071,paragonreportcom complimentary market update on freddie mac nyse fre best buy co inc nyse bby american express company nyse axp and merck co inc nyse mrk,https://www.benzinga.com/09/08/1612/paragonreport-com-complimentary-market-update-on-freddie-mac-nyse-fre-best-buy-co-inc-nys,Benzinga Staff,2009-08-10 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.8982
854072,paragonreportcom complimentary market update on alumina ltd nyse awc csb corporation nyse cbs merck co inc nyse mrk and nvidia corporation nasdaq nvda,https://www.benzinga.com/09/08/675/paragonreport-com-complimentary-market-update-on-alumina-ltd-nyse-awc-csb-corporation-nyse,Benzinga Staff,2009-08-07 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7202
854073,wall street news alert stocks this morning green star alternative energy july ,https://www.benzinga.com/09/07/245/wall-street-news-alert-stocks-this-morning-green-star-alternative-energy-july-27-2009,Benzinga Staff,2009-07-27 00:00:00,MRK,1,2,1,1,1,1,1,1,1,0.7553000000000001
